<SEC-DOCUMENT>0000950170-23-010428.txt : 20230329
<SEC-HEADER>0000950170-23-010428.hdr.sgml : 20230329
<ACCEPTANCE-DATETIME>20230329063108
ACCESSION NUMBER:		0000950170-23-010428
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		102
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230329
DATE AS OF CHANGE:		20230329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SYNLOGIC, INC.
		CENTRAL INDEX KEY:			0001527599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				261824804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37566
		FILM NUMBER:		23771682

	BUSINESS ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		SUITE 402
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-401-9975

	MAIL ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		SUITE 402
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mirna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20110809
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sybx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-28T22:59:02.7429+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:sybx="http://www.synlogictx.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_66a7420d-4ae6-4ebb-a5a4-555a6a7cbcad" name="dei:AmendmentFlag" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780">false</ix:nonNumeric><ix:nonNumeric id="F_c5640fb7-a3ab-4596-a6cd-95b9bcaf8185" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0">true</ix:nonNumeric><ix:nonNumeric id="F_7f387997-6c11-488d-a93d-d766b380d82b" name="dei:EntityCentralIndexKey" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780">0001527599</ix:nonNumeric><ix:nonNumeric id="F_9ad71e03-2303-4ee4-883d-5ed6738ea62b" name="sybx:AgreementExpirationDate" contextRef="C_e3e7babb-b939-40de-97da-4a92ec952e88" format="ixt:datemonthdayyearen">December 31, 2022</ix:nonNumeric><ix:nonNumeric id="F_05e3c282-5e7a-4d07-8c4f-40eddf5219a8" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" contextRef="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0">true</ix:nonNumeric><ix:nonNumeric id="F_fc7e96aa-31ea-42d3-bcfb-bc7577c11e53" name="us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780">true</ix:nonNumeric><ix:nonFraction id="F_cb04f5e1-07b2-4b27-b75e-4b304dd2e751" name="us-gaap:CommitmentsAndContingencies" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_95ac8cfc-e3ce-469b-9f55-e96edd374653" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_5c3d6c09-e07c-48fc-b6d8-d5ad92538a25">true</ix:nonNumeric><ix:nonNumeric id="F_5618cde7-2a4e-4e7a-bb47-0807b4054826" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780">true</ix:nonNumeric><ix:nonNumeric id="F_7eef8a2a-292f-43fe-97a4-d52a16e845a6" name="dei:CurrentFiscalYearEndDate" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780">--12-31</ix:nonNumeric><ix:nonNumeric id="F_4b419055-80ef-43cc-a74a-f33b8a1e40f5" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e">greater than 50%</ix:nonNumeric><ix:nonNumeric id="F_825913e6-7f7b-4ea6-ba26-8a4ffd18af64" name="dei:DocumentFiscalPeriodFocus" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780">FY</ix:nonNumeric><ix:nonFraction id="F_ee6be37b-9a01-4f47-82d0-a166404c555a" name="us-gaap:TreasuryStockValue" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_02c6b8c4-1e53-4fc1-994a-906cacc53571" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_28c409d5-6a3b-428a-8521-04958db80cd2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_cafdd680-6b10-4569-88ff-00aa7168f202" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_5c3d6c09-e07c-48fc-b6d8-d5ad92538a25">true</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sybx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99fd2321-f1d7-43cf-b178-e7348f290f1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sybx:EmployeesAndNonemployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4516b6b5-54fe-44c6-ab9c-eee027b01c2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sybx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9b859fc-2a96-4b54-97cb-88cba1858033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b99e72e-cd69-4ebb-a947-0d73db833415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5e1f167-a526-4fc5-995f-8c2fa7bc03e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0abad65e-efe7-4687-9248-a9c45acb22de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60a114fa-eeba-4606-ada0-5fecd8dae2ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e60fb3b-c7d3-4ac6-83b2-f6a6547f6e1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d79f3e7f-b5d8-44b8-8e74-072b254299d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a5c39e0-05a3-412d-9021-2ac827b89c7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3e7babb-b939-40de-97da-4a92ec952e88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:NewAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sybx:AzzurGroupLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b826f3c-b239-4a65-b43d-e759471f2756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_769545e9-0aa1-4ec6-a368-611478b8ff27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_282387b9-90c8-4462-9a1a-f4e3a22907e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c440647-2473-4161-b76b-146d516bb47b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30a0f2b0-9a2a-4a96-a075-e5e89fb12427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42df9a46-4a26-442d-8081-eac11aa26210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b9caf09-f6c8-47cf-a222-c8667dca98fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37a703b8-c41b-42c8-9707-370b726139cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0754e8dc-f387-45d7-8ad5-2f37ecf370c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb7c3478-1f6c-45ea-b035-e3a9a00b30bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e08b8831-bd01-48c6-a8f9-50a61b822302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sybx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd16f567-f183-4c6e-8b80-74f9c2966fb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_627e4d45-a0cb-4fa4-be83-89cafaf6b705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_698c1855-5f3d-4405-b9dd-9cbf05cddeda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73d91fb1-2e62-48f7-92de-e383722c15e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db9aee41-d847-4892-9d0a-5f6f3588bb50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76fcaa28-0554-4900-bf7f-e8311ed88698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8618276-8b30-4637-beb0-a8e46a028cc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53c113d0-26f8-4751-aac3-06cad9a19780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73945c68-b522-4635-afec-a62d38320354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd0ccefb-dd51-4e98-b605-3e1a046f1576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91376d3a-55e0-47d7-8f1d-b1e000c4da64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d9937da-b5ee-4340-92e5-8a0477c4b960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_127f40d5-4261-4e87-a5a5-a06ab8251d92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7347bbee-a9f6-4c87-a6a2-eddd53ccfd0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71a618da-156f-461d-a56d-61c9010a19f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0558df53-fc4c-4356-aa92-1218af4ad35e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8114c460-4d06-4e71-8f72-16758968f429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_125495a8-4ea5-4da7-b352-1c1c4f816a98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a326c280-7be6-41bc-88c6-584d5e7052d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23b05112-0191-4539-844d-dcff33882fec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc33945e-b2f0-4255-915f-8f700291d29e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b538def-63ae-4f4b-9140-89b96b2a5ea7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39ffddbf-7d15-4ff1-8e01-541286c83ab8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e617d399-c879-434f-a4fb-b4d8855f9c6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_261be9b1-a487-4761-8558-63f62fe17054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3545a731-60bf-461a-b2f6-a8fd246306f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2ff957f-8810-4fc7-8b03-9624137f2f79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13abf79b-a461-4ee1-8d29-6b819cbd08f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97aff091-2a04-46a5-9057-7373ad98593b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd023e56-8402-47a8-bace-8ad6f1a75d5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sybx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e5987d8-c576-4625-8759-66ebd0405f3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0091dbbf-6c21-4edd-9df7-2c4b934ef7d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sybx:EmployeesAndNonemployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ce13154-7826-4547-a938-f6040b13872f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c3d6c09-e07c-48fc-b6d8-d5ad92538a25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201708Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5706570-7d04-4e8e-814e-029647b3f073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df2e79da-2d09-4270-8ce2-2f9e4b85b0ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2007-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7af75ad-b1e6-4aef-851f-04fd45e648cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ce653bf-490d-4819-8e5a-529c46c9a649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d97b6644-79ff-4699-9f6b-e83cf66bd673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94ebd146-59d5-436b-8185-ff6c733be386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cee0ff06-3a82-48ed-bc1e-7798fb043a99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c959ef41-4848-4db3-9e53-0dd492572f29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b65842df-41e9-4ad0-b418-74bfc423b622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df578021-db7b-44d1-8405-c09b71d9bf97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_794b0fde-85f9-4229-b743-26bedc55e777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_961a013f-154c-4b93-ac17-2c189db1fa4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7130c6be-123a-4941-b59a-2b8f5cdd887b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0dd3811-b7af-4902-afcd-ce7c054f5cb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91268588-0fb2-48c3-8afe-0148ee56a770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:MasterContractServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sybx:AzzurGroupLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92b7da2a-7418-436a-9524-56701b660c25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c9b51e6-d273-4c40-9880-9ef1e241ffbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_640feb28-ca33-4b33-8050-74bd8f92c9c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99657c65-259d-41fd-986b-5c347fbc45d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c13194e-33fe-40bd-90ef-6bbee6ee67f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3f01399-c70d-4fc2-8fb9-042eab32457b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e13a3127-83d8-4882-9c9b-f8eadac41d7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01e34769-71da-4fdd-af5a-ed9f45d058c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29fed40c-524b-495e-b738-feab12394d3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94afbb83-f2d7-4546-a4ae-0e428a53c728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ad07922-17ac-4c18-97a9-21067c51ee17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52001b96-65b6-4786-9e84-a405520ac86d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_406221e2-1ef7-4393-9e2d-3f9516e8e4c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8caafedd-e06d-4a10-aa7a-0b8fa55c8b9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cb51fda-168e-4bf9-88e4-f2c1dde4f357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83994bcc-897b-4ecf-9900-6f87c0a0397c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-31</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe7d4a4c-340f-4bfe-9353-91af7151de36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44eb79d0-8fc4-42f7-a690-e5796a479806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9cba784-5870-4180-9446-6bedd109f39c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14cab79b-31e9-441e-9110-e4bc26c0833c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d820518-ff46-4605-b3e8-6459f151a8a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52f0109e-38a0-4183-afac-f6722c5543d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a7a2cff-5d8f-4521-9e09-ba2479d086ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sybx:USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eaa3b6a1-b527-43fd-9863-6130ce0c85bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0897e117-252f-49bf-8a93-cb69564f1408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0aaf0697-e409-448d-ba6a-dc57c7587a33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be0c663b-cd69-4808-83ec-81ad0fa98a39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbe4b5e6-1273-43ae-8a7f-b8ea915f3ed1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96b303f7-61a6-4679-becd-a1dd839a0a5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6edf54b0-befe-46f1-a01a-5d4ad86e422a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c6943e9-6e4c-48b4-ac4a-76f2723a410c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b35d2ba3-ee9d-4986-b9f1-a7a0e81af1d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cb1f60e-ec3f-44d1-b1f6-3bcaa075be67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b910752-910d-4808-a82b-55cf3ff96bd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80b6d2b4-7e32-4f90-a5bf-55d9ff118805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d77ddcfe-10f7-4a58-90fe-828bf55ff466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4d75229-eaf1-4029-9ef7-4b3edaa0a833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3934f648-405d-4a5e-b610-f5dc014cbfd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43b99e43-1090-41dc-af3b-41ef21ba7597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1266c6b-f79b-47ac-9d44-b00ab08b1491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87720378-333d-485a-b610-abbe5ef1182d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ad92b9f-963d-493a-a1e4-49542d62bb26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fc8483b-ee81-4369-a735-5813ac304b5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fa40dbc-7f7b-4478-86f2-ad847e50f5fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83e56954-5a79-4d4a-a1b6-981f26235c7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b98e403-528d-433b-81fb-64269d42e27a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3bc4242-7016-4d08-911e-e53fb03921c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cedb62c-bc49-42b5-ab00-88dd9ea24194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d6680fe-ccfc-4e24-8fd9-1fa014c4a0b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61230b0b-84df-43f0-a9b0-98509a23ed34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sybx:USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d128f60-ec2d-4e7e-ad00-15156530da9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17b056dc-d7fb-4fda-b280-76eec780b5fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d15380e7-f98d-4b93-b4f8-739dab563868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1edfa35-041c-4e12-af32-4f8cfaf160b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f81bc0ea-4cc8-4008-8667-3a9f04ab0640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sybx:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e56b967-590d-4bb7-93db-326ebc48a3e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_654a16e2-8083-4d9a-92ce-ca57cab55a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75851d76-14c4-43a0-8d91-11383d574278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85363944-bc80-4236-b736-030f11ca6ff3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae409a4f-4065-4a38-ac8d-81447767cd16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92c74e7a-30c1-4b8a-9f5c-579a596fbd61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9e9134b-680f-4e16-baa0-cd8a64b991b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_634cb392-9161-4709-9f2a-a13f53a4e68e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_427833e4-00a7-483a-9685-f0f6c211b01c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb6f0279-648d-4922-bffa-1e1ac712993d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sybx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02234d32-33f3-4416-bdc7-483f3c549a5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b16d8204-0369-41df-93d2-7ec43c203587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_967baf2d-6be3-4b7f-ae16-eff0641c22f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d51691b1-bfd1-4bf1-a65f-d5da006787a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cec03e1-9dc1-4ffd-9623-0c876a46a0c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">sybx:OptionsExercisableToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c420274-37ac-41c4-9722-54e874446423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bc26f36-034f-4f53-93d9-b443f6b5e6c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e186ace1-c417-4554-ab06-b27470bd2ea0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cc1a710-27f8-444c-90e6-5c3676f0f7bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_436ec13c-b090-47c3-b27f-abd9ac6ebda8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sybx:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_526bc3f6-6d8d-4822-b52e-24e5d384e725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3282432a-339d-4c93-9545-b3ee55a0a3ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9404c746-39af-4f16-b76d-b8630bcb901d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54406899-ec4d-4081-a75a-a534c1e59a14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b914988-f15e-45d7-8299-f5e9f4596f51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_489afa5b-74fd-452f-b937-8e7dab8a46e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sybx:AzzurGroupLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:MasterContractServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e59e7474-5287-48e3-b13c-7a4105517fbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20e586e5-e63b-4dc5-be33-c69ee29693d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3c4febd-5bb8-42c3-974f-1da160403289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8434699-f20b-4949-8f3d-8de4ac28fe77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>sybx:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>sybx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>sybx:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_4518ba34-7fe5-4a26-958e-210cdeeec538" fromRefs="F_b1376be1-f20e-47e5-bdac-d1d9dcc329ea F_5154fc7b-67d1-47e6-ad1b-f94da79478e2"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e48cf6d-f676-43fd-8717-b6ebf371131f" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_5f10e957-12af-444e-b564-d58682b3b6b6" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2b64fa54-a2a8-4411-bed2-59975d95c997" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b361ea5c-f669-4f95-945e-c2cc6fc58c30" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_9a12eb00-ab18-400c-8da6-bf0a8d84f5ec" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cc32a7d4-e13f-4032-ba54-589bccf3d873" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dbf2f941-8d26-487e-99ef-0e2fa630a408" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16411f3d-25a4-427f-986a-857a3e80fd5e" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2eebe8ad-de28-4333-ad41-21f39dec349b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26-1824804</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81c303b6-1c12-4fca-b1cf-781f2b07fc6e" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">301 Binney St</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">., </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_47a877c4-f54a-4cc0-91e4-67c53a357d62" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 402</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09122a29-1d3a-4346-ab50-4bd338055d4b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81e25f1a-14ed-4b69-98a6-15ca8259d68a" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MA</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bb991efa-820b-4115-b128-8c734a7e2757" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02142</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_06dc931f-0aa3-418e-995f-abd45a1622e8" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9851dfd2-1031-4e36-9c92-494baa81c9e4" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">401-9975</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.346%;"></td>
    <td style="width:33.336%;"></td>
    <td style="width:33.318%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d55c798-7f64-4db2-a83c-7d3f99091602" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d73e592-882d-4c8f-b548-c086797613c3" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYBX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_76534ec9-1f07-407c-b7a6-11a7746f7525" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Global Market</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of The Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d95b44ba-2bf6-44c1-ab1d-431969b6087f" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3bdfc1d-ef63-49cf-b685-40d04f9b18b2" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2ddbb4ab-b738-4bfc-b86e-7c24106d13e6" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_04e1bb6a-4b42-4550-93b2-8b78d414a48e" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.898%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cb0ab9e7-3a40-4185-bac5-c4f128008550" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Small reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_5d28b42c-2387-4023-b938-8d1086ae36a5" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_3fc3ea9a-51a9-4478-adf3-320fc7af1a4d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.833%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_8e6fb8bb-383a-43ad-a659-6b0559e105b8" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.833%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.833%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.833%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    YES  </span><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_31aae5b6-0026-4a9a-858b-a7cfd29d7926" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    NO  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.833%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of common stock held by non-affiliates of the registrant as of June 30, 2022, the last business day of the registrant&#x2019;s most recently completed second quarter, was $</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d502e9d7-75fc-49a5-961d-179110d907c7" contextRef="C_2b98e403-528d-433b-81fb-64269d42e27a" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">41.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, computed based on the closing price of $1.15 per share on June 30, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 22, 2023 there were </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_348e6058-ae99-4e6a-a67b-b467c41d6e0e" contextRef="C_75851d76-14c4-43a0-8d91-11383d574278" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">67,728,025</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the registrant&#x2019;s common stock, par value $0.001 per share, outstanding.</span></p>
  <div style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ecf66e9f-524b-484c-9646-39b5199743e5" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant&#x2019;s definitive proxy statement for the 2023 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.259%;"></td>
    <td style="width:16.657%;"></td>
    <td style="width:12.204%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:13.343%;"></td>
    <td style="width:25.537%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditor Firm Id:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6a799ce8-5212-431a-9265-4cf83ea8ba5b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditor Name:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d35eae9-cc52-4ee5-be80-a498ed30ab90" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditor Location:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_783cb9cb-9824-491e-b670-e189e8a461ff" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts, U.S.</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:86.0%;"></td>
    <td style="width:4.0%;"></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_consolidated_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosureforeignjurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item16"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained herein are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;expects,&#x201d; &#x201c;intends,&#x201d; &#x201c;plans,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue&#x201d; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></p>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our research and development efforts;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initiation, progress, timing, costs and results of clinical trials for our product candidates;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time and costs involved in obtaining regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our collaborations with third parties;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The progress, timing and costs involved in developing manufacturing processes and in manufacturing products, as well as agreements with third-party manufacturers;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rate of progress and cost of our commercialization activities;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expenses we incur in marketing and selling our product candidates, if approved;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The revenue generated by sales of our product candidates, if approved;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The emergence of competing or complementary technological developments;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms and timing of any additional collaborative, licensing or other arrangements that we may establish;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The acquisition of businesses, products and technologies;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our need to implement additional infrastructure and internal systems;</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our need to add personnel and financial and management information systems to support our product development and potential future commercialization efforts, and to enable us to operate as a public company; </span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The extent to which our business is adversely impacted by the effects of the coronavirus outbreak (COVID-19) or by other health epidemics or pandemics; and</span></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other risks and uncertainties, including those listed under Part I, Item 1A. &#x201c;Risk Factors.&#x201d;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any forward-looking statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A. &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">siness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a late-stage clinical biotechnology company advancing the design and development of biotherapeutics based on synthetic biology. Synthetic biology is the application of engineering principles in the design of biological systems, genetic circuits and molecular components. We apply the power of synthetic biology to medicine, combining precision engineering with rational drug development to produce Synthetic Biotics: living probiotics genetically engineered to deliver therapeutic benefit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that this approach confers advantages in the design, development and commercialization of new medicines. Our drug candidates are designed through precise engineering to target validated biological pathways known in the pathophysiology of a given disease. Our current pipeline includes drug candidates that are all orally administered, based on the probiotic chassis of Escherichia coli Nissle 1917, which has more than one hundred years of human dosing experience. The activity of our drug candidates is restricted to the gastrointestinal (GI) tract, avoiding systemic exposure and associated risks that limit the success of other modalities.  Our drug candidates are also designed to be non-colonizing, and fully reversible via GI clearance. These attributes have allowed us to advance the development of potential medicines for both rare and common diseases, with a focus on metabolic and immunological indications. Our platform leverages manufacturing processes with familiar foundations, including fermentation and lyophilization, facilitating process design and scale-up, combined with unique and proprietary innovations tailored to our unique products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our founding, based upon technology from the Massachusetts Institute of Technology (MIT) in 2014, we have progressed our Synthetic Biotics to a pipeline of multiple drug candidates across different stages, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB1934 has successfully completed its Phase 2 study. We expect to start a pivotal, Phase 3 study of SYNB1934 for the treatment of patients with phenylketonuria (PKU) in the first half of 2023;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB8802, a potential treatment for enteric hyperoxaluria, a well-recognized cause of recurrent kidney stones, has demonstrated clinical proof of concept through a Phase 1b study in patients who have undergone Roux-en-Y gastric bypass surgery;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB1353, which was designed to consume methionine as a potential treatment for homocystinuria (HCU), has achieved proof of mechanism in a Phase 1 study in healthy volunteers and will be advancing towards a Phase 2 study; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB2081, which was announced as a drug candidate for gout this year, and is currently in IND-enabling studies; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our preclinical research focusing on immunological opportunities such as inflammatory bowel disease (IBD). </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_0.jpg" alt="img119790510_0.jpg" style="width:493px;height:286px;" />&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our mission is to treat diseases underserved by other modalities by researching, developing and commercializing a new class of medicines through the application of synthetic biology to therapeutics. We intend to become a differentiated, global biopharmaceutical company through our approach to Synthetic Biotics. Our near-term priorities include advancing SYNB1934 through Synpheny-3, our pivotal, Phase 3 trial.  We are also advancing our earlier-stage pipeline, while continually optimizing our approach to drug discovery, development and manufacturing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elements of our strategy include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advancing our rare metabolic portfolio, including SYNB1934 for PKU and SYNB1353 for HCU, through clinical development, registration and commercialization.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our formation, we have established expertise in rare metabolic disorders, and specifically inborn errors of metabolism.  Designing our Synthetic Biotics has entailed increasing knowledge of disease biology in diseases like PKU and HCU. Through our development work to date, we have established strong connections with the patient and clinician communities, a crucial requirement in drug development and commercialization in rare diseases. Given this investment, we believe that we are best suited to lead activities for late-stage development through commercialization for our rare metabolic portfolio.  For PKU, this includes initiation and execution of Synpheny-3, a pivotal Phase 3 study for SYNB1934, and for HCU, this includes advancing SYNB1353 to a Phase 2 study.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Progressing additional programs through clinical development via strategic partnerships: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2022, we achieved proof of concept for SYNB8802, in development for enteric hyperoxaluria, a well-recognized cause of recurrent kidney stones. During 2022 we also announced the naming of SYNB2081, a Synthetic Biotic designed to metabolize uric acid as a potential biotherapeutic for gout, which is currently in IND-enabling studies. We believe that both of these product candidates present compelling opportunities to help patients in significant need of new treatment options.  We also believe that the programs would be best enabled in partnership with organizations with clinical and regulatory experience and expertise in relevant therapeutic areas, which would be complementary to our expertise on the Synthetic Biotic platform, and benefit from the progress we continue to make in the rare metabolic space. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Optimizing the potential of Synthetic Biotics: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continually build on our leadership position in biotherapeutics based on synthetic biology. We add to our expertise in design, optimization, and manufacturing to ensure that we are advancing the best possible Synthetic Biotics to address serious medical needs. We pursue this internally, and through select collaborations such as those currently in place with F. Hoffmann-La Roche Ltd. (Roche Basel) and Hoffmann-La Roche Inc. (Roche US, and together with Roche Basel, Roche) and Ginkgo Bioworks, Inc. (Ginkgo). In 2019, we entered a collaboration with Ginkgo to discover additional preclinical assets, combining our approach to Synthetic Biotics with Ginkgo&#x2019;s Codebase and Foundry services. This collaboration has since resulted in SYNB1353 for HCU and SYNB2081 for gout. In 2021, we entered into a Pilot Collaboration and Option Agreement with Roche for the discovery of a novel Synthetic Biotic for an undisclosed novel target in IBD. During 2021, we received the upfront, nonrefundable technology access fee due under the terms of the agreement and achieved the first milestone payment for the completion of the research and development services for the first phase of the research plan. During 2022, we received a second milestone payment. We may opportunistically enter into collaborations around certain targets, product candidates or disease areas to maximize their market potential and expand our capabilities.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are supported by our Board of Directors and our Scientific Advisory Board, each of which offers complementary experience in drug discovery and development, as well as expertise in building public companies, management, commercialization, and business development. Our founding science came from the laboratories of MIT professors James Collins and Timothy Lu, who remain engaged in guiding development and application of our product engine as members of our Scientific Advisory Board.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline: Synthetic Biotics in Clinical Development</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current clinical-stage pipeline consists of drug candidates targeting significant medical needs caused by an underlying metabolic disorder.  These include SYNB1934, which we expect to enter a pivotal, Phase 3 study in PKU in the first half of 2023, and drug candidates designed to treat HCU, enteric hyperoxaluria, and gout. Our preclinical work includes additional metabolic disease research, target exploration, and focused efforts on immunology, specifically IBD.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_1.jpg" alt="img119790510_1.jpg" style="width:611px;height:309px;" />&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Pipeline: Metabolic Diseases</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Metabolic diseases are disorders resulting from defects or alterations in how our bodies break down or produce important metabolites or molecules. These can be caused by a genetic mutation, such as PKU or HCU, or organ dysfunction, such as enteric hyperoxaluria, or a combination of genetic predisposition and environmental factors, as is the case with gout. In patients with these diseases, the absence of certain enzymes causes metabolites to accumulate in the GI tract and systemically throughout the body. In patients with PKU and HCU, these metabolites can build up to toxic levels, resulting in life-threatening medical risks and/or serious complications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our PKU Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, based on the positive findings of the Synpheny-1 Phase 2 study, we confirmed that SYNB1934 would be the drug candidate to enter Synpheny-3, a pivotal, Phase 3 study expected to commence in the first half of 2023. SYNB1934 is an orally administered, non-systemically absorbed drug candidate based on the probiotic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle, genetically engineered to metabolize Phe. Findings to date support SYNB1934&#x2019;s potential to be an efficacious, safe, convenient, orally-administered medical option that can be used regardless of age, or genotype of PKU and can be used for both monotherapy or adjunctive treatment option. In January 2023, we announced that SYNB1934 was granted Rare Pediatric Drug Designation (RPDD) by the FDA. Prior to confirming SYNB1934 as the lead candidate, we developed a first-generation PKU drug candidate, SYNB1618, through Phase 2 studies. SYNB1618 received both Orphan Drug and Fast Track designations by the FDA, and a positive opinion for orphan designation from the European Medicines Agency (EMA). We expect to receive these designations for SYNB1934 given its similarity as a more potent version of SYNB1618.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Science of PKU</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PKU is an inherited metabolic disease that causes the amino acid phenylalanine (Phe) to build up in the body. Phe is found in the natural protein contained in foods including all meat and dairy products, most beans, grains and potatoes, as well as some artificial sweeteners. People with PKU have inherited genetic defects in the phenylalanine hydroxylase (PAH) enzyme, which is required to break down Phe, resulting in potentially neurotoxic levels. Uncontrolled Phe levels during childhood can interfere with normal brain development, causing permanent developmental disabilities, and severely elevated Phe levels at any age can result in neurocognitive symptoms such as slower cognition, difficulty concentrating or &#x201c;brain fog.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To reduce the risk of complications in PKU patients requires lifelong control of Phe levels. During the 1960&#x2019;s, countries began newborn screening to ensure that Phe control was implemented immediately through a highly restrictive, low-Phe diet to avoid permanent, severe intellectual disability. Per EU and U.S. guidelines, any newborn infant with a plasma Phe concentration of &gt;400&#x2013;600 &#x3bc;M should be started on a low-Phe diet as soon as possible. The diet includes extreme restrictions of natural foods to keep daily protein at levels that can be as low as 4-6 grams per day, This generally includes elimination of all sources of animal protein and dairy, legumes and nuts, and limited intake of bread, pasta, rice and some vegetables. Low-protein bread and pasta products made from starch are used to provide needed energy.  The dietary regimen required also includes the addition of amino acid-based, Phe-free formula or other specific medical foods to provide adequate protein, vitamins, minerals and energy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is extremely challenging to adhere to this restricted diet. Particular challenges arise during times of increasing independence during adolescence. Access to low protein foods can pose difficulties as they are costlier and less nutritious than their higher protein, non-modified equivalents, and the needed formula can also be costly or otherwise difficult to access.  As a result, the vast majority of people living with PKU, and especially adults living independently, have Phe levels well above the recognized targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is estimated that there are more than 150,000 people diagnosed with PKU living across the United States, Europe and Asia. They are typically diagnosed through newborn screening. Of these, the vast majority remain untreated, reflecting limitations of current treatment options.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Limitations of Current PKU Treatment Options</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are currently two medications that have been approved by the FDA, EMA, and other regulatory agencies globally as medical treatments for PKU based on safety and efficacy in reduction of plasma Phe levels. These approved medications provide precedents for clinical development and regulatory processes, yet have different limitations that we believe leave significant need for a new medical treatment approach for PKU, as outlined below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sapropterin dihydrochloride (Kuvan&#174;), a biopterin, was approved by the FDA in 20117, and is now as a generic in the United States and other markets in tablet and sachet formulations. Prior to genericization, Kuvan generated ~$500 million per year globally for Biomarin, despite use by only an estimated 15% of U.S. patients. Now, where available, a trial of sapropterin is standard of care for infants diagnosed with PKU, and those that respond with a sufficient reduction in Phe will remain on lifelong sapropterin treatment. However, we believe a significant proportion of sapropterin-responsive patients would still benefit from additional Phe-lowering, and we see this segment as an important opportunity for SYNB1934 as an adjunctive medical treatment option. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Palynziq&#174; Injection (pegvaliase-pqpz) was approved by the FDA in 2018 for adult patients with PKU and uncontrolled blood Phe. Due to instability and other complexities, the PAH enzyme that is impaired in PKU is not a viable candidate for enzyme replacement therapy. Palynziq is a pegylated form of recombinant phenylalanine ammonia lyase (PAL), a non-mammalian enzyme that also metabolizes Phe. Safety considerations include risk of severe allergic reactions, including a 10% risk of anaphylaxis, resulting in FDA labeling that includes a boxed warning and requirement to carry auto-injectable epinephrine at all times while they are taking the medication. Despite these challenges, Palynziq generated $255 million in 2022, largely from the United States, despite maintaining an estimated ~10% market share. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the limitations of sapropterin in terms of responder rates, and the safety challenges of Palynziq, we believe the approved therapies&#x2019; limitations leave a large majority of those living with PKU in need of an orally-administered medical treatment option that provides Phe-lowering efficacy with an acceptable safety and tolerability profile. We believe that SYNB1934, as a potentially safe, orally dosed product that provides significant and sustained reductions in Phe levels, and as both a monotherapy or adjunctive medical treatment option, could meet that need.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_2.jpg" alt="img119790510_2.jpg" style="width:709px;height:359px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SYNB1934 for PKU</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our approach to designing a Synthetic Biotic to metabolize Phe is based on a strain of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle engineered to metabolize Phe as it transits through the GI tract, thereby targeting both Phe from dietary sources, and Phe that has circulated to the GI tract via enterorecirculation. Phe metabolism is done through the addition of Phe-consuming L-amino acid deaminase (LAAD) and phenylalanine ammonia lyase (PAL) enzymes. The strains were also designed to produce a Phe transporter, PheP, which brings Phe into the cell, where it is metabolized by PAL. It is provided to patients as a sachet containing a lyophilized powder formulation, to be mixed with water and taken with meals, three times a day. This product presentation is familiar to PKU patients, as sapropterin is provided as a sachet, and often their nutritional supplemental formula requires mixing with liquid.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_3.jpg" alt="img119790510_3.jpg" style="width:707px;height:381px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB1934 was engineered as a next-generation version of first-generation PKU drug candidate SYNB1618, by modifying five amino acids in PAL, which increased productivity of PAL&#x2019;s conversion of Phe to the metabolic byproduct trans-Cinnamic acid (TCA). A detailed description of the engineering of SYNB1618 and data from preclinical studies in an animal model of disease and healthy non-human primates was published in 2018 (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nat. Biotechnol</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. 36, 857&#x2013;864 (2018)), and an overview of the engineering and early development of SYNB1934 was published in 2021 (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nat Commun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. 12, 6215 (2021)).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Phase 1 studies of healthy volunteers, both SYNB1618 and SYNB1934 have been found to be safe and well-tolerated at doses up to 2x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">live cells administered three times a day for seven days. Higher doses were associated with mild to moderate gastrointestinal symptoms, mainly nausea and vomiting. In July 2019, we announced data that demonstrated that SYNB1618 was safe and well-tolerated and achieved proof-of-mechanism of strain activity in both healthy volunteers and patients with PKU. Improved tolerability of the lyophilized SYNB1618 over the early liquid formulation enabled us to determine a maximally tolerated dose (MTD) to take forward to test in patients. In September 2021, we announced that Phase 1 results in healthy volunteers and predictive modeling indicate SYNB1934 may have greater potency than SYNB1618.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we shared positive top-line results from the Phase 2 Synpheny-1 study that demonstrated proof of concept in PKU patients for both candidates, and confirmed greater potency of SYNB1934 in PKU patients, the candidate that we have selected to advance to pivotal Phase 3 studies.  The complete results were presented at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting in March 2023. Results presented included successfully meeting the primary endpoint (change in area under the curve of D5-Phe following a meal challenge) for SYNB1618 and SYNB1934. The study also confirmed greater activity in PKU patients for SYNB1934, the next-generation Synthetic Biotic designed to consume Phe, as compared to first-generation candidate SYNB1618. Results for SYNB1934 included a -40% mean reduction in plasma Phe levels for SYNB1934, and -53% among those considered responders (with &gt;20% reduction from baseline). 60% of patients achieved the &gt;20% criteria for Phe reduction considered the threshold for a clinically meaningful response. The study also included experience with both candidates when provided in combination for patients who were already taking sapropterin (Kuvan) at baseline, indicating the potential for adjunctive medical treatment.  Safety and tolerability findings were consistent with prior experience and favorable, with no serious adverse events (SAE) across the PKU program, and those adverse events that did occur being predominantly GI in nature.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_4.jpg" alt="img119790510_4.jpg" style="width:693px;height:360px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the PKU program has included &gt;240 individuals dosed across four clinical trials. We anticipate starting Synpheny-3, the pivotal Phase 3 study of SYNB1934 as a potential treatment for PKU, in the first half of 2023. We expect that the design for this trial will build on the successful precedents provided by the two therapeutics that have already been approved by regulators as treatments for Phe-lowering in PKU.  Both of those currently approved medicines were approved based on a single, registrational study, with Phe-reduction as a primary endpoint, and share a similar, three-part structure to the design of their Phase 3 trials.  Synpheny-3 is expected to include both adults and adolescent patients between ages 12-18 years of age. We anticipate a separate study will be needed to support use in patients under 12 years of age.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are pursuing broad US and Ex-US patent protection for SYNB1934, including composition of matter patent exclusivity to 2041, composition of matter directed to the engineered bacterium and its drug formulation, and methods of treatment and administration &amp; manufacturing methods. Coverage will continue to grow as the program progresses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our HCU Program</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021 we announced the nomination of SYNB1353, a novel, orally administered, non-systemically absorbed drug candidate designed to lower plasma levels of homocysteine (Hcy) in patients with HCU by consuming methionine, a precursor to Hcy, in the GI tract. We also shared at that time that mechanistic modeling data suggests that SYNB1353 may lower plasma Hcy by up to 58%  and may increase protein intake in HCU patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, we announced that proof of mechanism was achieved with SYNB1353 through positive results in the Phase 1 study of healthy volunteers using a dietary model of HCU.  SYNB1353 has received Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA as a potential treatment for HCU.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Science of HCU</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HCU is a rare inherited metabolic disorder that affects the metabolism of the amino acid methionine (Met), a protein found in many foods including meat, fish, and dairy products. HCU is caused by a genetic defect which results in the absence of an enzyme known as cystathionine beta-synthase (CBS). When CBS is absent, Hcy and other toxic chemicals and their byproducts, including Met, build up in the blood and urine.  In HCU, elevated total homocysteine (tHcy) levels are associated with a multisystem disorder, including impairments of the eye (ectopia lentis and/or severe myopia), skeletal system (excessive height, long limbs, scoliosis, pectus excavatum), vascular system (thromboembolism), and CNS (development delay and intellectual disability). The goal in treating HCU is to reduce and control levels of tHcy, thereby reducing risk of acute, potentially life-threatening blood clots and chronic, multisystem complications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_5.jpg" alt="img119790510_5.jpg" style="width:720px;height:368px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is currently no cure for HCU and treatment options are limited. Patients must follow a rigid diet low in protein to avoid dietary Met intake. Other therapeutic approaches include vitamin supplements to minimize some of the disease side effects.  Approximately 5,000 individuals in the United States and Europe suffer from CBS or &#x201c;Classical&#x201d; HCU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Limitations of Current HCU Treatments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approved pharmacological treatment options for HCU are limited due to efficacy and tolerability. People with more mild phenotypes of HCU typically respond effectively to, and are sufficiently managed by, taking Vitamin B6 (also known as pyridoxine-responsive). Non-responders require a combination of betaine (brand name Cystadane&#174;) and a moderate to severe dietary Met restriction. The severely protein-restricted diet is complex and challenging to adhere to. Compliance with treatment often deteriorates, particularly in adolescence, as in other disorders requiring dietary adherence. Patients report significant challenges with the burden of the low protein diet, intake of amino acid mixtures, and the palatability of protein substitutes as well as betaine. Reaching tHcy treatment targets remains a challenge despite existing pharmacotherapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SYNB1353 for HCU</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A diet low in Met, a precursor to Hcy, is standard treatment for lowering tHcy levels in patients with HCU. This dietary model provided the scientific rationale for SYNB1353, which was engineered to produce an enzymatic pathway to metabolize Met, and thus lower plasma levels of tHcy. SYNB1353 metabolizes Met via the methionine decarboxylase (MetDC) enzymatic pathway, which prevents the conversion of Met into Hcy, thereby lowering tHcy in HCU patients and reducing risk of complications. SYNB1353 is taken as an orally administered, non-systemically absorbed live biotherapeutic drug candidate that, like our PKU drug candidates, is provided as a lyophilized powder in a sachet, to be orally administered with meals three times a day. We hold worldwide development and commercialization rights to SYNB1353, which was developed as part of our research collaboration with Ginkgo.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_6.jpg" alt="img119790510_6.jpg" style="width:706px;height:400px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, we announced that proof of mechanism was achieved with SYNB1353 through positive results in the Phase 1 study of healthy volunteers using a dietary model of HCU.  Top-line results demonstrated that SYNB1353 reduced in plasma Met when measured over 24 hours as area under the curve (AUC) following a Met meal challenge. SYNB1353 was generally well tolerated, and adverse events (AEs) were all mild to moderate, transient, and predominantly GI in nature. The frequency and severity of GI-related AEs were similar in the active and control group. During 2023, we plan to continue to progress development of SYNB1353 towards a Phase 2 study in patients with HCU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Enteric Hyperoxaluria Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB8802 is a novel, orally administered, non-systemically absorbed drug candidate being developed for the treatment of enteric hyperoxaluria, a chronic, progressive disease characterized by high levels of urinary oxalate (Uox), a well-recognized cause of recurrent kidney stones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enteric hyperoxaluria often occurs as a result of a primary insult to the bowel, such as Crohn&#x2019;s disease, short bowel syndrome, or surgical procedures such as Roux-en-Y bariatric weight-loss surgery.  This results in GI malabsorption, causing increased absorption of oxalate across the GI tract into the circulation. Oxalate crystals can damage kidneys, leading to chronic kidney disease and end-stage renal disease (ESRD). There are no approved treatments for enteric hyperoxaluria. SYNB8802 was designed using precision genetic engineering of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nissle to lower Uox levels by consuming oxalate through the addition of three different enzymes, which together convert oxalate to the byproduct formate. In 2021, we reported positive proof-of-mechanism for SYNB8802 from a Phase 1b study that demonstrated lowering of urinary and fecal oxalate levels in healthy volunteers with diet-induced hyperoxaluria, and in December 2022, we announced proof of concept based on the lowering of Uox in patients who have undergone Roux-en-Y gastric bypass surgery.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Science of Enteric Hyperoxaluria</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hyperoxaluria is a disease which results from excessive levels of oxalate in the body. Oxalate can be found naturally in the body or in foods with high oxalate levels such as leafy greens, potatoes, almonds, coffee, and beans. Humans do not have an inherent physiological need for oxalate and it is normally excreted through the kidney. Excessive levels of oxalate, when present in the urine, bind with calcium in the kidney and lead to nephrolithiasis (kidney stone formation), nephrocalcinosis, chronic kidney complications and renal disease.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a direct link between elevated Uox and increased probability of kidney stone events or other renal adverse outcomes in patients with enteric hyperoxaluria. Even modest reductions in Uox can reduce the odds of developing a kidney stone. A recent epidemiological study conducted in 297 patients with enteric hyperoxaluria demonstrated that a 20% reduction in Uox resulted in as much as a 25% reduction in the annual risk of having a kidney stone in the subsequent year in patients with recurrent kidney stones (D&#x2019;Costa, Nephrol Dial Transplant 2020).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The vast majority of hyperoxaluria cases are idiopathic, or of unknown origin. A small percentage are caused by rare, genetic disorders, and an estimated 12% of highly recurrent kidney stone formers generate oxalate stones due to a clear enteric etiology. Conditions that commonly result in enteric hyperoxaluria include inflammatory bowel disease, certain kinds of bariatric surgery, short bowel syndrome, cystic fibrosis and celiac disease.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are currently few approved treatments for primary hyperoxaluria, a rare genetic disease wherein the liver produces excessive levels of oxalate. Approved treatments for primary hyperoxaluria target the liver, and thus are not beneficial to patients with enteric hyperoxaluria, given its etiology is in GI malabsorption, and not hepatic over-production.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on qualitative market research and analyses using real world evidence, we estimate that there are 200,000 to 300,000 patients with recurrent kidney stones due to enteric hyperoxaluria in the United States. Currently there are no approved pharmacological therapies for the reduction of oxalate levels in the urine in patients with enteric hyperoxaluria. Existing treatment options are generally non-specific and include high fluid intake to increase urine output to more than two to three liters per day, a diet low in salt and oxalate, oral citrate and/or calcium and/or magnesium supplementation. We believe a clear need exists for therapies that lower dangerously high levels of Uox to reduce the risk of recurrent kidney stones in this patient population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_7.jpg" alt="img119790510_7.jpg" style="width:616px;height:329px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SYNB8802 and Enteric Hyperoxaluria</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, we announced the nomination of a clinical candidate for enteric hyperoxaluria, SYNB8802, which was designed using precision genetic engineering of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nissle to lower Uox levels by consuming oxalate throughout the GI tract.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In vivo studies in both mice and non-human primates demonstrated that SYNB8802 decreased Uox levels in an acute model of hyperoxaluria induced by dietary intervention. A detailed description of the engineering of SYNB8802 and data from these preclinical studies in an animal model of disease and healthy non-human primates was published in Molecular Systems Biology (Lubkowicz et al 2022).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we reported positive proof-of-mechanism for SYNB8802 from a Phase 1a study that demonstrated -29% lowering of Uox and significant fecal oxalate lowering in healthy volunteers with diet-induced hyperoxaluria. In December 2022, we shared data confirming that SYNB8802 demonstrated proof of concept through clinically significant -38% lowering of Uox in a Phase 1b study in patients with a history of gastric bypass surgery.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_8.jpg" alt="img119790510_8.jpg" style="width:693px;height:424px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB8802 has the potential to be the first approved medical treatment for enteric hyperoxaluria. Our approach will be to target an enriched, high risk patient population who represent the greatest unmet medical need due to a history of highly recurrent kidney stones due to enteric hyperoxaluria. Our focus in 2023 is to advance development activities with a focus on formulation and dose frequency evaluation, prior to a future registrational Phase 3 study utilizing a clinical endpoint that incorporates kidney stone formation and/or events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Gout Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB2081 is a Synthetic Biotic designed to consume uric acid in the GI tract with the goal of lowering systemic uric acid levels as a potential treatment for gout, a complex form of inflammatory arthritis. Current treatment options present limitations in both safety and efficacy. SYNB2081 presents a novel, orally administered, non-systemically absorbed drug candidate created through our research collaboration with Ginkgo, the leading horizontal platform for cell programming.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Science of Gout</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gout occurs when excess uric acid in the body forms crystals in the joints. Patients can experience symptoms such as intense joint pain, inflammation and redness, and limited range of motion in the affected joints due to excessive levels of uric acid. In</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addition, gout is a recognized risk factor in chronic kidney disease. Due to present limitations in current treatment options, we believe that there is a clear need for a new approach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gout Development Plan</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022 we announced SYNB2081 as our drug candidate for the potential treatment of gout and the second product to advance to clinical development through our collaboration with Ginkgo. Our plan is to continue moving SYNB2081 to the next stage of our drug development pipeline. SYNB2081 is currently in IND-enabling studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Pipeline Programs in Metabolic &amp; Immunological Diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Synthetic Biotic approach is well-suited for disease targets that are associated with validated biological pathways in metabolic and immunological diseases. For metabolic diseases, we have applied learnings across our programs in PKU, HCU, enteric hyperoxaluria and gout. In immunological diseases, we are focused on opportunities to address the significant need for new treatment modalities in IBD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IBD is a group of diseases characterized by significant local inflammation in the GI tract typically driven by T cells, activated macrophages and compromised function of the epithelial barrier. IBD pathogenesis is linked to both genetic and environmental factors and may be caused by altered interactions between gut microbes and the intestinal immune system. Compromised gut barrier function also plays a central role in autoimmune diseases pathogenesis. A single layer of epithelial cells separates the luminal contents of the gut from the host circulatory system and the immune cells in the body. Disrupting the epithelial layer can lead to pathological exposure of foreign antigens from the lumen resulting in increased susceptibility to autoimmune disorders. The interplay between the gut microbiota and the host is thought to play a key role in the maintenance of the epithelial barrier as well as homeostatic immunity. Thus, enhancing barrier function and reducing inflammation in the gastrointestinal tract are potential therapeutic mechanisms for the treatment or prevention of autoimmune disorders. Our Synthetic Biotic platform allows for the effective programming of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle to execute these functions, including the metabolic production of factors such as short chain fatty acids to enhance barrier function, and secreting proteins, such as immunomodulatory cytokines.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current approaches to treat IBD are focused on therapeutics that modulate the immune system and suppress inflammation. These therapies include steroids, such as prednisone, and tumor necrosis factor inhibitors, such as Humira&#174;(adalimumab). However, these approaches are associated with systemic immunosuppression, which includes greater susceptibility to infectious diseases and cancer. According to the CDC, in 2015 an estimated three million adults in the United States are reported as being diagnosed with IBD. In June 2021, we entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic for the treatment of IBD. In addition, we continue to advance additional, wholly-owned preclinical research efforts in IBD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among immune conditions, working to treat IBD allows us to leverage knowledge and expertise gained from our oral metabolic programs to develop living medicines that can act locally at the site of disease in the gut. Because our approach is based on local delivery to the site of inflammation and not on systemic administration, we anticipate that our Synthetic Biotics may offer an attractive safety profile in this therapeutic category, where safety is a particularly desirable attribute in a product profile compared to options available today.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We developed a portfolio of Synthetic Biotics to treat certain cancers which were designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. These Synthetic Biotics could be used in combination with other cancer therapies such as checkpoint inhibitors. Our Synthetic Biotic clinical immuno-oncology (IO) candidate was SYNB1891, an intratumorally administered Synthetic Biotic medicine engineered to act as a dual innate and adaptive immune activator. On November 10, 2021, we announced that our Phase 1 trial of SYNB1891 in combination with PD-L1 checkpoint inhibitor patients with advanced solid tumors or lymphoma had completed enrollment. No further studies are planned for SYNB1891 and we are focusing our research and development efforts specifically on metabolic and immunological diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designing and Developing Synthetic Biotics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synthetic Biotics have unique advantages as potentially safe, effective, orally administered biotherapeutics. Engineered microbes can be programmed to carry out functions that cannot be performed by conventional drug treatments, such as small molecules or antibodies. Unlike other targeted approaches such as gene or RNA-targeted therapies, Synthetic Biotics are reversible, as they are engineered to be non-colonizing and are rapidly cleared via excretion. They have a reduced risk of adverse events due to the lack of systemic absorption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Using Synthetic Biology to Generate Synthetic Biotics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bacteria have evolved over millions of years to adapt, survive, and actively metabolize to consume or produce metabolites in the human body. They are also amenable to genetic manipulation. To confer a therapeutic effect, we use basic biological properties of bacteria and the tools of synthetic biology to develop Synthetic Biotics from non-pathogenic microbes, focusing initially on a single strain of the bacteria </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nissle.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our scientists genetically engineer probiotic, non-pathogenic bacteria to create biological circuits to direct cellular processes in a manner analogous to designing electrical circuits. We aim to precisely and appropriately control the amount, location and activity of our Synthetic Biotics to address specific diseases and target biology of interest.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The critical parts of an engineered Synthetic Biotic medicine include (1) the &#x201c;chassis,&#x201d; or non-pathogenic bacterium, (2) the effector module, which is a gene or pathway encoding the core biological activity that provides the therapeutic function, and (3) tunable switches to precisely determine the circumstances under which the effector module will be active, as well as the potency, performance and output of the effectors themselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_9.jpg" alt="img119790510_9.jpg" style="width:453px;height:257px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Chassis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Our Synthetic Biotic platform starts with a well-characterized probiotic to serve as the chassis upon which we build our living medicines. Our research and development programs use </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle, which is one of many non-pathogenic probiotics isolated from the human microbiota. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nissle is non-colonizing and has been used as a probiotic bacterial supplement for many years to promote gut health. Clinical studies have demonstrated that </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle is rapidly cleared from most individuals with no significant safety issues (Clin. Transl. Sci. (2017) 00, 1&#x2014;8). We also observed complete clearance from subjects in our Phase 1 clinical trial of SYNB1618 in healthy volunteers (Puurunen et al 2021 Nature Metabolism 3; 1125-1132). We believe </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle's widespread use as a probiotic is evidence of its utility as a safe background chassis to apply synthetic biology to confer a therapeutic benefit. There are several additional features of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle organism that makes it an attractive chassis for our platform:</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:13.602%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8577281881525036%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle&#x2019;s genetic and metabolic machinery are well understood and provide a robust cellular context into which genetic information can be introduced with high efficiency and little or no damage to the fitness of the bacterium. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:13.602%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8577281881525036%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The advanced nature of the synthetic biology toolkit available for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle enables rapid iterative design, assembly, and testing of prototype product candidates and remains unique among other bacterial and cellular engineering approaches.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:13.602%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8577281881525036%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Starting from known principles of manufacturing helps de-risk Synlogic&#x2019;s proprietary large-scale manufacturing platform.</span></div></div>
  <div style="margin-left:13.602%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.8577281881525036%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a Gram-negative bacterium, with a protective outer wall, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle survives well in the human GI tract.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Effector Module or Circuit:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Synthetic Biotics have the advantage that they can be designed with multiple pathway components. We have engineered integration systems to direct stable insertion of multiple genetic circuits and pathways </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">into optimal chromosomal locations, or &#x201c;landing pads,&#x201d; of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nissle. This enables efficient and stable expression of multiple genes encoding enzymes and other proteins. Our approach allows us to engineer two types of mechanistic activities into our Synthetic Biotics: 1) we can engineer Synthetic Biotics capable of metabolic transformations that can substitute or compensate for missing or defective pathways in a patient, and 2) we can engineer Synthetic Biotics to produce therapeutically beneficial molecules.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:-3.618%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       The enzymatic pathways needed to produce or consume molecules are protected from the harsh GI environment by their location within the cell cytoplasm of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle, allowing them the potential to function throughout the GI tract. We have leveraged proprietary tools, know-how and intellectual property to build multiple Synthetic Biotics that produce therapeutically relevant effects in pre-clinical experiments. Progression of these product candidates in diseases with high unmet need is based on prioritizing those with feasible drug development paths in terms of availability of informative animal models and existence of biomarkers to guide efficient clinical development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tunable Switches:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We also design and engineer proprietary switches to control the activity of the genetic pathways we introduce into our Synthetic Biotics, with the goal of controlling the engineered circuit or its therapeutic output. To optimize the fitness and activity of a Synthetic Biotic, it is critical that the effector is activated at the appropriate time and place to mediate its function. Switches are based on engineering DNA elements called &#x201c;inducible promoters&#x201d; that are designed to respond to disease states, specific environmental signals, or exogenously added inducing molecules. Our goal is to design and develop Synthetic Biotics programmed with switches to produce therapeutic effects at precisely the right time and location such as the anaerobic environment of the gut, or in the context of local inflammation or other pathogenic factors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advantages of Synthetic Biotic Biotherapeutics</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our Synthetic Biotics will provide safe and effective therapies given the following attributes:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synthetic Biotics Have Potential to Address Unmet Needs Not Possible with Other Modalities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Degrading Toxic Metabolites:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Unlike other therapeutic approaches, Synthetic Biotics can be programmed with a unique mechanistic activity. In internal metabolic programs, we are engineering Synthetic Biotics with entire pathways designed to degrade or &#x201c;consume&#x201d; toxic metabolites. We believe that using a metabolizing pathway is advantageous compared to gene, RNA or enzyme replacement therapies because the latter are limited to targeting a single gene or protein defect and may require several unique drug products to address genetically heterogeneous patient populations. Compensating with an entire pathway delivered in bacteria Synthetic Biotics may provide a safe, therapeutic solution to broader disease populations as a single engineered therapeutic. Our clinical stage programs, SYNB1934, SYNB8802 and SYNB1353, are examples of Synthetic Biotics designed and engineered to eliminate metabolites from the GI tract and prevent their absorption. Learnings from these programs are being applied to additional preclinical programs where metabolite dysregulation is relevant to disease.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Production of Therapeutic Molecules:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Synthetic Biotics can also be programmed to produce beneficial molecules, such as bacterial metabolites that may improve disease or proteins that can be secreted from the bacteria into the local environment. Examples of this approach include production of short chain fatty acids (Reeves et al. DDW 2022), aryl hydrocarbon (AHR) agonists (Shu et al. DDW2022) and secretion of human IL-22 protein (Reeves et al. DDW 2022).</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combinations of Mechanisms:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> By incorporating multiple effectors or enzymes into a single strain, Synthetic Biotics have the potential to address multifactorial disease biology more effectively. For example, Synthetic Biotics can be engineered with multiple enzymes which consume toxic metabolites more effectively than a single effector could otherwise provide. Alternatively, pathways that degrade a metabolite of interest can be engineered into a Synthetic Biotic that also produces one or more therapeutic molecules.</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synthetic Biotics Have Potential to Reduce Safety Risks by</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Providing Local Therapeutic Delivery </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that when delivered locally, Synthetic Biotics have the potential to avoid the risks often associated with systemic therapies, especially when combinations of systemic therapies are required. Our Synthetic Biotic drug candidates are orally administered, and act locally while transiting through the gut. Consequently, they decrease toxic metabolite levels in the blood to provide a systemic therapeutic benefit to the patient. Given the potential for chronic oral dosing, Synthetic Biotics may have benefits in terms of dose prediction and reversibility of activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Synthetic Biotic Approach is a Favorable Engine for Pharmacology</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Features of our Synthetic Biotic product engine enable a highly efficient drug discovery and development with the potential of advancing clinical candidates more rapidly and efficiently than traditional approaches. We have demonstrated the ability to move a program from concept to clinical development within a year, and also to apply learnings across programs to facilitate development. Reasons for this include:</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli Nissle</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> chassis is used across programs. Because our lead programs are based on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle, experience can be leveraged broadly across the portfolio to further optimize the efficiency and reproducibility of discovery, development and manufacturing efforts. The non-colonizing nature of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle can be combined with engineering approaches to enhance safety in terms of impact on the patient and the environment. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle can be engineered to require a specific exogenous nutrient supplement for growth, which limits the ability to replicate in the human body and environment. By controlling replication, we can control the number of cells being administered to a patient, which limits patient-to-patient variability. Also, dependence on an essential nutritional supplement not available in the environment reduces biocontainment risk.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Predictive pharmacology and biomarkers. Synthetic Biotic programs are designed to achieve a target activity and support an iterative design-build-test cycle to improve performance for achieving this target. For example, Synthetic Biotic programs can be optimized by including multiple copies or regulated control of certain genes, by adding transporters for particular substrates or by optimizing enzymes for basic bacterial metabolism. These tools enable rational and iterative engineering cycles in the discovery phase.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biomarkers as indicators of mechanistic and clinical activity may also be engineered into Synthetic Biotics to drive optimization and decision-making. By assessing the activities of our Synthetic Biotic programs using in vitro and in vivo preclinical models, we can model activity in humans. As we progress through clinical studies, we expect our predictive pharmacology models are further refined to inform dosing and development decisions for our additional programs.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stability and manufacturing. Starting from known principles of manufacturing helps de-risk Synlogic&#x2019;s proprietary large-scale manufacturing platform. Our lead Synthetic Biotic programs have advanced the platform by defining manufacturing processes that can be used for the entire portfolio. Our use of synthetic biology switches permits the precise control of engineered metabolic pathway activation. We use switches to suppress effector activity during manufacturing, enabling development of reproducible processes for biomass generation while maintaining robust and cost-efficient scale up of product candidates.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing campaigns have demonstrated production reproducibility and robustness at multiple scales. The stability profile of our material has translated through the development and scale up efforts, supporting the shelf life of our strains. The implemented late stage and scale up capabilities have enabled us to produce 10,000 to 15,000 drug product doses at multiple strengths. In March 2022, we invested to expand our current good manufacturing practices (cGMP) clean-room space at the Azzur Group, LLC.  The expansion of our in-house manufacturing space allows us to produce scaled up drug substance to support late stage pivotal studies. Our solid formulation capabilities have enabled multiple drug product presentations. Depending on scale, we can manufacture drug product either internally within our in-house facility or externally at a large-scale fill finish CMO. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To accelerate the development and commercialization of Synthetic Biotics to patients, we have formed, and intend to seek, other opportunities to form strategic alliances with collaborators that can expand our pipeline of therapeutic development and product candidates. We also intend to seek additional opportunities to work with multiple academic, research and translational medicine organizations and entities to deepen our understanding and development of living medicines with the potential to treat disease and disorders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Roche</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, we entered into a Pilot Collaboration and Option Agreement (the Roche Collaboration and Option Agreement) with F. Hoffmann-La Roche Ltd (Roche Basel) and Hoffmann-La Roche Inc. (Roche US, and together with Roche Basel, Roche). Under the terms of the Roche Collaboration and Option Agreement, we and Roche will seek to collaborate to research and pre-clinically develop Synthetic Biotics for addressing an undisclosed novel target for the treatment of inflammatory bowel disease (the Product Candidate).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Roche Collaboration and Option Agreement, Roche agreed to pay us an upfront, nonrefundable technology access fee of $1.0 million, which we received in July 2021. In August 2022, the Company completed the research and development services for the second phase of the research plan and achieved a milestone payment of $1.5 million, which was paid by Roche in October 2022. We are eligible to receive up to $5.0 million in milestone payments upon the achievement of certain success criteria. Following the research period, Roche holds an exclusive option right (the Option) to negotiate a definitive Collaboration and License Agreement (CLA) for further development and commercialization of the Product Candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Roche Collaboration and Option Agreement, during the term of such agreement, each party has granted to the other party a non-exclusive, non-transferrable, non-sublicensable, royalty-free right and license to certain intellectual property and know-how controlled by such party, solely as necessary for the party to perform its obligations under the Roche Collaboration and Option Agreement. The parties have established a Joint Research Committee (JRC) to oversee and manage the execution of the underlying study plan for the Roche Collaboration and Option Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Collaboration and Option Agreement includes various representations, warranties, covenants, indemnities, and other customary provisions. Roche may terminate the Roche Collaboration and Option Agreement without cause immediately upon written notice where certain success criteria have been met for parts of the study plan, or upon ninety (90) days&#x2019; prior written notice to us. Either party may terminate the Roche Collaboration and Option Agreement in the event of an uncured material breach of the other party.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to perform the research and development under the Roche Collaboration and Option Agreement. We have received and are eligible to receive milestone payments from Roche upon the achievement of success criteria for respective milestones.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ginkgo Bioworks, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2019, we entered into an agreement with Ginkgo. The agreement provided an $80 million equity investment at a premium in Synlogic by Ginkgo and entry into a long-term strategic platform collaboration to expand and accelerate the development of Synlogic&#x2019;s pipeline of Synthetic Biotics. We are using Ginkgo&#x2019;s cell programming platform to build and test thousands of microbial strains to accelerate progression of early preclinical leads to drug candidates optimized for further clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the agreement, Ginkgo purchased 6,340,771 shares of our common stock and accompanying Pre-Funded Warrants (the Pre-Funded Warrants) to purchase up to 2,548,117 shares of our common stock, at a combined price of $9.00 per share and Pre-Funded Warrant. Gross proceeds were approximately $80 million. Under the agreement, we made a prepayment to Ginkgo of $30 million for its foundry services that are being provided to us over an initial term of five years which can be extended. Upon the expiration of such initial term and, if applicable, such additional period, any portion of our prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo. We have exclusive rights to any Synthetic Biotics that we develop as part of the collaboration and to intellectual property covering such products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Potential Future Collaborations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe strategic alliances can be important drivers for accelerating our goal of developing Synthetic Biotics, and we will continue to seek collaborators who can help fund, develop and commercialize our novel therapeutic candidates, particularly in large metabolic and immunological indications. As the potential application of our Synthetic Biotics platform is extremely broad, we also plan to continue to identify academic, research and translational medicine organizations and entities that can contribute expertise and resources to our programs, to allow us to expand our impact more rapidly to broader patient populations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property and Technology Licenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from our collaborators or other third parties. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in certain jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of synthetic biology. We additionally rely on data exclusivity, market exclusivity, and patent term extensions when available, and  are seeking and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">plan to rely on additional regulatory protection afforded through orphan drug designations when applicable. Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets; to maintain our licenses to use intellectual property owned by third parties; to defend and enforce our proprietary rights, including our patents; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe we are well positioned in terms of intellectual property because we:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Have built and expanded, and intend to continue expansion in, a broad worldwide portfolio of intellectual property, including patents and patent applications, in areas relevant to the development, manufacturing and formulation of human therapeutic products using live biotherapeutics based on synthetic biology; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intend to take additional steps, where appropriate, to further protect our intellectual property rights, including, for example, through the use of copyright and trademark protection, as well as regulatory protection available via orphan drug designations, data exclusivity, market exclusivity and patent term extensions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our intellectual property portfolio provides broad coverage of our Synthetic Biotic platform and applicable disease-related technologies. As of March 22, 2023, we had 182 Synlogic-owned patents and patent applications in U.S. and foreign jurisdictions, of which 46 have been issued or allowed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Synlogic Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disease-related applications</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The disease-related applications in our intellectual property portfolio relate to certain pathological conditions including, but not limited to, hyperammonemia, hyperphenylalaninemia, hyperoxaluria, homocystinuria, hyperuricemia, certain other inherited metabolic diseases and conditions, metabolic disorders, diseases and conditions associated with an inflammatory state, diseases associated with gut inflammation, compromised gut mucosal barrier (leaky gut), and various autoimmune disorders and provide coverage for engineered bacteria having genetic circuitry designed to specifically address those conditions and the associated disease states. The intellectual property portfolio provides coverage for engineered bacterial strain compositions, related formulations, methods of making the bacterial strains, methods of measuring strain activity, and methods for treating diseases. Currently, intellectual property relating to this technology includes pending applications in U.S. and foreign jurisdictions, as well as several issued U.S. patents directed to composition of matter and pharmaceutical composition claims covering our clinical candidates. The patent term for our current patents and patent applications have expiration dates ranging from December 2035 to December 2043, depending on the indication and excluding any patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platform Technology Applications</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the disease-related technology, our intellectual property portfolio also includes applications directed to platform technologies developed internally by us. Exemplary platform technologies include bacterial chassis-related and genetic circuitry-related technological developments, including, for example, improvements in inducible gene regulation, control of bacterial cell growth, including autoregulation thereof, and systems for importing metabolites, as well as systems for prevention production of potentially genotoxic metabolites. These platform technologies, and our intellectual property coverage thereof, are broadly applicable to our therapeutic Synthetic Biotics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General Considerations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the United States are effective for 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to account for delays in prosecution at the U.S. Patent and Trademark Office (USPTO) and/or to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. For regulatory delays, the restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective non-provisional filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent positions of companies like us are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of synthetic biology has emerged in the United States. The patent situation outside of the United States is even more uncertain. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us the future will be commercially useful in protecting our products and the methods used to manufacture those products. For additional risks, please see the section entitled &#x201c;Risk Factors&#x2014;Risks Related to Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trademarks</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our registered trademark portfolio currently contains 35 registered trademarks, 5 allowance and 4 pending applications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, we seek to protect our technology and product candidates, in part, by entering into confidentiality agreements with those who have access to our confidential information, including employees, contractors, consultants, collaborators, and advisors. In some circumstances, we may rely on trade secrets to protect our technology. We seek to preserve the integrity and confidentiality of our proprietary technology, trade secrets and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or may be independently discovered by competitors. To the extent that company employees, contractors, consultants, collaborators, and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology, inventions, improvements and products, please see the section entitled &#x201c;Risk Factors&#x2014;Risks Related to Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory Matters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Regulation and Product Approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the New Drug Application (NDA) process and a new biologic must be approved by the FDA through the Biologics License Application (BLA), process before such products may be legally marketed in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Drug Development Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates drugs and biologics under the Federal Food, Drug, and Cosmetic Act (FDCA) and in the case of biologics, also under the Public Health Service Act (PHSA) and implementing regulations. Our product candidates will be regulated by the FDA as biologics. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#x2019;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completion of required preclinical (or nonclinical) laboratory tests, animal studies and formulation studies performed in accordance with Good Laboratory Practice (GLP) and other applicable regulations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Submission to the FDA of an investigational new drug application (IND) which must become effective before shipment of investigational product for human clinical trials may begin;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval by an independent institutional review board (IRB) or ethics committee at each clinical trial site before each clinical trial may be initiated;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance of adequate and well-controlled human clinical trials performed in accordance with applicable IND regulations, Good Clinical Practice (GCP), and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Good Manufacturing Practice (GMP) to prepare a drug substance and drug product analyzed using validated analytical methods;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and approval of a companion diagnostic device, if the FDA or the sponsor believes that its use is essential for the safe and effective use of a corresponding product;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Submission to the FDA of a BLA for marketing approval, including payment of application user fees;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the biologic is produced to assess compliance with current Good Manufacturing Practice (cGMP) regulations to assure that the facilities, methods and controls are adequate to preserve the product&#x2019;s identity, strength, quality and purity;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential FDA audit of the clinical trial sites to assure compliance with GCP and the integrity of the clinical data submitted in support of the BLA; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the BLA, including satisfactory completion of an FDA advisory committee review of the product candidate, where appropriate or if applicable, prior to any commercial marketing or sale of the product in the United States.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry and formulation, animal toxicity and pharmacology studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The Consolidated Appropriations Act for 2023, signed into law on December 29, 2022, (P.L. 117-328) amended the FDCA and the Public Health Service Act to specify that nonclinical testing for drugs and biologics may, but is not required to, include </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> animal testing. According to the amended language, a sponsor may fulfill nonclinical testing requirements by completing various </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> assays (e.g., cell-based assays, organ chips, or microphysiological systems), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in silico</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> studies (i.e., computer modeling), other human or nonhuman biology-based tests (e.g., bioprinting), or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> animal tests. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. In June 2016, the FDA issued an updated guidance for the industry entitled &#x201c;Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing and Control Information,&#x201d; which included recommendations from the FDA regarding the chemistry, manufacturing and control information that should be included in an IND for early clinical trials with live biotherapeutic products. This guidance reflects the FDA&#x2019;s thinking on the topic at the time the guidance was issued and although it is not binding on the FDA or a sponsor, it provided us with additional information about what should be included in INDs for our Synthetic Biotic product candidates. The sponsor will also include in the IND a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if a first phase study lends itself to an efficacy evaluation. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after an IND for an investigational product candidate is submitted to the FDA and human clinical trials have been initiated. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about ongoing or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All clinical trials must be conducted under the supervision of one or more qualified investigators, and in accordance with GCP requirements. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB rules and regulations. Study subjects must sign the IRB-approved informed consent form in order to participate in the clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, an IRB representing each institution that is participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct a continuing review and reapprove the trial at least annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to clinical trial subjects. An IRB must operate in compliance with FDA regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1: The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is usually conducted in patients.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2: This phase involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3: Larger clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk: benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a BLA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the Consolidated Appropriations Act for 2023, Congress amended the FDCA to require sponsors of a Phase 3 clinical trial, or other &#x201c;pivotal study&#x201d; of a new drug to support marketing authorization, to submit a diversity action plan for such clinical trial. The action plan must include the sponsor&#x2019;s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. A sponsor must submit a diversity action plan to FDA by the time the sponsor submits the trial protocol to the agency for review. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. It is unknown at this time how the diversity action plan may affect Phase 3 trial planning and timing or what specific information FDA will expect in such plans, but if FDA objects to a sponsor&#x2019;s diversity action plan and requires the sponsor to amend the plan or take other actions, it may delay trial initiation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, cGMP or IRB requirements or if the product candidate has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. Phase 1, Phase 2, and Phase 3 clinical testing may not be completed successfully within any specified period, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the development of a new biologic, sponsors have the opportunity to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before a BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results with the FDA and to present their plans for the pivotal Phase 3 clinical trial that they believe will support approval of the investigational biologic. If this type of discussion occurs, a sponsor may be able to request a Special Protocol Assessment (SPA), the purpose of which is to reach agreement with the FDA on the design of the Phase 3 clinical trial protocol design and analysis that will form the primary basis of an efficacy claim.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete the additional animal studies that may be required for approval and must also develop additional information about the chemistry and physical characteristics of the biologic and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing acceptable quality batches of the product candidate and, among other things the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the IND is active and before approval, progress reports must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse reactions, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. The annual report is customarily submitted in the form of a Development Safety Update Report (DSUR) which is accepted as being equivalent to an IND Annual Report and also meets requirements of the EU (European Union) and International Conference on Harmonization (ICH).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of most clinical trials of FDA-regulated products are required to register and disclose specified clinical trial information, which is publicly available atClinicalTrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to submit the results of their clinical trials after completion, but disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The NIH&#x2019;s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both NIH and FDA recently began enforcing those requirements against non-compliant clinical trial sponsors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Review and Approval Processes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the nonclinical studies and clinical trials, along with detailed information relating to the product&#x2019;s chemistry, manufacturing, and controls, stability, quality control and product release procedures, proposed labeling, and other relevant information are submitted to the FDA as part of a BLA, requesting approval to market the product for one or more indications. The submission of a BLA is subject to the payment of a significant user fee (for example, for FY2023 this application fee exceeds $3.2 million); although a waiver of such fee may be obtained under certain limited circumstances, including where the biologic has been designated as an orphan drug. The sponsor of an approved BLA is also subject to an annual program fee, currently more than $390,000 per program. These fees are typically increased annually, but exemptions and waivers may be available under certain circumstances (such as a waiver for the first human drug application submitted by a qualifying small business and exemptions for orphan products).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews all BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept a BLA for filing. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification and a sponsor&#x2019;s process to respond to such inquiries. Specifically, the review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving a BLA, the FDA will typically conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. These pre-approval inspections may cover all facilities associated with the BLA submission, including component manufacturing, finished product manufacturing, and control testing laboratories. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with GCP requirements and the integrity of the clinical data submitted to the FDA. If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information. This may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance with GCP, the FDA may, for example, determine the data generated by the clinical site should be excluded from the primary efficacy analyses provided in the BLA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may refer any BLA including applications for novel biologic candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The approval process is lengthy and often difficult, and the FDA may refuse to approve a BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. Even if such data and information are submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the BLA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure, potent and effective and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#x2019;s continued identity, strength, quality, potency and purity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product receives regulatory approval, the approval is limited to the conditions of use (e.g., patient population, indication) described in the BLA, which could restrict the commercial value of the product. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require a sponsor to conduct Phase 4 testing which involves clinical trials designed to further assess a drug&#x2019;s safety and effectiveness after BLA approval and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a REMS (Risk Evaluation and Mitigation Strategies), to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Pediatric Research Equity Act (PREA), as amended, an initial BLA or certain supplements to a BLA for a novel product must contain data to assess the safety and effectiveness of the product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirement. Unless otherwise required by regulation, PREA does not typically apply to any therapeutic product for an indication for which orphan designation has been granted. The Food and Drug Administration Safety and Innovation Act (FDASIA), enacted in 2012, made permanent the PREA requirement that a sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (PSP), within sixty days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from pre-clinical studies, early phase clinical trials or other clinical development programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Term Restoration and Marketing Exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of our drugs, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (referred to as the Hatch Waxman Amendments). The Hatch Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one half the time between the effective date of an IND, and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for, prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of its currently-owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the filing of the relevant BLA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric exclusivity is a type of non-patent marketing exclusivity available in the United States, and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This six-month exclusivity may be granted if an NDA/BLA sponsor submits clinical pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application for the same drug/biologic. The issuance of a written request does not require the sponsor to undertake the described clinical trials. To date, we have not received or requested any FDA written requests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biologics Price Competition and Innovation Act of 2009</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, ACA), which included the Biologics Price Competition and Innovation Act (BPCIA), amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. A biosimilar product is defined as one that is highly similar to a reference product notwithstanding minor differences in clinically-inactive components and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. An interchangeable product is a biosimilar product that can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the BPCIA, a manufacturer may submit an abbreviated application for licensure of a biologic that is biosimilar to or interchangeable with an FDA-licensed reference biological product. This abbreviated approval pathway is intended to permit a biosimilar to come to market more quickly and less expensively than if a &#x201c;full&#x201d; BLA were submitted, by relying to some extent on the FDA&#x2019;s previous review and approval of the reference biologic to which the proposed product is similar.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the abbreviated approval pathway, the biosimilar applicant must demonstrate that the product is biosimilar based on data from (1) analytical studies showing that the biosimilar product is highly similar to the reference product; (2) animal studies (including toxicity); and (3) one or more clinical trials to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. If pediatric studies are performed and accepted by the FDA as responsive to a Written Request, the 12-year exclusivity period will be extended for an additional six months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#x201c;First licensure&#x201d; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#x201c;first licensure&#x201d; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The BPCIA is complex and is still being interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the FDA has approved a number of biosimilars, and numerous biosimilars have been approved in Europe. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars and interchangeable biosimilars.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally defined as a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use will be disclosed publicly by the FDA; the posting will also indicate whether a drug is no longer designated as an orphan drug. More than one product candidate may receive an orphan drug designation for the same indication. The benefits of orphan drug designation include research and development tax credits and exemption from FDA prescription drug user fees. Orphan drug designation, however, does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, if a product that receives orphan designation receives the first FDA approval for the orphan indication, the product is entitled to orphan drug exclusivity, which means that for seven years, the FDA is prohibited from approving any other applications to market the same drug or biological product for the same indication, except in limited circumstances described further below. Orphan exclusivity does not block the approval of a different drug or biologic for the same rare disease or condition, nor does it block the approval of the same drug or biologic for different conditions. As a result, even if one of our product candidates receive orphan exclusivity, the FDA can still approve different drugs or biologics for use in treating the same indication or disease, which could create a more competitive market for us. Additionally, if a drug or biologic designated as an orphan product receives marketing approval for an indication broader than what was designated, it may not be entitled to orphan drug exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Orphan exclusivity will not bar approval of another product with the same drug or biologic for the same condition under certain circumstances, including if a subsequent product with the same drug or biologic for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety or a major contribution to patient care, or if the company with orphan drug exclusivity cannot assure the availability of sufficient quantities of the drug or biologic to meet the needs of persons with the disease or condition for which the drug or biologic was designated. Thus, orphan drug exclusivity could also block the approval of one of our products for seven years if a competitor obtains approval of the same drug, as defined by the FDA, and we are not able to show the clinical superiority of our drug or if our product candidate is determined to be contained within the competitor&#x2019;s product for the same indication or disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent court cases have challenged FDA&#x2019;s approach to determining the scope of orphan drug exclusivity; however, at this time the agency continues to apply its long-standing interpretation of the governing regulations and has stated that it does not plan to change any orphan drug implementing regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2017, the FDA granted SYNB1618 Orphan Drug designation for the treatment of PKU and in November 2022, the FDA granted SYNB1353 Orphan Drug designation for the treatment of HCU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fast Track, Breakthrough Therapy, Rare Pediatric Disease and Priority Review Designations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include Fast Track designation, breakthrough therapy designation and priority review designation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To be eligible for a Fast Track designation, the FDA must determine, from the request of a sponsor, based on preclinical studies, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast Track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the NDA or BLA for a Fast Track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. In addition, Fast Track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging in the clinical trial process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, with the enactment of FDASIA in 2012, Congress created a new regulatory program for product candidates designated by FDA as &#x201c;breakthrough therapies&#x201d; upon a request made by the IND sponsors. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval of their respective marketing applications. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finally, the FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case- by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#x2019;s goal for taking action on a marketing application from ten months to six months for an original BLA or for an NDA for a new molecular entity from the date of filing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA grants Rare Pediatric Disease Designation (RPDD) for serious and life-threatening diseases that primarily affect individuals from birth to 18 years old and fewer than 200,000 persons in the U.S.  Under this program, a sponsor who receives an approval for a drug or biologic for a &#x201c;rare pediatric disease&#x201d; designation may qualify for a pediatric priority review voucher (pPRV) that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The Rare Pediatric Disease Priority Review Voucher program was reauthorized in the Creating Hope Reauthorization Act in December 2020, allowing a product that is designated as a product for a rare pediatric disease prior to October 1, 2024 to be eligible to receive a Priority Review Voucher upon approval of a qualifying NDA or BLA prior to October 1, 2026.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, Fast Track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2018, the FDA granted Fast Track designation for the use of SYNB1618 for the treatment of PKU. In August 2022, the FDA granted Fast Track designation for the use of SYNB1353 for the treatment of HCU. We expect to also receive Fast Track designation for SYNB1934, given prior receipt for SYNB1618 and regulatory interactions to date. In January of 2023, Synlogic announced the FDA&#x2019;s granting of RPDD for SYNB1353 for HCU and for SYNB1934 for PKU.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accelerated Approval Pathway</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accelerated approval pathway is usually contingent on a sponsor&#x2019;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#x2019;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of the drug. All promotional materials for product candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the Consolidated Appropriations Act for 2023, Congress provided FDA additional statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under the act&#x2019;s amendments to the FDCA, FDA may require the sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The sponsor must also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports are published on FDA&#x2019;s website. The amendments also give FDA the option of using expedited procedures to withdraw product approval if the sponsor&#x2019;s confirmatory trial fails to verify the claimed clinical benefits of the product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting biologics for unapproved uses or patient populations (i.e., &#x201c;off-label use&#x201d;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the applicant to develop additional data or conduct additional pre-clinical studies and clinical trials. The FDA may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and finished product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities before any product is approved and our commercial products can be manufactured. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic prescheduled or unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved BLA, including voluntary recall and regulatory sanctions as described below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur or are discovered after the product reaches the market. Later discovery of previously unknown problems with a product may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <p style="margin-left:2.96%;text-indent:-4.901%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></div></div>
  <p style="margin-left:2.133%;text-indent:-4.857%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of product approvals;</span></div></div>
  <p style="margin-left:2.133%;text-indent:-4.857%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <p style="margin-left:2.133%;text-indent:-4.857%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties; and</span></div></div>
  <p style="margin-left:2.133%;text-indent:-4.857%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Most recently, the Drug Supply Chain Security Act, or DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a ten&#x2011;year period that is expected to culminate in November 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative changes will be enacted, or FDA regulations, guidance or interpretations will be changed or what the impact of such changes, if any, may be.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing the performance of clinical trials outside the United States and commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">European Union drug development, review and approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, our product candidates also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of pre-clinical and clinical research in the European Union are subject to significant regulatory controls.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The new Clinical Trials Regulation, (EU) No 536/2014, which took effect on January 31, 2022, aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#x201c;EU clinical trial portal and database&#x201d;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the appointed reporting member state, whose assessment report is submitted for review by the sponsor and all other competent authorities of all European Union member states in which an application for authorization of a clinical trial has been submitted (Concerned Member States). Part II is assessed separately by each Concerned Member State. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the Concerned Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As in the United States, similar requirements for posting clinical trial information are described in the European Union (EudraCT) website: https://eudract.ema.europa.eu.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To obtain a marketing authorization of a drug in the European Union, we may submit marketing authorization applications, or MAA, either under the so-called centralized or national authorization procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Centralized procedure</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the European Medicines Agency (the EMA) that is valid in all EU member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use, or the CHMP. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding stop-clocks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">National authorization procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU member state, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the member states of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conditional approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In specific circumstances, EU legislation (Article 14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the risk-benefit balance of the product candidate is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) the product fulfills unmet medical needs and (4) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric studies</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">European Union regulatory exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">European Union orphan designation and exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The criteria for designating an orphan medicinal product in the European Union, are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </span></div></div>
  <p style="margin-left:5.467%;text-indent:-5.037%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The applicant consents to a second orphan medicinal product application; or </span></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The applicant cannot supply enough orphan medicinal product.</span></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PRIME designation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EMA grants access to the Priority Medicines, or PRIME, program to investigational medicines for which it determines there to be preliminary clinical data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated Agency contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies, or CAT, are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#x2019;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the E.U. market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United Kingdom Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From January 1, 2021, European Union law no longer directly applies in the United Kingdom. The United Kingdom has adopted existing European Union medicines regulation as standalone United Kingdom legislation with some amendments to reflect procedural and other requirements with respect to marketing authorizations and other regulatory provisions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market medicines in the United Kingdom, manufacturers must hold a United Kingdom authorization. On January 1, 2021, all European Union marketing authorizations were converted to United Kingdom marketing authorizations subject to a manufacturer opt-out. For a transitional period, Great Britain will adopt decisions taken by the European Commission on the approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of new marketing authorizations in the community marketing authorization procedure. Such applications must include all information provided to the EMA during the relevant licensing procedure including the final CHMP opinion. The MHRA&#x2019;s guidance states that the United Kingdom will have the power to take into account marketing authorizations made under the European Union decentralized and mutual recognition procedures. In addition, the MHRA&#x2019;s guidance has been updated to refer to new national licensing procedures including new routes of evaluation for novel and biotechnological products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United Kingdom medicines legislation is subject to future regulatory change under the Medicines and Medical Devices Act 2021. This act sets out a new framework for the adoption of medicines regulation.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Different rules will apply in Northern Ireland following implementation of the Northern Ireland Protocol. In Northern Ireland, European Union central marketing applications will continue to apply.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Trade and Cooperation Agreement contains an Annex in relation to medicinal products with the objective of facilitating availability of medicines, promotion of public health and consumer protection in respect of medicinal products between the United Kingdom and the European Union. The Annex provides for mutual recognition of Good Manufacturing Practice (GMP) inspections and certificates, meaning that manufacturing facilities do not need to undergo duplicate inspections for the two markets. The Annex establishes a Working Group on Medicinal Products to deal with matters under the Trade and Cooperation Agreement, facilitate co-operation and for the carrying out of technical discussions. It is expected that further bilateral discussions will continue with respect to regulatory areas not the subject of the Trade and Cooperation Agreement, including pharmacovigilance. The Trade and Cooperation Agreement also does not include reciprocal arrangements for the recognition of batch testing certification. However, the United Kingdom has listed approved countries, including the EEA which will enable United Kingdom importers and wholesales to recognize certain certification and regulatory standards. The European Commission has not adopted such recognition procedures.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is expected that the establishment of a separate United Kingdom authorization system, albeit with transitional recognition procedures in the United Kingdom, will lead to additional regulatory costs. In addition, additional regulatory costs will be incurred with respect to the lack of mutual recognition of batch testing and related regulatory measures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rest of the world regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage, Pricing and Reimbursement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of pharmaceutical products depend in significant part on the availability of third-party coverage and reimbursement. Third-party payors include government healthcare programs such as Medicare, managed care providers, private health insurers and other organizations. We anticipate third-party payors will provide reimbursement for our products. However, these third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors often rely on Medicare coverage policy and payment limitations in setting their own reimbursement rates but also have their own methods to individually establish coverage and reimbursement policies. As a result, obtaining coverage and adequate reimbursement can be a time-consuming and costly process. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost effectiveness of our products. Moreover, a payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. Our product candidates may not be considered cost effective. It is time-consuming and expensive for us to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medicare is a federal healthcare program administered by the federal government that covers individuals aged 65 and over as well as individuals with certain disabilities. Drugs may be covered under one or more sections of Medicare depending on the nature of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the drug and the conditions associated with and site of administration. For example, under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which provide coverage for outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medicare Part B covers most injectable drugs given in an in-patient setting and some drugs administered by a licensed medical provider in hospital outpatient departments and doctors&#x2019; offices. Medicare Part B is administered by Medicare Administrative Contractors, which generally have the responsibility of making coverage decisions. Subject to certain payment adjustments and limits, Medicare generally pays for a Part B-covered drug based on a percentage of manufacturer-reported average sales price, which is regularly updated. We believe that our product candidates that are intended to be administered intratumorally will be subject to the Medicare Part B rules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs. For example, the ACA enacted in March 2010, was expected to have a significant impact on the health care industry. The ACA has been under scrutiny by the U.S. Congress almost since its passage, and certain sections of the ACA have not been fully implemented or effectively repealed. As a result, its longevity continues to be uncertain. In addition, ongoing initiatives in the U.S. have increased and will continue to increase pressure on drug pricing. The announcement or adoption of any such initiative could have an adverse effect on potential revenues from any product candidate that we may successfully develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Moreover, a payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on our profitability placing the medicinal product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union and other countries do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution (arbitrage between low-priced and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other U.S. Health Care Laws and Regulations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our product candidates are approved in the United States, we will have to comply with various U.S. federal and state laws, rules and regulations pertaining to health care fraud and abuse, including anti-kickback laws and physician self-referral laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, including Medicare and Medicaid. These laws include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the AKS or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA or federal civil money penalties statute;</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payers if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program or making false statements relating to health care matters; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal transparency requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services (HHS) information related to payments and other transfers of value to physicians, certain advanced non-physician health care practitioners, and teaching hospitals or to entities or individuals at the request of, or designated on behalf of, such physicians, non-physician health care practitioners, and teaching hospitals as well as certain ownership and investment interests held by physicians and their immediate family members; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by nongovernmental third-party payors, including private insurers.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, HHS finalized significant changes to the regulations implementing the Anti-Kickback Statute, as well as the Physician Self-Referral Law (Stark Law) and the civil monetary penalty rules regarding beneficiary inducements, with the goal of offering the healthcare industry more flexibility and reducing the regulatory burden associated with those fraud and abuse laws, particularly with respect to value-based arrangements among industry participants.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finally, the majority of states also have statutes or regulations similar to the aforementioned federal laws, some of which are broader in scope and apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that business activities can be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that business arrangements with third parties comply with applicable healthcare laws and regulations is costly and time consuming. If business operations are found to be in violation of any of the laws described above or any other applicable governmental regulations a pharmaceutical manufacturer may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of operations, any of which could adversely affect a pharmaceutical manufacturer&#x2019;s ability to operate its business and the results of its operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Health Care Reform in the US and Potential Changes to Health Care Laws</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, Congress must reauthorize the FDA&#x2019;s user fee programs every five years and often makes changes to those programs in addition to policy or procedural changes that may be negotiated between the FDA and industry stakeholders as part of this periodic reauthorization process. Congress most recently reauthorized the user fee programs in September 2022 but without any substantive policy changes. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As previously mentioned, the primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies. For example, in March 2010, the Affordable Care Act was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#x2019; outpatient drugs coverage under Medicare Part D; and established a Center for Medicare Innovation at the U.S. Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court upheld the ACA when it dismissed a legal challenge to the ACA&#x2019;s constitutionality. Further legislative and regulatory changes under the ACA remain possible, although it is unknown what form any such changes or any law would take, and how or whether it may affect the biopharmaceutical industry as a whole or our business in the future. We expect that changes or additions to the ACA, the Medicare and Medicaid programs, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act that affect health care expenditures. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and was extended by the Consolidated Appropriations Act for 2023, and will remain in effect through 2032 unless additional Congressional action is taken.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Notably, on December 20, 2019, President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (the CREATES Act). The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#x201c;commercially reasonable, market-based terms.&#x201d; Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More recently, in August 2022, President Biden signed into the law the Inflation Reduction Act of 2022, or the IRA. Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the drug product&#x2019;s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negotiation, it is expected that the revenue generated from such drug will decrease. In addition to the IRA&#x2019;s drug price negotiation provisions, President Biden&#x2019;s Executive Order 14087, issued in October 2022, called for the CMS innovation center to prepare and submit a report to the White House on potential payment and delivery modes that would complement to IRA, lower drug costs, and promote access to innovative drugs. As of February 3, 2023 the report had not been released but it is expected to further inform the current Administration&#x2019;s priorities and activities in this area.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#x2019; ability to regulate pharmacy benefit managers (PBMs) and other members of the healthcare and pharmaceutical supply chain, an important decision that appears to be leading to further and more aggressive efforts by states in this area. The Federal Trade Commission in mid-2022 also launched sweeping investigations into the practices of the PBM industry that could lead to additional federal and state legislative or regulatory proposals targeting such entities&#x2019; operations, pharmacy networks, or financial arrangements. Significant efforts to change the PBM industry as it currently exists in the United States may affect the entire pharmaceutical supply chain and the business of other stakeholders, including biopharmaceutical developers like us. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug, which could have an adverse effect on customers for our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Regulatory Matters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. These operations may involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations may also produce hazardous waste products. We contract with third parties for the disposal of these materials and wastes. Our products are defined as Genetically Modified Organisms (GMO) or Genetically Modified Micro-organisms (GMM) and, dependent on their classification and containment, may be subject to regulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States does not have any federal legislation that is specific to genetically modified organisms. GMOs are regulated pursuant to health, safety, and environmental legislation governing conventional products. The U.S. approach to regulating GMOs is premised on the assumption that regulation should focus on the nature of the products, rather than the process in which they were produced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical development and marketing of GMM within the European Union, and elsewhere, falls under different regulations and practices in each country, which may involve approval by environmental or other regulatory bodies, as well as health authorities, and may establish the requirement for a risk assessment for the testing or authorization of the product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have made and continue to make significant investments in our manufacturing organization, including process development and cGMP production infrastructure to establish manufacturing processes designed to support production of clinical trial material. The manufacturing processes are designed to enable us to reproducibly manufacture high quality living medicines at clinical scale and, later, at commercial scale to enable approval of our product candidates. We have built a fully integrated development and manufacturing organization with an internal process development group, quality group and manufacturing capabilities with the lease of cGMP cleanroom space in Waltham, Massachusetts. This facility enables us to produce clinical trial material for early to mid-stage studies of our clinical pipeline. We continue to build the organization to support scale-up and development towards commercialization. We currently expect to continue to work with contract manufacturing organizations (CMOs) for production of late-stage clinical trial material.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trial material for our Phase 1 study of SYNB1618 for PKU were manufactured by a CMO. These first clinical trials used a frozen liquid and solid formulation as the drug presentation. Since then, we have made additional investment in our formulation development that optimizes our production of solid dose formulations for our clinical programs. The powder for oral suspension formulation capability allows us to produce a more user-friendly presentation for later stage clinical development and future commercial use. We are continuing to invest and investigate the utility of additional presentations for solid formulations of our Synthetic Biotics including capsules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To enable the production of high levels of cells, or biomass, we can engineer our Synthetic Biotics with switches. These switches are comprised of transcription factor and promoter pairs that allow for controlled expression of the therapeutic effectors produced by our Synthetic Biotics. To ensure the metabolic capacity of the cells is allotted to the production of a high level of biomass during manufacturing, the effector circuits in the Synthetic Biotic programs are not expressed during this growth phase. At the end of the manufacturing process, the circuits are then induced, or activated. This two-step approach was designed to enable a high level of biomass production as well as to deliver the required activity necessary at the time of administration. We continue to devote resources to process development and the generation of improved products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we progress in clinical development, we will need to increase our production scale to support late stage clinical trials and commercial manufacturing. We are in the process of assessing CMOs who meet our criteria to supply our late-stage clinical development and commercial supply. We will compare the merits of working with one or more CMOs who meet our criteria with the possibility of building cGMP manufacturing capacity and capabilities internally.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology industry is extremely competitive in the race to develop new products. While we believe we have significant competitive advantages with our industry-leading expertise in synthetic biology and metabolic engineering of non-pathogenic bacteria, our clinical development expertise, and strong intellectual property position, we currently face and will continue to face competition for our development programs from companies that use synthetic biology or cell therapy development platforms and from companies focused on more conventional therapeutic modalities such as small molecules and antibodies. The competition is likely to come from multiple sources, including larger pharmaceutical companies, biotechnology companies and academia. Many of these competitors may have access to greater capital and resources than us. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in accessing technologies to enable our programs. For any products that we may ultimately commercialize, not only will we compete with any existing therapies and those therapies currently in development, but we will also have to compete with new therapies that may become available in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors include other synthetic biology companies developing other synthetic biology methods, cellular and microbiome-based companies, DNA and RNA-based companies, as well as companies developing small molecules or other biologics. In the case of indications that we are targeting with our own Synthetic Biotics, competitors include, but are not limited to:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PKU</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:7.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.617714099641811%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BioMarin, Inc. has two approved products and a development-stage investigational therapy;</span></div></div>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:7.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.617714099641811%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PTC Therapeutics, Inc., Nestle Health Sciences S.A. (Codexis, Inc.), Homology Medicines, Inc. and Jnana Therapeutics have products in clinical trials; and</span></div></div>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:7.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.617714099641811%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agios Pharmaceuticals, Inc., Generation Bio Co., American Gene Technologies International Inc., SOM Biotech SL,  and others are developing product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HCU</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:7.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.617714099641811%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Travere Therapeutics, Inc. and Aeglea BioTherapeutics have products in clinical trials.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enteric hyperoxaluria</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:7.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.617714099641811%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Novome Biotechnologies, Inc. and Oxidien Pharmaceuticals, LLC have drug candidates in clinical trials; and</span></div></div>
  <p style="margin-left:10.84%;text-indent:7.477%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:7.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.617714099641811%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federation Bio, Inc. and others are developing product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gout</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:7.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.617714099641811%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selecta Biosciences, Jiangsu HengRui Medicine Co., Ltd., Horizon Pharma Inc., Dyve Biosciences, Arrowhead Pharmaceuticals, and HemoShear Therapeutics and others are developing product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Team: Executives, Founders and Scientific Advisors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our team of executives has proven track records of successfully translating scientific visions into successful commercial therapeutic products, solving complex issues in developing novel therapeutics and progressing new and novel products through regulatory approval. Our scientific founders, Timothy Lu, M.D., Ph.D., and James Collins, Ph.D., are experts in the emerging field of synthetic biology. In addition to our management team and founders, we have established advisory relationships with researchers and clinicians dedicated to the development of Synthetic Biotic therapeutic products for patients with significant unmet medical needs and whose expertise spans synthetic biology, metabolic engineering, metabolism, and immuno-modulation arenas. Our scientific advisors include Dr. Lu and Dr. Collins; Paul Miller, Ph.D., Christopher Voigt, Ph.D., Cammie Lesser, M.D., Ph.D. and Kristala Prather, Ph.D., experts in synthetic biology and bacterial metabolism. We expect to expand our advisory boards as we grow. All of our founders and advisors are equity holders in us and receive compensation as scientific advisors. Although they are regularly available for scientific consultation, our arrangements with these individuals do not entitle us to any of their existing or future intellectual property derived from their independent research or research with other third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 22, 2023, we had 72 full-time employees. Of our full-time employees, 58 were primarily engaged in research and development activities. None of our employees are subject to a collective bargaining agreement. We believe that we have good relations with our employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Talent Acquisition and Retention</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize that our employees are essential to our success. To this end, we support business growth by seeking to attract and retain best-in-class talent. We use internal and external resources to recruit highly skilled candidates for open positions. We believe that we are able to attract and retain the talent that is required to meet our business goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Total Rewards</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our total rewards philosophy has been to invest in our workforce by offering a competitive compensation and benefits package. We provide employees with compensation packages that include base salary, annual incentive bonuses and long-term equity incentive awards. We also offer comprehensive employee benefits, such as life, disability and health insurance, health savings and flexible spending accounts, paid time off, a 401(k) plan with market-competitive company matching contributions, and an Employee Stock Purchase Plan. It is our express intent to be an employer of choice in our industry by providing a market-competitive compensation and benefits package.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Health, Safety and Wellness</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have always invested, and will continue to invest, in the health, safety, and wellness of our employees. We provide our employees with access to a variety of innovative, flexible, and convenient health and wellness programs. Program benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact their financial well-being.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investments and the prioritization of employee health, safety, and wellness have taken on particular significance in light of the COVID-19 pandemic. To protect and support our team members, we have implemented health and safety measures that include maximizing personal workspaces, altering work schedules, mandating vaccines, and providing asymptomatic COVID-19 testing if requested. We continue to monitor this evolving situation and will continue to seek programs to educate and assist employees whenever possible.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diversity, Equity, and Inclusion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe a diverse workforce is critical to our success. Our mission is to value differences in races, ethnicities, religions, nationalities, genders, ages and sexual orientations, as well as education, skill sets and experience. We are focused on inclusive hiring practices, fair and equitable treatment, organizational flexibility and training and resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Training and Development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe in encouraging employees to be lifelong learners by providing ongoing learning and leadership training opportunities. While we strive to provide real-time recognition of employee performance, we have a formal annual review process not only to determine pay and equity adjustments tied to individual contributions, but to identify areas where employees may benefit from additional training and development opportunities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Information About Our Executive Officers and Directors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following persons were our executive officers and directors as of March 29, 2023:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.519%;"></td>
    <td style="width:3.657%;"></td>
    <td style="width:62.824%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Position</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Executive Officers</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aoife Brennan, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MB, BCh, BAO, MMSc</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Jensen</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Antoine Awad</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Operating Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Directors</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Peter Barrett, Ph.D.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of the Board of Directors, Partner at Atlas Venture</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Burgess, MB, CHB, Ph.D.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interim Chief Medical Officer, Turnstone Biologics</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lisa Kelly-Croswell</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SVP &amp; Chief Human Resources Officer, Boston Medical Center Health System</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Heffernan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer, Avenge Bio, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patricia Hurter, Ph.D.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer, Lyndra Therapeutics</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nick Leschly</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer, 2seventybio, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Edward Mathers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Partner at New Enterprise Associates</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard P. Shea</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting CFO, Danforth Advisors</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information and History</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were originally incorporated in the State of Delaware in December 2007 under the name &#x201c;Mirna Therapeutics, Inc.&#x201d; We carry on our business directly and through our subsidiaries.</span></p>
  <p style="text-indent:4.173%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our subsidiary, Synlogic Operating Company, Inc. was incorporated in Delaware as TMC Therapeutics, Inc. on March 14, 2014. On July 15, 2014, TMC Therapeutics, Inc. changed its name to Synlogic, Inc. (Private Synlogic when referred to prior to the Merger (as defined below)). On July 2, 2015, the common and preferred shareholders of Private Synlogic executed the Synlogic, LLC Contribution Agreement, pursuant to which such common and preferred shareholders contributed such shareholders&#x2019; equity interests in Private Synlogic in exchange for common and preferred units in a newly formed parent company named Synlogic, LLC (the 2015 Reorganization). In addition, IBDCo was formed as a subsidiary of Synlogic, LLC, as part of the 2015 Reorganization, and we entered into a license, option and merger agreement with AbbVie for the development of treatments for IBD. On December 22, 2021, IBDCo was merged with and into Synlogic Operating Company, Inc. and IBDCo ceased to exist as a separate entity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2017, Private Synlogic completed a reorganization (2017 Reorganization) pursuant to which Synlogic, LLC merged with and into Private Synlogic, with Private Synlogic continuing as the surviving corporation. Pursuant to the 2017 Reorganization, the common units and preferred units of Synlogic, LLC, together consisting of Class A preferred units, contingently redeemable Class A preferred units and Class B preferred units, were exchanged for common stock and preferred stock of Private Synlogic, respectively. Additionally, Private Synlogic issued equity awards under the Synlogic 2017 Stock Incentive Plan (2017 Plan) to replace the canceled incentive units pursuant to the termination of the Synlogic, LLC 2015 Equity Incentive Plan (2015 LLC Plan).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 28, 2017, Synlogic, Inc., formerly known as Mirna Therapeutics, Inc. (NASDAQ: MIRN) (Mirna), completed its business combination with Private Synlogic pursuant to the Agreement and Plan of Merger and Reorganization, dated as of May 15, 2017, by and among Mirna, Meerkat Merger Sub, Inc. (Merger Sub), and Private Synlogic (the Merger Agreement), pursuant to which Merger Sub merged with and into Private Synlogic, with Private Synlogic surviving as a wholly owned subsidiary of Mirna (the &#x201c;Merger&#x201d;). On August 25, 2017, in connection with, and prior to the completion of the Merger, Mirna effected a reverse stock split of its common stock (the Reverse Stock Split), and on August 28, 2017, immediately after completion of the Merger, Mirna changed its name to &#x201c;Synlogic, Inc.&#x201d; (NASDAQ: SYBX).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Merger Agreement, Mirna issued shares of its common stock to Private Synlogic&#x2019;s stockholders, using an exchange ratio, after taking into account the Reverse Stock Split, for each share of Private Synlogic common stock and preferred stock outstanding immediately prior to the Merger (Exchange Ratio). In addition, Mirna assumed all of the stock options outstanding under the Synlogic 2017 Stock Incentive Plan (2017 Plan), with such stock options henceforth representing the right to purchase a number of shares of Mirna&#x2019;s common stock equal to the Exchange Ratio multiplied by the number of shares of Private Synlogic common stock previously represented by such options. Mirna also assumed the 2017 Plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Internet address is www.synlogictx.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through our website as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the Securities and Exchange Commission (SEC).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. Our business, prospects, financial condition or operating results could be materially adversely affected by the risks identified below, as well as other risks not currently known to us or that we currently consider immaterial. Furthermore, these factors represent risks and uncertainties that could cause actual results to differ materially from those implied by forward-looking statements. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in this Annual Report on Form 10-K and our other public filings with the SEC. The following risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the following discussion of risk factors, References to &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d; and similar terms refer to the combined business of Synlogic, Inc. after the Merger on August 28, 2017.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those highlighted in this section below, that represent challenges that we face in connection with the successful implementation of our strategy. The occurrence of one or more of the events or circumstances described in more detail in the risk factors below, alone or in combination with other events or circumstances, may have an adverse effect on our business, cash flows, financial condition and results of operations. Such risks include, but are not limited to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a history of losses, and we expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional funding, which may not be available on acceptable terms, or at all. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our quarterly and annual operating results may fluctuate in the future. As a result, we may fail to meet the expectations of research analysts or investors, which could cause our stock price to decline. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price is volatile, and our stockholders may not be able to resell shares of our common stock at or above the price they paid. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our short operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The approach we are taking to discover and develop novel therapeutics using synthetic biology to create novel medicines is unproven and may never lead to marketable products. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our costs might be higher than expected and our receipt of necessary regulatory approvals could be delayed or prevented. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may face potential product liability claims, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our product candidates harm patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals, if any, could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. If we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage, such liability could adversely affect our financial condition. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, or geopolitical tensions, such as the armed conflict between Russia and Ukraine, may materially and adversely affect our business and our financial results.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to, or may in the future become subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and process personal information. Our actual or perceived failure to comply with such obligations could result in liability or reputational harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition or results of operations. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ethical, legal and social concerns about synthetic biology and genetic engineering could limit or prevent the use of our technologies and limit our revenues. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to Synthetic Biotics, product candidates and processes for our development pipeline through acquisitions and in-licenses. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have sufficient patent term protections for our product candidates to effectively protect our business. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct some aspects of our product formulation, research, preclinical, and clinical studies, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such formulation, research or testing. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party supply and manufacturing partners for drug supplies for our late-stage clinical activities and may do the same for any commercial supplies of our product candidates. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face substantial competition, and our competitors may discover, develop or commercialize products faster or more successfully than us. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our employees, independent contractors, principal investigators, CROs, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our employment agreements with our executive officers may require us to pay severance benefits to any of those persons who are terminated in connection with a change of control, which could harm our business, financial condition or results of operations. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future sales of our common stock or securities convertible or exchangeable for our common stock may depress our stock price. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders and could make it more difficult for you to change management. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not anticipate paying any cash dividends on our common stock in the foreseeable future; therefore, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may fail to comply with the continued listing requirements of the Nasdaq Global Market, such that our common stock may be delisted and the price of our common stock and its ability to access the capital markets could be negatively impacted. We have received a written notice from Nasdaq regarding our failure to meet the listing requirements by Nasdaq, which has triggered a 180 calendar-day grace period for us to regain compliance.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Condition, Capital Requirements and Operating Results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a history of losses, and we expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on the development of Synthetic Biotics and we have incurred significant operating losses since our inception. Our net loss was approximately $66.1 million and $60.6 million for the fiscal years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of approximately $357.0 million. To date, we have not generated any product revenue. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We have no products on the market and expect that it will be many years, if ever, before we have a product candidate approved for commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials, the regulatory review process for product candidates, and the development of manufacturing and marketing capabilities for any product candidates approved for commercial sale. The amount of our potential future losses is uncertain. To achieve profitability, we must successfully develop product candidates, obtain regulatory approvals to market and commercialize product candidates, manufacture any approved product candidates on commercially reasonable terms, establish a sales and marketing organization or suitable third-party alternatives for any approved product candidates and raise sufficient funds to finance our business activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in our value could also cause our stockholders to lose all or part of their investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require substantial additional funding, which may not be available on acceptable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have used substantial funds to discover and develop our programs and proprietary drug development platform in synthetic biology and will require substantial additional funds to conduct further research and development, including preclinical studies and clinical trials of our product candidates, seek regulatory approvals for our product candidates and manufacture and market any products that are approved for commercial sale. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and corporate activities. Because we cannot be certain of the length of time or activities associated with successful development and commercialization of our product candidates, we are unable to estimate the actual funds we will require to develop and commercialize them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not expect to realize any appreciable revenue from product sales or royalties in the foreseeable future, if at all. Our revenue sources will remain very limited unless and until our product candidates complete clinical development and are approved for commercialization and successfully marketed or we enter into third-party arrangements with collaborators. To date, we have primarily financed our operations through sales of our securities, our third-party collaborations and the Merger. We intend to seek additional funding in the future through collaborations, equity or debt financings, credit or loan facilities or a combination of one or more of these financing sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity or convertible debt securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of equity securities received any distribution of corporate assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain funding on a timely basis or on acceptable terms, or at all, we may have to delay, limit or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our product candidates or technologies that we would otherwise pursue on our own.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our quarterly and annual operating results may fluctuate in the future. As a result, we may fail to meet the expectations of research analysts or investors, which could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financial condition and operating results may fluctuate from quarter to quarter and year to year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following factors, as well as factors described elsewhere in this Annual Report on Form 10-K and others:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to achieve or maintain profitability; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to develop and maintain Synthetic Biotic technologies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to manage our growth; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outcomes of research programs, clinical trials, or other product development and approval processes; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to accurately report our financial results in a timely manner; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our dependence on, and the need to attract and retain, key management and other personnel; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to obtain, protect and enforce our intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to achieve milestones with our collaborators, such as Roche;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential advantages that our competitors and potential competitors may have in securing funding or developing competing technologies or products; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to obtain additional capital that may be necessary to expand our business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the various factors mentioned above, and others, the results of any prior quarterly or annual periods should not be relied upon as indications of our future operating performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our stock price is volatile, and our stockholders may not be able to resell shares of our common stock at or above the price they paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, such as reports by industry analysts, investor perceptions, general industry trends, macro-economic conditions, or negative announcements by other companies involving similar technologies or diseases. These factors also include those discussed in this &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K and others such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcements relating to collaborations that we may enter into with respect to the development or commercialization of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcements relating to the receipt, modification or termination of government contracts or grants; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination or delay of a development program; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product liability claims related to our clinical trials or product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prevailing economic conditions; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Perspectives on synthetic biology and genetic engineering;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Perspectives on the programs of competitors;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions or departures of key personnel; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business disruptions caused by natural disasters; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disputes concerning our intellectual property or other proprietary rights; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA or other U.S. or foreign regulatory actions affecting us or our industry; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of our common stock by the company, our executive officers and directors or our stockholders in the future; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future sales or issuances of equity or debt securities by us; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lack of an active, liquid and orderly market in our common stock; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fluctuations in our quarterly operating results; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of new or changed securities analysts&#x2019; reports or recommendations regarding us. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that have been often unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our short operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history. We commenced active operations in 2014. Our operations to date have been limited to organizing and staffing our company, research and development activities, business planning and raising capital. We will need to transition from a company with a focus on research and clinical development to a company capable of commercial activities. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Typically, it takes many years to develop one new product candidate from the time it is discovered to the time that it becomes available for treating patients. We may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may hinder our success in commercializing one or more of our product candidates. Further, drug development is a capital-intensive and highly speculative undertaking that involves a substantial degree of risk. You should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development and clinical trials. Any forward-looking statements regarding our future prospects, plans or viability may not be as accurate as they may be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or the FDIC, as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although a statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we review our banking relationships as we believe appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of access to working capital sources; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential or actual breach of contractual obligations that require us to maintain letters or credit or other credit support arrangements; or </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by parties with whom we conduct business, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Development of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical trials are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical development of a product candidate is expensive, time consuming and involves significant risk. We cannot guarantee that any clinical trials we undertake to conduct will be conducted as planned or completed on schedule or at all. A failure of one or more clinical trials can occur at any stage of development. Events that may prevent successful or timely completion of clinical development of our product candidates include but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inability to generate satisfactory preclinical or other nonclinical data, including, toxicology, or other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> data or diagnostics to support the initiation or continuation of clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays in reaching agreement on acceptable terms with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays in obtaining required institutional review board approval at each clinical trial site; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to permit the conduct of a clinical trial by regulatory authorities, after review of an investigational new drug or equivalent foreign application or amendment; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays in recruiting qualified patients in our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure by clinical sites or CROs or other third parties to adhere to clinical trial requirements; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure by us, clinical sites, CROs or other third parties to perform in accordance with the good clinical practices requirements of the FDA or applicable foreign regulatory guidelines; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients dropping out of the clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Occurrence of adverse events, unacceptable side effects or toxicity issues associated with our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Imposition by the FDA of a clinical hold or the requirement by other similar regulatory agencies that one or more clinical trials be delayed or halted; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in regulatory requirements and guidance that require amending or submitting new clinical protocols or performing additional nonclinical studies; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ultimate affordability of the cost of clinical trials of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Negative or inconclusive results from our clinical trials that may result in us deciding, or regulators requiring us, to conduct additional clinical trials or abandon such clinical trials and/or clinical trials or development programs in other ongoing or planned indications for a product candidate; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays in identifying or reaching agreement on acceptable terms with third-party manufacturers, delays in developing and transferring a reproducible, scalable manufacturing process, or delays or failure in manufacturing sufficient quantities of our product candidates for use in clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any inability to successfully complete clinical development and obtain regulatory approval for our product candidates could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional preclinical studies and/or clinical trials, or the results obtained from such new formulation may not be consistent with previous results obtained. Clinical trial delays could also shorten any anticipated periods of patent exclusivity for our product candidates and may allow competitors to develop and bring products to market before we do which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The approach we are taking to discover and develop novel therapeutics using synthetic biology to create novel medicines is unproven and may never lead to marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scientific discoveries that form the basis for our efforts to generate and develop our product candidates are relatively recent. The scientific evidence to support the feasibility of developing drugs based on our approach is both preliminary and limited. Synthetic Biotics represent a novel therapeutic modality and their successful development by us may require additional studies and efforts to optimize their therapeutic potential. Any product candidates that we develop may not demonstrate in patients the therapeutic properties ascribed to them in laboratory and other preclinical studies, and they may interact with human biological systems in unforeseen, ineffective or even harmful ways. We have also not yet succeeded and may never succeed in demonstrating efficacy and safety for our current or any future product candidates in a pivotal clinical trial. If we are not able to successfully develop and commercialize product candidates based upon this technological approach, we may never become profitable, and the value of our capital stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Synthetic Biotic product candidates are based on a relatively novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have concentrated our research and development efforts to date on a limited number of product candidates based on our Synthetic Biotic therapeutic platform, including demonstrating proof of concept for SYNB1934 for PKU, proof of concept for SYNB8802 for enteric hyperoxaluria, and proof of mechanism for SYNB1353 for HCU. Our future success depends on our successful development of viable product candidates. There can be no assurance that we will not experience problems or delays in developing our product candidates and that such problems or delays will not cause unanticipated costs, or that any such development problems can be solved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical trial and manufacturing requirements of the FDA, the EMA and other regulatory authorities, and the criteria these regulators use to determine the safety and efficacy of a product candidate, vary substantially according to the type, complexity, novelty and intended use and market of the product candidate. The regulatory approval process for novel product candidates such as Synthetic Biotics may be more expensive and take longer than for other, better known or more extensively studied therapeutic modalities. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in either the United States or the European Union or how long it will take to commercialize our product candidates, even if approved for marketing. Approvals by the EMA or national regulatory agencies may not be indicative of what the FDA, and vice versa, may require for approval and different or additional preclinical studies or clinical trials may be required to support regulatory approval in each respective jurisdiction. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to use and expand our development platform to build a pipeline of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A key element of our strategy is to use our targeted focus and experienced management and scientific team to create Synthetic Biotics that can be deployed against a broad range of human diseases in order to build a pipeline of product candidates. Although our research and development efforts to date have resulted in potential product candidates, we may not be able to continue to identify and develop additional product candidates. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. For example, these potential product candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position. There is no assurance that we will be successful in our preclinical and clinical development, and the process of obtaining regulatory approvals will, in any event, require the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or terminate our clinical trials or result in a restrictive label or delay regulatory approval by the FDA or comparable foreign authorities. Undesirable side effects and negative results for other indications may negatively impact the development and potential for approval of our product candidates for their proposed indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, even if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities may withdraw approvals of or revoke licenses for such products; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities may require additional warnings on the labels of such products; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to conduct additional clinical trials or costly post-marketing testing and surveillance to monitor the safety of the product;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product development program may not uncover all possible adverse events that patients who take our product candidates may experience. The number of subjects exposed to our product candidates during clinical trials and the average exposure time in the clinical development program may be inadequate to detect rare adverse events, or chance findings, that may only be detected once the product is administered to more patients and for greater periods of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials by their nature use a sample of the potential patient population. However, with a limited number of patients and limited duration of exposure, we cannot be fully assured that uncommon or severe side effects of our product candidates will be uncovered. Such side effects may only be uncovered with a significantly larger number of patients exposed to the drug. If such safety problems occur or are identified after a product candidate reaches the market, the FDA may require that we amend the labeling of the product or recall the product or may even withdraw approval for the product. Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are heavily dependent on the success of our product candidates. Some of our product candidates have produced results in preclinical and clinical settings to date, but none of our product candidates have completed all required clinical trials, and we cannot give any assurance that we will generate data for any of our product candidates sufficient to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have invested substantially all of our efforts and financial resources to identify, acquire and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully further develop, obtain regulatory approval for, and commercialize one or more product candidates. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, none of our product candidates have advanced into any pivotal clinical trial for our proposed indications and it may be years before any pivotal clinical trials are initiated and completed, if at all. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to obtain or maintain orphan drug exclusivity for some of our products, our competitors may obtain approval to sell competing drugs to treat the same conditions and our revenues will be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our business strategy, we have developed and may in the future develop product candidates that may be eligible for FDA and European Commission orphan drug designation. In October 2017, the FDA granted orphan drug designation to SYNB1618 for the treatment of PKU. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat, diagnose or prevent rare diseases or conditions that affect fewer than 200,000 people in the United States. In the EU, orphan drug designation may be granted to drugs intended to treat, diagnose or prevent a life-threatening or chronically debilitating disease having a prevalence of no more than five in 10,000 people in the EU. In May 2022, the EMA granted orphan designation to SYNB1618 for the treatment of PKU. In November 2022, we received orphan drug designation from the FDA for SYNB1353 as a potential treatment for HCU. The company that first obtains FDA approval for a designated orphan drug for the associated rare disease receives marketing exclusivity for use of that drug for the stated condition for a period of seven years. Orphan drug exclusive marketing rights may be lost under several circumstances, including a later determination by the FDA that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. Similar regulations are in effect in the EU with a ten-year period of market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because the extent and scope of patent protection for some of our product candidates may be limited, obtaining orphan drug designation is especially important for any product candidates that may be eligible for orphan drug designation. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain orphan drug designation for our product candidates that do not have broad patent protection, our competitors may then seek to sell a competing drug to treat the same condition and our revenues, if any, may be adversely affected thereby.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even though we have obtained orphan drug designation for one of our product candidates and intend to seek orphan drug designation for other product candidates, there is no assurance that we will be the first to obtain marketing approval for any particular rare indication. Further, even though we have obtained orphan drug designation for certain of our product candidates, or even if we obtain orphan drug designation for other potential product candidates, such designation may not effectively protect us from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions and potentially used off-label in the orphan indication. Even after an orphan drug is approved, the FDA can subsequently approve a competing drug for the same condition for several reasons, including, if the FDA concludes that the later drug is safer or more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek a Rare Pediatric Disease Designation, or RPDD, for one or more of our product candidates. However, a BLA for one or more of our product candidates may not meet the eligibility criteria for a priority review voucher upon approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, SYNB1934 received Rare Pediatric Drug Designation (RPDD) for phenylketonuria and in December 2022, SYNB1353 received RPDD for homocystinuria. With enactment of the Food and Drug Administration Safety and Innovation Act in 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications that meet the criteria specified in the law. This provision is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#x201c;rare pediatric disease&#x201d; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the purposes of this program, a &#x201c;rare pediatric disease&#x201d; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (b) rare disease or conditions within the meaning of the Orphan Drug Act. The FDA may determine that a BLA for one or more of our product candidates does not meet the eligibility criteria for a priority review voucher upon approval. Moreover, due to the current statutory authority for the RPDD and voucher program, the FDA may not award the voucher to sponsors of marketing applications unless either (i) the drug has received rare pediatric disease designation as of September 30, 2024, and is then approved by the FDA no later than September 30, 2026; or (ii) Congress reauthorizes the program. Even though we received rare pediatric disease designation for SYNB1934 and SYNB1353 by the current statutory deadline of September 30, 2024 we may not receive the voucher if we do not obtain approval by September 2026. Even if legislation is enacted that extends the date by which approval of the rare pediatric disease-designated drug must obtain approval to receive a priority review voucher, we may not obtain approval by that date, and even if we do, we may not obtain a priority review voucher.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results from preclinical studies or early clinical trials of a product candidate may not predict the results that will be obtained in subsequent subjects or in later stage clinical trials of that product candidate or any other product candidate. Flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and we may be unable to design and execute clinical trials to support regulatory approval of our product candidates. In addition, preclinical study and clinical trial data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory authority approval. Product candidates that seemingly perform satisfactorily in preclinical studies and clinical trials may nonetheless fail to obtain regulatory approval. There is a high failure rate for drugs proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Any such setbacks in our clinical development could negatively affect our business and operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our costs might be higher than expected and our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials of a new product candidate require the enrollment of a sufficient number of healthy volunteers or patients suffering from the disease or condition the product candidate is intended to treat and who meet other eligibility criteria. The timing of our clinical trials depends on our ability to recruit eligible subjects to participate as well as the completion of required follow-up evaluations. Patients and healthy volunteers may be unwilling to participate in our clinical trials because of negative publicity from adverse events related to novel therapeutic approaches, competitive clinical trials for similar patient populations, the existence of current treatments or for other reasons including due to concerns posed by the COVID-19 pandemic. Rates of patient enrollment are affected by many factors, including the size of the potential patient population, the age and condition of the patients, the stage and severity of disease or condition, the nature and requirements of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease or condition, the perceived risks, the clinical trial administration practices of the contract research organization, or CRO, or clinical trial sites, labor shortages at the CRO or clinical trial sites, benefits and convenience of administration of the product candidate being studied, the patient referral practices of physicians, the amount of attention provided to our trial by clinical trial sites, our efforts and CRO, our efforts to facilitate timely enrollment in clinical trials, and the eligibility criteria for the clinical trial. Delays or difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments, can result in increased costs, longer development times or termination of a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our success may depend, in part, on our ability to identify patients who qualify for our clinical trials or are likely to benefit from any product candidate that we may develop, which will require those potential patients to undergo a screening assay for the presence or absence of a particular genetic sequence or clinical trait. Genetically defined diseases generally, and especially those for which our current product candidates are targeted, may have relatively low prevalence. For example, we estimate there are approximately 150,000 patients that may be diagnosed with PKU in the United States, Europe and Asia. If we, or any third parties that we engage to assist us, are unable to successfully identify patients with these diseases, or experience delays in doing so, then we may not realize the full commercial potential of any product candidate we develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may face potential product liability claims, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals, if any, could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. If we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage, such liability could adversely affect our financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The use or misuse of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval exposes us to the risk of potential product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates and approved products, if any. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. Patients with the diseases targeted by our product candidates may already be in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which an adverse event is unrelated to our product candidates, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may delay our regulatory approval process or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we have product liability insurance, which covers any clinical trial we may conduct in the United States or internationally, our insurance may be insufficient to reimburse us for any expenses or losses we may suffer. We will also likely be required to increase our product liability insurance coverage for the advanced clinical trials that we plan to initiate. If we obtain marketing approval for any of our product candidates, we will need to expand our insurance coverage to include the sale of commercial products. There is no way to know if we will be able to continue to obtain product liability coverage and obtain expanded coverage we may require, in sufficient amounts to protect us against losses due to liability, on acceptable terms, or at all. We may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage. Where we have provided indemnities in favor of third parties under our agreements with them, there is also a risk that these third parties could incur liability and bring a claim under such indemnities. An individual may bring a product liability claim against us alleging that one of our product candidates or products causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. Any product liability claim brought against us, with or without merit, could result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withdrawal of clinical trial volunteers, investigators, patients or trial sites or limitations on approved indications; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The inability to commercialize, or if commercialized, decreased demand for, our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If commercialized, product recalls, withdrawals of labeling, marketing or promotional restrictions or the need for product modification; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of revenues; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantial costs of litigation, including monetary awards to patients or other claimants; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The diversion of management&#x2019;s attention from our business; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of key employees; and  </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Damage to our reputation and the reputation of our products and our technology. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We or the third parties upon which we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">or geopolitical tensions, such as the armed conflict between Russia and Ukraine,</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> may materially and adversely affect our business and our financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Over the past several years, the coronavirus outbreak has affected segments of the global economy and it may continue to materially affect our operations, including potentially significant interruption of our clinical trial activities. In addition, there could be a continuing effect of COVID-19 to the business at FDA or other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates. For example, in 2021, we experienced delays with the FDA that were related to COVID-19. In addition, clinical site initiation and patient enrollment may be delayed due to prioritization of healthcare system resources toward the COVID-19 pandemic. For example, in 2021, the ability of site IRBs to meet and review protocol amendments were delayed due to COVID-19. Sites were also unable at times to schedule in-person screening visits with potential patients during certain times in 2021.  Our CROs and clinical trial sites also experienced labor shortages in 2022, 2021 and 2020. Some patients may not be able to comply with clinical trial protocols if quarantines or their concerns about COVID-19 impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 has adversely impacted our clinical trial operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The continued spread globally could also have a material adverse effect on our clinical trial operations in the United States and elsewhere, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to monitor the potential impact of the coronavirus outbreak, and any associated restrictions on travel and work that have been implemented, on our business and pre-clinical and clinical trials. The extent to which the coronavirus impacts us will depend on future developments, which are uncertain and cannot be predicted. We will continue to carefully monitor the situation with respect to each of our clinical trials and follow guidance from local and federal health authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 may also affect employees of third-party contract research organizations and contract manufacturing organizations located in affected geographies that we rely upon to carry out our clinical trials. For example, there were delays in laboratory analyses of patient samples due to pandemic related staffing issues at our CROs in 2021. In addition, we have taken precautionary measures, and may take additional measures, intended to help minimize the risk of the virus to our employees. We will continue to adjust these measures as necessary and as we are able in the future to balance the needs of our business with the safety of our employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot presently predict the extent to which potential business shutdowns and disruptions may impact or limit our ability or the ability of any of the third parties with which we engage to conduct business in the manner and on the timelines presently planned. Any such impacts or limitations could have a material adverse impact on our business and our results of operation and financial condition. While the potential economic impact brought by and the duration of the coronavirus outbreak may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, potentially reducing our ability to access capital, which could in the future negatively affect our liquidity.  Similarly, the current conflict between Ukraine and Russia has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. A recession or market correction resulting from the continued spread of COVID-19 or the geopolitical tensions in Russia and Ukraine, could materially affect our business and the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time required to obtain marketing approval for a novel therapeutic product from the FDA and other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, laws or regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for commercialization, of any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain that approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to demonstrate to the satisfaction of the FDA or other comparable foreign regulatory authorities that our product candidates are safe, pure and potent or effective for their proposed indications; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of clinical trials may not meet the level of statistical significance required by the FDA or other comparable foreign regulatory authorities in order to support approval; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA, to the FDA or other equivalent marketing authorization application submissions to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon review of our clinical trial sites and data, the FDA or comparable foreign regulatory authorities may find our record keeping or the record keeping of our clinical trial sites or investigators to be inadequate; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or other comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The approval policies or regulations of the FDA or other comparable foreign regulatory authorities or the laws they enforce may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, financial condition and results of operations. The FDA and other comparable foreign regulatory authorities have substantial discretion in the approval process and determining when or whether to grant regulatory approval will be obtained for any of our product candidates, and whether to impose any conditions on such marketing approvals as described below. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or other comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, if any, they may grant approval contingent on the performance of costly post-marketing clinical trials, or they may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate or with restrictive risk mitigation measures or warning language or contraindications that make the approved product more difficult or costly to commercialize. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek breakthrough therapy designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek a breakthrough therapy designation from the FDA for some of our product candidates. A breakthrough therapy is defined as a drug or biological product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and for which preliminary clinical evidence indicates that the drug or biological product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biological products that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development. Drugs designated as breakthrough therapies by the FDA could also be eligible for accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to grant such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify and are designated as breakthrough therapies, the FDA may later decide that the drugs or biological products no longer meet the conditions for designation and the designation may be rescinded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have received Fast Track designation for one of our product candidates and may seek such designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for the condition, a product sponsor may apply for Fast Track designation. We were awarded Fast Track designation for SYNB1618 in April 2018 and for SYNB1353 in August 2022. Fast Track designation does not ensure that we will receive marketing approval for the product candidate or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#x2019;s priority review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates are approved for marketing, we will be subject to ongoing regulatory requirements, including with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing clinical trials, and submission of safety, efficacy and other post-approval information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers and manufacturers&#x2019; facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current good manufacturing practices (cGMP) regulations and corresponding foreign regulatory manufacturing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA or marketing authorization application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial in order to confirm the clinical benefit for our products. An unsuccessful post-marketing clinical trial or failure to complete such a trial could result in the withdrawal of marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issue untitled or warning letters; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impose civil or criminal penalties; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suspend or withdraw regulatory approval or revoke a license; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suspend any of our ongoing clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refuse to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impose restrictions on our operations, including closing our contract manufacturers&#x2019; facilities; or </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Require a product recall. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and our value and operating results would be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in obtaining marketing approval of our current and future therapeutic product candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable foreign regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our future products will also be subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may submit marketing applications in other countries in addition to the United States. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. The coronavirus pandemic has also adversely affected the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operations of necessary government agencies. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. In addition, competing demands from other companies or issues can affect the timeliness for which the FDA can review and process our regulatory submissions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#x201c;ACA&#x201d;), was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and biologics, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased from 50% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs and biologics to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs or biologics to be covered under Medicare Part D.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further legislative and regulatory changes under the ACA remain possible, although it is unknown what form any such changes or any law would take, and how or whether it may affect the biopharmaceutical industry as a whole or our business in the future. We expect that changes or additions to the ACA, the Medicare and Medicaid programs, such as changes allowing the federal government to directly negotiate drug prices, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the US.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. As another example, the 2021 Consolidated Appropriations Act signed into law on December 27, 2020, incorporated extensive healthcare provisions and amendments to existing laws, including a requirement that all manufacturers of drugs and biological products covered under Medicare Part B report the product&#x2019;s average sales price, or ASP, to HHS subject to enforcement via civil money penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, over the past several years there has been heightened governmental scrutiny over the manner in which biopharmaceutical manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. The probability of success of these newly announced policies, many of which have been subjected to legal challenge in the federal court system, and their potential impact on the U.S. prescription drug marketplace is unknown. There are likely to be continued political and legal challenges associated with implementing these reforms as they are currently envisioned. For example, in July 2021, President Biden issued a sweeping executive order on promoting competition in the American economy that included several mandates pertaining to the pharmaceutical and health care insurance industries and called on HHS to release a comprehensive plan to combat high prescription drug prices. The drug pricing plan released by HHS in September 2021 in response to the executive order makes clear that the Biden Administration supports aggressive action to address rising drug prices, including allowing HHS to negotiate the cost of Medicare Part B and D drugs, but such significant changes will require either new legislation to be passed by Congress or time-consuming administrative actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most recently, in August 2022, President Biden signed into the law the Inflation Reduction Act of 2022, or the IRA. Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product&#x2019;s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, CMS will negotiate drug</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. The effect of Inflation Reduction Act of 2022 on our business and the healthcare industry in general is not yet known. There remains a large amount of uncertainty regarding the federal government&#x2019;s approach to making pharmaceutical treatment costs more affordable for patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, California requires pharmaceutical manufacturers to notify certain purchasers, including health insurers and government health plans at least 60 days before any scheduled increase in the wholesale acquisition cost (WAC), of their product if the increase exceeds 16%, and further requires pharmaceutical manufacturers to explain whether a change or improvement in the product necessitates such an increase. Similarly, Vermont requires pharmaceutical manufacturers to disclose price information on certain prescription drugs, and to provide notification to the state if introducing a new drug with a WAC in excess of the Medicare Part D specialty drug threshold. In December 2020, the U.S. Supreme Court also held unanimously that federal law does not preempt the states&#x2019; ability to regulate pharmaceutical benefit managers, or PBMs, and other members of the healthcare and pharmaceutical supply chain, an important decision that appears to be leading to further and more aggressive efforts by states in this area. The Federal Trade Commission in mid-2022 also launched sweeping investigations into the practices of the PBM industry that could lead to additional federal and state legislative or regulatory proposals targeting such entities&#x2019; operations, pharmacy networks, or financial arrangements. Significant efforts to change the PBM industry as it currently exists in the United States may affect the entire pharmaceutical supply chain and the business of other stakeholders, including biopharmaceutical developers like us. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or EU member state level may result in significant additional requirements or obstacles that may increase our operating costs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action. We expect that additional federal and state health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, which imposes specified requirements relating to the privacy, security, and transmission of individually identifiable health information; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal physician payments sunshine requirements under the ACA require manufacturers of drugs, devices, biologics, and medical supplies to report annually to the HHS information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including governmental and private payors, to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the ACA provides that the U.S. government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to, or may in the future become subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and process personal information. Our actual or perceived failure to comply with such obligations could result in liability or reputational harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In many activities, including the conduct of clinical trials, we are subject to laws and regulations governing data privacy and the protection of health-related and other personal information. The regulatory framework for collecting, using, safeguarding, sharing, transferring and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the General Data Protection Regulation, or GDPR, which took effect across all Member States of the European Economic Area, or EEA, on May 25, 2018. The withdrawal of the United Kingdom from the European Union and the subsequent separation of the data protection regimes of these territories mean we are required to comply with separate data protection laws in the European Union and the United Kingdom, which may lead to additional compliance costs and could increase our overall risk. Similar laws and regulations govern our processing of personal data, including the collection, access, use, analysis, modification, storage, transfer, security breach notification, destruction and disposal of personal data. We must comply with laws and regulations associated with the international transfer of personal data based on the location in which the personal data originates and the location in which it is processed. Although there are legal mechanisms to facilitate the transfer of personal data from the European Economic Area (EEA), and Switzerland to the United States, the decision of the European Court of Justice that invalidated the safe harbor framework has increased uncertainty around compliance with EU privacy law requirements. As a result of the decision, it was no longer possible to rely on safe harbor certification as a legal basis for the transfer of personal data from the European Union to entities in the United States. In February 2016, the European Commission announced an agreement with the Department of Commerce, or DOC, to replace the invalidated safe harbor framework with a new EU-U.S. &#x201c;Privacy Shield.&#x201d; However, in July 2020, the Court of Justice of the EU (CJEU) limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield for purposes of international transfers and imposing further restrictions on use of the standard contractual clauses (SCCs) including, a requirement for companies to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. The European Commission subsequently issued new SCCs in June 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board, and which are in turn relatively more onerous.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The privacy and security of personally identifiable information stored, maintained, received or transmitted, including electronically, is subject to significant regulation in the United States and abroad. While we strive to comply with all applicable privacy and security laws and regulations, legal standards for privacy continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause reputational harm, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerous foreign, federal and state laws and regulations govern collection, dissemination, use and confidentiality of personally identifiable health information, including state privacy and confidentiality laws (including state laws requiring disclosure of breaches); federal and state consumer protection and employment laws; HIPAA; and European and other foreign data protection laws. These laws and regulations are increasing in complexity and number, may change frequently and sometimes conflict.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA establishes a set of national privacy and security standards for the protection of individually identifiable health information, including protected health information, or PHI, by health plans, certain healthcare clearinghouses and healthcare providers that submit certain covered transactions electronically, or covered entities, and their &#x2018;&#x2018;business associates,&#x2019;&#x2019; which are persons or entities that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting PHI. While we are not currently a covered entity or business associate under HIPAA, we may receive identifiable information from these entities. Failure to receive this information properly could subject us to HIPAA&#x2019;s criminal penalties, which may include fines up to $50,000 per violation and/or imprisonment. In addition, responding to government investigations regarding alleged violations of these and other laws and regulations, even if ultimately concluded with no findings of violations or no penalties imposed, can consume company resources and impact our business and, if public, harm our reputation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California&#x2019;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. In addition, California enacted the California Consumer Privacy Act (the CCPA), which took effect on January 1, 2020, became enforceable by the California Attorney General on July 1, 2020, and has been dubbed the first &#x201c;GDPR-like&#x201d; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act (the CPRA) recently passed in California. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Although the CCPA currently exempts certain health-related information, including clinical trial data, the CCPA and the CPRA may increase our compliance costs and potential liability. Similar laws have been adopted in other states (for example Nevada, Virginia, Connecticut, Utah and Colorado) or proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our clients and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the interpretation and application of consumer, health-related, and data protection laws are often uncertain, contradictory, and in flux.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The legislative and regulatory landscape for privacy and data security continues to evolve, and there has been an increasing focus on privacy and data security issues which may affect our business. Failure to comply with current and future laws and regulations could result in government enforcement actions (including the imposition of significant penalties), criminal and civil liability for us and our officers and directors, private litigation and/or adverse publicity that negatively affects our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development activities and our third-party manufacturers&#x2019; and suppliers&#x2019; activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#x2019; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our research and development efforts, commercialization efforts and business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of specified materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Given the nature of the research and development work conducted by us, we do not currently carry biological or hazardous waste insurance coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:17.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop, implement and maintain costly compliance programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To develop, manufacture and sell certain products outside the United States, we must dedicate resources to comply with numerous laws and regulations in each jurisdiction in which we operate. The Foreign Corrupt Practices Act (FCPA), prohibits any United States individual or business from paying, offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees may be considered government employees or foreign officials. In other circumstances, certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-United States nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. These laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the U.S., which could limit our growth potential and increase our development costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#x2019;s accounting provisions and export control laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our internal computer systems and those of our current and any future collaborators and other contractors, consultants, or clinical trial sites are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering, phishing and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. The number and complexity of these threats continue to increase over time.  If any of the above events were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of preclinical or clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed. The market perception of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have processes to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to vendors, engage in more electronic transactions with payors and patients, and rely more on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those of our third-party contractors, or our consultants&#x2019; efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks which could result in financial, legal, business or reputational harm.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ethical, legal and social concerns about synthetic biology and genetic engineering could limit or prevent the use of our technologies and limit our revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our technologies involve the use of synthetic biology and genetic engineering. Public perception about the safety and environmental hazards of, and ethical concerns over, synthetic biology and genetic engineering could influence public acceptance of our technologies, product candidates and processes. If we and our collaborators are not able to overcome the ethical, legal and social concerns relating to synthetic biology and genetic engineering, our technologies, product candidates and processes may not be accepted. These concerns could result in increased expenses, regulatory scrutiny and increased regulation, trade restrictions on imports of Synthetic Biotics, delays or other impediments to our programs or the public acceptance and commercialization of Synthetic Biotics. Further, there is a risk that Synthetic Biotics made using our technologies could result in adverse health effects or other adverse events, which could also lead to negative publicity. We design and produce product candidates with characteristics comparable or disadvantaged to those found in naturally occurring organisms or enzymes in a controlled laboratory; however, the release of such organisms into uncontrolled environments could have unintended consequences. Any adverse effect resulting from such a release could have a material adverse effect on our business, financial condition or results of operations and we may have exposure to liability for any resulting harm.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to Synthetic Biotics, product candidates and processes for our development pipeline through acquisitions and in-licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Presently, we have rights to certain intellectual property, through licenses from third parties and under patents and patent applications owned by us. The growth of our business will likely depend in part on our ability to obtain, maintain or enforce our and our licensors&#x2019; intellectual property rights and to acquire or in-license additional proprietary rights. For example, our programs may involve additional product candidates or delivery systems that may require the use of additional proprietary rights held by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our product candidates may require specific formulations to work effectively and efficiently, and these rights may be held by other third parties. We may be unable to develop, acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of other companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These companies could have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, we have previously and may continue to collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to it. If we are unable to do so, the institution may offer intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We intend to rely on patent rights and the status of our product candidates, if approved, as biologics eligible for exclusivity under the Biologics Price Competition and Innovation Act (BPCIA). If Synlogic is unable to obtain or maintain exclusivity from the combination of these approaches, Synlogic may not be able to compete effectively in our markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our licensors&#x2019; ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own, or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, independently or together with our licensors or collaborators, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection, data exclusivity or orphan drug exclusivity, for our product candidates, we believe that our product candidates will be protected by exclusivity that prevents approval of a biosimilar in the United States for a period of twelve years from the time the product to which it claims similarity was first approved. However, The Biologics Price Competition and Innovation Act of 2009, Title VII, Subtitle A of the Patent Protection and Affordable Care Act, Pub.L.No.111-148, 124 Stat.119, Sections 7001-02 signed into law March 23, 2010, and codified in 42 U.S.C. &#167;262 (the BPCIA), created an elaborate and complex patent dispute resolution mechanism for biosimilars that could prevent us from launching our product candidates in the United States or could substantially delay such launches. Current biosimilars litigation are addressing certain requirements of the BPCIA which is creating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">uncertainty over how certain terms of the BPCIA should be construed and this presents uncertainty for both the biologics innovator and biosimilar party. The BPCIA mechanism required for biosimilar applicants may pose greater risk that patent infringement litigation will disrupt our activities and add increased expenses as well as divert management&#x2019;s attention. If a biosimilar version of one of our product candidates were approved in the United States, it could have a negative effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not have sufficient patent term protections for our product candidates to effectively protect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition. In addition, upon issuance in the United States any patent term can be adjusted based on specified delays caused by the applicant(s) or the USPTO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of our product candidates. We will likely seek patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our product candidates for an extended period after regulatory approval, if any, which would negatively impact our business, financial condition, results of operations and prospects. If we do not have sufficient patent terms or regulatory exclusivity to protect our product candidates, our business and results of operations will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. and foreign patent law could diminish the value of patents in general, thereby impairing our ability to protect our products, and recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case with other biotechnology companies, our success is heavily dependent on patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in specified circumstances and weakened the rights of patent owners in specified situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">European patent practice is expected to change when the European Unitary Patent (UP) and Unified Patent Court (UPC) enter into force on June 1, 2023. The new system will impact both pending European applications and granted European patents, and uncertainty remains about long-term implications of this change. The UPC may particularly present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. While the UPC is being implemented to provide more certainty and efficiency to patent enforcement throughout Europe, it will also provide our competitors with a new forum to use to centrally revoke our European patents. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. We will have the right to opt our patents out of the UPC system over the first seven years, but doing so may preclude us from realizing the benefits of the new unified court.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining And Maintaining Our Patent Protection Depends On Compliance with Various Procedural, Document Submission, Fee Payment and Other Requirements Imposed by Governmental Patent Agencies, And Our Patent Protection Could be Reduced or Eliminated For Non-Compliance With These Requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees on any issued patents are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Although an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">properly legalize and submit formal documents. In any such event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent. We also utilize processes for which patents are difficult to enforce. In addition, other elements of our products, and many elements of our product candidate discovery and development processes involve proprietary know-how, information or technology that is not covered by patents. Trade secrets may be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, collaborators, advisors, independent contractors or other third parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets, including by maintaining physical and electronic security of our premises and our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, collaborators, advisors, independent contractors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business, financial condition or results of operations. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technology without infringing the patent rights of third parties. Numerous third-party U.S. and non-U.S. issued patents and pending applications exist in the area of Synthetic Biotics. We are aware of U.S. and foreign patents and pending patent applications owned by third parties that cover similar therapeutic uses as the product candidates we are developing. We are currently monitoring these patents and patent applications. We may in the future pursue available proceedings in the U.S. and foreign patent offices to challenge the validity of these patents and patent applications. In addition, or alternatively, we may consider whether to seek to negotiate a license of rights to technology covered by one or more of such patents and patent applications. If any patents or patent applications cover our product candidates or technologies, we may not be free to manufacture or market our product candidates as planned, absent such a license, which may not be available to us on commercially reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patents may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">published can, subject to specified limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been many lawsuits and other proceedings filed by third parties involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination, post-grant review and equivalent proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend, in part, on our licensors to file, prosecute, maintain, defend and enforce patents and patent applications that are material to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we normally seek and gain the right to fully prosecute the patent applications relating to our product candidates, there may be times when the patent applications enabling our product candidates are controlled by our licensors. If any of our existing or future licensors fail to appropriately and broadly prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, importing, and selling competing products. In addition, even where we now have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a party to certain intellectual property license agreements and expect to enter into additional license agreements in the future. Our existing agreements impose, and future license agreements may impose, certain obligations, including the payment of milestones and royalties based on revenues from sales of our products utilizing the technologies licensed from our licensors, and such obligations could adversely affect the overall profitability for us of any products that we may seek to commercialize. In addition, we will need to outsource and rely on third parties for many aspects of the clinical development, sales and marketing of our product candidates covered under our license agreements. Delay or failure by these third parties could adversely affect the continuation of our license agreements with our third-party licensors. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, these agreements may be subject to termination by the licensor which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensors. To cease such infringement or unauthorized use, we or one of our licensing partners may be required to file patent infringement claims against a third-party to enforce one of our patents which can be expensive, time-consuming and unpredictable. In addition, in an infringement proceeding or a declaratory judgment action against us, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or one of our licensing partners were to initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, clarity or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or other jurisdictions, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review and equivalent proceedings in foreign jurisdictions, such as opposition or derivation proceedings. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity, unpatentability and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions or correct inventorship with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation, derivation or interference proceedings may result in a decision adverse to our interests and, even if successful, may result in substantial costs and distract our management and other employees. In addition, we may be unable to raise the funds necessary to conduct our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. Any disclosure of confidential information could adversely affect our business. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may in the future be subject to claims that former employees, consultants, collaborators, advisors, independent contractors or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor or other claims challenging the inventorship of our patents or ownership of our intellectual property (including patents and intellectual property that we in-license). Therefore, our rights to these patents may not be exclusive and third parties, including competitors, may have access to intellectual property that is important to our business. In addition, co-owners from whom we do not yet have a license or assignment may raise claims surrounding inventorship or ownership of patents that ultimately issue from this patent family, potentially resulting in issued patents to which we would not have rights under our existing license agreements. Further, in jurisdictions outside the United States, a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. In addition, we may have inventorship disputes arising from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship of our patents. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, collaborators, advisors, independent contractors or other third parties have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at universities, academic research institutions and at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements with and make every effort to ensure that our employees, consultants, collaborators, advisors, independent contractors or other third parties do not use the proprietary information or intellectual property rights of others in their work for us, we may in the future be subject to claims that our employees, consultants, collaborators, advisors, independent contractors or other third parties have inadvertently or intentionally used or disclosed confidential information of these third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited intellectual property rights outside the United States. Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the United States can have a different scope and strength and be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties (including competitors) from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but where enforcement rights are not as strong as those in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries, particularly some developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patents and other intellectual property rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have filed for trademark registration of certain marks relating to our current branding. If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct some aspects of our product formulation, research, preclinical, and clinical studies, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such formulation, research or testing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, contracted laboratories and third-party CROs, to conduct our preclinical studies and clinical trials, as well as certain product candidate discovery and development activities, in accordance with applicable regulatory requirements and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with good laboratory practices (GLP), as applicable, and good clinical practice (GCP) requirements, which are regulations and guidelines enforced by the FDA, the EMA and other comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GLP and GCP through periodic inspections of laboratories conducting GLP studies, and clinical trial sponsors, principal investigators, CROs, and trial sites when auditing for GCP compliance. If we, our investigators or any of our CROs or contracted laboratories fail to comply with applicable GLP and GCP, as applicable, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, the EMA or other comparable foreign regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving our marketing applications for our therapeutic product candidates. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">determine that any of our preclinical studies or clinical trials comply with applicable GLP or GCP regulations. In addition, our clinical trials must be conducted with product produced in compliance with applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat preclinical studies or clinical trials, which would delay the regulatory approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, these laboratories, investigators and CROs are not our employees, and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent laboratories, investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, CROs or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical studies or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Switching or adding additional laboratories or CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, clinical investigators may serve as scientific advisors or consultants to us from time to time and may receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the utility of the preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our clinical-stage product candidate or any future therapeutic product candidates it may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third-party supply and manufacturing partners for drug supplies for our late-stage clinical activities and may do the same for any commercial supplies of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party supply and manufacturing partners to supply the materials and components to manufacture late-stage clinical trial drug supplies. We have not yet manufactured or formulated any product candidate on a commercial scale and may not be able to do so for any of our product candidates. We will work to develop and optimize our manufacturing process, and we cannot be sure that the process will result in therapies that are safe, potent, effective, or in an amount that satisfies our commercial needs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, we have agreements with Azzur Cleanrooms-On-Demand to lease clean-room space at their facility for manufacturing and formulation of cGMP material for our clinical trials and we have agreed to pay Azzur to renovate and upgrade the cleanroom space for expanded use. If Azzur were to not adhere to our agreement or suffer a material adverse event that affected their delivery of services to us, our ability to conduct clinical operations would be impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of any product formulation manufacturer we may engage could require significant effort and expertise because there may be a limited number of qualified replacements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synthetic Biotics are complex and difficult to manufacture. We could experience production or technology transfer problems that result in delays in our development or commercialization schedules or otherwise adversely affect our business. Issues with the manufacturing process, even minor deviations from the normal process, could result in insufficient yield, product deficiencies or manufacturing failures that result in lot failures, insufficient inventory, and product recalls.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many factors common to the manufacturing of most biologics and drugs could also cause production interruptions, including raw materials shortages, raw material failures, growth media failures, equipment malfunctions, facility contamination, labor problems, natural disasters, disruption in utility services, terrorist activities, or acts of God beyond our control. We also may encounter problems in hiring and retaining the experienced specialized personnel needed to operate our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any problems in our manufacturing processes or facilities could make us a less attractive collaborator for academic research institutions and other parties, which could limit our access to additional attractive development programs, result in delays in our clinical development or marketing schedules and harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP regulations. Any of our suppliers or manufacturers could fail to comply with such requirements or to perform our obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials could become limited or interrupted for other reasons. Under these circumstances, we may choose or be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, manufacture in collaboration with a third-party at their facilities, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and may be required to conduct bridging studies or repeat clinical trials to assure comparable safety, purity and potency. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third-party&#x2019;s failure to execute on our manufacturing requirements could adversely affect our business in a number of ways, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An inability to initiate or continue clinical trials of product candidates under development, which may impact our potential economic benefits; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss of the cooperation of a collaborator; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subjecting our product candidates to additional inspections by regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Requirements to cease distribution or to recall batches of our product candidates; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#x2019; exercise of rights under the agreement. With respect to our collaboration agreements, we typically indemnify our collaborators from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third-party. With respect to consulting agreements, we indemnify consultants from claims arising from the good faith performance of their services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should our obligation under an indemnification provision exceed applicable insurance coverage or should we be denied insurance coverage, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">To the extent we are able to enter into collaborative arrangements or strategic alliances, we may be exposed to risks related to those collaborations and alliances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biotechnology companies sometimes become dependent upon collaborative arrangements or strategic alliances to complete the development and commercialization of product candidates. If we elect to enter into collaborative arrangements or strategic alliances, these arrangements may place the development of our product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dependence on collaborative arrangements or strategic alliances would subject us to a number of risks, including the risk that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to control the amount and timing of resources that our collaborators may devote to the relevant product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our collaborators may experience financial difficulties; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to relinquish important rights, such as marketing and distribution rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business combinations or significant changes in a collaborator&#x2019;s business strategy may also adversely affect a collaborator&#x2019;s willingness or ability to complete our obligations under any arrangement; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our drug candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may attempt to form strategic collaborations, create joint ventures or enter into licensing arrangements with third parties with respect to our programs or platform that we believe will complement or augment our existing business. We may face significant competition in seeking appropriate strategic collaborators, and the negotiation process to secure appropriate terms is time consuming and complex. We may not be successful in our efforts to establish such a strategic collaboration for any product candidates and programs on terms that are acceptable to us, or at all. This may be because our product candidates and programs may be deemed to be at too early of a stage of development for collaborative effort, our research and development pipeline may be viewed as insufficient, the competitive or intellectual property landscape may be viewed as too intense or risky, the macro-economic conditions may disfavor a collaboration, and/or third parties may not view our product candidates and programs as having sufficient potential for commercialization, including the likelihood of an adequate safety and efficacy profile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any delays in identifying suitable collaborators and entering into agreements to develop and/or commercialize our product candidates could delay the development or commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. Absent a strategic collaborator, we would need to undertake development and/or commercialization activities at our own expense. If we elect to fund and undertake development and/or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we are unable to do so, we may not be able to develop our product candidates or bring them to market and our business may be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Commercialization of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our product candidates is approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no sales, marketing or distribution capabilities or experience. If any of our product candidates is approved for marketing and commercialization, we will need to develop internal sales, marketing and distribution capabilities to commercialize such products, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our products or decide to co-promote products with collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved for marketing and commercialization in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the small number of patients who have the diseases that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidates. Our projections of both the number of people who have applicable diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition and our competitors may discover, develop or commercialize products faster or more successfully than us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of new products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities and other research institutions worldwide with respect to our product candidates that we may seek to develop or commercialize in the future. For example, BioMarin, Inc., Nestl&#xe9; Health Science S.A. (Codexis, Inc.), Homology Medicines, Inc., American Gene Technologies International Inc., Generation Bio Co., Agios Pharmaceuticals, Inc., SOM Biotech SL, Jnana Therapeutics and other discovery stage companies have developed or are developing product candidates for the treatment of PKU.  Novome Biotechnologies, Inc., Federation Bio, Inc., Oxidien Pharmaceuticals L.L.C. and others are developing product candidates for enteric hyperoxaluria. Aeglea BioTherapeutics and Travere Therapeutics are both developing product candidates for HCU.  Selecta Biosciences, Jiangsu HengRui Medicine Co., Ltd., Horizon Pharma Inc., Dyve Biosciences, Arrowhead Pharmaceuticals, and HemoShear Therapeutics are developing drug candidates for gout. Our competitors may succeed in developing, acquiring or licensing technologies and products that are more effective or less costly than the product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive. In addition to the competition, we face from alternative therapies for the diseases we intend to target with our product candidates, we are also aware of several companies that are also working specifically to develop engineered bacteria as cellular drug therapies, such as Precigen, Inc. Further there are several companies working to develop other similar products. Third-party payors, including governmental and private insurers, may also encourage the use of generic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors have materially greater name recognition and substantially greater financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors. Failure of our product candidates to effectively compete against established treatment options or in the future with new products currently in development would harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even with approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the health care providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients and third-party payors. The degree of market acceptance of any of our products will depend on a number of factors, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The efficacy of the product as demonstrated in clinical trials and potential advantages over competing treatments; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The safety and side effect profile of the product as demonstrated in clinical trials and potential advantages over competing treatments; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The prevalence and severity of the disease targeted; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical indications for which approval is granted, including any limitations or warnings contained in a product&#x2019;s approved labeling; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The convenience and ease of administration; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of treatment; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The willingness of the patients and physicians to accept products engineered from bacteria and these therapies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The perceived ratio of risk and benefit of these therapies by physicians, patients, and payers, and the willingness of physicians to recommend these therapies to patients based on such risks and benefits; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The marketing, sales and distribution support for the product; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The publicity concerning the products or competing products and treatments; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pricing and availability of third-party insurance coverage and reimbursement. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product remains uncertain. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investment and resources and may never be successful. If our products fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and other health care providers, we will not be able to generate sufficient revenue to become or remain profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in any efforts to identify, license, discover, develop, or commercialize additional product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although a substantial amount of our effort will focus on the clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may not succeed in preclinical or clinical testing; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may develop alternatives that render our product candidates obsolete or less attractive; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product candidates we develop may be covered by third parties&#x2019; patents or other exclusive rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market for a product candidate may change during development or commercialization so that such a product may become unreasonable to continue to develop or commercialize;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of these events occur, we may be forced to abandon our development efforts for one or more product candidates, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business, financial condition or results of operations and could potentially cause us to cease operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to obtain or maintain adequate reimbursement or insurance coverage for products, if any, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pricing, coverage, and reimbursement of our approved products, if any, must be sufficient to support our commercial efforts and other development programs and the availability and adequacy of coverage and reimbursement by third-party payors, including governmental and private insurers, are essential for most patients to be able to afford expensive treatments. Sales of our approved products, if any, will depend substantially, both domestically and abroad, on the extent to which the costs of our approved products, if any, will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government payors and private payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free or we may not be able to successfully commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services (CMS), an agency within the HHS, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel product candidates such as ours and what reimbursement codes our product candidates may receive if approved. No uniform policy for coverage and reimbursement for drug products exist among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic/biosimilar drug or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidate and other therapies as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidate over other available and comparable products, pricing of existing drugs may limit the amount we will be able to charge for its product candidate. These payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed products at levels that are too low to enable it to realize an appropriate return on our investment in product development. If coverage and reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on products that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. For example, under these circumstances, physicians may limit how much or under what circumstances they will prescribe or administer our products and patients may deliver to purchase such products. This, in turn, could affect our ability to commercialize our products successfully and impact our profitability, results of operations, financial condition, and future success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products, if any. Accordingly, in markets outside the United States, the potential revenue from the sale of our products may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, increasing efforts by governmental and private payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs has, and is expected to continue to increase in the future. As a result, profitability of our products, if any, may be more difficult to achieve even if they receive regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business Operations and Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our failure to attract and retain senior management and key scientific personnel may prevent us from successfully developing our product candidates or any future product candidate, conducting our clinical trials and commercializing any products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of our senior management, particularly our president and chief executive officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of the products we develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we have not historically experienced significant difficulties attracting and retaining qualified employees, we could experience such problems in the future. For example, competition for qualified personnel in the biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, independent contractors, principal investigators, CROs, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants and collaborators may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) regulations of regulatory authorities in jurisdictions where we are performing activities in relation to our product candidates, including those laws requiring the reporting of true, complete and accurate information to such authorities; (2) manufacturing regulations and standards; (3) fraud and abuse and anti-corruption laws and regulations; or (4) laws that require the reporting of true and accurate financial information and data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, bias, misconduct, kickbacks, self-dealing and other abusive practices, and these laws may differ substantially from country to country. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting ourselves from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending itself or asserting our rights, those actions could have a significant impact on our business including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in subsidized healthcare programs in a given country, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the beneficial ownership of our common stock as of March 22, 2023, our executive officers and directors, together with holders of 5% or more of our common stock outstanding and their respective affiliates, beneficially own approximately 47.3% of our common stock. Accordingly, these stockholders have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, consolidation or sale of all or substantially all of our assets or any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of the company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#x2019; perception that conflicts of interest may exist or arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future sales of our common stock or securities convertible or exchangeable for our common stock may depress our stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our existing stockholders or holders of our options sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. The perception in the market that these sales may occur could also cause the trading price of our common stock to decline. As of March 22, 2023, there were a total of 67,728,025 shares of our common stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variations in the level of our operating expenses; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receipt, modification or termination of government contracts or grants, and the timing of payments we receive under these arrangements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make under these arrangements; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of the company&#x2019;s stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders and could make it more difficult for you to change management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control that our stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. In addition, these provisions may frustrate or prevent any attempt by our stockholders to replace or remove our current management by making it more difficult to replace or remove our Board of Directors. These provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A classified board of directors so that not all directors are elected at one time; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A prohibition on stockholder action through written consent; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No cumulative voting in the election of directors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The exclusive right of our Board of Directors to elect a director to fill a vacancy created by the expansion of our Board of Directors or the resignation, death or removal of a director; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A requirement that special meetings of our Stockholders be called only by our Board of Directors, the chairman of our Board of Directors, the chief executive officer or, in the absence of a chief executive officer, the president; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An advance notice requirement for stockholder proposals and nominations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The authority of our Board of Directors to issue preferred stock with such terms as our Board of Directors may determine; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A requirement of approval of not less than 66 2/3% of all outstanding shares of our capital stock entitled to vote to amend any bylaws by stockholder action, or to amend specific provisions of our certificate of incorporation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, Delaware law prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person who, together with its affiliates, owns or within the last three years has owned 15% or more of the company&#x2019;s voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Delaware law may discourage, delay or prevent a change in control of the company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our amended and restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our charter and other provisions of Delaware law could limit the price that investors are willing to pay in the future for shares of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not anticipate paying any cash dividends on our common stock in the foreseeable future; therefore, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund our operations. In addition, the terms of any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in, or interpretations of, accounting rules and regulations could result in unfavorable accounting charges or require us to change our compensation policies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting methods and policies for biopharmaceutical companies, including policies governing revenue recognition, research and development and related expenses and accounting for stock-based compensation, are subject to further review, interpretation and guidance from relevant accounting authorities, including the SEC. Changes to, or interpretations of, accounting methods or policies may require us to reclassify, restate or otherwise change or revise our financial statements, including those contained in this periodic report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we continue to fail to comply with the continued listing requirements of the Nasdaq Global Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is currently listed for trading on the Nasdaq Global Market (&#x201c;Nasdaq&#x201d;). We must satisfy Nasdaq&#x2019;s continued listing requirements, including, among other things, a minimum bid price for our common stock of&#x2009;$1.00 per share, or risk delisting, which would have a material adverse effect on our business. A delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 6, 2022, we received a written notice from Nasdaq notifying us that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, our common stock did not meet the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5450(a)(1), initiating an automatic 180 calendar-day grace period for us to regain compliance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a period of 180 calendar days from the date of the notification, or until June 5, 2023, to achieve compliance with the minimum bid price requirement. We will regain compliance with the minimum bid price requirement if at any time before June 5, 2023, the bid price for our common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may choose on or before June 5, 2023 to transfer to the Nasdaq Capital Market and apply for a second 180 calendar day period to regain complaince. If we do not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that our common stock will be subject to delisting. At such time, we may appeal the delisting determination to a hearings panel.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to continue to monitor the bid price levels for our common stock and will consider appropriate alternatives to achieve compliance within the 180 calendar-day compliance periods, including, among other things, a potential reverse stock split. There can be no assurance, however, that we will be able to do so.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolved</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters and operations are located in Cambridge, Massachusetts. We currently lease laboratory and office space at 301 Binney Street in Cambridge. Our 301 Binney Street lease expires in 2028. We believe that our facilities are suitable and adequate for our needs for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we are subject to various legal proceedings, claims and administrative proceedings that arise in the ordinary course of our business activities. Although the results of the litigation and claims cannot be predicated with certainty, as of the date of this report, we do not believe we are party to any claim, proceeding or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock has been traded on The Nasdaq Capital Market under the symbol &#x201c;SYBX&#x201d; since August 28, 2017, prior to which it was traded under the symbol &#x201c;MIRN&#x201d;.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 22, 2023, there were approximately 105 stockholders of record of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any dividends to our stockholders since our inception, and we do not plan to declare or pay cash dividends in the foreseeable future. We currently anticipate that we will retain any future earnings for the operation and expansion of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information with respect to our repurchases of common stock during the quarter ended December 31, 2022:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.9%;"></td>
    <td style="width:2.447%;"></td>
    <td style="width:13.332%;"></td>
    <td style="width:2.447%;"></td>
    <td style="width:13.042%;"></td>
    <td style="width:2.447%;"></td>
    <td style="width:16.432%;"></td>
    <td style="width:2.447%;"></td>
    <td style="width:26.508%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Period</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Number of Shares Purchased(1)</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Average Price Paid per Share(2)</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 1, 2022 to November 30, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,196,889</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$0.60</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">__</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">__</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(0,0,0,1);padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 1, 2022 to December 31, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">__</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">__</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">__</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">__</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended December 31, 2022, we purchased an aggregate of 4,196,889 shares of common stock in a privately negotiated transaction. See Note 13 of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information related to share repurchases.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Average price paid per share includes costs associated with the repurchases.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. [Rese</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rved.]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forward-Looking Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Risk Factors in Part I, Item 1A of this Annual Report on Form 10-K, the audited financial statements and accompanying notes, included elsewhere in this Annual Report on Form 10-K, and this Management's Discussion and Analysis of Financial Condition and Results of Operations should be read together. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. Operating results are not necessarily indicative of results that may occur for the full fiscal year or any other future period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic is a late clinical-stage biotechnology company advancing the design and development of biotherapeutics based on synthetic biology. Synthetic biology leverages the application of engineering principles in the design of biological systems, genetic circuits and molecular components. We apply the power of synthetic biology to medicine, combining precision engineering with rational drug development to develop Synthetic Biotics. Synthetic Biotics are living probiotics genetically engineered to perform specific functions in the gastrointestinal (GI) tract targeting validated biology. Because Synthetic Biotics are orally administered and are based on familiar probiotics as their delivery method, or chassis, they offer a potentially convenient and safe approach to treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Drug Candidate Pipeline</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic&#x2019;s pipeline includes SYNB1934, its lead program in phenylketonuria (PKU), which has demonstrated clinical proof of concept and is anticipated to enter Synpheny-3, its pivotal Phase 3 study in the first half of 2023. Our pipeline also includes novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. Synlogic is working with Roche under a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD) and with Ginkgo Bioworks, Inc. (Ginkgo) on additional undisclosed preclinical assets, combining Synlogic&#x2019;s approach to Synthetic Biotics with Ginkgo&#x2019;s Codebase and Foundry services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img119790510_10.jpg" alt="img119790510_10.jpg" style="width:611px;height:309px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Metabolic Disease</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Metabolic diseases are disorders resulting from defects or alterations in how our bodies break down or produce important metabolites or molecules. In patients with these diseases, the absence of certain enzymes causes metabolites to accumulate in the gut and systemically throughout the body. In patients with PKU and HCU, these metabolites build up to toxic levels resulting in serious health consequences, including the possibility of irreversible neurological dysfunction.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PKU</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead PKU program, SYNB1934, is an orally administered, non-systemically absorbed drug candidate based on a genetically engineered form of the probiotic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nissle. SYNB1934 was designed to produce the enzymes LAAD and PAL to metabolize the amino acid phenylalanine (Phe), which can reach neurotoxic levels in people with PKU or hyperphenylalanemia (a term for less severe forms of inherited deficits in Phe metabolism). Treatment options for PKU are currently limited due to efficacy and safety, with the vast majority remaining in need of treatment, and many of those who are treated in need of additional Phe-lowering. Findings to date support the potential for an efficacious, safe, convenient, and flexible treatment option for PKU.  An earlier generation of the same drug candidate, SYNB1618, received both Orphan Drug and Fast Track designations by the FDA and a positive opinion on orphan designation from the EMA. In October 2022, we announced positive findings for both SYNB1618 and SYNB1934 from the Phase 2 Synpheny-1 study and confirmed that SYNB1934 would be the candidate advancing to Synpheny-3, a pivotal Phase 3 study, expected to begin during the first half of 2023. In January 2023, we announced that the FDA granted Rare Pediatric Disease Designation to SYNB1934 for the treatment of PKU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We completed a Phase 1/2a clinical trial of an early liquid formulation of SYNB1618 and announced top-line data from healthy volunteers evaluated in this study in September 2018. In July 2019, we announced data that demonstrated that SYNB1618 was safe and well-tolerated and achieved proof-of-mechanism of strain activity in both healthy volunteers and patients with PKU. Following the study using the liquid formulation, we developed a solid oral lyophilized formulation of SYNB1618. We have evaluated this oral formulation in a bridging study in healthy volunteers. The study of this more patient- and commercialization-appropriate presentation of SYNB1618 demonstrated activity and improved tolerability over the liquid formulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated a Phase 2 clinical trial with SYNB1618 in the third quarter of 2020, referred to as the Synpheny-1 Study. The Synpheny-1 Study was designed to evaluate safety and tolerability of a solid oral formulation of SYNB1618 as well as its potential to lower blood Phe levels in adult PKU patients. In September 2021, an interim analysis of the ongoing Synpheny-1 study found that SYNB1618 demonstrated statistically significant reductions in blood Phe levels.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our second development candidate for PKU, SYNB1934, was engineered to potentially provide increased Phe lowering activity compared to SYNB1618. In July 2021, we initiated clinical studies of a solid oral formulation of SYNB1934 following preclinical in vivo and in vitro studies demonstrating an approximately two-fold improvement in the ability of SYNB1934 to metabolize Phe compared to SYNB1618.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, we announced results from a comparison of SYNB1618 and SYNB1934 activity in a Phase 1 healthy volunteer study. SYNB1934 showed an approximately two-fold higher activity level than SYNB1618 in a comparative analysis based on biomarkers of Phe metabolism. Additionally, SYNB1934 demonstrated a safety and tolerability profile similar to other Synthetic Biotics, including SYNB1618, at equivalent doses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB1934 clinical results in healthy volunteers were consistent with preclinical data and previously presented prospective biomarker-driven modeling. We believed that the increased activity of SYNB1934, relative to SYNB1618, could provide the opportunity to optimize the clinical profile based on individual patient needs. Accordingly, we added an arm evaluating SYNB1934 to the ongoing Synpheny-1 Phase 2 study. Positive top-line data from the Synpheny-1 Phase 1 study were announced in October 2022, and in March 2023, the data was presented in full at the Society for Inborn Metabolic Disorders (SIMD) Annual Meeting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on data obtained across the PKU program, we have decided that SYNB1934 will advance to Synpheny-3, a Phase 3 pivotal study, which we plan to begin in the first half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Homocystinuria</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Homocystinuria (HCU) is a rare inherited metabolic disorder that affects the metabolism of the amino acid methionine, a protein found in many foods including meat, fish, and dairy products. HCU is caused by a genetic defect which results in the absence of an enzyme known as cystathionine beta-synthase (CBS). When CBS is absent, homocysteine and other toxic chemicals and their byproducts, including methionine, build up in the blood and urine. Elevated homocysteine levels are associated with a multisystem disorder, including impairments of the eye (ectopia lentis and/or severe myopia), skeletal system (excessive height, long limbs, scoliosis, pectus excavatum), vascular system (thromboembolism), and CNS (development delay and intellectual disability).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021 we announced the nomination of SYNB1353, a novel, orally administered, non-systemically absorbed live biotherapeutic drug candidate engineered to consume methionine, a precursor of homocysteine, in the GI tract thereby lowering tHcy in HCU patients. The rationale for this approach includes the methionine-restricted diet which is a standard of care in HCU to lower and control homocysteine levels. SYNB1353 was developed as part of a research collaboration with Ginkgo. We hold worldwide development and commercialization rights to SYNB1353. In November 2022, we announced proof of mechanism was achieved based on the positive findings from a Phase 1 study in healthy volunteers using a dietary model of homocystinuria, which showed that SYNB1353 reduced plasma methionine by metabolizing methionine and preventing its absorption in the GI tract. To date, the FDA has granted SYNB1353 Fast Track, Orphan Drug, and Rare Pediatric Disease designations as a potential treatment for HCU.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enteric Hyperoxaluria</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enteric hyperoxaluria is a chronic, progressive disease characterized by high levels of urinary oxalate (Uox), a well-recognized cause of recurrent kidney stones with no approved treatment options. It is caused by fat malabsorption due to insults to the GI tract typically caused by surgery or disease such as Crohn&#x2019;s, which leads to increased absorption of dietary oxalate, which is present in many common foods including leafy greens, nuts, and chocolate, and elevated urinary oxalate levels. The increased absorption into the circulation can crystal formation in the kidneys, reflected in dangerously high levels of Uox and with the potential to result in both recurrent kidney stones and progressive kidney damage. In May 2020, we announced the nomination of a clinical candidate for enteric hyperoxaluria, SYNB8802. In 2021, Synlogic reported positive proof-of-mechanism for SYNB8802 from a Phase 1b study that demonstrated lowering of urinary and fecal oxalate levels in healthy volunteers with diet-induced hyperoxaluria.  In December of 2022, we announced that SYNB8802 achieved proof of concept, and that dosing with SYNB8802 was associated with a dose-dependent reduction in Uox, with a -28% lowering (-37.2, -18.2) from baseline in Uox vs. placebo at the 1x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> TID dose, and a -38% (-46.4, -28.7) lowering from baseline in Uox vs. placebo at the 3x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> TID dose.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gout</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB2081 is a Synthetic Biotic designed to consume uric acid in the GI tract with the goal of lowering systemic uric acid levels as a potential treatment for gout, a complex form of inflammatory arthritis. Current treatment options present limitations in both safety and efficacy. SYNB2081 presents a novel, orally administered, non-systemically absorbed drug candidate created through a research collaboration between Synlogic and Ginkgo, the leading horizontal platform for cell programming.  Gout occurs when excess uric acid in the body forms crystals in the joints. Patients can experience symptoms such as intense joint pain, inflammation and redness, and limited range of motion in the affected joints due to excessive levels of uric acid. In addition, gout is a recognized risk factor in chronic kidney disease. Due to present limitations in current treatment options, we believe that there is a clear need for a new approach. In August 2022, we announced SYNB2081 as our drug candidate for the potential treatment of gout and the second product candidate to advance to clinical development through our collaboration with Ginkgo. Our plan is to continue moving SYNB2081 to the next stage of our drug development pipeline, and it is currently in IND-enabling studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Pipeline Programs in Metabolic &amp; Immunological Diseases</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Synthetic Biotic approach is particularly well-suited for addressing known disease targets that have been associated with validated biological pathways in metabolic and immunological diseases.  IBD is a group of diseases characterized by significant local inflammation in the GI tract typically driven by T cells, activated macrophages and compromised function of the epithelial barrier. IBD pathogenesis is linked to both genetic and environmental factors and may be caused by altered interactions between gut microbes and the intestinal immune system. Compromised gut barrier function also plays a central role in autoimmune diseases pathogenesis. A single layer of epithelial cells separates the luminal contents of the gut from the host circulatory system and the immune cells in the body. Disrupting the epithelial layer can lead to pathological exposure of foreign antigens from the lumen resulting in increased susceptibility to autoimmune disorders. The interplay between the gut microbiota and the host is thought to play a key role in the maintenance of the epithelial barrier as well as homeostatic immunity. Thus, enhancing barrier function and reducing inflammation in the gastrointestinal tract are potential therapeutic mechanisms for the treatment or prevention of autoimmune disorders. Our Synthetic Biotic platform allows for the effective programming of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Nissle to execute these functions, including the metabolic production of factors such as short chain fatty acids to enhance barrier function, and secreting proteins, such as immunomodulatory cytokines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current approaches to treat IBD are focused on therapeutics that modulate the immune system and suppress inflammation. These therapies include steroids, such as prednisone, and tumor necrosis factor inhibitors, such as Humira&#174;(adalimumab). However, these approaches are associated with systemic immunosuppression, which includes greater susceptibility to infectious diseases and cancer. According to the CDC, in 2015 an estimated three million adults in the United States are reported as being diagnosed with IBD. In June of 2021 we entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic for the treatment of IBD. In addition, we continue to advance additional, wholly-owned preclinical research efforts in IBD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among immune conditions, working to treat IBD allows us to leverage knowledge and expertise gained from our oral metabolic programs to develop living medicines that can act locally at the site of disease in the gut. Because our approach is based on local delivery to the site of inflammation and not on systemic administration, we anticipate that our Synthetic Biotics may offer an attractive safety profile in this therapeutic category, where safety is a particularly desirable attribute in a product profile compared to options available today.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We developed a portfolio of Synthetic Biotics to treat certain cancers which were designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. These Synthetic Biotics could be used in combination with other cancer therapies such as checkpoint inhibitors. Our Synthetic Biotic clinical immuno-oncology (IO) candidate is SYNB1891, an intratumorally administered Synthetic Biotic medicine engineered to act as a dual innate and adaptive immune activator. On November 10, 2021, we announced that our Phase 1 trial of SYNB1891 in combination with PD-L1 checkpoint inhibitor patients with advanced solid tumors or lymphoma had completed enrollment. No further studies are planned for SYNB1891 and we are focusing our research and development efforts specifically on metabolic and immunological diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently operate in one reportable business segment&#x2014;the discovery and development of Synthetic Biotics. To date, we have dedicated substantially all of our activities to the research and development of our product candidates. We have funded our operations to date primarily with proceeds from the sale of preferred stock, common stock, preferred units, warrants, payments received under the Roche Collaboration and Option agreement, prior collaborations, interest earned on investments, and cash received in the Merger.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated any revenue to date from product sales and have incurred significant operating losses since our inception. We have incurred net losses of approximately $66.1 million and $60.6 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, we had an accumulated deficit of approximately $357.0 million and $290.9 million, respectively, and we expect to incur losses for the foreseeable future as we develop our product candidates. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities, as we:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Complete preclinical studies, initiate and complete clinical trials for product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract to manufacture product candidates or manufacture product candidates internally;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance research and development related activities to expand our product pipeline;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Seek regulatory approval for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maintain, expand and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hire additional staff, including clinical, scientific, commercial and management personnel;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expand our existing infrastructure and secure space in a facility to support continued growth in our research and development efforts; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add operational and finance personnel to support product development efforts and to support operating as a public company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not expect to generate product revenue unless and until we successfully complete clinical development and obtain regulatory approvals for our product candidates, either alone or in collaboration with third parties. Additionally, we expect to utilize third-party contract research organizations (CROs) and contract manufacturing organizations (CMOs) to carry out our clinical development and manufacturing activities, and we do not yet have a commercial organization. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution. Accordingly, we anticipate that we will seek to fund our operations through public or private equity or debt financings, collaborations or licenses, finance lease transactions or other available financing transactions. However, we may be unable to raise additional funds through these or other means when needed. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if it will be able to achieve or maintain profitability. Even if we are able to generate product revenue, we may not become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impact of the COVID-19 pandemic on our business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic continues to affect economies and business around the world. The extent and duration of such effects remain uncertain and difficult to predict, particularly as virus variants continue to spread. We are actively monitoring and managing our response and assessing actual and potential impacts to our operating results and financial condition, as well as developments in our business, which could further impact the developments, trends and expectations described below. See the risk factor related to the impact of the COVID-19 pandemic, &#x201c;A pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, or geopolitical tensions, such as the armed conflict between Russia and Ukraine, may materially and adversely affect our business and our financial results&#x201d; described in &#x201c;Risk Factors&#x201d; in Part I, Item 1A of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Effects of Inflation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not believe that inflation has had a material impact on our business or operating results during the periods presented. However, inflation has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to conduct clinical trials and other operational costs. Inflationary costs could adversely affect our business, financial condition and results of operations. In addition, increased inflation has had, and may continue to have, an effect on interest rates. Increased interest rates may adversely affect our borrowing rate and our ability to obtain, or the terms under which we can obtain, any potential additional funding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue for the year ended December 31, 2022 was generated from the Roche Collaboration and Option Agreement. See Note 10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Roche Collaboration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the notes to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K for a full discussion of this arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expense</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates, including the conduct of preclinical and clinical studies and product development, which are expensed as they are incurred. These expenses consist primarily of:</span></p>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation, benefits and other employee related expenses;</span></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplies to support our internal research and development efforts;</span></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development related facility and depreciation costs;</span></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leased manufacturing space; and</span></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party contract costs relating to research, process and formulation development, preclinical and clinical studies and regulatory operations.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lengthy process of securing regulatory approvals for new drugs requires the expenditure of substantial resources. Any delay or failure to obtain regulatory approvals would materially adversely affect our product candidate development efforts and our business overall. Given the inherent uncertainties of pharmaceutical product development, we cannot estimate with any degree of certainty the likelihood, timing or cost of obtaining regulatory approval and marketing our product candidates and thus, when, if ever, our product candidates will generate revenues and cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The successful development of our product candidates is highly uncertain and subject to a number of risks. Refer to the risk factors under the heading </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to the Development of Our Product Candidates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in Part II, Item 1A, found elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When we invest in our pipeline, the commitment of funding for each subsequent stage of our development programs is dependent upon the receipt of clear, supportive data. We anticipate that we will make determinations as to which additional programs to pursue and how much funding to direct to each program on an ongoing basis in response to the scientific and clinical data of each product candidate, as well as the competitive landscape and ongoing assessments of such product candidate&#x2019;s commercial potential. We expect our research and development costs will be substantial for the foreseeable future. We expect costs associated with our drug development candidates to increase as the programs progress through clinical trials and new programs progress toward IND and into development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We track direct research and development expenses, consisting principally of external costs, such as costs associated with contract research organizations and manufacturing of preclinical and clinical drug product and other outsourced research and development expenses, to specific product programs. Costs related to specific product candidates are tracked upon the selection of a product candidate. We do not allocate employee and consulting-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product candidate programs because these costs are deployed across multiple product candidate programs under research and development and, as such, are separately classified. The table below summarizes our research and development expenses by categories of costs for the periods presented (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.268%;"></td>
    <td style="width:1.725%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.02%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.725%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.261%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB1934</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,380</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,189</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB1618</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,436</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,577</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB8802</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,197</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,499</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB1353</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,259</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNB1891</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,223</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,541</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">External pre-development candidate expenses and unallocated<br />&#160;&#160;&#160;expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,129</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,526</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,420</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,795</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,044</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,127</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expense</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of compensation, benefits and other employee-related expenses for personnel in our administrative, finance, legal, information technology, investor relations, business development and human resource functions. Other general and administrative costs include the legal costs of pursuing patent protection of our intellectual property, facility and information technology infrastructure costs, directors&#x2019; and officers&#x2019; insurance, and professional fees for accounting, tax, legal and consulting services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that our general and administrative expenses will increase in the future as we support our continued research and development and potential commercialization of our product candidates. Additionally, if and when we believe a regulatory approval of the first product candidate appears likely, we anticipate an increase in payroll and related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and investment income consists of income earned on investments. Interest expense consists of expense related to our finance leases. Other expense consists primarily of gains and losses on foreign currency invoices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses during the reported periods and related disclosures. These estimates and assumptions, including those related to revenue recognition and research and development expenses are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. These critical estimates and assumptions are based on our historical experience, our observance of trends in the industry, and various other factors that are believed to be reasonable under the circumstances and form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from our estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the application of the following accounting policies, each of which require significant judgments and estimates on the part of management, are the most critical to aid in fully understanding and evaluating our reported financial results. Our significant accounting policies are more fully described in Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We evaluate collaboration agreements with respect to FASB ASC Topic 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, considering the nature and contractual terms of the arrangement and the nature of our business operations to determine the classification of the transactions. When we are an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, we will record our transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step analysis to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assesses whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may enter into collaboration agreements for research and development services, under which we may license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed to not be at a significant risk of reversal.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements for which the collaboration partner is also a customer, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. As part of the accounting for these arrangements, we must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. We use significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services we expect to provide. We use estimates to determine the timing of satisfaction of performance obligations, which may include the use of full-time equivalent time as a measure of satisfaction of performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in our consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Services</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement is determined to contain a promise or obligation for us to perform research and development services, we must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, we consider the capabilities of the customer to perform these same services. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The estimates we use to record revenue relating to the combined performance obligation on an over time basis, include input methods such as full-time equivalent time incurred compared to the full-time equivalent time expected to be incurred in the future to satisfy the performance obligation, which require management judgment. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. With this method, we must estimate total inputs required to satisfy a performance obligation and measure efforts expended to date to determine revenue recognition. This estimate of remaining inputs is subjective, as the research is novel, and therefore efforts to be successful may be different than the estimated efforts at the balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Options</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. We evaluate the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, we allocate the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Payments</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of each arrangement that includes milestone payments, we evaluate whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, we evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, we reevaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjusts our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contract Costs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, we recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, we have not incurred any incremental costs of obtaining a contract with a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expense</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All research and development expenses are expensed as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including compensation, benefits and other employee costs; equity&#x2011;based compensation expense; laboratory and clinical supplies and other direct expenses; facilities expenses; overhead expenses; fees for contractual services, including preclinical studies, clinical trials, clinical manufacturing and raw materials; and other external expenses. Nonrefundable advance payments for research and development activities are capitalized and expensed over the related service period or as goods are received and services are performed. When third-party service providers&#x2019; billing terms do not coincide with our period-end, we are required to make estimates of our obligations to those third parties, including clinical trial costs, contractual service costs and costs for supply of our drug candidates, incurred in a given accounting period and record accruals at the end of the period. We base our estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.161%;"></td>
    <td style="width:1.701%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.237%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.701%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.202%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,180</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,754</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,044</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,127</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,555</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,392</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,599</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,519</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(67,419</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(60,765</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and investment income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,267</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,272</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(66,147</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(60,561</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31, 2022 Compared to Year Ended December 31, 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.552%;"></td>
    <td style="width:1.218%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.218%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.351%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.218%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.191%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.896%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.155000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,180</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,754</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(574</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(33</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue was $1.2 million for the year ended December 31, 2022 compared to $1.8 million for the year ended December 31, 2021. Revenue for both periods was primarily related to services performed under the Roche collaboration that we entered into in June 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.678%;"></td>
    <td style="width:1.277%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.272%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.277%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.479%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.277%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.318%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.955%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.468%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,044</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,127</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,917</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,555</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,392</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,163</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,599</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,519</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,080</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expense</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expense was $52.0 million for the year ended December 31, 2022 compared to $47.1 million for the year ended December 31, 2021. The increase of $4.9 million was due to increases of clinical development costs of $2.0 million for SYNB1353, and $0.3 million for SYNB1934, as well as an increase of $1.3 million of manufacturing costs and an increase of $0.8 million of non-clinical costs. There were additional increases of $1.3 million in compensation, benefits and other employee-related expenses, of which $0.7 million were a result of the reduction in workforce announced in November 2022. In addition, there were increases of $1.3 million in research and development support costs and $1.1 million in professional services. These increases were offset by decreases of clinical development costs of $2.1 million for SYNB8802 and $1.1 million for SYNB1891.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expense</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expense was $16.6 million for the year ended December 31, 2022 compared to $15.4 million for the year ended December 31, 2021. The increase of $1.2 million was primarily due to an increase of $0.9 million in compensation, benefits and other employee-related expenses, of which $0.1 million were a result of the reduction in workforce announced in November 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.185%;"></td>
    <td style="width:1.265%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.433%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.277%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.398%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.277%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.023000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.957%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.184999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and investment income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,267</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,057</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">503</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(275</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,272</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,068</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">524</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income for the year ended December 31, 2022 was $1.3 million compared to $0.2 million for the corresponding period in 2021. The increase in other income of $1.1 million was due to an increase in income earned on our cash, cash equivalents and short-term investment balances, primarily related to higher interest rates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred losses since our inception on March 14, 2014 and as of December 31, 2022, we had an accumulated deficit of $357.0 million. We have financed our operations to date primarily through the sale of preferred stock, common stock, preferred units and warrants, payments received under collaboration agreements, including the technology collaboration with Ginkgo, the Roche Collaboration and Option agreement, and prior collaborations, interest earned on investments, and cash received in the Merger. At December 31, 2022, we had $77.6 million in cash, cash equivalents, and short-term marketable securities. Our cash and cash equivalents include amounts held in money market funds, stated at cost plus unrealized gain and loss, which approximates fair market value. Our available-for-sale securities include amounts held in commercial paper and U.S. treasuries. We invest cash in excess of immediate requirements in accordance with our investment policy, which limits the amounts we may invest in any one type of investment and requires all investments held by us to maintain minimum ratings from Nationally Recognized Statistical Rating Organizations so as to primarily achieve liquidity and capital preservation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, our cash, cash equivalents and marketable securities balance decreased $59.0 million. This decrease was primarily due to the cash used to operate our business, including payments related to, among other things, research and development and general and administrative expenses as we continue to invest in our primary drug candidates and support the development of our proprietary platform. These decreases were offset by the proceeds from maturity of marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the major sources and uses of cash, cash equivalents and restricted cash for each of the periods below:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.161%;"></td>
    <td style="width:1.701%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.237%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.701%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.202%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash, cash equivalents and restricted cash (used in) provided by</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(56,888</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(52,198</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,351</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(53,253</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,040</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,382</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(577</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16,069</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash, cash equivalents and restricted cash used in operating activities was $56.9 million for the year ended December 31, 2022. The primary use of cash was our net loss of $66.1 million, partially offset by changes in our assets and liabilities of $0.7 million and $8.5 million of non-cash items primarily including depreciation, equity-based compensation, and the right of use asset. The changes in our assets and liabilities include decreases in the operating lease liability, decreases in prepaid expenses and other current assets, increases in prepaid research and development expenses, increases in accounts payable and accrued expenses, and increased deferred revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash, cash equivalents and restricted cash used in operating activities was $52.2 million for the year ended December 31, 2021. The primary use of cash was our net loss of $60.6 million, changes in our assets and liabilities of $0.2 million, partially offset by $8.2 million of non-cash items primarily including depreciation, equity-based compensation, and the right of use asset. The changes in our assets and liabilities include decreases in prepaid research and development expenses, as a result of the work being completed on the Ginkgo collaboration, decreases in prepaid expenses and other current assets, decreases in the operating lease liability, increases in accounts payable and accrued expenses, and increased deferred revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by investing activities for the year ended December 31, 2022 was $58.4 million and resulted primarily from the proceeds from maturity of marketable securities of $141.9 million. This was offset by the purchases of marketable securities of $82.8 million and property and equipment of $0.7 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2021 was $53.3 million and resulted primarily from the purchases of marketable securities of $167.9 million and property and equipment of $0.7 million. This was offset by the proceeds from maturity of marketable securities of $114.0 million and proceeds from redemption of marketable securities of $1.3 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2022 totaled $2.0 million, primarily related to the repurchase of our common stock of $2.5 million, partially offset by $0.3 million from the sale of our common stock in the ATM offering program, and $0.2 million of proceeds received from stock option exercises and purchases made pursuant to our employee stock purchase plan.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2021 totaled $89.4 million, primarily related to net proceeds of $81.0 million from the sale of our common stock in underwritten public offerings in April and September 2021, $8.0 million from the sale of our common stock in the ATM offering program, and proceeds of $0.4 million from exercise of stock options and ESPP contributions, offset by payments of withholding taxes for employees relating to restricted stock awards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Funding Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have not commercialized any products and have not achieved profitability. We anticipate that we will continue to incur substantial net losses for the next several years as we further develop our product candidates, invest in our proprietary platform technology and operate as a publicly traded company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently generating revenue from our Roche collaboration and have historically generated revenue from previous collaborations, but have not generated any product revenue since our inception and do not expect to generate any product revenue unless we receive regulatory approval for our product candidates. We believe that our cash, cash equivalents, and short-term marketable securities as of December 31, 2022, will be sufficient to meet our anticipated cash requirements for at least the next 12 months from the date of this filing. Specifically, based on our current forecast, our existing cash, cash equivalents and short-term marketable securities balances are expected to provide a cash runway extending into the second half of fiscal 2024. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, including the factors discussed in the section entitled &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K. We have based our estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the numerous risks and uncertainties associated with the development of our product candidates, we are unable to estimate precisely the amounts of capital outlays and operating expenditures necessary to complete the development of, and to obtain regulatory approval for, our product candidates. Our funding requirements will depend on many factors, including, but not limited to, the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our research and development efforts;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initiation, progress, timing, costs and results of clinical trials for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time and costs involved in obtaining regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The progress, timing and costs involved in developing manufacturing processes and agreements with third-party manufacturers;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rate of progress and cost of our commercialization activities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expenses we incur in marketing and selling our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The revenue generated by sales of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The emergence of competing or complementary technological developments;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms and timing of any additional collaborative, licensing or other arrangements that we may establish;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The acquisition of businesses, products and technologies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our need to implement additional infrastructure and internal systems; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our need to add personnel and financial and management information systems to support our product development and potential future commercialization efforts, and to enable us to operate as a public company; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The extent to which our business is adversely impacted by the effects of the coronavirus outbreak or by other health epidemics or pandemics; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other risks and uncertainties, including those listed under Part I, Item 1A. &#x201c;Risk Factors&#x201d;.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contractual Commitments and Obligations</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have certain significant contractual obligations and commitments that require funding. Our commitments for operating leases relate to our lease of office and laboratory space at 301 Binney Street in Cambridge, Massachusetts and the cGMP clean-room space leased from the Azzur Group, LLC, in Waltham, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2017, we entered into an agreement to lease 41,346 square feet of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts. Annual rent is $3.4 million. The ten-year lease commenced in January 2018 and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. Additionally, we have paid for a tenant improvement investment of $2.9 million. In conjunction with the lease, we established a letter of credit of a $1.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 7, 2018, Synlogic Operating Company, Inc., a wholly-owned subsidiary of the Company, entered into a Statement of Work (the First SOW) with Azzur Group, LLC (Azzur) pursuant to a Master Contract Services Agreement (the Master Services Agreement), dated September 8, 2018, between the Company and Azzur.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the First SOW, Azzur agreed to provide the Company with access to, and the use of, an approximately 700 square foot cleanroom space to be constructed in Waltham, Massachusetts (the Azzur Suite), for a period of 44 months, from May 1, 2019 to December 31, 2022 (the Initial Term). Azzur also agreed to provide the Company with storage space and personnel support at the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Azzur Suite. The total estimated project cost during the Initial Term for access to, and use of, the cleanroom and storage space, and the personnel support and other services, was $4.8 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, Synlogic entered into a new agreement (the Second SOW) with Azzur which replaced the First SOW. Pursuant to the Second SOW, Synlogic was granted access to, and use of, the Azzur Suite for a period of 20 months, from May 2021 to December 2022 (the Second Term). The Company determined that the agreement contained an embedded lease because the Company controls the use of the Azzur Suite. Accordingly, the fixed and in-substance fixed consideration under the agreement was used to remeasure the right-of-use (ROU) asset and lease liability at the effective date of the Second SOW.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 21, 2022, the Company entered into two Statements of Work with Azzur. Pursuant to the first of these SOWs (the Third SOW), the Company has agreed to pay Azzur $0.7 million to renovate and upgrade the cleanroom space at Azzur for the Company&#x2019;s expanded use. The second of these SOWs (the Fourth SOW) replaces the Second SOW that the Company entered into with Azzur on April 29, 2021. The Fourth SOW extends the term of the lease, for the period beginning January 2022 through March 2023 (the Third Term). The Third and Fourth SOWs resulted in an adjustment to the operating lease right-of-use asset and corresponding operating lease liabilities of $1.8 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, the Company entered into a new agreement (the Fifth SOW) with Azzur that extended the term of the lease, for the period beginning April 2023 through December 2023 (the Fourth Term). The Fifth SOW contains two options to extend the lease, the first option goes through June 2024, and the second option goes through December 2024. As of December 31, 2022, the Company determined that it was reasonably certain to exercise the first option to extend the lease. The Fifth SOW resulted in an adjustment to the operating lease right-of-use asset and corresponding operating lease liabilities of $1.0 million. The total remaining liability associated with the Azzur lease is approximately $2.9 million as of December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may terminate the Fifth SOW on three months&#x2019; prior written notice at any time during the Term. In addition, either party may terminate the Master Services Agreement (including the SOWs) due to a breach by the other party and failure to cure. The Company is reasonably certain not to exercise the termination option through June 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we are a clinical stage company, we expect our most significant clinical trial expenditures will be with CROs and CMOs. These contracts generally are cancellable, with notice, at our option and do not have cancellation penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an early-stage company, we are subject to a number of risks common to other life science companies, including, but not limited to, the ability to raise additional capital, development by our competitors of new technological innovations, risk of failure in preclinical studies, the safety and efficacy of our product candidates in clinical trials, the regulatory approval process, the ability to efficiently manufacture our products, market acceptance of our products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. Our therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate revenue from product sales. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or alliances. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships. We enter into guarantees in the ordinary course of business related to the guarantee of our performance and the performance of our subsidiaries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Please read Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide this information required under this item.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_consolidated_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Consolidated Financial St</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">atements and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated financial statements, together with the independent registered public accounting firm report thereon, appear at pages F-1 through F-26 respectively, of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definition and limitations of disclosure controls</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluates these controls and procedures on an ongoing basis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. These limitations include the possibility of human error, the circumvention or overriding of the controls and procedures and reasonable resource constraints. In addition, because we have designed our system of controls based on certain assumptions, which we believe are reasonable, about the likelihood of future events, our system of controls may not achieve its desired purpose under all possible future conditions. Accordingly, our disclosure controls and procedures provide reasonable assurance, but not absolute assurance, of achieving their objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Form 10-K, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In addition, our principal executive officer and principal financial officer have concluded that the impact of the COVID-19 pandemic did not impact our ability to maintain our internal controls over financial reporting and disclosure controls and procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have not been any changes in our internal controls over financial reporting identified in connection with the evaluation of such internal control that occurred during our fiscal year ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as amended. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on our assessment, management believes that, as of December 31, 2022, our internal control over financial reporting is effective based on those criteria.</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inherent Limitations on the Effectiveness of Controls</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9at"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the controls are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues or misstatements, if any, within a company have been detected. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosureforeignjurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Rega</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rding Foreign Jurisdictions That Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#x201c;Management and Corporate Governance Matters,&#x201d; &#x201c;Section 16(a) Beneficial Ownership Reporting Compliance,&#x201d; and &#x201c;Code of Conduct and Ethics&#x201d; in the Company&#x2019;s Proxy Statement for the 2023 Annual Meeting of Stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#x201c;Executive Officer and Director Compensation&#x201d; in the Company&#x2019;s Proxy Statement for the 2023 Annual Meeting of Stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item13"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; in the Company&#x2019;s Proxy Statement for the 2023 Annual Meeting of Stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item14"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#x201c;Certain Relationships and Related Person Transactions&#x201d; and &#x201c;Management and Corporate Governance&#x201d; in the Company&#x2019;s Proxy Statement for the 2023 Annual Meeting of Stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#x201c;Independent Registered Public Accounting Firm&#x201d; in the Company&#x2019;s Proxy Statement for the 2023 Annual Meeting of Stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15(a).	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents are filed as part of this Annual Report on Form 10-K:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15(a)(1) and (2)	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See &#x201c;Consolidated Financial Statements and Supplementary Data&#x201d; at Item 8 to this Annual Report on Form 10-K. Other financial statement schedules have not been included because they are not applicable, or the information is included in the financial statements or notes thereto.</span></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15(a)(3)	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:35.0%;"></td>
    <td style="width:6.898%;"></td>
    <td style="width:19.583%;"></td>
    <td style="width:17.398%;"></td>
    <td style="width:11.12%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with this</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference herein</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">from Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File/Reg.</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;2.1&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000110465917032941/a17-13113_1ex2d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger and Reorganization, dated as of May 15, 2017, by and among Mirna Therapeutics, Inc., Meerkat Merger Sub, Inc. and Synlogic, Inc.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 2.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">05/16/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000110465915069368/a15-14644_8ex3d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 3.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/6/2015</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation, dated August 25, 2017</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 3.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/28/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;3.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 3.2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/28/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;3.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000110465915069368/a15-14644_8ex3d2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 3.2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/6/2015</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000104746915007386/a2226006zex-4_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Common Stock Certificate</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 4.2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/18/2015</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-206544</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312519170721/d766098dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-Funded Warrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 4.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">06/12/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459020010261/sybx-ex43_732.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 4.3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/12/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459018006323/sybx-ex101_397.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2015 Equity Incentive Award Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/20/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_9b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2015 Equity Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.9(B))</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/11/2015</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-206544</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_9c.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Award Agreement and Restricted Stock Unit Award Grant Notice under the 2015 Equity Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.9(C))</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/11/2015</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-206544</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459018006323/sybx-ex104_396.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2017 Stock Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.4)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/20/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517340965/d458814dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under 2017 Stock Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.17)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/13/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459018006323/sybx-ex106_235.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non&#x2011;Employee Director Compensation Program.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">01/31/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:35.0%;"></td>
    <td style="width:6.898%;"></td>
    <td style="width:19.583%;"></td>
    <td style="width:17.398%;"></td>
    <td style="width:11.12%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with this</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference herein</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">from Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File/Reg.</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_13.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement between the Company and each of its directors and officers</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.13)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">09/11/2015</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-206544</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter by and between Synlogic and Aoife M. Brennan, MB, BCh, BAO, MMSc, dated as of June 22, 2016</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.6)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/28/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Offer Letter by and between Synlogic and Aoife M. Brennan, MB, BCh, BAO, MMSc, dated as of November 7, 2016</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.7)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/28/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Offer Letter by and between Synlogic and Aoife M. Brennan, MB, BCh, BAO, MMSc, dated as of May 8, 2017</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.8)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/28/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459018020755/sybx-ex101_100.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Offer Letter dated as of June 5, 2018, between Synlogic, Inc. and Aoife Brennan, MB, BCh, BAO, MMSc</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/9/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459018029326/sybx-ex101_305.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Letter Agreement by and between Synlogic, Inc. and Aoife M. Brennan, MB, BCh, BAO, MMSc, dated as of October 1, 2018</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/13/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312522064445/d291506dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement dated as of January 24, 2022, by and between Synlogic and Michael Jensen</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/03/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459021015256/sybx-ex10141_239.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Letter Agreement dated November 28, 2018, by and between Synlogic and Antoine Awad</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.14.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/25/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459021015256/sybx-ex10142_240.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Promotion Letter, dated July 21, 2020, for Antoine Awad</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.14.2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/25/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15&#134;&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger by and among AbbVie S.&#xe0;.r.l., Suffolk Merger Sub, Inc., Synlogic IBDCo, Inc., Synlogic, LLC, Synlogic, Inc. and the founders named therein, dated as of July 16, 2015; as amended by a First Amendment to Agreement and Plan of Merger, dated as of December 14, 2015</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.12)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/28/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16&#134;&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459018029326/sybx-ex102_304.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Agreement and Plan of Merger by and among AbbVie S.&#xe0;.r.l., Synlogic IBDCo, Inc. and Synlogic Operating Company, Inc., dated as of September 27, 2018</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/13/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17&#134;&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459019007367/sybx-ex1025_537.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Agreement and Plan of Merger and First Amendment to License Agreement by and among AbbVie S.&#xe0;.r.l., Synlogic IBDCo, Inc. and Synlogic Operating Company, Inc., dated as of December 18, 2018</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.25)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/12/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement by and between Synlogic, Inc. and Synlogic IBDCo, Inc., dated as of July 16, 2015</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.13)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/28/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:35.0%;"></td>
    <td style="width:6.898%;"></td>
    <td style="width:19.583%;"></td>
    <td style="width:17.398%;"></td>
    <td style="width:11.12%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with this</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference herein</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">from Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File/Reg.</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312517310897/d671201dex11.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales Agreement, dated as of July 23, 2021 by and between the registrant and Jefferies LLC</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 1.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/10/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312518109307/d564416dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Subscription Agreement, dated as of April 6, 2018, by and among Synlogic, Inc. and certain investors.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">04/6/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459019007367/sybx-ex1029_621.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Master Contract Services Agreement, dated as of September 8, 2018, between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.29)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/12/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459019007367/sybx-ex1030_620.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statement of Work dated September 10, 2018 pursuant to Master Contract Services Agreement between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.30)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/12/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459019007367/sybx-ex1030_620.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statement of Work dated December 7, 2018 pursuant to Master Contract Services Agreement between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.31)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/12/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312519170721/d766098dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subscription Agreement dated June 11, 2019 by and between the Company and Ginkgo Bioworks, Inc.</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">06/12/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.25&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459019030838/sybx-ex102_134.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foundry Terms of Service Agreement dated June 11, 2019 by and between Synlogic Operating Company Inc. and Ginkgo Bioworks, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/08/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312519273622/d820489dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement effective as of October 13, 2019 by and between the Company and Danforth Advisors, LLC, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/24/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.27</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000119312519321039/d853861dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic, Inc. 2015 Employee Stock Purchase Plan, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/20/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459021043681/sybx-ex101_149.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and Services Agreement and Statement of Work, dated April 28, 2021, by and between Synlogic Operating Company, Inc. and Azzur Cleanrooms-On-Demand &#x2013; Boston, LLC.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/12/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.29</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001527599/000156459021043681/sybx-ex102_148.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pilot Collaboration and Option Agreement, dated June 16, 2021, among Synlogic Operating Company, Inc. and Hoffman-La Roche Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08/12/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.30</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459022010714/sybx-ex1030_463.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statement of Work dated January 21, 2022 pursuant to Master Contract Services Agreement between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC), SOW P-10558-01</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.30)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/17/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.31</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1527599/000156459022010714/sybx-ex1031_464.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statement of Work dated January 21, 2022 pursuant to Master Contract Services Agreement between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC), SOW P-10558-2</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exhibit 10.31)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/17/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-37566</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:35.0%;"></td>
    <td style="width:6.898%;"></td>
    <td style="width:19.583%;"></td>
    <td style="width:17.398%;"></td>
    <td style="width:11.12%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with this</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference herein</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">from Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File/Reg.</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.32</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sybx-ex10_32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statement of Work dated November 22, 2022 pursuant to Master Contract Services Agreement between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC), SOW P-10558-01 Extension A</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sybx-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsidiaries of the registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sybx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included in the signature page hereto)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sybx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sybx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sybx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sybx-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document - &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#94; The schedules and exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># Management contract or compensatory plans or arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134; Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item16"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form </span><span id="item_16_form_10k_summary"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K Summ</span><span id="item16_form10k"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ary.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic, Inc.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ AOIFE BRENNAN</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aoife Brennan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="power_of_attorney">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:5.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Aoife Brennan and Michael Jensen his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:5.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated opposite his name.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant in the capacities indicated below and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.009%;"></td>
    <td style="width:1.046%;"></td>
    <td style="width:43.306%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:21.537%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ AOIFE BRENNAN</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer, and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aoife Brennan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MICHAEL JENSEN</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Jensen</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ PETER BARRETT</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Peter Barrett</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of the Board</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MICHAEL BURGESS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Burgess</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MICHAEL HEFFERNAN</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Heffernan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ PATRICIA HURTER</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patricia Hurter</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ LISA KELLY-CROSWELL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lisa Kelly-Croswell</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ NICK LESCHLY</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nick Leschly</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ EDWARD MATHERS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Edward Mathers</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ RICHARD P. SHEA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard P. Shea</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2023</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Index to Consolidated Financial Statements of Synlogic, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:95.5%;"></td>
    <td style="width:4.5%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (KPMG LLP, Boston, MA, Auditor Firm ID: 185)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_stockholders_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_stat2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Regis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and Board of Directors<br />Synlogic, Inc.:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Synlogic, Inc. and subsidiaries (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="margin-left:7.507%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Evaluation of accrued expenses related to research and development activities performed by third parties</span></p>
  <p style="margin-left:7.507%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed in Note 2 to the consolidated financial statements, costs incurred in research and development are expensed as incurred. When third-party service providers&#x2019; billing terms do not coincide with the Company&#x2019;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs, and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on its knowledge of the research and development programs, services performed for the period and the expected duration of the third-party service contract, where applicable. As discussed in Note 7 to the consolidated financial statements, the accrued expenses balance related to research and development activities performed by third parties was $1.6 million at December 31, 2022.</span></p>
  <p style="margin-left:7.507%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We identified the evaluation of accrued expenses related to research and development activities performed by third parties as a critical audit matter. The estimates made by the Company in determining the accrued expenses balance are based on a number of factors that can be challenging to assess, including the completion status of the research and development programs and the associated estimate of unbilled costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:7.507%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following are the primary procedures we performed to address this critical audit matter. We inspected contracts with third-party service providers, including any subsequent amendments, confirmed costs incurred to date with the respective third parties under the contracts, and inspected invoices to evaluate the amounts billed to date under the contracts. Furthermore, to assess that all services rendered by the third parties prior to December 31, 2022 were appropriately included in the Company&#x2019;s accrued expenses balance at December 31, 2022, we (1) inquired of the individuals at the Company who are responsible for overseeing the research and development activities of the third-party service providers to understand the progress of the respective programs, (2) inspected correspondence received from the third-party service providers, including status reports, and compared them to the estimates underlying the accrued expenses balance, and (3) compared amounts ultimately invoiced by the third-party service providers subsequent to December 31, 2022 to the amounts accrued by the Company.</span></p>
  <p style="margin-left:7.507%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ KPMG LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2015.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts<br />March 29, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="item8"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">alance Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.488%;"></td>
    <td style="width:1.736%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.02%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.736%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.02%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2a72505-0321-4da4-929f-7bc8abe30cf6" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,861</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90ba628a-2ef7-4147-a96b-4cfb1ab250a3" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_492de647-1212-4827-a83a-3b719cd250f2" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,768</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75d8f88a-7cea-409e-adb2-4cb823b2ff26" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47f46b94-4419-45ad-a585-506f8771769d" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4925532-f685-436c-ba9f-7cc797dfea05" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,721</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb4a3e25-02ed-4488-821a-db2fedb0a743" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23fafdb6-a11c-4db2-9e41-96ce700de668" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,309</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_28c409d5-6a3b-428a-8521-04958db80cd2;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72c96f68-23ba-41a9-bb5d-c0067b5b51f7" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01762bed-b042-411f-be7b-b0f5437085af" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c12cc1a-d779-4246-9c6e-da1e0243f59e" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,088</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use asset - operating lease</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_849a1642-45d7-440b-914f-2b91ea944319" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3ee6d95-1abf-4648-86c9-81cf37c43245" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,889</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d630182-2029-4b73-ae49-ea2034d11411" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57c0d1a7-beba-4d33-96ba-3f3defcef56a" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6451e08-e0f1-468f-a6f4-4d7aaf26d94e" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:PrepaidResearchAndDevelopmentNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d664419-90c3-4228-b292-7b845cc271fe" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="sybx:PrepaidResearchAndDevelopmentNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,309</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c046bb8-8681-4ac0-a31d-14f40e336931" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84635ac4-acd8-4770-96f5-bd50814ceea2" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2e9d198-5c82-4321-be2b-2e550c88a071" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f58d68e-12e4-4735-a7c9-d609245f06dd" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174,736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76f12012-b207-4c4a-8213-9c3047b4dcca" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f15d5d49-e955-4be8-9092-175889dcadfb" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_408b6e08-5a83-4197-9605-ad45ddcacaca" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85a7f16b-fb46-4c4e-980f-51c06400199d" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a345246-8be4-4a75-bed9-38167eafc411" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">882</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4226e836-6cc7-4956-add0-ae5521bd53b0" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability - operating lease</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70c92661-9f88-4f2d-8ee8-a57b5f146ca4" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4435eea6-de4a-4a34-9cf2-53cfe18c095d" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,191</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finance lease obligations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdd70d2e-3ca5-4317-ba4e-bc3870ff67e9" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40ebde16-18b2-466a-9350-f53ccae9d941" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77baebcb-b45e-4a8f-9183-4a6b8985e847" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e2584fc-4f92-4179-9f5b-84f87d33fcae" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,080</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability - operating lease, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0bd26a1-aa41-4919-9f4a-640c83555ca5" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18e25103-657a-4ab9-92c3-05cfbb07958e" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,372</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finance lease obligations, net of current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce0af1c6-658a-4f53-a31f-9e3249dfe833" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd142faa-90a3-4c47-b995-d27d1f05e2d9" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84c83248-c791-4a1a-887f-ddc3599d029e" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8d3e221-424d-4c20-9c90-5c0c75a0c0ce" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,390</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_02c6b8c4-1e53-4fc1-994a-906cacc53571;"><span style="-sec-ix-hidden:F_cb04f5e1-07b2-4b27-b75e-4b304dd2e751;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 14)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e94a95b-6fc3-4aba-a5aa-543e301126ea" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_c8c37cec-02ee-481e-b33b-00d6cd7355c4" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60ce85e3-7d70-402b-bab8-fba20ed63964" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_17a4f353-d68c-4f5c-95f6-eb02eca96c91" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">250,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized as of December 31, 2022 and December 31, 2021;<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b55632c8-da70-4d40-9ff3-77b29ae75bcb" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,933,140</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8a57625-fb63-4ca0-9113-380d6e764e9a" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">66,736,251</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares outstanding as of December 31, 2022 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b198359-9eb2-4b0f-b9c5-561597f1b962" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_8711b4c9-7b7c-445a-83bf-13b60ed18d0e" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,698,844</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_086aaf3b-179f-4a7e-88a5-b0e9a54d1e22" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4b6e17d-231e-42e1-82d5-9756dd22c1f8" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_083fa0b6-6905-4cbe-b652-4c7fe295b5f5" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">442,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c55c9da1-9ce2-454f-a4ba-34f1873ea5d0" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">438,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b15c4c5-a693-4447-826b-56bfc84e462c" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">161</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49cc07b5-1ccb-4fb8-b120-7ea967760c19" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80fbb400-7f7d-4941-8665-0eb9d9c9b810" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">357,019</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf848d72-7f0f-47c9-8312-40b80f60a4d8" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">290,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury stock, at cost (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edad5b93-4bdf-4988-9a26-9969858ad70d" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:TreasuryStockShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,196,889</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares at December 31, 2022 and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_137645d2-83b4-4b83-8f0b-f2b46b3453f0" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:TreasuryStockShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares at December 31, 2021)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b73f814-0b58-40c8-9819-a69039123459" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:TreasuryStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_ee6be37b-9a01-4f47-82d0-a166404c555a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac99377e-6cde-4b80-be2b-533cf678a3a2" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,610</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_449325c6-f9d6-4e9e-a240-9531212c9978" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">147,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_053c93f0-6f74-4037-9f31-980db7055e4d" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcf61e76-ca22-4e91-95ca-ec4bb30eaf64" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174,736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic, INC. aND SUBSIDIARIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ents of Operations and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.617%;"></td>
    <td style="width:1.739%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.855%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.739%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.049000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_383b5e38-0842-4731-9e9f-2cc1653c1640" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67470fa1-69e4-44fe-9d5e-f726d7fc0627" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,754</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c7d00c1-3609-463a-a82d-fc2147ff72d5" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,044</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_616dc689-51db-4d12-8e9c-4f624d4ec961" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a94b007d-b0f4-4c95-b03c-e061efa49290" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6968962a-3851-4ccb-9402-a5723cd5a912" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87f404fc-3f5e-4da3-b16c-93541118ab4d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,599</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0a7d2de-00be-440c-9873-523a71f730c9" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a5b8d76-c7b7-4c09-9d97-e983cfce357c" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">67,419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12e0a993-a3bd-4b0f-b39b-3097f112db1a" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and investment income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_169b6b68-279b-4c6e-9c57-2942ce75745d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:InvestmentIncomeNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,267</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1986cc4e-debb-4067-9493-3148743d465c" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:InvestmentIncomeNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">210</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb16f518-cefe-401d-a32c-27d0f9c15ab7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f022628-ca3f-4835-a005-756f7ce983cf" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d54c21ad-7f9e-4ac2-b5b2-4b2e6ff3af2d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ba5f300-0453-4587-8840-3c3fc334023b" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79cab1b6-0767-4301-8dfa-ff2f0a078da2" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,272</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dbf82f1-0cf2-4dae-9180-51a5781e551e" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccf60bff-6d28-41ab-a45b-c4119dbc22b6" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,147</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b3d44ab-0b78-4656-a926-ffb7295a4725" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,561</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d557b26d-3ed9-4b29-aff6-12eb76a50856" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_e26ef360-bde0-4afb-ae0c-abb0e081ea11" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.92</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a345c2f-92ef-46ab-acf5-eecc31881606" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_dbb16380-b314-4ea1-9b05-94a5b464ba2e" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.09</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common stock outstanding - basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bfbb01c-b283-45a6-90f3-a2e770f2266e" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_761e16e7-cac4-4458-86da-dadf4d703a8d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">71,725,479</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4232594-f44b-4856-884b-042b8bddd687" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_735a79ce-884d-4588-9909-e7749466fc46" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">55,329,711</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb0f1bc3-5209-4c76-b151-968065c25249" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,147</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8d35e4b-fd68-47c8-af06-f1b6d9c5389c" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,561</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c20f03f8-342e-477e-b664-50c0b0b2b4ec" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5085d7e4-a5b4-4137-894b-f7e690450716" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7617b89c-b8fe-4872-b6ae-a96e491eb2b7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,263</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_262c6afb-afa7-4677-9443-fd34a5b13219" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,620</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic, INC. aND SUBSIDIARIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_stockholders_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Stockholders&#x2019; Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.337%;"></td>
    <td style="width:0.457%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.946999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.423%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.384%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.457%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.134%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.412%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.744000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.423%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.552000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.435%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.5120000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.178%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.451%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.067%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.086%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$0.001 par value</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">income (loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ca1ec81-e349-4349-a8ec-38d92c708542" contextRef="C_c1edfa35-041c-4e12-af32-4f8cfaf160b2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,183,273</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1092480-6988-49e2-91af-f2bb8cde78a9" contextRef="C_c1edfa35-041c-4e12-af32-4f8cfaf160b2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">38</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21195120-cca1-44c7-a7d5-b95b92eb5905" contextRef="C_9cedb62c-bc49-42b5-ab00-88dd9ea24194" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_216ab10a-c169-41df-a017-db087495aff3" contextRef="C_01e34769-71da-4fdd-af5a-ed9f45d058c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78a4688c-d2e2-4e07-b66b-84c316cf4543" contextRef="C_0897e117-252f-49bf-8a93-cb69564f1408" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">230,311</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8f72903-7a5f-4b00-8705-84adfc1272cf" contextRef="C_4ce13154-7826-4547-a938-f6040b13872f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,135</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba36d9b8-1f3e-4df4-91a6-b4169a829ff8" contextRef="C_eaa3b6a1-b527-43fd-9863-6130ce0c85bd" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,447,211</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3410fa3d-d330-453a-b435-71689d5ad68d" contextRef="C_eaa3b6a1-b527-43fd-9863-6130ce0c85bd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31f57028-53b2-47ac-b957-bde7380927aa" contextRef="C_5cc1a710-27f8-444c-90e6-5c3676f0f7bb" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_063b757e-4160-4e3d-994c-6f492d855242" contextRef="C_e9cba784-5870-4180-9446-6bedd109f39c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,050</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e1b282d-ffc5-4a3b-99c1-4a907285a3a7" contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,750,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d1f33e6-6818-4c0b-a4e3-d7aae4dd0189" contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8eacc64-c47d-46a4-81d4-d73ab600e635" contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,010</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bb98c65-759a-4904-b178-057ae4a932b9" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,039</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c7518fe-cfee-406c-b290-2df1a6c04740" contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">139,772</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f13c5518-f3e6-4c4b-8c34-355b420895f1" contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98ff8eea-dcb8-493d-9c9a-bb5a1789f160" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abbc64d5-e549-43f0-a213-1577d43d66e6" contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">242,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b942c067-efb2-440d-a24b-e5ceef0312c2" contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">42,653</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d75b1703-1ed5-4423-a34e-64c84407849c" contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4db84fc5-6340-42d2-adb6-1efb5d9eb814" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share withholding</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d35e6618-8a58-4b86-915f-53a16bc18256" contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a" name="sybx:StockIssuedDuringPeriodSharesWithholding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e66db553-a0e1-4a33-9bcc-62938e686c12" contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0" name="sybx:StockIssuedDuringPeriodValueSharesWithholding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc4e354f-aaef-47d6-afb0-f487c0a8f9d3" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:StockIssuedDuringPeriodValueSharesWithholding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancellation of restricted stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17e36ad7-9c60-4845-a707-da74c854ab5f" contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">77,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8512a62b-f8eb-4d21-9e5f-64489a923f33" contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_396a8e80-3de6-46de-b0a6-d430593c69f4" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain (loss) on securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c07ffe96-0176-4bab-848d-369efb7c5114" contextRef="C_71a618da-156f-461d-a56d-61c9010a19f5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca887e33-bec6-4ebb-907a-dec3a12134a8" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5d53baf-b912-4cf4-9042-47dca5e0c4b2" contextRef="C_406221e2-1ef7-4393-9e2d-3f9516e8e4c3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,561</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_017bb629-6dcc-4cb7-9a52-ce4c334be842" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,561</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef8afb95-5c90-4bbf-9bee-c928545ebfe9" contextRef="C_e59e7474-5287-48e3-b13c-7a4105517fbc" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,698,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4951cb0d-a0e7-41cf-8b18-a07d693eb405" contextRef="C_e59e7474-5287-48e3-b13c-7a4105517fbc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0104a438-eaa9-43da-9468-f2bfc0ed8a98" contextRef="C_282387b9-90c8-4462-9a1a-f4e3a22907e2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">438,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e958cddd-20bb-47a3-8268-8704922a4703" contextRef="C_a3bc4242-7016-4d08-911e-e53fb03921c0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8657088c-d118-4318-a6b4-c3eb92ea6aaa" contextRef="C_52001b96-65b6-4786-9e84-a405520ac86d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">290,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad9da325-1b40-44cc-a7ee-fdc725e21e74" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">147,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fa36664-961a-4076-adc1-1acb21ad1745" contextRef="C_6c440647-2473-4161-b76b-146d516bb47b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">481,451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_467fa90c-424b-400c-bfeb-3e279fe9fc73" contextRef="C_0c9b51e6-d273-4c40-9880-9ef1e241ffbd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d056f89d-3d0f-4edb-b7f6-6ca4911d1707" contextRef="C_0aaf0697-e409-448d-ba6a-dc57c7587a33" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f821a6f-90c2-44b7-882d-6f1413b0504e" contextRef="C_30a0f2b0-9a2a-4a96-a075-e5e89fb12427" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,196,889</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d98f72a-cf59-4471-a2a9-558e3f67300b" contextRef="C_30a0f2b0-9a2a-4a96-a075-e5e89fb12427" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ea84886-aad5-4a6d-afd2-8bb3c14e4661" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a404a76c-b161-4ff6-a00c-6f3980259c57" contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,562</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cd11d71-3c0c-4ecf-8477-84d74e4c5c43" contextRef="C_4a5c39e0-05a3-412d-9021-2ac827b89c7f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12384b38-6e49-4eee-9628-9909a5b030ff" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of restricted stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f62e6cf-55bb-4c35-8f10-217922d4fc62" contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">762,772</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_783a169c-0c21-44ab-af4b-6ba647abe241" contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1666ae9c-05db-4d97-8a84-60b47329cf5d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3c7709a-af87-475f-9a51-d31085c9f9f5" contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">106,629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d280dd45-0220-4fd2-8d43-97760d584893" contextRef="C_4a5c39e0-05a3-412d-9021-2ac827b89c7f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">137</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c7b587d-4404-41f2-b659-698c73d9325f" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">137</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share withholding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancellation of restricted stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe469d8e-b3f1-4367-a8ef-d664c04ad8c2" contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">152,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66e416da-6ee5-47f3-9a9b-7e0eb963836a" contextRef="C_4a5c39e0-05a3-412d-9021-2ac827b89c7f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,639</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bbbf434-ae71-4429-a630-b566949d25c1" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,639</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain (loss) on securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c35046db-aca6-438d-beef-df94635fd26d" contextRef="C_94afbb83-f2d7-4546-a4ae-0e428a53c728" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a988e87d-693e-4011-b612-5a9281365bb0" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf408ff2-f997-4ef8-a3ff-627f0213129c" contextRef="C_4e5987d8-c576-4625-8759-66ebd0405f3d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,147</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4308d543-1e12-49fa-8220-11306e96a5e1" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,147</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_003620ff-f537-4db5-bb9e-61ca40237790" contextRef="C_20e586e5-e63b-4dc5-be33-c69ee29693d1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,933,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b21ab97d-ec5a-4af5-8f9f-c38615165daa" contextRef="C_20e586e5-e63b-4dc5-be33-c69ee29693d1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b7c42b7-a978-4b04-9355-ec2daec9bf2c" contextRef="C_f9b859fc-2a96-4b54-97cb-88cba1858033" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">442,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49392669-f2a5-4d52-84d6-98028205e17d" contextRef="C_db9aee41-d847-4892-9d0a-5f6f3588bb50" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">161</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1726beda-7b52-4bbb-b9b6-7ef01375e948" contextRef="C_9cb1f60e-ec3f-44d1-b1f6-3bcaa075be67" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">357,019</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73e00466-2808-4719-b665-6b61010555d0" contextRef="C_e13a3127-83d8-4882-9c9b-f8eadac41d7a" name="us-gaap:TreasuryStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">4,196,889</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13089165-5e7a-4e96-a87d-139a352bc24e" contextRef="C_e13a3127-83d8-4882-9c9b-f8eadac41d7a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c2e3a0d-0d29-4629-9ecc-cee5e869952f" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,610</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic, INC. AND SUBSIDIARIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.485%;"></td>
    <td style="width:1.736%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.020999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.736%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.020999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07583c8b-ad0a-41a1-97f6-334fb24086f8" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,147</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3d7dea5-762e-4244-86ac-784039a1ffec" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,561</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d582f75-9eaa-4f14-a4d4-0daebc5a5bb8" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,520</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b71d5f3c-2bf7-4d2b-9b94-6367604f8442" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,443</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b1d8507-c7bb-4914-97fe-dc7af9aef1c7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,639</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99c48f9a-33f1-4254-ad8b-2443a5070769" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accretion/amortization of investment securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bca1c73b-b08e-4571-b17f-806514e75b0a" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">772</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4b78289-73f4-4e42-b1e8-6f66c603f20e" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reduction in carrying amount of operating lease right of use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5243093-5f0c-46bd-bf61-1cb4aa57d75d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,149</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfd0458a-1369-401a-b278-6556726168bd" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c01033f1-13ed-4381-b7bb-b9f31f5f8177" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86b04685-35e9-4224-ada7-ee8c840b180b" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,681</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development, net of current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6919da2-4ca7-4157-a747-f72f070bdee6" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d4bb67f-f9ce-4b84-9dbd-5d56aa0c905c" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">281</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a24c6310-6fc3-4d33-b395-82da4e49a36a" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_945ce0a2-cf4f-48dd-9999-cfb7e01a0688" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09305e01-09c5-4c1c-8aed-592b1c9dbfdc" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">697</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17f728e9-afd3-44c5-9ef3-a4f26629a34f" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2cec352-24bb-4da5-8777-334ff19a464a" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">351</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17eb35dc-f26a-4ed3-9ecc-6d49f2f7df34" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a19e2363-549d-420a-86ee-411606640f2d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,898</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36b76539-e389-434e-8de7-6709b38fad96" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,701</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:25.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0f8062d-46f0-4aae-94bf-0789446b643d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b5e67ca-0379-4e09-b5dc-d6fd58cec81d" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">131</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bed814b-2a24-41cd-9b1f-8d72cef5569d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_022cc223-722f-4476-865d-d0fc0dd8ee8a" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52,198</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_984667dd-f468-4c86-82e6-99366e7d446b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfd158c6-75cb-41fc-914f-85c72be0f9e8" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167,866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from maturity of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f133060b-a54d-44c5-a47b-6b38dea74f2b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_897aa3f9-9abb-4a79-b270-b5708cea5093" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from redemption of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_624f985d-c4cf-4cc1-887c-c26fb28bf947" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cab687e6-6709-4844-b669-3e820efaec97" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,270</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2442b0fa-3bed-4d55-86c7-48d1c1ae0d9f" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">728</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_900f04b2-a628-4bdf-8dd8-214b32ed91a2" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">679</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7cba684-c09a-44dc-8856-ba03a633cc25" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,351</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_309197bb-2169-43c9-8a3f-570f4a73d4e6" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53,253</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments on finance lease obligations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be12b5d8-7fe2-4d84-b665-b58afc20f6c2" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c174bd65-657a-4f53-addd-d75fd0cfe7d2" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards withheld for payment of employees'<br />&#160;&#160;&#160;withholding tax liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97546da2-e0a6-48cd-a084-81977cef0f0d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c96dd53-f08a-4b55-b90d-d8fa80122aa7" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39e7c335-367b-4c27-8e95-e38db9698f17" contextRef="C_0aaf0697-e409-448d-ba6a-dc57c7587a33" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">293</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca5e2357-bed0-4541-928c-4415b102977d" contextRef="C_e9cba784-5870-4180-9446-6bedd109f39c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from employee stock purchases and exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a971e13-617d-4eb4-97b5-5a698ae5c364" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">198</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1dd0b0d-577d-4368-a9f4-b01ddd51f7f0" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae690038-2ee6-40b4-99ff-bafbec4647f7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc1942a5-5ed6-4cfe-8fe2-80a7e0281ebd" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of Common Stock (Treasury Stock)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1f7b39b-48f4-4c32-bad3-628abfe95778" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:PaymentsForRepurchaseOfEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20b76bf5-614b-44de-8148-965a379c040d" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:PaymentsForRepurchaseOfEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash (used in) provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_438a1d7c-5340-44a6-ba07-7f40b2ac41f2" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,040</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32af10a6-e95d-4adf-8aad-4d3a4bed8c27" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,382</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a56b638-7097-4713-b083-8d7088107057" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">577</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56d93959-b75e-476b-beb5-22dfb5faeb0f" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_409d8a31-c040-4c01-be67-7d3df6486d22" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f39f86-d650-4366-a1e9-9284f576c853" contextRef="C_4ce13154-7826-4547-a938-f6040b13872f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d260c9b9-3a08-4981-8337-821149d180c8" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2954dfbf-7bba-4403-bc82-56383c10ca27" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of non-cash investing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment purchases included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0b5cb97-f206-470f-9591-7ef2efe166d8" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e38f30e1-f002-44fd-ae2c-2631449e80ec" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets acquired under operating lease obligation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cba4b91e-80a1-421c-839a-e4956ef5b1c5" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:AssetsAcquiredUnderOperatingLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8f52305-9028-412d-a5c7-5883e1ad8702" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:AssetsAcquiredUnderOperatingLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of non-cash financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase under finance lease</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_006beaf2-39b0-473f-8c36-1a97efc4d5a3" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:CapitalLeaseObligationsIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8c3f708-b7f5-45ce-92da-21909dacbe81" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:CapitalLeaseObligationsIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance costs included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf8bc26e-956b-48ce-aa81-ebfa5041ec35" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c246bf5-a60b-4ea5-80f0-a15cf732d1dd" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99b4d02e-5431-446c-8d39-d12613c67261" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68926ad5-c488-49fd-94ea-b59eeaa2ebbf" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_stat2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f1b55057-1107-4c97-acd7-1ce1145a2caf" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nature of Business </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (Synlogic or the Company), is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of Synthetic Biotics. Synthetic Biotics are generated from Synlogic&#x2019;s proprietary platform, leveraging a reproducible, modular approach to the generation of novel drug candidates that perform or deliver critical therapeutic functions. Synthetic Biotics are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways or deliver combinations of therapeutic factors. Synlogic&#x2019;s goal is to discover, develop and ultimately commercialize Synthetic Biotics. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />The Company&#x2019;s consolidated financial statements have been prepared on the basis of continuity of operations, and the realization of assets and the satisfaction of liabilities in the ordinary course of business. At December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31f4b194-1fa9-479a-8dfc-c3bbbddbf808" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">77.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash, cash equivalents and short-term marketable securities. The Company has historically generated negative cash flows from operations and has an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb7e24f2-953f-4eb9-a7ce-9e9fc7509ea9" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">357.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022. In the absence of positive cash flows from operations, the Company is highly dependent on its ability to secure additional sources of funding in the form of debt or equity financings, or through the execution of additional collaboration agreements. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance date of these financial statements. If the Company cannot secure additional funding, it may be required to undertake further organizational changes, including reducing research and development spending on certain clinical stage and preclinical research programs and implementing additional reductions to its workforce. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), the regulatory approval process, market acceptance of the Company&#x2019;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company&#x2019;s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or alliances.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the Company is not aware of a material impact from the continuation of the COVID-19 pandemic through December 31, 2022, the full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations, and financial condition, including expenses and manufacturing, clinical trials, and research and development costs, depends on future developments that are uncertain at this time.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bdf00752-5557-455f-88f5-e721a797fc2f" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e52517af-7c1b-4e55-9b17-01337d251981" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP or GAAP).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c4bcbfd4-eb02-45e0-9dc2-70dd14084a24" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9838492b-2b20-4589-9be8-c6cd3ba26216" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, the Company&#x2019;s management evaluates its estimates, including those related to research and development accruals and prepaids, accrued expenses, contingencies, and investments. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_47fa7ae5-b90f-4333-a36d-b757f1cdf0c7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_24808f0f-1eca-43e4-800f-5160190ce820" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:AdditionalCashAndCashEquivalentRelatedText"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months or less</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b145fd8e-7fcc-461d-bf7b-90c31989329e" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39e0a7ce-ef80-49f4-ad03-f480f847ab03" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022 and 2021, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f9b34f75-e35f-44ac-985c-7c2283796076" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b800a7b0-4b9e-4a2b-b725-9a56d9503c48" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company held cash of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7914cf67-f7e5-41f5-a3f1-557ed9de9d93" contextRef="C_5c13194e-33fe-40bd-90ef-6bbee6ee67f1" name="us-gaap:Cash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_34ed262a-c330-4dd4-86ec-2ebe81eb9af9" contextRef="C_42df9a46-4a26-442d-8081-eac11aa26210" name="us-gaap:Cash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022 and 2021 in a letter of credit to secure its lease at the 301 Binney Street facility. The Company has classified this deposit as long-term restricted cash on its balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_945db849-5f03-4e42-8b12-da5cb0eac755" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.102%;"></td>
          <td style="width:1.483%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.466000000000001%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.483%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.466000000000001%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efc5a682-62b5-4a29-81b4-38de960b6d47" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,861</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d8f6ced-93d2-4638-aab6-137b91fb2b93" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,438</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1ce1d53-7273-4758-a03f-209a1f89cd28" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,097</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_868ae4cc-d27a-4d9c-8253-6eff8faacd27" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,097</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash shown in<br />&#160;&#160;&#160;the consolidated statement of cash flows</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8332cd0f-e562-4958-b45b-3d00f21117fa" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,958</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04c6e5f6-24dc-428f-b0bc-b9465af2b2e6" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,535</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_00e971c9-972e-4485-9c93-37c227b86ff3" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. Accounting Standards Codification (ASC) Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). The hierarchy consists of three levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 &#x2013; Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 &#x2013; Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 &#x2013; Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates transfers between levels at the end of each reporting period. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3ea4a92-866c-4237-b489-d0be7a4c0ce4" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d1a02450-2439-4320-b468-ec373cee3f72" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_92365ba2-c21a-4acf-bbcd-ab7934eb2f2b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Available-for-Sale Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies all of its investments as available-for-sale based upon its intent with regard to such investments. The Company classifies investments as short-term when their</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">remaining contractual maturities are one year or less from the balance sheet date, and as long-term when the investment has a remaining contractual maturity of more than one year from the balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4ae23102-921a-41d9-a91f-747aa51a002c" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight&#x2011;line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08a94873-b0b7-42a1-8fd5-ebc2407dd17b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"></td>
          <td style="width:2.077%;"></td>
          <td style="width:48.955%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset classification</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer and office equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5fca0e4d-cfe0-4b78-8ef5-b0761d12c99a" contextRef="C_e08b8831-bd01-48c6-a8f9-50a61b822302" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0e01a487-83a7-4927-9353-9842e01052d7" contextRef="C_df578021-db7b-44d1-8405-c09b71d9bf97" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db39496b-a5b4-4d52-abee-496dfd9e58e6" contextRef="C_13abf79b-a461-4ee1-8d29-6b819cbd08f8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c1379dd-55a0-4010-a92b-8e6b7bca7310" contextRef="C_c959ef41-4848-4db3-9e53-0dd492572f29" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lesser of useful life or remaining lease term</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7e9e53c1-9a2e-4cfc-9437-d8606ef96a0e" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:PropertyPlantAndEquipmentImpairment" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long&#x2011;Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long&#x2011;lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe86b117-65a1-47eb-a012-3dee0c894aff" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:TangibleAssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairments have been recognized.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_84b8256c-fe02-4cec-a8c8-ce145fc1eac3" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (ROU) assets, current operating lease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations in our consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets represent the right-to-use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease term includes </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6764cf7-329e-4600-bea9-fac6d92fb5b9" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">options to extend the lease when it is reasonably certain that option will be exercised</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leases with a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_574e5c1f-7cc2-4af7-a911-d898fa3f640b" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months or less are not recorded on the Company&#x2019;s consolidated balance sheet.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08f204b6-3f03-43d9-a1d5-8e8dd2255e92" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When third-party service providers&#x2019; billing terms do not coincide with the Company&#x2019;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f6f06d4c-5e53-488f-98ff-89a6944ed3ee" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenue through a collaboration and option agreement with Roche for the development and commercialization of product candidates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full-time equivalent time as a measure of satisfaction of performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Services</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement is determined to contain a promise or obligation for us to perform research and development services, we must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, we consider the capabilities of the customer to perform these same services. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The estimates we use to record revenue relating to the combined performance obligation on an over time basis, include input methods such as full-time equivalent time incurred compared to the full-time equivalent time expected to be incurred in the future to satisfy the performance obligation, which require management judgment. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. With this method, we must estimate total inputs required to satisfy a performance obligation and measure efforts expended to date to determine revenue recognition. This estimate of remaining inputs is subjective, as the research is novel, and therefore efforts to be successful may be different than the estimated efforts at the balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Payments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contract Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f764276d-decf-4f3c-9935-d579fcbf62f4" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:RevenuePracticalExpedientRemainingPerformanceObligationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_232384b9-d35f-4645-bd4b-c19edcba38ed" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity&#x2011;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (ESPP) is estimated on the date of grant using the Black&#x2011;Scholes option&#x2011;pricing model. Expected volatility for the Company&#x2019;s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer&#x2011;group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The risk&#x2011;free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipients&#x2019; service payments are classified.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f73670f9-8d37-45b0-a9aa-d76ee978de84" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#x2019;s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d7928ed2-a345-4b59-8f3b-fb2d3c5fd7cb" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater than 50%</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3d075423-0017-4d68-8877-cfeca94ee672" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d5524fc9-4432-4136-9981-0b25240549e1" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c739f27c-2697-4d9e-9a95-f89d94187ec7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company&#x2019;s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company&#x2019;s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_090b0e30-3978-4a65-bc6d-6a071e6b2ec0" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:TreasuryStockPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_47e78922-4a8d-4510-b267-4fe57cad6b26" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, recently issued pronouncements that are or will be applicable to the Company did not have, or are not expected to have, a material impact on its present or future consolidated financial statements or disclosures.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_483b9051-dc9c-4b11-b4f9-49f47f559d62" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value of Financial Instruments</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tables below present information about the Company&#x2019;s assets that are measured at fair value on a recurring basis as of December 31, 2022 and 2021 and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s investment portfolio includes many fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations. In addition, model processes were used to assess interest rate impact and develop prepayment scenarios. These models take into consideration relevant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">credit information, perceived market movements, sector news and economic events. The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7874ee02-75f4-41cc-b2a9-7d2bd2b58290" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.134%;"></td>
        <td style="width:0.944%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.048%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.944%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.029%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.944%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.8%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.944%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.212%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active<br />Markets for Identical<br />Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br />Observable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c0a1675-0828-409c-ad44-ed7a9cbe64f0" contextRef="C_3934f648-405d-4a5e-b610-f5dc014cbfd7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b790626-1990-454a-bfd9-41f862d0d036" contextRef="C_29fed40c-524b-495e-b738-feab12394d3c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bd3cbac-ccf2-48a6-a841-27fa65c5fce0" contextRef="C_92b7da2a-7418-436a-9524-56701b660c25" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc5ed1ee-d6de-4c64-a680-41a403b9ed63" contextRef="C_3bc26f36-034f-4f53-93d9-b443f6b5e6c4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c43a074-4807-4738-8630-3f60958c353a" contextRef="C_127f40d5-4261-4e87-a5a5-a06ab8251d92" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e9d8e6b-d57f-4dae-8885-2a681c151bd3" contextRef="C_b65842df-41e9-4ad0-b418-74bfc423b622" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3da6b54-b2cd-4f96-a56e-bda57dd163ee" contextRef="C_2a7a2cff-5d8f-4521-9e09-ba2479d086ca" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9603af96-b856-47b5-88f9-b8a27dd12942" contextRef="C_d77ddcfe-10f7-4a58-90fe-828bf55ff466" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d4029f0-d54e-40c9-af21-fa83458781b0" contextRef="C_52f0109e-38a0-4183-afac-f6722c5543d4" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7612db2-2a8e-4674-97bc-02cc660a375c" contextRef="C_3b538def-63ae-4f4b-9140-89b96b2a5ea7" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1742483-75d9-4496-8c68-bb3027b849be" contextRef="C_cd16f567-f183-4c6e-8b80-74f9c2966fb5" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a84f826-f125-40b3-a4b2-d0622903443f" contextRef="C_c8434699-f20b-4949-8f3d-8de4ac28fe77" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1273d446-1779-40b8-996a-d0dd611bdf58" contextRef="C_d4d75229-eaf1-4029-9ef7-4b3edaa0a833" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,629</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6c80019-492d-4c19-b0f5-ea78f4b8bd97" contextRef="C_0abad65e-efe7-4687-9248-a9c45acb22de" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7212a272-aa67-40a9-9bf6-456e1f4c6d93" contextRef="C_967baf2d-6be3-4b7f-ae16-eff0641c22f0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f47f57a7-6b1a-483d-88f0-8a670b02e6d3" contextRef="C_6fc8483b-ee81-4369-a735-5813ac304b5a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active<br />Markets for Identical<br />Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br />Observable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2759e29d-207f-471a-9e76-e660de22be93" contextRef="C_91376d3a-55e0-47d7-8f1d-b1e000c4da64" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eba7a38d-5a83-42a0-9e76-74ec72ce08a9" contextRef="C_8b9caf09-f6c8-47cf-a222-c8667dca98fd" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_745271b1-70dd-4eac-82e6-dc87794508fe" contextRef="C_39ffddbf-7d15-4ff1-8e01-541286c83ab8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ae11435-d385-4004-b6d2-dcdbc5024180" contextRef="C_02234d32-33f3-4416-bdc7-483f3c549a5f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_859c1bc2-baf8-43b8-ad29-c35a0a628054" contextRef="C_cd0ccefb-dd51-4e98-b605-3e1a046f1576" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,277</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d316f1f6-881b-44ee-8649-ea3bc0a76bad" contextRef="C_8e60fb3b-c7d3-4ac6-83b2-f6a6547f6e1a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06bac7e7-b3aa-45ef-ac00-63d751868715" contextRef="C_76fcaa28-0554-4900-bf7f-e8311ed88698" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,277</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a632914-37cb-4c3a-be04-c668c8e4d088" contextRef="C_cee0ff06-3a82-48ed-bc1e-7798fb043a99" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c46fc2da-bb8f-4a2f-a881-e66a95b69d1e" contextRef="C_94ebd146-59d5-436b-8185-ff6c733be386" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,873</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_760b2283-1328-469a-8e03-5c399cd7acc5" contextRef="C_e186ace1-c417-4554-ab06-b27470bd2ea0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1d445f2-de77-4589-b33e-a6c2716c5e32" contextRef="C_dbe4b5e6-1273-43ae-8a7f-b8ea915f3ed1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,873</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a442a111-b33c-49ae-89c5-821650bc8dbf" contextRef="C_99657c65-259d-41fd-986b-5c347fbc45d5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1904bf0f-0047-4ac7-8306-e60345d0124d" contextRef="C_9c420274-37ac-41c4-9722-54e874446423" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7749222a-e1ba-41b8-8958-418999dc52d3" contextRef="C_0091dbbf-6c21-4edd-9df7-2c4b934ef7d5" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_808d1712-077b-492f-834a-d2ac1aa02119" contextRef="C_3b826f3c-b239-4a65-b43d-e759471f2756" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cff09b4-0fd3-4518-9a3f-3b6e6296de55" contextRef="C_7347bbee-a9f6-4c87-a6a2-eddd53ccfd0e" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc31236a-51e9-4ebb-b722-efeacaf70a33" contextRef="C_85363944-bc80-4236-b736-030f11ca6ff3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">136,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_442d0889-9210-415a-ad7f-dc8281fd35c3" contextRef="C_a326c280-7be6-41bc-88c6-584d5e7052d8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,478</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05b04583-9389-4a42-9f63-30aba215415d" contextRef="C_b16d8204-0369-41df-93d2-7ec43c203587" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,150</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecca7e90-b65d-4569-8cc1-16dd357a4ed1" contextRef="C_92c74e7a-30c1-4b8a-9f5c-579a596fbd61" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at December 31, 2022 and December 31, 2021 are carried at amounts that approximate fair value due to their short-term maturities. Finance lease obligations at December 31, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> approximate fair value as they bear interest at a rate approximating a market interest rate.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8ad1fc08-07b8-4e62-865c-cf369e7ebd93" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:AvailableForSaleSecuritiesDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available-for-Sale Securities</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d793947c-64b1-4e33-a41c-9fad2991d7f0" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the available-for-sale securities held at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.836%;"></td>
        <td style="width:1.447%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.417%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.322%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.445%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.322%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.445%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.322%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.445%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br />gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br />losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fb183ac-9fe7-4da8-9045-651788e24013" contextRef="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d087323-873b-4322-95a6-6f7d52fa83ce" contextRef="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7b45648-1617-4f03-b7f2-de25dfc213e7" contextRef="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fcea62b-7434-4bbf-a8ef-bc5e69ac6c5f" contextRef="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5f26402-d8b5-46da-92c0-6f1c8b9ffe8b" contextRef="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e524593-a4c5-4528-8311-0622c26fb347" contextRef="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_352fd678-451a-4d43-84f6-dd0c0e3c9c89" contextRef="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d858a18-3466-403d-8238-9276ca4169e8" contextRef="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de60b63c-b7dc-437d-abdb-98162dbe9d2e" contextRef="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30960a0b-5955-42b9-a806-5ce51237517a" contextRef="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4bdff62-cadd-4405-92e8-afee46387d4d" contextRef="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9803420a-cbb0-40d9-8a0c-912f5b4477ad" contextRef="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8668fe20-946d-4ccc-98d6-a7df1a058cb6" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,929</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eb604be-bb5a-4aab-b4fd-30481e379779" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d0a37b4-448f-406f-959c-df90c7a73b95" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6dff15a-36dc-4a2a-a186-a665004970bb" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,768</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br />gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br />losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3131b2cb-5e67-48f0-a95d-c85a0892dcb1" contextRef="C_e617d399-c879-434f-a4fb-b4d8855f9c6d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,298</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9888e2d4-57b8-4852-b2ab-5775b8250392" contextRef="C_e617d399-c879-434f-a4fb-b4d8855f9c6d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d486dbcc-8625-4ee5-a5eb-f6288cb8a18d" contextRef="C_e617d399-c879-434f-a4fb-b4d8855f9c6d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5409415-02b9-4531-961f-c78d5f7a0b65" contextRef="C_e617d399-c879-434f-a4fb-b4d8855f9c6d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,277</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8927d325-0f50-4bc0-bed9-efd1850b886c" contextRef="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,876</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d8784db-9ba3-4878-bac4-6faa45cdc4cf" contextRef="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3308b54d-0dea-4225-a5bb-74db0d264dd2" contextRef="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8152cb90-6640-4fbb-be1d-15aad0feca5c" contextRef="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,873</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed5a6cf9-20f3-4530-98f9-fe66e5ff79af" contextRef="C_61230b0b-84df-43f0-a9b0-98509a23ed34" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,062</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ca2e864-70a0-4af7-b3e8-54eaeccea7e3" contextRef="C_61230b0b-84df-43f0-a9b0-98509a23ed34" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_599e42b8-805b-40f4-82ae-5b9886e0a65a" contextRef="C_61230b0b-84df-43f0-a9b0-98509a23ed34" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e88dc892-8708-4260-a4f4-7eb785fa86a7" contextRef="C_61230b0b-84df-43f0-a9b0-98509a23ed34" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a806696-e588-420e-a306-1f5b6712cd51" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,236</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a6f44ae-eb7b-4d8d-97c8-bdfd4ddaa906" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee0699de-7d89-473b-8047-adf4d55b6822" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa16b1ff-b399-4314-beee-1e3a716b9779" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The contractual maturity of all securities held at December 31, 2022 was six months or less. There were fifteen investments in an unrealized loss position at December 31, 2022. The aggregate fair value of the securities in an unrealized loss position at December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04d21350-7cd4-45b8-a7b0-0e28ed7e7e93" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bf5cd84-5f72-46ff-a2bc-bbf0670a490a" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">72.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until maturity or a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2afa986b-3ca5-430f-8afc-5577d9377a71" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t hold any securities with an other-than-temporary impairment at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross realized gains and losses on the sales of investments have not been material to the Company&#x2019;s consolidated statement of operations.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_70117a94-8bb3-43d4-a974-b73fcdec8e2e" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(5)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_04ad664a-084d-41b1-8085-802e217380e6" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.102%;"></td>
        <td style="width:1.483%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.466000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.483%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.466000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5daa234f-1b8d-4cff-ae7a-3aaabf9b7460" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">887</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b180542e-54d1-4bc1-856f-58b659705d5a" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">979</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_030ca9f0-c564-4eaa-b925-0568f15881fd" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:PrepaidResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21d143d9-ca24-429d-ba86-da997371b643" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="sybx:PrepaidResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,721</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9cac654-22c1-4a3b-bc51-e945314dcb8c" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27404a4c-6f8f-46c3-acfe-d0e3b77cc907" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">710</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85a490eb-5cd6-4ebc-a3ce-69eeba1fdde2" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0953304-75d3-405e-b452-39718565c6e1" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">311</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27259bca-c23a-425a-9c64-68cc8e3825f2" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2176ea6b-4873-476c-8a30-939b699a72ef" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,721</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc817454-bb6d-46a5-90c3-8e9a48a2555d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(6)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, net</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d62e52c-51b4-46d8-845e-50b2eed6fa70" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.751%;"></td>
        <td style="width:1.389%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.735%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.389%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.735%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ba28103-c488-486a-afd6-22a92cf5880b" contextRef="C_a7af75ad-b1e6-4aef-851f-04fd45e648cd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,313</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76ea80bc-0a00-4021-8d73-7538146f0006" contextRef="C_3545a731-60bf-461a-b2f6-a8fd246306f2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84e35c7c-4159-4f2e-bac6-4ceda42d9798" contextRef="C_dd023e56-8402-47a8-bace-8ad6f1a75d5d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">793</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a79b6f8-296c-4af4-bc47-d92923a89b2f" contextRef="C_eb6f0279-648d-4922-bffa-1e1ac712993d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88c036f4-b79e-4dfa-8ac1-cd62e4d6ca1f" contextRef="C_7d6680fe-ccfc-4e24-8fd9-1fa014c4a0b7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd29522c-8252-46eb-b765-ec212e5a617c" contextRef="C_f9e9134b-680f-4e16-baa0-cd8a64b991b8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13e16928-0007-445a-8591-4137b56b6408" contextRef="C_3d820518-ff46-4605-b3e8-6459f151a8a3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f6bbf8e-a01f-4fe5-baa7-1809ed0cc409" contextRef="C_3b99e72e-cd69-4ebb-a947-0d73db833415" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,561</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_507fea92-dba7-45d6-986b-39e7441caad4" contextRef="C_6ad07922-17ac-4c18-97a9-21067c51ee17" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29a4cb4c-16f6-4465-8635-e410285cc6d9" contextRef="C_54406899-ec4d-4081-a75a-a534c1e59a14" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">623</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a94e368-eb9e-4f66-988e-8a26b1b70a41" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,463</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9ca01b5-5f7d-40a4-9dbe-bbb4a72878f2" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,714</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82094622-f51b-47c8-a1c1-41f698659b55" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,140</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1752202-9bc1-4c25-a4fc-083e8b3fecd8" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae1216f8-b284-4e68-98f0-89407595ef48" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b577ccca-0df2-45fb-b8bc-d724c97e2425" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,088</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense on property and equipment was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9181779-b640-4be9-b813-ea99145ccd94" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72cbb75d-dee3-422a-979f-e3c4427064a8" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9088d6d1-f1d6-42f3-a84a-59c40e89d36f" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(7)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Expenses</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_32e45de6-17c1-4d79-872f-33faf6c41365" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.902%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.563%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.563%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll related</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cae13549-a605-41bc-9a9e-91290e1de2cf" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,401</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52881085-9272-4d1d-83e0-1e14e00116a5" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5b8eb0b-8f16-42d5-92c7-f76658358381" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2bb92d9-a17d-46b6-a27e-34b7b4ffb16f" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a47e991d-224d-458d-810c-99e5d8bfd62e" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:AccruedResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,624</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_302dd3b0-9167-4291-8dcd-ddc3f00b5384" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="sybx:AccruedResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">336</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b37df92-5afc-4814-9c0e-3a121137bedf" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38b3f5f0-9554-4b0c-a0fb-c01239bb9326" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d8590ce-6979-4ece-92fd-0bf1c3fda4a3" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_697fe0f3-478c-4e53-8b88-69aec36ac2f3" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(8)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' Equity</span></div></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_532dffea-d760-4d6c-9307-4e7b863eed30" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s common stock has the following characteristics:</span></p><div style="margin-left:12.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.810754261802134%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of common stock are entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8df3eb6a-bcf9-409a-9ed0-38fc371669fe" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:NumberOfVotesEntitledToEachShareOfCommonStock" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders.</span></div></div><div style="margin-left:12.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.810754261802134%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of common stock are entitled to receive dividends, if and when, declared by the Company&#x2019;s board of directors. Since inception, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4644746-97ed-40a0-b3ca-71f9b3826a5d" contextRef="C_df2e79da-2d09-4270-8ce2-2f9e4b85b0ff" name="us-gaap:DividendsCommonStockCash" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash dividends have been declared.</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2019, the Company issued to Ginkgo Bioworks, Inc. (Ginkgo) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_600ead77-3c3a-452a-b502-52af8cbdad52" contextRef="C_73d91fb1-2e62-48f7-92de-e383722c15e2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,340,771</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and accompanying Pre-Funded Warrants (the Pre-Funded Warrants) to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a2a90af-e7ba-4503-925c-43f10c6034d4" contextRef="C_2e56b967-590d-4bb7-93db-326ebc48a3e5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,548,117</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, at a combined purchase price per share and Pre-Funded Warrant of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba80db4c-433a-45a2-bdb1-837037612e20" contextRef="C_627e4d45-a0cb-4fa4-be83-89cafaf6b705" name="sybx:SaleOfCommonStockAndPrefundedWarrantPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">9.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Pre-Funded Warrants have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59be5194-026d-49b0-a645-f5ff083ff9c6" contextRef="C_7d128f60-ec2d-4e7e-ad00-15156530da9e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">9.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, with $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c954b24-571c-47a4-bfa8-e47e619ead9a" contextRef="C_7d128f60-ec2d-4e7e-ad00-15156530da9e" name="sybx:ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">8.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of such exercise price paid at the closing of the offering. The proceeds, net of issuance costs, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4b8d6df-e205-4a77-81c3-353381d411fb" contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597" name="sybx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">79.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83aa0be1-3008-43ba-b1b0-41baaf398ba5" contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">57.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to the proceeds from sale of the common stock and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_170256d9-3177-4809-930a-b1a2d3002514" contextRef="C_97aff091-2a04-46a5-9057-7373ad98593b" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to the proceeds from sale of the Pre-Funded Warrants. The Pre-Funded Warrants may be exercised at any time until all of the Pre-Funded Warrants are exercised in full to the extent that, after giving effect to such issuance after exercise, Ginkgo would not beneficially own in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dd4bab2-48d4-4384-bf92-b15cdecdc652" contextRef="C_5cb51fda-168e-4bf9-88e4-f2c1dde4f357" name="sybx:UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">19.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding immediately after giving effect to the issuance. The Pre-Funded Warrants were classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, such warrants do not provide any guarantee of value or return. In addition, in connection with the issuance to Ginkgo of common stock and Pre-Funded Warrants, the Company expanded its existing collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0aa72205-e1c3-43ff-8db2-52425a47e7ec" contextRef="C_7130c6be-123a-4941-b59a-2b8f5cdd887b" name="sybx:WarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">None</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Pre-Funded Warrants have been exercised as of December 31, 2022. (See Note 10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ginkgo Collaboration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 13, 2017, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) with respect to an at-the-market (ATM) offering program. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc928adb-8772-4b84-864e-58871d9147ef" contextRef="C_73945c68-b522-4635-afec-a62d38320354" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,447,211</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81667de4-c388-4dbe-a557-9cf6ef0b34c9" contextRef="C_73945c68-b522-4635-afec-a62d38320354" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. This sales agreement with Cowen was terminated in July 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company entered into a new sales agreement with Jefferies, LLC (Jefferies) with respect to an ATM, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having aggregate sales proceeds of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ad2f960-04b2-4d82-b620-29c8a29948d3" contextRef="C_17b056dc-d7fb-4fda-b280-76eec780b5fc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Jefferies is not required to sell any specific amount but acts as the Company&#x2019;s sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. During the year ended December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8ebc65c-707f-4006-a109-ab46103a53c0" contextRef="C_44eb79d0-8fc4-42f7-a690-e5796a479806" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">481,451</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were sold pursuant to the sales agreement with Jefferies, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02375f02-2a25-4d11-b909-d3a1363ff75d" contextRef="C_44eb79d0-8fc4-42f7-a690-e5796a479806" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8e35b03-3622-4e79-8e57-ac51f3285b12" contextRef="C_a1266c6b-f79b-47ac-9d44-b00ab08b1491" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a35777b5-91a4-4117-8d95-ae80b718fc98" contextRef="C_4b914988-f15e-45d7-8299-f5e9f4596f51" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share pursuant to an underwritten public offering. The net proceeds to the Company from the offering, after deducting the underwriting discounts and commissions and offering expenses payable by the Company, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2454ae03-8138-4662-91a9-e1de67444c64" contextRef="C_6edf54b0-befe-46f1-a01a-5d4ad86e422a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All shares of common stock sold in the offering were sold by the Company.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7add6260-954a-4e66-83c5-ce94b0f81f21" contextRef="C_769545e9-0aa1-4ec6-a368-611478b8ff27" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">17,250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_796c66fa-bc39-4d1e-ab94-52ae6e173fcd" contextRef="C_d79f3e7f-b5d8-44b8-8e74-072b254299d5" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share pursuant to an underwritten public offering. The net proceeds to the Company from the offering, after deducting the underwriting discounts and commissions and offering expenses payable by the Company, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14b692d5-78b9-46b2-a209-53874ab9255d" contextRef="C_769545e9-0aa1-4ec6-a368-611478b8ff27" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">48.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All shares of common stock sold in the offering were sold by the Company.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e77a90d-fd45-4591-ae1d-110df7cc2d2c" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has  reserved for future issuance the following shares of common stock related to the potential exercise of Pre-Funded Warrants, exercise of stock options, and the employee stock purchase plan:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.27%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:29.73%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issuable under pre-funded warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_513ea67b-2909-4aaf-8526-e5c82f171082" contextRef="C_526bc3f6-6d8d-4822-b52e-24e5d384e725" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,548,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77342450-5f14-4cc1-a789-b5590e95ee81" contextRef="C_5cec03e1-9dc1-4ffd-9623-0c876a46a0c9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,328,011</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_383e1188-e1ad-4af2-9f25-e5b6fda9eb6a" contextRef="C_125495a8-4ea5-4da7-b352-1c1c4f816a98" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">52,648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae42d8d4-1b9e-4838-ac7b-ef5539355978" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,928,776</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f23192e9-3f6e-4020-9937-e795161cb5e1" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(9)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity&#x2011;based Compensation and Equity Incentive Plans</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Plans</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently has three active equity plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2015 Equity Incentive Award Plan (2015 Plan) functions as the primary equity plan for the Company. The 2015 Plan includes an &#x201c;evergreen provision&#x201d; that allows for an annual increase in the number of shares of common stock available for issuance under the 2015 Plan, which annual increase will be added on the first day of each fiscal year from 2016 through 2025, inclusive, and will be equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d5aef23-2d49-4daf-833e-2cb3ce1da02a" contextRef="C_ae409a4f-4065-4a38-ac8d-81447767cd16" name="sybx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent of the shares outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board of Directors. On January 1, 2022, the Company added </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2116f387-e3f3-46f6-bcfe-a0b7ccdd92e5" contextRef="C_427833e4-00a7-483a-9685-f0f6c211b01c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,484,942</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares to the 2015 Plan pursuant to the &#x201c;evergreen provision&#x201d;. The 2015 Plan provides for the granting of a variety of stock&#x2011;based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, deferred stock awards, dividend equivalent awards, stock payment awards, performance awards and other stock&#x2011;based awards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2017 Stock Incentive Plan (the 2017 Plan) provides for the grant of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2015 Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faff9135-6df1-4fc6-a447-cb0e7f793804" contextRef="C_9404c746-39af-4f16-b76d-b8630bcb901d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation, subject to any plan limitations. The ESPP generally provides for set offering periods, and at the end of each offering period, employees are able to purchase shares at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_749e2a9d-b58f-4981-8d18-208ec2e95cbc" contextRef="C_9404c746-39af-4f16-b76d-b8630bcb901d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. The Company suspended the ESPP in 2017. In December 2019, the Board reactivated the 2015 ESPP and approved an amendment to the ESPP to (i) reduce the permitted payroll deduction and number of shares of the Company&#x2019;s common stock that a participant may purchase per calendar year and offering period under the ESPP and (ii) establish a period for enrollment for eligible participants. The reactivation of the 2015 ESPP was effective immediately. The Company&#x2019;s executive officers are eligible to participate in the 2015 ESPP. The ESPP includes an &#x201c;evergreen provision,&#x201d; allowing for an annual increase in the number of shares of common stock available for issuance. On January 1, 2022, the Company added </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af80030a-83ab-4278-9cfa-cb154c255c95" contextRef="C_d15380e7-f98d-4b93-b4f8-739dab563868" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">696,988</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares to the ESPP pursuant to the &#x201c;evergreen provision&#x201d;. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_013a7350-c277-4905-ad07-278ae0c05146" contextRef="C_961a013f-154c-4b93-ac17-2c189db1fa4f" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">106,629</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock purchased under the ESPP during the year ended December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8e51b6e-43b7-4e38-bfaa-a398c53b84b9" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 were:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.931%;"></td>
        <td style="width:1.701%;"></td>
        <td style="width:14.525%;"></td>
        <td style="width:1.701%;"></td>
        <td style="width:14.525%;"></td>
        <td style="width:2.616%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3a8cd0c8-d8a9-4fd5-8cb8-3147e4af5191" contextRef="C_99fd2321-f1d7-43cf-b178-e7348f290f1f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08aae4b9-3da8-442c-896f-547e6411a1e3" contextRef="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average, risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36956048-49b4-4a20-97ea-ff16528fe4c2" contextRef="C_99fd2321-f1d7-43cf-b178-e7348f290f1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_004a5627-f9ba-45d4-8cc3-0c9ba866b0d6" contextRef="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f763ca9e-e71c-42d3-97b7-7baf369054fa" contextRef="C_99fd2321-f1d7-43cf-b178-e7348f290f1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">82.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_664319e7-ee36-4d8b-94bb-fb9302901b69" contextRef="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">84.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_988a8900-30b6-468d-8dc2-728df1e94684" contextRef="C_99fd2321-f1d7-43cf-b178-e7348f290f1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daf8d09d-2eb4-4d13-9760-cb3769902d99" contextRef="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_503af8cb-24b8-4ee8-bc61-9ca184d58ec9" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_503af8cb-24b8-4ee8-bc61-9ca184d58ec9_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity under the 2015 and 2017 Plans.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.377%;"></td>
        <td style="width:0.651%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.47%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.17%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.126%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.651%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.046%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.665%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.846%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">remaining</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contractual</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">intrinsic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exercise</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(a)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bee0887b-5164-43f2-b485-dfc3d0ea107d" contextRef="C_698c1855-5f3d-4405-b9dd-9cbf05cddeda" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,500,913</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0770fcfe-866f-4842-a876-6012c3a5b440" contextRef="C_698c1855-5f3d-4405-b9dd-9cbf05cddeda" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a0deb5af-d914-4c2f-8880-1188dce3211d" contextRef="C_83e56954-5a79-4d4a-a1b6-981f26235c7f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1032556-0ebf-460d-a9d5-bdc2dea4963c" contextRef="C_698c1855-5f3d-4405-b9dd-9cbf05cddeda" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">588</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03a8a716-9720-488a-885b-852f4950ad55" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,738,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e593a120-e312-4ac9-9865-8e7b3c507106" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f10c1942-3871-4a96-aed3-9a1213e1eadc" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,562</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7cd07e8-aa5f-4b7a-ba16-1d94f059921d" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ede5bf8-c13b-45c3-b935-a81ebf162c80" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled/Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17af17c5-c886-4dad-aeb2-62637cb5873e" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">956,655</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fef5d456-35b1-42c2-8d6b-7483b0e41b27" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8722bd3-d090-4b8f-9eff-4704347451c8" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,247,695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e51a5d1-8a03-468a-8d5d-535f43cc40f7" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2b268de9-e60a-400f-b542-babce8658213" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee0a6b3f-22e2-41c4-897e-2e391afc1d73" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested or expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb965bf5-0397-49ea-acd6-b3b62d84a7ac" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,247,695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c1bc8da-fd09-4428-9a0b-f979bf69aa7f" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_646c0771-5579-4eac-b8d7-398e78363f1e" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79d5efdf-fa1e-48a5-9bca-ffbebf320c93" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_489851c4-1373-4c41-9837-c555d13237de" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,328,011</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_923b3461-1225-40ae-b124-6a880968de77" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bdb32d24-cd6b-4845-886b-8dc19f5e8e26" contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc0d55fa-cf54-4799-a778-9bdb142c28e8" contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.03pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_503af8cb-24b8-4ee8-bc61-9ca184d58ec9_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2022 and 2021. </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb9389f4-0cd8-477e-9fe4-86e199597e63" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">185,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38447786-f731-455e-98ea-d8b495eacd86" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,210,026</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options were in the money at December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, respectively.</span></ix:continuation></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value per share of options granted during the years ended December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6041538e-c838-4aae-b721-c57e646119bc" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.16</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e16b184-6efc-49ab-bf85-1c5fc4f28ecf" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.42</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The total fair value of awards that vested during the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbdb20ed-3ea9-452e-bac6-b7fc05670618" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a7e5c03-d40a-4bee-9482-8cc8a4a61a0f" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ff2641b-30c0-4f4c-b972-5ebafad0109a" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized share-based compensation for unvested stock option grants which is expected to be recognized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6377048a-3238-4164-8bc2-9eead9d134ac" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Common Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7507b254-abdd-42d4-8cdd-8739928b5472" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">762,772</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec99894c-69e7-4a9e-b922-a35cf643d669" contextRef="C_654a16e2-8083-4d9a-92ce-ca57cab55a7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">242,454</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of restricted common stock were granted, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c27007ad-ebb6-44be-807f-d03ae3fa80f8" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows restricted common stock activity:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.195%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.458%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.444%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.474%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />average<br />grant date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(per share)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_757cc1b4-6d8f-4dc5-9865-781d73172ed1" contextRef="C_6ad92b9f-963d-493a-a1e4-49542d62bb26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">299,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7fd0174-3f76-455b-8cfc-552eb2021f94" contextRef="C_6ad92b9f-963d-493a-a1e4-49542d62bb26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_697ff864-06d1-46e8-b372-256d42712658" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">762,772</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0586f781-0a9e-4b86-98fa-76908db79dc9" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b2806f6-0dc3-443f-ba61-919eb7d5724b" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">83,637</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ac08a19-cce9-4351-9418-f3c9221cd92e" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.71</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ff7ef97-6800-4083-a5c0-18273f0c47eb" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">152,118</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_674a0491-4420-4927-b0bd-b144b5c72bc9" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fd111a9-c84b-4fc1-9bfe-045118ea0361" contextRef="C_14cab79b-31e9-441e-9110-e4bc26c0833c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">826,265</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93d5324b-66a6-4a07-8f0e-0b4b22e3b6ea" contextRef="C_14cab79b-31e9-441e-9110-e4bc26c0833c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.89</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total fair value of shares that vested during the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_303745bf-d96e-483f-b8fd-6909fb5a863f" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40f02bf2-c492-49ed-a17c-e7b108ffb18c" contextRef="C_654a16e2-8083-4d9a-92ce-ca57cab55a7c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db8735ff-1d3e-49f5-a319-92e858a4b5e4" contextRef="C_14cab79b-31e9-441e-9110-e4bc26c0833c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2930781f-ef58-4155-872f-2dd1b63fe188" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP is considered a compensatory plan with the related compensation expense recognized over the six-month offering periods. The compensation expense for the years ended December 31, 2022 and December 31, 2021 was less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_623a59e1-9284-4b61-a069-2558b3120467" contextRef="C_9404c746-39af-4f16-b76d-b8630bcb901d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_cfbdf3d3-a29f-4c76-9736-964d6250cf23" contextRef="C_8fa40dbc-7f7b-4478-86f2-ad847e50f5fd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in both years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded total equity&#x2011;based compensation expense of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4936fb73-2ab5-40c2-b77e-eb6927cd3feb" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea3c0538-d29a-4e49-8157-e0786f33f8a4" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, during the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021, respectively. Equity compensation during the years ended December 31, 2022 and 2021 is derived from stock options, restricted stock awards, and the ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_78e357e7-2fa3-4bf9-b9cc-0cb489b11c8c" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity&#x2011;based compensation expense within the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.667%;"></td>
        <td style="width:1.451%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.143%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.451%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.289%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f813732-f084-4356-a794-a61ca0eb52f6" contextRef="C_8114c460-4d06-4e71-8f72-16758968f429" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,565</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c08d166-6551-47d5-ab87-ce0209adee8f" contextRef="C_0754e8dc-f387-45d7-8ad5-2f37ecf370c9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b91141a-885c-430c-9807-15f65d0e647b" contextRef="C_80b6d2b4-7e32-4f90-a5bf-55d9ff118805" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,074</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f58a5cdd-057c-4d92-89ec-4cac67797608" contextRef="C_7c6943e9-6e4c-48b4-ac4a-76f2723a410c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,988</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c374c748-33c5-41ca-ba29-6aaf36fe3f6e" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,639</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19e64af8-c793-4eee-8b26-c8d1d0c38c28" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,361</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c0120b4-4e1e-4215-854d-b33dc684459b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity&#x2011;based compensation expense by type of award for the years ended December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.548%;"></td>
        <td style="width:1.504%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.155999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.491%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.302%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd8fb8a1-ba26-4e95-bd86-e45f2508aeff" contextRef="C_fe7d4a4c-340f-4bfe-9353-91af7151de36" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,168</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e368374-129a-408b-9ca1-e1c84ee4b3ad" contextRef="C_87720378-333d-485a-b610-abbe5ef1182d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a20833ca-71e9-4466-8a88-bafba27d449d" contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47f00c78-b69c-4bf7-aa86-4c07159a71e8" contextRef="C_654a16e2-8083-4d9a-92ce-ca57cab55a7c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">334</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa9c853f-0e7d-41a0-a6f8-1b77b53ccdc4" contextRef="C_9404c746-39af-4f16-b76d-b8630bcb901d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5eb19ed1-7f0a-419a-b12e-331a93b81e35" contextRef="C_8fa40dbc-7f7b-4478-86f2-ad847e50f5fd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06262b22-3616-40b2-bf91-1b2aab1fac9d" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,639</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e656356-8249-478b-8c8a-2d37c780ff58" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,361</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3206c20-69cd-4d6c-8f04-3cd0a2c2a86a" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(10)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreements</span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Roche Collaboration</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, the Company entered into a Pilot Collaboration and Option Agreement (the Roche Collaboration and Option Agreement) with F. Hoffmann-La Roche Ltd (Roche Basel) and Hoffmann-La Roche Inc. (Roche US, and together with Roche Basel, Roche). Under the terms of the Roche Collaboration and Option Agreement, the Company and Roche will seek to collaborate to research and pre-clinically develop Synthetic Biotics for addressing an undisclosed novel target for the treatment of inflammatory bowel disease (the Product Candidate).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Roche Collaboration and Option Agreement, Roche agreed to pay the Company, an upfront, nonrefundable technology access fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_995010e6-1ac4-4944-82ec-f6b2be19ace6" contextRef="C_e8618276-8b30-4637-beb0-a8e46a028cc2" name="sybx:CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company received in July 2021. In addition, the Company is eligible to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43065f2d-6e89-41e3-aeec-b04ec2ba82bb" contextRef="C_e8618276-8b30-4637-beb0-a8e46a028cc2" name="sybx:PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in milestone payments upon the achievement of certain success criteria. Following the research period, Roche holds an exclusive option right (the Option) to negotiate a definitive Collaboration and License Agreement (CLA) for further development and commercialization of the Product Candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Roche Collaboration and Option Agreement, during the term of such agreement, each party has granted to the other party a non-exclusive, non-transferrable, non-sublicensable, royalty-free right and license to certain intellectual property and know-how controlled by such party, solely as necessary for the party to perform its obligations under the Roche Collaboration and Option Agreement. The parties will establish a Joint Research Committee (JRC) to oversee and manage the execution of the underlying study plan for the Roche Collaboration and Option Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Collaboration and Option Agreement includes various representations, warranties, covenants, indemnities, and other customary provisions. Roche may terminate the Roche Collaboration and Option Agreement without cause immediately upon written notice where certain success criteria have been met for parts of the study plan, or upon ninety (90) days&#x2019; prior written notice to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company. Either party may terminate the Roche Collaboration and Option Agreement in the event of an uncured material breach of the other party.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research and development will be performed by the Company for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a85a9217-f514-4770-b4de-172402868a5b" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s according to three phases of research as defined in the research plan. The Company is eligible to receive milestone payments from Roche upon the achievement of success criteria for respective milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and concluded that the contract counterparty, Roche, is a customer. The Company identified the following material promises made by the Company to Roche at the outset of the arrangement: (1) a non-exclusive royalty-free research and development license; (2) research and development services for pre-clinical activities under the research plan; (3) implicit renewal options created by Roche&#x2019;s decision not to terminate the contract; (4) the Company&#x2019;s participation on the JRC; and (5) an exclusive right to negotiate a definitive CLA for further development and commercialization of the Product Candidate. The Company determined that the license and research and development activities were not distinct from one another, as the license has limited value without the performance of research and development activities. The Company&#x2019;s participation on the JRC was determined to be quantitatively and qualitatively immaterial and therefore is excluded from performance obligations. As such, the Company determined that the promises associated with the license and research and development services should be combined into a single performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company next evaluated the milestone payments relating to the three phases of research as defined in the research plan and the option to negotiate and enter into the CLA, to determine whether they provide Roche with any material rights. The Company concluded that the option was not issued at a significant and incremental discount, and therefore do not provide material rights. As such, they were excluded as performance obligations at the outset of the arrangement. If Roche elects to exercise the options, the additional consideration will be added to the transaction price and allocated to the resulting performance obligations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on these assessments, the Company identified one performance obligation at the outset of the Roche Collaboration and Option Agreement, which consists of: (1) the non-exclusive license and (2) the research and development activities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the outset of the arrangement, the transaction price included only the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2c78482-f505-4e7d-9219-0f21b6fc5c30" contextRef="C_e8618276-8b30-4637-beb0-a8e46a028cc2" name="sybx:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million up-front consideration received and which was allocated to the single performance obligation. The milestone payments that may be received are excluded from the transaction price until each respective milestone has been achieved. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, the Company began work on the research and development services for the first phase of the research plan and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c13a8f2-fd37-49a7-a318-a61aa0fad903" contextRef="C_e8618276-8b30-4637-beb0-a8e46a028cc2" name="sybx:UpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront payment was recognized over the time of the first phase of the research plan. In September 2021, the Company completed the research and development services for the first phase of the research plan and achieved a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7efdd48-40bb-4e2c-8a47-4e60a79f27c7" contextRef="C_3282432a-339d-4c93-9545-b3ee55a0a3ee" name="sybx:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was paid by Roche in November 2021. At this time, the milestone payment was allocated to a new performance obligation consisting of the underlying research and development services to be performed over the second phase of the research plan. In August 2022, the Company completed the research and development services for the second phase of the research plan and achieved a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9e00254-169a-41e6-9b67-bcdb26aa18a5" contextRef="C_83994bcc-897b-4ecf-9900-6f87c0a0397c" name="sybx:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was paid by Roche in October 2022. At this time, the milestone payment was allocated to a new performance obligation consisting of the underlying research and development services to be performed over the third phase of the research plan. Upon the Company&#x2019;s completion of these activities and subject to Roche&#x2019;s termination right, the additional milestone payments based on the achievement of specific events outlined in the Roche Collaboration and Option Agreement will become due.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue associated with performance obligations under the Roche Collaboration and Option Agreement are recognized as the research and development services are provided using an input method, according to the full-time equivalents incurred. The transfer of control occurs over time and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#x2019;s consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aaf20ca0-ace7-48f0-be92-e915ccc5e9c8" contextRef="C_a5e1f167-a526-4fc5-995f-8c2fa7bc03e0" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86a280aa-84c9-4e0f-b252-bc6ea7f7e387" contextRef="C_3d9937da-b5ee-4340-92e5-8a0477c4b960" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively, as collaboration revenue in the Company&#x2019;s consolidated statements of operations and comprehensive loss. Deferred revenue from the collaboration amounted to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_709077db-54b0-4a0e-9c6f-663db03e4f62" contextRef="C_4516b6b5-54fe-44c6-ab9c-eee027b01c2d" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022, all of which is included in current liabilities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ginkgo Collaboration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2017, the Company established a technology collaboration with Ginkgo. In June 2019, in connection with the issuance to Ginkgo of an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a2f3616-bef4-4b59-a2f6-35ad6e291536" contextRef="C_73d91fb1-2e62-48f7-92de-e383722c15e2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,340,771</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and Pre-Funded Warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b49bbeb6-1343-4e42-be8e-5cbd437b48f1" contextRef="C_7d128f60-ec2d-4e7e-ad00-15156530da9e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,548,117</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common stock (See Note 8), the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_291e8d99-006c-41f6-a014-878519db2c9b" contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597" name="sybx:PrepaymentToRelatedPartyForCollaborationAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for its foundry services that will be provided to the Company over an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_120861f7-bb43-49eb-bbbf-e294d8161c68" contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597" name="sybx:RelatedPartyTransactionCollaborationAgreementInitialTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The current and non-current balances relating to the prepayment of foundry services is recorded in prepaid expenses and other current assets and prepaid research and development, net of current portion, respectively, on the December 31, 2022 consolidated balance sheet. At December 31, 2022, the Company had remaining balances of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c39d2d9-df46-4dd2-96b5-d7f15afd17ba" contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72" name="sybx:CurrentPrePaidResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c9a0507-0e73-446f-9eb7-423ffe8c65ce" contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72" name="sybx:NonCurrentPrePaidResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of current and non-current pre-paid research and development costs related to this transaction, respectively. Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c437b5a6-8c9d-48b2-9f6e-81fbefe833d2" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(11)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss per Share</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f4283d2e-7ae0-40df-9c82-c9744cc8bbc5" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.517%;"></td>
        <td style="width:1.069%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.334000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.747%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.334000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68b9bd3b-14ec-4511-a64a-538a9559f818" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,147</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_398dc519-db5a-4b00-9881-67b8dfa43c17" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,561</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding - basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0aea2cb7-c071-45ec-ab52-81da3faefacb" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_2b2d4d97-c70d-4d21-b406-02acdf74a864" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">71,725,479</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_194760ed-302b-4559-9aa3-63145e6a54fb" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_a5924677-b584-490a-bd9b-4c68c1e858ae" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">55,329,711</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62e48655-fc4e-4a27-8e51-43f45fbf29b0" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_33137879-9b14-44aa-bacb-e9b7487f6255" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.92</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a439428-8386-478b-be1f-d9184f923c51" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_9fbd87a0-c3bb-402b-b9d6-216b01a5ec36" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.09</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s potentially dilutive shares, which include outstanding stock options, unvested restricted common stock and potential shares issuable under the ESPP, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_403e1410-e07d-49c2-835d-83f3f5a43ada" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.669%;"></td>
        <td style="width:1.131%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.609%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.737%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.854%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted common stock awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e35fb19a-111d-4215-8f8e-bec0b2c9dcf9" contextRef="C_436ec13c-b090-47c3-b27f-abd9ac6ebda8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">826,265</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5643a044-ffa7-45b6-b9b9-dfe4c58d700d" contextRef="C_f81bc0ea-4cc8-4008-8667-3a9f04ab0640" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">299,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5f729f6-6b39-4c46-9af2-baa96615a015" contextRef="C_640feb28-ca33-4b33-8050-74bd8f92c9c0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,247,695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f1a671e-960c-4cb6-8a0c-25aee31ee8d5" contextRef="C_bb7c3478-1f6c-45ea-b035-e3a9a00b30bd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,500,913</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c3251e5-f12e-4239-bd5c-8f9befa44cfc" contextRef="C_634cb392-9161-4709-9f2a-a13f53a4e68e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">52,648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7ca3a12-b3cf-4149-b1db-107075cdd2d0" contextRef="C_d51691b1-bfd1-4bf1-a65f-d5da006787a0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">21,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e234146c-4eef-4e76-9e83-75d02e6c13a7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(12)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recorded </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9335d409-115a-4f04-ab0e-074850985c51" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b017e75b-af46-409b-99ba-ab58971125be" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> income tax benefits for the net operating losses incurred due to its uncertainty of reclaiming a benefit for those losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eb1b94e0-b868-4402-91ff-76af2fbaf0a6" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Deferred tax assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.101%;"></td>
        <td style="width:1.721%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.721%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.222999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_980fb483-5862-445a-afd4-016100e02b15" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1bea7dc-2197-4092-b5a3-50ff3daa6ebb" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,802</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d075375-f19c-4673-90c0-ac1748549d03" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,118</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a60f16a9-6f6e-4091-abab-94b57e118f62" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e7cc162-79bb-4f7a-b7e0-5d08255e036c" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3">127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_363957bc-8312-42a6-86bd-5d734c662cc9" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3">181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b235969-9d35-493c-a41f-b16cc90207ad" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">888</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45ca3f79-3751-4a24-bbfb-8d005bb192e8" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e3dceec-b8df-452b-9d35-f0328e1c12d1" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,541</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f390e730-924a-49fd-a51a-45d43de8e95a" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="sybx:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efd02e60-c1da-4560-a9ca-ac86c59557fe" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,516</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62c211c1-b153-4f46-8672-928e82aa9fac" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortizable intangibles</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bb16854-a60b-4bed-940f-17d3667daf92" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d435ebc5-7c65-43e0-91e4-6b010b2473c4" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,197</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortizable research expenditures </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5154fc7b-67d1-47e6-ad1b-f94da79478e2" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:DeferredTaxAssetsAmortizableResearchExpenditures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1376be1-f20e-47e5-bdac-d1d9dcc329ea" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="sybx:DeferredTaxAssetsAmortizableResearchExpenditures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60f53285-19f4-4c0f-893d-f3eb699a7e8b" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3">363</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0dcfc23e-1e54-4c50-9212-e41306c89435" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3">238</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b275234d-2b46-421f-a2d5-621bdeb95c14" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113,521</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ea5c7a2-2548-4f68-abc7-770a097f0041" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53ead05f-a55b-4b5e-9269-ca90409b2c48" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,922</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3712324-022a-47ad-9884-73671d8086f9" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="sybx:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2308abf7-764f-4650-bab5-054ff4493be6" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,922</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8e2b991-ccec-448c-aaba-9e436df7cc07" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32a33a6c-a2c4-49e6-8124-d5ae77149901" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,599</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04d003fb-89a9-4ae9-ae9f-12b7f34c32d2" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.365pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_4518ba34-7fe5-4a26-958e-210cdeeec538" xml:lang="en-US"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.365pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Under the Tax Cuts and Jobs Act (TCJA), research and experimental (R&amp;D) expenditures are capitalized and amortized under section 174 for tax years beginning after December 31, 2021. These costs are amortized for tax purposes over 5 years since the R&amp;D was performed in the U.S. The unamortized balance of these costs is presented as a deferred tax asset in the table above.</span></p></ix:footnote></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s deferred tax assets, which are comprised principally of net operating loss carryforwards, and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1b0ed9d-076f-4934-841c-fd9475db9ce1" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">109.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_298e8b7f-575f-4cbe-a89d-1bb60c2e9178" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">90.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was established at December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021, respectively.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6eb58073-bca2-40d5-bb4d-f144726518c0" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective income tax rate is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.802%;"></td>
        <td style="width:0.969%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.863%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.982%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.385%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f94c4de7-2de0-4245-8919-eb2d237d468c" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af5573ea-c01b-4772-9bc4-c3040d22eca6" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccaa02e6-e950-4f9e-979d-83e22c577349" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f6fb0b2-ad97-414d-a94f-efeae9ea461a" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14514c74-1ebe-4121-9543-9d6e4f216c90" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="2" sign="-">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5f21c40-0a94-4f9f-b6b4-180352228fc0" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="2">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f46e020-9b6a-4c6f-a263-d6a5aad02537" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="2">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48b5dbbb-1d8d-4de4-9bd1-20a9c6658eb6" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="2">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afd42e8a-6cac-465b-942e-0ce9b0f75328" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="2">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_707e8879-302a-461c-b05f-653760a7d079" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="2">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2170fa76-9d2b-41e2-9556-a4bc3c53d26a" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-">29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0db105f6-c45b-4e11-951d-2bbce8e4402f" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-">29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_deefaeac-ec0e-46b0-8311-eb19f0d137d4" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:SummaryOfValuationAllowanceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A roll-forward of the valuation allowance for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.421%;"></td>
        <td style="width:1.592%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.203999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.557%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.227%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e011b182-2551-43d6-a123-7236839743a2" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2da51c3b-8821-4102-ac75-1a8301882e7d" contextRef="C_4ce13154-7826-4547-a938-f6040b13872f" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,791</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_442e4b88-e4a7-493f-873f-e27b64d443c3" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a44801d1-b1d7-4634-9874-ef35f0ebd592" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">17,686</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b379277-dc72-46cf-b85e-3c83c9972104" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,599</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25364eab-ff61-4a65-bda5-56705a12b87a" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had federal net operating loss carryforwards that may be available to reduce future taxable income of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f724a3d9-6e2d-461b-81d3-0875d9a3f097" contextRef="C_d2ff957f-8810-4fc7-8b03-9624137f2f79" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">302.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e145490b-dcaf-4aa8-b93e-a0b7e1764cdb" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">302.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating loss </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carryforwards, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97cee7bb-f4a8-4e00-84e5-31053f05d866" contextRef="C_d2ff957f-8810-4fc7-8b03-9624137f2f79" name="sybx:OperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">79.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will expire on various dates from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6f520fb0-1c75-4baf-bd42-c0757cbc0c68" contextRef="C_23b05112-0191-4539-844d-dcff33882fec" name="sybx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3766db4b-a0d4-4385-964b-a2789408dc95" contextRef="C_261be9b1-a487-4761-8558-63f62fe17054" name="sybx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41fe09d5-9239-4fa7-897b-d75ca7a3db7b" contextRef="C_d2ff957f-8810-4fc7-8b03-9624137f2f79" name="sybx:OperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">223.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating loss carryforwards do not expire. The Company also had state net operating loss carryforwards that may be available to reduce future taxable income </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c4cde17-d25b-4537-aa56-366cb72feb0e" contextRef="C_e0dd3811-b7af-4902-afcd-ce7c054f5cb5" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">289.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">illion for the period ended December 31, 2022. The state net operating loss carryforwards begin to expire i</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9391e572-a6a6-4787-b800-4dee1174ea0a" contextRef="C_d97b6644-79ff-4699-9f6b-e83cf66bd673" name="sybx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ddition, as of December 31, 2022, the Company had federal and state research and development tax credit carryforwards available to reduce future tax liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76d43021-7601-4fb6-a0cb-bfc29a503c48" contextRef="C_794b0fde-85f9-4229-b743-26bedc55e777" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f69b5424-f94c-4b3c-a8ac-7f99243426c1" contextRef="C_0558df53-fc4c-4356-aa92-1218af4ad35e" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law which contained provisions that include a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_259c8512-2c23-42db-a787-3b0dbe1b8903" contextRef="C_8caafedd-e06d-4a10-aa7a-0b8fa55c8b9c" name="sybx:CorporateMinimumTaxEffectPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% corporate minimum tax effective for taxable years beginning after December 31, 2022 and a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5650328-22c9-43c3-b29a-47084d00dd85" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="sybx:ExciseTaxPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% excise tax on certain stock buybacks after December 31, 2022. The Company expects the impact of these provisions to be immaterial.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 382 of the Internal Revenue Code of 1986 (IRC), certain substantial changes in the Company&#x2019;s ownership may result in a limitation on the amount of net operating loss (NOL) carryforwards and research and development credit (R&amp;D credit) carryforwards that may be used in future years. Utilization of the NOL and R&amp;D credit carryforwards may be subject to a substantial annual limitation under Section 382 of the IRC due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax. The Company has not completed a study to assess whether an ownership change has occurred, or whether there have been multiple ownership changes since its formation, due to the significant complexity and related costs associated with such a study. There could be additional ownership changes in the future that may result in additional limitations on the utilization of NOL carryforwards and credits.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6910963-f588-4252-af89-97c3c3539461" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognized any liability for unrecognized tax benefits as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company&#x2019;s policy is to record interest and penalties related to unrecognized tax benefits on the income tax expense line in the consolidated statement of operations. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0ffd8ac-55c6-4328-bfad-2787576c242c" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8f1b368a-fd97-46b2-b556-aa29f164bb08" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest or penalties accrued at December 31, 2022 and 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files tax returns, on an entity-level basis, as prescribed by the tax laws of the jurisdictions in which it operates. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_da8109a1-72c4-4670-96f8-c0b906b48ea8" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:IncomeTaxExaminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2019 to the present are open to examination under the statute.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company&#x2019;s net operating losses and other attributes generated in a closed tax year may still be adjusted to determine the amount of carryforward deduction available in an open year under examination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f33a15f1-1874-4e6f-b3f2-41aeb20d6d59" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:ShareRepurchaseTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13)   Share Repurchase</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 25, 2022, the Company entered into a definitive share repurchase agreement with a stockholder, as part of a privately negotiated transaction, to repurchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11092bb3-3b4a-4dd3-b33d-13178a4a6bb0" contextRef="C_be0c663b-cd69-4808-83ec-81ad0fa98a39" name="sybx:RepurchaseOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,196,889</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock held by them for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6645b6f1-d3fc-4b8b-8e45-067a4c08ffba" contextRef="C_be0c663b-cd69-4808-83ec-81ad0fa98a39" name="sybx:AggregatePurchase" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d56a8c3-65cb-4516-8ae6-2f51dccf244e" contextRef="C_be0c663b-cd69-4808-83ec-81ad0fa98a39" name="sybx:AggregatePurchasePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. This repurchase was completed on November 28, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchased shares are held as treasury stock at cost until they are retired or re-issued.  There were no retirements or re-issuances of treasury stock during the year ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c636d8bc-6ab8-4537-bf72-e51d4bcb4308" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(14)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2017, the Company entered into an agreement to lease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db05eacd-c2a3-44d7-9ec8-471eece86607" contextRef="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0" name="sybx:RentableSpaceUnderLeaseAgreement" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">41,346</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts. Annual rent is approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2c2d959-6539-4c6b-a418-688f82e08410" contextRef="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0" name="sybx:OperatingLeasesRentExpenseAnnualRentalPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b833da7e-e17e-4915-8c2b-84d1b7946314" contextRef="C_37a703b8-c41b-42c8-9707-370b726139cb" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease commenced in January 2018 and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company has paid for tenant improvements of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58d88c28-da03-4672-923c-09737f8d2a90" contextRef="C_37a703b8-c41b-42c8-9707-370b726139cb" name="sybx:TenantImprovementInvestmentObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Additionally, the Company has capitalized approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e458ca5e-4f90-430a-a3a1-e8c87feb251c" contextRef="C_b35d2ba3-ee9d-4986-b9f1-a7a0e81af1d8" name="sybx:TenantImprovementInvestmentObligation" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of landlord-funded tenant improvements. The Company was deemed to be the accounting owner of the tenant improvements primarily because it was responsible for project cost overruns, and as such, the amounts were recorded as a leasehold improvement. The landlord-funded tenant improvement allowance is being amortized as a reduction to lease expense ratably over the lease term. In conjunction with the lease, the Company established a letter of credit of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45b96467-0040-4d0e-852c-c5331817b51f" contextRef="C_37a703b8-c41b-42c8-9707-370b726139cb" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">secured by cash balances included</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restricted cash. Variable payments based on our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. The Company has an option to extend the term by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_39d36217-ed9f-4dbc-b52a-985b5093a6ce" contextRef="C_37a703b8-c41b-42c8-9707-370b726139cb" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and an option to terminate the agreement if a similar agreement is executed with the landlord or an affiliate of the landlord. Neither option is reasonably certain of exercise and both are excluded from the lease liability calculation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2018, the Company entered into an agreement (the First SOW) with Azzur Group, LLC (Azzur) whereby Azzur agreed to provide the Company with access to, and the use of, an approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d1e0f1a-6dde-4ba0-8964-98ebf16647ad" contextRef="C_91268588-0fb2-48c3-8afe-0148ee56a770" name="sybx:AccessAndUseOfSpaceUnderAgreement" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">700</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square foot cleanroom space to be constructed in Waltham, Massachusetts (the Azzur Suite), for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_660b11c4-b5f6-4a2f-88b8-7210739ff464" contextRef="C_91268588-0fb2-48c3-8afe-0148ee56a770" name="sybx:TermOfAgreement" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months, from May 1, 2019 to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ed0778e4-0699-45f3-a459-673440397135" contextRef="C_60a114fa-eeba-4606-ada0-5fecd8dae2ac" name="sybx:AgreementExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the Initial Term). In April 2021, Synlogic entered into a new agreement (the Second SOW) with Azzur which replaced the First SOW. Pursuant to the Second SOW, Synlogic was granted access to, and use of, the Azzur Suite for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fc072a4d-5a06-48b7-9738-6410aa472f06" contextRef="C_e3e7babb-b939-40de-97da-4a92ec952e88" name="sybx:TermOfAgreement" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, from May 2021 to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9ad71e03-2303-4ee4-883d-5ed6738ea62b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2022</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the Second Term). On January 21, 2022, the Company entered into two agreements with Azzur. Pursuant to the first of the agreements (the Third SOW), the Company has agreed to pay Azzur $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a27e323-6641-4f59-938d-363469c734f8" contextRef="C_489afa5b-74fd-452f-b937-8e7dab8a46e6" name="sybx:RenovateAndUpgradeExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to renovate and upgrade the cleanroom space at Azzur for the Company&#x2019;s expanded use. The second of the agreements (the Fourth SOW) replaces the Second SOW that the Company entered into with Azzur in April 2021. The Fourth SOW extends the term of the lease, for the period beginning January 2022 through March 2023 (the Third Term). In November 2022, the Company entered into a new agreement (the Fifth SOW) with Azzur that extended the term of the lease, for the period beginning April 2023 through December 2023 (the Fourth Term). The Fifth SOW contains two options to extend the lease, the first option goes through June 2024, and the second option goes through December 2024. The Company determined that the agreement contained an embedded lease because the Company controls the use of the Azzur Suite. Accordingly, the fixed and in-substance fixed consideration under the agreement was used to measure the ROU asset and lease liability at the effective date. The ROU asset and lease liability are subsequently remeasured to reflect the impact of each subsequent modification. As of December 31, 2022, the Company determined that it was reasonably certain to exercise the first option to extend the lease under the Fifth SOW, and thus was included in the lease liability calculation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases classified as operating leases are included in operating lease ROU assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheets. The operating lease right-of-use asset and operating lease liability represents the Binney Street lease and the Azzur Suite lease. Cash paid for amounts included in the present value of operating lease liabilities was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6f20e79-0423-44b0-a225-006d6814b678" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_938e2a6d-1f0b-4dd6-b5ba-7577885995ee" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, 2022 and 2021, respectively, which is included in operating cash flows.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3e0f8696-39dc-4d95-8d2e-25c26688e082" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease cost for operating leases for the years ended December 31, 2022 and 2021 were (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.501%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:23.987000000000002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.227%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.285%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97a2c0a3-520c-41eb-9a79-9442492f64f7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,812</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0e8c57b-ec5d-427a-be11-78278f47938e" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,824</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_562fa081-821e-40c4-942d-24cce741aa0a" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ac88890-b5c9-4058-8a0a-962da42cab61" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47e1062f-aec0-4450-b195-7535aee598d6" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:OperatingAndVariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,221</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d452a31-375d-47b6-8301-5fc50062d203" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="sybx:OperatingAndVariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,324</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The right-of-use asset for the operating lease is disclosed on the consolidated balance sheets.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_174de797-254d-4e4b-989c-29f3c14923b7" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate for operating leases were:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.375%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:24.341%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.864%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.419%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f0ba1f3-0d7b-4af7-a84c-a18cbc15c4a6" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3">8.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8759ee92-61f1-460d-8968-b67e04653a23" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3">8.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a660a9db-ce13-4457-9106-94b72bdef448" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_982ec5f3-ef9b-497e-b3ab-1d2a1d1f3697" contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SYNLOGIC, INC. AND SUBSIDIARIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements (continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f17d4353-8c87-46e3-aa6f-1a2e618aa0fc" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="sybx:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2022 to the operating lease liabilities recorded on the balance sheet: December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.945%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:32.056%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c835392-6aa2-4029-af61-8b1890cedf85" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7adacbc9-18d0-46dd-a1d6-ec67b0b4a138" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,749</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3cfc9a4-91fd-4460-aac9-aea2c7dc3795" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21866b66-e101-4319-9b9a-6bfb97beea14" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,905</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6f40df2-24dd-41f0-804b-47fd7b8f9503" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,022</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c18012df-d6bd-421c-8071-caa28f3f2f1e" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65dbd057-8756-423e-9779-4fd5c6beec99" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,761</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06792c8e-f9f0-4cda-800e-1c60935dfc0e" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,480</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2f4221e-9beb-4fd8-b606-9bbce11c8d21" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c2596dc-a5ed-404c-82d2-4ef047d0e756" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,152</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccbf4886-0f01-43e3-9508-6f80187299b0" contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,129</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease cost for finance leases during the years ended December 31, 2022 and 2021, and the finance lease liability at December 31, 2022, were not material.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6dae8846-ace5-4c33-9e34-dfa19606c019" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(15)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_217f23cb-6a58-4444-8451-2da1c7a39139" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(16)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Benefits</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a defined contribution 401(k) plan for eligible employees. Employees are eligible to participate in the plan beginning on their date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation. The Company started to match employee contributions effective January 1, 2019. The Company matched </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51cb5903-c87a-4569-b5bd-6cd3597dca52" contextRef="C_c3c4febd-5bb8-42c3-974f-1da160403289" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the employee contributions to the 401(k) plan up to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa556252-3745-4201-8dfd-6f4e44f9314c" contextRef="C_c3c4febd-5bb8-42c3-974f-1da160403289" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the participating employee&#x2019;s eligible earnings, resulting in a maximum company match of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bf159f1-001b-48f4-a1ad-6731a9992010" contextRef="C_c3c4febd-5bb8-42c3-974f-1da160403289" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the participating employee&#x2019;s eligible earnings, and subject to certain additional statutory dollar limitations. In 2021, the Company increased the match to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_492143f5-ac48-4313-88a4-161d21ef8e80" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the employee contributions up to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d3e21d5-fb01-43eb-9299-23fab04a9fc2" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the participating employee&#x2019;s eligible earnings, resulting in a maximum company match of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b15f1e3-39e4-4197-9df3-7a67cd056a30" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the participating employee&#x2019;s eligible earnings, and subject to certain additional statutory dollar limitations. For the years ended December 31, 2022 and 2021, the Company made </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a580f165-011c-495b-8ed2-1d60eba21f66" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44f5daf0-85d2-440f-8bfb-b34f83b7f128" contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million contributions to the plan, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_59aaaa3b-437f-4e79-aa34-29703c46f5b1" contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(17)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related-Party Transactions</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of December 31, 2022, Ginkgo owns </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_629dc26d-2575-4b8d-a14f-39b360b614b8" contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,340,771</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s outstanding common stock.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ginkgo Collaboration.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the agreement the Company made a prepayment to Ginkgo of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef86328b-1c6d-4c6b-a166-b329d0067d7a" contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597" name="sybx:PrepaymentToRelatedPartyForCollaborationAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for its foundry services that will be provided to the Company over an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_78d5c825-e4a3-4226-9964-e0118eb8b067" contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597" name="sybx:RelatedPartyTransactionCollaborationAgreementInitialTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At December 31, 2022, the Company had remaining balances of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cf99ec0-deeb-46d5-819a-1a1fe4640ec0" contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72" name="sybx:CurrentPrePaidResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6a1c667-6163-4804-a799-70db579bc3a6" contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72" name="sybx:NonCurrentPrePaidResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of current and non-current pre-paid research and development costs related to this transaction, respectively. For the year ended December 31, 2022, the Company used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19d50bf5-9820-49c7-96b7-34dfed6744d5" contextRef="C_a3f01399-c70d-4fc2-8fb9-042eab32457b" name="sybx:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the pre-paid research and development expenses.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>sybx-ex10_32.htm
<DESCRIPTION>EX-10.32
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:61.6%;text-indent:24.306%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scope of Work (SOW)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.05pt;text-align:center;"><img src="img51355790_0.jpg" alt="img51355790_0.jpg" style="width:483px;height:103px;">&#160;</p>
  <p style="margin-left:21.8%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.84%;text-indent:0.0%;font-size:10.0pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:30.843%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scope of Work</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:30.84%;text-indent:0.0%;font-size:10.0pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:30.843%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P-10558-01 Extension A</font></p>
  <p style="margin-left:30.84%;text-indent:0.0%;font-size:10.0pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:30.843%;text-align:left;"><font style="white-space:pre-wrap;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img51355790_1.jpg" alt="img51355790_1.jpg" style="width:284px;height:123px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.373%;text-indent:0.0%;font-size:10.0pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:2.574%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scope of Work for Cleanroom 3 Use</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.373%;text-indent:0.0%;font-size:10.0pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:2.574%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(April 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:12.06pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2023 to December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:12.06pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2023</font></p>
  <p style="margin-left:2.373%;text-indent:0.0%;font-size:10.0pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:2.574%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With Options through Q4 2024)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.083%;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(18,85,154,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 1 - Background/Scope</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:3.815%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Azzur Cleanrooms On Demand (&#x201c;COD&#x201d;) facilities are designed for clients to utilize controlled clean areas and services related to early phase cGMP manufacturing. This Scope of Work (&#x201c;SOW&#x201d;) is for 9 months, subject to terms and conditions specified in the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LICENSE AND SERVICES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, of cleanroom use (&#x201c;CR3&#x201d;) and support related services at the COD facility located at 411 Waverley Oaks Rd., #126, Waltham, MA 02452.  This SOW is an Extension to P-10558-01 for the duration of April 2023 to December 2023.  This SOW is entered into by and COD (&#x201c;Licensor&#x201d;)  and Synlogic (&#x201c;Licensee&#x201d;) effective as of the approval date of this SOW. Upon execution of this SOW, this SOW will be incorporated into the mutually approved License and Services Agreement (&#x201c;LSA&#x201d;) that contains additional terms and conditions of the COD Cleanrooms and support services use.</font></p>
  <p style="text-indent:2.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(18,85,154,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2 &#x2013; License and Technical Requirements</font></p>
  <p style="margin-left:2.88%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:3.815%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commencing on the Effective Date and subject to the terms and conditions of the LSA, Licensor grants to Licensee a license to access and use the cleanroom with specification described in Section 3.  Licensor will provide the support services described in this Section 3 using Licensor personnel. Licensor personnel will perform the services in a timely, professional and workmanlike manner and in accordance with all applicable laws, regulations and guidelines. Licensor will maintain all permits, licenses or other approvals necessary for the operation of the Cleanroom in accordance with the requirements set forth herein. Specifically, Licensor will perform Services in accordance with the following:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;margin-right:3.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensor personnel will be experienced with FDA facility compliance expectations. Licensor has based this Statement of Work upon the following documents.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;margin-right:3.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Code of Federal Regulations Title 21 Part 210 &#x2013; Current Good Manufacturing Practice in the Manufacturing, Processing, Packing, or Holding of Drugs; General</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;margin-right:3.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Code of Federal Regulations Title 21 Part 211 &#x2013; Current Good Manufacturing Practice for Finished Pharmaceutical</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;margin-right:3.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ISPE Good Practice Guide &#x2013; Science and Risk-Based Approach for the Delivery of Facility Systems and Equipment</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;margin-right:3.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ISPE Good Practice Guide &#x2013; Good Engineering Practices</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;margin-right:3.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PDA Technical Report 56 &#x2013; Application of Phase Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.083%;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:6.815%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensee personnel using the classified areas are to be trained on Licensor SOPs on gowning, personnel movement, material control, gowning training, safety training etc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(18,85,154,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3 &#x2013; Detailed Scope</font></p>
  <p style="margin-left:1.867%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This SOW provides details of the licensed cleanroom space, office space, support services and the related inclusions.</font></p>
  <div style="margin-left:1.87%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:3.396514827269949%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cleanroom</font></div></div>
  <p style="margin-left:5.227%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dedicated CR3 cleanroom space for a duration of 9 months with a start date of April 2023, with the automatic option by Licensee to extend through the end of Q2 2024. (June 30, 2024) (the &#x201c;First Option&#x201d;).   Licensee shall notify Azzur by October 1, 2023 if it seeks to exercise the First Option.  If Licensee exercises the First Option, Licensee shall then have the automatic option to extend through the end of Q4 2024 (December 31, 2024) on the same 2024 monthly cost terms as set forth below.  Licensee shall notify Azzur by April 1, 2024 if it seeks to exercise the Second Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:3.463%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All entry/exit door to controlled or classified spaces will be access controlled via badge access     and security controls</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:1.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cleanroom entry/exit doors will be interlocked with access only to Licensee and Licensor personnel.</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:5.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Room differential pressures which will meet ISO 7 classification in the core. </font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:5.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:4.935%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Room differential pressures which will meet ISO 8 classification in the gown-in and gown-out areas.</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:1.75pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Temperature specification range of [***] &deg;C with operational control of [***]&deg;C</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:5.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Differential pressure, temperature and humidity will be continually monitored and alarmed.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remote alarm management is performed by Licensor.</font></p>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:5.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ISO 7 core will be furnished with a Biosafety Cabinet (ISO 5), two 6 ft. stainless steel tables and associated chairs. Additional room furnishings can be installed upon request, the costs for which are not included in this SOW.</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:5.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Qualified ISO5 BSC in the cleanroom</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:5.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On-going BSC certification/maintenance</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.083%;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.667%;text-indent:-3.509%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NOTE: BSC cleaning and disinfection during routine use is </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x2019;s responsibility.</font></p>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cleanroom Cleaning</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:6.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:6.935%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weekly &#x2013; Horizontal and vertical surfaces including wiped using IPA, floors vacuumed and mopped using the latest version of the following approved cleaning solution ([***]).</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:0.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:6.935%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Monthly &#x2013; Same as weekly cleaning followed by second cleaning using approved cleaning solution on all surfaces ([***]).</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:1.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:7.204%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quarterly (once every 3 months) &#x2013; Same as monthly cleaning ([***]).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.667%;text-indent:-3.509%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NOTE: Changes in cleaning regimen including type of agents and frequency as well as enhanced cleaning for changeover can be implemented, the costs for which are not included in this SOW.</font></p>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Routine Environmental Monitoring (EM)</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:6.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weekly TAP, Viable Air and Surface Monitoring</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:5.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data review and quality support (in-case of any deviation)</font></div></div>
  <div style="margin-left:6.0%;text-indent:0.0%;display:flex;margin-top:5.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.545744680851064%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trending and reporting of EM data on a periodic basis</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.667%;text-indent:-3.509%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NOTE: Changes in environmental monitoring including additional in-process monitoring costs are included in Table 4 of this SOW.</font></p>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.796%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Access to consumable including gowning materials, cleaning supplies (wipes, alcohol) and dry ice.  Licensor    personnel will stock and re-stock such materials on a routine basis.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.083%;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.87%;text-indent:0.0%;display:flex;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:3.396514827269949%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facility Infrastructure/ Quality Management (Licensor owned assets)</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security and access control for cGMP areas. Issuance and management of badges.</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:6.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Back-up power for entire facility with all controlled assets (both Licensor and client owned)</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:6.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pest control, housekeeping and non-gmp cleaning</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:6.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waste removal and disposal (Biological, Hazardous, Non-Hazardous)</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:6.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:3.333%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensor owned asset management including installation, calibration, qualification, routine monitoring, maintenance, alarm management and documentation.</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quality management of all Licensor owned assets including incident management.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:17.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:4.0%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:3.396514827269949%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Material Storage for 9 months in Licensor owned assets in dedicated qualified, controlled, monitored and maintained environments in the following Standard Minimum Units (SMU) monthly amounts.  The monthly SMU amounts are determined based on the previous usage rates.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.463%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4525622300257934%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] ambient pallets</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4525622300257934%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] CTUs ([***]&#x2da;C) or equivalent controlled storage space</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4525622300257934%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] CTU ([***]&#x2da;C) or equivalent controlled storage space</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4525622300257934%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] CTU ([***]&#x2da;C)</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:17.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:3.396514827269949%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel Support (180 hrs per month)</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:2.667%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Materials management including receipt, inspection, labeling, inventory management, segregation, movement, staging/kitting and raw materials quality release based on CofA.</font></div></div>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:6.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Routine project meetings for scheduling, reporting, budget updates and issue resolution.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On-site support on an on-going basis.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:7.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Coordination/scheduling of shipment pickup and drop-off activities, packaging and labeling of samples, product shipments etc. Reconciliation of temperature monitors used for shipments.</font></div></div>
  <p style="margin-left:5.987%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:7.815%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:7.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standard hours of support are Monday-Friday 0700-1900. Off-hour support must be coordinated with Facility management.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:0.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.083%;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.87%;text-indent:0.0%;display:flex;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:7.602%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:3.396514827269949%;">e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dedicated office space for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> personnel with access to telephone, printer/scanner, wireless internet, television/Monitor, office supplies and cafeteria.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:1.867%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(18,85,154,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4 &#x2013; Fees</font></p>
  <div style="margin-left:1.87%;text-indent:0.0%;display:flex;margin-top:16.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.396514827269949%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Fee</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.96%;text-indent:-0.014%;padding-left:0.013%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:1.287%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The License Fee will be pre-paid on a monthly basis and includes items listed under the relevant category in Table 1 below.  A monthly Variable Budget for support services overage compared to SMU amounts and out of scope activities has been established at $</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">per month. Specifically, the   variable budget will cover the following known items, as needed:</font></p>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:9.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:8.537%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:8.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:9.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></div></div>
  <div style="margin-left:8.537%;text-indent:0.0%;display:flex;margin-top:8.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:9.87%;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6440965199042243%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></div></div>
  <p style="margin-left:0.987%;text-indent:0.0%;font-size:10.0pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:3.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table 1 below shows the costs related to support services for monthly overages and other services to be covered by the Variable Budget, if required. 2023 Monthly Costs have stayed as proposed previously, while 2024 Monthly Costs have been added as an option and include the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% annual rate adjustment to account for increased facility maintenance and personnel costs etc. Note that the unit costs of overages are higher than unit   costs included in the License Fees as unplanned activities result in additional costs such as offsite storage, material movement and personnel time.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.136%;"></td>
    <td style="width:17.742%;"></td>
    <td style="width:20.061%;"></td>
    <td style="width:20.061%;"></td>
   </tr>
   <tr style="height:14.4pt;">
    <td colspan="4" style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table 1: 2023 Monthly Costs and 2024 Monthly Costs (Extension Options)</font></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item Description</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"># of Units/ month</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023 Monthly Costs</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024 Monthly Costs</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Personnel Support</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Material Management Warehouse Movement</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:20.9pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consumables</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Waste Surcharge</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:12.95pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:1pt solid;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Monthly Totals</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:1pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td colspan="2" style="border-top:1pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:1pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Variable Budget</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:1pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.734%;"></td>
    <td style="width:37.266%;"></td>
   </tr>
   <tr style="height:15.85pt;">
    <td colspan="2" style="border-top:1.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.5pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Table 2: Overage/Other Costs</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Type</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unit Cost</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Materials Management Warehouse Movement</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3rd party costs</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Personnel Support</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Enhanced EM*</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.5pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Personnel Training</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1.5pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;border-left:1.5pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.5pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Non &#x2013; Standard Business Hour Support</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:1.5pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(18,85,154,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5 &#x2013; Payments and Invoicing</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.35pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:3.815%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All invoices are due net +30 days from the invoice date. Fixed amounts for the monthly License Fee    will be generated at the start of each month. Monthly invoices for variable amounts will be generated out at the end of each month, if required based on actual usage.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:3.815%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total amount for cleanroom use and related services for 9 months starting April 2023 to December 2023 is $</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,707,074</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In addition, the variable budget of $</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/month, total amount $</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">will also be required.  A Purchase Order (&#x201c;PO&#x201d;) for the total amount is required for the reservation of the cleanroom and related services specified in this SOW.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:3.815%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(18,85,154,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 6 &#x2013; Approvals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SOW Generated by (COD):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: 22 Nov 2022	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: /s/ Daniel Dernbach</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Email: daniel.dernbach@azzur.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SOW Accepted by (Synlogic):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DATE:   11/22/2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NAME: Michael Jensen, CFO   /s/ Michael Jensen</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>sybx-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUBSIDIARIES OF SYNLOGIC, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsidiary</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jurisdiction</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic Operating Company, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic Securities Corporation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>sybx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (Nos. 333-207299, 333-210466, 333-220841, 333-223798, 333-230224, 333-237104, 333-237105, 333-254688, 333-254689, 333-263629 and 333-263630) on Form S-8 and (Nos. 333-233139 and 333-258151) on Form S-3 of our report dated March 29, 2023, with respect to the consolidated financial statements of Synlogic, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ KPMG LLP<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 29, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>sybx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 302</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Aoife Brennan, certify that:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.  I have reviewed this annual report on Form 10-K of Synlogic, Inc.;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.  The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c)  evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d)  disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.  The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ AOIFE BRENNAN</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aoife Brennan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>sybx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 302</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Michael Jensen, certify that:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.  I have reviewed this annual report on Form 10-K of Synlogic, Inc.;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.  The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c)  evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d)  disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.  The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MICHAEL JENSEN</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Jensen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>sybx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Synlogic, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Aoife Brennan, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ AOIFE BRENNAN</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aoife Brennan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>sybx-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Synlogic, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Michael Jensen, Chief Financial Officer, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.537%;"></td>
    <td style="width:4.139%;"></td>
    <td style="width:2.824%;"></td>
    <td style="width:48.5%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 29, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MICHAEL JENSEN</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Jensen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img51355790_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img51355790_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $#!+X# 2(  A$! Q$!_\0
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MM^E;>RBOB9C[:4O@1Z-/\=]$1B(-+OY!ZL47^IJ(?'G2_P"+1;P?2536/;?
M74&7-SK=K&QZB.%G'YDK5E_@&V/D\0KGWM?_ +.BU$5ZQOV?QO\ #$Y N(+^
MV]WB# ?D<_I76:3XV\-ZV56PUBV>0](W;8__ 'RV#7D-[\"M=A4M9ZC97..S
MED)_0C]:XO6O _B/P^"^H:5.D0ZS1_.@^K+D"ER4Y?"Q^TJ1W1]8T5\N>&_B
M/XC\-.B0W;75H#S;7!+KCV/5?PXKW7P;\0M(\81B*%OLVH*N7M)&R?JI_B'Z
M^HJ)TI1UZ&D*L9'74445F:!63XB\0V7AC2'U/4!*;=&53Y2[FR>G&16M7 ?&
M3_DGES_UWB_]"JHJ[2)D[)LM:!\4= \2:S#I=BEZ+B;=M,L0"\*6.2&/85VM
M?,WPC_Y*/IO^[+_Z+:OIFJJ1479$TIN2NPHHHK,T"BBB@ HHHH **** "N6\
M4^/]&\(7<%MJ:W1DG3S$\F,,,9QSDBNIKP?X\?\ (P:5_P!>I_\ 0S5PBI2L
MR*DG&-T=C_PNWPI_SSU'_OPO_P 51_PNWPI_SSU'_OPO_P 57DO@OX?7OC6"
M[EM;V"W%JRJPE#<Y!(Q@>U=3_P *'UC_ *"]C_WR_P#A6CA33LV8J=5JZ1V/
M_"[?"G_//4?^_"__ !5'_"[?"G_//4?^_"__ !5<;_PH?6/^@O8?]\O_ (4?
M\*'UC_H+V'_?+_X4N6EW*YJO8[+_ (7;X4_YYZC_ -^%_P#BJ/\ A=OA3_GG
MJ/\ WX7_ .*KC?\ A0^L?]!>P_[Y?_"C_A0^L?\ 07L/^^7_ ,*.6EW#FJ]C
MLO\ A=OA3_GGJ/\ WX7_ .*H_P"%V^%/^>>H_P#?A?\ XJN-_P"%#ZQ_T%[#
M_OE_\*/^%#ZQ_P!!>P_[Y?\ PHY:7<.:KV._TCXL^'-:U:VTVUCOA/<N$3?$
MH7)]?FKNJ\<\,?!W5-"\2Z?JDVIVDL=K*'9%#9('IQ7L=1/EO[II!RM[P444
M5!84444 %%%% %74=0M]*TVXO[M]EO;QF1S[#T]ZX+_A=OA3_GGJ/_?A?_BJ
MR?CAXE^SZ=:^'H'_ 'EP1/<8[(#\H/U;G_@->'F"86RW!C<0LY19,?*6 !(S
MZX(_.MZ=)25V<]2JXRLC[(MKB*[M8KF!P\,J!T8="I&0:EKS#X+>)?[3\.R:
M-.^;C3SF/)Y:)NGY'(^A6O3ZQE'E=F;1ES*X4444B@HHHH **** &R.(XV=L
MX4$G%>>P_&KPG+,D9^WQAF"[W@&U<]SANE=_=?\ 'G-_US;^5?&=:TH*5[F-
M6HX6L?9Z.DL:R1L'1@&5E.00>A%.KQ/X0>/Q&T?AG5)OD8XL96/0_P#/,GW[
M?EZ5[942BXNS-(24E=!1114E!1110 4444 %<EXH^(FB>$=2CL-22[,TD0E7
MR8PPVDD=21S\IKK:^??CI_R.EE_UX)_Z')5TXJ4K,SJ3<(W1[)X6\7:;XOLY
M[K3%G$<,GEMYR!3G&>,$^M;U>3_ ?_D7=4_Z^Q_Z *]8I35I-(J$N:*;"N<\
M5^+K?PI':O/:R3_:"P4(P&,8]?K71UYA\9/^/72?]^7_ -EK7#052JHRV9%>
M;A3<H[DW_"X=/_Z!=S_W\6C_ (7#I_\ T"[G_OXM>045ZOU*CV_$\[ZW5[GK
M_P#PN'3_ /H%W/\ W\6C_A<.G_\ 0+N?^_BUY!11]2H]OQ#ZW5[GK_\ PN'3
M_P#H%W/_ '\6C_A<.G_] NY_[^+7D%%'U*CV_$/K=7N>Q1_&#2R?WFFW:C_9
M*G^HK4M/B?X9NB \\]L3_P ]HC_[+FO":*F6 I/R_KS*6,J+S^1].6&JZ?JD
M>^QO8+A1U\IPQ'U':KE?+<%Q-;3+-!*\4B\AT8J1^(KT'PU\4[VS=+?6P;JW
MX'GJ,2)]?[P_7WKEJX"45>#O^9O3QD6[35CV.BH+.]MM0M([JTF2:"095T.0
M:GKSSM"BBB@ HHHH **P_$7BS2_#4&Z\EW3L,I;Q\NW^ ]S7DFO_ !)UO5V:
M.WD^PVIZ) ?F(]VZG\,5TT<+4JZK1=S&K7A3T>_8]EU'7])TC/V_4((&_N,^
M6_[Y'-<Q=_%?P];DB!;JY/JD84?^/$?RKQ%G:1BSL68\DDY)I*[X9?!?$VSB
MEC9OX4D>MR?&.U!/E:/*P'=IP/Z&FI\8[<GY]&D ]IP?_9:\FHK7ZE0VM^)G
M]:J[W_(]JM?BUH4Q GM[RW]RJL!^1S^E=+IOBO0M6*K9ZG [MTC9MC?D<&OG
M"BLIY?3?PNQI'&S7Q69]445\^:'XZUW0BBQ71GMQU@N"67\.Z_@:]9\,>/=*
M\1[8-WV6](_U$A^]_NGO].OM7#6PE2EKNCLI8F%31;G54445RFX4444 %%%%
M !03@9/2J6JZM9:+827M_,L4*>O5CV '<UXGXJ^(&H^(6>W@+6FGGCR4;YG'
M^T>_TZ<]^M=%##3K/3;N8U:\:6^_8]*U[XCZ'HI:**0WURO6. C:#[MT_+->
M?ZG\5=>O"RV@@L8^VQ=[?FW] *X:BO4IX*E#=79YU3%5);.WH:=UXDUN]R;C
M5;QP>QE8#\LXK.,CL^\NQ;U)YIN,TH1B,A21]*ZHQ4=C!MO<NVNN:K9$?9M1
MNX@.FR9@/T-='IWQ-\26)42W$=W&#]V>,$X^HP?U-<=BBHE2IRTDDRHU)1V;
M1[7HGQ4TC4"L6HQO83'^)OFC/X]1^(KNHI8YXEEBD62-AE60Y!'L:^6JWO#G
MB_5?#4X-K,9+<GY[:0Y1OIZ'W'ZUPUL FKT_N.NEC&M*GWGT516)X;\4:?XF
MLO.M'VS(/WL#'YD/]1[UMUYDHN+Y9+4]!-25T%%%%2,*XO6/B5I6BZM<:=/:
M7CRP$!F15VG@'C)]Z[2OGKQ__P CSJG_ %T'_H(KJPE&-6;4NQSXFK*G"\3T
M/_A;^B_\^-__ -\I_P#%4?\ "W]%_P"?&_\ ^^4_^*KQFBO1^HT>QP_6ZG<]
MF_X6_HO_ #XW_P#WRG_Q5=GHVKVVN:5!J-H6\J4' ;JI!P0?>OF:O3/A)KWD
MW<^B3/\ +-F6')_C ^8?B.?^ UAB<'"%-RAT-Z&*E*:C/J>N4445Y9WA1110
M 4444 9'B/Q%9^&=-%[>!V5G"*D>-S'VR?05R?\ PM_1?^?&_P#^^4_^*KDO
MB?KO]J>(_L,3YM[$%,=C(?O'^GX5P]>M0P5-TU*>[//K8J2FU'9'LW_"W]%_
MY\;_ /[Y3_XJC_A;^B_\^-__ -\I_P#%5XS16OU&CV,?K=3N>^^'/'VG>)M3
M:QM;:ZBD6(R[I0N, @=B?6NKKQ+X2_\ (WR_]>C_ /H2U[;7F8JE&G4Y8G?A
MZDIPYI!1117.;A14-U=065K)<W4JQ0QKN=V. !7D7BCXHWEZ[VNB9M;;D&<_
MZQ_<?W1^M;4:$ZKM$RJU8TU>1ZGJ6N:7HZ;M0OX+?T5V^8_0=37)WOQ9T"W)
M6WBNKH^JH%7]3G]*\5EFDGE:661Y)&.69SDGZFFUZ4,OIKXFV<,\;-_"DCU6
M7XR+NQ%HIQ_MW&#_ .@U&OQCES\VBICVN#_\37EU%:_4J';\3/ZU5[GKL'QB
ML6/^D:5/&/6.4/\ S K<L?B7X9O"%:[DMF/:>,C]1D5X-142P%)[:?,I8RHO
M/Y'U!9W]GJ$0EL[J&X3^]$X8?I5BOERWNKBSF$UM/)#(.CQL5(_$5VVB?%/6
M-/*Q:BJW\ X);Y9 /8]_Q]*Y:F7S6L'<Z88R+^)6/;:*Q- \6:1XCBS97 $P
M&6@D^5U_#O\ A6W7!*+B[-'6I*2N@HHHI#"BBB@ JEJVK66AZ9-J&H3"*WA7
M+,>I] !W)]*N$A022 !R2:^:OB=XW?Q5K9M;63_B56;%80IXE;H9#_3V^IJX
M0YG8B<^57*7C?Q]J/C&\(+-!IJ-^YM5;C_>;^\?Y=JT?!'PMU+Q2L=[>,]CI
M9Y$A'SS#_8'I[GCZUJ?"SX<#6W77=9A_XEZ-^X@;I.P[G_9![=_P.??5544*
MJA548  P *UG44?=@8PI\WO3,7P_X2T3PQ (]+L8XWQAIF&Z1OJQY_#I6W11
M7.=*5@HHHH *" 001D'M110!P'B[X4:)XBCDN+&--.U \B2)<1N?]I1_,<_6
MO"[WP]X@\->)(;!K>:+4@X^S-#G+G/!0CK7UG44EK;S3Q3R01O+#DQ.R@LF1
M@X/;(K2%5Q\S*=)2\BCX?&K+H-H-<:%M2V#SC%TS_+..N.,YQ6G1169J%<!\
M9/\ DGES_P!=XO\ T*N_K@/C)_R3RY_Z[Q?^A54/B1,_A9Y+\(_^2D:;_NR_
M^BVKZ9KYF^$?_)2--_W9?_1;5],UI6^(SH?"%%%%8FP4444 %%%% !1110 5
MX/\ 'C_D8-*_Z]3_ .AFO>*\'^/'_(P:5_UZG_T,UK1^-&5;X&;'P$_Y!VM_
M]=8OY-7L%>/_  $_Y!VM_P#76+^35[!2J_&QT?@04445F:!1110 4444 %%%
M% !1110 4444 %17-Q%:6LMS.X2&)"[L>BJ!DFI:\Q^-/B3^S?#D>C0/BYU
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M-((]L?(0G@;CT'/&.M>74QE6H[4]$>A##4Z:3GJRW9>&]%T]0+72[2,CHWE
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M.Q+,QZDFFT45] >.%%%% '=_"7_D;Y?^O1__ $):]MKQ+X2_\C?+_P!>C_\
MH2U[;7BX_P#C'J8/^&%%%87C'4VTCPGJ%VC;9!'L0CJ&8[0?PSG\*XXQ<FHK
MJ=,FHIMGE?Q%\72:UJCZ=:R$:?:L1@?\M7'5OIUQ_P#7KB***^CITU3BHQZ'
MB3G*<G)]0HHK:\,^&+[Q1?M;VFU(T&99G^Z@]_4GT_\ KFG.:@N:6Q,8N3Y8
M[F+17LUK\(M'CC'VJ]NYG[E-J#\L'^=)<?"'1W!^SWU[$W;<5<?R%<OUZC?<
MZ/JE6VQXU17HFH_"+58 S6%[;W0'17!C;^H_,UQFIZ!JNC/MU"PF@&<;F7Y6
M^A'!K>%>G4TC(RE2J0^)&=114MK;2WEU#;0(7EE<(BCN2<"M2#T7X3:!Y]]/
MK<R_NX/W<&>[D<G\%/\ X]7KU9V@Z1%H>B6NG18(A0!F_O-U8_B<UHU\_B*O
MM:CDMNA[-&G[."B%%%%8&H4444 <)\6/$W_"/^#Y8(6Q=ZAFWC]0I'SM^1Q]
M6%>"^$?#LWBKQ):Z7$657;=-(.=D8ZG\N![D5T_QEUEM1\;O9H^8;")8@.VX
M_,Q_4#\*[;X&Z$MMHEWK<B_O;N3R8CZ1KU_-O_0:Z(^Y3OU.67[RIR]$>I6=
MI!864%I;($@@01QJ.R@8%3445SG4%%%% !1110 4444 %%%% !1110 5P'QD
M_P"2>7/_ %WB_P#0J[^N ^,G_)/+G_KO%_Z%50^)$S^%GDOPC_Y*1IO^[+_Z
M+:OIFOF;X1_\E(TW_=E_]%M7TS6E;XC.A\(4445B;!1110 4444 %%%% !7@
M_P >/^1@TK_KU/\ Z&:]XKP?X\?\C!I7_7J?_0S6M'XT95O@9L? 3_D':W_U
MUB_DU>P5X_\  3_D':W_ -=8OY-7L%*K\;'1^!!11169H%%%% !1110 4444
M %%%% !1110 A(4$D@ <DFOE;X@>(QXG\87E]&0UM&?)M\?\\U) /XG)_&O<
M/BOXE_X1_P '30POMN[_ #;Q8/(4CYV_+CZL*\4^'/AL^)O&%K;RINM(#Y]Q
MD<%%(X_$X'T-;T59.;.>LVVH(]R^&'AP^'?!ELLJ%;J\_P!)F!ZKN'RK^"X_
M'-=G116+=W<W2LK'G?QB\.'6?"/V^%"USIK&4 =XSC>/T!_"O)_A;XD'A[QG
M;B9@MK>#[-,>PR?E;_OK'/IFOIJ2-)HGBD4,CJ593T(/45\G>,O#\GA?Q3>:
M:0?+1]\#D]8SRI_ <?4&MZ34HN#.>LN62FCZSHKD_ASXD'B;P?:W$CAKN ?9
M[GGG>H'/XC!_&NLK!JSLSH3NKH****0PHHHH BNO^/.;_KFW\J^-8_\ 6I_O
M"OLJZ_X\YO\ KFW\J^-8_P#6I_O"NC#]3FQ'0^S8_P#5)_NBO(/C!X#:Z5_$
M^FQEI44?;8EZLH'$@]P.#[<]J]?C_P!4G^Z*4@,I5@"",$'O6,9.+NC>45)6
M9\K>!/&$_@[7UNPI>TF 2YBQRR9ZCW'4?EWKZCLKVVU&RAO+259K>9 \;J>"
M#7SU\4O )\-:C_:>G1'^RKE_N@9$#GG;]/3TZ=JL?"?Q]_8-Z-%U*7&FW+_N
MG8\02'_V4_IU[FMIQ4USHPIR<'R2/H2BBBN<Z0HHHH *^??CI_R.=G_UX)_Z
M')7T%7S[\=/^1SL_^O!/_0Y*UH_&8U_@.J^ _P#R+NJ?]?8_] %>L5Y/\!_^
M1=U3_K['_H KUBIJ_&RJ7P(*\P^,G_'KI/\ O2_^R5Z?7F'QD_X]=)_WI?\
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M;\#?#S^U435-81ELSAHH,D&7W/HO\_Y^PQQI#$L<:A44851T I54*H50 H&
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M****]@\T]"\)Z'_;_P .M9M57,\=SYT'^^%''XC(_&O/>AQ7L?P?_P"0#?\
M_7R/_017#?$'0_[$\53^6NVVNOW\6.G)^8?@<_@17'1J?OY4WZK]3HJ4[THS
M7S.5K?\ !FN_V!XFMKIGQ;N?*G'0;#U/X<'\*P**ZI14X\LM481;B^9;H^J
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M6I7-L=04444 177_ !YS?]<V_E7QK'_K4_WA7V5=?\><W_7-OY5\:Q_ZU/\
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M)XOT"/Q-X7O=+<#S)$S"Q_AD'*G\_P!"::KROJ)T(V=CROX'>)?*NKKP[<.
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M_CUTG_>E_P#9*VP?\:/]=",5_"9Y-1117O'D!UKN;3X5ZU>64%U'<V02:-9
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M_-(WH/;U/:N'UKXNQ!&BT:S8N<@37/ 'T4'^9KS+4M4O=7O'NKZX>>=OXF/
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M(Q7\)GDU%%%>\>0(.M?3&@?\BYIG_7I%_P"@"OF<=:^F- _Y%S3/^O2+_P!
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M?E_\5^AQXWX%ZG.4445[!YI['\'_ /D W_\ U\C_ -!%>BUYU\'_ /D W_\
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MG ?^04)>V4N(S_[-4"_"[QFQP-#E'UEC'_LU>WMXOO3]VW@ ]\G^M-'BZ_\
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M5=DMR+M['-VVFW-Z^((6<YY;L/J:VK?PA(P!N+A4_P!E!G]:ZI$2- B*%4=
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M_/:?\Q_A7044<S#E1BVGAJTM+N.X268M&<@$C'\JVJ**5QI6"N2\6INOK?\
MZYG^==;7,^)4W7<'_7,_SIQW)EL4-$T2#4XYFF>12A &S'>M7_A$;+_GM/\
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M/F'_ $U_H*WZQ?#2[;*;_KI_05M5$MRX[!1112&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 C,$4LQP ,DURE].U[<F1N%'"CT%;FK2D0"%3R_7Z5G
MV%H)[D;A\B_,?\*I=R7V+&D:8L2BYE7YSR@/\(]?K6Q114LI*P4444 %%%%
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M'GW[5[O97MMJ-E%>6<R36\R[DD0Y!%1*#CN7":EL3T445)84=**CG_X]Y/\
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MV*BBBL#H"N>\>?\ (A:[_P!><G\JZ&N>\>?\B%KO_7G)_*G'="ELSS#X"?\
M(1UO_KE%_P"A-7M[HLB,CJ&5A@J1D$>E>(? 3_D(ZW_URB_]":O<*NM\;,Z/
MP(^;_B-X.N/!/B&/4]+W16$TGF6TB'F"0'.S/;U'M]#7L?P_\:0^,="65RJZ
MC;@)=1#U[,/8X_ Y%;NN:+9^(-(N-,OX]\$RX/JI[,/<5\WHVL?"SQT01N:%
MOF .%N8#_C^A'M5I^TC9[HA_NI76S-'P7_R6U/\ K]N?Y25]'U\U?#ZZ2]^+
M]K=QA@D]S/(H;J R.1G\Z^E:FMNBJ'PA11161L%>!?'7_D;-/_Z\1_Z,:O?:
M\"^.O_(V:?\ ]>(_]&-6M'XS*M\)[7X=_P"19TK_ *\X?_0!6E6;X=_Y%G2O
M^O.'_P! %:59&J"H[B>*UMI;B9PD42%W8] H&2:666.&)I)76.-1EF8X 'N:
M\1^*'Q,@U.UDT#09?,@<XN;I>C@?P+ZCU/?ITJHQ<G9$SDHJ[.>\ *_B#XMQ
M7RJ=IN)KQ_\ 9')_F0*^DJ\W^$?@N7P]I$FJ7\>R_O@-J$8,474 ^Y/)^@KT
MBJJR3EH12BU'4****S-0HHHH ,4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ110 444
M4 %&*** "BBB@ HHHH **** "BBB@ HHHH Y_P 5>#=)\7V0@U"(B9 ?)N(^
M'C/L>X]C7C.I?"GQAX<O#<Z+,]VJG*36DOER >ZY!_(FOH:BKC-QV,Y4XR=V
M?.@UOXKV^+?&M9Z#=9[B?Q*DT+X)^(GC"X4ZK]I6+/#ZA,55/HG7\A7T713]
MIV0O97W;.'\$_#+2_")6[D;[;J>/]>ZX6/U"#M]>OTZ5W%%%0VV[LT225D%%
M%%(85RWQ'L[G4/ .J6MG;R7%Q(J!(HU+,W[Q2< >U=3133L[B:NK'EOP6T;4
M]'L-734["XM&DEC*":,IN #9QFO4J**)/F=Q1CRJP5P7Q.\"KXKTC[79(/[6
MM%)BQ_RU7J4/\Q[_ %KO:*$VG=#:35F>"_";PUKFE^-X[G4-)O;: 6\B^9-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4K^6C"-GRV">P/85SW_"W/!G_03D_P# :3_XFI46]D-R2W9W%%85GXPT2_\
M#UQKMM=,^G6Y822^4P(VX)X(SW%8G_"W?!G_ $$Y/_ :3_XFA1;Z#<DNIW%%
M<]X?\;:#XHN9;?2;MIY8DWN#$R8&<=P*FTGQ=HVN:K=Z98732W=IN\Y#&R[<
M-M/)&#S19A=&W16)KGBW1O#MW:6VIW+0RW9(A41LV[! [#CJ*E\0>)=*\,6<
M=UJUP889)/+5A&S9;!.. >P-%F',C6HKG3XXT#^V;/24O?,O;L*4B1"=H8;A
MN/0<'IUKHJ5AWN%%<G\0?&2^#= ^T1HLE]<,8[:-NF>['V']17G^E?#_ ,4^
M-K1-8\0>(;BU^T /##@L0IZ':" H/H*M1NKMD.=G9*Y[917EOAOP3XS\,>)[
M:.#7A<Z(<M-YA)&!_#L)X)[$'^6#WGB#Q+I?ABSCN]6N###))Y:L$9LM@G&
M#V!I-:V6HU+2[T-:BN<;QUX>&JV&F+>^9>7H0Q1(A) 897=Q\O!Z'FK'B+Q;
MHOA6W675;P1,_P#JXE&YW^@'\^E*S'=;FW17#:1\6O"NKWJ6BW,UK(YPANH]
MBL?J"0/QQ77ZEJ-KI.FSZA>2&.V@7?(X4G ^@H::T8*2:NBU16=H>NZ?XBTU
M=0TR8RVS,5#%"O(Z\$9JK:>+=&OO$5QH-O<LVHV^[S(O+8 8QGG&.XHLPNC;
MHK!O?&>A:=KZZ+=WODWS*&VLC!0,$Y+8VC@'O6./BSX.-]]E_M-NN/-\E_+_
M #Q0HM] YDNIVU%,BECGA2:&19(G4,KH<A@>A!I](845Y;\0_'&JQZY#X2\,
M _VE-@32K]Y"PR%7T..2>P_&LX?!K6KBW^TW?BN7^T3\QX=U#?[Y;/XXJU#2
M[=B'/5J*N>QT5PWP]T[QEI9OK3Q)=)<6D+!+9V?S'?W#==N/[W.?3%:WB7QS
MH/A0JFI79^T,-RV\2[I"/7'8?4BIMK9#4M+O0Z.BN.\/_$[PSXCO%L[:YD@N
M7.$BN4V%SZ Y()]LYKH=:UJP\/Z9)J.I2F*UC*AG"%L$G X'/4T--.PTTU=&
MA17&WOQ2\)6-M;3OJ+.+A-Z)'$Q8+G&6&/E^AYJY)\0?"\6AQZNVJQ?99&**
M "7+#JNS&<CZ4<K["YX]SIJ*YKP[X\\/>*+AK;3;TFY4;O)E0HQ'J,]?PJSK
MOB[1O#=S:V^J730RW6?) C9MV" >@XZBCE=[#YE:YN45QFH?%/PEINH-9RZB
M9'0E7>&)G12/<=?PS74Z?J-GJUE'>6%Q'<6\@RLB'(/^!]J&FMP33V+5%<KK
M?Q%\,:!>O9WVH_Z5&</%%&SE?J0,#\ZM>'_&WA_Q.[1:7?K),HW&%U*/CUP>
MH^E'*[7#F5[7.@HK#U[Q=HWAF:UBU6Y:%[HD1 1,^[! /0''45D7WQ4\(V&H
MM92ZD7=&VN\4;.BGZCK^&:%%O9 Y);L[.BLR\\0:98Z$=;DN0^G!5?SHE+C:
M2 #QVYJ31M:L-?TR/4--G\ZVD)"M@@Y!P<@\BD._0OT5AR>+]%C\3)X=-TQU
M1L8A6)CCC=R0,#CFMR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW^(YO1)+\#T[X?\ @>W\&Z3A]LFI7 !N)1T'^POL/U_+'$_"S_DIWBKZS?\
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MKGLTR$^1V:/86.U2<$X&<"O#/AIHUIXW\3ZUKNO(+N2*166"7E<N6Y([@!<
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M"I/$-^#MGG"94[1MR 0>.,9P,^]<IYJ6GQ6T*>QT&ZT!I)XEEM900"6;:2G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img51355790_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img51355790_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ![ 1P# 2(  A$! Q$!_\0
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MQ(MU&D6GS)$T!4[GW8Y!Z=ZQ;2'S)1Q7NWB71K/3_AAXFO\ 2\#2=7EM;ZT
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MD\'QW$<>NZ9.UWIZ2M@3H?O(/?D_I[UYIJ.FWVD7TEGJ%I-;7,9PT4J%2/\
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M=.M=[X'7_BB/&Q."ILD&??YL5$UH5#<QOAKIR:E\0M*BD4,L<AF(_P!P$_S
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M@'!N8QP>0>M2WEBTP@V3VAV0JI'VJ/KSQUI9X["[:*0ZDD;>4B%#"YP0H!Y
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D<#)Z;<U1N9Y%E\M7*H&Z#BK4,\CH2S$D'%93YMT:PY=F?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img119790510_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &_ P(# 2(  A$! Q$!_\0
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M'.J?_'J/^'>O[47_ $=?XB_\'.J?_'J_2?(HR*.;R#7N?FQ_P[U_:B_Z.O\
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MG5/_ (]1_P .]?VHO^CK_$7_ (.=4_\ CU?I/D49%'-Y!KW/S8_X=Z_M1?\
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M#R[_ ()Q_P#)TW[:'_8YK_Z7:K7W_7P!_P $X_\ DZ;]M#_L<U_]+M5K[_H
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M%\D>WF/HI,BEJ"PHHIN\9QD9H =1110 44FX4C. 0,\F@!U%%)0 M%-+!>I
MI: %HHI-P]10 M%-W#.,C-+D4 +13 X)(!!(ZT[<* %HI*6@ HHHH **** "
MBBB@ HHHH **** "BBB@ KY@_P""E_\ R8]\4/\ KA9?^EUM7T_7S!_P4O\
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MH **** "OF#_ (*7_P#)CWQ0_P"N%E_Z76U?3]?,'_!2_P#Y,>^*'_7"R_\
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M:AQ4M&AIN.J=A0,4M%%6(**** $VBC:*6B@!*-HI:2@ HI:* $VBC:/2EHH
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MHVG7%_>S+;VENADDE?HJCO0!<Y]*.?2N#C^,WAR10R?;V5AD,+*3!'KTI_\
MPN3P_P#W-0_\ 9/\*KE?8GF7<[JBN$_X7)X?_N:A_P" ,G^%'_"Y/#_]S4/_
M  !D_P *.278.9'=T5PG_"Y/#_\ <U#_ , 9/\*/^%R>'_[FH?\ @#)_A1R2
M[!S([NBN$_X7)X?_ +FH?^ ,G^%'_"Y/#_\ <U#_ , 9/\*.278.9'=TE<)_
MPN+P[_=U#_P"D_PJ:Q^*NA:A>P6L(OC+,P1=]G(HR?4D<4<DNP[H[/[N*I7F
ML6%A*D5U>V]O+*<(DLJJ6^@)YJ]S7YK?$S3;#1?CAXP?XYV?B3[!?W'_ !)=
M>TV5Q;VL6?E( ]/2M*-/VC:OL95*GLTG8_2D,#R#D4NX5\RZE\:'^%5U\(+'
M0Y(=?^'&O!=..M7$K/<+(>$8M[YYSZ56U3]ISQ,TWQIU#3-.T^70/!$:PV=P
MY;=<7.1N#?[(YZ4_8S>W]:V#VL5O_6A]0\?A3=XW;=P^F>:^+8_VO/B;IG_"
MO/$NO>%-*L?!?BBXBM%\F<O<,S$ N!_",G@&LSQ!XN^*S?MMW%AI-OI\UW;V
M>RWL9KAEMFL203*P_P">F#5K"SUNUL_P(]O'HC[/L/%NC:IK5YH]IJ=K<:I9
M@&XLXY 9(L]-R]JV?2OS]MM=\<^&_P!JKXS7/@#1K'5-6%NDES)J$NR*"-1D
MD#N2:]*A_;7NH/V<-)\;W.CV[>)M1U*31H;3S"MN9T.&D)[(.M.6'DK<NM[?
MB$:\7?FTL?6YJEJ&JV>CZ?<W]Y<QV]E;(9)II&PJ*!DDFOE+P'^TYXX\0:MX
MC\'78\.:IXN72&U/2;S2+@O:.0,M'(>S 9_*N!_9;\8>.)?@WX_OM9L;#6_"
M<8OIIFOIF>5[K@M#C_GGUI_59)-R>UOQ)]O%M)(^X/"OB[1_'&B0:QH&HP:K
MID^?*NK9MR-@X.#6UU%?%_AG]IC_ (5S^S/X%OO#WA'3[;7O$ET]CI>B6)*6
MRONY8]\<@U] _!:^^)M]87Y^)-EH]E<AU-I_94A;<I'.[T(/%8U*3C=]/Q-(
M55*RZGH5QJUC:2>7/>6\,G]R255/Y$U2\1^+=&\(Z%<ZWK.HV^G:3;KNENYG
M C4=.M?!?[0C>'YOVO-;B\6:?KNLZ.-)C9++16?S1)MX;"]J7X7^+I-%_9%^
M)M]J"0^*M-M=2Q:>'==D,CVD18868=03U'TKH^JOEC*^]OQ,?K'O.-MK_@??
MVD:O9:]IEMJ.G7,=Y8W48EAGB.5=3T(/I5[-?)FN?M&:WX;\-_"[P=X#\-Z<
M?%OB;3HYX+1V*6=E%C^7!J'3?VC/'OB'PC\2_"M_H^GV'Q)\+VK22".0_99H
M"/F=3V8 Y_*LOJT[_P!=[7-?;QV/J77O$6F>%]#N]7U6]AL--M4,D]S,V$C4
M=232^']?T[Q1H]KJNDW<5_IUT@DAN8&W(ZGN#7PQ\%_&GC"U_9&\7:GXCTK3
M?$/A"WL)9;(:A*TDMW*9/G24?W1VKO[S]I&_\#_"7X5Z/X-\+6'_  E?BVW5
M=/TN(E+2V7H3ZXS52P[5TM7>PHUD]7V/KK=ZTOXU\R^/OC=\3_@O\#[WQ%XS
MT/29O$OV];6W&GNSVT<;?\M93V KM?V=O'?C/QYH]Y?>*+CP[J%F2C65]X?N
M#(L@(RRNO\)'O6+HRC%SNK%JJG+EZGLOX4ZLS7=<MO#^FR7MWYGD(0#Y49=N
M?8<UR_\ PN3P_P#W-0_\ 9/\*R46]D:MI;G=T5PG_"Y/#_\ <U#_ , 9/\*/
M^%R>'_[FH?\ @#)_A5<DNPN9'=T5PG_"Y/#_ /<U#_P!D_PH_P"%R>'_ .YJ
M'_@#)_A1R2[!S([NBN$_X7)X?_N:A_X R?X4?\+D\/\ ]S4/_ &3_"CDEV#F
M1W=%<)_PN3P__<U#_P  9/\ "C_A<GA_^YJ'_@#)_A1R2[!S([NBN-T?XI:!
MK6J0Z;#/-#>3@^4ES \7F8ZA2PY/M794FG'<::>P4444AA1110 4444 %%%%
M #!R*.>]'<5F:QK5KH-N)[R38K,$4 $EF/0 #J:F5HJ\GH-1E)J,5=LT^:*Y
MK_A/],_NW7_@._\ A4UGXSTZ^N([>,7 D<X7= RC\\5DJL&[)FKH58J[BS=W
M?-UJM'J5M(Q1;B-G';>":+Y<V<K+PVQOY5\G>!?AU'XN\(^*M8^W7EKJUC>S
MF"XCG8;=I) (_"N'%8R6'E&$8\S:;WML>IE^7T\53G.I/E46EM?5NQ]2:_XJ
MTOPO';MJ=[#9I<2"*(RMMWN>@%1ZYXPT7PVL1U34K>P$QQ'YT@7=]*^=KCXF
M3ZM\,/!EYK&EVFM73WZV[-=@D JP'F#W_P *B\=6VL>(/CYI]I<:=9WRI;JU
MO;7#9C,?4L1_>!KSZF:OEO"-[VMH]+]SU:.0\T^6K+ELI-NZUY=-/^"?15]X
MXT+3=0M;*ZU6V@N[G'E0O( SYZ8'O6\/N\#)KY2\)KJ4WQRUJ\UC3+*Y:Q0/
M/YAW"VC7[K1_[6!6Q_PTIK#S'6(X-.70!<>3]D:;_2V3=C?BKHYM&SE67*KM
M+1WLMVS/$9!44E'#OFT3;NK7>J2/I4>A_E1Z"O#?$GQB\4CQ]/X9\.:7;WLT
MEI'<6TDSE0FX9)?VJKXN^-VOV>N+X?L!IEOJ=G;K)?7%Y)MC,F,E$]:ZY9IA
MX\S=]';;=]D<,,DQ<^5*VJONM%W?Y'OF V>]&WCWKP'5/VB-07P+H&M6&FPR
M7=Y??8KBW9CMW@X^0^]7?#OQ8\7_ /"<77AO7--LX+JXLWN;/R)"P4@9"N:7
M]IT.91BV[VZ/JM/O'_8N*4'.22M?1M7T=GIY'MLEPD<;,SJH49)]!6=X?\2:
M9XHM7N=*O8;VW5RADA;< PZBOGSX)ZWXLU#7O$[W,<-UIWVB8W_F2$F.0*<)
M&/[M;_PO\97C_"?4K_0-%TVPO([R11!YGE0XW8+LWKWK*EF4:MI6:33=K:Z6
M-L1DTL/S1YE)IQ5TU9<W<]Z^M,60.<!@?H:\'\"_&S7]<\2:GX=NUTZ\OUM6
MGM+FQD)A+@?=8UA_ WQ9XHAU#Q'J.H"*71H[F:2^=Y"7BD4'Y(Q_=XIK-:4G
M!13:DVMMK;W!Y%7A"I*I))Q2:5][[6_K<^E.-O'7VH9@J[F.% R:^;;7]I+6
M9+NVU:6VTX:%/<B$6:RDW:H3@.172>*/BMXDUKQM>^'?".GVUQ'8V_FW<UTY
M4'(^ZM5_:N'<>:+;ULE;5^A']A8N,^6:25KMMJRM:]WWU1[#I6N6&N0O+8W<
M-W$K%&>%@P##J*G;4+:.;RFN(U<?PEP#^5>+_LH_\B7J>5PQOYBR^ASR*Y1O
M!=IX_P#COXRT_4I[A(X+=)(C#,4*,0!GCZU'U^?L:=2,$Y2=K7M_6Q?]E4EB
M:U&=1J--7O:]]4OU/IO<6&1T]:!C.*^;?A_\1-;\(^"_'5K-<_VK+X;F"6TM
MT22R$D88^P%;,7Q=\:-X'U+Q;/I5G::5':+):1LY+R29P2WHM5#-*4HIR33L
MVU:]DG9W9%3(\1&4E%II-).]KMI-63UU3/>"-O./PIV?7K7C'B#XR:II5CX"
MFBM;9GUZ5([G<3B,,!G;61XQ^-7B6'7O$-OHUM806>A(&G^V.1)-D9^05I/,
MZ$$[WTMT[J_Y&-/)\54:225[ZM]G;\SWQF^;;C-5KB^M[,#[3<10EC@>8X7/
MYUR7PQ\4:MXD\"PZUJ\%O#/.AFCCMR2-F,C.>]>._#[P7'\=M0\1Z]XEO+J0
M1WCVMM;0RE%A5<X(QWZ45<:[05*-W/57TT[L5'+E^]EB)\L:;2;2N[MV21]+
MI()%RIR#T(I6_2O+O%DFL?#'PAING^'9;6:.$%7O-9N<>6HY!/\ >KF?"?QY
MU75_ _BF^N+6U?5-%7(DA8F&8=B*J>84Z514JB:E:_EHKNSZBIY37KTW6HVE
M&Z6]GJ[)M=-3W=_O#%(S+'RQP!R:^=5^._C&U_X1K6+_ $>SAT'594@"I(6D
M+'JP]!Z5O>+/BMXEU3QO=^&O">GVTXL[?S;N:Z<@'(^ZOYUE_:M!Q;5[W2M9
MW=U=61O_ &'BE-1E:UFV[JRL[.[[W/3[KQWH%GILVI2ZK:I8PR>7)<>8-BOT
MVD^M;-K=17EO'-"ZR0R*'1UY# C((KY*\,ZPNB_!#Q+=7.E6VHC^U&WVEUDQ
M[B_/Y5Z9XB^*NLZ==>'/#'A;3;:35KVU6=A,2L4,>T' K&EFD7!3J*UTG9)M
MW;:L=-?(YQJ.G2=[-J[:2LDFV^UKGKUEKEAJ5W<6MI=PS7%L=LL<;@M&?0CM
M6@H'7%?./P1O-3A\3?$*[DMH?[9$@9X?,Q&9!GC=Z5;T'X\>(;7QQIVC:['I
M=Q%?/Y6W3IM[0.>@8]ZNGFE-PC.HFN9M;>=E<RK9)5C4G"BU+E2;UWNKNW<^
M@?,7S&7<"W]VI%/'/7TKYE\)Z_XTNOCMK*I';NZ;%NH9)3Y:0!N&0?WL5<\0
M_M$ZRVJZK-I$6G1Z7I,OER1W<A6:YP?F\L40S:C9N:<=6MM[;L<LAQ'.H4VI
M>ZI-WVOLO\CZ,P5SZ4Y?:O!_&WQVU.WF\-P:)#:V@U:V%P+O4B1""?\ EGGU
MS7K7@V]U74O#]G<ZLEM'?2+E_LLF^,\\%3[BNVEC:=>;IPN[=;:'EXC+ZV&I
M1JU+)/97UT_X8WZ*QM6\3VFBS)%<"3S&7=^[B9QCZ@54_P"$^TSKBZ_\!G_P
MKJ=2,79M7.2-"K)*48MIG3=:^8?^"E__ "8_\3_^N%E_Z76U?06C^*+#6II(
M;>1A-& S1NI1@#WP>U?/O_!2[_DQ_P")_P#UPLO_ $NMJTC*,E=.Z,Y1E&7+
M)690_9I_Y-Q^%7_8J:5_Z1Q44?LT_P#)N/PJ_P"Q4TK_ -(XJ*HD\N_X)Q_\
MG3?MG_\ 8YK_ .EVJU]D?&7GX=:N#R-J?^ABOC?_ ()Q_P#)TW[9_P#V.:_^
MEVJU]D?&3_DG>K_[J?\ H8JH[HF6QU=C$GV*W^1?]6O\(]*L^2G]U?RJ&Q_X
M\[?_ *YK_(59J2AGDI_=7\J/)3^ZOY4^B@!GDI_=7\J/)3^ZOY4^B@!GDI_=
M7\J/)3^ZOY4^B@!GDI_=7\J3R4'(1<_2I** &^N.M?)OQ+^%?Q_\22^(] BU
M[PUK?A76G<1R:C;8FL8VXVJ,=AT-?6;4#I5PJ.F[I&<X*:LV?&GQR\!^$?@G
M^R/8^!]9UU5UFS19]*DQ^^GO%8-^[7KU)%;WPU^ NN7W[&^J^'6\JW\7^*K5
MKRYEO,J!-(5(WGKPH_6OI#7?!>A>)KNTN]5TBSU&YLVW6\EU"LAB/JN>E;4:
MA5  P!TK9UWR)+>]S/V*YK]+6/E'QM^R[XM\0?"'X0>&+:\TU=1\)WL-Q?O(
M[>6ZJP)$9QDGCO6O\4/@CX_M_P!H;3OB;X!N-+F>2T6QOK/5"0 G )7 _N_K
M7TUUI:CVTOS_ !'[&/Y?@?.O@OX!^(]"^-7Q1\775S8G3O%%B+>TCC=C(CXY
MW\8QGTKSW3OV*]?NOV<[;P7J6IZ?!XGTS7)]9L+F+=);DNV0C@C.".#7V7M%
M)M%/ZQ-;>7X"]C'\_P 3Y[^!OPI\8Z-J&H3>,?#_ (/T>-K(VD$OA^ BX9B,
M,[,>Q&>*XKX5_L[_ !+\ >'O'?@:6XT6Z\(ZNEW+97>]A.LTOW=PQTQUKZYS
M1NH^L3U\_P!!^QCIY'Q[=_L>>)[GX!>!_#T>KV-EXY\(WCWUE=1[FMV8MDJ2
M1GIBO<?@I!\4H[?4'^)4VBL[%!:1:2I^4 88L3UR>:]3HJ95935I#C2C%W1\
MK?$+X(_%2W_:%U'XB^!;OP^J75@ED(M6+D@ <G %8:?L?>+9/A9\2X+[6]/O
M?''C6>.>=XU,5G"5(.  ,_I7V$Q^:BK6(FDK=+?@+V,&VV?*OC+]F/Q@ME\-
M?$GA34["W\>>#[%;)X[G)M;E .5SC/<_G6M\(?V;?$-G=>/O$_CS5+:X\6>,
M+9K65-/!\BUC*X 7/4]/RKZ5[T=Z3Q$VOZ]0]C"]SX[\#_LY_%+1?@?XT^%V
MHW&ARZ1/:21:/>1NP?S&?/[SC[N,5?\ %G[*7BRX\ _#"ZT'5K*R\?>!X@D4
MCY-M.,Y*YQGK7UL>E)VH^L2O^(>QC:Q\^W&A_'76OAK=PZI+X1G\0RW8;[!-
M;F2TDM<<Q-D?>)[U2_98_9^\0?"?7_%OB'7CI^EOKLBM'H.C,QM+4#J5SW/M
M7T?^%)G ]*7MI<KBDDF/V:NI-["LH88(R/>D\E/[J_E3Z*Q-AGDI_=7\J/)3
M^ZOY4^B@!GDI_=7\J/)3^ZOY4^B@!GDI_=7\J/)3^ZOY4^B@!GDI_=7\J/)3
M^ZOY4^B@#@/B)&J^)/!.%4'^U.N!G[C5W]<#\1O^1D\$?]A/_P!D-=]5/9$K
M=A1114E!1110 4444 %)2TE #.PKE/&BAM5\.9&1]N'7_<:NK["N4\9_\A;P
M[_U^C_T!JYZWP/Y?FCIPWQKT?Y'5K"F/NK^5'EJ.0HS]*>OW12UM9'/=E2\A
M,UM*@."RD#\J^<]-^"_Q"TRSU70[75M/L=*U*Y>::6,,TH5CR!QZ5])=>O?M
M3BOS UQ8C!T\2XN;:M?9VWW/1PF85<'&4::34K/57U6S^1X?XM^ MR_A/PQH
M>@S0B/2[I)IGN207Y!8\=S6S=?#;5KCXPZ;XH$T']GVUE]F=23YA;U QC%>K
M<\T!<>PJ/[/HK96U3^[8U_M7$N-FT])+5?S;GD^@_"G4+;XD>*]:OI8#IFK0
M+%&B9\SWS7%Z'\$?$WA34CI]G;Z)J.D?:/,2YO82TR1DY*_6OHSMS2!>G:LI
M9;1E9ZIIM[]W=KT+CG&)A=:--)6MIIHGZGE>G_#/5+7XT3>*GDMETM[%;98U
M)\P,/;&,5@^/_@SJ[^-IO$WAY-/OFND"7-CJ2DKN'&]:]S_#-(JX[<5;R^C*
M+@[ZN_H_(F&;8F%1336D>6W1I=&>'^+/@]KOB+PKX:M(TTRTO[&^6ZN5MU,<
M) /\( ZXK<N/AGJDWQDL/%(E@_LZ&Q:V:,D^9N(QD#&,5ZK11_9]'FYM;W3W
M[;"_M7$<O+I:TEMTEO\ \ \2\&_#3Q5X)\8ZY%;RV<WAS5I99W=B1,C,#M _
M$UAK\ _$<?PEE\/?;;==0^WM> 1LWER(6SL8U]$;>GK2,-S=?K4?V;1M97MJ
MM]D][&W]LXE2YE:]TWINUM<\*\ _"#Q%I7Q M?$.I_V=! MF;=K6R4J$. !C
MCGW-3>"_A5XD\,^(=>TV5[.?PIJTDLDK9(F7<#C'YU[@6QVY- &#BE#+:%.W
M+?1M[]]_O%/.<34YG)+5);;6=U;S1\\>&?@MXI\*:A#I\=MHFH:1'-N6\NHB
M;CR\YV_6M?Q%\*_%.D?$._UWPE=6B0:K$(KF.Z!.P@8W =Z]O!^;GK2MT//%
M"RN@HJ&JL[K75>C*EG>*E-U)6;:LU;1[;KY'FOP1^'VI?#G0+NQU.:&>::Y>
M<20YP0Q[Y[UR.O?#+QW:_$C7O$/AJ\TZVBU*-8LW 9G11CD#'6O>?QZT@X^;
M-;2P%*5.---I1VL]?O,(9I7C6G7LFYJS35T]NGR/$[?X%W6C_#'Q#I$5\E[K
M^L_/<74V0C/G./H.:Z&Y^&-W??!E?",T\:7WV00>:F2F\=/PKTH_*O/..]+F
MB.7T8II+1JWR_P Q3S7$U&I2=VI<U[=59+Y)(^<;7X+^.=3;PLNJWUAY&AW2
M,L,><F->K9QR>U<OXHSK'Q)\5W:6^EZE%9E8GBU27RBNT<A5_B'UKZV/''05
MS.K?#CPUKVH?;K_1K6YNSUE9.3]<=?QKSJV4IP4:,NJ;N[WLK+[CU\/GTE4<
MZ\=+-*RM:[3?5;^IB_!GQ@?'7@2"[ETM--1&:W$4?^J*KQE/]FN&;X4^-O .
MN:M+X&U"S_LO4I#,]M? YB<]2OYU[C8V4&GVZ6]M"D$$8VK'&H50/8"K  Z=
M:]!X-5*<%4D^:/5:/S/)68NC5J2HQ2A-_"]5;=;]4>$^.OA3XO\ $5AX5NWO
MK74]4TS<;J&X!6WE8GAMOM_2H-!^!_B"QT#QM!<W-C]JUM!Y'D@HJ-CD$8X
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M/_['-?\ TNU6OLCXR?\ ).]7_P!U/_0Q51W1,MCKK'_CSM_^N:_R%6:K6/\
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M\ZIWU?0%A:SI2K<ONQ:3?J=]124M=)S!2;12T4 %%%% '(2?\E*C_P"O!O\
MT-:\/_X*7?\ )D'Q/_ZX67_I?;5[A)_R4I/^O!O_ $-:\/\ ^"EW_)D'Q/\
M^N%E_P"E]M6%+[7JSHK?9]$4/V:?^3<?A5_V*FE?^D<5%'[-/_)N/PJ_[%32
MO_2.*BMSG/+O^"<?_)TW[9__ &.:_P#I=JM?9'QD_P"2=ZO_ +J?^ABOC?\
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MH:OK?LV]MKZZLFHHHKV3Y\**** "BBB@#D)/^2E1_P#7@W_H:UX?_P %+O\
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MJ_[%32O_ $CBHK<YSR[_ ()Q_P#)TW[9_P#V.:_^EVJU]D?&3_DG>K_[J?\
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MVMP=H+S8V%V_A49Y-3:=UW8[PL_(Z&3X<Z3-KFNZNWF_:]9LULKGYN/+4$#
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M1-N7Z&NRKCDK.QU)W04444AC*Y3QI_R%O#?_ %_#_P! :NKKE/&G_(6\-_\
M7\/_ $!JPK?!]WYHZ,/_ !/D_P CK5^Z*6D7[HI:W.<**** "BDHR* #:*6B
MB@!-H]*6BB@ HHHH 2EHHH **** "BBB@ HHHH 2EHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH Y"3_DI4?_7@W_H:UX?_ ,%+O^3(
M/B?_ -<++_TOMJ]PD_Y*4G_7@W_H:UX?_P %+O\ DR#XG_\ 7"R_]+[:L*7V
MO5G16^SZ(H?LT_\ )N/PJ_[%32O_ $CBHH_9I_Y-Q^%7_8J:5_Z1Q45N<YY=
M_P $X_\ DZ;]L_\ ['-?_2[5:^R/C)_R3O5_]U/_ $,5\;_\$X_^3IOVS_\
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M6IZW=:[H\MOI\#7#QQJP9@HR0..M>CAZ5&24IRLSBK5*J;48W1R7[%?C'1?
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MY6T[ZGM4\GP<*T>>IS))-JZZMIW>FBMT[GTOJ'Q&\.Z*PCU'5K6TF"H6CDD
M92PXXJ2T\>Z#J=]-86.IVUS?1Q^9Y*."<8Z\5XCXC\!7>I^*/'UQ-H\ER9-+
MC6SE9,[I O\ ![TWPUX#O=+USX=W$&D2VKIITRWTNS!#F/ #GUK;Z]BN:W(K
M7MUO:]O^"<G]FX+DO[1\UK]+7M?_ (!ZQX3^(2S>'TO/$=[IEI+)<R0H]O/F
M-MIX&3_%CJ*3Q%\1K>;PC?:IX:O]/O9K=PF^>;;$IS@ACVKPRU\!ZQ-X'\*V
M<^C7!V>(I9IH63[L1=OF8>A%7?$W@/4[?2_B59V&C3I;W,]LUM#%'Q)C&XH*
MS^O8GDMR=-];WM<W_LW!>TOSK?;2UE)+UV=SWBZ\?:+HZZ?#JVJ6MM?74:,(
ME?@D@=/;/3-9^F_%_0M0\;77AI)0+J%%*3%QLD8]47W%>/\ C31[W3/$UA>:
M1I5]-KCVUO#)%-;"2UG4!<C)^X5K930)]%^,6H23Z')LU2S1;6\ABW1PS;?F
M)/\ #SWJWCL2Y))))-)Z/9KOWN8_V;A%!R<FVXMK5+5-=.UCV&T\=Z!>:U)I
M,&JVTNI1CYH%D!88ZCW-$?CS0)]06SCU6VDNF+*(5D!;*_>R.V*^=/A[X#U*
M/Q)IVG:K%J5OJ%A>23AH[<&$Y).\RYR0172^"?AM>W7ASQVQTTV>NW-U<+:7
M$J[7*'IM/8'^M53Q^)J6_=VW[]$G;U)KY7@J+?[UM)+MU=K^G70]GT?QUH.O
MWEQ:Z?JEM=7$'^LCC<$C'?Z5Q?BSXV6.E>(-$TS1IK74Y[N^%I=*LF3$".HQ
MUYKR[X:>"=1N+ZWC=-2LM7L+&6#;);".%69<;3(#\V3T-9N@^'-1+>"]-7PI
M>6E_I.I[K^[:'"G)/S;NXK!X_$RA%*'*V]]7U6GE\SKCE."IU9/VG,HK:Z6Z
M>KVNM%MW/J37/$FF^&=--]JEY#86H('F3.%!)Z >I]JH7'Q"\-VF@PZU+K-K
M'I<QVQW!DX=O0=R?:N'^,5E-:^)?!?B"ZTR;6= TN>;[9;0Q^88F=,)-L_B
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M=301Q91KQ=LN"<X([=>E '64444 %%%% !1110!R$G_)2H_^O!O_ $-:\/\
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MV+G.T4ZBJY21-H]!^5&T>@_*EI*H0;1Z#\J-H]!2T4 -V*?X12[1Z#\J6BD
MW8N<[1FC:!VIU%,!H4+T %&U?[H_*G44@"BDW"EI@%%)10 M%)D44 +1124
M+1110 4444 %%%% !1110 4444 <A)_R4J/_ *\&_P#0UKP__@I=_P F0?$_
M_KA9?^E]M7N$G_)2D_Z\&_\ 0UKP_P#X*7?\F0?$_P#ZX67_ *7VU84OM>K.
MBM]GT10_9I_Y-Q^%7_8J:5_Z1Q44?LT_\FX_"K_L5-*_](XJ*W.<\N_X)Q_\
MG3?MG_\ 8YK_ .EVJU]D?&3_ ))WJ_\ NI_Z&*^-_P#@G'_R=-^V?_V.:_\
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MUM&,O+(P51]2:\.T'XJ>,6UG2;74TL6BUZR:>S\E2/)<+G#^HKD]'\1>(?\
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M2_\ H(VO_?Y?\:\.75_#\T:2P:"CPR*'C8MG*D9!I?[4T3_H7X_SKE^H>O\
M7S']<]#W'_A(]+_Z"-K_ -_E_P :/^$CTO\ Z"-K_P!_E_QKP[^U-$_Z%^/\
MZ/[4T3_H7X_SH^H/S_KYA]<]/Q/<?^$CTO\ Z"-K_P!_E_QH_P"$CTO_ *"-
MK_W^7_&O#O[4T3_H7X_SH_M31/\ H7X_SH^H>O\ 7S']<]/Q/<?^$CTO_H(V
MO_?Y?\:/^$CTO_H(VO\ W^7_ !KP[^U-$_Z%^/\ .C^U-$_Z%^/\Z/J#\_Z^
M8OKGFOQ/<?\ A(]+_P"@C:_]_E_QH_X2/2_^@C:_]_E_QKP[^U-$_P"A?C_.
MC^U-$_Z%^/\ .CZ@_/\ KYA]<\U^)[C_ ,)'I?\ T$;7_O\ +_C1_P )'I?_
M $$;7_O\O^->'?VIHG_0OQ_G1_:FB?\ 0OQ_G1]0?G_7S#ZYYK\3W'_A(]+_
M .@C:_\ ?Y?\:/\ A(]+_P"@C:_]_E_QKP[^U-$_Z%^/\Z/[4T3_ *%^/\Z/
MJ#\_Z^8?7/-?B>X_\)'I?_01M?\ O\O^-'_"1Z7_ -!&U_[_ "_XUX=_:FB?
M]"_'^=']J:)_T+\?YT?4/7\/\P^N>GXGN/\ PD>E_P#01M?^_P O^-'_  D>
ME_\ 01M?^_R_XUX=_:FB?]"_'^=']J:)_P!"_'^='U#U_#_,?UST_$]P_M:T
MF1O)O()&QP!(.OYUX+\#_#OC.U^,7C;6=7U"WOM+NIO(D6)C\DB8*!!Z!3@_
M6I[K5?#5O:S7-SH;Q1P(TA>.0K@ 9K+^$ZQVWAF&ZM?$-WI.HWTLEV\<OS1G
M<WR@@^P%<5; \U2*3:M=_ITN>SA,?['"5I<J:E9>??2]CZ7_ (>E*O/6O,[;
MQQKWA]5.L6*:G8][[3N2!ZE*[?0?$6G^)+,7.GW*7,??:>5/H1V-92HSI[ZK
MN<<*L9[;FO11161L%%%% !1110 4444 <#\1O^1D\$?]A/\ ]D-=]7 _$;_D
M9/!'_83_ /9#7?53V1*W85Y3XV_Y&2X^@_E7JU>4^-O^1DN/H/Y5=/<F>QA4
M445T& 4444 %>F^ =.^QZ*)F&)+@[S].U><V-JU]>P6Z\M(X6O9K>%;>".)1
MA44*/PK*H]+&L%U'-TKE?&G_ "%O#?\ U_#_ - :NJ;I7*^-/^0MX;_Z_A_Z
M U>?6^#[OS1W8?\ B?)_D=:OW12TB_=%+70<X4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%)D4 +1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <A)_R4J/_KP;_P!#6O#_ /@I=_R9!\3_ /KA9?\
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MV^FV=^^K6RV=[D6\V\;7(&2 :\P^*&DZMI:>'K#2-%9M(:-UN&L8%>:-RH
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M%IL]_?SQVMG N^2:0X51ZFO#/^%E>+-!TC7-$EU"#4-8MM>M]&M=4FB" +,
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M "4J/_KP;_T-:\/_ ."EW_)D'Q/_ .N%E_Z7VU>X2?\ )2D_Z\&_]#6O#_\
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MFF*?OKT/TK#_  M^8^EHHKD.L**** .!^(W_ ",G@C_L)_\ LAKOJX'XC?\
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M\;_\$X_^3IOVS_\ L<U_]+M5K[(^,G_).]7_ -U/_0Q51W1,MCKK'_CSM_\
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M:3T\^J/)P. HUHQK)M:^70\5\1_#GQ/=^(M4FCT:X>.2ZD96&,$%C@]:H?\
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MSRK':"W36^EK)6U\MSP'7OAAJ]YXSU=;"P^Q6EWH2VJW*85/-&/D.*Q_A_\
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M %%%% !1110!R$G_ "4J/_KP;_T-:\/_ ."EW_)D'Q/_ .N%E_Z7VU>X2?\
M)2D_Z\&_]#6O#_\ @I=_R9!\3_\ KA9?^E]M6%+[7JSHK?9]$4/V:?\ DW'X
M5?\ 8J:5_P"D<5%'[-/_ ";C\*O^Q4TK_P!(XJ*W.<\N_P""<?\ R=-^V?\
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M>$;+5Y[74KVX@N)7NOLZJT?&0J'L!^M<S9_%[QNUCIVO2ZA;O8-JYTZ2U6
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M8KXW_P""<?\ R=-^V?\ ]CFO_I=JM?9'QD_Y)WJ_^ZG_ *&*J.Z)EL==8_\
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M '_QKH_M!_S/[O\ @G-]17\B^_\ X!YE_P *H3^Y8?D*/^%4)_<L/R%>F_\
M"G_#'_/E)_W_ '_QH_X4_P"&/^?*3_O^_P#C3_M#^\_N_P""'U%?R+[_ /@'
MF7_"J$_N6'Y"C_A5"?W+#\A7IG_"G_#'_/G)_P!_W_QH_P"%/^&/^?.3_O\
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MT5_L^B*'[-/_ ";C\*O^Q4TK_P!(XJ*/V:?^3<?A5_V*FE?^D<5%;G.>7?\
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M(?\ H?-6_P"_:?X5\4?\-:_MF_\ 1%_"O_@T@_\ DNC_ (:U_;-_Z(OX5_\
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M]$7\*_\ @T@_^2Z/^&LOVS/^B+^%?_!I!_\ )='U>/G][#ZS4\ON7^1]V_\
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M?\(;JO\ T,MY_P!\+7PE_P -9?MF?]$7\*_^#2#_ .2Z/^&LOVS/^B+^%?\
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M\&D'_P ET?5X^?WL/K-3R^Y?Y'W;_P (;JO_ $,MY_WPM'_"&ZK_ -#+>?\
M?"U\)?\ #67[9G_1%_"O_@T@_P#DNC_AK+]LS_HB_A7_ ,&D'_R71]7CY_>P
M^LU/+[E_D?=O_"&ZK_T,MY_WPM'_  AVK?\ 0R7G_?"U\)?\-9?MF?\ 1%_"
MO_@T@_\ DNC_ (:R_;,_Z(OX5_\ !I!_\ET?5X^?WL/K-3R^Y?Y'WQH/A/\
MLG4)+VYOIK^Z9/*$DV!M3.< #WKP7_@I=_R8_P#$_P#ZX67_ *7VU> _\-:?
MMF_]$6\*_P#@T@_^2ZX/XZ?$[]K?]H#X4Z[X"UCX1>'[+3-:6*.6XLM5MA*N
MR:.5=NZZ(^]&!R.A-:QA&"LC&4Y5'>3U/JO]FG_DW'X5?]BII7_I'%17<_ _
JX/:[X/\ @KX T'5A!;ZII?A_3[&[A7$@2:*VC1U#!L-AE(R.#15D'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img119790510_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U F,# 2(  A$! Q$!_\0
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M;@K^\,&=A/MGG%3U)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS@9P/85JT44F[NXTK!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P :T:*+L+(SO["T[_GB_P#W^?\ QH_L+3O^>+_]_G_QK1HHNPLC._L+3O\
MGB__ '^?_&JFIZ5:6M@\\"2)*C(583/Q\P]ZW*S];_Y!,WU3_P!"%--W!I#=
M802QVD3EMDERBL%8KD8/&12_V%IW_/%_^_S_ .-+JGWK'_K[3^1JQ<7UI:,B
MW-U!"S_=$D@7=],]:6O0-"M_86G?\\7_ ._S_P"-']A:=_SQ?_O\_P#C5N.Z
MMYIYH(YD>6';YB*V2F1D9';(J:B["R,[^PM._P">+_\ ?Y_\:/["T[_GB_\
MW^?_ !K1JH=3L!.8#>0>:)1"4WC/F$;@N/7'.*+L+(A_L+3O^>+_ /?Y_P#&
MC^PM._YXO_W^?_&M&FJZN"48, 2"0<\BB["R*']A:=_SQ?\ [_/_ (T?V%IW
M_/%_^_S_ .-:-%%V%D9W]A:=_P \7_[_ #_XT?V%IW_/%_\ O\_^-6_M=O\
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M,VU;:4MG;M$9SGKC&.M:^P\S/VOD?2/D>'?^?J#_ ,##_P#%4>1X=_Y^H/\
MP,/_ ,57S6T+*6#1LI3[P*D;?KZ4OV>3<5\E]P7=C8<X]?I1[#S#VOD?2?D>
M'?\ GZ@_\##_ /%4>1X=_P"?J#_P,/\ \57S9' \K*(X6<L=JA5)R?0>]2P6
MT+1S37&]4B*J50#<2<XZ].AH]CYA[7R/H[R/#O\ S\V__@8?_BJ/(\._\_4'
M_@8?_BJ^<O\ B6#^&[_-/\*/^)9_=N_S3_"CV/F'M?(^C?(\._\ /U!_X&'_
M .*H\CP[_P _4'_@8?\ XJOG3[/:30RM;F</$N\B4*01D ]._-5-H]!1['S#
MVOD?2WD>'?\ GZ@_\##_ /%4>1X=_P"?J#_P,/\ \57S3M'H*-H]!1[#S#VO
MD?2WD>'?^?FW_P# P_\ Q5'D>'?^?J#_ ,##_P#%5\T[1Z"C:/04>P\P]KY'
MTMY'AW_GZ@_\##_\51Y'AW_GZ@_\##_\57S3M'H*-H]!1[#S#VOD?2WD>'?^
M?J#_ ,##_P#%4>1X=_Y^H/\ P,/_ ,57S3M'H*-H]!1[#S#VOD?2WD>'?^?J
M#_P,/_Q5'D>'?^?FW_\  P__ !5?-.T>@HVCT%'L/,/:^1]+>1X=_P"?J#_P
M,/\ \51Y'AW_ )^H/_ P_P#Q5?-.T>@HVCT%'L/,/:^1]+>1X=_Y^H/_  ,/
M_P 51Y'AW_GZ@_\  P__ !5?-.T>@HVCT%'L/,/:^1]+>1X=_P"?J#_P,/\
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MS_GQA_\  A:/^%7>+/\ GQA_\"%HYX]PY)=CCJ*['_A5WBS_ )\8?_ A:/\
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M!\Y %*[ADJ"PZ]!FMN:/8RY9=SBO^$R\3?\ 0>O_ /O\:/\ A,O$W_0>O_\
MO\:W;OP]9K8W4MEIT$K1:SY43"YW"6#GCJ. <+D8^M7KKP_HR2:LD=C#&5MH
MY4ED8[+=O*)96&_*,6Q@?-@T<T>PK2[G*?\ "9>)O^@]?_\ ?XU-!XI\43J[
M_P#"0WD<:8#/).0,GH/<U)XHTVUL=.T>6*TCM;F:-_M$2.3R",'&X\8/WL\^
M@Q6(O_()E_Z[K_Z":I)-72%=I[FW_P )-XB_Z&R7_O\ M_A1_P )-XB_Z&R7
M_O\ M_A5:T@T+^SHI;J5C.$)D17.<Y. !ZX _K4RV6ALFXSHN44X-R,@8&6Z
M?>!+#;[4678=V.D\3>)UB:5/$ES,J8W>7<'*Y[X(Z4D7B?Q/)%YK>([J*,DJ
MIDG(W$=< "L:U_X];[_KB/\ T8M$W_(-L_\ >E_FM%EV%=FW_P )-XB_Z&R7
M_O\ M_A1_P )-XB_Z&R7_O\ M_A5/3K73);.-[J1!(2=VZ?:=V?E7']TCG=V
MI-1M=+BLF>UF5I0PP!-N).?F&/0=F[T678=V6Y?$_BB*+S5\1W<L>[:6CG)V
MGWR*5/$WB=HDDD\2W,*OG:)+@Y8=,X Z5BQ?\@NZ_P"NL7\GHN_]39?]>_\
M[.]'*A79M_\ "3>(O^ALE_[_ +?X4?\ "3>(O^ALE_[_ +?X5CV8LA:7,ER-
MTJE!"F2,YSNZ?A4>HBV74;A;0#[.KD1D-NR/7-/E079L3^*?%$ 1O^$AO)(W
MSM>.<D''4?6H?^$R\3?]!Z__ ._QK.?_ )!4'_79_P"2U5H45V$VS;_X3+Q-
M_P!!Z_\ ^_QH_P"$R\3?]!Z__P"_QK$HI\J[!S/N;?\ PF7B;_H/7_\ W^-'
M_"9>)O\ H/7_ /W^-8E%'*NP<S[FW_PF7B;_ *#U_P#]_C1_PF7B;_H/7_\
MW^-8E%'*NP<S[FW_ ,)EXF_Z#U__ -_C1_PF7B;_ *#U_P#]_C6)11RKL',^
MYM_\)EXF_P"@]?\ _?XTH\9^)@0?[>O_ ,9<UAT4N5=@YGW/5/!7Q0NWU"'3
M=?=98YF"1W6T*R,>@;'!!]:]>KY,)(!(ZCI7U1I;2OI%D\V?-:!"^?[VT9KF
MKP2LT;TI-Z,MT445@;!1110 4444 %%%% !1110!2U?_ ) U[_UQ?^56X_\
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MDBCBBTV[CB0D@-&S$D]23@>@[5!]@O?^?*Z_[\-_A7:?\+=\3?W-/_[\-_\
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M%>7L\\<7^K61\A>,<?A52K5^I+\@HHHIB"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!5D:)A*C%70AE(Z@CD&OJ?3;A[O2K.Y?[\
ML"2-]2H-?.7A;PS>>*-7CM;>-OLX8&XGQ\L:=^?4]A7TI%&D,211C"(H51Z
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M_P#]^#19A<T:*SO[7'_/A?\ _?@T?VN/^?"__P"_!HLPN:-%9W]KC_GPO_\
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M6Q&LOV>=(XI8@LL>04D<.0>?51CT%>@?\*V\-_\ /MK_ /WR/\*/^%;>&_\
MGVU__OD?X5M[2'8SY)GG[^--5D1MRVGFM<BZ,PA ?S0>&S[#CZ4X>-M64R[%
MM$5T"(BPX6$89?E&?1FZY'-=]_PK;PW_ ,^VO_\ ?(_PH_X5MX;_ .?;7_\
MOD?X4N>'8.29Y=J.L3:G;65O+!;1I9Q^5$88]IV^AYYYR?Q-9]>P_P#"MO#?
M_/MK_P#WR/\ "C_A6WAO_GVU_P#[Y'^%4JL4+V<CQZBO8?\ A6WAO_GVU_\
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MQ_SX7_\ WX-']KC_ )\+_P#[\&BS"YHT5G?VN/\ GPO_ /OP:/[7'_/A?_\
M?@T687-&BL[^UQ_SX7__ 'X-']KC_GPO_P#OP:+,+FC16=_:X_Y\+_\ [\&C
M^UQ_SX7_ /WX-%F%S1HK._M<?\^%_P#]^#1_:X_Y\+__ +\&BS"YHT5G?VN/
M^?"__P"_!H_M<?\ /A?_ /?@T687)-7_ .0->_\ 7%_Y5;C_ -4G^Z*Q[_4&
MN=/N((]/O]\D;*N8,<D?6MA 1&H/4 4/8!U%%%(90U7<8K= [H'N$5BC%21G
MID4[^RX/^>MS_P"!#_XTW5.EG_U]1_SJ_4VNS;GE&"L^Y2_LN#_GK<_^!#_X
MT?V7!_SUN?\ P(?_ !J[13LB?:S[E+^RX/\ GK<_^!#_ .-']EP?\];G_P "
M'_QJ[119![6?<I?V7!_SUN?_  (?_&C^RX/^>MS_ .!#_P"-7:*+(/:S[E+^
MRX/^>MS_ .!#_P"-5=2LDMM-N)XIKE9$0LI\]S@_G6O5'6?^0-=_]<S2:5BZ
M52;G%-]0U(,[6<2RR1K)/M8QMM)&QCC/U I/[+7_ )^[W_O^U.O_ /CXT_\
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M_119![6?<H?V6O\ S]WO_@0U']EK_P _=[_X$-5^BBR#VL^Y0_LM?^?N]_\
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M([5VU%'LHE_VG7O?3[N[O^>IP%UX+U&?1DLHA:1[WE>57?<%9E 4J=@P..0
M/K5BX\(:C<75X4FMX%N;3RI)<EV=]J@'D94<<X.".U=O12]E$/[3K^77\=?T
M.1C\.W-KX.U*R6-5N9\R"-)-ZD@#@?*N,[>F.],U/PY?:H;ZYB\M/M<UI.D<
MC,A C7YE) R#]*[&BG[-;$+'U5)R6][_ )?Y(XF'PQK-F;.6VDLC)"UR1'([
ME8Q+C SC+8P3D]:T=%T673-3LX &:"RT_P DS%<"1V?) ^FW\,BNEHH5-()X
M^K4BXRMK_P '_-_>%?.>L_\ (>U'_KZE_P#0S7T97DNH?#^2YU.[G&NZ:GFS
MN^UFY7+$X/O66(BY)6/3R#$TJ$YNH[72. HKMO\ A7$G_0?TO_OJC_A7$G_0
M?TO_ +ZKE]E/L?3?VIA/Y_P?^1Q-%=M_PKB3_H/Z7_WU1_PKB3_H/Z7_ -]4
M>RGV#^U,)_/^#_R.)HKMO^%<2?\ 0?TO_OJC_A7$G_0?TO\ [ZH]E/L']J83
M^?\ !_Y'$T5VW_"N)/\ H/Z7_P!]4?\ "N)/^@_I?_?5'LI]@_M3"?S_ (/_
M ".)K7\+V$NI>)]/MXE)Q,LC$?PJIR3^E='#\-))953^WM/.3TC^8_@,UZ#X
M;\)Z?X9@86^Z6XD&))Y/O-[#T'M6E.A)O78XL?G6'ITFJ;O)K31_?J;U%%%=
MY\,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!4U3_D%7?\ UQ;^568_]6OT%5M4_P"05=_]<6_E5F/_
M %:_04NIH_X:]7^@ZBBBF9E#5.EG_P!?4?\ .F:AH5CJ<LLERCLTMLUJV'(_
M=DY(^N1UI^J=+/\ Z^H_YU?J;)[FZG*$8RB[/4R&\-Z:TKR&-]SRPS'YS]Z(
M83]*8GA;2XT1%BDPD<T8_>'I*<O6U11R1[!]9K;<S^_RM^6A@OX/TAYXYC',
M#&L2A1,P4^7]PD=R*G7PSI:E,PLP62:3:S$@F48?/L<UKT4<D>PWBJ[T<W]Y
M@)X.TE+26WVSL)#&?,:9BZA#E I/0#M1-X4L0]U<6H:.YE241[W9HXGD&&8+
MG@GO6_11R1[#^MU[WYV<7!X1U6/1;S33?0>3<(D0B;<ZQC^)P< [NF!TXK?O
MK6.Q\,R6L(Q'#;^6OT Q6K5'6?\ D#7?_7,TN116A;Q52M4CS][_ #T0M_\
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MU1;AL^N/N\'ZU;M;J.\MQ-%G!X*L,%2.H([$5RLOAW50L\L-X+=I0N\"Y<\
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M]%4-NK?\]++_ +X?_&C;JW_/2R_[X?\ QHN+V:_F1?I" P((!!X(-4=NK?\
M/2R_[X?_ !HVZM_STLO^^'_QHN'L_P"\BS;VEM:*5MK>*%6.2(T"@G\*FJAM
MU;_GI9?]\/\ XT;=6_YZ67_?#_XT7\AN%W=R1?HJAMU;_GI9?]\/_C1MU;_G
MI9?]\/\ XT7%[/\ O(LP6=M;,[6]O#$7Y8QH%W?7'6IJH;=6_P">EE_WP_\
MC1MU;_GI9?\ ?#_XT7\AN%W=R1?(!!!&0>HJB-&T\# MP!V 8@#]:3;JW_/2
MR_[X?_&C;JW_ #TLO^^'_P ::FUL2Z,7NT*=&T\C!MP1W!8D'\,U>  &!P*H
M;=6_YZ67_?#_ .-&W5O^>EE_WP_^-#FWN"HQ6S1?KQ35/!'B.?5[V:+3BT<E
MQ(Z-YB\@L2#UKUS;JW_/2R_[X?\ QHVZM_STLO\ OA_\:RJ053<]# XVI@G)
MTW%W[W/&/^$"\3?] QO^_B_XT?\ "!>)O^@8W_?Q?\:]GVZM_P ]++_OA_\
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MOYD7Z*H;=6_YZ67_ 'P_^-&W5O\ GI9?]\/_ (T7#V:_F1?HJAMU;_GI9?\
M?#_XT;=6_P">EE_WP_\ C1</9K^9$FJ?\@J[_P"N+?RJS'_JU^@K.N+?5+BW
MD@:6S"R*5)$;9 /XUI*-J@>@Q0MQR24$KW_I"T444S(BN;=+JW:%V=5;&2C%
M3P<]167/IM\;FYN(+E5>24%,_P "!,<>^:V:*:=A-&(UOJ\+7,WG/)B*00J&
M!R>JDC&,]JAMK?79H=TEVT891@,%W ^_'K^GO70T4^8+&)]EUSRY2UVA?YMH
M7"CG&.QZ#/XU&+'6U7=]J5I3]XEQW Z?+P >WI]:WZ*.8+&+-9:I)93(\XEE
M+J\>&V@'G(.!]WIQ^M0RZ/J?FAX;XCYL%6D;&S<IQ^ #<UT%%',PL<W;Z5J\
M-JL7VCYL."WG$XR@ XQS\P)]LT^73M7>'8DH0[8N1,W5=V>,>ZY]<5T-%',P
MY3#FL-52\N)+6Z"I,Q8;FSM^4 <8]N/3WI;S2+V>>66#4)(6(C6-@<D8(W$C
MH>YQZUMT'/I2YF%C%@L=3C9\RJN(W\LB0L-Y50.".Q4G\:0VNMK+)MNU9-QV
M9P,#'!/'//4=_6MK)]*,GTHN%C#2SUU8\B\B$K##%AG&!QV]>/I2+I^KR%_M
M%R&_T9XT(?&&8#&0!U!!Y^G%;U%/F"Q@?8]<8 /=84$'"R ' 8':3MY.,\]#
MTQWIYTW41I\<#3><48?*92N1L ^\!GALFMRBCF"QS9T?5,$&8,<G)\]AO8[L
M/TXQD<#KBKDUKK+W3".Z1(/+4 @C<6 Z]#CG-;%%',%C!&EZG.LXN;D!I)(S
MD-D;5))P,# P1QS]:EETRZBM+Q+1]K3S;AB0@[-H& 2#CG)Z5LT4N9A8P8[+
M6U01R74;KDJ1G VXP.V:CM$UV97D>5D9'.$EP%8>V!G&/U]:Z*BGS!8YZ.QU
MP+ODN@TN!GYQTZ$+\O!QWY^E6%MM:66-GNT<;E+J, 8'7'RYZ9_&MFBES!8Q
M$M]6@O@JS$V\DY)!(;:F2Q.<<?PC'/4U&VGZRAF>"\P[$@"1]V5RQ';@\J!]
M.];]%',%C#N=*O9G,S3"1O*B387*;B&R_(Z9''%+;V.KP"=VN4D9X=B*6/RD
M=#D]^6R<=AUK;HHY@L<])8Z])9LCWB,SH5<*P7M@$';QWS5I[;5OM!V7(6W"
MKPI!)P!D#(ZY!YST(Z5KT4<P6.?BL];*+<&X E* >6[CT.<D+UR>/ZU8MK76
M5B;S[Q#(T148QA6^7!''^]G\*V**.8+&&;/75*B._0CYB2X!.<<=NG]:9#I^
MK1HP,P*R%RP,F3DDXR=O(&>@Q6_13Y@L84UGK;#8EU&49LL2V,#G('R],8]\
MT_R-7>\*I,8K=0@R2#G@9QQGKGDFMJBE<+'.R6.O2>43=)E"67YQUP1S\O()
M/ [>]6$MM8>:-YY\*LJN5CD &W)RI^7GK^-;5%/F"QSZV.N+=R2B[4*[_-A@
M> #C (P![?K4;Q:ZES!&';#C+O'@@-M ^8D>V?\ &NDHHY@L8,EEK;R@&Z!B
M7'W7P7P>_P OIU]:<MIK8ROVM%"XQ@C!(Z?P\#U%;E%+F"QB/;ZM#>N89CY,
MLW3(8!3U/3Y<#W.3BFR:?JXGGFM[S:S,VP2/N7:2Q'&.,9&/I6[11S!8P+G2
M]2N-A,_SFT,1<2;2KDGYL ?K3[?3]6@NTGDNDF",Q:/<0'W=?IC P.>_3-;E
M%/F"P4445(PHHHH **** *]]:)?6C6\A(1BI..O!!_I49TV%A=*S,5N"I8 X
MQ@ =?PHU*\>SMT=/+4O($,DOW$SW/MQC\16,/$EPPYCMX\[!AR?W>=GS-_L_
M,<=.E4D^@FT:5SHT4XDVRLC/ L )YPH)/3OG.*AM- 2TNX;CSS(8CP&0$_<V
MDYZY.!_A5BUU*6X2U)M),3*2SK]U>OZ'&1]:H1^(Y I:2W20>69#Y38\L!6)
M5L_Q#'ZT>\+0L7'A^.>%T$[*65TSM!P&<L?YXI(O#Z1S02?:7)@D+J=HR^<?
M?/\ %TX]./2H5\2X9W>VQ"!A7#@C=\W&>X.W@U(OB#SK6:6.V9-L!F0R$8.
MI(..F-P_6G[P:$,/AZ5IKMYY(U:1G,;*-Q&X]\^@&!WY-2#PQ %C_?N60J=S
M*#G;MQ^6WCTS0OB()&S3P@JF09D8;&/SXVY['8?S%#>(#+:RRPQQQ!)UAWSM
M\HR<$G'3%'O![H^T\.QVD]O*+AG\DY^9<DG##@D\9W<XZD"FVF@?9+R!TFS$
MA+. -H;  48'OR3W-,C\3JR_/9RQE2JL6(&TD9Z=3_GI21^)PX(%F[% "Q#
M?PECQ]!^HH]X/=)_^$>18HHXKET5%P?E!).X,#D].0*O:=IZ:;;F"*1VCW;E
M#G)&>OZY/XUE'Q.K3E([8F-6*E]V=V&0?*._#_ABI[77UN9HHQ:N [!2X<$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img119790510_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<GD@0F5T
M:"!3871W:6-Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Y
M.0  DI(  @    ,Y.0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]_6I/".KW&O^$M/U2\2-)[J+>ZQ A0<D< DGMZU7*[<PKJ]C9HHHJ1A1110
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M'_(BWG_82?\ ]%14XV4&["E=R2,'4-1\4?"OQ/8-K&N7.N:3>$[_ #F9B0"
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MGXC>!+?=K-I!K^EP#YKB-OG51W)'(X[LI^M3"W+I:_F.5[Z['H_A^\U"_P!
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M-</\2/\ DM'A#_KI;?\ I0:M-2DXV[DZJ*=SV"BBBN8W"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@""]L[?4;&:SO(EE@G0QR(W1
ME(P:\6E\(>-_ASJTUQX/:34-/F.2B*')'8/'UR/[R_IG%>X45<9N)$HJ1XK+
MK/Q3\8+_ &8NE-I$,PV2S?9GMQM[Y9R2/^ \UZ7H_A==-\#KX=N;R6Z0VSP/
M*_7# @@#T&>!Z5OT4Y3OHE8(PMJ]3Q/PO<>-/AM+=Z.WA:YUBTDF\Q'MPVW.
M -P=588( X(&,?6G>+O"/CKQMI\6JWULJ3B4);Z1'*JB&(J2TC,S ;B0HQUY
M[8Q7M5%5[5WYDM2?9Z6OH9WB**2?POJD4*-)))9S*B(,EB4(  [FN-^"^FWV
ME>#+N#4[*XLI6U!W$=Q$T;%?+C&<$#C(//M7H=%9J5H\I?+K<YSX@6MQ>^ -
M7M[."2XGD@PD42%F8[AP .36=\)[&[TWX?VUOJ-K-:3K-*3%/&48 L<<'FNT
MHI\WN\H<OO<QS_C7PI!XP\-RZ;,XBE#"2";&?+<=#]#D@_6N!TCQ%X_\&6B:
M1JGA:XUJ&W&R&:VW,=HZ#<JL"!VR >U>O44XSLK-70G&[NCC?".L^,=:U>6X
MUW18M*TKRB(XW8B4OD8.#R>,]@*YKXH:/J>H>/O#EQ8:==W4$)3S988&=4_>
M@\D# XYYKU>BA3M*Z0.-U9L*\K\ :1J5G\6O%-Y>:?=6]K.]P8IY8&5),SY&
MUB,'(YXKU2BIC*R:[C<;M,X3XL^$[WQ1X9A_LI/-N[.;S%AR 9%(PP&>_0_@
M:J^$?&/BN[O-.TK5/!]W:Q(!'<7SHZ+@*0& *@#D#/)KT6BJ4_=Y6A<OO73"
MBBBLRSRN+2-2'[1<^I'3[H6!0 77D-Y1_P!&5?OXQUXZ]:]4HHJI2YK$QC:Y
MY7XUTC4KOXU>&[ZUT^ZFM(4@$MQ' S1QXF<G+ 8& 0>?6O5***)2NDNP*-FS
MR[QAX,US2_%P\7^!P)+IN;FTX^<XP2 ?O ]QUSR/91\0O'-U"+:U\ W45Z>/
M.F$@BS]"H'_CU>H45?M--5<GDUT9@/INIZ[X!ETW7C%!J5W9M%,T)RJN00#_
M ") ]Z\V\+:MXT\!6,F@R>#;G4465FBF@#;<GN756!'Y&O:**2G9--#<;NZ9
MXMX@\*_$#Q9J&F:OJEI %BG!2PBE1?LT>5)8[CR3CGDGCMTKUW5[ :KHE]I[
M-L%W;R0%O3<I7/ZU<HI2FY6\@44KGB?A/4/&GP^MKK1&\(W6IHTQDBEA5MJL
M0!G<JD%3@''!KI_BI::GKGPVLA;:;<RWDD\,LMM!$TCQG8VX$#)X)Q7HM%4Z
MGO<UA<FG+<R?"D,MMX,T6"XC>*6/3X$>-U*LC"-000>A![5P,ND:D?VBX-2&
MGW1L A!NO(;RA_HS+]_&.O'7K7JE%2IV;?<IQNEY&=XBBDG\+ZI%"C2226<R
MHB#)8E"  .YKC?@OIM]I7@R[@U.RN+*5M0=Q'<1-&Q7RXQG! XR#S[5Z'124
MK1Y0Y=;GD^N^$O$7@_QA-XE\#0B[M[HEKFQ Z9.2-O&1GD8Y'TJP?'GCS4XQ
M:Z7X&GL[IAM-Q=;Q&I]1N51^9->H45?M+[JY/);9F7=+>S>$9TO(U-\]BPEC
MARP,A3D+Z\]*XGX*:5J&E>'M1CU2PN;*1[H,JW,+1EAL'(# 5Z514J5HM=RN
M75,\\^-&FWVJ^#+2#3+*XO95U!',=O$TC!?+D&< 'C)'/O79>'8I(/"^EQ3(
MT<D=G"KHXP5(0 @CL:T:*3E>/*'+[USQ/2K7Q5\,?%6JBQ\.W.M:=?/E3;JQ
MW %BAW*&VD;B""/\:]8\.:C?:KH,%YJVGOIUW)NWVS]4^8X_3!K4HJI3YMUJ
M*,>7J5[]6?3;E4!9FA<  9).#7@/A'5/'O@RQGM=+\*7,L<\GF,;G3IV(.,<
M;2/2OH:BB$^5-6N$H\SO<\9_X6-\3?\ H3O_ "EW/_Q5:_QMTG4=6TG2DTO3
M[J]:.=RZVT+2%1M')V@XKT^BG[1*2:0N1M--F-J4$LG@6[MTB=IFTUT6,*2Q
M;RB,8ZYSVKE?@OIM]I7@R[@U.RN+*5M0=Q'<1-&Q7RXQG! XR#S[5Z'14\WN
MN)7+K<\K^-^D:EJUIHXTK3[J],;REQ;0-)MR%QG:#CI7JE%%)RO%+L"C9M]S
MROP5I&I6GQJ\27UUI]U#:3).(KB2!ECDS,A&&(P<@$\>E,^+>CZGJ7BCP]+I
MVG7=W'"3YCP0,X3YU/) XKU>BK]H^;F)Y%RV(KJW6[LYK:3(2:-HVQZ$8KQ7
MPP_C'X:7-_I:^%KG5[>>7='+;JVW(X#;E5A@C'!P17M]%3&?*FFARC=W/,_B
M%X<UKQKX)TF_M[(PZI:_O9;%B,_,!N SW! P#U'O4=MXY\?ZC;K96O@J6WOB
M-K7=R'2('INPP ]_O&O4**:J:6:#DUNF>7^ ?!GB30OB-J6J>(-MQ'<V;*;U
M)%(ED9HV(VYW#&&'( X^E:OQ9\)WOBCPS#_92>;=V<WF+#D R*1A@,]^A_ U
MW=%'M'S<P<BY>4\Z\(^,?%=W>:=I6J>#[NUB0".XOG1T7 4@, 5 '(&>36;X
MET?4Y_CMI&H0:==R648AWW*0,8UQNSE@,"O5Z*/:6=T@Y+JS9SGCGPC#XR\.
MO8.XAN(V\VWF(SL<#&#[$'!_/M7#Z5XH\?>$[%-(U/PC<ZO]G7RX;B#<V5'3
M+*K C\C7K=%$9V5FKH'&[NCRC0?"/B+Q9XSA\4^.(5LXK;!MK''/RG*C;S@
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M>"9+B^'RK=6X=X2?[V%!'_CPJQ\.O!&J6>M77BGQ8?\ B:W>[9%D$QANK''
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBL74O%VC:/K4>F:I=BUGEB$J-(I"$$L/O=!]T]<4FTMS2G2J57RTTV_(VJ*9
M#-%<0K+;R)+&XRKHP8,/8BGTS-IK1A1110 4444 %<IXW\;_ /"&_8?^)?\
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MO:0[?:7JOZ]#TNBD1UD17C8,K#*LIR"/6EKH/ "BBB@ HHHH **** "BBB@
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M<#DRK!K-,1/&XE75]%_71*QI7WB;6]2D+WNJW<I/4>:0O_?(X%2:?XLU[2Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5ROBWQ_IWA*X2UN8)[BZDB$J1Q@!=I) RQZ<J>@-=57B7QF_Y'*T_P"O!/\
MT9)6->;A"Z/8R;"4L7BU2J[6;(M7^+NO7^Y-/6'3HST*#>__ 'TW'Y 5Q=[J
M-YJ4_G:A=374G]Z:0L1^=5P"S *"23@ =ZZO1/AKXCUK:_V3[# ?^6MWE/R7
M[WZ8]Z\R]2J^Y^B1IX'+H<R48+OU^_=G)U;T_2[[5;CR--M)KJ3NL2%L>Y]!
M[FO9=$^$.B6&V359)=2E'\)_=Q_]\@Y/XG'M7<VEG;6%N(+&WBMX5Z1Q(%4?
M@*Z(863^)V/#Q7$]"'NX>/,^[T7^?Y'CVB?!S4[K;)K=U'8Q]XH\22?3(^4?
MF:]#T3P#X>T':]M8K/.O_+>Y_>/GU&> ?H!7245UPHPALCY7%9QC,5I.=EV6
MB_KU"BBBMCR0KF_B#J?]E>!M1E5L22Q^0GU?Y3^A)_"NDKS+XU7WEZ1IM@#S
M-,TQ'LBX_P#9_P!*RK2Y:;9Z65T?;XVG!][_ ':_H>.UK^%; :GXLTRT8922
MY3>/50<G] :R*[3X46HN/'UNY&?L\,DG_CNW_P!FKR::O-(_4,=5]EA:E1=$
M_P CWNBBBO;/QT*\F^-ELV_2+H?=Q+&?8_*1_6O6:XCXLZ:U]X(>>,9:SF68
MXZ[>5/\ Z%G\*QKJ]-GKY+55+'TY/O;[]#P>O3/@K/MUS4K?_GI;J_\ WRV/
M_9J\SKJ?AQJJZ3XXLGE;;%<$V[G/][I_X]MKS*,N6HF?HF:TG6P-6"WM^6I]
M#4451UK4H]'T.\U"8_+;Q,X'J<<#\3@?C7L-V5S\FA%SDHQW9\Y^)YQ<^+-6
MF4Y5[R4J?;><5E4K,78LQRS'))[FIK.UDOKZ"T@&Z6>18T'J2<#^=>&]6?L\
M(JE34>B7Y'T/X"MFM/ >DQOP3 )/P<EA_P"A5T-16MNMI9PVT?W(8UC7Z 8J
M6O;BK12/QRO4]K6E4[MO[V4]3TC3]9MOL^J6<5U&#D"1<[3Z@]0?I7*2_"3P
MO))N2.ZB&?N).<?J"?UKMZ*4H1ENC6CC<3AU:E-I>3,'1?!.@:!()=/T]//'
M2:4EW'T)Z?ABM'6-4M]%T>ZU&\.(K>,N1GECV4>Y. /K5VO(OC%XD\VYA\/V
MK_+#B:ZP>K$?*OX Y_$>E14DJ4+HZL%0JYGBXPJ2;[M]E_5CS?4]1N-6U2XO
M[QMTUQ(78]AGL/8=!7N?PR\-_P!@^%TN+A-MY?XFDR.57'R+^1S]2:\K^'WA
MO_A)/%,4<Z;K.VQ-<9'# 'A?Q/'TS7T-7-A87;FSZ+B3&*$8X*GZOTZ+]?N/
M,_C5=,FBZ;:@X66X:0CUVKC_ -FKQRO7?C;$39Z/+V625?S"G^E>15AB?XK/
M9X>2670MY_FSZ>\/6ZVGAG3;=!@1VL:_^.BJ'CRV6Z\!ZO&PR%MS)^*D-_2M
M31W$NAV,B\AK:-A^*BJ'C.41>"-89NALY%_-2/ZUZ4K>S^1^>T92^NQEUYE^
M9\UU[C\';IIO!<L+G/V>[=5'H"JM_,FO#J]K^#$17PK>RGH]X0/P1?\ &O/P
MO\0^]XD2> =^Z/1****]0_- HHHH **** "BBB@".XGBM;>2>YD6**-2SNQP
M% ZDUSFJQ^&/'.F"R?4+6X.=T30SKYD;>H'7\"*N>+O#[^)O#TNG1WCVC,0X
M9?NL1_"P[K_4 ]L5X+=:&=!UAK#Q/!<V_I)!M;C^\ >''XC^E<U:HXNS5T?1
M91@*6)BYQJN-2.R6]N_G\OU.D,?B7X4ZP63_ $G3IF&2 ?*F'O\ W'_SR*]8
M\->*=-\4Z?\ :-.DQ(H_>P/]^(^X]/0]*\UL? VN76C^=X7\3PW^GS+M,4C.
MBL/[I0[AGV/2H?#7P^\5Z?XMMII =/C1][W4,B$%>Z@ ]^F",5C3E.#LEH_Z
MW/4QU+!XRE*52K%58]=F[=XO6_I_P#VFFQQI#$L<*+'&@"JBC 4#H *=17>?
M$A2.ZQQL\C!4499F. !ZT,P52S$  9))Z5XI\1/B$VLR2:3HTA73T.)95/\
MQ\'_ .)_G652HJ:NST<OR^KCZO)#;J^W]=!_Q ^)#ZLTFE:#(T=B"5EG7AI_
M8>B_S^E><T45Y,YRF[L_4L)@Z.#I*E25E^?FPHHHJ#K"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 4'
M!R*]8^'OQ)+M%H_B.;+'"V]VYZ^BN?Y-^?K7DU%:4ZDJ;NCAQV!HXZE[.JO1
M]4?5]!&1@\BO*/AO\0R6BT/7IL]$M;ES^2,?Y'\/2O5Z]:G452-T?EN.P57!
M5G2J?)]T>.>/O!-QX=OO^$C\-[HH%<22)%P;9L_>'^S_ "^G3N/ ?C.+Q7I9
M6?;'J-N )XQQN'9P/0_H?PKJ9(TEC:.55='!5E89!!Z@BO$O%?AZ_P#A[XDB
MUK0F9;)Y,Q-U$9/6-O4$9Q[>XK"2=&7/';J>UAJL,VH_5:[M5C\,N_D_Z_X/
MM]%9'AGQ%:^)]$BO[,X)^66+/,3]U/\ 3U%:]=2::NCYNI3G2FX35F@HHHIF
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<=XG^'MMXK\1PZC?WLD4$5LL/DPJ-S$,S9W'.!\WI78T5,HJ2LSHP^)JX
M:?/2=GL8^C>%-$T #^R]/BBD QYQ&Z0^OS'G\.E;%%%-))61G4J3JRYJC;?G
MJ%%%%,S"BBB@ HHHH *\7^-%QO\ $UC;@\16F_Z%G;_XD5[17@OQ8G\WQ].G
M_/&&-/\ QW=_[-7+BG:F?2<-PYL??LF_T_4XJO1O@O#N\47LW]RS*_FZ_P"%
M><UZE\$DS>:Q)CE8XE_,M_A7%0UJ(^RSN7+E]5^2_%H]=HHHKUS\I"H;NUBO
MK*:UN5WPSQM&Z^JD8-344#3:=T?,?B'19_#^O76FW&287^1L??4\JWXBLT'!
MR.#7T#X[\$1>++%9+<K#J4"_N9#T<?W&]O0]OSKPG4]*OM&O6M-3MI+>9?X7
M'7W!Z$>XKR*U)TY>1^J95F=/'45=^^MU^OH>B:%\8Y;2PCM];L7NI(UQ]HBD
M 9_3<I'7WS^%8/C3XAW?BN);2*#['8HV\Q[]S2$="QXX]OYUQM%)UJCCRMFM
M+*<%2K>WA"TOG;[M@KT7X1^&S?ZV^LW"_P"CV/RQ9'#2D?T!S]2*Y[PGX)U+
MQ5=IY,;06(;][=NOR@=PO]X^WYXKW_2=)M-$TN&PTZ+RX(1@#NQ[DGN36V'H
MN4N9['DY_FL*-%X:D[SEH_)?YLN4445Z1^=A1110!G:_K$.@:%=:E<\K F57
M/WVZ*OXG KYHO;R?4+Z>\NWWS3R&1V]23DUZ%\7_ !)]LU6+0[9\PV?[R?'\
M4I' _ '\V/I6-\-?#?\ ;_BE)9TW6=CB:;(X9L_(OXD9^BFO-KR=6HH1/T')
MJ$,NP,L96W:O\NB^?ZH]4^'?AO\ X1WPM$)TVWEWB:?(Y7(^5?P'ZDUU=%%>
MA&*BK(^%Q%>>(JRJSW;N<=\4=)?5/ \[Q+NDLG%R![ $-^A)_"O :^KG19$9
M)%#*PPRL,@CTKP+QYX%N?#.H/<VD;2Z7,Q:.11GR?]AO3V/>N+%4W?G1]APU
MCX1B\)-V=[K]4>F?#/Q';ZQX5M[,RJ+RQ00O&3R5'"L/;&!]16?\6O$=O9^'
M6T:*56O+PKO13RD8.<GTR0![\UXK%+)#()(7:-UZ,AP1^-([M(Y>1F=F.2S'
M)-9/$MT^2QZ,>'Z4<;]9YM+WM;KZ]KC:^C/ &DMHW@FPMYEVS2(9I!Z%SG'X
M @?A7F7PZ\!3ZS?Q:IJL#)IL)#HKC'V@]@/]GU/?IZX]PK;"TVO?9Y7$N/A4
M<<+3=[.[]>B_S"BBBNX^,"BBB@ HHHH ***\X^(>A>*I]7@UK0+B1X[5-L<-
MLQ66//WCC^+/<>F!@U$Y.*NE<Z\'AXXFK[.4U&_5_D>CUF:]X>T[Q)IS6>J0
MB1>J..'C/JI[?U[UY_X:^+F)!9>+(3%(K;3=1IC!_P!M.WU'Y5Z?;W$-U;QS
MVTJ2PR*&21&R&![@U,9PJK0VQ&$Q6754YJSZ-;?)GC]GX;\6^!O%T$6B9N[6
M[D"A\'RI!Z2#^$@9.?K@GD5[(.G/6BBG3IJG=(6-QT\:XRJ17,E9M=?4***X
M3XE>-3X?T\:=ILH&HW2\L#S"G][ZGH/Q-5.:A'F9AA<-4Q594::U?]7.>^)_
MCSSFE\/Z/+^[4[;R93]X_P#/,>WK^7K7EE*2223R3U-)7CU*CJ2NS]8P."I8
M*BJ5/YON^X4445F=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>T_#/QW_:L":+J\N;
MZ)?W$KG_ %ZCL?\ :'ZCZ&O&$1I)%2-2[L0%51DD^@%>M^!OAH=.>+6O$K>5
M)#B6*WW[?*QSN<^W7'Y^E=.'Y^?W3Y_/OJCPK6(=G]GO?_+N>I54U33+76=,
MGL-0C\R"9=K#N/0CT(/(KDX_BAI,WBJ+2X03:N3&;UCA=_; _N]L^_IS7;U[
M-2C.G935KGY?1KQD^:E+5,\+T^ZU#X7>-WMKO=)83$"3 XFBSPX_VA_B*]P@
MGBNK>.>WD62*50Z.IR&!&0:YOQYX33Q3H+)$JB_M\O;.>Y[H?8_SQ7(?"GQ7
M)!<-X9U0LK*6-J9."I'WH_YD?B/2N"'[J?(]GL?4XJ*S3"?6X+]Y#2:[KO\
MU^AZO11176?,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M88]'U7^RYQHY9IOLZS;E\X?+M;@<D'/M6A8>&7TJ/4=1U'4IM4U&XMFC:>1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=F;!/KMSMS[XK<HI<D;6L7]:K\[GSN[W=W=F8_AS29- 719+-7T]5"K"S,<
M'/WLYZ]\U/I6DV6B:>MEI<'D6Z$E4#%L$]>22:N44^5)WL1*M5E%Q<G9N^_7
MOZ^84444S(**** /._B;XHU"RN+/0=!=TO;P!G:(X?!.U54]B3GGVKD9-1\;
M?#_4+:;5IYYK>8Y,4UQYT<@'5<Y.T\]1^M'BS6KO2_BM+K$MBSI:RA(4G1E5
MPJ[<@_7)!%5?&OCQ?&-G80?8S9>1(S2Y?>#D  C@>]>;4FFY.^JV/T+ X.4*
M5&DJ494Y*\V[7N]?PV.^U/XOZ!:+BPCN+]R,_*GEJ/8EN?R!KKM"U&35]!M-
M0F@^SM<QB01;MVT'IS@=L5PWAG1OAM.T:64\%[<,0%%[(0['T"-@$_05Z.B)
M%&L<:JB* JJHP !V KKI.;UDU\CY7,882DE2H4Y)]7+1OY?\ =5+6-132-%O
M-0EP5MH6DP?XB!P/Q/%7:\_^,&J_8_"<5BAP]], 1ZHGS']=M:5)<L'(X\#A
M_K.)A1[O\.OX'BD\TES<23S-NDE<N['N2<DU'117B'["DDK(****!A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4H&3@=:GL;&ZU*\CM+"!YYY#A8T&2?\^M>Q^%O >F>#K/^VO$L\+W4:[L
MN?W=N?;^\WO^7K6U*C*J[1/+S'-*&7T^:H]>B_K9>9@^"?A<]V(]3\3*8K?[
MR6AX9QZO_='MU^E:GB_XDP:;$VD>%!'NC&PW,8&R(>B#H3[]/K7/^-/B-=:_
MYECI>ZUT[.&.</./?T'M^?I7#5]A@<KC27-47R_S_P C\:SC/Z^/J;Z?@O3_
M #'RRR3RM+,[22.<L[G)8^I-,HHKW#Y<****8!1110 4444 %%%% !1110![
M1\(]7^V>&YM.D;,EC+\HS_ _(_7=^E=_7A7PMU,V'C:&%FQ'>1M"WIG&Y?U7
M'XU[K7S&/I\E=VZZGTN!J<]!>6AXC+_Q1GQG##Y+:6XS[>7+U_ $G_OFO;J\
MF^-6F8DTS54'4-;R'Z?,O\VKT7PUJ?\ ;'AC3[\G+30*7/\ M@8;]0:\BC[L
MY0^9]AFG^T83#XOK;E?JOZ9J4445TGSH4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D^*O^1-UK_KPG_\
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M>?6J=/6Z,:>8)QY:LI7<6F]WJ[KJOZ9KT445L>.%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS2Q\#Z6D8QYD F8^I?YOZUY^/K2I4O=W9W8&C&K5][9&^B+&BI&H55&%51@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYP*PBJ*]FDEJ_P!3:3K/VC;>B_0S-8\<W^B>#=!U"SM+)6O4_>1>6P1  .%
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M#?)&&88*G/RG%<]J:>+=;T#3?"\GAZ6$6I0?:2K;&"KM7)Z#@\\_ETJ_XO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3=\/[H_W)8C_ ./@?UKP*O.Q7\0_0.&7? O_ !/\D%%%%<A],%%%% !1110
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M7G?Q6DO;OP_:7,\;6ML+H+% ^-[DHQWMZ=, >YSZ#IKKQ=X1\.1,(+BUW_\
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MQGW^8C/M5*CL[]OQ,:F;2:E%PLGSI-2UO!-]M/)ZZ]#QS64TZ/6;E=$DDEL
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ME[$DP^8W.7WGYLY^]SUK3H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHKIGN'CWP^LT(US3PK*0//V<AAV<8_7\#7G]=9\*O%RW5L?#6JLK$*?LI?\
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MGKE2HZ +W.GJ.NW$_B>_TU+R_L(;&*/#V.GM<O+(XW98^6X50,#& 22>>,4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGI%_HUV;;5+62VE'9QPP]0>A'N*W*W;7Q*TEF-/U^V35;#ILF^_'VRK]0?\
M.16T*U2GINOQ_KU.>IAZ=35:/\#SJBNXO_ D&I1/>>#;O[6H^9["<A9X_IV8
M?YYKBYH);:9X;B)XI4.&212K*?0@]*[Z=:%1>ZSSJE&=)^\B.BBBM3(****
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M*6BWUU=Q1JJ1"YV$QJ!@ %57/XY-:%%% !1110 4444 %%%% !1110 4444
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M_1YR!VZJ?YC\17DM>-5AR3:/UO*\5];PD*O79^J_JX4445D>D%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >F?"CQC
M]BNAH&HR8MYVS:LW\$AZK]#V]_K5SQMX<_L?4?M5JF+.X;*@?\LW[K].X_\
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M0\D AD(+]&0< C;T_G7<>&X;B?X=:;%97/V2X>QC$<_EA_+.T<[3P?I45CX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKQ!HDN@ZM):R9:,_-%(1]]?\>QK+KT]S9_$3P;'=V>U;I02H)YBE ^9#['_
MUYG+$\$SQ2J4D1BK*1R".HKZW#UE5A<_%\30GAZCA-6:.S'CX6.E:?:Z3:!3
M"@$PDY4X&"!]3SFM:W\3>'_$R0PZS$+>:-PR+*WR9]F_QKS.BAT(/;1D*M+J
M>HZMX234=4O-4NG-U$T'[B"+@A@.!GO_ /7J7P'I=UI^CR/>F5&F?Y89"?D
MXZ'IG_"O/])\2ZIHS 6=P3%GF&3YD/X=OPKN=+^(NG7*!=2C>TD]0-R'\N16
M%2G54>7=&T)TW*^S-3Q7H<6LZ+-MB#742%H6 ^;(YV_CTKR":"6VF:*XC:*1
M>JN,$5ZD?B%HGVQ80TQC/6;R\*/PZ_I4?B$:%XEMH[:+4K1+LD-%)G/_  $G
M^E*C.=/W9+0*D8SUB]3RVBM;5O#>IZ.Q-W;DQ=I8_F4_CVK)KN335T<C33LP
MI\<CPR+)$[(ZG*LIP0?K3*WO"6@-KNKJ)5;[)#\TS#OZ+^/\LT2DHJ['%-NR
M/0/"*W=WI,&H:PL<ETRE89C&!)Y1QP6]\9_*LEO'5WIFMS6VN:<\-N7/EE1\
MRKV/HP^E=LJA5"J  !@ #I5;4--L]4MC!?P)-&>FX<K[@]0?I7S^(52I[U.5
MG^![N$G1I7C6CS)_>O-'#?$CQG:Q>$EMM(NDEEU+,>Y#RD8^]GN"<@8/J:L_
M"KPY_8_AG[?<)BZU'$G(Y6,?='XY)_$>E9?B+X;RQ*TNF#[; #GR'_UB_3U_
MG]:VM"\>VTFVSUJ(6,R?('"XCX[$?P_R^E<,*S5;_:%ROIV^\]^JHO+O8X+W
MDW>7?R5OZV.THI$=9$#QL&5AD,IR"*6O3/EPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** $95=2K@,K#!!&017ANLVES\-/B
M#%>V )LI27B7L\9/SQ_4?_$FO<ZP?&/AF+Q3X?ELVPEPG[RWD(^ZX_H>A_\
MK5C6IN<;K='KY5C8X:LX5=:<])+]?D:UC>P:EI\%[9N)()T#HP[@_P!:L5X]
M\,O$\VAZM)X8UK,*/*5B$G6*;."GT/\ /ZU[#54ZBG&YAF."E@J[IO5;I]T%
M>$?$GP8?#VJ?;["(C3;IN .D+]2OT/4?B.U>[U4U32[36=,FL-0B$D$RX8=Q
MZ$>A!YJ:M-5(V-,KS"> KJ?V7NO+_-'RW16UXJ\-77A;6Y+*Y!:,_-!-CB5/
M7Z^HK%KR&FG9GZM2JPK052#NF%%%%(T"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .J\ ^+7\+:X//9CI]R0EP@_A]
M''N/Y9KT;Q[X?2:$:YIX5E*CS]G(8=G&/U_ UX?7K?PJ\7+=6Y\-:JRL0I^R
ME_XU[QGZ=1[9':O1P6(=.=F?&<2Y2J]/ZU36JW]._P NOEZ'*45N^*_#S:#J
MI6,,;2;+0L>WJOU'^%85?41DI*Z/S"2<79A1115$A1110!N:5XLU/2E$8E%Q
M;]##/\RX]O2H]=U'2]2\J;3K!K*<Y\X!OD/T%8]* 6( &2> !WJ.2*?,B^9V
ML36=I-?WD5K:IOEE;:JU[-H&C0Z%I,=I%AG^]+(!]]NYK'\%>&/['M/MEZ@^
MVS#@'K$OI]3W_*NJKS\15YWRK8ZZ-/E5WN%%%%<IT!61K?AC3==0FZBV3XPL
M\?##Z^H]C6O143A&:Y9*Z-*=2=*7-!V9D^'-#_X1_2S:?:&N"9"Y8C &>P&>
M*UJ**<(1A%1CL@J5)59N<WJPHHHJC,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#S+XI^#6N8SXATJ/%Q",W2)U91T<>X[^
MWTK7^''C0>(]+^Q7\F=3M5^?/69.@?Z]C^?>NU(#*0P!!&"#WKQ7QGX;O/ O
MB*+7O#VZ*S:3<A7D0L>J'_9/./RKEJ)TI>TCMU/IL%4AF.'^HUG::^!_I_7Z
M(]KHK#\)>*+7Q5HJ7D&$F7Y;B'.3&W^![&MRNE-25T?.U:4Z-1TZBLT8WBCP
MU9^*='>RO!M<?-#,!\T3>H]O4=Z^>-9T>\T'59M/U&+RYHCU[..S ]P:^H*Y
M[Q?X0L_%FF>5/B*[C!,%P!RA]#ZJ>XKGKT?:*ZW/>R7-W@I^RJZTW^'G_F?.
M-%7M7TB]T/4Y;#4H3%/&?P8=F![@^M4:\MIIV9^E1E&<5*+NF%%%%(H****
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MK5I=ZM=:;'O6YM0"ZNN,CU'J.1^8K0IM-;B33V"BBBD,**** "BBB@ HHHH
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M .M7+5Z+X-U^W\=^%)=-U4AKV! DV>KC^&4>_K[_ %KCKCP]J$.O/I,<#2W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+4+&6'R9K*11C=N#QL,HXX&,X88[%36A0 4444 %%%% !1110 4444 %%%%
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M\P7.!U/ X]J9)X5TB6XEFDMY6\Z;SY8C<R^3))D'<T6[8>0#R.PH K>.<_\
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M%/\ #&C?\(_X=MM.RI,6YB$)*J68MM4GG S@$\G&30!K4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9
MNN>(-,\-Z>+W6KG[-;F01A_+9_F() PH)[&L*'XK>"IY1&FN(">A>"5!^94"
MJ49-72$Y);LZ^BLS5?$>DZ)I"ZIJ5XL=BY4+.BM(K;NF-H.0?6FMXGT=/#8U
M][U5TPIO%PR,,C./NXW9SVQFE9A=&K16#;^-= NO#UQKD%ZQTVV;;)<&WE4
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MWB:U_P"$9\-1Z6Y.)7MB2F<_?8@*%Q],GW-*%W#70)V4M#Z7HHHKC.H****
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M/J!6%!XGEU?P"FIOJ#:+<XB,UU_9\CQJ6?: @<8<$X&03C- '8JH10J *JC
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M..%&3CD<]!GFM*FV[*X)*X4445(PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *1T61&1P&5A@@]Q2T4 <[X9\$:3X3GN9M+\]I+G 8S.&VJ#G:,
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M65@$&#@<%NU=110!YSJ&E7]EX7\4Z#';WEXGF+<VDOV?/G"1E9U 10N0P;@
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M[)!)</#=03-'$NYRJR G [G':J]R)-0\=:!J%M;77V5;:Z5Y)+=X]A.T ,&
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MO2+KTX9?8]STJ[K?B^?2[O3=,L](>_UF^C\S[$LZH(E ).9",=00.QP>G&>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %(RAT96&588(I:* *VFZ=:Z1IT-CI\7DVT(Q&FX
MMM&<]22>]6:** "BBB@ HHHH **** ,[7=%@\0:1)IUY)+'!*RE_*(!8*P8#
MD'C(%1^(M+O]8TIK/3-5_LQI"1+*+<2ED*D%1DC'7J.>*U:* ,[0=$M?#VBV
M^F6 ;R80?F;[SDG))]R36C110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUB*>".UOM/AW_N9?.3YD+*02J\\'(*^G7-:L^GV=S<1W%S:02S1JRI))$&9
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M;2"U:"6)4EAEBF;]X!.B$;B@7G.,JS#J"1TKK5TRQ2\:\2RMUN78,TXB4.Q
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M&[RECB51'N^]M '&>^.M '.)XTF-BMP^F1@W%O'<VJK=[MZ/(J?.=OR-\ZG
MW#KSQ2CQ%JD^MV-HMI;Q;;N6WO$6Y+J=L2OE&\O)P&SC"_,-I]:U[CPYI,]G
M<6R6,%NEU(DD_D0HIE*N&&[CYN>N?4U8_L?3/L<-I_9UI]F@?S(8?(79&^2=
MRKC .2>1ZF@#G;3QM=7MFD\.BR 7#0BV,C21HXE.!N=H@,C()V;QCH3W>?$V
MH0>9''8K=3^9<EUENPBQB$+D*PBR1\V!D9]3Z;T6BZ7!,\T&FV<4LCB1W2!0
MS,#D,2!R<\YJ;[#:;BWV6'<V[)\L9.[&[\\#/KB@#)O-;=5TZXM8Y)!<VLMP
ML.]5#XC#!6)4XZ]01COFA/$;MX=EU%[5!/'+Y7V<2/RQ8 #F,2 \_=V;CV!R
M,ZDNG64\*13V=O)'&NQ$>)2%7I@ C@<#CVIBZ/IJZ<VGKIUH+)CDVP@7RSSG
M[N,=>: ,N/Q+/<>%X]5M-.,LSRM$;?>XQMD9&/W-Y^Z3@)N]ASB.'Q:9=D?V
M-/M#JLJ(L^5:$QLQ?=M[%&7&.N,XSQL/H^F2Z>MC)IUH]FARMNT"F-3G.0N,
M=S4<.C6T.H/=#+?N!;10E5$<$7&40 #@D G.>G&!Q0!SUQXKU66SA$.GV]O=
M3-92QJ;LL#%-*5PQ\OAOEVG . V021BEM?$MUIEQ>'4K<RVGVNZ"RK<%W4QQ
MF0J$*XVX4@'<.>PZUTTNEZ?/"T4UC;21M&L3(\*D%%.54C'0'D#H*=%86</E
M^3:01^6Q=-D8&QB,$CT.#C/I0!RR>*=7OCIIM],%J9KU8G$S2HDB&)VP"\()
M^Z<X'9<$[CBYIWB.YN98+6WMOM,FUIIWN+A494\YHQM"H Y^4\?*/NY))S6H
MGA[14MWMTTBP6%W#M&+9 K,.A(Q@D>M23:-I=R(1<:;:2B!BT/F0*WEDG)*Y
M'!)&>* .?O\ 5KNS\871,/G1QQ6L%M']L>-/,F=QEU *\X/S<D;5P#N.+4/B
M:[N+F*VBTV(S!K@7.;KY(A"R!BIV9?/F#'"\C!Q6W/86=RLPN;2"83J$E$D8
M;S%&<!L]0,G@^M$&GV=M''';6D$21(T<:QQA0BL064 #@$@$CO@4 <W%XOU%
MDCFFT:!(&@MKEV2^+,D<[E5X\L988)(SCC[U7M5\22:=>W,<=FLT%E'%)=2-
M/L<+(Q4;%VG>?E/4KZ#-:WV"S\O9]D@V;$3;Y8QM0Y1?H"20.V:2?3;&ZNH;
MFZLK>:X@.8I9(E9X^<_*2,C\* .5CO\ 4X?#?B/46=DN8[J9(66X,NT(Q4!4
M<;5Q[#GJ:2/7=6M)3;R_;)YDOX4^SS+;_:&B>-C@E"(N64D8(.!SU%=:UC:/
M;2V[VL+0S$F6(Q@K(3R21T.>^:CMM)TVRA6*ST^UMXUD\U4BA50'QC=@#KCC
M/6@#B]1\6ZM%I>H&.&[MIH[F;$IM/-^SHBH5C)C#)N8GJ3@ -SG%=[&XDC5U
M# , 0&4J>?4'D?0U&;.V,4T1MH3'.2TJ&,8D)ZEAWS[TZ*WA@:0PQ)&97WR%
M% WM@#<?4X &?84 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  2%4EC@#D
MD]JYGPIK%G-;7D;:U'?,-0DCCDDN49F#$E ,<<X. !C ..E=-10!PVOZAJ5E
M?:U)#<3FUWPP85S_ *.Q165U] 3E3CNR^]*MOJT]WJE]#=210VUU<9D-_,Q9
M A C$)&Q>2#N!R,5W%% '!6VIWD.FFXUB[EBNT2RN%"3L4^R>;'O?'<CY_,)
M!X(YVD"I;[6)M2^VV^CW-S=+?WJI;264PW+''$AD:-BRK@-\I(8<L>]=Q10!
MEZ#K4.KZ; S2QB]$0-Q;AP6B<$JP(!X&Y6'X5S%IXWO9-(DNY+C39_\ 1(9F
MDMT(2TD=POE29DQNYXRR8VG. <CM5M84O)+I4_?2*$9RQ/RCH!GH.>U+:VT5
ME9PVMLFR&"-8XUR3M4# &3ST% '!CQ-J%VMM?7%W;VT,VG7FV%@R"XDCD*C8
M5EP&("D;2Q W8)R"+(\8:A%JQLA!;I'''\J32+YD@$._S 6FWL-W& AZ'YLY
MQW%% '"7VO:T;"/[3>6-JRFPNGN$A=8XXYG<%7S)R 4&3D @D8&>-?7M;U&R
MD?\ LQ[-HH=-EOG:6)G\W9C"KAQ@'/7G'H:Z2B@#E7\7,-1^Q(;?[3]KD3R&
M!WB$6S2JY&>[!1GH1G'K5>'Q!KZB.:X;36A\FSN'1+>16*W$A38"9" 5P3NP
M<\<"NRHH \]LO$][IEG<167V34?+:\=K2%3YUL5F8AI#NP5.>F%ZCDX)K0T[
MQ1J>H+;!)=.4/)-YD^%D79&B-TCF<*?F(Y<] <=CV5% '%IK]WK'@77I6N;5
MKFWMI 9+9,H/W9) (D8'V.X'D908Y-/UNYT[4+;2(QIR+'+%;BQA@,<LJ/&&
M:=!O(" L<C!^XWS \5VE% ',+KNHQ^"AK%W/I\4\RH\09"B("1D'=( S8R1\
MRC/4@9-9Y\;W)U#2(8C:RK>>3YBB/:S"20IN7,F0!C^$2#_:Q@GMZ* .$B\:
MZE):22PR:;=R"WDD>*%&!M661542'><[MQ.,*>.XS6@WB+4;;Q NG7,]A+*M
MQ%#]F2!TFN5=06FCRYPBY.1AO]6_(R*Z6TM(+&U2VM4\N*/[JY)QSGJ:FH \
M\F\5ZKJ6@WWV:[LGE^P23N;.-P]DRNHPYW]64L1T(VYP15__ (3"^'B&.Q1[
M"XMRJ;949$%R"F3)'F;<5#9&%5_ND;L].NM+2&QM([:U3RX8QA%R3@?4\U-0
M!Q/]OZO':Q7LWV1[J?3XIXU595B3S)47:5WD,1N/S8!_#KO:-J\EPUQ:ZG/:
M_;(KI[=/*'EB;:JME4+$\!N>3TK8J)[:*6XBGD7<\.[R\DX4D8)QTSCC/4 D
M=SD Y,>++[^V)[>+['>&*>XC-A;HWVA4C5BKD[B,$A5^Z.6&,]*H1^.=2;1_
MM+MIRGSTC,NZ(A-R.Q4K]HP""H&7D3.>F>#W5M:0VBR"W38))&E?DG+,<D\^
M]17^F6VII&MT)08FW(\,[Q.IP1PR$'H>F: .>M/$NHOY,$[6$\\D277FVRL8
MO(V'S,89LE77;N!/WUX/?-T_Q--KUS9?;&M]D.I1!)8<*K!X90!Q(XSD8Z@Y
M., UW-K:PV5K';VJ;(HQA5R3^))Y)/4D\D\FI: .$M_&4]M<:):YM_*N+>V:
MX61BSKYBY+;WDW8!(YVN/5@341\=Z@-/#[K&1_/\N6XC5/)A^0G&6G"G)Z$N
MC>J XSZ!10!S6H^(;BVT[2)7GL=/^W1[Y;JY_>PQML#; 5=0223@[L$*<9K%
MT;Q->V<?A[2HX8(X'LK)09V16F#JH8J6E4_+Z*CY(QQFN_HH XZ'6=9N+>UO
MB+:2:2QN+J*&)95&$>(;"/,PQ(9L$CY21COF#5/&NH6R13VD=G]DN3*]M/,5
M19$4A54M)*@!;YFR,_*1\IP37<44 <7_ &S)J7C;3H)9[6/[/?SQBR"GSXPL
M$@#N=V,-U&%'!')I#+J%MXLU.2T:P,]SJ$5FDLUJQ:.,VXDQD."1P/EX!.3Q
MGCM:* .)_P"$QU%8KMLV,TT-M=R-:I&PDM&ASM,OS'AL>B]1C/6KD6LZW!K/
MV>^?3Y8([V.T?R;=T9M\6_()<@8) Z'/M7544 <#K6I26_C"Z07I1XYK7RH5
MU&19&4E=RQVWW9-PR,GIG/:I9_%5YI]FHC>T@VK<2H+LR2-=NL[*(8R7SNP!
M_>QN7"@#%=S10!R9UK7KC55@M7T^"*6]DM$$UN[M'LCW[B1( QX(P,>N>U54
M\;7;ZGHL&RUQ>Q6S3Q ?,IE7.02X. 2.B,/5@3BNVHH XEO$&K)IMOJDWV5Y
MYM-GN8HT$J1J0T( 8;R&^^><9'0=\W=0O]0E\,>)[>YF@^U6$4B":&%D5E,"
MR9VER0?F(Z]@?:NIHH XRPN+^Q9--TP6,$C7D5MN,,GDHOV4RDK$),*<CH"
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MFN;7=$;M/L<:$36X!VCS"6/)"Y'RK^/6NUHH X*_UN6\\1PJ]S:AK2>\1;-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img119790510_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<GD@0F5T
M:"!3871W:6-Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Y
M,   DI(  @    ,Y,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0_B)XCC +P:/I[6MO\O2?G'_ (]O_*O4/$6K)H7AR_U.3&+6!G4'NV/E'XG
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MCKWKCOB;8SZG\9="LK2]DL)I[2)$N8L[HCYDO(P0?U%73BXRL^Q$VG'0]/\
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MPWX>U*[6255GED55$2$\MP2.!ZD58^*/A*_UZQLM4T+_ )"FE2&6)1]YQD'
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M]OI]H6W.Q.0TC'W!./P],EIQ=W83YE;4[FO&_B[?Q:5\1O"^H7"NT5H4G=4
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MH1+R(P20 3QC!&5R,;1[5=U?XJ1>*M-GTGPQX:OM1GNHS&/M$2E4)&"<*6Z
MYY(K:S:2MIZF5U=N^OH;_CK6+'7O@[J>HZ5.)[::)-K $8(E4$$'D$5I_#;_
M ))OHO\ U[_^S&D^'7AFX\*>#H+"^8&Y=VFE53D(S8^4'O@ ?CFNIK"327*N
MYM%-OF9Y5-_R<K!_UYG_ -$M5SXD>&]7BU[3_&/A>+S[[3P%FMU4EG0$\@#K
MPQ! YP:])HI^T=TQ<FC1Y=#\<+!H1#)H.I?VET-L@4KN],YW?^.UV4"W'BSP
M/)%K%A)IDVH6\D<EO)RT6<@'^1YP:WZ*ERC]E6&D^K/$?"_C&]^%T<_A[Q;I
M-RUO',SP3VX!SGKMR0&4]<YR,G/H,[XA^(M3\61Z5J+:--I^D0W/EV\MP,/,
M[8)..F,)VS]?3W^BM%57-S6U)]F[<M] K%\8Z7-K/@W5-/M1NGGMV$:YQN8<
M@?B1BMJBL4[.YH]58\7\!?$B'PUH=KX8U32+\7T$S1H$C'1Y"Q+ D$8W'H#T
MK5\=Z+K/A[QQ!XX\.VIO5VA+RW126("[<X'."N!GL1FO4Z*T]HN:Z1'([6;/
M)[WXS_VE8M9>&=#U"35YE**KH"(F/&1M)+8]P*Z3X8>$)_"GAI_[1_Y"%[)Y
MTZYSLXPJY[D<D^Y-=I12<U:T58:B[W;"O)-=T/7/A_XTN/%'A>R-_IEX2;NS
M0'*$G+<#G&>0P!QT/'7UNBE&7*.4>8\M?XX64T'DZ;H.HSZB1@6[*NT-VY!+
M'M_#71:?IVN>*OA[=V/C*.*VN[Y7"+&N#$IY3</4'MZ 9YS7844W)?95A*+Z
ML\9\.^-=0^&EH?#WC'2;MK>W=OLUS;J"&4DG W$!AG)!SD=,43-JOQ?\3Z>X
MTV:P\.6#[VDF&/-Z%AGH20  !G')[U[-15>T5[I:D\CV;T/./CC_ ,D_B_Z_
MH_\ T%Z[G0_^1>T[_KUB_P#0!5ZBLW*\5$OE]ZYY5X)_Y+EXL_ZYO_Z&E:.L
M_$;5O"GB&ZA\1^'ICI1D_P!%N[0[LK@=<\$]\9!'OUKT2BJ<TW=HE1:5DSQ&
MXOG^)7Q#T6^\,Z/<64%C*LESJ$B!68!@?F()' 4@#))R>U;?Q=T_4K35M#\4
MZ9;O<C39!YJ*I.W#!E)QV."">W'K7J=%5[35-+8/9Z.[/+G^)E[XRLSI7@K1
M;K[;<)LEN+D*(K8$8+9!.<9[X^AZ5-\"E*>![Y6&&74Y 1Z?NXZ]+HJ7-<O*
MD"B[W;/*O!/_ "7+Q9_US?\ ]#2KWQQ_Y)_%_P!?T?\ Z"]>CT4>T]Y2#D]U
MHHZ'_P B]IW_ %ZQ?^@"O,OAK_R5SQG_ -?$W_H\UZW124K)KN4XW:\CR7Q'
M8:UX!\?W'BS1+%]0TR_!^V0H"2F<%LX''(R&^H/O<'QIM]05;?P_X=U*]U!N
M/)95"J?JI8X_ 5Z=15<Z:]Y$\K6S&0NTMO&\D;1,R@M&Q!*$CH<<<5ROQ2_Y
M)EK'_7-/_1BUUM%9Q=G<MJZL<E\+?^29:/\ ]<W_ /1C5UM%%$G=M@E96/*O
MCE_QYZ#_ -?C?R%>JT44W*\4NPE&S;/*O@]_R,WC3_K\C_\ 0YJKZY9ZU\.O
M'UYXFTFQ?4=(U(E[N.,$F,DY;. <?-D@].<5Z[15^T]YNVY/)I8\R7XSP:D4
MM_#GAW4[Z^;@Q,JJJGZJ6./J!7IB,6C5F4H2,E6QD>W'%+142:>R*2:W8444
M5)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>)_%6F>$M+
M^VZM*5#';%$@R\K>BC^O05LUX;\>X;K^W-*F8-]D-LR(?X0^[+?CC;^5:4XJ
M4K,B<G&-T:1^/]O]HP/#TAAS]\W8W8_W=F/UKL;#XAV&N>%;_5O#T#W=S8Q>
M9+82OY4@'4\X(Z D8SG&*X;P3JGPUU'P]:Z5J^G6=I?",+-)=Q@>:^,%A-U
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M@N(YY(V'<$1$5V/AS_DA2?\ 8)G_ /07J'!*"?4I2?.T<K_PT#_U+/\ Y/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N8^(^L7V@_#_4M2TF?[/=P>5Y<FQ6VYE13PP(Z
M$]JZ>N*^+_\ R2G6/^V'_H^.HJ:09UX**EBJ49*Z<E^8?\(QXY_Z*'_Y1(/\
M:/\ A&/'/_10_P#RB0?XUVM%'LUY_>ROKM7M'_P"'_R)Q7_",>.?^BA_^42#
M_&C_ (1CQS_T4/\ \HD'^-=K11[->?WL/KM7M'_P"'_R)Q7_  C'CG_HH?\
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M_",>.?\ HH?_ )1(/\:[6BCV:\_O8?7:O:/_ (!#_P"1.*_X1CQS_P!%#_\
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M%'._Z2#E7],XS_A&?&__ $4#_P HL/\ C1_PC/C?_HH'_E%A_P :[.BCG?\
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M:C<J%D= =D:CG:N>O/)/TKIG)*#3=S",6YW2L8WQTTFWN/"EKJA&+FTN!&K
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M.=_TD'*OZ9QG_",^-_\ HH'_ )18?\:/^$9\;_\ 10/_ "BP_P"-=G11SO\
MI(.5?TSC/^$9\;_]% _\HL/^-'_",^-_^B@?^46'_&NSHHYW_20<J_IG&?\
M",^-_P#HH'_E%A_QH_X1GQO_ -% _P#*+#_C79T4<[_I(.5?TSC/^$9\;_\
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MHU<9\1O^95_[&2S_ /9Z[.B6J3%'1M!1114%A1110 5Q7Q?_ .24ZQ_VP_\
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M** "BBB@ HHHH **** "N*^+_P#R2G6/^V'_ */CKM:XKXO_ /)*=8_[8?\
MH^.HJ? _0[<!_OE+_%'\T=K1115G$%8WC'_D1=>_[!MQ_P"BFK9K&\8_\B+K
MW_8-N/\ T4U..Z$]@\'?\B+H/_8-M_\ T4M;-8W@[_D1=!_[!MO_ .BEK9HE
MNP6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,FE6")I'. HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4 17=RMK"6/WCPH]365;1-<3&23DDY.:8\CW]UN/W0<**U(8A%& .O>@!X
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M>P>#O^1%T'_L&V__ **6MFL;P=_R(N@_]@VW_P#12ULT2W8+8****0PHHHH
M**** "BBB@ HHHH **** "LNP\.:;IFM7^JVD3+=Z@5-PY<D-CIP>!6I12LF
M7&<HII/?<R[KPYIM[XBL]<N(F:_LD*0N'("@YSQT/WC5"/P'X>CT:]THV/F6
ME],9YD>1B?,/\0.<@\=JZ.BERQ[&BQ%:*24GI;KVU7W,Q/#GA+2O"RSC28YE
M,^WS&EF:0D+G Y/&,FO,/BGKNN1^*'L?.GM;*-5,*QL5$@(&6)'7G(]L5[54
M4\$,Z?OX$FV\@.@;GVS6=2GS0Y8NQW8',/J^)^L5H\[MU_/J<7\*KC6+GPU*
M^L/-)#YG^BO,26*XYY/)&>GXU0\3?"8:SK\VH6&H+;+<OOECDC+;6/4C![]<
M5Y_=^/?$3Z\]['J,\.V0[+=6_=J,\+LZ&O?-(O3J6BV5\R>6US DI3^Z64'%
M8TW"K'D?0]?,(XS+*_UNFU'VG1;+RU7X]R+0=&M_#^B6^FVA9HX5/S-U8DY)
M_$FM&BN?MO&^@W6O7&CK?(EW ^S]Y\JR-W"MT)!XQ76DDK(^6G.523G)W;U9
MT%%%%,@**** "BN=\6^,[/PA!%)>VMU.9LB/RD&W([%B<"O/)?BUKNNZG!I^
M@V<%DUS*(D9OWK@DXSS@?I0![+6'K6CF[NA.D\:$@ B0X_*MJ)62%$=S(RJ
M7/5CZUR&K6U^^IR&2.1\L=A4$C';%9U-CMP:;J74K'0:?I$=G920L^]IAAV'
M'&.WYUGQ>%@+C=+<;HP<X48)_P *L1"\T_PVQ8$S*,@=2@)_R:Q-.EO9M3C,
M3R,Y8%B3V[Y]JE\NBL=%-5GSSC/^OT.S50JA5& !@#TKEK3PX]Y?ZBU^]S#
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M)9;2)W=NK,4!)--23V%4HRIJ\C1HHHJC$**** "BBB@ HHHH **** "BBB@
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M(I4FC#Q,&4]Q56>W2=<,.?6LTQ7&G2[[<_+W7L: -^BJ=GJ,5V-OW).Z&KE
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <9\1O^95_[&2S_P#9
MZ[.N,^(W_,J_]C)9_P#L]=G5OX42OB84445!04444 %<5\7_ /DE.L?]L/\
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M=V.\V3_GH_\ WT:/-D_YZ/\ ]]&FT4!=CC(Y&"[$>A8TVBBF(**** "BBB@
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M#GD=QFJ<LFLGQ"VN#3I6O&N_M9VVS["^_=T],^]:.FZDTU*UC23M'8Z#Q9X
MT[7M;U.Y\/:M.;L:ZME<P30!(HFE;^ CDA<X]\&N;\>_#>V\+:$=2M+VZ<PW
MOV.2*\2-&EX)$L>QC\F1C!P:KZAXQ\16%Q>JT2V<VH:@FINY@9665&W+LR?N
MY['-9^K:YJ/CF]2RM?#VEI?W$_G22Z?9[)IWP<EF).!SD]!GDUVX>.*@XMR]
MQ;[;:?\ !.6I[-W5M3G;&]%I<(TT0N(0?FA9BH8?4=#7LWAWP];W.E0:IHXO
M;!9AGR)RV#]5.01Z$5I>!/@]I^AI'J7B?R[_ % ?,EOUA@/O_?;]/YUVM[(I
M8D 8[5X&<U\+B*EZ,=>LN_\ GZGM98\11C:;T[=CG[.6>']W<#!7HW8TZZE!
M!IUVPYQ6;--7SNVA[\5S/F*.HL/);ZU0T\;M2B!_O4Z^N [8!^4?K5[0[$^<
M+B88X^13_.HW9T?#$ZBR4)&/SK2C? K,C;%6%EP*V6AYM2+;+KS8%4YI^N35
M>:[ X')JA=7@@"F3=)(YQ'$GWG/M_CVH<@A3+4UPJQL[L$0=68XK.C-Q+JC7
M,$3>3Y(12YV[CDDG'7]*NV6ERW,JSWY#2#E(U^Y']/4^_P"6*VTT]57TI*+9
M4JD8:&=;RS@CS47'J&JWYW'6I6M O2LW4KN#38=\[99CA(U&6<^@%5L9W4WH
M1ZC?Q6ENTTS[0.GN?ZU2TRSDED-W>+MDD^Y&?X%]/KW/_P!:F6VGSWMPM_JH
M *\PVX.5C]SZM[_E6M&<&IW9O\*LC1M$52*T7N52/ K)CE"K44]WQ@&M+V1R
M.FY2"^N=Q/-<SK5P(K%V.2<K@*,DG<,8]ZT[B?J36/;!M7U!'CYM86RK=I&Z
M9'L/U/TK&3N>A2BH*[-#1[:]N91/>2>6.H@C PH_VFZD_3 KH9$V14MC:B.,
M<4FH3+#$Q/85HE9').?/.R.:UN4+&5'4UWW@+3VL/"L)D7:]RQF(/H>!^@!_
M&N+\/:2WB;Q#F8'[) =\OOZ+^/\ +->L*H50J@  8  Z55&-WS&>.J*,526^
M[%HHHKI/)"BBB@ KBOB__P DIUC_ +8?^CXZ[6N*^+__ "2G6/\ MA_Z/CJ*
MGP/T.W ?[Y2_Q1_-':T4459Q!6-XQ_Y$77O^P;<?^BFK9K&\8_\ (BZ]_P!@
MVX_]%-3CNA/8/!W_ "(N@_\ 8-M__12ULUC>#O\ D1=!_P"P;;_^BEK9HENP
M6P4444AA7-))]LU2YNS]Q3L3Z#_/ZUNW\WD:?/(.JH<?7M7- _9M#)'#./Y_
M_6K>DM&SCQ$M4NVICZG>9,UP?HH_E7,DDDDG)/4UIZO)Q'$/]XUF5ZE-61X%
M:3E(****T,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#3TF?[T+'_ &E_
MK73I.QM+>[3_ %MLX5O<5Q5K)Y-U&_H<'Z5U^G?O%N+<_P#+2,D?45S5EU.[
M#2;T.UC<21JZ\JP!%.K.T*;SM(BSU3*'\/\ ZU:->5)6=CZ&$N:*D%%%%(H*
M*** "BBB@ HHHH **** "BBB@"O=645TF'&#V-8DUM<:?)E<E,\8KHZ1T5U*
MN,B@#+M-028 .<&KO7I6=>Z24)EM3CVJ&VU!X6\N<8^M &O13(Y5E7*'-/H
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M+F[SGFLEM40#@D_05/::9K.KL/L-C($/_+20;5_,\5R\S>B-514-9:$%S<@
MEFP*Q+R_SE5X'ZFN@U[P-K]C:K<1*MXNW,@@)9D_#'(^E<40P8AP0P."#U!J
M))K<Z:<J<E>#N;>GZ>&"W%R,D\JG8>YK74D-D<&L>SU>-85CN P*C&X#(-32
M^(-,MAF:Z5?;!S^5.,7)V2";2U9/=>(X].OQ;W:%590RR@9'XBM"&^2\B#V\
MRR)ZH:X#Q/K<%ZMM/;0RJGS*)I4*J_3H>^/ZUF:?9>(=3W/HEG>3;1EF@C)
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M JI4]]_Q_2Y]?Z5!7IQV/!E\3"BBBF2%%%% !1110 4444 %%%% !110 68
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MB.88>I]6_P#K<UU4420QA(Q@"@!R@*H Z"EHHH **** "BBB@ HHHH ****
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MH,@K^!Q[5RXS$.,?947ZO_([L(X7O6,V'4WVC&UQZJ:634R!E]J#U9L5F/\
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M=">P>#O^1%T'_L&V_P#Z*6MFL;P=_P B+H/_ &#;?_T4M;-$MV"V"BBBD,"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10!Q7Q1\0'1O"K6T#[;G4"85P>0F/G/Y<?C7A&ZNR^+&KG4/&TELK9BL(UA
M_P!H_,W\P/PKB=U?68"C[.@N[U/,K3YIG3^!_#9\4>)(K:0'[)#^]N6']T?P
M_4GC\Z^@W>WL+/=(\=M;PKC<Q"HBCWZ 5Q_PJT,:5X/CNY$Q<:@?.8D<A.B#
M\N?QKPOXP^.[WQ-XLN]-AG==*T^5H8H5.%D=3AG/J<@X]!^-<4J,\QQ3IQ=H
MQ-E)4*?,]V?1MKXX\+7MX+6T\0Z;+.3@1K=(23Z#GFMVOCO5/!$=EX+'B/3]
M=M-3@2X2VN(X8W4Q2,N[ +##8[XKUCX!>.[W5/M'AG5IVN&MXO.M))#E@@(#
M(3W R"/Q]JC%97&G1=:C*Z6]U8=/$.4N6:M<]LHKC[SQO>IXSNO#VEZ U^]H
ML+S3&]CA"B09& W)[]*T_P#A-_#/]K'3/[;L_MPD:,P>9\P9>JD=CQ7E/#U4
MEITOWT^6WS.GGCW-VBN3T?XE^&-8TB\U*/48[>WLY?*F,[!2,DA3P3D-@X[G
MTJY/X[\+VNG6U_<:Y9I:W6[R93)Q)M(# >XR,CK2>'K)\KB[^@<\6KW.@HK&
M3QAX>DU[^Q4UBT;4<[?LPD&[.,[?K[=:GUGQ#I'AV".;6]0ALHY"51IFP&(&
M2![XJ?9SNERN['S*U[FE16*GC#P])J\.EIK%J;V95:.#S/F;<-RCZD<XZUFZ
M[\0M&TVUU%-.OK&]U*P4-):/="(#YPIR^"!C=^?%5&A5DU%18G.*5[G645B-
MXR\/1ZC-I\VKVD=Y;HSS0M)S$%4,Q/H #G-&G>,O#NK&V&FZO;7!NI7AA"-R
M[HNYE'N 0?H:7L:EK\K^X?-'N;=%<E=>/K"/7]'MK66WFTW4(;N66^\W"PB
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MZO[-IG_/?_Q[_P"M1]FTS_GO_P"/?_6H]LP^K+^F<I_9$O\ ST3\C1_9$O\
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MX>:7<ZO9P[([G^R;#_GUC_*C^R;#_GUC_*LR_P#'/AK2]>CT6_UBV@U"0J!
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M]I;-REG&?NA1_>(P2W6J'BJZ'B7Q-9>$[,[X8Y!<ZFR]%1<$(?<\?B5]Z[D
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M&1H8EC+GJQ  S4]=!X323L@HHHH$%%%% !1110 4444 %%%% !1110 4444
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M K^9%<)J6VXNRZ=%4*&]<=ZN6\NHZ1 L^EZE/$2H9E1B ?7ZXKE5.*=T_O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQO&/_(BZ]_V#;C_T4U..Z$]@\'?\B+H/_8-M_P#T4M;-8W@[_D1=!_[!MO\
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M%_\ Y)3K'_;#_P!'QU%3X'Z';@/]\I?XH_FCM:***LX@HHHH **** "BBB@
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M7-*X4444R HHHH *XKXO_P#)*=8_[8?^CXZ[6N*^+_\ R2G6/^V'_H^.HJ?
M_0[<!_OE+_%'\T=K1115G$%8WC'_ )$77O\ L&W'_HIJV:QO&/\ R(NO?]@V
MX_\ 134X[H3V#P=_R(N@_P#8-M__ $4M;-8W@[_D1=!_[!MO_P"BEK9HENP6
MP4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEYIT:VS)&2)S]G<80_Q<D#CUJ74+*[>R\&".VF9K:Y@,X6,YB B();T&>.:
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M,/,*E1 OR[.V3M/?Z[ND_P#([>(?^N=K_P"@O0!OT5SNK2&_UPV%G]LFN(H
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MOJ "BBB@ HHHH **** "BBB@#C/B-_S*O_8R6?\ [/79UQGQ&_YE7_L9+/\
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MQ*^MS3W3JC?8YH81%.2V-@VHK GMANW>@#T&BN2\9:UJUH\%MH#!+F."6^N
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M&?7_ !1(T4D+->IF.0 ,A\L9!QD?B"0>Q(YH Z^BBB@ HHHH **** "BBB@
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MJ58!E(P01UJ7&^IK"HXIQ>J?3^NHM%'3I15&04444 %<5\7_ /DE.L?]L/\
MT?'7:UQ7Q?\ ^24ZQ_VP_P#1\=14^!^AVX#_ 'RE_BC^:.UHHHJSB"L;QC_R
M(NO?]@VX_P#135LUC>,?^1%U[_L&W'_HIJ<=T)[!X._Y$70?^P;;_P#HI:V:
MQO!W_(BZ#_V#;?\ ]%+6S1+=@M@HHHI#"BBB@#F?$>GWMWK=E))93ZGI"Q.)
MK*"9$W2[@59U=E61<#&TGKVK"3PMJJ^&9[2/38K>1]=6\2WBE38D.Y3P>!@
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MRPO)TFN[&VGE08226%69><\$CCF@#D8DEU2;P@-95I'E@G,JN2/,&Q2-P[Y
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M_P!/7_5:=J$UM"/[L?#J/P#@?A70U@>#XW;2KC4)%*?VG=R7B*P((1B F?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%8WC'_D1=>_[!MQ_Z*:MFL;QC_R(NO?]@VX_]%-3CNA/8/!W_(BZ#_V#;?\
M]%+6S6-X._Y$70?^P;;_ /HI:V:);L%L%%%%(84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <9\1O^95_[&2S_P#9
MZ[.N,^(W_,J_]C)9_P#L]=G5OX42OB84445!04444 %<5\7_ /DE.L?]L/\
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MK>E-IYOUU.S-FK;3<"X7RP>F-V<9YKSW0M*N)_&&JZWI^BW&A:1]A:'R)X1
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M!QGQ&_YE7_L9+/\ ]GKLZXSXC?\ ,J_]C)9_^SUV=6_A1*^)A1114%!1110
M5Q7Q?_Y)3K'_ &P_]'QUVM<5\7_^24ZQ_P!L/_1\=14^!^AVX#_?*7^*/YH[
M6BBBK.(**** "BBB@ HHHH **** "BBB@ HHHH *XN>/5&^+F+>\M$3^R0P#
MVC,?+\X97(D'S9_BZ <;3UKM*Q+_ $*ZE\30:UIM_';3+;&UFCGMS*DD>\,,
M892K YYR1STJHNQ,E<YV]\<:M:^';IHK2UFUFVU*:S:$!MCK&K2%PN<C,2^O
M4_A5Z\\;BWN]0N(8UETS3]+CO93M/F/))DQH#G RH]#U%7(_"$2>-I]?:XW1
MS1$&S,7'F%50N6SS\JXQCN>:KZ)X$MM-\.ZCI%_=-?QWX$;R%-C+$L:QH@Y/
MW0O!J[P)M(#KNMZ6VD7.N+8O::G.ELT5K$ZR6LDG^KRS,1(,_*>%ZY'I5[Q;
MK=QH.EPW%LB*LEPD4UU+$TD=JASF1U4@D<8Z@98$GUKP^%KR:734UG5EOK/3
M)!-;PI:^4\DBC$;2OO.[:.<*%!.">F*UM3MM2N/(;2M1CLFC8EQ+;><LHQC!
M&Y2/7@@].W!7NW0];&'<>)KVTT.TDCFTS5+O4KT6=C/9L1 ^<_.PRQ 7:V0&
M.<=1GB:'7-2L/$3:-K1M)Y)K1[JTN;:)HE;9@,C(68@\YSNP1Z&H4\#)_9MP
MLM\5U&;43JBW4$(1(K@<*5B)/RXX());+<\C%^R\/S_VZVL:U>17UV(#;PK%
M;^5%"A(+84LQ+$CDYZ<8H]T/>,=/&.H-\.])UXPVWVJ]F@CD3:VP!Y=AP-V>
MGO5^/5]8O_%^JZ19&QM[?3UMY#--$\C,)%)*[0RCL?FSQC&ULY%!? =T-#MM
M%.MC^SK*X6:V06G[S"R[PLC%SNP,KE0O8G.,'?L=$^Q>)=6U;[1O_M%(%\K9
MCR_*##KGG.[T&,=Z;<=;"7-U,K3-:U[Q$MS?:/\ V?;V$5RT$,=U$[/<!&VN
MV]6 3.#CY6Z<U0U#QVPOM62TU/1;%=,<Q+!J$G[V[=1EMN'78N?E!P^3GCC%
M:EOX9U/2FNHM UF&TLKB<W AGLO.:%F.7"-O48)[$'&:D/A[4+'4KZY\/ZI#
M9QW[^;-!<VAG59<8+IATP2 ,@Y&1VHO&X>]8R[WQK*TVE&"YL=(L]0L%NTO=
M2B:2-Y&Y\G<'0*P&223SD8%=A:M,]G"UT(A.T:F00L63=CG:3@D9Z&L;4-)U
MR\CDBCUJT$$UMY$L-QIWFJ3C#.,2+UR>#D8QQUSHZ-I<6BZ+::;;O))%:Q+$
MK2'+$ =34RM;0I7OJ7:***@H**** "BBB@ HHHH **** "BBB@ HHHH ****
M "N*^+__ "2G6/\ MA_Z/CKM:XKXO_\ )*=8_P"V'_H^.HJ? _0[<!_OE+_%
M'\T=K1115G$%8WC'_D1=>_[!MQ_Z*:MFL;QC_P B+KW_ &#;C_T4U..Z$]@\
M'?\ (BZ#_P!@VW_]%+6S6-X._P"1%T'_ +!MO_Z*6MFB6[!;!1112&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8^M>&K/7=0TN[NY)T
MDTR<3PB)@ S94X;(.1\HZ8K8J.2XAADB2::.-YFV1JS %VP3@>IP"?PH 6:(
M3P21/D+(I4D=<$8KFX/ &D0^$)?#A>XELY)#)YDC*9$;(.0=N!T]/6NEDD2&
M)Y9G6.-%+,[' 4#J2>PK!TWQUX;U?4QI^GZK'+<G.U"CJ&QZ%@ ?P- $=]X'
MTW4M#L=.O;B\D?3\?9;WS0MQ%R#PP&.@ Y'8'KS4WA_PAI_AZZN;R&:[O+ZY
MXEN[V;S)2O'RYP..!VS[\##-5\>>&]$U*2PU34O(N8P"\?D2-C(R.54CH15F
M]\6:'I^C6^JWM^D5G= -"Y1LR C(PH&[].* &>(O">G>)A;M>-/!<6K[X+JU
MDV2QG(/!P>X';CM5&Y\ :?>^'QI-[?ZE<JMQ]I6YFG#3*_LQ7ISTQ^M;FDZO
M8:YIZWNE7*7-NQ(#KD8([$'D'V-7: .=B\%V,>MRZJUU>2W4UD+-S)(IW+M"
M[C\N=QVYSTSGBJC_  XTA_"4?AXW%[]DCN/M <.GF;N>,[<8Y]*ZVB@##7PG
M8+XI77O,N#="W^S^667RRN,=,9S^-9UG\.M,TW4OM.FZAJEG%YXG%G#<@0;Q
MT^4CGIW)].G%=;10!Q-S\*]#N?M:&[U*.WN93,;:.X BC?/WE7;UQD<YX)]L
M:UQX-L+C6-*U-;B\@NM,C6&-H9 /-1?X7XY'4'&,[C3?%7BO_A&9M,3[']J^
MWW @SYNSR^G/0YZ].*Z*@#@?B;I%UJ]WX=BMK6YGB6\_?M;HQ\M25R21]WOS
M6SI7@73-*74&6>\N[K4(VBGN[N822[",8!QCWZ?RKI:P/&7B?_A$M!&I?9/M
M?[Y8O+\WR^H/.<'T]* +&C>&;#1?#?\ 8</F7%F5=6%P02ZN3N!P!QR:R++X
M:Z+97UO/Y]_<6]K(TMM8W%QO@@8G/RKC/!]2<]\UUD3^;"CXQN4''IFG4 >0
MZQ9:E;>*=?G>P\3VTEQ)NM7T(GR9@ 0K2'GGITZ9/ KJM%\(7NH:9H-UXONK
MAM4TF5Y8PLJMG+*0';!W<(.0>_4UVE% &!K_ (/L?$&H6M_)=7UC>6JLD=Q8
MS>6^T]LX/J>GJ:H)\-M%BT+4-(AEO([6_G69P)%+1E3D*I*GCZY/O6CXP\3?
M\(GH)U+[)]KQ*L?E^9LZYYS@^GI6S;R^?:Q38V^8@;&<XR,T 8<G@W3Y=9TG
M4FFN?.TJ$0P*&7:R@$?-\N2>>Q%6-%\-6>A:AJEW:23O)J<YGF$K A6RQPN
M,#YCUS1KWB:Q\.S6$=^EPQOYQ!&88]VTG')YZ<]LGT!K8H YW6_!5AK6M0ZL
M+N^T^^AC\L3V,PC9E]\@^I'T.#GBJ^L?#W2=7U*XO1<W]A+=ILNELIQ&MP/]
ML$'/]?K755B>+O$7_"+>'I-4^R_:O+=5\KS-F<G'7!_E0!HV.FV>FZ;%I]E
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M]C_M#]UL^[G+[L?AMK*N&O\ 5_B)XET^3Q%J.G6EI;BX1;>X*[2J+S[+\Q)
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M;VK:I;>>UI)YL)\QEV-Z\$9Z=Z8GAO24U*^U!;7%U?Q^5<R>8_[Q< 8QG X
MZ8H \N/C'6S\.-$0Z@\$E[>/:SZBQRZ(#U+'H<-UZX7KGFM?Q[HHT7X>ZE$-
M9U'4]]Q"2+^X$K1<]C@$9S_+\>T3PAH,>@-HHTY#I[,7\EW9L,>X8G(/N#4-
MKX&\.66EW>G6^FA;2\QY\9FD;?@Y');(P>F* .774;R'XE>$;)+R>.SFTH%X
M!*1&[>7)@E<X)X'Y"L6P\6ZM:>%O%]_!?3W4D-XD=M))(95A5G(RN<@#'3MT
MKT&Z\!^&KVQM+2ZTQ9(;)2L ,T@* G)&X-DC/8DU:M/"FAV%O?6]IIT,<%^<
MW$0R4?KT4G"CGH,4 >7O8RVOBCP--/K-WJCWA6=C<R^9Y9;;G:3R%/H?0UI#
M6-3\KXBG^T;O-G(HMOW[?N/FD^YS\O0=/2NQL?A]X7TVZ@N;+2EBFMY/-CD\
MZ0E6_%N>G0\5<_X1/1=NJ#[%QJQ!O?WK_O3DGU^7[QZ8H \TBU#6=,'@S5GU
M[4;J35)1'<0339A* J@ 3IG:>6.23\W6CQ%?:_?>*-?M;6ZUZ:>VDCCL5T=S
M]GC!R<3;>AP1SUR#G@5Z3)X1T.6WTV"2RS'I;;K1?-?]T<@_WN>0.N:X#7/!
MFK7.OZU<7/A:'66O)"UI>1WXMQ I&%R@(W$<9SU(/)S0!W=E9C2/ K1:]-<W
MHCM'>]-Q+YKME277=W'4#VQ7":;I&MRW?G?#^QU/P]8,V[.IW0\EOE&2(&5V
MR>,/DCCMV[_PAHUUX?\ "UGIM_<_:9X00SAB5')PJYYP!@5M4 <#\1UO;GP]
MJO\ 8C:2;98Q_:98_P"D!E((''&<=FYQT[5A1S6D_B#X?/;QS1Z7Y++ MPV2
M)1QR1P3N"^G;@=*[C4/A_P"%]4U"2]O=)C>XD;<[)(Z!CW)"L 2>YQSWJ_J?
MAK1M8TR+3]0T^&2UAQY4:@H(\?W2N"OX4 <I\/1_Q5WC VVS[%]M79L^[NR^
M<8_#]*S);W5+'XU:Y)HFD_VI.UE&IB-RL.U=L7S9;KS@8]Z]%TG1M/T+3ULM
M)M4MK=26VKDY)ZDD\D^Y]!3(="TZWUZXUF*WVZA<1B*6;>QW*,8&W.!]T=!V
MH \LUCPQ>>&?A!?IJ7EK<W=['.T,)RL.2OR_4<YQD>F>M3^ )9M+\;*OBJ#%
M_JEG&UA<.V0J8_U8[#( 'K\N.]>GZOH]CKNGM8ZK!Y]LS!BF]ER0<CE2#5;4
M?"^D:M!9Q7]H9%L<&V*S.C18 '#*0>P[]J ..\&LMO\ %/Q='.ZHY/F@,<?+
MNSGZ?,/SJ7X0H6TK6+A<&*747V,/XL <_J*Z;6O!GA_Q#=+<ZOIJ3SJ-OF*[
M1L1[E2,_CTK3T_3K32K&*RTZW2WMXAA(T& /\3ZD\F@#S*9]0U;QSXJLI?$6
MI6%K90&XC2WN2H4JH]>BC)R!C.1SP*@A\67UY\-M,%]?ZD+^YNVM818%5FNP
MN, R$97DJ"PR3W!R:V(O "ZKX^UN\\1Z8)M-G*O;2>?M)8 #^!@PXSUXKK;[
MPGH>I:1!I=YIT3V=L088E)39]"I!^O//>@#SGPY?:O?6/BW0M5OK]!:P-*A>
M\$T\++G*>:!R#@ CIUZ9-1^'H)M.^"^H:M9:I?I.Z,JQ+<$1P$2]4 Y4D=3G
MG->E:5X4T31)YI=*T]+=IHEBDPS$,JC !!)';D]2<DY)JI!X!\,VL5Y%;Z9Y
M<=ZFR=%GDPZ[@V,;N.1VQ0!P6J^(->N8?"FCV<UX_P!LT])Y&@O1;S7$A!&/
M.?.,8!QWSCKC$NKW?BS2/AM?KJTUW:3PWR"VE-ZLDXC;G:TB'DCU.,YZ8P*]
M"O?".A:CI-KIE[IR2VMHH6!2[!HP!C <'=V'?G'-1+X)\/+H3:,NGXL&D\UH
M1-)R_KG=G]: .,M9]4TOXB:)9RZYJ%[%K%B9+E9Y?E5V5B3&H&$ *@@ <=,X
M-1_#W1Y/^$L\320ZK?&;3[QXD62?*7!/F*&F&/G(QG/'->@OX;TF35;/4GM<
MW=C'Y5O)YC_(N",8S@]3U!JO-X+\/SZT^K/IR_;9,[Y5E==V5*G*@X.02#QS
MF@#@_#-[JEEXIT]/%&JZNMQ?R,]O)'<I/8W:G/"@<)SCIG (^[D5ZA;7]G>2
M31VEU!.]N^R98I QC;T8#H>#P:Q],\"^&]'U(7^G:7'%<KG:Y=WVY[@,2 ?H
M*I^#_"\NC:IJVISVL-B;^0;+2"8R"-03\Q8]V))P. /R !E'4K[_ (6IXAM/
MMMQ]FAT<R1P^:VQ'Q'\P7. >3S[UQG]I:[!\.K+Q+_PD6J/=QW_D)$TY,90;
MF^8=7.>[$\<8P*]A_P"$=TLZQ=:I]E_TV[@^SS2^8WSQ\<8S@?='(&>*J-X)
M\/MH*Z*VGYT])?.6'SI.'YYW;L]SWH W(G\V%'QC<H./3-.I%4(BJHPJC %+
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QGQ&_YE7_L
M9+/_ -GKLZXSXC?\RK_V,EG_ .SUV=6_A1*^)A1114%!1110 5Q7Q?\ ^24Z
MQ_VP_P#1\==K7%?%_P#Y)3K'_;#_ -'QU%3X'Z';@/\ ?*7^*/YH[6BBBK.(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XKXO_\
M)*=8_P"V'_H^.NUKBOB__P DIUC_ +8?^CXZBI\#]#MP'^^4O\4?S1VM%%%6
M<05C>,?^1%U[_L&W'_HIJV:QO&/_ "(NO?\ 8-N/_134X[H3V#P=_P B+H/_
M &#;?_T4M;-8W@[_ )$70?\ L&V__HI:V:);L%L%%%%(84444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7':7XFUK7?&VHV&GPV,6EZ7,(;EY@YF<_,/EP<=5/4=/
M6NP90Z,K#*L,$5XUX?TB+3[KQQ=:+:D7NDM)%8%78F)3Y@..?F.T<9R<B@#V
M:BO!X'L[73?#>I^'+UY?$UW=,+S;.7DERQR)%).!G'4<CGGK6Q)?VNE>-O'0
MU*XCMC-9.L2R-@R%E& H[DY'2@#V"BO!YPQ^%?A81R-$QU-]KH<,IW-R#ZU[
M)I&@V/AS39;;1+;RPQ,A#.6,CXQDDG/84 :E<9IGC'4;N^\61-IZW7]BR!;:
M"U5A)-RXP<D\_*.@]>#TKD_!D?A_5Y[C4?&5]_Q42WX"B>Z:)XR"-H101QNR
M,#ICM38Y$23XFPNZK*_SK&3AF4-)D@>@W+S[CUH ]4T>^FU/1[:\NK*6PFF3
M<]M+]Z,YZ'@?R%2W]Q)::=<7,-N]U)#$SK!']Z0@9"CW->.W=N+S0OAS:N\D
M:3RO$S1-M8!G0'![<&K6EVT6D:YX\TC3PT5C%ILK)#O+ '9UY/\ M&@#U#0M
M1N-6T6"]O-/FTV:4'=;3?>3!(] ><9Y K0KQ"2ZE7P#X-LKV>2WT*ZGE6^DC
M)&[$QPK$=L9./;/85T'B.3PIH/@6XA\/QF]M+B]2.2*UU%_+#[=WS/N/RD#!
M&><]00" #T?4+A[32[JYC"EX87D4-T)"D\UB^!O$%UXF\+0ZE?QPQS/(ZE85
M(7 .!U)/ZUYOX(+VWB/Q'IMM+:-;-I4DABTZ5Y(-X" %2Y))^8\Y/)..*['X
M0S1OX!AC216>.:0.H8$KELC([<4 =S63:^(K2\\3WVA11S"ZL8TDE=E&PA@"
M,'.?XAVKR6U.G:=XPM[N[GAUYKW4/W-[97TB741W;0KQYY'I@<_WB"!6GH&C
M:%:?&+5;:^CC@-O(DM@DLS(3(2I&W)^8G.<<T >NT5X1%?VMCX0\:6%W<1PW
MDUZJQP,V'8B3G Z\8.:T-1D2XB\"Z;K<S0Z#-9H\VYRD;N!T9N.GR]^ W:@#
ML]/\9ZE<:MXIMCIZ70T?_CVAME823'+<$DGT'0?@>E=/H]]-J>CVUY=64MA-
M,FY[:7[T9ST/ _D*\?TI+2.S^(4>F2>;9I#M@8.7&P%P,,>H X!YXJ+5Y[T^
M#?!MDSPQZ9<(WFFY=UA=P_ D*'(4=1^)[< 'N55=2O?[-TV>\-M/="%=QAMD
M#2,/8$C->4VNES6O@77+,^*-(MK2>>)(/L5W))#$6)W1DG+!6!&>O ;/ -:?
MPW32Y+O6-%6Q2.18 EQ)97SS6MPIR-R\_*2".Y/7[N"* -OP1X\/BR6YA>PG
M0QR.5G2+$03/R!CN/SD=>W%=E6?IV@Z7I,[S:9916SO&D3F,8W*OW<CH2/7K
M6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '&?$;_ )E7_L9+/_V>NSKC/B-_
MS*O_ &,EG_[/79U;^%$KXF%%%%04%%%% !7%?%__ ))3K'_;#_T?'7:U2UC1
M['7M*FTW5H/M%I/M\R/>R[L,&'*D'J!WJ9KFBT=&%JJC7A4EM%I_<R[17%?\
M*@\#?] /_P FY_\ XNC_ (5!X&_Z ?\ Y-S_ /Q=*\^R^_\ X!KR8/\ GE_X
M"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\^R^__@!R
M8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\
M^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P F
MY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#
M?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\
M%T?\*@\#?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z
M?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_
MX5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\
MY,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\^R^__@!R8/\
MGE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\^R^_
M_@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\
MXNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /
M_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\
M*@\#?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW
M/_\ %T?\*@\#?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X
M&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6
MBN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\^R^__@!R8/\ GE_X
M"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\^R^__@!R
M8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P FY_\ XNB\
M^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#?] /_P F
MY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\ %T?\*@\#
M?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z ?_DW/_\
M%T?\*@\#?] /_P FY_\ XNB\^R^__@!R8/\ GE_X"O\ Y,[6BN*_X5!X&_Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img119790510_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<GD@0F5T
M:"!3871W:6-Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Y
M.0  DI(  @    ,Y.0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+1KG&1_M$G ^A]J3IOFY4-3]V[/0**\IM?@E'=V8N==UV_DU9QN:6-P51O\
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MB:J=VH:?,;>9\??XX8^_4'Z5YGX1TK4_$7C#Q%HEI?&RTZXNC+J#Q\2.B2.
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M\3RSVILKE&5(U=O,&0HY&W'\)[UI?$+PK<^,/"QTVRN8[>=9EF4RYV-@$8.
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M+"MSN'<GW)))^M$Y*RN[L(IWTV/.?@)_R+.I_P#7X/\ T 5L_&7_ ))K=?\
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M@C%7^$X?2W&F?M(7R7Q"FZWB)F[EHPRX_ 8KV6N)\>_#F#Q?)#?V=S]@U2W
M"3@<. <@-CG([$=*QH_!'Q U*%=/\0^,(UT[&UQ: F61?0ML4G/N3^-*7+-)
MWL-7BVK&?\'V#^./%;(0RM+D$'((\QZ;\3&$7QB\)2R';&KVY+'H,7&377^"
MOAY!X*U;4KFTOFG@O %CA:+!B4$D MD[NOH*7XA> E\:V-NUO<BTO[0DPRL,
MJP.,JV.>P(/;\:?/'VE^A/++DL=@[K'&SR,%11EF8X 'K7C_ ,')4G\:>*I8
M7#QR/N5E.0P,CD&M2W\">-]5A33_ !=XK232A@20VG,DR_W6<HIY]\UO^$?
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M@^]CID;%&?<YJI<LY<UR5S17+8/@-:S1^&]2N74B*:Z"QD_Q%5Y_F*J> O\
MDO7BG_KG<?\ H^.O5-(TFST/2;?3M-B\JVMUVHO7ZDGN2>2:X_PSX'U+1OB9
MK/B*ZGM7M+]91$D;L9!ND5AD%0.BGH31SIN3[ARM**-KX@?\D\UO_KS?^58'
MP4_Y)VG_ %]2_P!*ZSQ1I<^M^%=1TRU:-)KJ!HT:0D*"?7 )_2LOX>>&;SPE
MX473-2E@EF$SR;H&)7!QCJ >WI4IKV;7F59\]SJ:***R- HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  _X)QG_  MSP1_T&_\ R4G_ /B*/^%N>"/^@W_Y*3__ !%=G11>'9_?_P
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M9O=J(3'#$!OB8#YRPZKGD'/7/>LC7+/4(_@-X?=]WV<7LDC+_=5B^PGVZ_\
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M/^$9\;_]%!_\HL'^-'_",^-_^B@_^46#_&NSHJO:/R^Y$\B_ILXS_A&?&_\
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MH:G9VDLGW$GG5&;Z GFO)_"&N:M<_''4K&YU2]FLEN+OR[=[AVC"ACMPI.,
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MB1/;>'["*>]%\\=L@:ZSD3?*/GSW!ZYIL/B'1;F\^R6^KV$MSG'DQW*,^?\
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M<B74("QCNY9G! 4D#.%&3C(!. :]-HHK&4N9W-(QY58****DH**** "BBB@
MKC/$W_)4_ __ &__ /H@5V=<9XF_Y*GX'_[?_P#T0*NGO\G^1$]ON_,[.BBB
MH+"BBB@ HHHH **** "N,^(__,J?]C)9_P#L]=G7&?$?_F5/^QDL_P#V>KI_
M$B)_"=G1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'N:VJQ_#7AC3/"FE+8Z3#L7K)*W+RMZL?\@=JV*XY6OH=*O;4****0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MC/AQ_P S7_V,EY_[)79UQGPX_P"9K_[&2\_]DJX_"R'\2.SHHHJ"PHHHH XS
MX<?\S7_V,EY_[)79UQGPX_YFO_L9+S_V2NSJZGQ,B'PA1114%A1110 4444
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M$B*O+;F)#?* >*Y[XVV<MMX9\-H_S"WW0NXZ;MB_SVG\JWK+7;#QE\+;O1-
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MRKYB_3H/SK.^#^I2:A\.;59B2UI(]N">X!R/R# ?A5Z>9+?X/-+*=JKH?/\
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M/17AUL96K?$].R/J,/EV&P_PQN^[U84445R'H!1110!3^+W_ "'M%_[ MO\
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M9XB\-:GX6U1K'5X#')U1QRDJ_P!Y3W'^37H0J*3MU.*4'%7,JBBBM" HHHH
M**** "I[*RN=2O8K2P@>XN)FVQQQC)8U>\.^&M3\4ZHMCI$!DDZNYX2)?[S'
ML/\ (KZ-\$^ M-\&6($ %Q?R+^_NV7YF]E_NK[?G652JH>II"FYF'\/?A7;>
M&?+U/6=EUJN,HO5+8^WJWO\ EZGT6BBO/E)R=V=D8J*L@HHHJ2@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N,^''_ #-?_8R7G_LE=G7&?#C_ )FO_L9+S_V2KC\+(?Q([.BBBH+"
MBBB@#C/AQ_S-?_8R7G_LE=G7&?#C_F:_^QDO/_9*[.KJ?$R(?"%%%%06%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7&>)O^2I^!_P#M_P#_ $0*
M[.N,\3?\E3\#_P#;_P#^B!5T]_D_R(GM]WYG9T445!84444 %%%% !1110 5
MQGQ'_P"94_[&2S_]GKLZXSXC_P#,J?\ 8R6?_L]73^)$3^$[.BBBH+"BBB@
MHHHH **** "BBB@ HHILDB11M)*P1$!9F)P !WH 5W6-&>1@JJ,LS'  ]:\X
M\4>/)+DR66BL8X/NM<#AG_W?0>_7Z52\6^,9-8=K.P9H[%3R>AF]S[>U<I7@
M8S'N7[ND].Y];EN4J"56NM>B[>OF!.>M%%%>,?2!1110 4444 %%%% %/XO?
M\A[1?^P+;_\ H3UP%=_\7O\ D/:+_P!@6W_]">N K](P_P#!CZ'Y'B?XTO5A
M1116Y@%%%% !1110!M^%_%VJ^$M1%UI4Y",1YMN_,<H]"/Z]17T9X,\;Z=XS
MTSSK,^3=1@?:+5VRT9]1ZKZ'^5?+%7=(UB^T+5(M0TNX:"XB.58=QW!'<'TK
M&I24UYFD*CCZ'U]17+>!/'%GXTTCS$VPW\( N;;/W3_>7U4_ITKJ:\]IQ=F=
MJ::N@HHHI#"BBB@ HHHH **** ,7QE_R(FO?]@VX_P#134>#?^1$T'_L&V__
M **6CQE_R(FO?]@VX_\ 134>#?\ D1-!_P"P;;_^BEJ_L?,C[9M4445!85B^
M,O\ D1->_P"P;<?^BFK:K%\9?\B)KW_8-N/_ $4U5'XD*6S#P;_R(F@_]@VW
M_P#12U+XA\-Z9XHTMK'5[<2Q]4<</&W]Y3V/^347@W_D1-!_[!MO_P"BEK:H
M;:DVA+6)\O>-O .I>#+X^<IN-/D;$-VJ\'_9;^ZWMW[5RM?8E[96VHV4MI?0
M)/;S+MDCD&0PKP'XA?"NY\->9J>B[[K2LDNO5[8>_JOOV[^I[*592TEN<U2E
M;5'G-%%%=)@%=5X)\ ZEXSOAY*FWT^-L37;+P/\ 97^\WMV[UN?#WX5W/B7R
M]3UK?:Z5D%%Z/<CV]%]^_;U'OUE96VG645I8P)!;PKMCCC& HKFJUE'2.YO3
MI7U91\/>&],\+Z6MCI%N(H^KN>7D;^\Q[G_(K5HHKB;;=V=>P4444@"BBB@
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M "/I\FP"E_M%1>G^?^04445X1]4%%%% !1110 4444 %%%% %/XO?\A[1?\
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ME7'X60_B1V=%%%06%%%% '&?#C_F:_\ L9+S_P!DKLZXSX<?\S7_ -C)>?\
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M=4M//)'G3QX1, GG\L5TJ_L[)?B8:<YW%%%%<QN%%%% !1110 4444 %%%%
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M? GA7X3ZSK.@Z%]EU"V\CRIOMD[[=T\:'Y6<@_*Q'([U[_7FW[0?_)"?$/\
MV[?^E,59MW=RTK*QZ31112&%%%% !1110 4444 %%%% !1110 4444 %5-58
MKIDQ4D' ''U%6Z1T612LBAE/4,,@T 1VK%K.%F)),:DD]^*EI  JA5   P .
MU+0 4444 %%%% !1110 4444 %%%>5^,M7U*U\6WL-MJ%U#$NS:D<[*H_=J>
M #7-B<0L/#G:OJ=N"P<L94=.+M97/5**\/\ [?UC_H+7W_@2_P#C1_;^L?\
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MZ6@ HHHH **** "BBB@ HHHH *\?\<_\CI??]L__ $6M>P5X_P".?^1TOO\
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M,O\ D1->_P"P;<?^BFH\&_\ (B:#_P!@VW_]%+5_8^9'VS:HHHJ"PK%\9?\
M(B:]_P!@VX_]%-6U6+XR_P"1$U[_ +!MQ_Z*:JC\2%+9AX-_Y$30?^P;;_\
MHI:VJQ?!O_(B:#_V#;?_ -%+6U1+XF*.R"BBBI*/.OB=J:&^T[1H/#=OKMX\
M<ET%GSB%%ZD8QUP<\CH.N16=X2\2ZWJ/B[2#=^']+TN'4K8^7=(IWS01KD1Q
MG) QD';Z#VKL]8\/7-QXOTG7K&>&/[*CV]W%,I(DA;G@]B#_ #]L'D?"/A:]
M/BBT8>(]/U+1-!>;[%#:RB21-X(VO@<8SW)Z<5T1<>2QBT^8]1HHHKG-@HHH
MH **** "BBB@ HHHH XSX2?\DMTC_MM_Z.>NSKC/A)_R2W2/^VW_ *.>NSJZ
MGQLF'PHYS5?!&FZQJ<M]<SW2RRXW"-U"C"@=U/I5/_A6NC_\_-]_W\3_ .)I
M^HZIXPN]8NK;PUI=C#:V9"M<ZJ9%%RQ&3Y87L.FX\9J'_A/)%\&R:G)IC?VF
MEX=.^PK)PUSOV[0WIGG-<DL!1D^9Q3;.^.9XJ$5&-1I+]!__  K71_\ GYOO
M^_B?_$T?\*UT?_GYOO\ OXG_ ,326>O^)=,U6PMO&%CIR0:E+Y,%QI\CD12[
M2RHX;J2 >5XR*BOO&6H6YU3488;4Z5I>HQV$T;*WG2$E SJV<#!D&!M.<'D4
MO[.P_P#(BO[6Q?\ S\9T>AZ';:!8O:V;RNCR&0F4@G) '8#TK2K(;5;B?Q6F
MEV*1F"VA\Z^E=22I;B.-<'ACRQSG@#U!K7K>,%3BHQ5D<<ZDJLG.;NV<!\4/
M^87_ -MO_9*X"N_^*'_,+_[;?^R5P%?)9E_O4OE^2/T#)O\ <8?/\V%%%%>>
M>L=!X'_Y'.Q_[:?^BVKUZO(? _\ R.=C_P!M/_1;5Z]7T^4?P'Z_HCX?B'_>
MH_X5^;,#QQ_R)E]_VS_]&+7D%>O^./\ D3+[_MG_ .C%KR"N#-_XZ]/U9Z_#
MW^ZR_P 3_)!1117CGT(5[]7@->_5]!DWV_E^I\GQ'_RZ_P"WOT"BBBO?/D@H
MHHH **** "N,^''_ #-?_8R7G_LE=G7&?#C_ )FO_L9+S_V2KC\+(?Q([.BB
MBH+"BBB@#C/AQ_S-?_8R7G_LE=G7&?#C_F:_^QDO/_9*[.KJ?$R(?"5]0LH=
M2TRZL;K/DW4+PR;3@[64@\_0UY0="LFFDL=4^(>C/IS0PVD\2M$DSPPL2D9.
M_P"4\X)'/%=YXSU;[#I+V/\ 9>LWO]H02P^9I5KYS0?+C)Y&#\W'T-<3HUYH
M5GHEG;:A\+]6FN885CEE&@H_F,!@MEN>>O/KU-:4[I7)G9L]9JGJ^JVFAZ3<
M:EJ,GEVUNF]V[GT ]23@ >IJY7G?Q-M==O9HEMM%_M+1;6UDGF_TJ.(><58
MLK<L$'S  <DCGBLH1YG9ER=E<W[CQUIEOX>T[5A;WLW]I_\ 'K9P0[YY#C)
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MJ6MR+\D:"UB/JQ(9OR 7\ZSJ2Y8-ETU>21[71117F'>%%%% !1110!B^,O\
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MLG31C]H****Y#I"BBB@ HHHH Q?&7_(B:]_V#;C_ -%-1X-_Y$30?^P;;_\
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M_+//HI'/N .QSYO7V^68%8:GS2^)GYQG&8O&5>6/P+;_ #"BBBO7/$"BBB@
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MS71W-%%%8&H4444 %%%% !1110 4444 <9\)/^26Z1_VV_\ 1SUV=<9\)/\
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M* "BBB@ HHHH *XSQ'^[^*7@T(%7S_MOFD*,OLARN3[$G\Z[.N,\3?\ )4_
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M&1;!MQ9?+VKD(3U0-N QQZ<5,HZ7147K8M>./^1,OO\ MG_Z,6O(*]?\<?\
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M8UAXNTG4;_[);S,)"<(73:)#[?\ U\5)K!_M6QN=,LAYDDB['D#82(^Y]?\
M9'/KCK7&Z-X*U6/7(7O(UA@@D#F3>#NP<X&#GFO&QN*Q=.O3AAX<T7N_^#T/
M6PN%PTZ,Y5Y\LELO^!U/2:***]D\D**** "BBB@ HHHH **** "N,\3?\E3\
M#_\ ;_\ ^B!79UQGB;_DJ?@?_M__ /1 JZ>_R?Y$3V^[\SLZ***@L**** "B
MBB@ HHHH *XSXC_\RI_V,EG_ .SUV=<9\1_^94_[&2S_ /9ZNG\2(G\)V=%%
M%06%%%% !1110 4444 %%%% !1110 5C>(/#-EX@A'GCRKA?N3H/F'L?45LT
M5$X1J1Y9*Z-*=6=*:G!V:/GSXOMJEMJ5KI1L9K/1+-=MH2<K.V/F<D<;O8\@
M>F37F]?86H:=9ZK926>HVT=S;R##1R+D'_Z_O7C_ (M^![ION_",V\=38SMS
M]$<]?HWYUWT:L(Q4-K'%6A.4G.][GCM%6M1TR^TB[:UU.TFM)UZI,A4_7GJ/
M>JM=9S!1110 4444 %%%% !1110 4444 %.CC>618XE9W8@*JC))] *[#PQ\
M+_$7B79,+?[!9MS]HN@5R/\ 97JW\O>O;_"/P\T3PA&KVD/VF]QAKR8 O]%[
M*/I^)-8SK1B:QI2D>?\ @/X-M+Y>I>+T9$R&CT_."WO(>W^[U]?2O9XHHX(4
MB@C6.- %1$7 4#H !TI]%<,YRF[LZXQ459!1114%!1110 4444 %%%% !111
M0!B^,O\ D1->_P"P;<?^BFH\&_\ (B:#_P!@VW_]%+1XR_Y$37O^P;<?^BFH
M\&_\B)H/_8-M_P#T4M7]CYD?;-JBBBH+"L7QE_R(FO?]@VX_]%-6U6+XR_Y$
M37O^P;<?^BFJH_$A2V8>#?\ D1-!_P"P;;_^BEK:K%\&_P#(B:#_ -@VW_\
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M'?\ >XS_ 'O0\RVVN:;X/\#?%3PKKER+?6+C4+G[+:NI#W*S*%C9!_$#UXZ
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MGPD_Y);I'_;;_P!'/79UQGPD_P"26Z1_VV_]'/79U=3XV3#X4%%%%04%%%%
M!1110 4444 %%%% !1110!@>./\ D3+[_MG_ .C%KR"O7_''_(F7W_;/_P!&
M+7D%?,9O_'7I^K/N.'O]UE_B?Y(****\<^A"O?J\!KWZOH,F^W\OU/D^(_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNU4@-.W/W.1TR3V!J[>>+=+M+G0K=9'N9=>DVV*P -YBB,R-)R1\@7DGW'%
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MZ***@L**** "BBB@ HHHH *XSXC_ /,J?]C)9_\ L]=G7&?$?_F5/^QDL_\
MV>KI_$B)_"=G1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:X2:S29GBA^SPF:9I/)BSG8FX\#@>_ YXHYDUJ'*TS8HHHK,L**** "BBB@
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M*/\ A;?@C_H-_P#DI-_\179T5-X=OQ_X!7O=_P"OO.,_X6WX(_Z#?_DI-_\
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M%%% !1110 4444 %%%% !1110 5QGB;_ )*GX'_[?_\ T0*[.N,\3?\ )4_
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MWC;KD1((LX7!VMDL0<# '')%-/BJ&;P_INHZ? UQ+JC1I;6S/L)9N6!.#@*
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M7([G2%%%%(84444 %%%% !1110!B^,O^1$U[_L&W'_HIJ/!O_(B:#_V#;?\
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M , 8O_B:/^$-\,?]"YI/_@#%_P#$T>YYA[X?\)EX8_Z&/2?_  .B_P#BJ/\
MA,O#'_0QZ3_X'1?_ !5'_"&^&/\ H7-)_P# &+_XFC_A#?#'_0N:3_X Q?\
MQ-'N>8>^'_"9>&/^ACTG_P #HO\ XJC_ (3+PQ_T,>D_^!T7_P 51_PAOAC_
M *%S2?\ P!B_^)H_X0WPQ_T+FD_^ ,7_ ,31[GF'OA_PF7AC_H8])_\  Z+_
M .*H_P"$R\,?]#'I/_@=%_\ %4?\(;X8_P"A<TG_ , 8O_B:/^$-\,?]"YI/
M_@#%_P#$T>YYA[X?\)EX8_Z&/2?_  .B_P#BJ/\ A,O#'_0QZ3_X'1?_ !5'
M_"&^&/\ H7-)_P# &+_XFC_A#?#'_0N:3_X Q?\ Q-'N>8>^'_"9>&/^ACTG
M_P #HO\ XJC_ (3+PQ_T,>D_^!T7_P 51_PAOAC_ *%S2?\ P!B_^)H_X0WP
MQ_T+FD_^ ,7_ ,31[GF'OA_PF7AC_H8])_\  Z+_ .*H_P"$R\,?]#'I/_@=
M%_\ %4?\(;X8_P"A<TG_ , 8O_B:/^$-\,?]"YI/_@#%_P#$T>YYA[X?\)EX
M8_Z&/2?_  .B_P#BJ/\ A,O#'_0QZ3_X'1?_ !5'_"&^&/\ H7-)_P# &+_X
MFC_A#?#'_0N:3_X Q?\ Q-'N>8>^'_"9>&/^ACTG_P #HO\ XJC_ (3+PQ_T
M,>D_^!T7_P 51_PAOAC_ *%S2?\ P!B_^)H_X0WPQ_T+FD_^ ,7_ ,31[GF'
MOA_PF7AC_H8])_\  Z+_ .*H_P"$R\,?]#'I/_@=%_\ %4?\(;X8_P"A<TG_
M , 8O_B:/^$-\,?]"YI/_@#%_P#$T>YYA[X?\)EX8_Z&/2?_  .B_P#BJ/\
MA,O#'_0QZ3_X'1?_ !5'_"&^&/\ H7-)_P# &+_XFC_A#?#'_0N:3_X Q?\
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MGAVY\%ZU!;Z_I<LLNGSI'&EY&S.QC8   \DGM6MX-_Y$30?^P;;_ /HI:/\
MA#?#'_0N:3_X Q?_ !-:\,,5M!'!;QI%%$H2.-%"JB@8  '0 =J&X\MD"3O=
MCZ***@L*Q?&7_(B:]_V#;C_T4U;5,FABN8)(+B-)8I5*21NH974C!!!Z@CM3
M3L[B>JL<EX3\6>';;P7HL%QK^EQ2Q:? DD;WD:LC"-0003P0>U:W_"9>&/\
MH8])_P# Z+_XJC_A#?#'_0N:3_X Q?\ Q-'_  AOAC_H7-)_\ 8O_B:MN#=]
M2$II6#_A,O#'_0QZ3_X'1?\ Q5'_  F7AC_H8])_\#HO_BJ/^$-\,?\ 0N:3
M_P" ,7_Q-'_"&^&/^A<TG_P!B_\ B:7N>8_?#_A,O#'_ $,>D_\ @=%_\51_
MPF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\
MXFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0
MN:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_
M\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P
M8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?
M#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\
M@=%_\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG
M_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC
M_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>
MD_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^
MA<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_
M (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_
M $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&
M^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\
M#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,
MO#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-
M'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8
M])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?
M#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,
M7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7A
MC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW
M/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_
M . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_
MPF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\
MXFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0
MN:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_
M\51_PF7AC_H8])_\#HO_ (JC_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P
M8O\ XFCW/,/?#_A,O#'_ $,>D_\ @=%_\51_PF7AC_H8])_\#HO_ (JC_A#?
M#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\ XFCW/,/?#_A,O#'_ $,>D_\
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MP]\/^$R\,?\ 0QZ3_P"!T7_Q5'_"9>&/^ACTG_P.B_\ BJ/^$-\,?]"YI/\
MX Q?_$T?\(;X8_Z%S2?_  !B_P#B:/<\P]\/^$R\,?\ 0QZ3_P"!T7_Q5'_"
M9>&/^ACTG_P.B_\ BJ/^$-\,?]"YI/\ X Q?_$T?\(;X8_Z%S2?_  !B_P#B
M:/<\P]\/^$R\,?\ 0QZ3_P"!T7_Q5'_"9>&/^ACTG_P.B_\ BJ/^$-\,?]"Y
MI/\ X Q?_$T?\(;X8_Z%S2?_  !B_P#B:/<\P]\/^$R\,?\ 0QZ3_P"!T7_Q
M5'_"9>&/^ACTG_P.B_\ BJ/^$-\,?]"YI/\ X Q?_$T?\(;X8_Z%S2?_  !B
M_P#B:/<\P]\/^$R\,?\ 0QZ3_P"!T7_Q5'_"9>&/^ACTG_P.B_\ BJ/^$-\,
M?]"YI/\ X Q?_$T?\(;X8_Z%S2?_  !B_P#B:/<\P]\/^$R\,?\ 0QZ3_P"!
MT7_Q5'_"9>&/^ACTG_P.B_\ BJ/^$-\,?]"YI/\ X Q?_$T?\(;X8_Z%S2?_
M  !B_P#B:/<\P]\/^$R\,?\ 0QZ3_P"!T7_Q5'_"9>&/^ACTG_P.B_\ BJ/^
M$-\,?]"YI/\ X Q?_$T?\(;X8_Z%S2?_  !B_P#B:/<\P]\/^$R\,?\ 0QZ3
M_P"!T7_Q5'_"9>&/^ACTG_P.B_\ BJ/^$-\,?]"YI/\ X Q?_$T?\(;X8_Z%
MS2?_  !B_P#B:/<\P]\/^$R\,?\ 0QZ3_P"!T7_Q5'_"9>&/^ACTG_P.B_\
MBJ/^$-\,?]"YI/\ X Q?_$T?\(;X8_Z%S2?_  !B_P#B:/<\P]\/^$R\,?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0[;I,G+$]&)SD$;1S7HM%-U+H2A8\XU ^%U\;^)F\7"U:/R+?REN^C?NCNV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img119790510_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<GD@0F5T
M:"!3871W:6-Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Q
M,@  DI(  @    ,Q,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MN^\)?#71_!NK2ZAIES?2RR0& K<2(R[2RMGA1SE17-_'I&/A;37"G:MY@G'
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MH]G?RSQ1Q:=;S@P,%)981@'(/'-,^,O_ "36Z_Z[1?\ H8K:\/\ _),-,_[
M\7_HD4TVH)KN+>;]#R_X1> ],UVQ3Q!=SW:7>GZD/*2)U$;;!&XW J3U/.".
M*T?$6L_\)IXWO]#N_$D.@:'IC>5+OG6)[F0'! R1G!!'<# XR:U?@1_R(MY_
MV$G_ /145<GIVA>&[7XI:YH_C:V4I<3&6RFFG>)0&8L!E6 ^8,.O=<5K>\Y7
MZ&=K15NH_5=,T?P' FN>!/&,=S-!(GFV+7L4AG4G!X3&>W&.F3D8KVVPNTU#
M3;:\B!"7$2RJ#V# $?SKB;SX<_#C3XHY+ZRM[=)" ADOY5WDG Q\_/6M#Q+\
M-=%\41V$=Y+>6T>GP^3 EM(H 7C .Y6)Z"LY2C*US2*E&]CKJQO&/_(BZ]_V
M#;C_ -%-67X1^'&D>#-1FO=+N;V62:+RF%PZ, ,@\;5'/%:GC'_D1=>_[!MQ
M_P"BFK/12T+UY=3G/@U_R36U_P"NTO\ Z&:L_%O_ ));J_\ VQ_]')5;X-?\
MDUM?^NTO_H9JS\6_^26ZO_VQ_P#1R5;_ (OS(_Y=_(Y/P[\/KWQIX5TZZ\4Z
MW=+:"V1+*RM"%6.-5"J6R""3C)X_'L)_AF]_X=\?ZUX-NKQ[BUMHC-!YAQC!
M7& >F5<$@>E=M\/_ /DGFB?]>:?RKC--_P"3E=7_ .O-?_1,55S.7,F3RI<K
M15^(#ZG_ ,+HTB'0IE@OKG31!',_2,,\H+?@,FNG\/> --\%7D_B"?4KZ]N4
MMI/M$MPP*D<,6 QG.%/4GK6%XK_Y.$\,_P#7FO\ Z%-7HVNV+ZGX=U*PCX>Z
MM)85Y[LA4?SI2DTHH<4FVSQRS-E\1Y9]4\:>+H=,L_-9;73%O(XV11W(8X'U
MP2?RJYI$]KX$\<:19>'?$L>LZ/JLOV>6V%PDK0,2 K?*<#EAS@9P:H_#/P]X
M,URRFTWQ)8J-<MYV1DEN9(VD7/& & R#D$#GI7?6W@+P#I?B"S2WLX8M4CD$
MUO%]ME+[D^8-M+\@8SR,5I*44W$B,6TF6_&'AC6?$US;6]GKTFF:7L8744*_
MO)#GC!&.,9!R<>QKS+Q=X3TWP';IJ_A;Q/(-2@E426\ERAD?)Y("X/7J"#QF
MMWQK>7GB7XGP^$)]6?2=+6$,Y1MIG8KNQU&>P Z<'@UD?$#P;X*\'^&)X;66
M236I-@MUEG+./F4LQ5< #;GDCOQ2IW5DWN.=G=H[OQ'I-GX^^'=I?WTL\(%H
M+Y5MG &\QYVG(.0#V]JX#X:?#71_%?AS^U=1N;Z.>.Z:,+!(@7"A2."I/?UK
MT;PRI?X.V:J"6;2B !W.PU@_ ^]M5\"W437$:R0WCM(K, 54JN"?;CK4J3C!
MV[C:3DKDGQ)\3W7]O6'A33=5AT?[6GFWE_+*(Q%'S@!CC!.T]"">!WKF[OP3
MX3T^R>^T+Q_&FKPH9$D.H0XD<<@?*01G'J:F^)&FZ=9_%C3-0\36YGT2^B$<
MIW,H1@"O52#QE&^F:ZL?#CX<M8"^%E;_ &0C/G_VA+LQ_O>9BJ348H33E)C=
M/\13>*/@CJ6H7?\ Q]#3;J*<@8#,L;#=^(P?J37(^!?!=]XW\(VK:WK=S!HU
MN6BMK*T(4MAB2S$@C.2>H/X5WUYIFC:5\*=8B\-HBZ?+IMS-&4E:0-NB;D%B
M35+X-?\ )-;7_KM+_P"AFIYK1;CW*M>23[',^%[.[\ _&"+PS%?2SZ7J$!=%
MF./X68''3=N0KD=<U=^-7_'YX6_Z_'_G'1XK_P"3A/#/_7FO_H4U'QJ_X_/"
MW_7X_P#..J6LXOR)>D6O,V?C+_R36Z_Z[1?^ABL'1_AM=>,M L]2\7:[=OYU
MLCVEM:L D,94%<@@@G&,X ^IK>^,O_)-;K_KM%_Z&*Z/P=_R(N@_]@VW_P#1
M2U"DXT[KN6XISU."^%<^H:-XNUWPA>7;74%D#)"7)^7# < ] 0RG'K^L?BE-
M1\<?%27PC_:,FGZ996XED$1P9LJK$XSR?G ]@"<5+X4_Y.$\3?\ 7FW_ *%#
M5;QI;W&M_%ZVL?#D\6D:M:VF][^20J9LCA !UX..^03Z5?V[^1'V;>9SWQ!^
M&FE^#+>QU&"\NI[&6Y6">&1E\T @ME6"XZ*>H].M>S^%_#-GX2T4:9ILL\L(
MD:3=.P+9/7H .WI7$V_PW\1Z[K5K>?$#7H;^"T<.EK;+A7/'!^50 <<X&3ZU
MZ=45)MI*]RX1LV[6.2^*7_),M8_ZYI_Z,6N&\)?&#0= \(V&EW5GJ,EQ:Q;&
M,<<>PG)/!+@]_2NY^*7_ "3+6/\ KFG_ *,6HO!.FVVL?"/3M/ODWV]S9F-Q
MWP2>1[CJ*(N*I^]W"5^?3L<5!<:I\5_'6DZ@FFR6>AZ5()!)*3A_F#$9Z$G:
MHP.@'6M+XF?\E/\ !'_7Y'_Z.2G_  RU2Y\.:]?^!-;?]Y;NTEB[9PZ]2![$
M?,/JU,^)G_)3_!'_ %^1_P#HY*O[=NEB/L7ZEOXR:KJ%E8:196EW)86=_<-'
M=W29&Q1MP"1SC!8X[[:K67PDM;=8-2\(>*[R*YW M<K(LB2#/.-N.V>"2#WK
MMO$.I>&O,AT3Q+-:9O@3'!<_=;'?)X4^AXYZ5YSXU\*V7@#3_P#A(/"&LSZ9
M/YB[;/SMZ3@GH >2 #GG(P*F#=E%:?J5)*[;U.A^-(*_#@@L6(N8@6/4]>>*
MB\2^,+C3/#VC^'_#G[[7]1M8DB53S I0?.?0]<?B>U5OBA>R:E\&K&^N$$<M
MU]FF=!_"S+DC\S6#)\.=3M/!,7BJ&\EE\1Q%+T%6R%B"\(!W(&#Z<8%.*7*N
M;N*3?,['H/AKPHG@?PC="R7[7JC0M--+U,\H4D*.^,\#\^]>;>#?"=C\1K>X
MU'Q'XCNY-6,K 6Z2J'C Z'# G'TP.,5ZGX<\::?K?@P:_-*EO'%&?M:D\0NH
M^8?U'J"*P[[P7X)\;6[:QI<T<$K#>;RPEV;3ZNO0'UR ?>IC)J_-OW&XIVL;
M_@[P_J'AO2Y;+4=8EU11*3;M*.8X\<+SD_KCTK;NKF.RLYKJ<[8H(VD<^B@9
M/\J\[^%.NZC=WVMZ+>W[:K;:9*%M[XG)=<L,9YR#MR.3WZUW.OV<FH^&]2LH
M?]9<VDL2<XY9"!_.HFFIV9<7>.AY'H>A:I\7KZ[UG7]1N+71XYC'!:P-Z8.
M#D# (RQ!R?I67\0_!L_A!=*AM]7N+S2Y;D^5;W)RT+C&<$<8(] .G2NO^"6M
M6?\ PCD^B32K#?V]R[^1(=K,IQR >N""#Z<>M9WQKUC3[JXT;3K:[CFNH+@O
M+'&V[RP< 9QT/MUKH4I*IR]#%I<G-U.A^-?_ "3M_P#KZB_K76^&/^11TC_K
MQA_]%BN4^-,;/\.96520ES$S$=AG&?S(K<\-:YIB?#_3-0DOH$M8;.-9)6<
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M*QR>F,,.N?I7J^@Z9)HWPXM;"X!$T.GXD!_A8J2P_ DBN5^!'_(BWG_82?\
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M1/Y\"PLH5FW(V&R#D90=,=ZW**$VM4#294U33+36=,GT_481-;7"[9$/?O\
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M:T]L^QF';.00<>N*TA.SU(E&ZT.&\2_"GPGX<T:XO3KU[9W$49>'SYHSN;'
M"A03D\<5V'PFO=2O_A_:S:L\DKB1UADE)+/&#P23UYR/H*I:?\%?"=C<++,+
MV^"G(CN9AM_)%7-=]%#';PI%!&L42*%1$4!5 Z  =!3G-.-KW%&+3OL4=?T2
MV\1:%<Z5>O+'!<J [0D!AA@>"01V]*=H>D6^@:):Z79O(\%JFQ&E(+$9SR0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU-SKNO.LG2;6G-NKK2WD<OIL'COQ-X1OO&*>*[FW: R216<;,J2*G+< A1W
M&#G':M3_ (3[4O$'P,UB^:YDMM6L)887N+=C&S RQX8%<8)!(./?UK+TV?QW
MX9\(WW@Y/"ES<-.9(XKR-69(U?AN0"I[D'(QGO6I_P (#J7A_P"!FL6+6TES
MJU_+#,]O;J9&4"6/"@+G) !)Q[^E0N:VE]G?U.NK['G7M.7^)'DM;X;J][=+
M=^I@H_C74?ABWBE_%EW#!8D1Q6\<CAY5#A2SN""3D]\Y [5-]I\=:_\ #F7Q
M5+XGFM8+!=D<%NQC:<*=K.[*1SSWSG':M[3M%U5/V=KS37TV\6_9FVVIMV$I
M_? _<QGISTJ71=&U.+]GN]TZ73KM+YEEVVK0,)3F3(PF,]/:A1?GM^(I8BFK
MM*.E7E6B^'K_ ,.9VH^,-9U#X"0:H;^X@U".\6W>Y@D,;N 3R2N.HQGUQ6=+
M#XZNOAQ#XQ_X2VY5((UV6D;LI,:MLW,0<,V1DY!SZ]J9?:?>Z9^SS]GU*TGL
MYQJ8;RKB)HVP3P<$9J*TU3QA??"^T\+:;X9GGMKI,1ZA""RM&7+$' VJ<Y!)
M(^E2VV];[?B;0IQC%NDHV]H[WM\/6U_T+_BWQ-/XK^ ]E?WN#=IJ*PSLHP&9
M5;YL>X(/UJWK>I7VE_L]Z!<:9>7%G,9(U,EO*T;8_><9!!QQ5W6?AUJ-E\$X
M=%LX_M6I17"WDT47.]CD%5]< CZ[?PK*U.RUS5/@38Z8?#^HPWMC?+%Y!MW,
MDB!6/F!=N0,MCZBJ?,F[[V,*<L/*,%3:Y55?W?Y%_5_B#J7ASX0^'Y+>=Y=5
MU.)@+J=O,90I^9N<Y;YE S6MX4\&>,H[K3-8U3QG>2))MFN;%F9UVD9"#<2O
ML?E&.<&L?6O &J>(?A#X>2VMWCU32XF/V29=CLK'YEP<8;Y5/-:GACQGXVDF
MTO2;[P7=*(BD5U>2*R!D QN&X!<]SR<]@*I?$N>_2QS5$OJ\OJO+?FGS7Y;V
MN[6OTMVZC?B"FI)X@<WGQ!3P]ICQJT$$6?.SW^5"&(R.N>^.U9'PO\3ZUXAN
M-<\+W.M37*FSE:TU-MQDB.0@<$X8_?# $@C':L[Q'X:UJQ^*M_J=]X5N/$MG
M<R,]NHW&/D#;N8 XV],-@<?0UI_"GP[KFD?$W5;C6-'DL$ELY/FC@*VX9I8V
MV(P^7 &< 'M[4KR=3Y^9O*%&& :<DWRIKX=_*VM^]]_O.1\%>'-5UWXA:MI]
MIXEO-.O($F:6_BW&2?;*JD-AP>20>2>E==XQUC5]/^-7A_3;?5[Y+5GLUEA2
MX=4ES)AMR@X.1US5--/\3?#_ .*>JZKIWAJZU>TO3*(_LZL5*2.''S*&VD$
M<CL?K5KQ;I.L:E\9?#NJP:/?-:AK)Y95MG*18DRP9@,#'?/2I2M&RWN;U*BJ
MXE3DTX.#MMO97\_O^18\6>)_$'B;XF)X-\-:D^EP1DI-<1DJQ8+N8Y'. .
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M'R1.,_X5S_U./BS_ ,&G_P!C1_PKG_J<?%G_ (-/_L:[.BCGD')$XS_A7/\
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MX5QNKPZ5)X;L;C0])OX_+VI>W]RV4>8C[B <8^5CZ_U]&^+6D75YX&\-7]M
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MJ);B10VUB-VT Y  7DG!_3GC=$U@_#/XE:P=:L+J2.?S(XO*49<%PRL,X!!
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M^P;;_P#HI:O[!/VC9HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<\5W]%<ZDTK&SC=W"BBBI*"BBB@ HHHH **** "BBB@#&\8_\B+KW_8-N/\
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M7;:ONFDK/3RW\SP6\LK]_A^GB"X6X%IKVKFZU<P AQ:[B%5L?P_>/I\RU#/
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M-O5M6M9:*R?FW9VL>6^)-!LO#WA/P[!JMVBW7D2WD]G?0W!M[B5\9W/$0PD
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MO$__ $"-)_\ !K+_ /(]>O"BZ2Y+WL?.5:WMI^TM:YLT5C?:O$__ $"-)_\
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M5S..5UIS=-27,EKO]U[6O\[>9ZUIVO:;JNH7]E87/FW&G2".Z3RV7RV.<#)
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M***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH QO&/\ R(NO?]@VX_\
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ME2.1VS1RQ>Z)CB:\7S1FT[6W>W;T%U_P?J/B3Q9ICWQTZ+0-+D$T$4:L9Y&
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M.3^]]K?EIZ'<T5F^'DNDT"S%]-#,_DH5:&$Q@+M& 06;)]\_@*TJHQ"BBB@
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MJM"N696( (!QZ].M %$^"[%K.^AEN[V22^N([J2X:1?,65-N'7Y<#E0<8QV
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MB./(AC(920N%SMX../PK>HH P-4T.]O/$$E_9W*6V=)GLHY 3OCE=E97 QC
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M%?\ ->?^Y:_]NJ[6HAU]3MQ?_+O_  H****LX@HHHH XSXC?\RK_ -C)9_\
ML]=G7&?$;_F5?^QDL_\ V>NSJW\*)7Q,****@H**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH \-^"G_ ".EW_V#W_\ 1D=>Y5X;\%/^1TN_^P>__HR.O<J
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MPZY-E(I_A?C\O_K5TX:5IV.3%QO"_8UZ***]$\H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*_YKS_W+7_M
MU7:UQ7_->?\ N6O_ &ZKM:B'7U.W%_\ +O\ PH****LX@HHHH XSXC?\RK_V
M,EG_ .SUV=<9\1O^95_[&2S_ /9Z[.K?PHE?$PHHHJ"@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **:DL<A81NK%3A@IS@^AIU !1110 8QT[]:*;'(DT8>)U=#T93D
M&G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\C>,_^1\U_P#[
M"=S_ .C6K*M+J:QO8+NU?RYX)%EC? .UE.0<'@\BM7QG_P CYK__ &$[G_T:
MU8M>++XF?KU!)T8I]E^1H#7=3%Z+H7LGF"[^V@9^3S\Y\S9]W/X>W2KVF^(/
M$$US<6EC_ISZA.9Y+1[..Y627DEQ$RL W7D <>U8-=#X#LCJ/CC3;1;NZLC*
M[#S[.7RY4^1C\K=O3Z&G%MNQ%>-*%*4W%:+MVU*T7BG5H1>JLMNT=^XDN(7L
MX7C9QG#!"I53R>5 JCIFIW>CZA'?:;-Y-S&&"OM#8#*5/!!'0D5T^E^&].U+
MPVFH'[?JE_()Y+I+"XC,MF 0$9H&!>4$D$L"H .,YYK-\#7\^G^.-)>V\L-)
M=Q1,7B23"LZ@XW [3CN,$>M.SNKLSYZ3A4Y(K3=;7MIK]W5;>10TS7=1T>.>
M*QF7R+@ 3030I-%)@Y!,;@J2".#C(K1_X2OQ!8.=XMXA,T=TD<NFP; 0@5)$
M1H\+\H&"H&:W+6[TFU\7>)1K,MA&DE](%-S:F9P!(^2G[IQWY7Y">,.N.<;Q
M?JT&L1Z1+;W%K(8K&.&6*&U\IXG50&W$(H8$],$@#/2GJEN9IQJU;.EH]VUY
M7[$9O_$ZVVI6<\$\L=P3>WB7-DLI0N,>=\ZDQDAOOC'4<]*J'Q-JY\0-K9N_
M^)BRE#-Y2<@Q^6?EQC[O'3]:[KQ#:/<ZMX@=+Z\MA;^'[64I;S;%F^2)=L@_
MB7#'BL^W\':!/JFE:-OU+[=J>EI>+<>;&(H9&@,FTILRRY!_B4@$#GK5.,KV
M3,:>)H<G-."U6METLF[^5CF+#Q5J^FVD%M;3PM%;2&2W%Q:Q3F!B028S(I*9
M(!^7'(SUJ,>)-4&EPZ>)T%O;R&2 ^1'YD#%@Q,<FW>GS '"D5T^G^"--33M)
M?6;GRY-3A\\S?VG:VZVD;$JC&.0[Y>A8XVCL"3FN4AO]0T#4+E-(U6>!E<Q-
M/93L@E /7*D9!ZBH?,MV=,)4*KE[.*;7YZ]=?/\ IEF^\6:QJ2G[7-;F1I%E
M:>.SACF+KT8RJ@<GWS4EYXSUV_@NXKF[CVWJA;HQVL4;3@$$%RJ@L01P3R,G
MGDYZSQC>#5OBM=Z)K^H:F^F/<(D,4,Y98)&10KB-@00"QR!@X)P>QY?Q;X?M
MO"]U!I+R22ZO"FZ_(8&%"WS(B?*"?E().2.<=JJ2DKZF5"="IR)TTFU=*U[+
MULMM/G8S]+U_4='AN(;&:/R+D 303P)-')@Y!*.I7(/0XR*L77B[7+VYN+BZ
MOC)+<6GV*5C$@W0Y#;.!QR!R.?>NTUC1--\2:YX7TRVCNK/?HT,SSO.LHC@5
M'<KM"+E^/O9 _P!FN7N=&TC4/#5_K'A\7MN--G2.>"]E64O'(2$=65%P<@@J
M0>H.>U#C):)CA6H5&I2A9NW1/=V5WYM%-/%FKK816;S6\\4,1@B-S9PS/'&<
MC8KNA8#D\ \=JKSZ_J-SHT.EW,L4MK;C;#OMXVDC&=V%D*[P,]@<5G45GS/N
M=JHTD[J*[[=0KZ>^$'_)*='_ .V__H^2OF&OI[X0?\DIT?\ [;_^CY*Z<+\;
M]#Y_B7_<X_XE^3.UHHHKT3X **** "BBB@ HJ.>>*UMWGN94AAC4L\CL%50.
MI)/2O&O'/QMPTFG^#<?W7U!U_P#1:G^9_ =ZSG4C!79VX/ U\9/EI+U?1'I?
MB7QIH?A.WWZQ>JDI&4MT^:5_HH_F<#WKQGQ1\;]:U0M!X?C&E6V?]9P\S#Z]
M%_#GWKS6YNI[VY>XO)I)YI#N>21BS,?4DU%7!4Q$I:+0^XP618;#VE4]^7GM
M]W^9+=7=Q?7#W%Y/)<3.<M)*Y9F^I-1445SGOI)*R"BBB@84444 %%%% !11
M10 4444 6M.U2^TB[6ZTN\FM)UZ20N5/TXZCVKU'PO\ '74+1D@\4VPOH<X-
MS H25?<K]UOTKR2BKC4E#9G'B<#A\4K5HW\^OWGU]H'B;2/$]E]IT2]CN4&-
MZCAXSZ,IY%:M?&VFZG?:/?)>:7=2VMQ']V2)MI^GN/;H:]O\"?&FWU)HM.\6
M>7:71PJ7H^6*0_[0_@/OT^E=U/$*6DM&?%YAD-7#IU*'O1_%?Y_UH>M44 AE
M!4Y!Y!'>BNH^:"BBB@ HHHH **** "BBB@##\21Y2"3L"1_*L"NE\1$?8$!Z
MF3C\C7-5YF(7[QGKX5WI(*KZA="QTVYNSR((FDQZX&:L5R_Q!O%M?"K1L3_I
M$J1D#NN<G]!6!VTH>TJ*'=GG<MRSPQMDR2%=S>K,3EOQYJ$EDD,D:,R-]\-\
MOXC-,N;7[/(!;7!"OC8N<Y![U#Y-V).<N.Q+]*L^N;=[(NW.H;KB'RP1%$00
MA&,>O'8^H!QFNP^%<A2QU*T)X2<2+]",9_\ ':\Z/FHS=""V"/[O^37:?#.4
MIK]Q'EL2VQ)SZAA_B:BQRXR">%DET_S(_B'<[_&5NO5;6!21[DEO\*Q5N-]@
M@8%Y(\[?IW'MZYY-6?&2R2^)+ZZ3YB)S'MSV4 5A6]PT<ZECRRD;/3H:=C3#
MQ2H0CULB\IE&Z3R_,=NA1_EQV'-7M)OSI_B+3[H;EVRA7R,94\']":RV\B5V
MD;,;8&,9'KUQUJL\PE#;"RDJ %)/RG\?K39JX\R<)=;GT$>#16?H5W]OT"QN
M<[C)"NXG^\!@_J#6A4GQ\DXNS"NE\/1E;%V/\3\?E7-5U>AD'28P.H)S^==&
M&_B''BW^[-"BBBO2/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#BO\ FO/_ '+7_MU7:UQ7_->?^Y:_]NJ[
M6HAU]3MQ?_+O_"@HHHJSB"BBB@#C/B-_S*O_ &,EG_[/79UQGQ&_YE7_ +&2
MS_\ 9Z[.K?PHE?$PHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BL3Q9XEC\)Z(=4N;2>Z@614D$&,H#P&.>V<#\17
M*0?'#PK*/WL>H0'_ &X%/_H+&K4)25TB7**=FST:H+V1H=/N)(SATB9E..A
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MPHT96G%>GY_\%=N@4445)TA7T]\(/^24Z/\ ]M__ $?)7S#7T]\(/^24Z/\
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M5HID$\5S;QSV\BR12H'1U.0RD9!!],4^O0/@]@HHHH **** "BBB@# \2/\
MO(4]%)_/_P#56'6SXC_X^XO]S^IK&KRJW\1GLX?^$@KB_B%^\BLXCR-LC?\
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MO_Q-'_"&>*/^A;U?_P  )?\ XFHY9=CN5:A%64E]Z,6BMK_A#/%'_0MZO_X
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M^2=9-D)9I=J':H7;OW;QC:!G/&.U:J^*=&;39[\WH2"V?RYA)&Z2(_\ =,;
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M<13?: 9"47)8Q@<+VSN)R1D#-1-J;0>+4LAI]N&N5PTR3 S[%5F#L@7B/=E
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M,-R DR#=M/&X#(#=1DX(R<]/I>F6VCZ;%8V2L(8LXWL69B268DGJ223^-6Z
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M+KW_ &#;C_T4U'@[_D1=!_[!MO\ ^BEJ_L$_:-FBBBH*"BBB@ HHHH ****
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M:[;:;>0_0/%_]A^%-<T7[#Y_]K(J>=YVWRL _P .T[NOJ*Z&R^+0AM].GO\
MP];WNM:7;M!::@]PRA05VY:,#YCCKR.^,9KGKSX=>+-/T1M6O-&FBLTC$CL7
M0LBGN4!W#'?(X[XKKY_#'A?3KKP5+>V$ M-1TP3Z@UQ?O"K-L0E\DYR,DA%Q
MDX%$?:+R)Q#P$W>W.Y-_"^JCJMUNE:VSZG*:QXXFUKP3::%=6N9X;V2\DO#*
M/WK.SD_(%&.9/7MTKEJ[#Q-#X6C\*V<FBP1Q:A)>2D;+MIF>V!.QI%SB-N0
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MRN#<VE\ENTR').595YS\[^@Z<\8.KX/UKPEX9D\1Z?:>)KJ""^LXH;?46LY
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M$XP.1N/RD-T8@ <E\3-$T#3/$>FPZ>L>ESW$2OJ=I%(9TLG8@GIZ9/RC' !
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MXSXC?\RK_P!C)9_^SUV=6_A1*^)A1114%!1110 4444 %%%% !1110 4444
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M9C#PR+)Y4I(501R,@D<&O+-)GTS6M+\9^*_%BPW=RFZ"UBG.?*)5MBJ#T.<
M$<C!/K5*[SI/[/UC!N"R:UJ1E*YQE5)&3_W[3\Q5QPZ35^Z_S(EB&T[=F>M>
M!/$@U'PSIB:UJ]K/K5S$9GA+QI*5))7]VN/X<=JZ"_UC3=*"G5-1M+(/]W[1
M.L>[Z;B,UY!XAT'2[+QYX)T?PK%!'?6[K+=RVR@DJ&1@[D=3A7//8CM3-"_L
MO7IO&WB'QB(;B6V+0Q1W!!$"_-@(#T/  [Y'J:ET8OW^G_!*5:2]SK_P#V2X
MU2PM+ 7UU?6T%H0"+B295C.>GS$XYIDVLZ7;_9//U*TB^VX^R[YU'GYQC9D_
M-]X=,]1ZUX#>RWT7P2T33+HLO]H:HS0>8>D('IZ;FS_^NNQU=;;5/C?X:T:Q
MD5[?1;?<^&SL9 6VG'?Y4_.AT$NO?\!JNWT[?B=3=_$K1K7QM#H'VBU,9C9I
M[YKM5C@<;OW9SP6R ,9XS78UX_X&TG2=;^*WBVYN-/LI8+6;RH89(4*AMY&]
M5(Z_NR<CU]Z]@K*K&,6DC2E*4DVSBO\ FO/_ '+7_MU7:UQ7_->?^Y:_]NJ[
M6N:'7U/3Q?\ R[_PH****LX@HHHH XSXC?\ ,J_]C)9_^SUV=<9\1O\ F5?^
MQDL__9Z[.K?PHE?$PHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%(HN6D'F>5AMS8\T<@9_A_"J4%)77<3DXNWD>K>$O%MCXRTF74-,BN(HHYS
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MQ)/3WI^C>']+T#2CINDVBP699F,19G!)ZY+$DU3Q"ULNWW(E8=Z7??[V</\
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M+3.%QN(49P,XYXH LT5G3ZA=F+3Y=-TYKN*ZD3S6,RQF"-ADN0?O8_NBM&@
MHHHH ***I1W5\VLS6TFG[+)(@T=YYRGS'[KLZC'K0!=HHHH **** "BO)/A3
MXJUG6_%NH0:G?2W$,ELTXC<Y",'4#;Z##'@5ZW0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-XQ_Y
M$77O^P;<?^BFH\'?\B+H/_8-M_\ T4M'C'_D1=>_[!MQ_P"BFH\'?\B+H/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD(3SMY[C^= %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH QO&/_ "(NO?\ 8-N/_134>#O^1%T'_L&V
M_P#Z*6CQC_R(NO?]@VX_]%-1X._Y$70?^P;;_P#HI:O[!/VC9HHHJ"@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH XKXO_P#)*=8_[8?^CXZ[6N*^+_\
MR2G6/^V'_H^.NUJ%\;]%^IVS_P!SA_BE^4 HHHJSB"BBB@ HJ*YN8K.TFN;E
MMD,*-)(V"=J@9)P.>@JK!KFG7-_!90W(:YGM1=QQ[2"T1. W(]3TZ^U '/\
MC.YL3J>G66HPZ8B.DDBW>L'=;1X*@@1DA7D(/&2N!G!Y(/.:#;IJ</A.SU,&
MYACN;^'RY$9 43(5"AYV@ #:V>!@UZE45W=0V-G-=W3B.""-I)'(SM51DGCV
M% 'FTZ1VNF7]F4,.B0>)O+NXXLK'%;&)6*D#I'O8$]N?2MGPJNE#QWK1T!;<
M6)L[8H;4#R2=TF=F/EQG.=O&<]\UV%I=0WUG#=VKB2">-9(W QN5AD'GV-2T
M >9:S)I)B\6GQ(8?[:4R_8/M'^M$/E_NO([XSNSM[[MU7M+O[31_%T5QJ=Q'
M;17&@VRPF0X\UE8Y51U9N1\HR>1Q7;ZA91ZEIMU8SEEBN87A<H<, P(.,]^:
M?:VZ6EG#;1EBD,:QJ6ZD 8&: /+]/N;$^&_#EGJ4&F1JUE+(MUK"F2%<28*)
M"2 \AX[@@$XSG%6_#-PV?!#7<Q)"7]NKRY4G#!47YN<X7 !YXKT&;4+6WU"V
MLI9=MQ=!VA3:3N" %N<8&,CK5F@#RJTM-*_L3P7>ZW;6C6:S7$5Q-=1J44%9
M=@8L,8W8QGC-:=Y:"'59/"UFJG3]<N([R,QCY$@^]<*".,$HN/\ KK7H59=O
MIUK!XAENYKZ2YOY(2L<<SH###OR515 ^7=MR3D\+DT 97BSR[?4_"[MMBACU
M0+N/"KF)PH]!DX KEM/@$UX6UC6M+TS7DU$[FGM2+TGS/E5',HW1LA"@!=FT
MD8ZUZE10!Y/K-_;3ZDVH62:?8ZA;ZO&A0JTNH-B;8SN^?W<94@!2&7! !Y H
MUW^RI-#\6?VV(3X@$T_D+-S.(1S'Y6?FV;.25XQNSQFO6** /-==_P"/7QO_
M -@>S_\ 09:TYM.MM+\5Z.=,A-M)>Z==BYD@&9)RHC(9CU=\L3N.22>37;U'
M<01W5K+;SKNBE0HX!(R",'D<B@#S'P?::/>:AH-S<2^'XKNVA8LL<ZO=W<S
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MY$77O^P;<?\ HIJ/!W_(BZ#_ -@VW_\ 12T>,?\ D1=>_P"P;<?^BFH\'?\
M(BZ#_P!@VW_]%+5_8)^T;-%%%04%%%% !1110 4444 %%%% !1110 4444 %
M%%% '%?%_P#Y)3K'_;#_ -'QUVM<5\7_ /DE.L?]L/\ T?'7:U"^-^B_4[9_
M[G#_ !2_* 5'/YWV:3[+L\[8?+\S.W=CC..<9J2HYX([JVDM[A \4J%'4]&4
MC!'Y59Q'!GQ/J>AZ5=R:I=73ZM%9JYL+^WB5 Y9%,L<D0 :,%^1DM@<E:T];
MGUGPUHKSC6'OY;AX;9'NK>-5@D=PID^0+\O/W3GD#GKG7M/"^D6AD*VSS^;#
M]G87<\EP/*_N#S&;"^PX.!Z4R'PEHT-O+ ;>6>&:$6[QW-U+.OECD* [$#'M
MC% &!K=YJ&F27^C7=_)J4-YH]S.LDT:+)"R+@_<505.[C(R".II(_$%YI-O"
M(_WMO:^&1>B#:/FD7 !SUQCWKI;7PWI=HMP([=Y#<Q>3*]Q/),[1XQLW.Q(7
MD\ XI]KH&FV<D;PVY+16OV13)*\G[G.=AW$Y&?7GMTH Y^/4-7TO^P;JZU3^
MT5U:589;=XD14+H75HBJ[L+C!W%L@]JIP:SK-C:7::WJ%W;ZL+"XF6VGM8C"
M[*NX/!(@Y"]U<EL'D#K72VGA31K&17M[5OD1XXE>>1UA5OO"-68B//3Y0..*
M2'PGH\"E5MY74P/;JLUU+((XV #*@9CL!  ^7' % &#?ZIK:6EE?SW=Y:Z8V
MFQRR7EE;Q3;)B,LTJ%2VP#'W!ZY([;FNZHMMH=O-'J#PFY=%BDM+?SI)R06"
MQ*<@%@."P( SGU#I_">CW Q)!,JF%8'2.[FC62-1@*X5@'&"1AL]3ZFKE_I%
MEJ=I%;7<)\N%U>+RI&B:-EZ%60@K@''!H XF3Q+K]O9ZA;--+%=6NJ6D$<E[
M%"TACE*DK(L1V'J>5(.#V-7-4U_4_#%QK4,EXVIBWTZ*\MWNT12CM(T>&\M5
M!7(#= >O/>MZ/PEHL4<J+9L?.GCN)"T\C,\D9RK%BV2<C\>^:N3Z/I]U=SW-
MS;)++<6XM9=Y)5X@2=I7IU8]N] ',R65[9>//#@OM5FU%F@NN988TVL%3.W8
MHX/H<D8ZU=NKS4=3\8W&CVFH2:9!9VB3L\,<;23,Y('WU8;1M[#.3UJ_8^%M
M)TZ[@NK:"4SVZ&.&2:ZEE,:$8VC>QP/;I4VHZ#IVJW$=Q=Q2">-#&LT$\D+[
M3U4LC E?8G% '*0ZYXAU+3;*Z4W*VL,L]O?3Z5#&\K.C[%=4D#90@$D*&;/2
MG:9YFI^.]/O(-=FN8I-&6;S888T68>8H(VE"5#$9(SN!R 1TKHY?"VD21P(E
MO);K;Q>3']DN9(,1YR5_=L,C//-//AO2M]FT5NUNUE'Y,#6\SPE8\@[#L8;E
MRH.&R* .7T+6_$VLQV&J06UZT-U<CS87%JMM'!NVM@[O.W*.>>I!&W%!U_6/
M^$2E\7"_(C2=F&E^2GE>4)#'L+8W^9QG.[&[C;CBNFC\,Z7#>FYMXIH&:43-
M'#=2QQ,XQ\QB5@A/ )XY/)I#X6T<Z@;PVAWM/]H,?G/Y)EQCS#%G9N[[MN<\
M]>: ,%[[6KP^)YHM9:T329V%LB6\14@1*^)"RDE<],;2,MDGC:[2]6U7Q7=R
M1P7[Z.MOI]M,1!"CM)+.F_)\Q6PBXP ,$G/-6H/!5M/J6L7&L+Y\=]=B9(XK
MF559 B@+(@(5N5/!R.?<UJZAX<TO4Y5ENH'6183!OMYY(&:,_P !,;*67V.0
M.?6@#F+'Q#J_B"\T&**]&GK?6MTUR;>%6RT4BJ&3>#C//7<,'N<$._M;6I]%
MUO6XM5: :5--'%9R0Q[)!#U\T[=VY\'[I4#(XKK$T?3X[RUN8K5(I+.)H;?R
M\JL:-C*A1QCY1V[55N/"VCW5[+<SVA+S,KS1B9UBF93D%XPVQSP.6!Z"@# N
M-:U6/4EOM1NKO3-+G-NUK)';QS6^&"[DF./,4EB5#?*HXY]7-J?B&]TZ^;3W
MFE-OK4L$AMEB\Y+9>T8<;"V<?>R<9[UO3>%])GNWN)8)6,DHFDC^TR^5(X((
M9H]VQC\J]1V'I1+X9TJ4']Q+&QN'N=\-S)&XD<89@RL",CC .,4 <\]A+XJT
MN/R&LM0*.T0U&]@,%Y8N),G"!/OJ,=/+Y&>AKMZK:?IUKI=K]GL8_+CW,YW.
M79F8Y9F9B2Q)/4DFK- !7-^(UQ?(WK&/YFNDK"\21_ZB0>X-88A7ILZ<*[54
M<V/N-_U\C_T&HY/OS_\ ;,_K3_\ EFW_ %\C_P!!IDWWY_\ <0_^/&LE\4?\
M)L_@E_B+D:[Y54=2<5W(&!BN+LN;^#/_ #T7^==I1A=FPQCU2,+Q+]VW_P"!
M?TK!KH/$G^J@^K?TKGZPQ'\1G3AOX2"BB@=1FL#H.OTE=FEPCV)_6KE16T?E
M6L4?]U /TJ6O8BK12/!F[R;"BBBJ)"BBB@ HHHH **** "BBB@ K$\6>*[#P
M=HZZEJD<\D3S+"JP*I8L03T) Z*>]4/B%XP_X0WPX+JWB6:]N)!#;1MTW$9W
M'V _7%><>+;3Q-=>(O"^@>*=6@OS?W,=P\4=NJ&V^;:RY7AA@GD]P?QZ*5+F
M:<MCGJU>5-1W/;XG\R%'*,FY0=KC!7/8^].KS[1O%6IZC\5]?LI+W;H>E0$F
M+RTX<;026QNZ[SU[5SNE?$_6++X=W_B#5Y5O+FXOS:Z?"\:HJX7<2=H!(&3[
M\8[TO83>WE^(_;P6_G^!['3)IHK>%YKB1(HD&YW=@JJ/4D]*\D\*_$#5+SQS
MI>F_\)##K]O?H_VB.*P-O]E8*6^4E06''4]LUJ_&^\O;3P;"EI?>3%=3_9YK
M81!FG!&X?-U4#;VZY ^I[%J:@^H>VBX.:Z'HL%Q#=0)/:RQS1.,K)&P96'L1
MUJ2O+;W4M<^'OA[2?#EO?QZKJ^HR)!9*]LL:6B *N#M^^<GJ3SR>W-O2=?\
M$FC?%"V\+>(=3AU>*^M3/',ENL)B(5CC"]OD8<^H/'2CV+M=,/;*]FCT2::*
MWA>:XD2*)!N=W8*JCU)/2L[5O$6GZ1X;GUR63[190H'W6Q5]X) &TYP>3ZUQ
M7QOO+VT\&PI:7WDQ74_V>:V$09IP1N'S=5 V]NN0/KA^.=.U/PQ\)[70;[53
MJ$MW=0P01K;K$(HU7.SY<[L,HY/)R*=.BI*+;W8JE9Q<DELCU?1=6AUW1;74
M[6.6*&ZC$B), & /3(!(_6KU>46FI^*?"OQ!\.>%[G5+>^M+BU4-:PVJHL*
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M*:CP=_R(N@_]@VW_ /12U?V"?M&S1114%!1110 4444 %%%% !1110 4444
M%%%% !1110!Q7Q?_ .24ZQ_VP_\ 1\==K7%?%_\ Y)3K'_;#_P!'QUVM0OC?
MHOU.V?\ N</\4OR@%%%%6<04444 %%%% !1110 4444 %%%% !1110 4444
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M7%?\UY_[EK_VZKM:RAU]3OQ?_+O_  H****LX@HHHH XSXC?\RK_ -C)9_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH QO&/\ R(NO?]@VX_\ 134>#O\
MD1=!_P"P;;_^BEH\8_\ (BZ]_P!@VX_]%-1X._Y$70?^P;;_ /HI:O[!/VC9
MHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH XKXO_ /)*=8_[8?\
MH^.NUKBOB_\ \DIUC_MA_P"CXZ[6H7QOT7ZG;/\ W.'^*7Y0"BBBK.(****
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MFP'G1><0DK;!\SJ,*S9D'..H]JOZ+\.+_P .7Q31/%-U:Z2UR+@V'V96)/\
M=\PG."!@\<T7?PUED\8:CK=AXAN;!-239<010@L00,@2$\#*@\#/H:;G"[UT
MMIH2H3LM-;ZZG(:9K.HZMX5\>ZW<ZSJ4=NLI%EY-TP\HABP5<Y"@YC!QSC([
MTGAQ7\ _"4>*H+R]DO+U"D5D\N;5'=\+)L_O;5!R3[5VNE_#6VL/AU>>%);]
MY5NY#(]RD6PALJ0=N3TV+WYI+;X<R2>")O#.N:T^HVV%%I(MLL+6VWIC!.[G
MU[<53JT]5TO^ E2J:/K;\3C=#O\ Q4WB'0;B#_A+IWN+A!J?]HVI6S$;$;B@
M&0H )Y..@/'2O:JY;PSX7UO1+F$ZCXKN-3M8(3#%;-:I& .,9.26(QUZUU-<
M]:2D]#>C%Q6IQ7_->?\ N6O_ &ZKM:XK_FO/_<M?^W5=K7-#KZGIXO\ Y=_X
M4%%%%6<04444 <9\1O\ F5?^QDL__9Z[.N,^(W_,J_\ 8R6?_L]=G5OX42OB
M84445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_H^.NUJ%\;]%^IVS_W.'^*7Y0"BBBK.(**** "BBB@ HHHH **** "BBB@
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M'K6Q7JTFW!.1XM:,8S:CL%%%%:&04444 %%%% !1110 4444 %%%% !1110
M4444 %9^M:M_8NFM>?8+Z_VL%\BP@\V4Y[A<C@5H44UOJ)[:&?HFK?VUIHO/
M[/OM/RQ7R+^'RI..^W)XKAK8^*[[QQXEU+PJFB^0MQ'8LVI>:6S$@R%V=LN<
M_AZ5Z36/X9T'_A'M-FMWN3=S3W4MU-,4V[W=B>F3VP.O:M(R4;LSE%RLCSZQ
MU36++_A.O$FK_96U.QA2RB:S#>4C*IZ;^3@LI.?0UVWA#PQIVC^%X(4@CGEN
MH0]W/(H=KAV&6+$]02>GI3]*\)P6>B:IIVH3?;EU6YGGN6\O9N\WJ,9.,# S
M[5DV'@/6+,06<GC+4)='@8&.T6%4DVK]U#,#NV]L<<5I*49)I.QG&,HM-JXZ
M2T@'Q0T33+2)(+71]*EN8XD7"KYC"( ?@&_R:DU4_P!I?%C0[, ,FF6<]](/
M0OB-<^_4BK/B/PC<:MK5MK.C:S-HVIP0F#STA659(R=VUD; /.3^-3>&/"@T
M"6[O+S4)M4U2]*_:+R90I(7HJJ/NJ/3_  %3S1M>^MK%<LKVMI<R_BM<O'X+
M%E#"\\FHW<-LL48R[Y;<54>I"$?C5?PHES=^.=2;Q7%&-8M((GLX8VS%;P.O
M(C']X,"K-W[<5TNKZ -6US1KZ2XV1:7*\WD;,^:Y7:ISGC;R>AS[47F@>?XL
MT_7;>Y\B6VADMYH]F1<1-@A2<C&&&1UH4TH<OJ#@W/F]#G_!=I!K6O:[XEOD
M6>[&H26=MY@!-O%%@  ?PD]344$MIIOQ4\0WEDBI;VVCI+?B/A3,&9@3[[!_
M.K5YX&U&+6+V]\,^)KC14U!S+=6XMDF5G/5EW$;2?7K5B/P);VO@W4=$L+V6
M.XU)6^U:A,OF22LW#,W(SQD8SW^N:<HWO??3T)496M;;7U)/AU9O9^ =,,XQ
M-<QFZD/J96+Y_)A73UR>B>&O%&EW=I]L\9?;;"W 4V@TN*+>H& -X)(QQ^5=
M96-2SDW>YM3NHI6L<5_S7G_N6O\ VZKM:XK_ )KS_P!RU_[=5VM8PZ^IZ&+_
M .7?^%!1115G$%%%% '&?$;_ )E7_L9+/_V>NSKC/B-_S*O_ &,EG_[/79U;
M^%$KXF%%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@'_Y-S__ !=%Y]E]_P#P Y,'_/+_ ,!7_P F=K17%?\ "H/ W_0#_P#)N?\
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M@\#?] /_ ,FY_P#XNC_A4'@;_H!_^3<__P 71>?9??\ \ .3!_SR_P# 5_\
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M_P#DSM:;(BRQLCC*L"#7&?\ "H/ W_0#_P#)N?\ ^+H_X5!X&_Z ?_DW/_\
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M?\*@\#?] /\ \FY__BZ+S[+[_P#@!R8/^>7_ ("O_DSM:*XK_A4'@;_H!_\
MDW/_ /%T?\*@\#?] /\ \FY__BZ+S[+[_P#@!R8/^>7_ ("O_DSM:*XK_A4'
M@;_H!_\ DW/_ /%T?\*@\#?] /\ \FY__BZ+S[+[_P#@!R8/^>7_ ("O_DSM
M:*XK_A4'@;_H!_\ DW/_ /%T?\*@\#?] /\ \FY__BZ+S[+[_P#@!R8/^>7_
M ("O_DSM:*XK_A4'@;_H!_\ DW/_ /%T?\*@\#?] /\ \FY__BZ+S[+[_P#@
M!R8/^>7_ ("O_DSM:*XK_A4'@;_H!_\ DW/_ /%T?\*@\#?] /\ \FY__BZ+
MS[+[_P#@!R8/^>7_ ("O_DSM:*XK_A4'@;_H!_\ DW/_ /%T?\*@\#?] /\
M\FY__BZ+S[+[_P#@!R8/^>7_ ("O_DSM:*XK_A4'@;_H!_\ DW/_ /%T?\*@
M\#?] /\ \FY__BZ+S[+[_P#@!R8/^>7_ ("O_DSM:*XK_A4'@;_H!_\ DW/_
M /%T?\*@\#?] /\ \FY__BZ+S[+[_P#@!R8/^>7_ ("O_DSM:*XK_A4'@;_H
M!_\ DW/_ /%T?\*@\#?] /\ \FY__BZ+S[+[_P#@!R8/^>7_ ("O_DSM:*XK
M_A4'@;_H!_\ DW/_ /%T?\*@\#?] /\ \FY__BZ+S[+[_P#@!R8/^>7_ ("O
M_DSM:*XK_A4'@;_H!_\ DW/_ /%T?\*@\#?] /\ \FY__BZ+S[+[_P#@!R8/
M^>7_ ("O_DSM:*XK_A4'@;_H!_\ DW/_ /%T?\*@\#?] /\ \FY__BZ+S[+[
M_P#@!R8/^>7_ ("O_DSM:*XK_A4'@;_H!_\ DW/_ /%T?\*@\#?] /\ \FY_
M_BZ+S[+[_P#@!R8/^>7_ ("O_DP_YKS_ -RU_P"W5=K7/:!X$\-^%[][W0M.
M^RW$D1B9_/D?*$@D89B.JC\JZ&B":6I&*J4YRC[.]DDM5;]7^844459RA111
M0!QGQ&_YE7_L9+/_ -GKLZS->\.Z7XFL4L]<M?M5O'*)53S&3# $ Y4@]&-<
M_P#\*D\$?] 3_P FYO\ XNKO%I)D>\G='9T5QG_"I/!'_0$_\FYO_BZ/^%2>
M"/\ H"?^3<W_ ,71:'?\/^".\NW]?<=G17&?\*D\$?\ 0$_\FYO_ (NC_A4G
M@C_H"?\ DW-_\71:'?\ #_@A>7;^ON.SHKC/^%2>"/\ H"?^3<W_ ,71_P *
MD\$?] 3_ ,FYO_BZ+0[_ (?\$+R[?U]QV=%<9_PJ3P1_T!/_ ";F_P#BZ/\
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M ,71:'?\/^"%Y=OZ^X[.BN,_X5)X(_Z G_DW-_\ %T?\*D\$?] 3_P FYO\
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M'_!"\NW]?<=G17&?\*D\$?\ 0$_\FYO_ (NC_A4G@C_H"?\ DW-_\71:'?\
M#_@A>7;^ON.SHKC/^%2>"/\ H"?^3<W_ ,71_P *D\$?] 3_ ,FYO_BZ+0[_
M (?\$+R[?U]QV=%<9_PJ3P1_T!/_ ";F_P#BZ/\ A4G@C_H"?^3<W_Q=%H=_
MP_X(7EV_K[CLZ*XS_A4G@C_H"?\ DW-_\71_PJ3P1_T!/_)N;_XNBT._X?\
M!"\NW]?<=G17&?\ "I/!'_0$_P#)N;_XNC_A4G@C_H"?^3<W_P 71:'?\/\
M@A>7;^ON.SHKC/\ A4G@C_H"?^3<W_Q='_"I/!'_ $!/_)N;_P"+HM#O^'_!
M"\NW]?<=G17&?\*D\$?] 3_R;F_^+H_X5)X(_P"@)_Y-S?\ Q=%H=_P_X(7E
MV_K[CLZ*XS_A4G@C_H"?^3<W_P 71_PJ3P1_T!/_ ";F_P#BZ+0[_A_P0O+M
M_7W'9T5QG_"I/!'_ $!/_)N;_P"+H_X5)X(_Z G_ )-S?_%T6AW_  _X(7EV
M_K[C:\8_\B+KW_8-N/\ T4U'@[_D1=!_[!MO_P"BEK%_X5)X(_Z G_DW-_\
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MHKO9:Q@1HTP,.X;M_P V!L/WARM$GAK77LY)!=ZH+HV-RP4:HX'VG=^XXWX
MVD\?=/&[-'*NX<S['>TR2:*'9YTB1^8P1-S ;F/0#U/M7$7FF>*6UW5)$FNC
M')'/]F:&3$>#$1&G,X"L&P=PBSD?>P2:;?>&]45U 74[ZVM[NVN$0:DWFO\
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M"".HH>:.-XUDD5&E;9&&8 NV"<#U. 3] :XC[+XGAUS2[B1;E+:UBA^U2/=
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M5XU/ W T<J?47-Y'I%%>>:/8ZGJ^DR7&F7VHC;9S+;33WS&-KK>VUOEEDW(
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MS[)-JPPGYQE,@#VX+#C!QBM6UTBTLKZ:ZMO/1YBQ=/M,ABRQW,1&6V*2><@
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M:XC(L4D<>?W;.5_>K@$,,$\'/?!XZ5D:=JNHR^*+G3;XVOEI"956.)XV3Y@
M SG]Z,'EU4 '@\FM.PLGLVNB\[RB><RJI)VQ+@ (H).!\N<# R20!G%5(/#.
MF6TCR0I<J[J4!^VS'RU+!B$^?Y 2JY"XS@9J-"M2KXBU?4M,NHC;B&"R$3/+
M=3VTDR;@?N,8S^Z7&29&!4?AS%<^.M,M=0OK*6*X\ZRB>5U4QLSA"H.$#[E^
M\,;PNX<C(J;Q%9Z7-=V:WUG=75Q>,;58K:X:+S$P682#>JN@ 8X;/4@ Y--O
M_!>EW5M>+;K)!-<I(@<S22+%YC!GV(6VKN(R=N,FJ7+97$^:^@O_  ET7G?9
M3I>H#4?-\H6'[KS#\F_=N\SR]NT'^+VZTQ/&^G27$$<=O=$36QN Y"+@#=N7
M:6#,05(.U2 2,D5;_P"$5TGR?+\F??YOG?:/MDWG[]NW/G;M_P!WY?O=.*AM
M?#V@W<<<EK#(T-NSP+$+B58@R;HF_=[MI888;L9[YZ&E[H>\0P^+DO3 L=K=
M63R26Q"W4*,9(IBVUAMD^7.QN3R,<K1X5\2KK&DAF+W,MO%FZN4"!!)U,?!!
MW 8)P,#IG/%27,6A6MP6,#/-:265L50ME#OVP=2 0#,2>O!YS@"KMGINFZ9?
M0QV=O+%+]F\I2OF&/RU;.&/W<@L<9^;EL<9INUM@UN9NB:_?7U]9B^>V6/4+
M4W4$$=K,#&AP5'G',<AP>0-I'N*F\0^,=+\-7$4&H,=\D9E($D:;4!P3\[KN
M_P!U<L<=*=+X3L$AN/[.:>SFEC=$=;B4K '.6,:;PL9]UQ^7!LW6EV&IW86<
M7BW%J@7SXI9K=F5N<>8A7>.,D9.#U S2]V]P]ZQ!HVNW&H+JKW5A- EC<R1(
M0JL957L K,2WX#.1CO5"P\80ZYJ&G+I;-'&;QX+E"\4FX"!I!AXV=>N.C9XP
M:VAH6GC[>/)<IJ((N8S,Y1\C!(7.%)'4J 3WK!U"+0=#OHX&LM1GEWK<S74=
MU([0;OW*N[M)O;(8J%7<<+TX%-<K!W1O:_J$FD^'KZ_@56DMH&D57!() SR!
MR:P[CQY9VE_>&XCFCL[>W@9?/MGMI'DDD=<?OM@VX4<G ZY/IT<]A;W6FO87
M"M+;O'Y3*\C$LN,<MG)/OG-0WFB:??S2374!:62-(S(LC*P",64J005(+$AA
M@\]:E./4;OT,9OB!I"6EA<D2>5>R&-6$L)"$2;#_ ,M/WG/_ #SWX&#T(RLO
MBZ9]4LK:RT>]DBFOY;-YG$05_+60,4S(#PT><D<J#CG HU72_#UJK?;UO)Y+
M2S>X*&\G=I(HV+_,2^'PS<!B<9XP!6H=%TZ[M+<>3(BQSM=Q&.9XW21RS,=R
ML#SO;(SCG&,57N]A>\4-3U75CJ.H0Z0;*./3;99I?M4;.9F8,P0%6&P87[Q#
M<GIQS+!XLM9[2&9+:Y9YIX[=8U"Y+O )P,D@8VL!DXY]N:MZEX>TW5YA+?0.
MS^68G,<[Q>;'G.QPC#>O)^5LCD\<G,<GA[2%U#^TY(626-Q-G[0ZQ*RIL#[-
MVP$(-N[&<<4KQL/WC-T?QC)?Z9ISS:5>/>75M]H>*W6/"1Y \SF3[I)X4$OP
M?EJ1_&]A%#+/+:7J6XBFE@F*(5N1$</L ;<#Z!@N1TJA'!X41+.'9?VS^4&0
M1S7.ZWBD(VK(\;$1QG;PK,%X.!UJ6"'PA/?7=L$F4LMQ$_V@7$<"@-^^$3/B
M->02?+(Z$]!56CV)N^Y<C\8P?;6M[S2M1LA'-Y$LLZQ%(Y/+\P*2DC9RN#\H
M(&1G%4X?B/I%S83W=O%-(D)CW!9K?A7W;69O-VH/E(PY4@D#&2*LQWWA_49X
MW6WG?[3>)*6FADBQ(8MB.5DVG:RIM! *DCUS5>YA\.Z=>+I,G]MI([!HHX'O
MV5<#_EFR$JJ@/@A2 . >E%EV"[[EG7]?N[-M*%@1"M\'9C)I\MVZ@*"!Y<3
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M+<1_>:/9'OVJ> 3GCG]*AL_&-I=31QS6-[9F1HAFX$8"K(K&-CM<X#;"/4'
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M:[;<Q:7>%W0-\Q.U-PRQZ8%6#X=UPZ78V'^@A()!)YHN'_=?O2_,?E[)\+M
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MNX+2>2>([OW4J3I&J,,Y7AB2#ST/U?OA[IL:UHEUJ'AD:?9V>GP,9M[V^_\
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M,;D2SHVZ0%"$*[$_O#.22H''8T45+=QI6"BBBD,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "L0>+]%,$DPN92B% #]EE_>[VVJ8QM_> MP"F1R/45MU
MQW_"O;2QMC'H<YM"UQ"X80P*T*)*'PKB+<Y ''F%L\9SR:J/+U)=^AKCQ3I[
M;95F1;40S22M*LD<L9B9%93&4R#EQP2&Y& <\5;/QA;2W&H&Z69(HKI8+:,6
M4WGR9A5SF+;OX);^$< 'WJ1O!MA);/'//=2R2),LD[.H=VD>-S(<* &!B3&
M ,=#4%UX#T^_BD_M"ZN;RXDN!<&XN(X';=Y8C^X8_+QM4#E.V>O-5[@O>+<_
MC+0[>1$>ZF8N(RIBM)I ?,&4&54C+#H.I/ &:!XKTT@S^>HM!!YN\I()=WF>
M7M\O9G.[Y<9W9XVTL'A6QMT14>4!9+>3"A$&80 ORJH !QR  /3%,F\(6,OF
MGS[I'=F=9%9=T;FX,X9?EZASQG(P,$'G*]P/>&R>*[/[3:R13(MBT=PUS)/&
MT;PF(+D%6P5/)R",]*G_ .$KTGR=_FW._P T0^1]BF\_=M+8\K9OQM!.=N,
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MQ1!CO$+C"1Y5C\K=P2HYQJZ=X;MM-O8[N&XN7F"RB5I"I\\R.'9FPHYR.-N
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MYMO/OKXVT2(H+X+;6')'I^-5K3QS'<,RS6#PM_9ZWD8,F?-8DCRQP.IQM/\
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MR2.%!D?RV3+ *!T<G@#D"L27X?Z3+<6LQ>0M:KY<7F0P3;(@Q9(AYD;;57)
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MB$EB=Q;<PC!;<6R23N) YZYV:AVOH4KVU"BBBD,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img119790510_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<GD@0F5T
M:"!3871W:6-Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,X
M-@  DI(  @    ,X-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C R,SHP,SHR-2 Q.#HQ,#HR.0 R,#(S
M.C S.C(U(#$X.C$P.C(Y    30!A '( >0 @ $( 90!T &@ ( !3 &$ = !W
M &D 8P!Z    _^$+)&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X
M<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC
M.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D
M+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(^/'AM<#I#<F5A=&5$871E/C(P,C,M,#,M
M,C54,3@Z,3 Z,CDN.#8P/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP
M=&EO;CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D
M-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D
M9CI397$@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX\<F1F.FQI/DUA<GD@0F5T:"!3871W:6-Z/"]R
M9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R
M:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'
M!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S
M+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( H<$=P,!(@ "
M$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  "
M 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1
M\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ?
M 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$
M!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0T
MX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _
M /I&BBN<\8^-M-\&6,4M\LD]Q.2L%M%]Z3'4^P&1S[TTFW9";25V='17FDGQ
M7U6SC%SJW@;5+2RZF?<3@>I!0 ?G6UXM\?CPG-I4MQICSZ=J! >Z$VTP]"?D
MVG)P<]1G!JO9RO8GGC:YV-%(CK)&KQL&1AE64Y!'K7)^&/'0\5>)=4T^QT\B
MQT_Y1?\ G9$K;L !=O&<,<Y/ ]ZE1;5RFTCK:*\WT[XQ6=WXS.AW>F-:1&Y:
MV2[-P&!8' RNT8!/N<9KTBG*+CN)24M@HKE? _C8>,X;^06!L_L<PBQYWF;^
M.OW1CITK#U#XI:A#XJU#1-(\*7&J26+$.T-P<D# SM"' R?6G[.5["YXVN>C
M45YU8_%I8]8AT[Q3X?O-!><XCDF)9?J<JIQ[C->B$A5)8@ #))[4I1<=QJ2>
MPM%><^(?C+I&DZHECI-N=6??LEE279&G^ZV#N_#CWKT:AQ<5=@I)[!17#:Y\
M2UL==GT?0="OM;O;8XF$ *JA],X)_3%1^'/BG;ZMX@&AZSI-SHNH.=J1SMN!
M;^Z<A2">W'-/V<K7L+GC>QWM%87C+Q,/"/AJ;5C:_:_+=%$7F;,[CCK@_P J
MY./XE^)YHDDB^'>H.CJ&5EG8@@]#_JJ%"35T-R2=F>DT5E>&]5O=9T9+S4])
METF=G93;3-N8 '@]!U^E<I?_ !29M5N;#PSX;U#7'M7,<TD0*(&!P<$*WZ@4
ME"3=D#DDKGH%%<1X1^)EGXFU=](O-/GTK4U!(MYCG=@989P#D=<$#BNWHE%Q
M=F---704445(PHKRS3OB_J^LQR2Z/X'N[V&-]I>&Y+8/OB,X.*W/"_Q.L=?U
M@Z-J-A<:/JG(%O<_Q$#.W. 0<=B!6CIS70A5(L[>BBBLRPHHK-T+Q#I?B6Q>
M\T2Z^U6Z2&)G\MDPP )&& /0C\Z=F!I4444@"BBB@ HHK,OO$>E:=K5GI-[=
M^5>WO_'O%Y;'?^(&!^)%-)O8-C3HJMJ5Z-.TJ[OC$\HMH'F,:?>?:I.![G%8
M_@KQ8GC+06U..SDLPLS0[';=G !R#@9'/Z&BSM<5U>QT-%%%(845QUQXOOXO
MBU:^%UAM_L4UJ9FD*MY@;:QX.<8^4=J[&FXM;B33"BLW7?$.E^&K%+S6[K[+
M!)*(E?RV?+$$@84$]%/Y5I468PHHHI %%%8_BSQ /"WA>\UEK<W(M@G[H/LW
M%G51S@X^]Z4TFW9";LKFQ17%^ _B-!XVFNK=K!M/NK=%D$32^9O0_P 0.T>W
M;N*[2G*+B[,$TU=!17 >-_BI!X0UD:;!IC:C,D0EG(G\L1 G@'Y3D]#^(KMM
M-O!J.E6EZJ%!<PI,$)SMW*#C]:'%I78E)-V19HHHJ2@HHHH **S];UW3O#NG
M&_UFY^S6P8(7V,_)Z#"@FKL,T=Q;QS0MNCD4.C8Z@C(-.SW ?117GWC3XJQ^
M#O$B:6^D/=KY2RO,MP$V@D]%VG/3U%.,7)V0I245=GH-%06-[;ZEI\%[9R"2
M"XC$D;CNI&17.)XV#_$J3PE]@(*0^;]J\[K\@;&S;[]<TE%L&TCJJ***0PHH
MHH **** "BN0^)7BV^\&^&[?4-,AMY99+M8"MPK%=I1VSP1S\HKKZ=FE<5U>
MP45'<W$=I:RW$YVQPH7<^@ R:\UT?QSXW\4>9J'A[P_8/I23>6HGE(E<#K@E
M@,X([8^M.,7)7$Y)'IU%%%24%%%% !117&_$#X@#P*NG_P#$M-^UZ9,#S_+V
M;-O^R<_>%.,7)V0FTE=G945E>&O$-IXH\/V^JV.5288:-CS&PX*GZ'^AK*\0
M>-AH7C#1M"-@9_[48#S_ #MOE9;;]W:<_F*?*V[!S*USJJ***D84444 %%%%
M !1110 45YW>_%RTL_'1T Z<S6R72VLE]Y^ CG@_+MZ Y'7L37HE5*+CN2I)
M[!1114E!1110 4444 %%%% !1110 4444 %%%97BC5)M$\*ZCJ=JD;S6L#2(
ML@)4D#O@@X_&FE=V!Z&K16'X,UNX\1>#[#5;U(HY[E&+K""%&&(X!)/;UK<H
M:L["3NKA1169K/B/2O#_ -F_MB[^S_:I/*A_=LVYO3Y0<=>]"3>P]C3HHHI
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M:2LNNI--.^O30^>].\,GQ/I_C1;1"=1T^_%S;[1RWS2Y0?4#\P*]7^&WBO\
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MR>7;V^G0O(WL(QT]^U<G\2M*AT/X,KIEM_J[4P1@_P!XAAD_B<G\:A\?F8?
MFQ\G=L,%F)<?W<+U_';0_?2]07N-^A)9>,_'GB6!M0\,>'+&/323Y+7TAWR@
M'''S+Z>F/>M[P1XW/B:2\T_4[)M.UBP.+BV/0C.-P_'J/<<G-<SX<L/B0WAC
M3#I&JZ"EB;6,VZLC[@FT8!_=]?7WS6AX4\%>)=/^(%SXE\17FG2O<VYBD%FS
MC<?E X*@8^4?C2DHV>PXN5T6?$?CZ_B\3'PWX/TM=4U1%W3O(^(H1Z'!'3(R
M<C&<<FJ)\?\ B7PUJUI!X^T:UMK*[;8EY9,2J-_M98_TXY&<5R7A6#Q7<^/_
M !4?#MYI]M?+=/\ :/MP8EAYC?=PI& 1_+%;_B+P7\1?%.F"PUC4]"D@602@
M)YBD, 0#D1^A-5RQ3L[$\TFKH;\:IO$']CR1&VL_["\R(B;)\[S.>,9QC\*Z
M+P7=>-I/L,>N6.EQ:2+5=DMNS>:?E&WJQ_'BLWXN0/:_"F"WE;>\4L",P[D
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MA^W@LKAMHN;)B0O_ (\P)]L@U!\$RK7GB8SG-Z;I3*6^]C+_ -<UO_&+[/\
M\*SOOM&WS/-A\C/]_P P9Q[[=WZT[14^2Q-Y./-<T?'/BF?PYX*?6M)6WN'W
M1^7YH+(RL1SP0>A]:YJR\>>,_$2I>>&/#=O-IB%4DFN&VM*W&\H"XX!SZ_GQ
M5+Q6)5_9WTX3[M_D6OWNN,C'Z8KT3PI%'#X.T=(45$%E"=JC Y0$_K4Z1C>U
M]2M92W-:O+OBT8AXN\#FX3?$+YMZD9W+YD.1CZ5ZC7E7QA_Y&;P7_P!?DG_H
M<-*E\8ZGPE?PC+)\//B9=^%;QV&F:FPDL7;. Q^[^)^X?=15CX@_\EA\'?\
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MU27I;0LZ@]VZ*/Q) K3KR_XSW]Q=VVE>%M+4RWFI3AS&K8) .%!SQ@L<Y/\
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M3M_^OJ+^M=;X8_Y%'2/^O&'_ -%BN2^-?_).W_Z^HOZUUOAC_D4=(_Z\8?\
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MNV<4+W,<<+*DH)3+NBG(!!Z,>]<[\<?^2?Q?]?T?_H+U;^)7_)&+S_KC;?\
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M(PQ*6\,7.X* N<DX[#WKUNBBB4W+<(Q4=BGJ]F^H:'?643*LES;21*6Z LI
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MQ9QYDT@1<^F37EWB&.\B^)>KZKI9)N]+AAN1%S^]CVJKK^1_2M;XCZC;ZO\
M#&&_LVW0W$T3J>XZ\'W!XK/ZTU&;MK&_S2-E@$YTDGI.U_)M7_X8[J]U"STZ
M$3:A=P6D3-M#SR!%)ZXR>_!_*JT'B'1;J816NKV$TC=$CN48G\ :Y?XK[/\
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M]6VH6/XDDUW\,*6\$<,*[8XU"*,YP ,"JUWI%C?:A9WMU!YEQ8EFMWWL-A8
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M8V*PCY6W,V,8 ]^#UZ5UND:='I&C6FGPXV6\2QY'<@<G\3DT0BI8AN+T6O\
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MT.]U#RS*;:%I0@_BP,XKGX=%-Y\2GUI-/DLX[6)HWN'/-W(5"C"Y^ZJ]^_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4?[>US4[76[G2[&WA8"S;S/+:;+$#EG(8XQT]::@VF^PG))V/2:*0D*I+$
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MF[/IC.:TZ+-#"BBD)"J2Q  &23VI +16=!XBT2ZNQ:VNL6$UP3@0QW2,^?\
M=!S6C19H HHHH **** "BBB@ HHHH **** "BBB@ HHJ&ZN[:QM7N;VXBMH(
MQEY9G"*O..2>!0!-15:PU*QU2W,^F7MO>0AMADMY5D4-UQD$\\C\ZAN=>T>R
MOEL[S5;&WNFQM@EN45SGI\I.>:=F*Z+]%%%(8454_M;3O[3_ +-^WVOV[&?L
MOG+YN,9SLSGISTJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >(?'(G_A+-%%UN^Q^1S_WW\^/?&VO9XOL
M:Z:AB\D62Q IC'EB/''MC%8GC7P99>--'%I=NT$\+%[>X49,;'KQW![BO-D^
M#GBYH5TV?Q+"-*#9\I9Y6 ]_*("Y_&NCW9Q2;M8Q]Z,FTKW'_'/_ )&'P_\
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M4;ANK=C'^$\_@^XU#4)?#=M=6-^\8\VTN9"XC0'^ ]QDC.>>E7OC7_R3M_\
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M _I6G-%M)/J1RR2;:Z&5X@UF[L/@;X9L+5VCCOFE$S*2"RJY^7Z$G]*E\8^
M])\/?#?2];TPS1ZB#"TDPE)\PNN20.V#TQV]>M=7H?@^W\8?!72-/NG-O,BM
M+!,%R4;>_;N"#TK-;X6>+]4M;/2=?\2V\FC6;#RHXMS. !@<%1R!P,DXJ5-)
M[VU97*VMNAS_ ,1-6N=9^'7@[4+QBUS(LV]^[%=J[OJ<9KK=*^'=CH?AF_\
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MR;W$DEL%0WDL\%C/+:6_VJXCC9HH-X3S6 R%W'@9/&3TJ:BD,XS_ (2;QO\
M]$__ /*U#_A1_P )-XW_ .B?_P#E:A_PKLZ*OF7;\_\ ,GE?<XS_ (2;QO\
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M"KE%%V!2O]&TO52AU33;2]V?=^TP+)M^FX'%68((;6!(;:)(8D&%CC4*JCV
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M110 4444 %%%% !1110 4444 >=?&3Q1>^'_  W;6VF2O!/?R,C3(<,J*!D
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MLVGB'1;;5-.8M;W"[EW#!4YP0?<$$5XE\6_$%[>>-K&TETN>!-,E)M]Y/^E
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MI<S:5*MTH3[5:2)_$R9R!GN1N7ZFO*-$NI?'>N>#M#GW21:;$1/GIM5R2/\
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MQ1-%(BRN85M 07,H)^7/3H,Y]/?BN7\%:+JMK%\11=:;>0F\5_LWF6[+Y_\
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M9\4:E=W45I<@;YY6E?!5<*NX]R>GO1\+_!D'_"!ZC_PD?AN/[?\ :9?*^WV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\8:WI<9&FW-C]CBE"[1=.J-O<>N,@9[UAF7^T_!=EKDLS+:Z'!IMO X/67?
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M!9&)'(.00000?I5VBC8"&SL[?3[*&SLHEAMX$"1QKT51T%9OB/0VUNTMS;7
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MX_YY0_D?\:/[;N/^>4/Y'_&CV*[?B'M7W-G_ (26/_H&ZC_WX'^-'_"2Q_\
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M];&K1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C/BW_ ,DMU?\
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MM/N!;W/[S_5N-KYKU)7MH>3&U]2K14]Y;&UN"G\)Y4^HJ"J3NKDM6=@HHHH
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M>726T<=M$0RQJ&VR%@<CL-NTCG);C'3F\;4/!9O74*USI_FE1T!:/./UH<;
MI7+6CZI#K>C6NIVJR)#=1B1%D # 'UP2/UJ[7F6DW>K>'OA?H^O1:FTT,"0"
M33S#&(GB9@FT'&\/\P.[=C(^[CBM.\\1WE_XAU>S@O\ 4=/BTYA!"++2GNO-
MD*!BTC"-P%!. HVDCG/(PW!WT$IZ:G=45B6MU+K'@E;C6O.T:6>T)N65S ]J
M<?,P+<KCJ">G?-8>E^(=6?6X;72)_P#A*=->5EGO?($'V50R#/G "*; +?*B
M@\5/*Q\R.I_MO2O[3_LW^T[/[=G'V7[0GFYQG&S.>G/2G:AJ^FZ2J'5=0M;(
M2$A#<SK'NQUQN(SUKD_&$5B;>S\(Z):0IJ%].EPBQ(%%LB.&>=L=#\I /4D]
M^E7=,ACO?B)XE-XBS&&VM;>-9!D")U9F&#V9NOKBJY5:XN9WL=)>7UIIUJUS
MJ%U#:P*0&EGD"*,G R3Q3K6ZM[VV2YLIXKB"0926)PZL/8C@UYIX7=[J?P1;
M71,EO!%?-#OY!:)_+C//]U.GI73^%@(/%?BRU@/^CI>Q3*HZ"22%6D_,\GW-
M#A8%*YU-%<I8:U?S:GXOBEGW)IS*+4;%_=YAW>G///.:RVU_6YO#_@QX-0$5
MSJ[HEU,T"-NW1$D[<  YY&,=!G(X*Y&/F1W]%<79-KU[XBUW1%\0S)'IZP2P
M7)MH3.6E0_*QV;"@*DX"!CD?,,<U[#Q5JFLZ+X4AAE6UO-;$AGNE0$QK$I+[
M%(*[FP,9! R>#1R,7,CM;Z\CT_3KF]F#-';Q-*X09)"@DX]^*AM]5MI]!BU?
MYH[62V%U\X *H5W<\XSCWKE-0U"_M3XC\/ZC=-?JNC/>V]RZ*L@1@Z%'"@*2
M"N00!P>:=(QG^&OA[2HR=^K06EI\O7RS&&E..X\M7I\H<QU-AJMMJ$-N4;R9
MY[=;D6LK*)41NA903CGCTS5VN6C 7XM2!0 !H2  =OW[5U-2U8I.X4445(PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .,^+?\ R2W5_P#MC_Z.
M2NSKC/BW_P DMU?_ +8_^CDKLZM_ OG^A/VG_7<****@H**** "BBB@ HHHH
M **** "N,^$G_)+=(_[;?^CGKLZXSX2?\DMTC_MM_P"CGJU\#^7ZD_:7]=CL
MZ***@H**** "BBB@ HHHH **** "BBB@ JO?OY>FW+CJL3G]#5BJNJ#.CW@'
M_/!__033CNA2V.;L_P!UX53_ *YG]6/^-<1K3;M0Q_=0#^O]:[>+GPJF/^>8
M_P#0JX;5QC4G]P#^E>SA?CD>1B_X:*5%%%>@>::%M-'>6XM+DX8?ZJ3T]JIS
MV\EM)LE7!['L:CJ]#?J\8AOD\V/LW\2U%G%W1=U)691HK1_LM9F#6LRR1$\^
MJBJ=S;26LQ20?0]B*:DGHA.+6K)+.9(O.WMMW1D#CO5D:A&['?\ (/*(/'5C
MC_"LVBN2K@J56;G+<[J.85J,%3A:R-2.^A\J,ED1T7&&C)/X$=*KF:*73Q&[
M['1BP&TG=U_QJG14QP%.#O%O>_3S\O-[ESS*K45I);6ZZ[>>^BVL%%%%=YY@
M4444 %%20V\UP^VWADE;T12Q_2B:WFMWVW$,D3>CJ5/ZTKJ]AV=KD=%%%,04
M444 %%%% !1110 4444 68K^>&+RT88'3(Z4EM>26\K/]_?]X'O3([:20;N%
M7U-/\B%?OSC/L*\BK7P$7*G:[>ZBF_OLCLCB<2G&2F_=VUV)X]0\R]22<!44
M$#'./>GZE=PRPB.,ASG.1VJK]GA;[DXS[BF26LD8SC</5:YZ?U"5>$E)Q:V3
M3C^:.MYCB?83I2L^;=]2*K^G^%+O7721&\FWP09B PR.V,YJA23ZIJ%G D5I
M>W$$>22L<A49_"O7Q-_9NQPX6WM5<Z1OA=%-"T=SJ>]&&"H@_P#LJ\IUJU'A
M_7[G0[+58Y[42!#<X.(L]0<9Y'?&>GKD5?U;Q%J=Q-]@M;VYDG?AF,S'8/SI
MEMI%O#8M;R+YAD_UC'J37F04H_$SU9-/9'I.E?#_ ,+:=I\6=1:8L@9I3.BB
M3CJ..GIR:Z?PU8Z#I=U*NBR13W3I\VVX#MMX[ ],XKP*":71;D6MV2UJY_=R
M?W:]&^'#$>,H0 2&BD!QVXK.<'9MLTA)7LD>K12S%MH&[V/:K@Z<T@ '08I:
MY#H"BBB@ HHHH **** .,^(W_,J_]C)9_P#L]=G7&?$;_F5?^QDL_P#V>NSJ
MW\*)7Q,****@H**** "BBB@ KC/A)_R2W2/^VW_HYZ[.N,^$G_)+=(_[;?\
MHYZM? _E^I/VE_78[.BBBH*"BBB@ HHHH *H:KH]OK"V@N7D7[)=QW<?ED#+
MH<@'(/'K5^BC8#/L]&M['6=2U.)Y3-J)B,JL1M7RUVC;QD<=<DT:%HUOX>T.
MVTJR>5X+92J-*06(R3R0 ._I6A13NQ61GZ)HUOH.G?8K-Y7C\V27,I!.78L>
M@'&35*/PAIB>%+;0&,[VUKM,$QDVS1.IW*ZNH&&!Z$?RS6[11S,+(RK/1);;
M4%O+G6M3OG1"BQSO&D8SW*1HH8^YSCM5&3P7:O!<V<6HZA;Z9=2-)-IT4B"$
M[CEU!*;U5CG*JP'S'&,UT=%/F861@:KIM]/KVA?V8]S:6=D[M/Y,RI T>W C
M:,<L<@8XP!N[X%7=8T2#6A9F:6:"2RN5N898=NY7 (_B!!!#'C%:5%*["R,.
MX\+QMJ-U>Z=J5]I<MX!]I%H8]LK 8#8=&PV.,KC/>EUWPI9>(M+MK+49KDBW
M;(FC<"1_D*,&..C*Q!  S6W13YF%D9FJZ#:ZHMJQ>6TN+-]]K<VQ"O"<8(&0
M5((X*D$$=NE5[KPRFH:'>:9JFJ7]['=E6:24Q!XRI!&W:@4<J#T//U-;=%+F
M861A7WAF2^-P)->U9(KJ$0SPH\6QP%VD@&,["P)SLV_A6C)I-C+HO]DR6RM8
M>2(/(.2-@& /7IWZU<HHNPLC!M_"RQ0BWNM8U.^LQ;O;?9;B2/8T;#!!*H&8
MXZ$L2/7DU#!X*MHY-,>XU34KO^RG5K19I(P$"J5VD*@W9!'+9;C@C)STE%/F
M8<J,>+PS9PZ;K%BLLYBUB6:6<EAN4RKM;;QP,#C.?QJY#ID,&B1Z6C2&".W%
MN&)&[:%VYSC&<>U7**5V%D<S:^!K&WMK"SDOK^YT^P*-#8SR(8]RCAF(4,W/
MS;2VT'H   +MSX;CDU:;4K#4+W3+FX4+<-:F,K/M&%++(C#( QD '%;-%/F8
M<J*JV$3:6MA>9OHO+$<AN@KF48Q\_&#GOQ5JBBI&<Q:>"18:G?:A9Z_JL=U?
MR;YY"+=V;T4%H20H' 4< 5=O_#45Y??;8-0O;"\:W^S33VK(&F3.1NW(0"#G
M#* 1DX-;5%5S,7*C&N?"VGRV.GVUF9=/.F$&SFM6 >'C:0-P8$$<$,#GZ\U:
MTG2(-'MI8X'EFDGF:>>>8@O+(W5C@ = !@     5?HI7861QMGX3NY_$WB.X
MOKF\M;*_GB(B@EC"748C (/!=><CY2I(/TK1M_!MG!::/;M>7DR:--YMJ9"F
M>%*A6P@R #]?>NAHIN3%RHS[31K>SUS4-5B>4SZ@L2RJQ&U1&"%VC&?XCG)-
M9T/@S3K?0-.TN":Y0Z8^^TNPZ^=$V3DYV[3D$@@J01U%=#12YF.R,6U\+V<"
M:@;F:XO;C4H_*N;FX9?,9-I4*-JA5 !/  ZYJI8:#/9ZWI<!,TVG:/8M';SS
M,FZ21B% (7'W8UQG:,[NI.:Z6BGS,.5&-?>'!=Z\-7MM4OK"Z^S"U)MQ$59
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M%2\NJ[?YD8JI76 ITYT[1Z/O_E?\1M%/A=8YE=T#J#DJ>]7?[1MO^?"/]/\
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M9O# (PB-;J55L=0,<'(/-=7%;PP?ZB&./_<4#^58WA5"]G=7K#!NKAF'T_\
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MEDM=A #YC51M;..0>5X/6K,'C.QG,$PM+Q-.N9Q!!J+HHAD<\+@;MX!/ 8J
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M;ZQ;ZQX)OC;)(OV35HK23S !ETG0$C!/'I73ZCK<EC<M!;Z-J6H%(_,=K6-
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M>;&?35N%,L"EA("KNVUL,,'+#CI2ZYI>I:[-I.KOI=U!)I\\R26"7PAFEAD
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MR2H(_$$5+X3L;C3/!^E65]'Y5Q;VL<<J;@=K!0",C@_A7*ZYX>U34;C7TO\
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M_O?H]'VO0?[WZ/1[:KY_<@^KTO+[V<__ ,([9_\ 00G_ / 4?_'*/^$=L_\
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MRC_A';/_ *"$_P#X"C_XY70?:]!_O?H]'VO0?[WZ/1[:KY_<@^KTO+[V<_\
M\([9_P#00G_\!1_\<IZ:'IR?ZR2YF^FV/_XJMW[7H78D_0/4B7FGY_T6PN)V
M[;8<_P S0ZU3S&J%+R,RULH8V L+% W]\J7;\SP/PQ6FFENVZ?4)MB]6);^9
M-6D_MFZ&VUTY+1,??N&Z?A_]8U8B\,B>19=8NI+MAR(Q\J#\/_U5SRJ?S/\
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MIP+ITO\ J[C=E7// QR3P>.O!JGH_C[PQKWGC2M5CG:WC,LB&-T8(.K!6 )
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@".XA%Q:RPL2HD0H2.HR,5R^G>#Y[75(IY[B-HH7
M#KLSN;!R,^E=917/5PU.M)2FM41*$9--G*ZYKFF27WV2\L#=+"VUI-^TJ>^,
M<_J.E='91V\=G$+-%2 J&0*.QYK%O_",%[J+W*W#Q+(VYT"YR>^#V_6MZ*)8
M(4BC&$C4*H] .*QP\*RJSE52\MOZ^\B"GS-R'T445W&P4444 %%%% !1110
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M4- T<:8=.&DV(L2V\VOV9/*+=<[,8S^%3R:;8RZ>MC+9V[V:J$6W:)3&%'
M7&,#TI>Q=K7Z&O\ ;$54Y^7[4G\I*WX?<>7:9HUJMQXIUM/&5KXAO)M&ECN$
MMK9(ARORN=C$$X3'3///ORL$,0_9ONI!&@=M1!+;1DD.H'/TXKW6UT+2;&"6
M"QTNRMHIE*R1PVZ(K@]00!R*0:!HXTPZ<-)L18EMYM?LR>46ZYV8QG\*;H_J
M1'-5%ZINTHOHM(]-$D>/^/@8_ 'P]OY=WDP10>8^,XS%&?\ V4UT/Q"'A_Q'
M)HE]8^+;'3M0@9Y+&X>0/"^"N=S=%P0.3[C![>BRZ983Z>MA-96TEFJA%MGB
M4QA0, !<8P!VJNWAO0WL4LGT;3VM$8LD!M4,:D]2%Q@&G[)Z^=C..8P7([-.
M+EM;:7JOZ1R?PI\47OB/3M334;>U$MG<[&NK1 J7)(Y;C@GY1R.H(K%\7^+;
MP_$2[T.&\TO08+>S!EU.]MUD>5"H8HN[AOOD!>Y#?2O4K2SM;"W6WL;:&VA7
M[L<,811] .*ANM'TR^NH[F]TZTN;B'_5RS0*[)]"1D53A+D2N8QQ=!8F=7V?
MNM:+L]-==/EMJ> : S?\,_\ BM&)PM[#A2>AWQ9_E79IX=@3X!M<Z%IT,>IW
M6F(99H8AYLJEE:0$CDY4'BO2!H&CBSGM!I-B+:Y??/#]F39*V0=S+C#'(!R?
M2KEO;P6EO';VD,<$,:[4CB4*J#T ' %1&C;?M8ZJ^;<[O"-O?YOP2L_N/!=!
MTNS\1^%]#M+OQ_9VJPSH8---A$LL,V2,!@P<Y/\ %T/!/.*]<\?JS_#S70BE
MC]BD. ,]!FM!/#FB1WIO(]&T];HG)G6U0/GUW8S6BRAE*L 01@@CK50I\L6C
MFQ6/5:M"I%:1=[:+=WZ)?>SYXUF>*7]G'P^D4B.T.JNDBJV2C?OVP?0X93]"
M*Z77XHYOCGX.25%=?[-A.UAD9!F(_45Z>?#&@&S-H=#TTVS2><8?LD>POC&[
M;C&[!QGK5A](TV6_AOI-/M7N[=0D-PT"F2-1G 5L9 Y/ ]34>Q??M^!URS6G
M=VB]>?\ \G_R/)O"%K;R?%/QV\D,;-&DX0E0=H9SG'UK!T,D_LV^),G.-23'
MM\UO7N\.D:;;75Q<V^GVL4]SGSY8X%5I<]=Q RWXU''X?T:+39=.BTBQ2QF;
M?):K;((G;CDKC!/RCGV'I3]B[??^(O[5AS7<7O!_^ ;_ 'GBWB]?*^&_P_OI
M,B"W*B1L9QD*?Y*:UOC!>#4E\,ZMIVH1R:-'=,)+N!!<1Q/N7#%>C8 ;Y3UP
M1WKUA]*TZ335T^2PM7LE4*+9H5,8 Z#;C&*2'2--M]/:PM]/M8K-LYMD@58S
MG_9 Q0Z3::OO;\"8YI",H3Y=8N7;:5_Q1Y?IFA"]UW4M7L/'%KK^L-I,T:PV
MEJD1(*80G8^.&*\$9Z=*Y/2]3T.W^!.KZ;<2VT>K-=?\>[@>:S;EPP'7A0W/
M;FO>K#1-*THL=+TRSLBWWC;VZ1Y_[Y IDGA[19;B:XETBP>:X4K-(ULA:0'J
M&.,D'WH=%]/,J.:P3M)-I.+6R^'IHK6,?X:?\DUT3_KW_P#9C74U%;6MO96R
M6]G!';P1C"11(%51Z #@5+6T59)'BUZBJU95%U;?WA1115&04444 %%%% !1
M110 4444 %%%% '&?%O_ ));J_\ VQ_]')79UQGQ;_Y);J__ &Q_]')79U;^
M!?/]"?M/^NX4445!04444 %%%% !1110 4444 %<9\)/^26Z1_VV_P#1SUV=
M<9\)/^26Z1_VV_\ 1SU:^!_+]2?M+^NQV=%%%04%%%% !1110 4444 %%%%
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M;U\L_M ?$2+Q+JP\,6EDT2Z/>2"6:0@F60?+\N.B]?KQZ5(S.\5?&?Q1\1=
MA\.6VDQQ22LAG-B'>2=@> J_PC...?K6=X.\5^,/A/J4FI7FBWAM;L>1+'J$
M4L:N0<_*Q'##GUZGBO?_ (7_  S'P^L[>YLYFGGU"WC&I).5^1P"<QD#H"Q!
M!SG@YXP>YUZUTB[T2YC\1Q6LFFA-TXNP/+"CG)SP,>M 'EGPK^.@\:Z])HFO
MVL5E?3NS6)@R4=0"=ASGY@ 3GH?;O[#)(D,3R2L$1%+,Q/  ZFOCC1_&>B^
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MEEHQM3)'<;%FN1)@0.^_RU*XYW&-AU';K5)20KQ-RVMX[2TAMH!B.%%C0>@
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M*** .,^+?_)+=7_[8_\ HY*[.N,^+?\ R2W5_P#MC_Z.2NSJW\"^?Z$_:?\
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M#>GZAHION)(4W2ET&W=*IS@,>GUHD\8WEAX<AU"ZU3S+"+7H[5=3>%5^UVF
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C/BW_ ,DMU?\
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MGX#:$_\ QZ:IJ$1_Z:%''Z**M5J?8GV50\?_ .$Q\3_]#'JW_@=+_P#%4?\
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MX3'Q/_T,>K?^!TO_ ,51_P )CXG_ .ACU;_P.E_^*K&HHY5V"[-G_A,?$_\
MT,>K?^!TO_Q5'_"8^)_^ACU;_P #I?\ XJL:BCE78+LV?^$Q\3_]#'JW_@=+
M_P#%4?\ "8^)_P#H8]6_\#I?_BJQJ*.5=@NS9_X3'Q/_ -#'JW_@=+_\51_P
MF/B?_H8]6_\  Z7_ .*K&HHY5V"[-G_A,?$__0QZM_X'2_\ Q5'_  F/B?\
MZ&/5O_ Z7_XJL:BCE78+LV?^$Q\3_P#0QZM_X'2__%4?\)CXG_Z&/5O_  .E
M_P#BJQJ*.5=@NS9_X3'Q/_T,>K?^!TO_ ,51_P )CXG_ .ACU;_P.E_^*K&I
M\4,L[[((WD;^ZBDG]*.5=@NS6_X3'Q/_ -#'JW_@=+_\51_PF/B?_H8]6_\
M Z7_ .*I+;PCXBO,?9M"U&0'^(6KX_/&*V+7X5>,[K!71GC4]Y9HTQ^!;/Z5
M+<%O8JTV9'_"8^)_^ACU;_P.E_\ BJ/^$Q\3_P#0QZM_X'2__%5V%K\#/$\V
M#<7&GVX[AI68C\EQ^M:]M\ ;EL?;-?BC]1%;%_U+"I=2DBN2HSSC_A,?$_\
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MJ6M_>68(6VG\/-9&]\P$-<M(';C.[!.[G'2O5(88[>%(8(UBBC4(B(H"JH&
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M3^%"7Q,****@H**** "BBB@ KC/A)_R2W2/^VW_HYZ[.N,^$G_)+=(_[;?\
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M"/,L8;8'O+<IQ_WR37TC14/$2[%>PB>#6OP&UU\&\U/3X?:/>Y'Z"MBV^ ,
M_P"/S7Y']HK4+^I8U[#14.O-]2O90/-K7X&^&(<&>XU"X/<-*JC]%!_6MFV^
M%/@RU^[HRR'UEFD?]"V*["BH=2;ZE*$5T,:V\(>'+/'V;0M.0CHWV9"?S(S6
MM%#' FR&-(U_NHH I]%2VWN59(****0PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#C/BW_P DMU?_ +8_^CDKLZXSXM_\DMU?_MC_ .CD
MKLZM_ OG^A/VG_7<****@H**** "BBB@ HHHH **** "N,^$G_)+=(_[;?\
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M([!5&<' YR3@X )KSC[.MSJ6I)KNMZ3I.K_VDQBENK1OM:IY@\HPRM*O[L@
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MB>[:TO$A7&&:( -DXX.<&E7Q )Q)%:64XO#$9((+D>4)B!D -SCIUQ67??\
M)/X/HG\ZT]-TB47-O?WMZUS)'$%A7RP@0$>W7K6M.M7E4C%:Z)OY[_\  &I3
M;2+^F:A#JNE6M_;9\JYB610>HR,X/N.A]ZS;GQ996GC*U\-W,%S%=7D+2V\S
M*OE28!)4'=G=P>"*P-";0ETGP\VLMBZ>_NFTOE^2TSX^[Q]PK][BJGQLLU_X
M09=7A=H;[3+A'MYD.&7>0C#/H00?P%>K)69M%W1IV?Q&CU>2V.A^']6OK674
M&LGNUC41H%ZR9#'Y<E>3M&"><C%=G7C_ (@TNWT6/X76%F,117\7_ F)1F/U
M))/XUPVJ?VNWCJ^_M2]L[#Q -1'V2XNQ=^>%W801^6K1^7CU&<9J2CWS3/%M
MAJWBG5- MXKA;K2PIF>15"-NZ;2"2>O<"G^%/%5EXPT9M2TR*XBA69H2MPJJ
MV5QGH2,<^M>9Z=X=_P"$B^,_B^/^V-6TOR?*;?IEUY+/E1PQP<BM[X%C;\.W
M&2<7\PR>_P!V@#TBBO(_#%GI6H7NCRWL^@)>VLLSLT\R-?7DQ)"":-ERK G<
M?F8Y QC.:F\,V\4MQIKZGK>EV.O1WH:ZB>T9-0E?)W1LYERR,IP/EVXQ@<"M
M73MU,U.YZM17E,>G6D?P_EUA(%_M*WUH^3=GF2(?;@I56/*KAF^4<98G&233
M]4@CN-<UT>(M8TK2;Q9\V=QJ%JQGC@V@Q/;R>:H&#GA!G<#NSFCV?F'.>IT4
MV-66)%D?>X4!FQC<?7%.K(T"BBB@#C/B-_S*O_8R6?\ [/79UQGQ&_YE7_L9
M+/\ ]GKLZM_"B5\3"BBBH*"BBB@ HHHH *XSX2?\DMTC_MM_Z.>NSKC/A)_R
M2W2/^VW_ *.>K7P/Y?J3]I?UV.SHHHJ"@JAK6N:?X>TQ]0UBX^SVJ,%:38SX
M).!PH)ZU?K@OC1_R3*\_Z[0_^ABIG)QBVCIPE*-;$0I2V;2.MMM>TR\\/_VW
M;W:OIOE--]HVD#8N<G!&>,'C&:CT#Q)I7BBP>]T*Z^U6\<IB9_+=,. "1A@#
MT8?G7A]GJ%]:^&[OX=Q;Q<WVH0+;$]1;S#>3]!A<_P"^:Z+X:7%M9_"/Q!,V
MJ-I$":C+MO4&\Q?)%@@'[W88ZG/'-81K-M(]>OE,*5*4DW?F2C_A>S=E?[NS
M/8JYS3O$&KW?C6_TBYT">VTZV3=%J+$[)3QP.,'.3T)QCFO*=-\6W=AX\T!=
M%UKQ!J&GZA<)!.=8SY<NYPI,>>PW9[8XYYKI-*\0ZA;_ !E\61W%[=3V-CIT
MD\=HTS&-2OE'Y5S@'D]!W-/VJ=O4AY7.DI<UG[MUNFM4MN_J>JT5X99WGB37
M/ &K>-Y/$^H6UY:SDP6EO+BW"J5R"G?[W&?3G.:L^*O&NN7OA7P3J^G7DEC=
MWDSB81NRQR.K*OS*/O*2"<'/!I^V5KV(_LBHYJ"FMW%[Z-*_],]*\8:]JN@:
M9#<:)H<VLS23"-HH<Y1<'YC@$^WXU;N?$FFV&H:=I^HS&VOM2'[BW*,Q8\9&
M5! QGN17EWCZR\1>"OAZCR^*]1O;VYU5";E)7B*)Y3Y0?,?ER,X&!TXXJGXP
MT>2Y^+'AJ)]5U1?[0ACD\Q;G#6Y.0?*./E^Z#WY)J95))[=C:CE]&I"-Y:>_
MJKW=DN_^1[E17E_B234?!/CKPM<C5]1N=(N,65REU<M(&?[OF,.A.&!SCJAJ
MW\/[_4/$/C;Q/K$U]=/ID-P;2TMVF8Q#!Y8)G:#A5_[Z-:>T][EMJ<,L U1]
MNI>[:_SO:WJ>BT5YGXYUS5+_ .(VC^#=,U"?2[>Z02W-S;MLD8?,<*W;A.W<
M]\8JKX?OM4@^(&M^ -0UK4+NT-OOM[XR_P"DPY16XDQUPW4]QQUH]JKVMY#C
METW2]HY*]N:W]V]K_P# .@T#X@W'B?Q-<6.C:%)+IEK,89M2:Y50I ;!"8R0
M=O&#W&<5T&L^)]'\/W5C;:O=_9Y;]S';+Y3MYC J",J#CEEZXZUY?\#-+W7&
MK7WVZ]'V>?ROLXF_=2Y!^9UQRP[&K'QP:X36O"#V,:R7*W$QA1NC/NAV@\CC
M..XK-5)*ESL[:F!H2S%86.D;?._*WK>_^5CT?7/%6C>')[.'6KS[-)>L5MQY
M3OO((!^Z#C[PZXZU+K?B'2?#EHMSK=]%9Q,<*7))8^P')_ 5X9X]O_&-[KGA
MS_A-=*L].V7#?9OLSAM^6CWYQ(_3"^G4]:Z+5[.V\2_M#_V9X@'FV5K;#[/;
MN?ED/EA\8_WF8^^VCVSNTEV&LJI1A"4Y77+*4K-/X7;W?OU/1=*\;^'-;LKJ
MZTO5(YXK2,RS@(RNB 9+;" V./2K6E>)=)UK17U;3+OS[&/=NE\MUQM&6X(!
M_2LO4?"VBZ3H>O7&C:9;6ES<Z?+&_D($!&QL  <#GTQG ]*Y/X5R(WP7U !A
M^[-R&]CLS_(BKYI*23./ZMAZE&56E>RE%:VZ[_\  /0M"\0Z7XFT\WVB7/VF
MV$AC+^6R?, "1A@#W%:5>;_ H$?#R3(QF^DQ[_*E9NIS:OJWQRN] AU_4M/L
M)+52Z6LQ&T"-6.S.0A)_B SU]:%4?(I-;CG@(O%5:,964+N[[+T/6J*\D\&>
M(M1AD\7^']=U^;RM)\SRM5E8/)" S*22<[CT('KD>E<R_C"ZTG7M&N_#^O\
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MN9+QXHC(J(B8BC^3;_%U*D@?7C9\-:E=W%[J^F7\PNI-,N1$MT%"F5&0.-P
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MHHHJ"@HHHH **** "N,^$G_)+=(_[;?^CGKLZXSX2?\ )+=(_P"VW_HYZM?
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MCIEU)I-YI"JMG<PJ&V*O0%3C=TS^?J:T/%WC32_!=E!<:JL\IN'*QPVR!G;
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M/I23Q:/:)=LK3K"H<I&4&<?W221^=)H]I/8:'8V=W/\ :+BWMXXI9C_RT95
M+<^I%7*WC!)\W<\:OBIU*:HO51;L_+1?I_F%%%%6<04444 %%%% !1110 44
M44 %%%% !1110!QGQ;_Y);J__;'_ -')79UQGQ;_ .26ZO\ ]L?_ $<E=G5O
MX%\_T)^T_P"NX4445!04444 %%%% !1110 4444 %<9\)/\ DEND?]MO_1SU
MV=<9\)/^26Z1_P!MO_1SU:^!_+]2?M+^NQV=%%%04<O86TGB.XU6>^O;V)(;
MN6TMXK6Y> 1*G&[Y2-S$Y/S9'3BH-.\4:@(;2QEM5O[][VYLFE\P1*QBS\Y^
M7@$#G ]< ]*TVT*]M;R\FT34H[-+UC)+%-;><%D(P73YEP3QD'(R.E%MX7@L
MIM):UG<)ISS2'S%#-.TBD$LPQSEL]/;BN/DJ)Z:/J^^O^5STG4HM/FU71:Z:
M/];;;[LKZWXIN- A$VH6=G'&J L&U +)*>-_DJ4^?;D==I)[="<+Q$ZRV_C2
M1#E6L;5E/J"K5M:CX1FO)M7,&H10QZJFV5FM?,F0; NU7W#Y> =N.YP0>0^[
M\)?:H]4B^V[8]2LX[=AY62CQ@A7!W<CGE<?B*BI"M.Z:TU[=FO\ (THU,-3L
MT]=+[]XO]&6;CQ&ME+JZ7MOY1TZ%9TP^?M$; X(X&#N!7'/./6KLMY>1:.ES
M]B3[254O"TX5(L]2SD=!W(!/'2L/5=/?6?$>EQ;)2;3)OYA;M'%*H*.J MPP
M,BJ< M@!LGUU]?T8:WIZ6YD1#',DRB6+S(W*G[KID;E/ID=CVK92J/FMTV_K
MRV.:4:*Y+Z7WW]/QW^:,F#QQ!+9WK>1%/<V\\<$<=E<B:.=Y/N!9,#OD'(XP
M>M59]2O+#Q9J-_J%E$DEIH;3".&X+K(%<M]XJ".F/N_G5V3PC-=&_GO-3W7E
MU)#-%-% $%O)%G:0I8Y'/0G.,\\Y#Y_#-W?37\^H:G&\MYI[V \JUV)&&S\P
M!<D]3P3S[5DXUVM?T\_^ ="EA8M\NS]?+;\=]1J^)=3-[9VQT5%?4(6FM2;P
M8 7:3YGR_+PP/R[_ $]2(#K%KJUUHKWNFLMTNHS6X N#BWEC5MQ&,!Q\N.0.
MM:_]B?\ $RTF[^T?\@ZWDAV[/]9O"#.<\8V>_6J</A7R;RWG^V9\C4I[[;Y7
MWO-#?)U[;NO?'053C6O;=?+R_P""9QGATKK1V>U_[W_ *X\7W7V.6_;256P@
MO#:RR&Z^?B7R]ZIMY'(ZD'KUQDLGUJTT6]\074-@?.CN;>.:5[AMDA=%VNQ(
M(C50V"0#P*MGPMGPY=:5]L_X^+LW/F^5]W,PDVXSSTQG/O5@Z+=PWVHWFGZB
ML$U[/%+\]OO50B!"I&X9!QG(((HY:UE?]-'9_P# &I89-VV^>JO&U]_/_A[&
M7K.K:PUKI,MO;6T?GZC$@:&_+1SH5W+A@F2C9(.0/N\!@<U)J/C6.PO;BT*Z
M>)K.-6N%GU!8LL5W;(@5RYQW(4<CWPZ/P<T5FXCO8HKHWZ7Z-%;;8$=0!@1;
MNA&<_-DDYSVJT-#U"VU">^T[4K>&>\1?M2R69>-W4 !T42 J<#H2U*U?=?I_
MP"N;"[.SM?NNWKYC+?Q-+J&I&VTVQ22,6L-V9Y[CRU$<@)Z!6.X8&!T/.2,#
M-*S\>VEY=6NS[&;>[N!!$$O5:X!)PK-"!PI/^T2,C(ZXV;31V@UNZU&>X69[
MFVBA=!%M&4W9;J>N[IV]ZKZ7HE_H\<5G9:G$=-A?*0RVI:54Z[/,#@8ZX.W/
MUJK5]->_;Y?@9WPMGIT5M7VU_'R2,/Q#K5UK'A:6XMK!5TQ[N!([AY\2,%G0
M;O+VX"E@0/FST.*WO%#%[&UL02%U"[CMI".NPY9Q^*J1^-4&\(77]DG2(=65
M-,6<311FUS(H$@D"%]V"N1_=!Z<^NEXDMI9=/@N;:)IIK&YCNEB49+A3A@/?
M:6Q[XJ5&IRR<^R[>=[6*<Z7-"--Z)OOY6O?KIKT*TVO7RZAJ5EIFD1SKIBJ6
M9[KRPX,88*H"'GM@X'O3;?Q4VK21IX=L5O#]E2YE:XF\E8P_W4R%;+G!XZ<=
M:J)INJW7B#Q UE=?8(+LP@236A<L/) )C.Y<$<@Y#<XX&#FY#X6;2IDD\.WJ
MV1^RI;2+/!YRR!/N/@,N'&3SG!STH3K-Z;7?;OI;_@@XX:*L[7LN_97O^EOF
M-M?&%O<20-);O#;S6DT^]V^97A;$D97ID=<YYQ3;/QBES8Z?-)9F&:ZFECFA
M:3_CW6,,SL3CG@+QC^(4V[\%03Z)9Z?;W;PFWE=Y)V3<TPD#"53R/O;C],"K
M2>%X1XDO=2EF\R&ZB9/LI3 0NJ*[9SU81KV'>FOK%]?+M\_Z\P?U.SMY]_.W
MWW3^7F8^I:K>ZM'X?NWTY;:RN-3AD@<S[I"OS;2R;<+D<\,U6'\?V8N&9#9M
M:K<>0?\ 3E%R?FV[Q#CE<_[0..<=,V(O"UZD.FVLVKK+9Z9.DMNGV7$C*F0J
MN^[!PIQD*OKBK-GH=_I3/#I6I0QV#3F803VID:/<VYE5@ZX!)/4$C/6I4:][
M]_3^K%RGA6K;VV^)=?1N_P"!)IFLW>IZC=Q1Z?'':VER]O).]Q\S%1P50+SU
M&<D8SQFLZZUBUT:^\27\.GL]Q;?9O/;SS^_RH"X!X3 /;KWK9TK2_P"S#?'S
MO-^UW;W/W=NS=CY>O/3K6?J'A?[>NM#[9Y?]J>3_ ,LL^5Y8 ]><X]L5I*-7
MD5M]>W9V,(2H>T:>D=.^NJO^%_\ ARQ9:S=2:Y_9FHV"6LCVQN8C'<>;E0P4
MAOE&&&Y>F1SUJ&Z\13IXAETJRLX9I841V6:[$4DH;))B4J0X '))'/%7FTO=
MXDCU;SO]7:/;>5MZ[G5MV<_[.,8[U0UOP]=ZX)+>YU"#[#)(CB-K3,L.WKY<
MFX;21GDJ2,GMQ3E[51TWOY;"@Z#FN;16\]'^;^_YD>L^*VT.[ O;:U2W,BH
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MEC-$(_L\UB)?+QGYD(9<'GN"!M& .<HGAMH-0ED@NU:UN;6.UNH+B(NTJH&
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M=[H/^$Q\,?\ 0QZ3_P"!T7_Q5'_"8^&/^ACTG_P.B_\ BJ/^$.\,?]"YI/\
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MPF/AC_H8])_\#HO_ (JC_A#O#'_0N:3_ . ,7_Q-'_"'>&/^A<TG_P  8O\
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M_0N:3_X Q?\ Q-'_  AWAC_H7-)_\ 8O_B:/<#W@_P"$Q\,?]#'I/_@=%_\
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M_P!"YI/_ ( Q?_$T?\(=X8_Z%S2?_ &+_P")H]P/>#_A,?#'_0QZ3_X'1?\
MQ5'_  F/AC_H8])_\#HO_BJ/^$.\,?\ 0N:3_P" ,7_Q-'_"'>&/^A<TG_P!
MB_\ B:/<#W@_X3'PQ_T,>D_^!T7_ ,51_P )CX8_Z&/2?_ Z+_XJC_A#O#'_
M $+FD_\ @#%_\31_PAWAC_H7-)_\ 8O_ (FCW ]X/^$Q\,?]#'I/_@=%_P#%
M4?\ "8^&/^ACTG_P.B_^*H_X0[PQ_P!"YI/_ ( Q?_$T?\(=X8_Z%S2?_ &+
M_P")H]P/>#_A,?#'_0QZ3_X'1?\ Q5'_  F/AC_H8])_\#HO_BJ/^$.\,?\
M0N:3_P" ,7_Q-'_"'>&/^A<TG_P!B_\ B:/<#W@_X3'PQ_T,>D_^!T7_ ,51
M_P )CX8_Z&/2?_ Z+_XJC_A#O#'_ $+FD_\ @#%_\31_PAWAC_H7-)_\ 8O_
M (FCW ]X/^$Q\,?]#'I/_@=%_P#%4?\ "8^&/^ACTG_P.B_^*H_X0[PQ_P!"
MYI/_ ( Q?_$T?\(=X8_Z%S2?_ &+_P")H]P/>#_A,?#'_0QZ3_X'1?\ Q5'_
M  F/AC_H8])_\#HO_BJ/^$.\,?\ 0N:3_P" ,7_Q-'_"'>&/^A<TG_P!B_\
MB:/<#W@_X3'PQ_T,>D_^!T7_ ,51_P )CX8_Z&/2?_ Z+_XJC_A#O#'_ $+F
MD_\ @#%_\31_PAWAC_H7-)_\ 8O_ (FCW ]X/^$Q\,?]#'I/_@=%_P#%4?\
M"8^&/^ACTG_P.B_^*H_X0[PQ_P!"YI/_ ( Q?_$T?\(=X8_Z%S2?_ &+_P")
MH]P/>#_A,?#'_0QZ3_X'1?\ Q5'_  F/AC_H8])_\#HO_BJ/^$.\,?\ 0N:3
M_P" ,7_Q-'_"'>&/^A<TG_P!B_\ B:/<#W@_X3'PQ_T,>D_^!T7_ ,51_P )
MCX8_Z&/2?_ Z+_XJC_A#O#'_ $+FD_\ @#%_\31_PAWAC_H7-)_\ 8O_ (FC
MW ]X/^$Q\,?]#'I/_@=%_P#%4?\ "8^&/^ACTG_P.B_^*H_X0[PQ_P!"YI/_
M ( Q?_$T?\(=X8_Z%S2?_ &+_P")H]P/>#_A,?#'_0QZ3_X'1?\ Q5'_  F/
MAC_H8])_\#HO_BJ/^$.\,?\ 0N:3_P" ,7_Q-'_"'>&/^A<TG_P!B_\ B:/<
M#W@_X3'PQ_T,>D_^!T7_ ,51_P )CX8_Z&/2?_ Z+_XJC_A#O#'_ $+FD_\
M@#%_\31_PAWAC_H7-)_\ 8O_ (FCW ]X/^$Q\,?]#'I/_@=%_P#%4?\ "8^&
M/^ACTG_P.B_^*H_X0[PQ_P!"YI/_ ( Q?_$T?\(=X8_Z%S2?_ &+_P")H]P/
M>#_A,?#'_0QZ3_X'1?\ Q5'_  F/AC_H8])_\#HO_BJ/^$.\,?\ 0N:3_P"
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MHX(1LYRHXSBV^N:M;V5SH^HV^HIJNI/');PF:/SBD@_?^4?,PH38Y&2NW<O
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M)[!/.MI'9=L)EWDB0 _=(VX'8Y[5GIX\O7U'1(-EIF]2W-Q"!\P\TX+*3("
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M7WX.>5[4N1CYD=K17!GQCKEOISW4T%G<&:RDNH(X(64Q;)DC)<L^& #[S]S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9MRO%(#Y@W.<N'PI!8#ME\JO:XN9V.ZJ&&ZAN)KB*%]SVT@BE&"-K%5?'O\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img119790510_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) F@# 2(  A$! Q$!_\0
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M8;<S';&';EC["BUPN7J*H_VSIO\ :PTO[;";[&[R V6 QGGTXYJ]18 HHHH
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M6\EW+:I,C7$(5I(P?F4'H2/?%34 %%,DFBBQYDB)DX&Y@,T^@ HHHH ****
M"BBF^9'NV[UW>F>: '45'/<0VL+37$L<42]7D8*!^)J3.1D4 %%%% !1110
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MLEC% MC(AEDB'SW!V C/OS@4R^\,7B^-]/U2QV?8&G-Q=QEL%91&R!U'?<"
M?IFB?PK<Z@OBNWG98H]4=&MY <XVH,$C_>%/W?Z]1:_UZ&GI-UXDN9H)M0L;
M""TF0L4CE8RQ<9 .1@GUQTKC]!U;7-*\'W=]96-I)8VES<22^=*1)*!(Q;8
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MK&W^TKY+DQ31X.",\CD8(J&^LM8FU+3?$=MIZK>P1203V$DZY:-CGY7'&X$
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M9W]LP?\ /&[_ / 9_P#"C^V8/^>-W_X#/_A19A=&C16=_;,'_/&[_P# 9_\
M"C^V8/\ GC=_^ S_ .%%F%T:-%9W]LP?\\;O_P !G_PH_MF#_GC=_P#@,_\
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M>6I:[%IYZF0M@K)@@H,=#[U''XUOH)-9>[TX/%;7J6EJL4HR[MM"J3[YSN[
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M$$ENJ."DHD1U;."& 'I]/>DX- I)G24445)0450EU6&*5XS%=$J<$K;N1^!
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M'4$1(F79\^#&6'0@X//TS1R>8N;R/0%8,H92"I&01T-+7"11>*4G5%6[5D7
M *" 0^1@#'7S/,_SBMGPQ#K$!G35);B56A@=6G*DB0I^\ QV#=J3C;J-2N=%
M1114E!1110 4444 8'C*\N;#PY)/:S&&7SHEWA@N 9%!Y(('!//:N<N]<U&V
M-U"+^.2W6RAEB"S;I&8R[6*R*!NQWXZ8]Z] =%D4JZAE/4$9%5;V:RTRPEN[
MH1QVUNA9VV9VKWX%7&26EB6NIQ&J^+;^ZL-0AC$4)V2E1"S>=;^7*JCS.PW
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M)Z5G67_(7U+_ +9?^@TT(T:***0PHHHH **** "BBB@ HHHH **** "BBB@
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M?^]%_P!_%_QH^SO_ 'HO^_B_XT7069%14OV=_P"]%_W\7_&C[._]Z+_OXO\
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M]A_]#%.UHL5[M'TY54DWA*J2+<<%A_RT]A[>_>@DWA*C(MAU/_/3V'M_.K(
M   P!T K@.P  H    X %+110!P?Q;N9[?P:%AE:,2W*(^TXW+@G'TX%>$8'
MI7N/Q?8-X.A*D$?;$''T:O#Z[*'P'+5^(F2RN9+5[I+69K=#AI5C)13[GI26
M]I/="4V\+RB&,RR;!G8@ZL?:NJN-0L[_ ,-Z7%%KOV".TM_(N=/VN3*V_)8
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M ]*,#TK<'A+6/L:W1@B"O$TR(9E\QD4$L0O7C!K-O["XTR[-K=H$F"JY4-G
M8 C/O@CBFFF%FBK@>E&!Z4M%,0F!Z"OI'P&[2>!=&9V+-]F49)S7S?7T?X!_
MY$/1O^O8?S-88CX4:T=S3UK_ (\%_P"N\7_H:U?7I5#6O^/!?^N\7_H:U?7I
M7+T.CJ+1112&%%%% !1110 4444 !Z5G67_(7U+_ +9?^@UHGI6=9?\ (7U+
M_ME_Z#30C1KRSXU?\>6C_P#763_T$5ZG7EGQJ_X\M'_ZZR?^@BKI?&B:GPL\
M@HHHKN.0*FM)Q:W<4Y@BG$;;O*F7<C^Q'I5V#3+=[6&:YODMC*C2*'7@@-M
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MMSZ4^PVPZ0J/I1]AMO\ GD/S-6**\X[2O]AMO^>?_CQH^PV_]P_]]G_&K%%
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M@!.,DXZG@5G5:OU)=N@4444Q#X?^/B+_ *Z+_,5]/QVL5O((7#!&/[MPY'_
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ML+</45N6'B!+;3XK*1KA419 )89 &0LRME<]/ND'V-2T-,@_MO5))O.5LO\
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MOJ7_ &R_]!IH1HTA 8$$ @\$&EHI#,MO#>ANQ9M(L23U/V=?\*3_ (1G0O\
MH#V'_@.O^%:M%.[%9&5_PC.A?] >P_\  =?\*/\ A&="_P"@/8?^ Z_X5JT4
M<S"R,K_A&="_Z ]A_P" Z_X4?\(SH7_0'L/_  '7_"M6BCF861E?\(SH7_0'
ML/\ P'7_  H_X1G0O^@/8?\ @.O^%:M%',PLC*_X1G0O^@/8?^ Z_P"%'_",
MZ%_T![#_ ,!U_P *U:*.9A9&5_PC.A?] >P_\!U_PJ[:6-I81F.SM8;=#R5B
M0*#^56**+L+(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%J6IM:U_QX+_ -=XO_0UJ^O2J&M?\>"_]=XO_0UJ^O2N7H;]1:***0PHHHH
M**** "BBB@ K.FTE9;J2X6ZNH7D #"*7:#CIQBM&LII]0GU"X@M6M4CA"<RJ
MS$DC/8BFA,=_9#?]!+4/^_P_PH_LAO\ H):A_P!_A_A2^7K/_/:P_P"_3_\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img119790510_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_8.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<GD@0F5T
M:"!3871W:6-Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,S
M.   DI(  @    ,S.   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<&*(D= 3O8?D4KG]6U_0?$7Q2OCXUU!HM&TMFAM;95D=965MI/R \$@DGC/
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MSUG38;_39UGMIUW)(O?\.Q]JR_$.A:9)X)O].^Q0):QVLACC6, 1D*<$>A!
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M$7S(3C)KE9QOQ6E_L[Q[X6U34HVDTF"0;^,A6#@MQZXVG'?;7I\&K:?=:?\
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M/](#"*.\M_.MA[R,!A?PF/\ WS[5ZWX6\+6/A#1O[-TQYGB,K2EYV!8L<#J
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MG9C4=)N[(G:+F!XB?3<I']:M45D:'A_PL\7VW@ZZU'PUXG<V.+@NDD@^5)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#DS1R^8<WD=G17&?\ %S?^I3_\F:/^+F_]2G_Y,T<OF'-Y'9T5QG_%S?\
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M_P"%'_"3>-_^B?\ _E:A_P *.1_TT',OZ1V=%<9_PDWC?_HG_P#Y6H?\*/\
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M4&I7N3T445@:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .,^$G_)+=(_[;?\
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MD>5]W;E>GM5*"C%^@G)RDO4]$^)'BQ?"OA65[>[^SZE<#;9_NM^Y@R[NH*\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )*3?_$4>SGV#GCW.SHKC/\ A;?@C_H-_P#DI-_\11_PMOP1_P!!O_R4F_\
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MV'9',:+\/]#T+4H[^V6YGG@0QVYNIS*+=?1 >G_US73T44-M[@DEL>9_'?\
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M1B1_<*/E'OR*\_\ !V[_ (2K0/LOV_\ X23[5/\ V]YWF?ZO/R[\\8V]/?\
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M\)/^26Z1_P!MO_1SUV=<9\)/^26Z1_VV_P#1SUV=74^-DP^%!1114%!1110
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MUROP^U'PY=^'S;>$5D6SLWV-YB%6+$9))/4GUKJJSJ?$S2'PH****@H****
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M4 %%%% !1110 4444 %%%% '&?"3_DEND?\ ;;_T<]=G7&?"3_DEND?]MO\
MT<]=G5U/C9,/A04445!04444 %%%% !1110 4444 %%%% '&>&?^2I>-_P#M
MP_\ 1)KLZXSPS_R5+QO_ -N'_HDUV=7/?[OR)CM]X4445!04444 %%%% !11
M10!1UR]ETWP]J-];IYDUM:RS1I_>94) _,5Y/X>\%:OXB\+1>*;'Q5>KKMP7
ME7][^[R&(V''3I]!TQBO7M0G^RZ9=7'V>2Z\J%W\B)=SRX!.T#N3T ]Z\R\'
M^(O WA74+](9-2T66_9&:RU.%E$6W=C:0#@'<?O'L*VIMJ+Y=S*=KJYS?CCQ
MO<ZOX#ATO51)8^(;#4$2[A^X741R#>,<8)(SCCD=B*]YKC=<\+>$?B+&LXN8
M9[B-=JW=A.I<#T.,@CZCCG&*[*E.2:22'%--ME6[BACAGNO+A$RQ-^]=,X&.
MYZXKS;PC\1O#%UHXC\4OI]MJ4;LLA6T_=N >&4A2.E>HRA&A<3!3&5(<-TQW
MS7C]EJWA[5?$-C!I_@&S&D7ERUO#J$T"KYQ4$DJNWV]?R/%.FDT[A-M-6/2_
M#^L:'K-O-)X=F@EBC<+(88]@#8[\#M6O7)?#S4-+U+0YWTS1X]&N(K@PWMFB
M!=DJCG/ S^(]1VKK:SDK.Q47=7"BBBI*"BBB@#S/X[_\B+9_]A)/_14M>F5Y
MG\=_^1%L_P#L))_Z*EKTRM)? OF0OC84445F6%8VB_\ (<\0_P#7['_Z30UL
MUC:+_P ASQ#_ -?L?_I-#5+9B?0V:***D84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <9\)/^26Z1_VV_P#1
MSUV=<9\)/^26Z1_VV_\ 1SUV=74^-DP^%!1114%!1110 4444 %%%% !1110
M!QGAG_DJ7C?_ +</_1)KLZXSPS_R5+QO_P!N'_HDUV=7/?[OR)CM]X4445!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F?P(_Y$6\_P"PD_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME#Z4**** "BBB@ KNJX6NZKV,K^W\OU/*S'[/S_0****]D\HY#XE?\BW;_\
M7VO_ * ]>85Z?\2O^1;M_P#K[7_T!Z\PKY3-/]Y?HC[W(O\ <UZL****\L]P
M**** "BBB@#WZBBBOOS\F"BBB@ HHHH **** "BBB@ HHHH **** .,^$G_)
M+=(_[;?^CGKLZXSX2?\ )+=(_P"VW_HYZ[.KJ?&R8?"@HHHJ"@HHHH ****
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M\:/?Z***\P[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2I>-_P#MP_\ 1)KLZXSPS_R5+QO_ -N'_HDUV=7/?[OR)CM]X4445!04444
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MNX["I]E/0KVD=2I7=5PIZ\=*[JO5RS[?R_4\W,?L_/\ 0****]@\HY#XE?\
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M\)/^26Z1_P!MO_1SUV=<9\)/^26Z1_VV_P#1SUV=74^-DP^%!1114%!1110
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M,Z:KC1[G4(KA7C+P ,(VQQN'H>?R->7Z%XHT"318&U'X>K>W)W;Y[2P41O\
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MI5)*\8MAKG_((D_WX_\ T-:T*PM8UO2I=+D2+4[-V+)@+<*3]\>]7?[?T?\
MZ"MC_P"!*?XUDJD.=ZK9?J;NC5]DO=>[Z>AH45G_ -OZ/_T%;'_P)3_&KT<B
M2QK)$ZNC@,K*<A@>A!K:,XRV9SRISA\2:'44451 4444 %%%% !1110 4444
M %%%% '&?"3_ ));I'_;;_T<]=G7&?"3_DEND?\ ;;_T<]=G5U/C9,/A0444
M5!04444 %%%% !1110 4444 <9X9_P"2I>-_^W#_ -$FNSKC/#/_ "5+QO\
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M2I>-_P#MP_\ 1)KLZXSPS_R5+QO_ -N'_HDUV=7/?[OR)CM]X4445!04444
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M -N'_HDUV=<9X9_Y*EXW_P"W#_T2:[.KGO\ =^1,=OO"BBBH*"BBB@ HHHH
M**** (KFXCL[2:YG;;%"C2.WHH&2:\MTR7QO\1EEU6QUE?#^CM(R6L<29D<
MXR2.3Z$YQD' KTK6;#^U=!O]/W;/M=M)!N_N[E*Y_6O,_A[X[TOPOH8\,>*C
M)I5]ITLB?O8V*N&8OU .#\Q]B,$$YK:"]UM+4SEND]B5]6\6_#O6K%/$^I1Z
MSH=[,(/M)7#PL>Y[^^"6! /0UZI7COCCQ'9_$G4-+\*^%A)>+]K6>YNU0JL:
M@%21GJ &))Z= ,YKV*E46B;6H0W=MB*ZD,-G-(K*I2-F#-T&!U/M7D>@^+?
M^O68G\<P::-:1V$LIM#ME /RMN (/&.O\J[)O$UR_P 4)_#5R+?^SO[.\\EE
M^8L2!@G.,8)XQ5O_ (0_P;_T!=)_[\I1&T5J#O)Z%[P]K>B:S8G_ (1RXAEM
MK8B/;"A18^. !@=JUJH:3I>E:5#)'HMI:VL;MN=;9 H)]3BK]9NU]"U>VH44
M44AA1110!YG\=_\ D1;/_L))_P"BI:],KS/X[_\ (BV?_823_P!%2UZ96DO@
M7S(7QL*^-*^RZ^-*Z,+U,:_0****[#F"O3/@1_R/5Y_V#7_]&Q5YG7IGP(_Y
M'J\_[!K_ /HV*LJOP,NG\:/?ZJ:M_P @6]_Z]Y/_ $$U;JIJW_(%O?\ KWD_
M]!->/6_AR]&>G2_B1]4>8T445^=GW84444 =QX+_ .0++_U\'_T%:Z&N>\%_
M\@67_KX/_H*UT-?=Y?\ [K#T/C,=_O,_4Y#XE?\ (MP?]?:_^@/7F%>G_$K_
M )%N#_K[7_T!Z\PKPLT_WE^B/L<B_P!S7JPHHHKRSW KV[0/^1;TW_KTB_\
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M'(O]S7JPHHHKRSW KV[0/^1;TW_KTB_] %>(U[=H'_(MZ;_UZ1?^@"O<R?\
MB2]#YCB+^%#U-"BBBOHSXT**** "BBB@ HHHH **** "BBB@#C/A)_R2W2/^
MVW_HYZ[.N,^$G_)+=(_[;?\ HYZ[.KJ?&R8?"@HHHJ"@HHHH **** "BBB@
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M%92HTIN\HIOT.BGB:]./+";2\FT8'_"#^'?^@?\ ^1Y/_BJ/^$'\._\ 0/\
M_(\G_P 56_14?5:'\B^Y%_7L5_S]E][..TKPCHES=:FDUEN6"Z\N,>:XVKL4
MX^]ZDUI?\(/X=_Z!_P#Y'D_^*JQH?_']K/\ U_'_ -%I6O65'#4'#6"Z]%W-
M\1C,2JEE4ELNK[(P/^$'\._] _\ \CR?_%4?\(/X=_Z!_P#Y'D_^*K?HK7ZK
M0_D7W(P^O8K_ )^R^]A11170<@4444 %%%% !1110 4444 %%%% !1110!QG
MPD_Y);I'_;;_ -'/79UQGPD_Y);I'_;;_P!'/79U=3XV3#X4%%%%04%%%% !
M1110 4444 %%%% !1110!QGAG_DJ7C?_ +</_1)KLZXSPS_R5+QO_P!N'_HD
MUV=7/?[OR)CM]X4445!04444 %%%% !1110 5P7Q*U'5(-0T#3--U>;2(=4F
MD@EN8H0Y#90)SD%>K="#^5=[7&_$7POI?B*PM)==UIM*M;1F^8NJH[-C&=W&
M1MX^IJZ=E+4F=^70ATOX3^'K.X-WJOVC6[QCEIK^0N"?]WH?^!9J_HW@6ST'
MQI=ZWI3I;6UU:^2UA%%M0-N4[P<X_AQ@ =37GK^'/"-K;EA\2[H1QK]V.[#'
M'H%!R?H*]KJYN2ZD12?0@OMO]G7/F.R)Y3;F7JHP>17C_A+X>W/B;PTFK'Q9
MJ40N2_DQI*7\L!B '.>3QR!BO9R 001D'J#7BNJ:#\.X=2NH[/QC<:;%(Y\Z
MTM92T0/<#"D8_$T4F[-(*BV;,RRLM0L/"^JZ_I?B?4/[0T*[,,T3REX)\.!D
M<\J0<X.?3WKWBTG^TV4$Y&WS8U?'ID9K@-)\)>#O$?A*'1] OYIM-M;Q9[HQ
M,0UP^WH[$#J,= .@QBO1  J@*, < #M15DF.G&QYM\5]&UO5-+O9SJ"V^AV5
MKYQMT'SW$P)X;_9'RGZ]NXS=;NYK3]G*R\ARAF@AB8@X.TMR/Q Q]#7H/C#3
M;G6/!^IZ?8J'N+B I&I8 $GW-83^"KC4_A';^&KUEM[V.W0!L[E213D9([=C
MCL:<9KE5^C)E%W=NQSWB;3++PIKW@.YT6VCM9/M"VLIA0*9D;8#N]3\S<GNQ
MKJ/%OQ+T?P;JT6GZG;7TLLD G#6\:,NTLRXY8<Y4UE6WAGQ-KVO:!/XH@M+.
MUT$;U\B8R-=2C;AL?PC*@\^_KQZ+2DUI?4<4];:'@?Q+^)>C^,O#=OI^F6U]
M%+'=K.6N(T5=H1UQPQYRPKWRO,_CO_R(MG_V$D_]%2UZ91-IP5O,<;\SN%?&
ME?9=?&E;87J95^@4445V',%>F? C_D>KS_L&O_Z-BKS.O3/@1_R/5Y_V#7_]
M&Q5E5^!ET_C1[_535O\ D"WO_7O)_P"@FK=5-6_Y M[_ ->\G_H)KQZW\.7H
MSTZ7\2/JCS&BBBOSL^["BBB@#N/!?_(%E_Z^#_Z"M=#7/>"_^0++_P!?!_\
M05KH:^[R_P#W6'H?&8[_ 'F?J<A\2O\ D6X/^OM?_0'KS"O3_B5_R+<'_7VO
M_H#UYA7A9I_O+]$?8Y%_N:]6%%%%>6>X%>W:!_R+>F_]>D7_ * *\1KV[0/^
M1;TW_KTB_P#0!7N9/_$EZ'S'$7\*'J:%%%%?1GQH4444 %%%% !1110 4444
M %%%% '&?"3_ ));I'_;;_T<]=G7&?"3_DEND?\ ;;_T<]=G5U/C9,/A0444
M5!04444 %%%% !1110 4444 <9X9_P"2I>-_^W#_ -$FNSKC/#/_ "5+QO\
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M -N'_HDUV=<9X9_Y*EXW_P"W#_T2:[.KGO\ =^1,=OO"BBBH*"BBB@ HHHH
M**** "O/?B796UWKWA/^V49]&^UR1W0^;:791Y8..>H(_.O0JY/QSXL?PY'I
M]G9Z2VK7^I2LMO;=CLP23P>F1_//%73OS:$SMRZGD6HV>@Z(UUI$>F,WB6QU
M@+9(5+K<P%P4#@Y4@J<8(ST]37T37F#^)_&SW2W3_#R%KA!A92X+J/0'K7I]
M75;=KD4TE>Q!?%!I]R92RQ^4VXIU P<X]Z\)\*>*/AYIN@QV6MZ']INX68-=
M-:+)YPW'#<G(XQQVKU^XU76D\3RV,6C^9IJVID6\W?>DQPF*Y#_A*?''_1/H
M_P#OX*=/16_6P3WO^AT?@/5O#6KZ?=2>$K 64"2A95$ BW-CK@=>*ZJN>\(:
MEK&I6=P^NZ&NCRI(!'&ISO&.M=#64OB+CL%%%%24%%%% 'F?QW_Y$6S_ .PD
MG_HJ6O3*\S^._P#R(MG_ -A)/_14M>F5I+X%\R%\;"OC2OLNOC2NC"]3&OT"
MBBBNPY@KTSX$?\CU>?\ 8-?_ -&Q5YG7IGP(_P"1ZO/^P:__ *-BK*K\#+I_
M&CW^JFK?\@6]_P"O>3_T$U;JIJW_ "!;W_KWD_\ 037CUOX<O1GITOXD?5'F
M-%%%?G9]V%%%% '<>"_^0++_ -?!_P#05KH:Y[P7_P @67_KX/\ Z"M=#7W>
M7_[K#T/C,=_O,_4Y#XE?\BW!_P!?:_\ H#UYA7I_Q*_Y%N#_ *^U_P#0'KS"
MO"S3_>7Z(^QR+_<UZL****\L]P*]NT#_ )%O3?\ KTB_] %>(U[=H'_(MZ;_
M ->D7_H KW,G_B2]#YCB+^%#U-"BBBOHSXT**** "BBB@ HHHH **** "BBB
M@#C/A)_R2W2/^VW_ *.>NSKC/A)_R2W2/^VW_HYZ[.KJ?&R8?"@HHHJ"@HHH
MH **** "BBB@ HHHH XSPS_R5+QO_P!N'_HDUV=<9X9_Y*EXW_[</_1)KLZN
M>_W?D3';[PHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,
M_@1_R(MY_P!A)_\ T5%7IE>9_ C_ )$6\_["3_\ HJ*O3*UJ_&R*?P(****R
M+"BBB@ HHHH **** "BBB@ HHHH **** "BJ=_I[7Q39?7=ILS_Q[LHW9]<@
MU4_L&7_H.:K_ -_4_P#B*SE*:=E&_P!QM&%-J[G;Y,-#_P"/[6?^OX_^BTK7
MK#B\,^0TK1:QJ:-*^]R)$^9L 9^YZ 5+_8,O_0<U7_OZG_Q%94W4C&SC^*-Z
MJI3GS*?;H^QKT4V)/*A2,NTA50N]S\S8[GWIU=)Q,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** .,^$G_ "2W2/\ MM_Z.>NSKC/A)_R2W2/^VW_HYZ[.
MKJ?&R8?"@HHHJ"@HHHH **** "BBB@ HHHH **** .,\,_\ )4O&_P#VX?\
MHDUV=<9X9_Y*EXW_ .W#_P!$FNSJY[_=^1,=OO"BBBH*"BBB@ HHHH ****
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MO_7O)_Z":MU4U;_D"WO_ %[R?^@FO'K?PY>C/3I?Q(^J/,:***_.S[L****
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M;_\ ;A_Z)-=G5SW^[\B8[?>%%%%04%%%% !1110 4444 ([K&C.[!549+$X
M'K7#>/O#\7C*/3TM/$EMIXLW:0\A]S';M8$,,$8//O797]E#J6FW-C= F"ZB
M:&0 X)5@0>?H:XK_ (4QX/\ ^?:Y_P# EJT@TG>Y$DVK&9;>!O%<T>+7XD3S
M*O&5#/CZG?7J%>+>.O"=A\-H],\1^%I;FWN([Q8GB:4LLBE68Y[X^7!'0@U[
M33J:I,4-&T1W"R/;2K ^R5D(1C_"<<&O.O\ A%_B=_T.5I_WX'_Q%:OBWP(N
MN:A+JLFO:E8(D(W0VKX7"@G./6N,\)?#VX\3>&DU8^+-2B^TL_DQI*7\H!B
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MM>W:!_R+>F_]>D7_ * *\S_X4C?_ /0YW'_@*W_QVKT?PL\211K'%\1M41$
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M$FNSJY[_ '?D3';[PHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGI]%<SXP\+ZGXD^Q_P!E>)+O0_L^_P S[,&_?;MN,[77IM/KUKF?^%7^)_\
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M+_\ 'J.6'\WYCYI=CTRBO,_^%7^)_P#HI.K?E+_\>H_X5?XG_P"BDZM^4O\
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M'OCH>^,'G!KV!'61%="&5AD$=Q1.-K6>@1=_46BBBLRPHHHH **** "BBB@
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MAZ?':"3[[ EF;V+,22/;-:U%%-MO5A:VP4444@"BBB@ HHHH **** "BBB@
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M;I'_ &V_]'/79UQGPD_Y);I'_;;_ -'/79U=3XV3#X4%%%%04%%%% !1110
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M'O!_PF/AC_H8])_\#HO_ (JC_A,?#'_0QZ3_ .!T7_Q5'_"'>&/^A<TG_P
M8O\ XFC_ (0[PQ_T+FD_^ ,7_P 31[@>\'_"8^&/^ACTG_P.B_\ BJ/^$Q\,
M?]#'I/\ X'1?_%4?\(=X8_Z%S2?_  !B_P#B:/\ A#O#'_0N:3_X Q?_ !-'
MN![P?\)CX8_Z&/2?_ Z+_P"*H_X3'PQ_T,>D_P#@=%_\51_PAWAC_H7-)_\
M &+_ .)H_P"$.\,?]"YI/_@#%_\ $T>X'O!_PF/AC_H8])_\#HO_ (JC_A,?
M#'_0QZ3_ .!T7_Q5'_"'>&/^A<TG_P  8O\ XFC_ (0[PQ_T+FD_^ ,7_P 3
M1[@>\'_"8^&/^ACTG_P.B_\ BJ/^$Q\,?]#'I/\ X'1?_%4?\(=X8_Z%S2?_
M  !B_P#B:/\ A#O#'_0N:3_X Q?_ !-'N![P?\)CX8_Z&/2?_ Z+_P"*H_X3
M'PQ_T,>D_P#@=%_\51_PAWAC_H7-)_\  &+_ .)H_P"$.\,?]"YI/_@#%_\
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MA<TG_P  8O\ XFC_ (0[PQ_T+FD_^ ,7_P 31[@>\'_"8^&/^ACTG_P.B_\
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M\(=X8_Z%S2?_  !B_P#B:/\ A#O#'_0N:3_X Q?_ !-'N![QB_"3_DEND?\
M;;_T<]=G4-I9VNGVJ6UA;0VMO'G9%#&$1<G)P!P.234U*3O)L<59)!1114C"
MBBB@ HHHH **** "BBB@#@-)UG3-)^*7C/\ M74;2Q\W[#Y?VF=8]^(3G&XC
M.,C\ZZ;_ (3'PQ_T,>D_^!T7_P 54UWX:T+4+I[F_P!%TZZN),;Y9K1'=L#
MR2,G@ 5#_P (=X8_Z%S2?_ &+_XFM&XO<A*2#_A,?#'_ $,>D_\ @=%_\51_
MPF/AC_H8])_\#HO_ (JC_A#O#'_0N:3_ . ,7_Q-'_"'>&/^A<TG_P  8O\
MXFE[@_>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T
M+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5
M'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\
MP!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[
MPQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T
M7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S
M2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_
M (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_
M .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_
M *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\
MXJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0
MQZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PA
MWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #
MHO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?
M#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 3
M1_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG
M_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#
M_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7
M_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^
MACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]
MP/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_
M^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8
M^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_
M^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T
M+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5
M'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\
MP!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[
MPQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T
M7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S
M2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_
M (0[PQ_T+FD_^ ,7_P 31_PAWAC_ *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_
M .!T7_Q5'_"8^&/^ACTG_P #HO\ XJC_ (0[PQ_T+FD_^ ,7_P 31_PAWAC_
M *%S2?\ P!B_^)H]P/>#_A,?#'_0QZ3_ .!T7_Q5'_"8^&/^ACTG_P #HO\
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M;*_BN$NTLY+/RE:9)'&4X5B"".05)Z_7$?B/P?;ZE9Z:NFVFGK_9DQDALKB
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M]U#['&);I[54*P*1N&=S+N.WG"[CC''(SF7GA.^N-&\66B2VXDUJ9GMR6;"
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MRB/RHIHT9KAG)"HFQV!8D8VD@C.3@<UGZWXAM;C1+^"_&KZ-<6S0-)' T:W
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MLL<J[R,NW.WRAM4\DC<V..M)K?@R_P!0TS28;&ZAMYX;0:??/N8"2V95$@7
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M.]5=)55&ACQ<"/#.V[-DM_\ ZE3O_<";?QCRMVS=[8YQ3=)=!*J^IZQ17+>
M]WV#4?LV[^R?MS_V9NSCR-J_<S_RSW;MOMTXQ74UC)<KL;1?,KA1114E!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img119790510_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_9.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ),! T# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&.!FE7YJ "BC!I* %HHHH
M**:7 [CT'O2JVZ@!:*** "BBB@ HK,\0>)M)\)Z7+J6MZG9Z1IT7W[J^G6&-
M?3+,0*S?"'Q*\*?$"*:3PQXDTKQ D'^M.FWD<WE_[VTG% '2T4BY[TM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44W<>.*7-(!:*3--:3:"3P
M* 'T57M;^VO=WV>XAGV_>\J0-CZXJ?-/8!:*3-&:5P%HI-U&:+@+129I:8!1
M110 4444 %%%% !129I-U #J*89,=1BD$P+$ J6'4 \B@"2BDW?G29/I0 ZB
MDS1W]J %HI,\T;CZ4"%HINZHIKZ"V($TT<1;[OF.%S],T#6NB)Z*:&R,TZ@
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M^%M%;4+K5/$D)FB1H0%L_E=@LQW<.0A.T9QD>M?0:YQS7R1_P3=\,:,W[/\
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M\K&BCA$!YQR2>M<5_P /+?A1_P ^?B+_ , !_P#%T?\ #RSX4?\ /GXB_P#
M ?\ Q=5_9F-_Y],/:1/K*BO&_A'^UK\,OC1>C3]!UW[/J[?=TS4HS;SO_N!N
M&_X"37L6X9QWK@JTJE"7)5C9^92DI;#J***R*"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#GK'X>^&--\27'B"TT#3K77;C=YNI0VR+<2;OO9<#)
MSBC0?AWX8\+:I>:EH^@:=I>H7A)N;JTMECDFRVX[F R<DYY[UT-%7[2;W8N5
M=CGM"^'GACPOJUYJFC^'].TS4KS(N;NTMDCEFR=QW,!DY///>JEQ\)?!5WXF
M'B*;PIH\NNAQ(-0:RC,V\=&W8^][]:ZRBG[2=[\S%RQ[&#X=\!^'/!\UY+H>
MAV&D2WK;[EK*W6(S,,X+X')Y/7UK,LO@_P" ].U6[U&U\(:);ZA=*Z37$=C&
M'<.,."0.X)SZYKL>XK\W/V1=>U6]_;@\4VMQJE]<VJR:KMMYKEWC&)>,*3CB
MO0PN'J8B%:K&=N17?F85)QIN,;;L_0OP[X/T/PCI)TO1-(L])TTLSFTLX%CB
M);[Q*@8YK M?@?\ #VQUI-6MO!.@P:DDGFI<QV$:NK@YW#C@Y[BNWHKSU4FK
MM2>IORKL<OXN^%WA#Q])%)XC\,Z7K<L0VI)>VJ2.H] Q&<>U/T[X:>$](\.W
M6@V/AO2[31+H$7&GPVJ+#,#P=Z@8;\:Z6BCVD[*/,[!RJ][&5X;\*Z-X-TP:
M=H6EVFD6"NT@M;*%8HPQZG:.,FM6BBH;;=V,****0PHHHH **** "N2UKX2^
M#/$6H2W^I^&=,O;R4[I)YK96=STR3CFNMHIW:V-:5:I1?-2DXOR=C*T/PGHO
MABW,&D:59Z9$QRRVD*QACZG YIFF^#="T?5+C4K#1[*SU"XSYUU! J229.3N
M8#)R>:V**+L;K5&VW)Z[Z[^IS>N_#7PKXHO%N]6\.Z;J-TO_ "VN+9'?\21S
M6J= TPZ2VEFPM_[-9/*-IY0\HK_=VXQBK](V>U%V#KU9)1<W9;:O3T,:W\$^
M'[70Y=%AT:QATB7[]C' HA;/7*XP:QO$T?@+P7X733M?_L'1?#[.%2UU!HH;
M=F)X 5L G/IWKY9_;%U']K726OIOAZNER^$@<J_AF'?JJ(!GYUER?QCK\G/%
MGB77?&>J3WGB35]1UG4F=O,FU*X>616SS]X\$'MQBB['[:K_ #O>^[W[^I_1
M!<>"?#U_H,>BSZ+8S:/& ([)H%,*CKPN,"JUO\,_"5HMFL/AO2XQ9MYEMMM4
M_<MD'<O'!R!S[5Y9^Q#\8!\:?V;_  IJ\TRR:K8P_P!E:@N[)$T("9/NR[6Y
M_O5[Q1=C6(K15E-V]68\O@[0IM<76I-(LWUA>E^85\X8&/OXSTXHUSP=H7B:
M6"75](L]3DM^86NH5D,?(/RY''05L4479/MJB::D[K;4P]>\#>'?%$T,NL:)
M8ZG+"NV-[NW60H,YP"1Q3=?\ ^'/%4,,.KZ'8ZC'"-L8N(%<H/0$C@5O4478
MXXBM"SC-JVVKT]#!TWP#X;T?2[G3;'0M/M+"Z&V>WAMU5)1T^8 ?-^-7=#\.
MZ7X9L_L>D:=;:;:[B_DVL0C3<>IP.]:-%%V*5:K.ZE)N^^NX5D-X/T.371K;
M:39MJX&T7QA7SL8QC?C/2M>BD1&<H7Y7:X@&*6BB@@**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HI,\FC- "T4UF"]6 ^IK)O/%VAZ>[+<
MZS80.OWEDN4!'X9JE&4M$C.52$%[SL> ?MZ?&74_A/\ !^*VT*X:SUKQ#<_8
M(KI&P\$6TM*R^C8PH/;=7Y81PB$$#EB<EF.2Q[DGN:^[/^"EOB[1?$?AWP'%
MI>J6NH2PZA<-(MO*'*@QK@G'TKX6K]+R.BJ.#3Y;-MW/4RE4J\IU4T[:+K]P
MM%)17O7/I^5=A:*2BC?<.5=@5I(9HKB"5[>ZA820SQ,5>-@<A@1T(-?KI^QU
M\7[WXT_ _2=7U9_-UJS=]/OI<8\V2/&)/JRE2??-?D77Z#?\$\?B/X9\(_!/
M4K/6=;M--NFUJ>013OM;:4CP?T-?/9Y0=?"J48WE%JUO,^4S=T<+4A5DU&][
M]/0^W:*X7_A>/@+_ *&O3C_VUH_X7EX"_P"AJT[_ +^U\!]4Q'_/N7W,\/\
MM#!_\_H_^!+_ #.ZHKA?^%Y> O\ H:M._P"_M'_"\O 7_0U:=_W]I?5,1_S[
ME]S#^T,'_P _H_\ @2_S.ZHKA?\ A>7@+_H:M._[^T?\+Q\!?]#5IW_?VG]4
MQ'_/N7W,/[1P?_/Z/_@2_P SNJ*X7_A>7@+_ *&K3O\ O[1_PO+P%_T-6F_]
M_:/JF(_Y]R^YA_:&#_Y_1_\  E_F=U17"_\ "\O 7_0UZ=_W]H_X7CX"_P"A
MJT[_ +^T?5,1_P ^Y?<P_M#!_P#/Z/\ X$O\SNJ*X7_A>/@+_H:M._[^T?\
M"\O 7_0U:=_W\H^J8C_GW+[F']H8/_G]'_P)?YG=45PO_"\O 7_0U:=_W]H_
MX7EX"_Z&K3?^_M'U3$?\^Y?<P_M#!_\ /Z/_ ($O\SNJ*X7_ (7CX"_Z&K3O
M^_M'_"\? 7_0U:=_W]H^J8C_ )]R^YA_:&#_ .?T?_ E_F=U17"_\+R\!?\
M0U:=_P!_:/\ A>7@+_H:M._[^T?5,1_S[E]S#^T,'_S^C_X$O\SNJ*X7_A>7
M@+_H:M._[^T?\+R\!?\ 0U:=_P!_:/JF(_Y]R^YA_:&#_P"?T?\ P)?YG=45
MPO\ PO+P%_T-6G?]_:/^%Y> O^AJT[_O[1]4Q'_/N7W,/[1P?_/Z/_@2_P S
MNJ*X7_A>7@+_ *&O3O\ O[1_PO+P%_T-6G?]_:/JF(_Y]R^YA_:&#_Y_1_\
M E_F=U17"_\ "\O 7_0U:=_W]H_X7EX"_P"AJT[_ +^T?5,1_P ^Y?<P_M#!
M_P#/Z/\ X$O\SNJ*X7_A>7@+_H:]._[^T?\ "\O 7_0U:=_W]I?5,1_S[E]S
M#^T,'_S^C_X$O\SNJ*X7_A>/@+_H:M._[^4?\+R\!?\ 0U:=_P!_:?U3$?\
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MJT[_ +^T?\+Q\!?]#7IW_?VCZIB/^?<ON8?VA@_^?T?_  )?YG=5^9W['?\
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MD$[U^5U*D#. ?E%?1^<T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;W.?TK1\'?#BT\5:/]NG\6:/HC^8T?V:_D(DX_B^AH>+HQIJLW[K\G^5KA'
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MZ/Y__L3,O^?+/+2H;J* H'8?E7J7_#.WB;_GYT__ +^-_A1_PSOXF_Y^=/\
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M_P ,[>)O^?G3_P#OXW^%']HX3_GX@_L3,O\ GRSRTJO]U?RI:]1_X9V\3?\
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MO#;=WT?K8]\7ZYIU-7.?:G5]\CY0****8!1110 4444 %%%% !1110 4444
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M^<_0KS$_YZ)_WV*/,3_GHG_?8K\]?^'9?CK_ **E9?\ ?JY_^+H_X=E^.O\
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MM==FNWDS@E9D965BCJ<JRG!!]1Z5],? S]I1C+;>'O%UQNR0EMJLA_ )*?\
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M=!9DM%1?;+;_ )^8/^_R_P"-'VRV_P"?F#_O\O\ C0%F2T5%]LMO^?F#_O\
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M (JNIJ_X?MX[S7],@F0212W44;H>A4N 1^1I<L>QG4X>R:G!S>%CHK[(X?\
MX5EX>_Y][K_P-F_^*H_X5GX>_P"?>Z_\#9?_ (JOO?XU:'\(O@OJ>EV-S\+S
MK#7T!F$EJS83!Q@Y/6O/O@W\*]$^-GQDEU2P\+MI'@*Q4?:-/DE *S!,JA&<
MD,>365X6O8^!P^-R"MA9XZ>7<E**;YFHZ]+*SO=O8^1Q\-?#O:"X/_;]+_\
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M^NITWK,S$;=HP<8QT'>E[E['FJ7",L32PL:=-RJ*Z=E;MOYO8^7O^%9>'O\
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MB,\B@':,X' ]S6+6T(\J2/T'A_*_['RZGA))<R6K75]_^'/J?4O^3![+@?\
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M:6F1D/&&W;@>0PI]?6IW/GPHHHI@%%%% !1110 4444 %%%% !1110 4444
M%%%% "&O$/VM/%!T;X=Q:7&Q6;5K@1'!_P"6:_,WX=!^->WMTKXX_:Y\0?VE
M\1+334D+1Z?:#<H/ =SD_C@"O>R/#K$8^">RU^X^3XHQ;PF5U''>7N_?_P
M\/K4TWP_JM]IM]JUC;2O::;M-Q<Q-CR=WW3G.>W:LNO3KK4+7P[\ +/3H9XS
MJ6O:DUQ<I'("PAC& & Z<@<'K7ZQBJTJ2C&"NY-+Y=?P/P+ X>%9SE4E91BW
M\^B^\\SED>:1I)&9W<[F9CDD]R36AX9T.7Q-X@L-+A!W7,H0D=E_B/X#-9M>
MN_LYZ"+K7=0U>1,K:1"&)O\ ;?K^@_6JQE;ZMAY371:&F685XW%TZ+ZO7\V>
M]V=K%I]K#:P+LAA18T4=E P*EHHK\M;N[L_?HQ44HK9!1112*"BBB@ HHHH
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MG^C/=Q%&GF5%XO"JTU\4?U1]7BEI <_2EK[='S(4444P"BBB@ HHHH ****
M"BBB@ HHHH **** $/:OSX^,&L#7?BAXENP<K]L:)3ZJGR _^.U^@5W,MM:S
M3,<+&C.?H!FOS6U.Z^VZI>W.<^=/))GZL37W?"=.]:I4?1)'Y7QY6M0HT;[M
MO[D5U!9@ ,DD #W-:_BSPCJ/@?6&TS5(XX[SRTF*Q.'&UAD<^M0>'(X9O$6E
M)<RI!;&[B\V20X55W@DD^F*Z3XSZW!XB^)VO7MK.MS:&58X98V#*45 !@CJ.
M*^\E5G]:C27PV;?X6_4_*84:;P4J[?O<R2^YWT^XXJOIKX#Z4NG_  ^@GQ^\
MO9GG8^H!VC^5?,C?=/TK['\'V*Z=X3T:V5=GEVL8(]]H)KQ\^J<M&,%U9]9P
MC1YL5.J_LK\S7HHHKX4_6 HHHH&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M5G>)/$FE>#]!O=:US4(-*TFS0R7%W<N%1%'OW/H!R:-%JP5V[&D 6( &2>@%
M>'?'/]L3X>? I9K*]O\ ^WO$:@[=%TME>16[>:_W8Q]<GVKY:^,7[9_CK]H+
MQ,? /P4T[4+2RNF,1O;==M]>+G!;=_RPB]\Y]2*]&^ ?_!.70?#/D:Y\39U\
M3ZVQ$QTF)S]CB8\_O6^],WKT'UKE=64WRTE\SKC1C!<U5_(\EOOCU^T3^U]?
M3Z9X!TNX\.>')28W;2R88E0G_EM>-@GZ+BN^^&O_  3$M&D74OB3XLN-3O),
M/+8Z02 6]'G?+-^ %?<FGZ?::/I\%CI]I!86,"[(K:VC$<:#T"C@5/35!-WF
M[L)8A[4U9'G?P_\ V=_AK\+XP/#G@S2[2;C-U/"+B=B.A,DF3GZ8KT;<VT+G
MY1T4<#\J;170HI;'*Y.6["BBBF(****8@HHHI#%J#4;&UUBU:VU"U@U"V;AH
M;N)94/U# BIJ* V/GSXE?L(_"'XC"::/0F\+:C*Q8WFAOY0+'N8CE#^0KYB\
M0?L9_&W]G/4GU_X4>)[C7+.'YFCTR0PW..X>V8E)!CT_*OT@I1VK"5"$M=F=
M$:\XZ/5'PA\(/^"D4VGZD/#_ ,8-!DTN\A;RI-6L;=D:-NG[^W/*_5?RK[:\
M,>*-&\:Z);ZQH&J6NLZ5<#,5W9R!T/MQT/L<$5Q'QG_9T\"?'C3C%XHTA#J*
MKM@UBT BO(?3#@?,/]ELBOA+Q5\+?C%^P3XDD\3>$=2DUOP9(_[ZXCC+VTBY
M^Y=0?P-T'F#CT-9\U2C\6J->6G6^'1GZ<45XE^S=^U=X5_:*TDQ6K+HWBFWC
MWWFB3R#=@=9(6/WX_P!1WI?#?[4_AWQW^T GPT\*^7K$=K9W%SJ.L(^85>/:
M!%%C[_)Y;IV%;JI%I.^YS.G--JVQ[91116AF%%%% !1110 4444 %%%% !11
M10 4444 %%%-EEBMX9)II%BAC4O)(QP$4#))]@!0!\R_M_?' ?"OX.R:%I]R
M(?$'BC=9Q[6P\-J!^^D_+Y1_O55_X)[_  /'PR^$?_"3:C:^5K_BC;<'>N&A
MLUSY*?CDO^(KYG9KC]NC]LO:IDD\&Z<_'7:FG0-UP>AE?\]WM7Z>0PQV\,<,
M$:PP1J(XXHQA44# 4#L ,"N2G^\J.IT6QVU+4J:IK=[CJ***ZSB"BBB@ HHH
MH **** "BBB@ HHHH **** %7[PSR*^0/'VE#1/&FLV:+MCCN6*#_9/S#^=?
M7U?-G[0-G]G\?>=C N+6-_KC*Y_2OI<CJ<N(<.Z/A^+*//@XU>L6>:,=JDX]
MZZOQUX$/@N#0)Q>"^BU:Q6]5U3:$R>4Z\XXKE:[;Q=XPT[Q!X \':7'YQU31
MTFAF9DPA1F!7![]*^NKRJJK24/A;:?W:?B?F>&C0E0JJH[227+]^OX'$^M?;
MG[+NM/JWPCTZ-R"]E+):CZ!LC]#7Q'7U=^QKJGG>&-?T\GFWO%F'_ TQ_P"R
M5\_Q-3Y\#S/HU_D?5\%5O9YGRW^*+_S/HJBBBOR<_?@HHHH **** "BBB@ K
MY[_:B^#G_"2:6WBO2+?&K6*9NHXQ\UQ".<C'\2]?I]*^A*8ZAE*D9!X(->;F
M&!IYA0E0J]?P?1G7A,5/!UE6I[K\?(\7_9G^+Q\?>&SI&IS;M<TU%!9CS/#T
M5_J.A_/O7M6X'H<U\7_$O1+O]GOXRV?B'2$*:5=2&XBC7[I4G]]"?SX^H]*^
MP=!UFV\1:/9:G9.)+2ZB6:-@>Q&:\C(\94G&>#Q/\2EH_-=&>EFF&A"4<50_
MAU-?1]4:%%%%?4GA!1110 4444 %%%% !1110 4444 %%%% &/XRE,/A'6G'
M\-E,?_'#7YN1#$:_2OT<\?,5\#Z\1U%C-_Z :_.2/_5K]*_1^$_@JOS7ZGXW
MQZ_WM!>3_0U?#7A^Y\6:]8Z/9E%NKR3RHS(<+G'?';BJNIZ?)I&I7=A+M,MK
M*T+F,Y7*G!Q[<5TWPAU:ST'XE:!J%_<1VMG!/NEFD.%4;3UK"\37$=YXDU:X
MA=9(9KN61'7HRER017V2J5'B7"WN\J^^_P#D?G4J5)8-5;^^Y-?+3]3/AB\^
M>*+_ )Z.J_F<5]L6\8BMX4'1(U4?@ *^+M+4-JMB#T^T1_\ H8K[4QMX]*^:
MS]ZTUZ_H?=<'1TK2] HHHKY _2@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***6@!**
M<%+<@''K2$;>#P:!V9B>-/&>B_#WPOJ'B+Q#?QZ=I%A$99YY#V[*H[L>@ ZF
MOS;\3>*?B'_P4.^*XT'0DDT7P-ILGF".7/D6D6<>?<8^_,P^ZO;MW-?HA\5/
MA5X;^,W@ZZ\,^*;(WNF3,)%*.4DAD&=LB$=&'Y57^#OP?\.? [P/;>&/#=N4
MM8R9)[F;!GNY3UDE8=3V] .E<]2G*I)*^AT4ZD:<6[7D4?@C\!O"?P!\+C1_
M#-I_I$H!O=4G -S>./XG;L/11P*]$HHK=)15D<\I.3NV%%%%4(****0!1110
M 4444 %%%% !1110 4444 %5-8N-/M='OI=6>VCTI(6-VUX5\@18.[?NXV_6
MK=<[X\^'?AWXG:"VB>*=,36-)9Q(]I)*Z([#INVD9'L<BA[:#5KZGX]?'[6/
M 4GQ<U6]^$\=[I?AW)5'$A1&D.1(8,?,L1[ GH?2O:O^"9%@)?CYJMSM_P"/
M;0I@/;>Z#^E?9LW[$?P.FSGX?V:?]<[B8?\ L]=)\,?V<_AO\%]>O-5\'Z*F
MC:A=P?9IG^UO(&CSG&&8XY[UYT,/.,^=L]5UE4IN$(MOT/3**5AMZ\=^:BM[
MB&ZC\R":.>/.-\3AUS]17HGE\LK-VT1)11102%%%% !1110 4454_MC3SJ/]
MGB^MC?XS]E\Y?-Z9^YG/2@N%.=2_(KV+=%+24$!1110 5!J&GVVK:?<V-[ E
MU9W,;0S02#*R(PPRD>A!J>E967&5(^HH#S/._A5^S_X&^"=]KEUX.T;^RGUA
MT>X7S#(J!<X2//*IDD[<]:]#HHH225D#;D[L**** "BBB@ HHHH **** "BB
MB@ HHHH **** "O!?VDX NL:'/CYG@D0GZ-G^M>]5X;^TI_Q\:!_NR_S6O:R
M=VQD?F?+<2)/+9W\OS/%.U=6W@F,?"\>+!=N9O[2^P-:[1@#;D-GUKE*["+Q
ME:K\)[CPL\<IO&U1;Z.0 >6$V@$$]<]:^ZQ/M5[/V7\ROZ=3\CP?L&ZGM_Y7
M;UZ''^M?2O[%\V+SQ3%GJD+8_P"^A7S57T;^QC_R&O$W_7"+^9KRL_UR^I\O
MS1[O"K:S>C\_R/JNBBBOQL_HT**** "BBB@ HHHH *,444 >;_'[P /'_P .
M-0MX8U;4+,&[M#WWJ.5_$9'Y5YQ^QYXZ.H^']0\+7#DS:<?M%L&_YXL>5_!O
MYU]',,C&,^U?&<:GX+_M0*D8,>G75U@#H/)G_GAC^E?%YLOJ./H8^.B;Y9>C
MV/ILO_VS"5<$]U[T?5;GV8OW12T45]H?,A1110 4444 %%%% !1110 4444
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MK\XX?]6OTK](X3^"KZK\F?C/'W\:AZ/\T;G@WPQ+XT\4:=HD$R6\UY)Y:RR
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M=Z78ZA(LEW8VMU*HP'G@5V'XD9JS119%JO5B^93=_4CDMH)HQ')!%)&OW4=
MRCZ C%/55C4*JA548"J, "EHH,W4G)6;"HXK6"!F,4$4);[QCC"Y^N!S4E%
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MQ!\5/Y_H?><'?#6^7ZB4445\D?I 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 'P*/L\/_/&/_O@4?5WW#_7&/_/G\3R:BO6?L\/_ #QC_P"^!1]GA_YXQ_\
M? H^KON'^N,/^?/XGDU"GYE^M>L_9X?^>,?_ 'P*/L\/_/&/_O@4UAVNI$N,
M(RBU['?S'K]U?H*6CVHKL/S:<N:3EW"BBB@DX#XV_!VP^.'@^+P]J.HW.F6\
M=VEV)K5%9BRA@%PW&/F_2MWX=^";?X<^"-'\,VES+>6^FP^0EQ, '<;B<D#C
M/-=%16WMJGL_97]U.]A6ZA1116(PHHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBE'S' Y- "45)]GE_P">;?E1]GD_YYM^5 $=%2?9Y/\
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M9Y/^>;?E1]GD_P">;?E2&1T5)Y$G_/-ORH\B3_GFWY4 1T4K*5.&!!]"*2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7XO\
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M]O=D@""1"K'/3 -.R.M93D\IN"I0NNFE_P SR/\ X4):_P#0\>./_!]+2_\
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M7MI_5*3T6_KV^1^K\&Y+["G]?K+WI?#Y+N I:**^%/U(**** "BBB@ HHHH
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MJS2ZL+F*\MG&1)"V15JOEY1<79[GW\91FE*+N@HHHJ2PHHHH **** "BBB@
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M&N+AA\D$?=F/\AW-?=O@'P)IOP]\.6^D:7'MBC^:25A\\SG[SL?4UXF>9O'
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M_:_FW^%1]0K?RO[CZ7_B)E/^6'_@1XI_8>I?] ^Z_P"_+?X4?V'J7_0/NO\
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M$O\ H/VWYM_A1_PM;PE_T'[;\V_PH^H5OY7]P?\ $3:?\L/_  (\3_L/4O\
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M^%J>$?\ H/6OYG_"C_A:GA'_ *#UK^9_PH^K5OY']P?7\)_S]C]Z.JHKE?\
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MWI:_+*E2=6;G-W;W/W2C1IX>FJ5)6BMD%%%%0;!1110 4444 %%%% !1110
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M/!Z'-:OA?X=:?XBT>.^N/&>BZ-*Q8&TOF82+@XR<>M*6+I1I*L_A?D_^'''
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M'_JUF_\ SX9X-C\*,#TKWG_ACGQ9_P!!C2/_ ")_\31_PQSXM_Z#&D?G)_\
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M6=9>]%57XF]'A7.Z\_9TL-*3?;4\OP/3]*#SUK9;PQ.&($T)'KS2?\(S<?\
M/6']:U_M; _\_5^)Z_\ Q#[BC_H"G^'^9CX'IBBMC_A&;C_GM#^M+_PC-Q_S
MUA_7_"C^UL#_ ,_5^(?\0^XH_P"@*?X?YF+M'H/RI<5L?\(S<?\ /6']:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HP/2BB@ HZ=:
M*\D_:"_:@\!_LW^'Q?\ BO4MU_,I-EH]GA[N[/\ LIGA?]IL 4 >M;AM)R
M,YKYO^.G[??PE^!LES8W&M?\)-X@BRITG0\3,C#M))G8GXG/M7Q!K_QS_:'_
M ."@&OW7A[P%I]QX<\%[_+GCL93#;QH?^?J[X+'&#L7\J^C?@+_P2O\  '@-
M;;4O']TWCO6E =K3!ATZ-^^$'S2=N6/X4 >':Q^WW^T-^T9JEQI/P>\&2:19
MDX$FFVIO+E5SC+SN!&GX 8J72?\ @F[\=_C7<#4OBO\ $!=/WL',-[>2:E.,
M\DA PC4CIP:_3[0?#NF>%M+ATW1M/M=*T^!0L5K90K%&@'8*H K1H ^*? W_
M  2=^#_AORI-<O-<\53(!E+BY%O"Q[_)& <?\"KW3PC^Q_\ !?P0JC2OAMH*
M.O\ RUNK87,G_?4NXU[%10!C:3X+\/:"P.F:#I>G'UM+..+_ -!45M9-)10
MN345S;0WD1BN(HYXCU210RG\#4E% '&:U\%_A_XBB:/4_!'AZ^5OO";3(6S^
M.VO'O&'_  3M^ WC!)2W@B/19Y.L^C7,ELR_0 E1^5?2E% 'YS^/O^"/NDR/
M]J\">/KS3+A3N2#6K<3*#V(ECVLOUP:\XD\'_MG_ +)6Z?3KS4?%GAZ EV%M
M+_:]ML7J3$_[U!CTQ]:_5^B@#\\/@[_P5KTB\N(]+^*GA6?P_>*VR74M)5I8
M5/\ MP-^\3WQN^E?<WP]^)_A3XK:&FL>$?$%AX@TU_\ EM93!]I]&7JI]B :
MXSXS?LI_"_X\6TG_  EOA>UFOR,+JUF/L]XGN)5P3]&R/:O@;XD?L"?%[]F'
M7)/&OP1\3:AK=K;_ #F&S;RM11!R5>+[EPOMC)_NT ?JID4M?GW^S/\ \%0K
M#7KZ'PK\8[-/#6MJ_P!G&N1QF.V>0'&+B,\P-GO]W_=K[]L[VWU"UANK6>.Y
MM9D$D4T+ATD4\AE(X(([B@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BDW#G!SCKCG%-8&1?O84CMUH ^2_VU_V[-*_9OL)?#?ASR-9
M^(5S%N6"0[H=-5AQ+-CJW]V/OU/'7YH_9K_82\7?M*:\/BC\<M1U+^S=087$
M5C<N5O=24\J6/_+&'&,*,$CI@<U]"^!O^";/A?P_^T'K'Q"\0ZU<>,M+DG^W
M6&EZN/-D2Z9B6>=S_K0O&P$?7.!7V.J[?8= /2@#(\)^$-%\#Z#:Z)X?TJUT
M;2+50D%G9Q".- !Z#O[GDUL;1Z4M% !1110 4444 %%%% !1110 4444 %%%
M% !UXI,#CBEHH ^;OVI/V&O O[25G<7Y@3PWXT"'R==LXA^]/9;A.DB^_P!X
M9X/:OA[X6_'CXL?\$[OB&G@'XBZ?<:MX(D?<EN&,B"+.//L93U'K$?I@&OUO
MDE2%&=V"(HW,QZ #J:_+3_@HI^V)X>^*FF2_#GPKX>77+*TN1)<>)[RT?$4J
MGI9DCZAGZ$9 !ZT >\?M(?\ !3'P1\/_  /:-\.KNW\8>*M6M1-:JN1;V"L.
M'N.^\'_EGUR.<#K];_#^^O=4\!^&[W4I/.U&YTVVFN9 H7=*T2LYP.G)/%?S
MHV,/VK4K2T0J)YYXXUC/!9F<#^M?T?Z'9_V=HFG6@Z6]M'%_WRH']* +U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO]H?QOX(^#9T9[[X=:3KUS?N[0M]D@4QLF"#DH3G)'2J&E?MDQZ?J]C8^-/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJCDK,]''Y]CLRI*CB6FE;[,4]-E=*]A:***S/G@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img119790510_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119790510_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U F,# 2(  A$! Q$!_\0
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M;@K^\,&=A/MGG%3U)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS@9P/85JT44F[NXTK!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P :T:*+L+(SO["T[_GB_P#W^?\ QH_L+3O^>+_]_G_QK1HHNPLC._L+3O\
MGB__ '^?_&JFIZ5:6M@\\"2)*C(583/Q\P]ZW*S];_Y!,WU3_P!"%--W!I#=
M802QVD3EMDERBL%8KD8/&12_V%IW_/%_^_S_ .-+JGWK'_K[3^1JQ<7UI:,B
MW-U!"S_=$D@7=],]:6O0-"M_86G?\\7_ ._S_P"-']A:=_SQ?_O\_P#C5N.Z
MMYIYH(YD>6';YB*V2F1D9';(J:B["R,[^PM._P">+_\ ?Y_\:/["T[_GB_\
MW^?_ !K1JH=3L!.8#>0>:)1"4WC/F$;@N/7'.*+L+(A_L+3O^>+_ /?Y_P#&
MC^PM._YXO_W^?_&M&FJZN"48, 2"0<\BB["R*']A:=_SQ?\ [_/_ (T?V%IW
M_/%_^_S_ .-:-%%V%D9W]A:=_P \7_[_ #_XT?V%IW_/%_\ O\_^-6_M=O\
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M,VU;:4MG;M$9SGKC&.M:^P\S/VOD?2/D>'?^?J#_ ,##_P#%4>1X=_Y^H/\
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M_P 51Y'AW_GZ@_\  P__ !5?-.T>@HVCT%'L/,/:^1]+>1X=_P"?J#_P,/\
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MS_GQA_\  A:/^%7>+/\ GQA_\"%HYX]PY)=CCJ*['_A5WBS_ )\8?_ A:/\
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M!\Y %*[ADJ"PZ]!FMN:/8RY9=SBO^$R\3?\ 0>O_ /O\:/\ A,O$W_0>O_\
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MGWR*5/$WB=HDDD\2W,*OG:)+@Y8=,X Z5BQ?\@NZ_P"NL7\GHN_]39?]>_\
M[.]'*A79M_\ "3>(O^ALE_[_ +?X4?\ "3>(O^ALE_[_ +?X5CV8LA:7,ER-
MTJE!"F2,YSNZ?A4>HBV74;A;0#[.KD1D-NR/7-/E079L3^*?%$ 1O^$AO)(W
MSM>.<D''4?6H?^$R\3?]!Z__ ._QK.?_ )!4'_79_P"2U5H45V$VS;_X3+Q-
M_P!!Z_\ ^_QH_P"$R\3?]!Z__P"_QK$HI\J[!S/N;?\ PF7B;_H/7_\ W^-'
M_"9>)O\ H/7_ /W^-8E%'*NP<S[FW_PF7B;_ *#U_P#]_C1_PF7B;_H/7_\
MW^-8E%'*NP<S[FW_ ,)EXF_Z#U__ -_C1_PF7B;_ *#U_P#]_C6)11RKL',^
MYM_\)EXF_P"@]?\ _?XTH\9^)@0?[>O_ ,9<UAT4N5=@YGW/5/!7Q0NWU"'3
M=?=98YF"1W6T*R,>@;'!!]:]>KY,)(!(ZCI7U1I;2OI%D\V?-:!"^?[VT9KF
MKP2LT;TI-Z,MT445@;!1110 4444 %%%% !1110!2U?_ ) U[_UQ?^56X_\
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MDBCBBTV[CB0D@-&S$D]23@>@[5!]@O?^?*Z_[\-_A7:?\+=\3?W-/_[\-_\
M%4?\+=\3?W-/_P"_#?\ Q5%Y]@M'N<7]@O?^?*Z_[\-_A1]@O?\ GRNO^_#?
MX5VG_"W?$W]S3_\ OPW_ ,51_P +=\3?W-/_ ._#?_%4[S[!:/<XO[!>_P#/
ME=?]^&_PH^P7O_/E=?\ ?AO\*[3_ (6[XF_N:?\ ]^&_^*H_X6[XF_N:?_WX
M;_XJB\^P6CW.+^P7O_/E=?\ ?AO\*/L%[_SY77_?AO\ "NT_X6[XF_N:?_WX
M;_XJC_A;OB;^YI__ 'X;_P"*HO/L%H]SB_L%[_SY77_?AO\ "C[!>_\ /E=?
M]^&_PKM/^%N^)O[FG_\ ?AO_ (JC_A;OB;^YI_\ WX;_ .*HO/L%H]SB_L%[
M_P ^5U_WX;_"@:??$@"QNB3_ -,&_P *[3_A;OB;^YI__?AO_BJ4?%[Q-GF/
M3R/^N+?_ !5*\^P6CW)/!7PXU#4M0AO=7MGM=/B8/Y<HP\Q'(&.H'J37N/2O
M/?!_Q/@UV\CT[4[=+2\D.(G1LQR'TYY!_G7H5<U5R;]XWIJ*6@4445D:!111
M0 4444 %%%% !1110!2U?_D#7O\ UQ?^56X_]4G^Z*J:O_R!KW_KB_\ *K<?
M^J3_ '13Z"ZCJ***0RAJ7^NT_P#Z^A_Z"U7ZH:E_KM/_ .OH?^@M5^FQ!111
M2&%%%% !1110 5GZW_R"9OJG_H0K0K/UO_D$S?5/_0A36XGL&J?>L?\ K[3^
M1K!\5:WJEAKFFV&GNRK<Q2.YCM#</E2N/E!''/)K>U3[UC_U]I_(TS5/#^EZ
MS+%+?VHFDA!$;;V4J#UZ$>@IQ:6XFF]C(?QA)%K!T_\ LR214NA9&X$J@-,8
M]ZC;UP?7M67;_$.>+1+"XO=++W=V)76.!^#&AP2."<]@.^.HKK1H.F"82BT3
MS!.MSNR?]:%VANO7;Q5;_A$M#$"PK8A425I4VR.I1F^]@@Y /<#CVJDX=A6E
MW,74?%\TL%[]FM+FWAM;B&%KH,F2SLA"A6'H_/I6WHVN2:S/=M%8M'8PR/%'
M<M(,R.C;6^3J!D'DU8DT+3)8[B-[1&2YF6>8$GYY%QACSU^4?E2VFB:=87]Q
M>VML(I[@DRLK'#$G).W. 2>IQ2;C;8:3N<?I?C;4[V32(C9RM)-]J,Q,.Q)_
M+#%1&WKP :T5\>1W$$4MEILMP)98($_>JN99%+;"3TVX /UK=30M/MXK5;6V
MCB>S\PVK<GRF?.XXSSG-8X\#6AT:VT^6X9@E]]NG=4V^<YSD8!^4<\8Z8IW@
M^@K213_X6-;G[&J:;</+*"T\:G)B D,9Q@?,<@^G JR?&TC"0PZ1*^Z]-C;Y
MF4>=*"<_[J@#.3]*UAX8T95M EDL?V0;83&[*5&<X)!Y&><'/-/F\.Z3/8R6
M<EDA@DF-PR@D'S"<E@0<@Y]*+P[!:7<Q4\=Q2MI:)ITQ?4B8X09%XD5]LBGT
MV\G/>J6K^.I!!K5K9PB&YM+=YH+A765'VR!#QC //3FND_X1?1=L2C3X@(41
M(L9&P*VX;>>/FYSW[U&/".@J;DC3H_\ 24>.4;FP5<AF &> 2,\=Z$X=@M+N
M4QXPC6<0-:2%A?-9%MXY98O,W?3MBJ5OXPFNY],NWMIK.VN;:>X2)Y8]LJHB
MD,Q_AZG'/N:VU\*Z(M]]M%@GVG(/F%F)R%VYZ]<<9[U*WAS2'MX+=K&,PV\#
MV\2'.%C889>O<"E>'8+2*_AKQ(GB*"Z86S6\MM+Y;H7W Y 8$' R"#Z5N50T
MS1M/T=)4L+<0B4AI#N+%B!@$DD]@*OU+M?0I7MJ%%%%(84444 %%%% !7S>+
M&SU'QU?VU_<-!;M=7!9UXY#,0,X(4$\9(P*^D*^8]3O;FP\5ZE<6=Q)!,MY,
M!)&V"/G-=%#J8UNANR>$=/BCG>>:[@D@NULWMW*L_F2,OED,!@J4+$_3WJ_)
MX TZWGS+>S/;D7,B.KJ@*1E0,D@X.2P/TKAFU*^=I&>\F9I)1,Y+D[I!T8^X
M]:EBUO58&5HM2N492Y4B0\%SEOS/)K;EEW,KQ['67'@&WBCNPMU=-+%<^7$O
MEKEH]Z+O"]6'SDY' P/6I'\ V0O&C6^N&BD*1P.@5QO82'<6'!4>5@XY!..U
M<>=;U0Q21'4KHI(_F./-/S-G.3[\#\J<^O:N\LLC:G=%YH_*D;S3\R?W3[<G
M\Z.67<+Q[%G5])M;'2=-O(7N5DNPQ:&X4 [1C#C'\).0,\\9K&JW=ZMJ%_%'
M%>7L\\<7^K61\A>,<?A52K5^I+\@HHHIB"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!5D:)A*C%70AE(Z@CD&OJ?3;A[O2K.Y?[\
ML"2-]2H-?.7A;PS>>*-7CM;>-OLX8&XGQ\L:=^?4]A7TI%&D,211C"(H51Z
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M_P#]^#19A<T:*SO[7'_/A?\ _?@T?VN/^?"__P"_!HLPN:-%9W]KC_GPO_\
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M6Q&LOV>=(XI8@LL>04D<.0>?51CT%>@?\*V\-_\ /MK_ /WR/\*/^%;>&_\
MGVU__OD?X5M[2'8SY)GG[^--5D1MRVGFM<BZ,PA ?S0>&S[#CZ4X>-M64R[%
MM$5T"(BPX6$89?E&?1FZY'-=]_PK;PW_ ,^VO_\ ?(_PH_X5MX;_ .?;7_\
MOD?X4N>'8.29Y=J.L3:G;65O+!;1I9Q^5$88]IV^AYYYR?Q-9]>P_P#"MO#?
M_/MK_P#WR/\ "C_A6WAO_GVU_P#[Y'^%4JL4+V<CQZBO8?\ A6WAO_GVU_\
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MQ_SX7_\ WX-']KC_ )\+_P#[\&BS"YHT5G?VN/\ GPO_ /OP:/[7'_/A?_\
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M52;G%-]0U(,[6<2RR1K)/M8QMM)&QCC/U I/[+7_ )^[W_O^U.O_ /CXT_\
MZ^?_ &F]/FU&U@OX;*63;/+&TB CC:N,G/0=11IU!.?*E#L_U(O[+7_G[O?_
M  (:C^RU_P"?N]_\"&INHZW8Z99_:99?,7S!$JQ$,S.3@*!GK2V6LV5];F9)
M/+42M#B;"G>IP1^='NWL5:OR\]G87^RU_P"?N]_\"&H_LM?^?N]_\"&JR]U;
MQL5>>)6 )(+@$8ZTINK==NZ>(;\;<N.<],4[(SYZI5_LM?\ G[O?_ AJ/[+7
M_G[O?_ AJLF\MA&LAN(0C':&+C!/IFHTU&SDN[BU2YC,]N TJ9Y0'IFE9#YJ
MK[D7]EK_ ,_=[_X$-1_9:_\ /W>_^!#59^U6XB67[1%Y;#*MO&#]#3UEC<J%
MD1MPR,,#D>M.R%[2H4_[+7_G[O?_  (:C^RU_P"?N]_\"&J#3_$FEZI<>1;3
MMYA5F4/&R;PIPQ4D8(!]*T4N8)%5DGC96S@AP0<=:2Y7L7/V\':::95_LM?^
M?N]_\"&H_LM?^?N]_P# AJM-<P*A=IHPB@,6+# !Z&H(]4MI=2FL$+&:&)9F
M./EVMG&#WZ&BR)4JK3:OH,_LM?\ G[O?_ AJ/[+7_G[O?_ AJIVWBS2KR&9[
M6225XHS+Y0C*NZC@E0<9YK52ZA<A?,42% YC+#<![BA<KV+FJ]/2::*W]EK_
M ,_=[_X$-1_9:_\ /W>_^!#59^V6HC63[3#Y;G"MO&&/L:=Y\(E,1E3S -Q3
M<,@>N*=D9\]4J?V6O_/W>_\ @0U']EK_ ,_=[_X$-4T]_;06$M\TJM;Q(79T
M.X8'7%49O$NFVT<K3/*C1&)7C\LEE:0948'4_2D^5;FD%7G\*;+']EK_ ,_=
M[_X$-1_9:_\ /W>_^!#53D\6Z-%#!,UPY28N%VPN2"GW\C&1COFKUMJMK=W?
MV>%]Y:!;A''W70DC(/?_ .N*2<6.4<1%7DFEZ#?[+7_G[O?_  (:N<F\4>&;
M>XD@EUV\62-RCC=*<$'!'2NRKYSUG_D/:C_U]2_^AFLJT^1*R/2R?"1QLIJI
M)JUMK?Y,]7_X2[PK_P!!Z\_.7_"C_A+O"O\ T'KS\Y?\*\;HKG^L2[(]W^P:
M'\\OO7^1[)_PEWA7_H/7GYR_X4?\)=X5_P"@]>?G+_A7C=%'UB79!_8-#^>7
MWK_(]D_X2[PK_P!!Z\_.7_"C_A+O"O\ T'KS\Y?\*\;HH^L2[(/[!H?SR^]?
MY'LG_"7>%?\ H/7GYR_X4?\ "7>%?^@]>?G+_A7C=%'UB79!_8-#^>7WK_(]
MFC\5>%I'"CQ!= GNSR*/S(KH(+.WNH5FM]0NI8G&5=+DD'\:^>:ZSP#XAGTC
M7H+-I";*[<1O&3PK'HP].>#5PQ%W:2.3&Y'R4G.A-W6MG;7\$>O?V6O_ #]W
MO_@0U']EK_S]WO\ X$-5^BNRR/E?:S[E#^RU_P"?N]_\"&H_LM?^?N]_\"&J
M_119![6?<H?V6O\ S]WO_@0U']EK_P _=[_X$-5^BBR#VL^Y0_LM?^?N]_\
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M([5VU%'LHE_VG7O?3[N[O^>IP%UX+U&?1DLHA:1[WE>57?<%9E 4J=@P..0
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MK6.Q\,R6L(Q'#;^6OT Q6K5'6?\ D#7?_7,TN116A;Q52M4CS][_ #T0M_\
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MU1;AL^N/N\'ZU;M;J.\MQ-%G!X*L,%2.H([$5RLOAW50L\L-X+=I0N\"Y<\
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M]%4-NK?\]++_ +X?_&C;JW_/2R_[X?\ QHN+V:_F1?I" P((!!X(-4=NK?\
M/2R_[X?_ !HVZM_STLO^^'_QHN'L_P"\BS;VEM:*5MK>*%6.2(T"@G\*FJAM
MU;_GI9?]\/\ XT;=6_YZ67_?#_XT7\AN%W=R1?HJAMU;_GI9?]\/_C1MU;_G
MI9?]\/\ XT7%[/\ O(LP6=M;,[6]O#$7Y8QH%W?7'6IJH;=6_P">EE_WP_\
MC1MU;_GI9?\ ?#_XT7\AN%W=R1?(!!!&0>HJB-&T\# MP!V 8@#]:3;JW_/2
MR_[X?_&C;JW_ #TLO^^'_P ::FUL2Z,7NT*=&T\C!MP1W!8D'\,U>  &!P*H
M;=6_YZ67_?#_ .-&W5O^>EE_WP_^-#FWN"HQ6S1?KQ35/!'B.?5[V:+3BT<E
MQ(Z-YB\@L2#UKUS;JW_/2R_[X?\ QHVZM_STLO\ OA_\:RJ053<]# XVI@G)
MTW%W[W/&/^$"\3?] QO^_B_XT?\ "!>)O^@8W_?Q?\:]GVZM_P ]++_OA_\
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MOYD7Z*H;=6_YZ67_ 'P_^-&W5O\ GI9?]\/_ (T7#V:_F1?HJAMU;_GI9?\
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M?/\ %TX]./2H5\2X9W>VQ"!A7#@C=\W&>X.W@U(OB#SK6:6.V9-L!F0R$8.
MI(..F-P_6G[P:$,/AZ5IKMYY(U:1G,;*-Q&X]\^@&!WY-2#PQ %C_?N60J=S
M*#G;MQ^6WCTS0OB()&S3P@JF09D8;&/SXVY['8?S%#>(#+:RRPQQQ!)UAWSM
M\HR<$G'3%'O![H^T\.QVD]O*+AG\DY^9<DG##@D\9W<XZD"FVF@?9+R!TFS$
MA+. -H;  48'OR3W-,C\3JR_/9RQE2JL6(&TD9Z=3_GI21^)PX(%F[% "Q#
M?PECQ]!^HH]X/=)_^$>18HHXKET5%P?E!).X,#D].0*O:=IZ:;;F"*1VCW;E
M#G)&>OZY/XUE'Q.K3E([8F-6*E]V=V&0?*._#_ABI[77UN9HHQ:N [!2X<$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>sybx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T22:59:00.1976+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="sybx-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:href="sybx-20221231.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:href="sybx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities" xlink:href="sybx-20221231.xsd#Role_DisclosureAvailableForSaleSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="sybx-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="sybx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="sybx-20221231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="sybx-20221231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:href="sybx-20221231.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="sybx-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchase" xlink:href="sybx-20221231.xsd#DisclosureShareRepurchase" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="sybx-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="sybx-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:href="sybx-20221231.xsd#Role_DisclosureEmployeeBenefits" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="sybx-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="sybx-20221231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="sybx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" xlink:href="sybx-20221231.xsd#Role_DisclosureAvailableForSaleSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="sybx-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="sybx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="sybx-20221231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="sybx-20221231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="sybx-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="sybx-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="sybx-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:href="sybx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" xlink:href="sybx-20221231.xsd#DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails" xlink:href="sybx-20221231.xsd#DisclosureShareRepurchaseAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="sybx-20221231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentNoncurrent" xlink:label="sybx_PrepaidResearchAndDevelopmentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="sybx_PrepaidResearchAndDevelopmentNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperating" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AtTheMarketOfferingMember" xlink:label="sybx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_StockIssuedDuringPeriodValueSharesWithholding" xlink:label="sybx_StockIssuedDuringPeriodValueSharesWithholding"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_StockIssuedDuringPeriodSharesWithholding" xlink:label="sybx_StockIssuedDuringPeriodSharesWithholding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_18"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_19"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sybx_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sybx_StockIssuedDuringPeriodValueSharesWithholding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sybx_StockIssuedDuringPeriodSharesWithholding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashInvestingItemsAbstract" xlink:label="sybx_NoncashInvestingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" xlink:label="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AtTheMarketOfferingMember" xlink:label="sybx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashFinancingItemsAbstract" xlink:label="sybx_NoncashFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AssetsAcquiredUnderOperatingLeaseObligation" xlink:label="sybx_AssetsAcquiredUnderOperatingLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" xlink:label="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" xlink:label="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" xlink:label="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_NoncashInvestingItemsAbstract" xlink:to="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sybx_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_NoncashFinancingItemsAbstract" xlink:to="us-gaap_CapitalLeaseObligationsIncurred" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_NoncashInvestingItemsAbstract" xlink:to="sybx_AssetsAcquiredUnderOperatingLeaseObligation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_NoncashFinancingItemsAbstract" xlink:to="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_NoncashFinancingItemsAbstract" xlink:to="us-gaap_InterestPaidNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sybx_NoncashInvestingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sybx_NoncashFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AvailableForSaleSecuritiesDisclosureTextBlock" xlink:label="sybx_AvailableForSaleSecuritiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="sybx_AvailableForSaleSecuritiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchase" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareRepurchaseAbstract" xlink:label="sybx_ShareRepurchaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareRepurchaseTextBlock" xlink:label="sybx_ShareRepurchaseTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareRepurchaseAbstract" xlink:to="sybx_ShareRepurchaseTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NewAccountingPronouncementsPolicyTextBlock" xlink:label="sybx_NewAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_TreasuryStockPolicyTextBlock" xlink:label="sybx_TreasuryStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sybx_NewAccountingPronouncementsPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sybx_TreasuryStockPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015And2017Member" xlink:label="sybx_LongTermIncentivePlan2015And2017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sybx_LongTermIncentivePlan2015And2017Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:label="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201708Member" xlink:label="us-gaap_AccountingStandardsUpdate201708Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashAndCashEquivalentRelatedText" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" xlink:label="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201708Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdditionalCashAndCashEquivalentRelatedText" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sybx_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Cash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sybx_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ComputerAndOfficeEquipmentMember" xlink:label="sybx_ComputerAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sybx_ComputerAndOfficeEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember" xlink:label="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sybx_FairValueAssetMeasuredOnRecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember" xlink:label="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale" xlink:label="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentCurrent" xlink:label="sybx_PrepaidResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="sybx_PrepaidResearchAndDevelopmentCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ComputerAndOfficeEquipmentMember" xlink:label="sybx_ComputerAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sybx_ComputerAndOfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AccruedResearchAndDevelopmentCurrent" xlink:label="sybx_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sybx_AccruedResearchAndDevelopmentCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AtTheMarketMember" xlink:label="sybx_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_GinkgoBioworksIncMember" xlink:label="sybx_GinkgoBioworksIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PreFundedWarrantsMember" xlink:label="sybx_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NumberOfVotesEntitledToEachShareOfCommonStock" xlink:label="sybx_NumberOfVotesEntitledToEachShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnderwrittenPublicOfferingMember" xlink:label="sybx_UnderwrittenPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CowenAndCompanyLLCMember" xlink:label="sybx_CowenAndCompanyLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_JefferiesLLCMember" xlink:label="sybx_JefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare" xlink:label="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" xlink:label="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_WarrantsExercised" xlink:label="sybx_WarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" xlink:label="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sybx_AtTheMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_GinkgoBioworksIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sybx_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_NumberOfVotesEntitledToEachShareOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sybx_UnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_CowenAndCompanyLLCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_JefferiesLLCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_WarrantsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PreFundedWarrantsMember" xlink:label="sybx_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OptionsExercisableToPurchaseCommonStockMember" xlink:label="sybx_OptionsExercisableToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sybx_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="sybx_OptionsExercisableToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015Member" xlink:label="sybx_LongTermIncentivePlan2015Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sybx_LongTermIncentivePlan2015Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015And2017Member" xlink:label="sybx_LongTermIncentivePlan2015And2017Member"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_EmployeesAndNonemployeesMember" xlink:label="sybx_EmployeesAndNonemployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sybx_LongTermIncentivePlan2015And2017Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sybx_EmployeesAndNonemployeesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015And2017Member" xlink:label="sybx_LongTermIncentivePlan2015And2017Member"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sybx_LongTermIncentivePlan2015And2017Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue" xlink:label="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" xlink:label="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CurrentLiabilitiesMember" xlink:label="sybx_CurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_GinkgoBioworksIncMember" xlink:label="sybx_GinkgoBioworksIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PreFundedWarrantsMember" xlink:label="sybx_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RocheCollaborationAndOptionAgreementMember" xlink:label="sybx_RocheCollaborationAndOptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" xlink:label="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AbbVieAgreementMember" xlink:label="sybx_AbbVieAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" xlink:label="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UpfrontPayments" xlink:label="sybx_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_MilestonePayments" xlink:label="sybx_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CurrentPrePaidResearchAndDevelopment" xlink:label="sybx_CurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NonCurrentPrePaidResearchAndDevelopment" xlink:label="sybx_NonCurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_11"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaymentToRelatedPartyForCollaborationAgreement" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sybx_CurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_GinkgoBioworksIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sybx_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sybx_RocheCollaborationAndOptionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sybx_AbbVieAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_UpfrontPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_MilestonePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_CurrentPrePaidResearchAndDevelopment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_NonCurrentPrePaidResearchAndDevelopment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_PrepaymentToRelatedPartyForCollaborationAgreement" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnvestedRestrictedStockAwardsMember" xlink:label="sybx_UnvestedRestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sybx_UnvestedRestrictedStockAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncomeTaxDisclosureLineItems" xlink:label="sybx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncomeTaxDisclosureTable" xlink:label="sybx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="sybx_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="sybx_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsExpirationYear" xlink:label="sybx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CorporateMinimumTaxEffectPercentage" xlink:label="sybx_CorporateMinimumTaxEffectPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ExciseTaxPercentage" xlink:label="sybx_ExciseTaxPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sybx_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_OperatingLossCarryforwardsSubjectToExpiration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_OperatingLossCarryforwardsNotSubjectToExpiration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="sybx_IncomeTaxDisclosureLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_OperatingLossCarryforwardsExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_CorporateMinimumTaxEffectPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_ExciseTaxPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="sybx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxAssetsLeaseLiabilities" xlink:label="sybx_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxAssetsAmortizableResearchExpenditures" xlink:label="sybx_DeferredTaxAssetsAmortizableResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="sybx_DeferredTaxLiabilitiesRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="sybx_DeferredTaxAssetsLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="sybx_DeferredTaxAssetsAmortizableResearchExpenditures" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareRepurchaseAbstract" xlink:label="sybx_ShareRepurchaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RepurchaseOfCommonStock" xlink:label="sybx_RepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AggregatePurchase" xlink:label="sybx_AggregatePurchase"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AggregatePurchasePerShare" xlink:label="sybx_AggregatePurchasePerShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareRepurchaseAbstract" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareRepurchaseAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareRepurchaseAbstract" xlink:to="sybx_RepurchaseOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareRepurchaseAbstract" xlink:to="sybx_AggregatePurchase" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_ShareRepurchaseAbstract" xlink:to="sybx_AggregatePurchasePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RentableSpaceUnderLeaseAgreement" xlink:label="sybx_RentableSpaceUnderLeaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_MasterContractServicesAgreementMember" xlink:label="sybx_MasterContractServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AzzurGroupLimitedLiabilityCompanyMember" xlink:label="sybx_AzzurGroupLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLeasesRentExpenseAnnualRentalPayments" xlink:label="sybx_OperatingLeasesRentExpenseAnnualRentalPayments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NewAgreementMember" xlink:label="sybx_NewAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_TenantImprovementInvestmentObligation" xlink:label="sybx_TenantImprovementInvestmentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AccessAndUseOfSpaceUnderAgreement" xlink:label="sybx_AccessAndUseOfSpaceUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_TermOfAgreement" xlink:label="sybx_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AgreementExpirationDate" xlink:label="sybx_AgreementExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RenovateAndUpgradeExpenses" xlink:label="sybx_RenovateAndUpgradeExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_RentableSpaceUnderLeaseAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sybx_MasterContractServicesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="sybx_AzzurGroupLimitedLiabilityCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_OperatingLeasesRentExpenseAnnualRentalPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sybx_NewAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_TenantImprovementInvestmentObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_AccessAndUseOfSpaceUnderAgreement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_TermOfAgreement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_AgreementExpirationDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_RenovateAndUpgradeExpenses" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLeaseCostAbstract" xlink:label="sybx_OperatingLeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingAndVariableLeaseCost" xlink:label="sybx_OperatingAndVariableLeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sybx_OperatingLeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_OperatingLeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_OperatingLeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sybx_OperatingLeaseCostAbstract" xlink:to="sybx_OperatingAndVariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_GinkgoBioworksIncMember" xlink:label="sybx_GinkgoBioworksIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaymentToRelatedPartyForCollaborationAgreement" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CurrentPrePaidResearchAndDevelopment" xlink:label="sybx_CurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NonCurrentPrePaidResearchAndDevelopment" xlink:label="sybx_NonCurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentExpenses" xlink:label="sybx_PrepaidResearchAndDevelopmentExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_GinkgoBioworksIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_PrepaymentToRelatedPartyForCollaborationAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_CurrentPrePaidResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_NonCurrentPrePaidResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_PrepaidResearchAndDevelopmentExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AgreedToPayRenovationAndUpgradationFee" xlink:label="sybx_AgreedToPayRenovationAndUpgradationFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AzzurMember" xlink:label="sybx_AzzurMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FirstSOWMember" xlink:label="sybx_FirstSOWMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CollaborationAgreementDescription" xlink:label="sybx_CollaborationAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FourthSOWMember" xlink:label="sybx_FourthSOWMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement" xlink:label="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sybx_AgreedToPayRenovationAndUpgradationFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sybx_AzzurMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sybx_FirstSOWMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sybx_CollaborationAgreementDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sybx_FourthSOWMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>sybx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T22:59:02.4815+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:label="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015And2017Member" xlink:label="sybx_LongTermIncentivePlan2015And2017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashInvestingItemsAbstract" xlink:label="sybx_NoncashInvestingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_MasterContractServicesAgreementMember" xlink:label="sybx_MasterContractServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" xlink:label="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_TenantImprovementInvestmentObligation" xlink:label="sybx_TenantImprovementInvestmentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015Member" xlink:label="sybx_LongTermIncentivePlan2015Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AccruedResearchAndDevelopmentCurrent" xlink:label="sybx_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember" xlink:label="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AggregatePurchasePerShare" xlink:label="sybx_AggregatePurchasePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OptionsExercisableToPurchaseCommonStockMember" xlink:label="sybx_OptionsExercisableToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UpfrontPayments" xlink:label="sybx_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingAndVariableLeaseCost" xlink:label="sybx_OperatingAndVariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" xlink:label="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RentableSpaceUnderLeaseAgreement" xlink:label="sybx_RentableSpaceUnderLeaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RocheCollaborationAndOptionAgreementMember" xlink:label="sybx_RocheCollaborationAndOptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncomeTaxDisclosureLineItems" xlink:label="sybx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NewAccountingPronouncementsPolicyTextBlock" xlink:label="sybx_NewAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AvailableForSaleSecuritiesDisclosureTextBlock" xlink:label="sybx_AvailableForSaleSecuritiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CowenAndCompanyLLCMember" xlink:label="sybx_CowenAndCompanyLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" xlink:label="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncomeTaxDisclosureTable" xlink:label="sybx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="sybx_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentNoncurrent" xlink:label="sybx_PrepaidResearchAndDevelopmentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RenovateAndUpgradeExpenses" xlink:label="sybx_RenovateAndUpgradeExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" xlink:label="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AgreedToPayRenovationAndUpgradationFee" xlink:label="sybx_AgreedToPayRenovationAndUpgradationFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashAndCashEquivalentRelatedText" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ComputerAndOfficeEquipmentMember" xlink:label="sybx_ComputerAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" xlink:label="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CurrentPrePaidResearchAndDevelopment" xlink:label="sybx_CurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentExpenses" xlink:label="sybx_PrepaidResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NonCurrentPrePaidResearchAndDevelopment" xlink:label="sybx_NonCurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare" xlink:label="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsExpirationYear" xlink:label="sybx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NewAgreementMember" xlink:label="sybx_NewAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareRepurchaseAbstract" xlink:label="sybx_ShareRepurchaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CollaborationAgreementDescription" xlink:label="sybx_CollaborationAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201708Member" xlink:label="us-gaap_AccountingStandardsUpdate201708Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLeasesRentExpenseAnnualRentalPayments" xlink:label="sybx_OperatingLeasesRentExpenseAnnualRentalPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue" xlink:label="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FirstSOWMember" xlink:label="sybx_FirstSOWMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_TermOfAgreement" xlink:label="sybx_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="sybx_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashFinancingItemsAbstract" xlink:label="sybx_NoncashFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaymentToRelatedPartyForCollaborationAgreement" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RepurchaseOfCommonStock" xlink:label="sybx_RepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" xlink:label="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ExciseTaxPercentage" xlink:label="sybx_ExciseTaxPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PreFundedWarrantsMember" xlink:label="sybx_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NumberOfVotesEntitledToEachShareOfCommonStock" xlink:label="sybx_NumberOfVotesEntitledToEachShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_GinkgoBioworksIncMember" xlink:label="sybx_GinkgoBioworksIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_EmployeesAndNonemployeesMember" xlink:label="sybx_EmployeesAndNonemployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" xlink:label="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AzzurMember" xlink:label="sybx_AzzurMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CorporateMinimumTaxEffectPercentage" xlink:label="sybx_CorporateMinimumTaxEffectPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale" xlink:label="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_WarrantsExercised" xlink:label="sybx_WarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AbbVieAgreementMember" xlink:label="sybx_AbbVieAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentCurrent" xlink:label="sybx_PrepaidResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AggregatePurchase" xlink:label="sybx_AggregatePurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AtTheMarketOfferingMember" xlink:label="sybx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CurrentLiabilitiesMember" xlink:label="sybx_CurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareRepurchaseTextBlock" xlink:label="sybx_ShareRepurchaseTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement" xlink:label="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxAssetsLeaseLiabilities" xlink:label="sybx_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_StockIssuedDuringPeriodValueSharesWithholding" xlink:label="sybx_StockIssuedDuringPeriodValueSharesWithholding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AssetsAcquiredUnderOperatingLeaseObligation" xlink:label="sybx_AssetsAcquiredUnderOperatingLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AzzurGroupLimitedLiabilityCompanyMember" xlink:label="sybx_AzzurGroupLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" xlink:label="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnderwrittenPublicOfferingMember" xlink:label="sybx_UnderwrittenPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnvestedRestrictedStockAwardsMember" xlink:label="sybx_UnvestedRestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FourthSOWMember" xlink:label="sybx_FourthSOWMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_MilestonePayments" xlink:label="sybx_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" xlink:label="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_TreasuryStockPolicyTextBlock" xlink:label="sybx_TreasuryStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxAssetsAmortizableResearchExpenditures" xlink:label="sybx_DeferredTaxAssetsAmortizableResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember" xlink:label="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_JefferiesLLCMember" xlink:label="sybx_JefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_StockIssuedDuringPeriodSharesWithholding" xlink:label="sybx_StockIssuedDuringPeriodSharesWithholding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AccessAndUseOfSpaceUnderAgreement" xlink:label="sybx_AccessAndUseOfSpaceUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLeaseCostAbstract" xlink:label="sybx_OperatingLeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="sybx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" xlink:label="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AtTheMarketMember" xlink:label="sybx_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AgreementExpirationDate" xlink:label="sybx_AgreementExpirationDate"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Weighted Average Remaining Lease Term And Weighted Average Discount Rate Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee weighted average remaining lease term and weighted average discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, practical expedient, incremental cost of obtaining contract [true/false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Practical Expedient, Incremental Cost of Obtaining Contract [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of awards vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LongTermIncentivePlan2015And2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 and 2017 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LongTermIncentivePlan2015And2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Incentive Plan2015 And2017 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LongTermIncentivePlan2015And2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term incentive plan 2015 and 2017.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashInvestingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashInvestingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashInvestingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash investing items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset - operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_MasterContractServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_MasterContractServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Master Contract Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_MasterContractServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Master contract services agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability - operating lease, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid included in operating cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price per share paid at closing of offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Paid At Closing Of Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right exercise price of warrants paid at closing of offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Shares of Common Stock Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Unvested Grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Unvested Grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TenantImprovementInvestmentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TenantImprovementInvestmentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Investment Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TenantImprovementInvestmentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount the lessee agrees to invest into a tenant improvement of a leased property.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LongTermIncentivePlan2015Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan 2015</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LongTermIncentivePlan2015Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Incentive Plan2015 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LongTermIncentivePlan2015Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long Term Incentive Plan 2015.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Related party transaction collaboration agreement, initial term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction collaboration agreement, initial term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Collaboration Agreement Initial Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction collaboration agreement, initial term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll related</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Weighted average remaining lease term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Shares of Common Stock Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Shares Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of shares of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development, current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasuries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities And Treasuries [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US government agencies debt securities and treasuries.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AggregatePurchasePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Purchase Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AggregatePurchasePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Purchase Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OptionsExercisableToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OptionsExercisableToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Exercisable to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OptionsExercisableToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercisable To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OptionsExercisableToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercisable to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled/Forfeited, Aggregate Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options forfeitures and expirations in period intrinsic value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Treasury Stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Treasury Stock, Shares, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingAndVariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating and variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingAndVariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Variable Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingAndVariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and variable lease cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Weighted average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common stock outstanding - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancellation of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration in research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anticipated Completion Of Research And Development Projects Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anticipated completion period for research and development projects.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Aggregate Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Aggregate Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RentableSpaceUnderLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and office space to be leased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RentableSpaceUnderLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rentable Space Under Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RentableSpaceUnderLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rentable Space Under Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RocheCollaborationAndOptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roche Collaboration and Option Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RocheCollaborationAndOptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Roche Collaboration And Option Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RocheCollaborationAndOptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Roche collaboration and option agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled/Forfeited, Number of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of options granted to employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renewal term of lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee contribution, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NewAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NewAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NewAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New accounting pronouncements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AvailableForSaleSecuritiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AvailableForSaleSecuritiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AvailableForSaleSecuritiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as a percentage of fair value under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cowen and Company, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cowen And Company L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cowen and company LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Cost for Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Equity-based Compensation Expenses by Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones payment upon achievement of certain success criteria</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestones Payment Upon Achievement Of Certain Success Criteria</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential milestones payment upon achievement of certain success criteria.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award percentage of shares outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of prepaid expenses and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and short-term marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common stock outstanding - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee unrecognized compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Useful Life of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment Useful Life Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RenovateAndUpgradeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renovate and upgrade expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RenovateAndUpgradeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Renovate And Upgrade Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RenovateAndUpgradeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Renovate And Upgrade Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in carrying amount of operating lease right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction In Carrying Amount Of Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction in carrying amount of operating lease right-of-use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase Of Common Stock (In Share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase Of Common Stock (In Share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AgreedToPayRenovationAndUpgradationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreed to pay renovation and upgradation fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AgreedToPayRenovationAndUpgradationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreed To Pay Renovation And Upgradation Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AgreedToPayRenovationAndUpgradationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreed to pay renovation and upgradation fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Cash and Cash Equivalent Related Text</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer And Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer and office equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax benefits for the net operating losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock purchases and exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Employee Stock Purchases And Exercise Of Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from employee stock purchases and exercise of stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Aggregate Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grants in period intrinsic value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other items, Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CurrentPrePaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current pre-paid research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CurrentPrePaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Pre Paid Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CurrentPrePaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current Pre-Paid Research and Development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled/Forfeited, Weighted-average price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NonCurrentPrePaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current pre-paid research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NonCurrentPrePaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Current Pre Paid Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NonCurrentPrePaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Current Pre-Paid Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of securities in unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturity of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Common Stock And Prefunded Warrant Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of common stock and prefunded warrant price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic value, Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options outstanding, weighted average exercise price, and additional disclosures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-Sale Securities Held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, Number of shares/units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2022 and December 31, 2021. 70,933,140 shares issued and 66,736,251 shares outstanding as of December 31, 2022 and 69,698,844 shares issued and outstanding as of December 31, 2021.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NewAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NewAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NewAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from redemption of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareRepurchaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareRepurchaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Repurchase [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CollaborationAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CollaborationAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CollaborationAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201708Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2017-08</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201708Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2017-08 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, Weighted-average price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLeasesRentExpenseAnnualRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease annual rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLeasesRentExpenseAnnualRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Annual Rental Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLeasesRentExpenseAnnualRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases rent expense annual rental payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">NetIncome Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of investments in unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability - operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock awards withheld for payment of employees' withholding tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options in money</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Arrangement Award Options Available For Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based arrangement award, options available for aggregate intrinsic value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Adopted Accounting Pronouncements Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently adopted accounting pronouncements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FirstSOWMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First SOW</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FirstSOWMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First S O W [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FirstSOWMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First SOW.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase Outstanding Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recognition of revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of discount for employees under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards not subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards not subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average price Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock $0.001 Par Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash financing items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepayment to related party for collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment to related party for collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment To Related Party For Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment to related party for collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase under finance lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Obligation Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase Of Common Stock (In Share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_RepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Asset Measured On Recurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Asset Measured On Recurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Asset Measured On Recurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, practical expedient, remaining performance obligation, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Practical Expedient, Remaining Performance Obligation, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets and liabilities between Level 1, Level 2, or Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Asset Liability Transfers Between Level1 Level2 And Level3 Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents net transfers in and out of assets and liabilities measured at fair value on a recurring basis using Level 1, Level 2 and Level 3 inputs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease obligations, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee unrecognized compensation cost, period of recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, weighted average remaining contractual term (Year)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturity of Lease Liabilities for Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating And Finance Lease Liability Maturity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating and finance lease, liability, maturity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net change in valuation allowance, Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion/amortization of investment securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ExciseTaxPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excise tax percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ExciseTaxPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Excise tax percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Issuable Under Pre-Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 14)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NumberOfVotesEntitledToEachShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes entitled to each share of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NumberOfVotesEntitledToEachShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Votes Entitled To Each Share Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NumberOfVotesEntitledToEachShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of votes entitled to each share of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_GinkgoBioworksIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ginkgo Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_GinkgoBioworksIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ginkgo Bioworks, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_GinkgoBioworksIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ginkgo Bioworks Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_GinkgoBioworksIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ginkgo Bioworks, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of investments in unrealized loss position, more than twelve months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average price, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit, Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_EmployeesAndNonemployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and Nonemployees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_EmployeesAndNonemployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees And Nonemployees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_EmployeesAndNonemployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and nonemployees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, Aggregate Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Research And Development Net Of Current Portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in prepaid research and development net of current portion.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Nonoperating, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and investment income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Nonoperating</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortizable intangibles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lessee, operating lease, existence of option to terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AzzurMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Azzur</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AzzurMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Azzur [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AzzurMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Azzur.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CorporateMinimumTaxEffectPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">corporate minimum tax effect percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CorporateMinimumTaxEffectPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">corporate minimum tax effect percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities with other than temporary impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Losses Investments Number Debt Securities Available For Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other than temporary impairment losses investments number debt securities available for sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent differences, Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based Compensation and Equity Incentive Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic value, Vested or expected to vest at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AbbVieAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Abb Vie Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AbbVieAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Abb Vie Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AbbVieAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Abb Vie agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Weighted-average price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Weighted-average price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on finance lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_PrepaidResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development, current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum matching contributions as a percentage of eligible compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds, net of issuance costs, from issuance of common stock and pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Pre Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related-Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AggregatePurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AggregatePurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of pre-funded warrants, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering,</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, Number of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareRepurchaseTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareRepurchaseTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_ShareRepurchaseTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Repurchase [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated project cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Project Cost In Access And Use Of Renovated And Upgraded Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated project cost in access and use of renovated and upgraded under agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Number of unvested shares/units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Number of unvested shares/units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding Beginning balance, Number of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding Ending balance, Number of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_StockIssuedDuringPeriodValueSharesWithholding_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share withholding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_StockIssuedDuringPeriodValueSharesWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Shares Withholding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_StockIssuedDuringPeriodValueSharesWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value shares withholding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AssetsAcquiredUnderOperatingLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets acquired under operating lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AssetsAcquiredUnderOperatingLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Acquired Under Operating Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AssetsAcquiredUnderOperatingLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets acquired under operating lease obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AzzurGroupLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Azzur Group, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AzzurGroupLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Azzur Group Limited Liability Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AzzurGroupLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Azzur Group Limited Liability Company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock, Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront, nonrefundable technology access fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Upfront Nonrefundable Technology Access Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement upfront, nonrefundable technology access fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury Stock, at cost (4,196,889 shares at December 31, 2022 and no shares at December 31, 2021)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Treasury Stock, Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential Shares Issuable Under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Common Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Stock Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FourthSOWMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fourth SOW</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FourthSOWMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fourth S O W [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FourthSOWMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fourth SOW.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restricted Common Stock Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of Common Stock (Treasury Stock)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments for Repurchase of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unbeneficial Percentage Of Ownership After Exercise Of Common Stock Outstanding Effect To Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TreasuryStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TreasuryStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_TreasuryStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire policy disclosure for treasury stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested, Number of shares/units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxAssetsAmortizableResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortizable Research Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxAssetsAmortizableResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Amortizable Research Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxAssetsAmortizableResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Amortizable Research Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible employees to contribute to 401(k) plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain (loss) on securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Equity-based Compensation Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, Number of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Gross deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities and Treasuries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury And Government Long Term Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US treasury and government long-term debt securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits, Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_StockIssuedDuringPeriodSharesWithholding_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share withholding, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_StockIssuedDuringPeriodSharesWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Withholding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_StockIssuedDuringPeriodSharesWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares withholding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AccessAndUseOfSpaceUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Access and use of space under agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AccessAndUseOfSpaceUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Access And Use Of Space Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AccessAndUseOfSpaceUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Access and Use of space under agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Asset Measured On Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Asset Measured On Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Asset Measured On Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Tangible Asset Impairment Charges, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tangible Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average, risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross unrealized losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Service (IRS) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_OperatingLeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, right of use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of tax benefit likely to be realized upon settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Likelihood of Unfavorable Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Purchase Of Property Plant And Equipment In Accounts Payable And Accrued Liabilities Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash purchase of property, plant and equipment in accounts payable and accrued liabilities adjustments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AtTheMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">at the market.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, Number of shares/units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted-average price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance costs included in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares available for issuance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially Common Shares Excluded from Calculation of Net Loss Per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sybx_AgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:to="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_LongTermIncentivePlan2015And2017Member" xlink:to="sybx_LongTermIncentivePlan2015And2017Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_NoncashInvestingItemsAbstract" xlink:to="sybx_NoncashInvestingItemsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_MasterContractServicesAgreementMember" xlink:to="sybx_MasterContractServicesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" xlink:to="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_TenantImprovementInvestmentObligation" xlink:to="sybx_TenantImprovementInvestmentObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_LongTermIncentivePlan2015Member" xlink:to="sybx_LongTermIncentivePlan2015Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" xlink:to="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AccruedResearchAndDevelopmentCurrent" xlink:to="sybx_AccruedResearchAndDevelopmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember" xlink:to="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AggregatePurchasePerShare" xlink:to="sybx_AggregatePurchasePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_OptionsExercisableToPurchaseCommonStockMember" xlink:to="sybx_OptionsExercisableToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_UpfrontPayments" xlink:to="sybx_UpfrontPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_OperatingAndVariableLeaseCost" xlink:to="sybx_OperatingAndVariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" xlink:to="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_RentableSpaceUnderLeaseAgreement" xlink:to="sybx_RentableSpaceUnderLeaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_RocheCollaborationAndOptionAgreementMember" xlink:to="sybx_RocheCollaborationAndOptionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_IncomeTaxDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_NewAccountingPronouncementsPolicyTextBlock" xlink:to="sybx_NewAccountingPronouncementsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AvailableForSaleSecuritiesDisclosureTextBlock" xlink:to="sybx_AvailableForSaleSecuritiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_CowenAndCompanyLLCMember" xlink:to="sybx_CowenAndCompanyLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" xlink:to="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="sybx_IncomeTaxDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="sybx_OperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_PrepaidResearchAndDevelopmentNoncurrent" xlink:to="sybx_PrepaidResearchAndDevelopmentNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_RenovateAndUpgradeExpenses" xlink:to="sybx_RenovateAndUpgradeExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" xlink:to="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AgreedToPayRenovationAndUpgradationFee" xlink:to="sybx_AgreedToPayRenovationAndUpgradationFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashAndCashEquivalentRelatedText" xlink:to="us-gaap_AdditionalCashAndCashEquivalentRelatedText_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ComputerAndOfficeEquipmentMember" xlink:to="sybx_ComputerAndOfficeEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" xlink:to="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_CurrentPrePaidResearchAndDevelopment" xlink:to="sybx_CurrentPrePaidResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_PrepaidResearchAndDevelopmentExpenses" xlink:to="sybx_PrepaidResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_NonCurrentPrePaidResearchAndDevelopment" xlink:to="sybx_NonCurrentPrePaidResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare" xlink:to="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_OperatingLossCarryforwardsExpirationYear" xlink:to="sybx_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_NewAgreementMember" xlink:to="sybx_NewAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ShareRepurchaseAbstract" xlink:to="sybx_ShareRepurchaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_CollaborationAgreementDescription" xlink:to="sybx_CollaborationAgreementDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201708Member" xlink:to="us-gaap_AccountingStandardsUpdate201708Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_OperatingLeasesRentExpenseAnnualRentalPayments" xlink:to="sybx_OperatingLeasesRentExpenseAnnualRentalPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue" xlink:to="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_FirstSOWMember" xlink:to="sybx_FirstSOWMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_TermOfAgreement" xlink:to="sybx_TermOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="sybx_OperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_NoncashFinancingItemsAbstract" xlink:to="sybx_NoncashFinancingItemsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_PrepaymentToRelatedPartyForCollaborationAgreement" xlink:to="sybx_PrepaymentToRelatedPartyForCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_RepurchaseOfCommonStock" xlink:to="sybx_RepurchaseOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="sybx_FairValueAssetMeasuredOnRecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" xlink:to="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ExciseTaxPercentage" xlink:to="sybx_ExciseTaxPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_PreFundedWarrantsMember" xlink:to="sybx_PreFundedWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_NumberOfVotesEntitledToEachShareOfCommonStock" xlink:to="sybx_NumberOfVotesEntitledToEachShareOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_GinkgoBioworksIncMember" xlink:to="sybx_GinkgoBioworksIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_EmployeesAndNonemployeesMember" xlink:to="sybx_EmployeesAndNonemployeesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" xlink:to="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sybx_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AzzurMember" xlink:to="sybx_AzzurMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_CorporateMinimumTaxEffectPercentage" xlink:to="sybx_CorporateMinimumTaxEffectPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale" xlink:to="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_WarrantsExercised" xlink:to="sybx_WarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sybx_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AbbVieAgreementMember" xlink:to="sybx_AbbVieAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_PrepaidResearchAndDevelopmentCurrent" xlink:to="sybx_PrepaidResearchAndDevelopmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:to="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AggregatePurchase" xlink:to="sybx_AggregatePurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AtTheMarketOfferingMember" xlink:to="sybx_AtTheMarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_CurrentLiabilitiesMember" xlink:to="sybx_CurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_ShareRepurchaseTextBlock" xlink:to="sybx_ShareRepurchaseTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement" xlink:to="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_DeferredTaxAssetsLeaseLiabilities" xlink:to="sybx_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_StockIssuedDuringPeriodValueSharesWithholding" xlink:to="sybx_StockIssuedDuringPeriodValueSharesWithholding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AssetsAcquiredUnderOperatingLeaseObligation" xlink:to="sybx_AssetsAcquiredUnderOperatingLeaseObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AzzurGroupLimitedLiabilityCompanyMember" xlink:to="sybx_AzzurGroupLimitedLiabilityCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" xlink:to="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_UnderwrittenPublicOfferingMember" xlink:to="sybx_UnderwrittenPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_UnvestedRestrictedStockAwardsMember" xlink:to="sybx_UnvestedRestrictedStockAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_FourthSOWMember" xlink:to="sybx_FourthSOWMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_MilestonePayments" xlink:to="sybx_MilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="us-gaap_PaymentsForRepurchaseOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" xlink:to="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_TreasuryStockPolicyTextBlock" xlink:to="sybx_TreasuryStockPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_DeferredTaxAssetsAmortizableResearchExpenditures" xlink:to="sybx_DeferredTaxAssetsAmortizableResearchExpenditures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember" xlink:to="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_JefferiesLLCMember" xlink:to="sybx_JefferiesLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_StockIssuedDuringPeriodSharesWithholding" xlink:to="sybx_StockIssuedDuringPeriodSharesWithholding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AccessAndUseOfSpaceUnderAgreement" xlink:to="sybx_AccessAndUseOfSpaceUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:to="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentCharges" xlink:to="us-gaap_TangibleAssetImpairmentCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_OperatingLeaseCostAbstract" xlink:to="sybx_OperatingLeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="sybx_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" xlink:to="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AtTheMarketMember" xlink:to="sybx_AtTheMarketMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sybx_AgreementExpirationDate" xlink:to="sybx_AgreementExpirationDate_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>sybx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T22:59:00.4863+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.synlogictx.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:sybx="http://www.synlogictx.com/20221231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sybx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sybx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sybx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sybx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2" id="DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2">
        <link:definition>100020 - Disclosure - Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100070 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>100090 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities" id="Role_DisclosureAvailableForSaleSecurities">
        <link:definition>100100 - Disclosure - Available-for-Sale Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100110 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100130 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100140 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans">
        <link:definition>100150 - Disclosure - Equity-based Compensation and Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements" id="Role_DisclosureCollaborationAgreements">
        <link:definition>100160 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100170 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchase" id="DisclosureShareRepurchase">
        <link:definition>100190 - Disclosure - Share Repurchase</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100200 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100210 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits" id="Role_DisclosureEmployeeBenefits">
        <link:definition>100220 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100230 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100240 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>100270 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" id="Role_DisclosureAvailableForSaleSecuritiesTables">
        <link:definition>100280 - Disclosure - Available-for-Sale Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100300 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100310 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100320 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables">
        <link:definition>100330 - Disclosure - Equity-based Compensation and Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100340 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100350 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100360 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100410 - Disclosure - Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" id="Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail">
        <link:definition>100420 - Disclosure - Available-for-Sale Securities - Summary of Available-for-Sale Securities Held (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail" id="Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Available-for-Sale Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100440 - Disclosure - Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
        <link:definition>100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100480 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" id="DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>100490 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail">
        <link:definition>100500 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail">
        <link:definition>100510 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail">
        <link:definition>100520 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail">
        <link:definition>100530 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail">
        <link:definition>100540 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail">
        <link:definition>100550 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail" id="Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail">
        <link:definition>100560 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail" id="Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>100580 - Disclosure - Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" id="Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail">
        <link:definition>100590 - Disclosure - Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100600 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>100610 - Disclosure - Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" id="Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail">
        <link:definition>100620 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail" id="Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail">
        <link:definition>100630 - Disclosure - Income Taxes - Schedule of Valuation Allowance - (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails" id="DisclosureShareRepurchaseAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Share Repurchase (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100650 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" id="Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail">
        <link:definition>100660 - Disclosure - Leases - Components of Lease Cost for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail" id="Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail">
        <link:definition>100670 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" id="Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail">
        <link:definition>100680 - Disclosure - Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail" id="Role_DisclosureEmployeeBenefitsAdditionalInformationDetail">
        <link:definition>100690 - Disclosure - Employee Benefits - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>100700 - Disclosure - Related-Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sybx_NoncashFinancingItemsAbstract" name="NoncashFinancingItemsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_NoncashInvestingItemsAbstract" name="NoncashInvestingItemsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_OperatingLeaseCostAbstract" name="OperatingLeaseCostAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_ShareRepurchaseAbstract" name="ShareRepurchaseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_AccessAndUseOfSpaceUnderAgreement" name="AccessAndUseOfSpaceUnderAgreement" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sybx_AggregatePurchase" name="AggregatePurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_AggregatePurchasePerShare" name="AggregatePurchasePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_AgreedToPayRenovationAndUpgradationFee" name="AgreedToPayRenovationAndUpgradationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_AgreementExpirationDate" name="AgreementExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" name="AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_AssetsAcquiredUnderOperatingLeaseObligation" name="AssetsAcquiredUnderOperatingLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" name="ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_CollaborationAgreementDescription" name="CollaborationAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" name="CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_CorporateMinimumTaxEffectPercentage" name="CorporateMinimumTaxEffectPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_CurrentPrePaidResearchAndDevelopment" name="CurrentPrePaidResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_DeferredTaxAssetsAmortizableResearchExpenditures" name="DeferredTaxAssetsAmortizableResearchExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement" name="EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_ExciseTaxPercentage" name="ExciseTaxPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" name="FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" name="IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" name="IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sybx_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" name="NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sybx_NonCurrentPrePaidResearchAndDevelopment" name="NonCurrentPrePaidResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_NumberOfVotesEntitledToEachShareOfCommonStock" name="NumberOfVotesEntitledToEachShareOfCommonStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_OperatingAndVariableLeaseCost" name="OperatingAndVariableLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_OperatingLeasesRentExpenseAnnualRentalPayments" name="OperatingLeasesRentExpenseAnnualRentalPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_OperatingLossCarryforwardsNotSubjectToExpiration" name="OperatingLossCarryforwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_OperatingLossCarryforwardsSubjectToExpiration" name="OperatingLossCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale" name="OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" name="PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_PrepaidResearchAndDevelopmentCurrent" name="PrepaidResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_PrepaidResearchAndDevelopmentExpenses" name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_PrepaidResearchAndDevelopmentNoncurrent" name="PrepaidResearchAndDevelopmentNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_PrepaymentToRelatedPartyForCollaborationAgreement" name="PrepaymentToRelatedPartyForCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" name="ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" name="ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" name="RelatedPartyTransactionCollaborationAgreementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_RenovateAndUpgradeExpenses" name="RenovateAndUpgradeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_RentableSpaceUnderLeaseAgreement" name="RentableSpaceUnderLeaseAgreement" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_RepurchaseOfCommonStock" name="RepurchaseOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare" name="SaleOfCommonStockAndPrefundedWarrantPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue" name="ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_StockIssuedDuringPeriodSharesWithholding" name="StockIssuedDuringPeriodSharesWithholding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_StockIssuedDuringPeriodValueSharesWithholding" name="StockIssuedDuringPeriodValueSharesWithholding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sybx_TenantImprovementInvestmentObligation" name="TenantImprovementInvestmentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sybx_TermOfAgreement" name="TermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" name="UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_UpfrontPayments" name="UpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sybx_WarrantsExercised" name="WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" name="FairValueAssetMeasuredOnRecurringBasisLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_AbbVieAgreementMember" name="AbbVieAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_AtTheMarketMember" name="AtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_AzzurGroupLimitedLiabilityCompanyMember" name="AzzurGroupLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_AzzurMember" name="AzzurMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_CurrentLiabilitiesMember" name="CurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_EmployeesAndNonemployeesMember" name="EmployeesAndNonemployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_FirstSOWMember" name="FirstSOWMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_FourthSOWMember" name="FourthSOWMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_GinkgoBioworksIncMember" name="GinkgoBioworksIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_JefferiesLLCMember" name="JefferiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_LongTermIncentivePlan2015And2017Member" name="LongTermIncentivePlan2015And2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_LongTermIncentivePlan2015Member" name="LongTermIncentivePlan2015Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_MasterContractServicesAgreementMember" name="MasterContractServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_NewAgreementMember" name="NewAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_OptionsExercisableToPurchaseCommonStockMember" name="OptionsExercisableToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_RocheCollaborationAndOptionAgreementMember" name="RocheCollaborationAndOptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_UnvestedRestrictedStockAwardsMember" name="UnvestedRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember" name="USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember" name="USTreasuryAndGovernmentLongTermDebtSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_FairValueAssetMeasuredOnRecurringBasisTable" name="FairValueAssetMeasuredOnRecurringBasisTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sybx_AvailableForSaleSecuritiesDisclosureTextBlock" name="AvailableForSaleSecuritiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" name="LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" name="LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_NewAccountingPronouncementsPolicyTextBlock" name="NewAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_ShareRepurchaseTextBlock" name="ShareRepurchaseTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sybx_TreasuryStockPolicyTextBlock" name="TreasuryStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>sybx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T22:59:00.3609+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:href="sybx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" xlink:href="sybx-20221231.xsd#DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="sybx-20221231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AtTheMarketOfferingMember" xlink:label="sybx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_StockIssuedDuringPeriodValueSharesWithholding" xlink:label="sybx_StockIssuedDuringPeriodValueSharesWithholding"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_StockIssuedDuringPeriodSharesWithholding" xlink:label="sybx_StockIssuedDuringPeriodSharesWithholding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sybx_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sybx_StockIssuedDuringPeriodValueSharesWithholding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sybx_StockIssuedDuringPeriodSharesWithholding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashInvestingItemsAbstract" xlink:label="sybx_NoncashInvestingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" xlink:label="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AtTheMarketOfferingMember" xlink:label="sybx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NoncashFinancingItemsAbstract" xlink:label="sybx_NoncashFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AssetsAcquiredUnderOperatingLeaseObligation" xlink:label="sybx_AssetsAcquiredUnderOperatingLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" xlink:label="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" xlink:label="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" xlink:label="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_NoncashInvestingItemsAbstract" xlink:to="sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sybx_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_NoncashFinancingItemsAbstract" xlink:to="us-gaap_CapitalLeaseObligationsIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_NoncashInvestingItemsAbstract" xlink:to="sybx_AssetsAcquiredUnderOperatingLeaseObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_NoncashFinancingItemsAbstract" xlink:to="sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_NoncashFinancingItemsAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sybx_NoncashInvestingItemsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sybx_NoncashFinancingItemsAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015And2017Member" xlink:label="sybx_LongTermIncentivePlan2015And2017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sybx_LongTermIncentivePlan2015And2017Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sybx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201708Member" xlink:label="us-gaap_AccountingStandardsUpdate201708Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashAndCashEquivalentRelatedText" xlink:label="us-gaap_AdditionalCashAndCashEquivalentRelatedText"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" xlink:label="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" xlink:label="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sybx_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201708Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdditionalCashAndCashEquivalentRelatedText" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ComputerAndOfficeEquipmentMember" xlink:label="sybx_ComputerAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sybx_ComputerAndOfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:label="sybx_FairValueAssetMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember" xlink:label="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:to="sybx_FairValueAssetMeasuredOnRecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_FairValueAssetMeasuredOnRecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember" xlink:label="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ComputerAndOfficeEquipmentMember" xlink:label="sybx_ComputerAndOfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sybx_ComputerAndOfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AtTheMarketMember" xlink:label="sybx_AtTheMarketMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_GinkgoBioworksIncMember" xlink:label="sybx_GinkgoBioworksIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PreFundedWarrantsMember" xlink:label="sybx_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NumberOfVotesEntitledToEachShareOfCommonStock" xlink:label="sybx_NumberOfVotesEntitledToEachShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnderwrittenPublicOfferingMember" xlink:label="sybx_UnderwrittenPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CowenAndCompanyLLCMember" xlink:label="sybx_CowenAndCompanyLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_JefferiesLLCMember" xlink:label="sybx_JefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare" xlink:label="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" xlink:label="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_WarrantsExercised" xlink:label="sybx_WarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" xlink:label="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sybx_AtTheMarketMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_GinkgoBioworksIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sybx_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_NumberOfVotesEntitledToEachShareOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sybx_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_CowenAndCompanyLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_JefferiesLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_WarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PreFundedWarrantsMember" xlink:label="sybx_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OptionsExercisableToPurchaseCommonStockMember" xlink:label="sybx_OptionsExercisableToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sybx_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="sybx_OptionsExercisableToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015Member" xlink:label="sybx_LongTermIncentivePlan2015Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sybx_LongTermIncentivePlan2015Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015And2017Member" xlink:label="sybx_LongTermIncentivePlan2015And2017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_EmployeesAndNonemployeesMember" xlink:label="sybx_EmployeesAndNonemployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sybx_LongTermIncentivePlan2015And2017Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sybx_EmployeesAndNonemployeesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_LongTermIncentivePlan2015And2017Member" xlink:label="sybx_LongTermIncentivePlan2015And2017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:label="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sybx_LongTermIncentivePlan2015And2017Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" xlink:label="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CurrentLiabilitiesMember" xlink:label="sybx_CurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_GinkgoBioworksIncMember" xlink:label="sybx_GinkgoBioworksIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PreFundedWarrantsMember" xlink:label="sybx_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RocheCollaborationAndOptionAgreementMember" xlink:label="sybx_RocheCollaborationAndOptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" xlink:label="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AbbVieAgreementMember" xlink:label="sybx_AbbVieAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" xlink:label="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UpfrontPayments" xlink:label="sybx_UpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_MilestonePayments" xlink:label="sybx_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CurrentPrePaidResearchAndDevelopment" xlink:label="sybx_CurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NonCurrentPrePaidResearchAndDevelopment" xlink:label="sybx_NonCurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaymentToRelatedPartyForCollaborationAgreement" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="sybx_CurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_GinkgoBioworksIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sybx_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sybx_RocheCollaborationAndOptionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sybx_AbbVieAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_UpfrontPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_CurrentPrePaidResearchAndDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_NonCurrentPrePaidResearchAndDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_PrepaymentToRelatedPartyForCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_UnvestedRestrictedStockAwardsMember" xlink:label="sybx_UnvestedRestrictedStockAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sybx_UnvestedRestrictedStockAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncomeTaxDisclosureLineItems" xlink:label="sybx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncomeTaxDisclosureTable" xlink:label="sybx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="sybx_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="sybx_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLossCarryforwardsExpirationYear" xlink:label="sybx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CorporateMinimumTaxEffectPercentage" xlink:label="sybx_CorporateMinimumTaxEffectPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ExciseTaxPercentage" xlink:label="sybx_ExciseTaxPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_IncomeTaxDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_OperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sybx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_OperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_CorporateMinimumTaxEffectPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="sybx_ExciseTaxPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sybx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RentableSpaceUnderLeaseAgreement" xlink:label="sybx_RentableSpaceUnderLeaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_MasterContractServicesAgreementMember" xlink:label="sybx_MasterContractServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AzzurGroupLimitedLiabilityCompanyMember" xlink:label="sybx_AzzurGroupLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingLeasesRentExpenseAnnualRentalPayments" xlink:label="sybx_OperatingLeasesRentExpenseAnnualRentalPayments"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NewAgreementMember" xlink:label="sybx_NewAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_TenantImprovementInvestmentObligation" xlink:label="sybx_TenantImprovementInvestmentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AccessAndUseOfSpaceUnderAgreement" xlink:label="sybx_AccessAndUseOfSpaceUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_TermOfAgreement" xlink:label="sybx_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AgreementExpirationDate" xlink:label="sybx_AgreementExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RenovateAndUpgradeExpenses" xlink:label="sybx_RenovateAndUpgradeExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_RentableSpaceUnderLeaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sybx_MasterContractServicesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="sybx_AzzurGroupLimitedLiabilityCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_OperatingLeasesRentExpenseAnnualRentalPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sybx_NewAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_TenantImprovementInvestmentObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_AccessAndUseOfSpaceUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_TermOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_AgreementExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sybx_RenovateAndUpgradeExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_GinkgoBioworksIncMember" xlink:label="sybx_GinkgoBioworksIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaymentToRelatedPartyForCollaborationAgreement" xlink:label="sybx_PrepaymentToRelatedPartyForCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" xlink:label="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CurrentPrePaidResearchAndDevelopment" xlink:label="sybx_CurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_NonCurrentPrePaidResearchAndDevelopment" xlink:label="sybx_NonCurrentPrePaidResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentExpenses" xlink:label="sybx_PrepaidResearchAndDevelopmentExpenses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sybx_GinkgoBioworksIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_PrepaymentToRelatedPartyForCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_CurrentPrePaidResearchAndDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_NonCurrentPrePaidResearchAndDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sybx_PrepaidResearchAndDevelopmentExpenses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AgreedToPayRenovationAndUpgradationFee" xlink:label="sybx_AgreedToPayRenovationAndUpgradationFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AzzurMember" xlink:label="sybx_AzzurMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FirstSOWMember" xlink:label="sybx_FirstSOWMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_CollaborationAgreementDescription" xlink:label="sybx_CollaborationAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_FourthSOWMember" xlink:label="sybx_FourthSOWMember"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement" xlink:label="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sybx_AgreedToPayRenovationAndUpgradationFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sybx_AzzurMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sybx_FirstSOWMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sybx_CollaborationAgreementDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sybx_FourthSOWMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>sybx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-28T22:59:00.1385+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2" xlink:href="sybx-20221231.xsd#DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="sybx-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="sybx-20221231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:href="sybx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" xlink:href="sybx-20221231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="sybx_PrepaidResearchAndDevelopmentNoncurrent" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentNoncurrent" xlink:label="sybx_PrepaidResearchAndDevelopmentNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNonoperating" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfEquity" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="7" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="9" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions" xlink:label="sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset" xlink:label="sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion" xlink:label="sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCash" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="sybx_PrepaidResearchAndDevelopmentCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_PrepaidResearchAndDevelopmentCurrent" xlink:label="sybx_PrepaidResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="sybx_AccruedResearchAndDevelopmentCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_AccruedResearchAndDevelopmentCurrent" xlink:label="sybx_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="sybx_DeferredTaxLiabilitiesRightOfUseAssets" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sybx_DeferredTaxAssetsLeaseLiabilities" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sybx_DeferredTaxAssetsAmortizableResearchExpenditures" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="7" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="sybx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxAssetsLeaseLiabilities" xlink:label="sybx_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_DeferredTaxAssetsAmortizableResearchExpenditures" xlink:label="sybx_DeferredTaxAssetsAmortizableResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sybx_OperatingAndVariableLeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sybx_OperatingAndVariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="sybx-20221231.xsd#sybx_OperatingAndVariableLeaseCost" xlink:label="sybx_OperatingAndVariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540124275360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYBX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SYNLOGIC, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001527599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,728,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1824804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">301 Binney St<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-9975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts, U.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant&#8217;s definitive proxy statement for the 2023 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2022.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540126624480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,861<span></span>
</td>
<td class="nump">$ 16,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">61,768<span></span>
</td>
<td class="nump">112,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,153<span></span>
</td>
<td class="nump">4,721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">79,782<span></span>
</td>
<td class="nump">133,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,323<span></span>
</td>
<td class="nump">9,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset - operating lease</a></td>
<td class="nump">14,356<span></span>
</td>
<td class="nump">13,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_PrepaidResearchAndDevelopmentNoncurrent', window );">Prepaid research and development, net of current portion</a></td>
<td class="nump">8,300<span></span>
</td>
<td class="nump">9,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">110,865<span></span>
</td>
<td class="nump">174,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,785<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,290<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - operating lease</a></td>
<td class="nump">4,152<span></span>
</td>
<td class="nump">3,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,122<span></span>
</td>
<td class="nump">10,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - operating lease, net of current portion</a></td>
<td class="nump">16,129<span></span>
</td>
<td class="nump">17,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">16,133<span></span>
</td>
<td class="nump">17,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2022 and December 31, 2021. 70,933,140 shares issued and 66,736,251 shares outstanding as of December 31, 2022 and 69,698,844 shares issued and outstanding as of December 31, 2021.</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">442,237<span></span>
</td>
<td class="nump">438,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(357,019)<span></span>
</td>
<td class="num">(290,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, at cost (4,196,889 shares at December 31, 2022 and no shares at December 31, 2021)</a></td>
<td class="num">(2,518)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">82,610<span></span>
</td>
<td class="nump">147,266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 110,865<span></span>
</td>
<td class="nump">$ 174,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_PrepaidResearchAndDevelopmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_PrepaidResearchAndDevelopmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125665856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, Issued</a></td>
<td class="nump">70,933,140<span></span>
</td>
<td class="nump">69,698,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">66,736,251<span></span>
</td>
<td class="nump">69,698,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">4,196,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540126531376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,180<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">52,044<span></span>
</td>
<td class="nump">47,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,555<span></span>
</td>
<td class="nump">15,392<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">68,599<span></span>
</td>
<td class="nump">62,519<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(67,419)<span></span>
</td>
<td class="num">(60,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest and investment income</a></td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,147)<span></span>
</td>
<td class="num">$ (60,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding - basic and diluted</a></td>
<td class="nump">71,725,479<span></span>
</td>
<td class="nump">55,329,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding - basic and diluted</a></td>
<td class="nump">71,725,479<span></span>
</td>
<td class="nump">55,329,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,147)<span></span>
</td>
<td class="num">$ (60,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (66,263)<span></span>
</td>
<td class="num">$ (60,620)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120621488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-market Offering</div></th>
<th class="th"><div>Common Stock $0.001 Par Value</div></th>
<th class="th">
<div>Common Stock $0.001 Par Value </div>
<div>At-the-market Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At-the-market Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 115,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">$ (230,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,183,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">81,039<span></span>
</td>
<td class="nump">$ 8,050<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">81,010<span></span>
</td>
<td class="nump">$ 8,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from issuance of common stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="nump">2,447,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_StockIssuedDuringPeriodValueSharesWithholding', window );">Share withholding</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_StockIssuedDuringPeriodSharesWithholding', window );">Share withholding, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">3,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on securities</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(60,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 147,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(290,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,698,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, shares at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from issuance of common stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">$ (2,518)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase Of Common Stock (In Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,196,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(152,118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation expense</a></td>
<td class="nump">3,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on securities</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 82,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (161)<span></span>
</td>
<td class="num">$ (357,019)<span></span>
</td>
<td class="num">$ (2,518)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,933,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, shares at Dec. 31, 2022</a></td>
<td class="nump">4,196,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,196,889)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_StockIssuedDuringPeriodSharesWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares withholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_StockIssuedDuringPeriodSharesWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_StockIssuedDuringPeriodValueSharesWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value shares withholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_StockIssuedDuringPeriodValueSharesWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125760208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (66,147)<span></span>
</td>
<td class="num">$ (60,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,520<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion/amortization of investment securities</a></td>
<td class="num">(772)<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset', window );">Reduction in carrying amount of operating lease right of use asset</a></td>
<td class="nump">3,149<span></span>
</td>
<td class="nump">2,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,568<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion', window );">Prepaid research and development, net of current portion</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(3,898)<span></span>
</td>
<td class="num">(2,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(56,888)<span></span>
</td>
<td class="num">(52,198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(82,787)<span></span>
</td>
<td class="num">(167,866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturity of marketable securities</a></td>
<td class="nump">141,866<span></span>
</td>
<td class="nump">114,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from redemption of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(728)<span></span>
</td>
<td class="num">(679)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">58,351<span></span>
</td>
<td class="num">(53,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease obligations</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock awards withheld for payment of employees' withholding tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions', window );">Proceeds from employee stock purchases and exercise of stock options</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Repurchase of Common Stock (Treasury Stock)</a></td>
<td class="num">(2,518)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(2,040)<span></span>
</td>
<td class="nump">89,382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(577)<span></span>
</td>
<td class="num">(16,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">17,535<span></span>
</td>
<td class="nump">33,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">16,958<span></span>
</td>
<td class="nump">17,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_NoncashInvestingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AssetsAcquiredUnderOperatingLeaseObligation', window );">Assets acquired under operating lease obligation</a></td>
<td class="nump">3,616<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_NoncashFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Purchase under finance lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Issuance costs included in accounts payable and accrued expenses</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sybx_AtTheMarketOfferingMember', window );">At-the-market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 8,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_AssetsAcquiredUnderOperatingLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets acquired under operating lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_AssetsAcquiredUnderOperatingLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in prepaid research and development net of current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_NoncashFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash financing items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_NoncashFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_NoncashInvestingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash investing items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_NoncashInvestingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash purchase of property, plant and equipment in accounts payable and accrued liabilities adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from employee stock purchases and exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in carrying amount of operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sybx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sybx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127473472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nature of Business </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (Synlogic or the Company), is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of Synthetic Biotics. Synthetic Biotics are generated from Synlogic&#8217;s proprietary platform, leveraging a reproducible, modular approach to the generation of novel drug candidates that perform or deliver critical therapeutic functions. Synthetic Biotics are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways or deliver combinations of therapeutic factors. Synlogic&#8217;s goal is to discover, develop and ultimately commercialize Synthetic Biotics. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/>The Company&#8217;s consolidated financial statements have been prepared on the basis of continuity of operations, and the realization of assets and the satisfaction of liabilities in the ordinary course of business. At December 31, 2022, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash, cash equivalents and short-term marketable securities. The Company has historically generated negative cash flows from operations and has an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022. In the absence of positive cash flows from operations, the Company is highly dependent on its ability to secure additional sources of funding in the form of debt or equity financings, or through the execution of additional collaboration agreements. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance date of these financial statements. If the Company cannot secure additional funding, it may be required to undertake further organizational changes, including reducing research and development spending on certain clinical stage and preclinical research programs and implementing additional reductions to its workforce. <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), the regulatory approval process, market acceptance of the Company&#8217;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company&#8217;s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or alliances.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the Company is not aware of a material impact from the continuation of the COVID-19 pandemic through December 31, 2022, the full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations, and financial condition, including expenses and manufacturing, clinical trials, and research and development costs, depends on future developments that are uncertain at this time.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125863968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP or GAAP).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, the Company&#8217;s management evaluates its estimates, including those related to research and development accruals and prepaids, accrued expenses, contingencies, and investments. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months or less</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022 and 2021, respectively.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company held cash of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022 and 2021 in a letter of credit to secure its lease at the 301 Binney Street facility. The Company has classified this deposit as long-term restricted cash on its balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.102%;"/>
          <td style="width:1.483%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.466000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.483%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.466000000000001%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,438</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,097</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,097</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash shown in<br/>&#160;&#160;&#160;the consolidated statement of cash flows</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,958</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,535</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. Accounting Standards Codification (ASC) Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). The hierarchy consists of three levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 &#8211; Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 &#8211; Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 &#8211; Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates transfers between levels at the end of each reporting period. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Available-for-Sale Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies all of its investments as available-for-sale based upon its intent with regard to such investments. The Company classifies investments as short-term when their</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">remaining contractual maturities are one year or less from the balance sheet date, and as long-term when the investment has a remaining contractual maturity of more than one year from the balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight&#8209;line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.077%;"/>
          <td style="width:48.955%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset classification</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer and office equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lesser of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long&#8209;Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long&#8209;lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairments have been recognized.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (ROU) assets, current operating lease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations in our consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets represent the right-to-use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease term includes </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">options to extend the lease when it is reasonably certain that option will be exercised</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leases with a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months or less are not recorded on the Company&#8217;s consolidated balance sheet.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When third-party service providers&#8217; billing terms do not coincide with the Company&#8217;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenue through a collaboration and option agreement with Roche for the development and commercialization of product candidates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full-time equivalent time as a measure of satisfaction of performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Services</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement is determined to contain a promise or obligation for us to perform research and development services, we must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, we consider the capabilities of the customer to perform these same services. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The estimates we use to record revenue relating to the combined performance obligation on an over time basis, include input methods such as full-time equivalent time incurred compared to the full-time equivalent time expected to be incurred in the future to satisfy the performance obligation, which require management judgment. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. With this method, we must estimate total inputs required to satisfy a performance obligation and measure efforts expended to date to determine revenue recognition. This estimate of remaining inputs is subjective, as the research is novel, and therefore efforts to be successful may be different than the estimated efforts at the balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Payments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contract Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity&#8209;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (ESPP) is estimated on the date of grant using the Black&#8209;Scholes option&#8209;pricing model. Expected volatility for the Company&#8217;s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer&#8209;group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk&#8209;free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients&#8217; service payments are classified.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#8217;s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater than 50%</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company&#8217;s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company&#8217;s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, recently issued pronouncements that are or will be applicable to the Company did not have, or are not expected to have, a material impact on its present or future consolidated financial statements or disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127700576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value of Financial Instruments</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tables below present information about the Company&#8217;s assets that are measured at fair value on a recurring basis as of December 31, 2022 and 2021 and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s investment portfolio includes many fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations. In addition, model processes were used to assess interest rate impact and develop prepayment scenarios. These models take into consideration relevant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">credit information, perceived market movements, sector news and economic events. The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.134%;"/>
        <td style="width:0.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.048%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.029%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.8%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.212%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active<br/>Markets for Identical<br/>Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br/>Observable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active<br/>Markets for Identical<br/>Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br/>Observable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,277</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,277</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,478</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at December 31, 2022 and December 31, 2021 are carried at amounts that approximate fair value due to their short-term maturities. Finance lease obligations at December 31, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> approximate fair value as they bear interest at a rate approximating a market interest rate.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127614784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AvailableForSaleSecuritiesDisclosureTextBlock', window );">Available-for-Sale Securities</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available-for-Sale Securities</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the available-for-sale securities held at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.836%;"/>
        <td style="width:1.447%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.417%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.322%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.445%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.322%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.445%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.322%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.445%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,929</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,768</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,298</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,277</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,876</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,873</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,041</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,236</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The contractual maturity of all securities held at December 31, 2022 was six months or less. There were fifteen investments in an unrealized loss position at December 31, 2022. The aggregate fair value of the securities in an unrealized loss position at December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until maturity or a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t hold any securities with an other-than-temporary impairment at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross realized gains and losses on the sales of investments have not been material to the Company&#8217;s consolidated statement of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_AvailableForSaleSecuritiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_AvailableForSaleSecuritiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540215431728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(5)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.102%;"/>
        <td style="width:1.483%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.466000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.483%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.466000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,721</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">710</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,721</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540130682928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(6)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, net</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.751%;"/>
        <td style="width:1.389%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.735%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.389%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.735%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,313</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">793</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">756</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,820</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,561</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">623</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,463</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,714</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,140</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,323</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,088</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense on property and equipment was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540130657744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(7)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Expenses</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.902%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.563%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll related</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,401</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">336</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,290</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127588848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s common stock has the following characteristics:</span></p><div style="margin-left:12.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.810754261802134%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of common stock are entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders.</span></div></div><div style="margin-left:12.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.810754261802134%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of common stock are entitled to receive dividends, if and when, declared by the Company&#8217;s board of directors. Since inception, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash dividends have been declared.</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2019, the Company issued to Ginkgo Bioworks, Inc. (Ginkgo) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,340,771</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and accompanying Pre-Funded Warrants (the Pre-Funded Warrants) to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,548,117</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, at a combined purchase price per share and Pre-Funded Warrant of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Pre-Funded Warrants have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, with $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of such exercise price paid at the closing of the offering. The proceeds, net of issuance costs, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to the proceeds from sale of the common stock and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to the proceeds from sale of the Pre-Funded Warrants. The Pre-Funded Warrants may be exercised at any time until all of the Pre-Funded Warrants are exercised in full to the extent that, after giving effect to such issuance after exercise, Ginkgo would not beneficially own in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock outstanding immediately after giving effect to the issuance. The Pre-Funded Warrants were classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, such warrants do not provide any guarantee of value or return. In addition, in connection with the issuance to Ginkgo of common stock and Pre-Funded Warrants, the Company expanded its existing collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Pre-Funded Warrants have been exercised as of December 31, 2022. (See Note 10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ginkgo Collaboration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 13, 2017, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) with respect to an at-the-market (ATM) offering program. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,447,211</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. This sales agreement with Cowen was terminated in July 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company entered into a new sales agreement with Jefferies, LLC (Jefferies) with respect to an ATM, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having aggregate sales proceeds of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Jefferies is not required to sell any specific amount but acts as the Company&#8217;s sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. During the year ended December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481,451</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were sold pursuant to the sales agreement with Jefferies, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share pursuant to an underwritten public offering. The net proceeds to the Company from the offering, after deducting the underwriting discounts and commissions and offering expenses payable by the Company, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All shares of common stock sold in the offering were sold by the Company.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share pursuant to an underwritten public offering. The net proceeds to the Company from the offering, after deducting the underwriting discounts and commissions and offering expenses payable by the Company, were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All shares of common stock sold in the offering were sold by the Company.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has  reserved for future issuance the following shares of common stock related to the potential exercise of Pre-Funded Warrants, exercise of stock options, and the employee stock purchase plan:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.27%;"/>
        <td style="width:1.0%;"/>
        <td style="width:29.73%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issuable under pre-funded warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,548,117</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,328,011</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,648</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,928,776</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127478736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-based Compensation and Equity Incentive Plans</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(9)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity&#8209;based Compensation and Equity Incentive Plans</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Plans</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently has three active equity plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2015 Equity Incentive Award Plan (2015 Plan) functions as the primary equity plan for the Company. The 2015 Plan includes an &#8220;evergreen provision&#8221; that allows for an annual increase in the number of shares of common stock available for issuance under the 2015 Plan, which annual increase will be added on the first day of each fiscal year from 2016 through 2025, inclusive, and will be equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> percent of the shares outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board of Directors. On January 1, 2022, the Company added </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,484,942</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares to the 2015 Plan pursuant to the &#8220;evergreen provision&#8221;. The 2015 Plan provides for the granting of a variety of stock&#8209;based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, deferred stock awards, dividend equivalent awards, stock payment awards, performance awards and other stock&#8209;based awards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2017 Stock Incentive Plan (the 2017 Plan) provides for the grant of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2015 Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation, subject to any plan limitations. The ESPP generally provides for set offering periods, and at the end of each offering period, employees are able to purchase shares at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. The Company suspended the ESPP in 2017. In December 2019, the Board reactivated the 2015 ESPP and approved an amendment to the ESPP to (i) reduce the permitted payroll deduction and number of shares of the Company&#8217;s common stock that a participant may purchase per calendar year and offering period under the ESPP and (ii) establish a period for enrollment for eligible participants. The reactivation of the 2015 ESPP was effective immediately. The Company&#8217;s executive officers are eligible to participate in the 2015 ESPP. The ESPP includes an &#8220;evergreen provision,&#8221; allowing for an annual increase in the number of shares of common stock available for issuance. On January 1, 2022, the Company added </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">696,988</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares to the ESPP pursuant to the &#8220;evergreen provision&#8221;. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,629</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock purchased under the ESPP during the year ended December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 were:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.931%;"/>
        <td style="width:1.701%;"/>
        <td style="width:14.525%;"/>
        <td style="width:1.701%;"/>
        <td style="width:14.525%;"/>
        <td style="width:2.616%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average, risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity under the 2015 and 2017 Plans.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.377%;"/>
        <td style="width:0.651%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.47%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.17%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.126%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.651%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.046%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.665%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.846%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">remaining</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contractual</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">intrinsic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exercise</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(a)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,500,913</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">588</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,738,999</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,562</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.73</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled/Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">956,655</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,247,695</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested or expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,247,695</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,328,011</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.03pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2022 and 2021. </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,210,026</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options were in the money at December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, respectively.</span></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value per share of options granted during the years ended December 31, 2022 and 2021 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The total fair value of awards that vested during the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized share-based compensation for unvested stock option grants which is expected to be recognized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Common Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">762,772</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242,454</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of restricted common stock were granted, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows restricted common stock activity:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.195%;"/>
        <td style="width:1.429%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.458%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.444%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.474%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>average<br/>grant date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(per share)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">299,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">762,772</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.60</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.71</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152,118</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.81</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">826,265</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.89</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total fair value of shares that vested during the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP is considered a compensatory plan with the related compensation expense recognized over the six-month offering periods. The compensation expense for the years ended December 31, 2022 and December 31, 2021 was less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in both years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded total equity&#8209;based compensation expense of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, during the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021, respectively. Equity compensation during the years ended December 31, 2022 and 2021 is derived from stock options, restricted stock awards, and the ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity&#8209;based compensation expense within the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.667%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.143%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.289%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,565</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,074</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,988</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,639</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,361</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity&#8209;based compensation expense by type of award for the years ended December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.548%;"/>
        <td style="width:1.504%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.155999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.491%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.302%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,639</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,361</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127570960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(10)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreements</span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Roche Collaboration</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, the Company entered into a Pilot Collaboration and Option Agreement (the Roche Collaboration and Option Agreement) with F. Hoffmann-La Roche Ltd (Roche Basel) and Hoffmann-La Roche Inc. (Roche US, and together with Roche Basel, Roche). Under the terms of the Roche Collaboration and Option Agreement, the Company and Roche will seek to collaborate to research and pre-clinically develop Synthetic Biotics for addressing an undisclosed novel target for the treatment of inflammatory bowel disease (the Product Candidate).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Roche Collaboration and Option Agreement, Roche agreed to pay the Company, an upfront, nonrefundable technology access fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company received in July 2021. In addition, the Company is eligible to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in milestone payments upon the achievement of certain success criteria. Following the research period, Roche holds an exclusive option right (the Option) to negotiate a definitive Collaboration and License Agreement (CLA) for further development and commercialization of the Product Candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Roche Collaboration and Option Agreement, during the term of such agreement, each party has granted to the other party a non-exclusive, non-transferrable, non-sublicensable, royalty-free right and license to certain intellectual property and know-how controlled by such party, solely as necessary for the party to perform its obligations under the Roche Collaboration and Option Agreement. The parties will establish a Joint Research Committee (JRC) to oversee and manage the execution of the underlying study plan for the Roche Collaboration and Option Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Collaboration and Option Agreement includes various representations, warranties, covenants, indemnities, and other customary provisions. Roche may terminate the Roche Collaboration and Option Agreement without cause immediately upon written notice where certain success criteria have been met for parts of the study plan, or upon ninety (90) days&#8217; prior written notice to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company. Either party may terminate the Roche Collaboration and Option Agreement in the event of an uncured material breach of the other party.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research and development will be performed by the Company for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s according to three phases of research as defined in the research plan. The Company is eligible to receive milestone payments from Roche upon the achievement of success criteria for respective milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and concluded that the contract counterparty, Roche, is a customer. The Company identified the following material promises made by the Company to Roche at the outset of the arrangement: (1) a non-exclusive royalty-free research and development license; (2) research and development services for pre-clinical activities under the research plan; (3) implicit renewal options created by Roche&#8217;s decision not to terminate the contract; (4) the Company&#8217;s participation on the JRC; and (5) an exclusive right to negotiate a definitive CLA for further development and commercialization of the Product Candidate. The Company determined that the license and research and development activities were not distinct from one another, as the license has limited value without the performance of research and development activities. The Company&#8217;s participation on the JRC was determined to be quantitatively and qualitatively immaterial and therefore is excluded from performance obligations. As such, the Company determined that the promises associated with the license and research and development services should be combined into a single performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company next evaluated the milestone payments relating to the three phases of research as defined in the research plan and the option to negotiate and enter into the CLA, to determine whether they provide Roche with any material rights. The Company concluded that the option was not issued at a significant and incremental discount, and therefore do not provide material rights. As such, they were excluded as performance obligations at the outset of the arrangement. If Roche elects to exercise the options, the additional consideration will be added to the transaction price and allocated to the resulting performance obligations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on these assessments, the Company identified one performance obligation at the outset of the Roche Collaboration and Option Agreement, which consists of: (1) the non-exclusive license and (2) the research and development activities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the outset of the arrangement, the transaction price included only the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million up-front consideration received and which was allocated to the single performance obligation. The milestone payments that may be received are excluded from the transaction price until each respective milestone has been achieved. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, the Company began work on the research and development services for the first phase of the research plan and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront payment was recognized over the time of the first phase of the research plan. In September 2021, the Company completed the research and development services for the first phase of the research plan and achieved a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was paid by Roche in November 2021. At this time, the milestone payment was allocated to a new performance obligation consisting of the underlying research and development services to be performed over the second phase of the research plan. In August 2022, the Company completed the research and development services for the second phase of the research plan and achieved a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was paid by Roche in October 2022. At this time, the milestone payment was allocated to a new performance obligation consisting of the underlying research and development services to be performed over the third phase of the research plan. Upon the Company&#8217;s completion of these activities and subject to Roche&#8217;s termination right, the additional milestone payments based on the achievement of specific events outlined in the Roche Collaboration and Option Agreement will become due.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue associated with performance obligations under the Roche Collaboration and Option Agreement are recognized as the research and development services are provided using an input method, according to the full-time equivalents incurred. The transfer of control occurs over time and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022 and 2021, respectively, as collaboration revenue in the Company&#8217;s consolidated statements of operations and comprehensive loss. Deferred revenue from the collaboration amounted to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022, all of which is included in current liabilities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ginkgo Collaboration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2017, the Company established a technology collaboration with Ginkgo. In June 2019, in connection with the issuance to Ginkgo of an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,340,771</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and Pre-Funded Warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,548,117</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common stock (See Note 8), the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for its foundry services that will be provided to the Company over an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The current and non-current balances relating to the prepayment of foundry services is recorded in prepaid expenses and other current assets and prepaid research and development, net of current portion, respectively, on the December 31, 2022 consolidated balance sheet. At December 31, 2022, the Company had remaining balances of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of current and non-current pre-paid research and development costs related to this transaction, respectively. Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127634576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(11)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss per Share</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.517%;"/>
        <td style="width:1.069%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.334000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.747%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.334000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,147</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,561</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding - basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,725,479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,329,711</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.92</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.09</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s potentially dilutive shares, which include outstanding stock options, unvested restricted common stock and potential shares issuable under the ESPP, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.669%;"/>
        <td style="width:1.131%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.609%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.737%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.854%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted common stock awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">826,265</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">299,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,247,695</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,500,913</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,648</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127524576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(12)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recorded </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> income tax benefits for the net operating losses incurred due to its uncertainty of reclaiming a benefit for those losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Deferred tax assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.101%;"/>
        <td style="width:1.721%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.721%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.222999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,803</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,802</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,118</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">888</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,541</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,618</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,516</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortizable intangibles</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,165</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortizable research expenditures </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">363</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,521</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,922</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,794</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,922</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,599</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.365pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.365pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Under the Tax Cuts and Jobs Act (TCJA), research and experimental (R&amp;D) expenditures are capitalized and amortized under section 174 for tax years beginning after December 31, 2021. These costs are amortized for tax purposes over 5 years since the R&amp;D was performed in the U.S. The unamortized balance of these costs is presented as a deferred tax asset in the table above.</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s deferred tax assets, which are comprised principally of net operating loss carryforwards, and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was established at December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021, respectively.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the statutory federal income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.802%;"/>
        <td style="width:0.969%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.863%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.982%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.385%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A roll-forward of the valuation allowance for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.421%;"/>
        <td style="width:1.592%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.203999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.227%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,791</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,122</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,686</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,599</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had federal net operating loss carryforwards that may be available to reduce future taxable income of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating loss </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carryforwards, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million will expire on various dates from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">223.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of federal net operating loss carryforwards do not expire. The Company also had state net operating loss carryforwards that may be available to reduce future taxable income </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">289.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">illion for the period ended December 31, 2022. The state net operating loss carryforwards begin to expire i</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ddition, as of December 31, 2022, the Company had federal and state research and development tax credit carryforwards available to reduce future tax liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law which contained provisions that include a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% corporate minimum tax effective for taxable years beginning after December 31, 2022 and a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% excise tax on certain stock buybacks after December 31, 2022. The Company expects the impact of these provisions to be immaterial.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 382 of the Internal Revenue Code of 1986 (IRC), certain substantial changes in the Company&#8217;s ownership may result in a limitation on the amount of net operating loss (NOL) carryforwards and research and development credit (R&amp;D credit) carryforwards that may be used in future years. Utilization of the NOL and R&amp;D credit carryforwards may be subject to a substantial annual limitation under Section 382 of the IRC due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax. The Company has not completed a study to assess whether an ownership change has occurred, or whether there have been multiple ownership changes since its formation, due to the significant complexity and related costs associated with such a study. There could be additional ownership changes in the future that may result in additional limitations on the utilization of NOL carryforwards and credits.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognized any liability for unrecognized tax benefits as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company&#8217;s policy is to record interest and penalties related to unrecognized tax benefits on the income tax expense line in the consolidated statement of operations. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest or penalties accrued at December 31, 2022 and 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files tax returns, on an entity-level basis, as prescribed by the tax laws of the jurisdictions in which it operates. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2019 to the present are open to examination under the statute.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company&#8217;s net operating losses and other attributes generated in a closed tax year may still be adjusted to determine the amount of carryforward deduction available in an open year under examination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127426144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchase<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ShareRepurchaseAbstract', window );"><strong>Share Repurchase [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ShareRepurchaseTextBlock', window );">Share Repurchase</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13)   Share Repurchase</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 25, 2022, the Company entered into a definitive share repurchase agreement with a stockholder, as part of a privately negotiated transaction, to repurchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,196,889</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock held by them for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. This repurchase was completed on November 28, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchased shares are held as treasury stock at cost until they are retired or re-issued.  There were no retirements or re-issuances of treasury stock during the year ended December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ShareRepurchaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ShareRepurchaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ShareRepurchaseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ShareRepurchaseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127471376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(14)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2017, the Company entered into an agreement to lease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,346</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts. Annual rent is approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease commenced in January 2018 and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company has paid for tenant improvements of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Additionally, the Company has capitalized approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of landlord-funded tenant improvements. The Company was deemed to be the accounting owner of the tenant improvements primarily because it was responsible for project cost overruns, and as such, the amounts were recorded as a leasehold improvement. The landlord-funded tenant improvement allowance is being amortized as a reduction to lease expense ratably over the lease term. In conjunction with the lease, the Company established a letter of credit of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">secured by cash balances included</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restricted cash. Variable payments based on our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. The Company has an option to extend the term by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and an option to terminate the agreement if a similar agreement is executed with the landlord or an affiliate of the landlord. Neither option is reasonably certain of exercise and both are excluded from the lease liability calculation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2018, the Company entered into an agreement (the First SOW) with Azzur Group, LLC (Azzur) whereby Azzur agreed to provide the Company with access to, and the use of, an approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square foot cleanroom space to be constructed in Waltham, Massachusetts (the Azzur Suite), for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months, from May 1, 2019 to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the Initial Term). In April 2021, Synlogic entered into a new agreement (the Second SOW) with Azzur which replaced the First SOW. Pursuant to the Second SOW, Synlogic was granted access to, and use of, the Azzur Suite for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, from May 2021 to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9ad71e03-2303-4ee4-883d-5ed6738ea62b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2022</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the Second Term). On January 21, 2022, the Company entered into two agreements with Azzur. Pursuant to the first of the agreements (the Third SOW), the Company has agreed to pay Azzur $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to renovate and upgrade the cleanroom space at Azzur for the Company&#8217;s expanded use. The second of the agreements (the Fourth SOW) replaces the Second SOW that the Company entered into with Azzur in April 2021. The Fourth SOW extends the term of the lease, for the period beginning January 2022 through March 2023 (the Third Term). In November 2022, the Company entered into a new agreement (the Fifth SOW) with Azzur that extended the term of the lease, for the period beginning April 2023 through December 2023 (the Fourth Term). The Fifth SOW contains two options to extend the lease, the first option goes through June 2024, and the second option goes through December 2024. The Company determined that the agreement contained an embedded lease because the Company controls the use of the Azzur Suite. Accordingly, the fixed and in-substance fixed consideration under the agreement was used to measure the ROU asset and lease liability at the effective date. The ROU asset and lease liability are subsequently remeasured to reflect the impact of each subsequent modification. As of December 31, 2022, the Company determined that it was reasonably certain to exercise the first option to extend the lease under the Fifth SOW, and thus was included in the lease liability calculation.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases classified as operating leases are included in operating lease ROU assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheets. The operating lease right-of-use asset and operating lease liability represents the Binney Street lease and the Azzur Suite lease. Cash paid for amounts included in the present value of operating lease liabilities was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, 2022 and 2021, respectively, which is included in operating cash flows.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease cost for operating leases for the years ended December 31, 2022 and 2021 were (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.501%;"/>
        <td style="width:1.0%;"/>
        <td style="width:23.987000000000002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.285%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,824</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,221</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,324</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The right-of-use asset for the operating lease is disclosed on the consolidated balance sheets.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate for operating leases were:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.375%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.341%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.864%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.419%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2022 to the operating lease liabilities recorded on the balance sheet: December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.945%;"/>
        <td style="width:1.0%;"/>
        <td style="width:32.056%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,749</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,792</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,905</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,761</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,480</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,281</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,152</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,129</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease cost for finance leases during the years ended December 31, 2022 and 2021, and the finance lease liability at December 31, 2022, were not material.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127536496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(15)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125865856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefits</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(16)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Benefits</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a defined contribution 401(k) plan for eligible employees. Employees are eligible to participate in the plan beginning on their date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation. The Company started to match employee contributions effective January 1, 2019. The Company matched </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the employee contributions to the 401(k) plan up to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the participating employee&#8217;s eligible earnings, resulting in a maximum company match of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the participating employee&#8217;s eligible earnings, and subject to certain additional statutory dollar limitations. In 2021, the Company increased the match to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the employee contributions up to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the participating employee&#8217;s eligible earnings, resulting in a maximum company match of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the participating employee&#8217;s eligible earnings, and subject to certain additional statutory dollar limitations. For the years ended December 31, 2022 and 2021, the Company made </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million contributions to the plan, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125657248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(17)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related-Party Transactions</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of December 31, 2022, Ginkgo owns </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,340,771</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s outstanding common stock.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ginkgo Collaboration.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the agreement the Company made a prepayment to Ginkgo of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for its foundry services that will be provided to the Company over an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At December 31, 2022, the Company had remaining balances of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of current and non-current pre-paid research and development costs related to this transaction, respectively. For the year ended December 31, 2022, the Company used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the pre-paid research and development expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125679248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP or GAAP).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, the Company&#8217;s management evaluates its estimates, including those related to research and development accruals and prepaids, accrued expenses, contingencies, and investments. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months or less</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022 and 2021, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company held cash of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at December 31, 2022 and 2021 in a letter of credit to secure its lease at the 301 Binney Street facility. The Company has classified this deposit as long-term restricted cash on its balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.102%;"/>
          <td style="width:1.483%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.466000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.483%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.466000000000001%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,438</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,097</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,097</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash shown in<br/>&#160;&#160;&#160;the consolidated statement of cash flows</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,958</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,535</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. Accounting Standards Codification (ASC) Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). The hierarchy consists of three levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 &#8211; Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 &#8211; Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 &#8211; Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates transfers between levels at the end of each reporting period. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Available-for-Sale Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Available-for-Sale Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies all of its investments as available-for-sale based upon its intent with regard to such investments. The Company classifies investments as short-term when their</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">remaining contractual maturities are one year or less from the balance sheet date, and as long-term when the investment has a remaining contractual maturity of more than one year from the balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight&#8209;line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.077%;"/>
          <td style="width:48.955%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset classification</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer and office equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lesser of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long&#8209;Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long&#8209;lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairments have been recognized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (ROU) assets, current operating lease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations in our consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets represent the right-to-use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease term includes </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">options to extend the lease when it is reasonably certain that option will be exercised</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leases with a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months or less are not recorded on the Company&#8217;s consolidated balance sheet.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When third-party service providers&#8217; billing terms do not coincide with the Company&#8217;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenue through a collaboration and option agreement with Roche for the development and commercialization of product candidates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full-time equivalent time as a measure of satisfaction of performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Services</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement is determined to contain a promise or obligation for us to perform research and development services, we must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, we consider the capabilities of the customer to perform these same services. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The estimates we use to record revenue relating to the combined performance obligation on an over time basis, include input methods such as full-time equivalent time incurred compared to the full-time equivalent time expected to be incurred in the future to satisfy the performance obligation, which require management judgment. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. With this method, we must estimate total inputs required to satisfy a performance obligation and measure efforts expended to date to determine revenue recognition. This estimate of remaining inputs is subjective, as the research is novel, and therefore efforts to be successful may be different than the estimated efforts at the balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Payments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contract Costs</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity&#8209;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (ESPP) is estimated on the date of grant using the Black&#8209;Scholes option&#8209;pricing model. Expected volatility for the Company&#8217;s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer&#8209;group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk&#8209;free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients&#8217; service payments are classified.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#8217;s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater than 50%</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company&#8217;s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company&#8217;s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_TreasuryStockPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, recently issued pronouncements that are or will be applicable to the Company did not have, or are not expected to have, a material impact on its present or future consolidated financial statements or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently adopted accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_TreasuryStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire policy disclosure for treasury stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_TreasuryStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127465200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.102%;"/>
          <td style="width:1.483%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.466000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.483%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.466000000000001%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,861</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,438</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,097</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,097</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash shown in<br/>&#160;&#160;&#160;the consolidated statement of cash flows</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,958</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,535</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of Useful Life of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.077%;"/>
          <td style="width:48.955%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset classification</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer and office equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lesser of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127634576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.134%;"/>
        <td style="width:0.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.048%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.029%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.8%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.212%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active<br/>Markets for Identical<br/>Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br/>Observable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active<br/>Markets for Identical<br/>Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other<br/>Observable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,277</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,277</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,478</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127482464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available-for-Sale Securities Held</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the available-for-sale securities held at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.836%;"/>
        <td style="width:1.447%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.417%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.322%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.445%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.322%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.445%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.322%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.445%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,929</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,768</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,298</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,277</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,876</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,873</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,041</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,236</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127461184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.102%;"/>
        <td style="width:1.483%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.466000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.483%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.466000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,721</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">710</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,721</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127455008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.751%;"/>
        <td style="width:1.389%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.735%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.389%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.735%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,313</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">793</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">756</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,820</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,561</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">623</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,463</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,714</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,140</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,323</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,088</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127536496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.902%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.563%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll related</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,401</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">336</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,290</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127634576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has  reserved for future issuance the following shares of common stock related to the potential exercise of Pre-Funded Warrants, exercise of stock options, and the employee stock purchase plan:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.27%;"/>
        <td style="width:1.0%;"/>
        <td style="width:29.73%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issuable under pre-funded warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,548,117</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,328,011</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,648</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,928,776</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of shares of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125774112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Common Stock Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows restricted common stock activity:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.195%;"/>
        <td style="width:1.429%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.458%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.444%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.474%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>average<br/>grant date</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(per share)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">299,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">762,772</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.60</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.71</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152,118</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.81</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">826,265</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.89</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity-based Compensation Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity&#8209;based compensation expense within the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.667%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.143%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.451%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.289%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,565</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,074</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,988</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,639</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,361</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Equity-based Compensation Expenses by Award Type</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity&#8209;based compensation expense by type of award for the years ended December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.548%;"/>
        <td style="width:1.504%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.155999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.491%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.302%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,639</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,361</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015And2017Member', window );">2015 and 2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 were:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.931%;"/>
        <td style="width:1.701%;"/>
        <td style="width:14.525%;"/>
        <td style="width:1.701%;"/>
        <td style="width:14.525%;"/>
        <td style="width:2.616%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average, risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity under the 2015 and 2017 Plans.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.377%;"/>
        <td style="width:0.651%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.47%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.17%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.126%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.651%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.046%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.665%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.846%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">remaining</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contractual</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">intrinsic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exercise</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(a)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,500,913</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">588</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,738,999</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.62</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,562</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.73</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled/Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">956,655</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,247,695</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested or expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,247,695</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,328,011</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2022 and 2021. </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,210,026</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options were in the money at December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015And2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015And2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540128931360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.517%;"/>
        <td style="width:1.069%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.334000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.747%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.334000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,147</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,561</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding - basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,725,479</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,329,711</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.92</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.09</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.669%;"/>
        <td style="width:1.131%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.609%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.737%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.854%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted common stock awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">826,265</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">299,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,247,695</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,500,913</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,648</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540124468608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Deferred tax assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.101%;"/>
        <td style="width:1.721%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.721%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.222999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,803</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,802</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,118</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">888</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,541</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,618</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,516</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortizable intangibles</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,165</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortizable research expenditures </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">363</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,521</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right of use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,922</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,794</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,922</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,599</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.365pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.365pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Under the Tax Cuts and Jobs Act (TCJA), research and experimental (R&amp;D) expenditures are capitalized and amortized under section 174 for tax years beginning after December 31, 2021. These costs are amortized for tax purposes over 5 years since the R&amp;D was performed in the U.S. The unamortized balance of these costs is presented as a deferred tax asset in the table above.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the statutory federal income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.802%;"/>
        <td style="width:0.969%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.863%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.982%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.385%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Valuation Allowance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A roll-forward of the valuation allowance for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021 is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.421%;"/>
        <td style="width:1.592%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.203999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.557%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.227%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,791</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,122</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,686</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109,599</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540124319776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Cost for Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease cost for operating leases for the years ended December 31, 2022 and 2021 were (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.501%;"/>
        <td style="width:1.0%;"/>
        <td style="width:23.987000000000002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.285%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,824</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,221</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,324</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock', window );">Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate for operating leases were:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.375%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.341%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.864%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.419%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturity of Lease Liabilities for Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2022 to the operating lease liabilities recorded on the balance sheet: December 31, 2022</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.945%;"/>
        <td style="width:1.0%;"/>
        <td style="width:32.056%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of lease liabilities</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,749</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,792</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,905</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,761</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,480</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,281</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,152</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,129</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating and finance lease, liability, maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee weighted average remaining lease term and weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540126659472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term marketable securities</a></td>
<td class="nump">$ 77,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (357,019)<span></span>
</td>
<td class="num">$ (290,872)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120738720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashAndCashEquivalentRelatedText', window );">Cash equivalents maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">three months or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="nump">$ 16,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount', window );">Transfers of assets and liabilities between Level 1, Level 2, or Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">options to extend the lease when it is reasonably certain that option will be exercised<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract', window );">Revenue, practical expedient, incremental cost of obtaining contract [true/false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription', window );">Revenue, practical expedient, remaining performance obligation, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Description of tax benefit likely to be realized upon settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">greater than 50%<span></span>
</td>
<td class="text">greater than 50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201708Member', window );">ASU 2017-08</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents net transfers in and out of assets and liabilities measured at fair value on a recurring basis using Level 1, Level 2 and Level 3 inputs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashAndCashEquivalentRelatedText">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashAndCashEquivalentRelatedText</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121825205&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient was elected to recognize incremental cost of obtaining contract as expense when incurred if amortization period would have been one year or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL51790836-203054<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130569-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of consideration that is not included in transaction price and not allocated to remaining performance obligation. Includes, but is not limited to, variable consideration that is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201708Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201708Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125719488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,861<span></span>
</td>
<td class="nump">$ 16,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</a></td>
<td class="nump">$ 16,958<span></span>
</td>
<td class="nump">$ 17,535<span></span>
</td>
<td class="nump">$ 33,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120735648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sybx_ComputerAndOfficeEquipmentMember', window );">Computer and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Useful life</a></td>
<td class="text">Lesser of useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sybx_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sybx_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125040080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 77,629,000<span></span>
</td>
<td class="nump">$ 136,628,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">15,861,000<span></span>
</td>
<td class="nump">16,437,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">44,375,000<span></span>
</td>
<td class="nump">106,277,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency Securities and Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">17,393,000<span></span>
</td>
<td class="nump">8,041,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,873,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">33,254,000<span></span>
</td>
<td class="nump">24,478,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">15,861,000<span></span>
</td>
<td class="nump">16,437,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Government Agency Securities and Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">17,393,000<span></span>
</td>
<td class="nump">8,041,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">44,375,000<span></span>
</td>
<td class="nump">112,150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">44,375,000<span></span>
</td>
<td class="nump">106,277,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | U.S. Government Agency Securities and Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,873,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | U.S. Government Agency Securities and Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Asset Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_FairValueAssetMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Asset Measured On Recurring Basis [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_FairValueAssetMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120593216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Securities - Summary of Available-for-Sale Securities Held (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 61,929<span></span>
</td>
<td class="nump">$ 120,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">61,768<span></span>
</td>
<td class="nump">120,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">17,492<span></span>
</td>
<td class="nump">8,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">17,393<span></span>
</td>
<td class="nump">8,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">44,437<span></span>
</td>
<td class="nump">106,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 44,375<span></span>
</td>
<td class="nump">$ 106,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540221033216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Securities - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value of securities in unrealized loss position | $</a></td>
<td class="nump">$ 36.6<span></span>
</td>
<td class="nump">$ 72.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale', window );">Number of securities with other than temporary impairment | Security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than temporary impairment losses investments number debt securities available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540128937600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_PrepaidResearchAndDevelopmentCurrent', window );">Prepaid research and development</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">2,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">771<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,153<span></span>
</td>
<td class="nump">$ 4,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_PrepaidResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_PrepaidResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120535344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 20,463<span></span>
</td>
<td class="nump">$ 19,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(13,140)<span></span>
</td>
<td class="num">(10,626)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,323<span></span>
</td>
<td class="nump">9,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,313<span></span>
</td>
<td class="nump">8,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sybx_ComputerAndOfficeEquipmentMember', window );">Computer and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,820<span></span>
</td>
<td class="nump">9,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sybx_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sybx_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540127602272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,520<span></span>
</td>
<td class="nump">$ 2,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540129706272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll related</a></td>
<td class="nump">$ 3,401<span></span>
</td>
<td class="nump">$ 3,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">1,624<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 5,290<span></span>
</td>
<td class="nump">$ 4,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125311760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">181 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_NumberOfVotesEntitledToEachShareOfCommonStock', window );">Number of votes entitled to each share of common stock | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 81,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sybx_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, shares | shares</a></td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="nump">$ 48,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember', window );">Ginkgo Bioworks, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants', window );">Proceeds, net of issuance costs, from issuance of common stock and pre-funded warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember', window );">Ginkgo Bioworks, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,340,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember', window );">Ginkgo Bioworks, Inc. | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,548,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering', window );">Warrants exercise price per share paid at closing of offering | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of pre-funded warrants, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_WarrantsExercised', window );">Warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember', window );">Ginkgo Bioworks, Inc. | Pre-Funded Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,548,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance', window );">Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC | ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,447,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_JefferiesLLCMember', window );">Jefferies, LLC | ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercise price of warrants paid at closing of offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_NumberOfVotesEntitledToEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitled to each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_NumberOfVotesEntitledToEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of common stock and prefunded warrant price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sybx_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sybx_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sybx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sybx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sybx_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sybx_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120748992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="nump">5,928,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="nump">52,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=sybx_OptionsExercisableToPurchaseCommonStockMember', window );">Options Exercisable to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="nump">3,328,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sybx_PreFundedWarrantsMember', window );">Common Stock Issuable Under Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="nump">2,548,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=sybx_OptionsExercisableToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=sybx_OptionsExercisableToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sybx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sybx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540118744080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of options granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee unrecognized compensation cost, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,639<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee unrecognized compensation cost, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762,772<span></span>
</td>
<td class="nump">242,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,629<span></span>
</td>
<td class="nump">42,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares available for issuance (in shares)</a></td>
<td class="nump">696,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Percentage of discount for employees under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percentage of fair value under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015Member', window );">Plan 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares available for issuance (in shares)</a></td>
<td class="nump">3,484,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125902176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail) - Employees and Nonemployees - 2015 and 2017 Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average, risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.50%<span></span>
</td>
<td class="nump">84.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sybx_EmployeesAndNonemployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sybx_EmployeesAndNonemployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015And2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015And2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540126710256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail) - 2015 and 2017 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Beginning balance, Number of options</a></td>
<td class="nump">4,500,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Number of options</a></td>
<td class="nump">3,738,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Number of options</a></td>
<td class="num">(35,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/Forfeited, Number of options</a></td>
<td class="num">(956,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Ending balance, Number of options</a></td>
<td class="nump">7,247,695<span></span>
</td>
<td class="nump">4,500,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, Vested or expected to vest</a></td>
<td class="nump">7,247,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable</a></td>
<td class="nump">3,328,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, Weighted-average price</a></td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted-average price</a></td>
<td class="nump">1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted-average price</a></td>
<td class="nump">1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/Forfeited, Weighted-average price</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, Weighted-average price</a></td>
<td class="nump">3.65<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average price Vested or expected to vest</a></td>
<td class="nump">3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average price, Exercisable</a></td>
<td class="nump">$ 5.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual term (Year)</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Vested or expected to vest</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Exercisable</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance, Aggregate Intrinsic value</a></td>
<td class="nump">$ 588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised, Aggregate Intrinsic value</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance, Aggregate Intrinsic value</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic value, Vested or expected to vest at December 31, 2021</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic value, Exercisable at December 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015And2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sybx_LongTermIncentivePlan2015And2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540128950896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue', window );">Number of options in money</a></td>
<td class="nump">185,500<span></span>
</td>
<td class="nump">1,210,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options outstanding, weighted average exercise price, and additional disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based arrangement award, options available for aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540118742912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail) - Restricted Common Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, Number of unvested shares/units</a></td>
<td class="nump">299,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Number of shares/units</a></td>
<td class="nump">762,772<span></span>
</td>
<td class="nump">242,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Number of shares/units</a></td>
<td class="num">(83,637)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, Number of shares/units</a></td>
<td class="num">(152,118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, Number of unvested shares/units</a></td>
<td class="nump">826,265<span></span>
</td>
<td class="nump">299,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, Unvested Grant date fair value</a></td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Grant date fair value</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Grant date fair value</a></td>
<td class="nump">2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Grant date fair value</a></td>
<td class="nump">1.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, Unvested Grant date fair value</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125176080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 3,639<span></span>
</td>
<td class="nump">$ 3,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 2,074<span></span>
</td>
<td class="nump">$ 1,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540126698736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 3,639<span></span>
</td>
<td class="nump">$ 3,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">3,168<span></span>
</td>
<td class="nump">2,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120959760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod', window );">Collaboration in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Recognition of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,180<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="nump">$ 531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember', window );">Ginkgo Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_CurrentPrePaidResearchAndDevelopment', window );">Current pre-paid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_NonCurrentPrePaidResearchAndDevelopment', window );">Non-current pre-paid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_PrepaymentToRelatedPartyForCollaborationAgreement', window );">Prepayment to related party for collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm', window );">Related party transaction collaboration agreement, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember', window );">Ginkgo Collaboration | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,548,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember', window );">Ginkgo Collaboration | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,340,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Ginkgo Collaboration | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,548,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sybx_RocheCollaborationAndOptionAgreementMember', window );">Roche Collaboration and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee', window );">Upfront, nonrefundable technology access fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria', window );">Milestones payment upon achievement of certain success criteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Recognition of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sybx_RocheCollaborationAndOptionAgreementMember', window );">Roche Collaboration and Option Agreement | Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anticipated completion period for research and development projects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement upfront, nonrefundable technology access fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_CurrentPrePaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Pre-Paid Research and Development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_CurrentPrePaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_NonCurrentPrePaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Current Pre-Paid Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_NonCurrentPrePaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestones payment upon achievement of certain success criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_PrepaymentToRelatedPartyForCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment to related party for collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_PrepaymentToRelatedPartyForCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction collaboration agreement, initial term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sybx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sybx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sybx_RocheCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sybx_RocheCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=sybx_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=sybx_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120621376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,147)<span></span>
</td>
<td class="num">$ (60,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">71,725,479<span></span>
</td>
<td class="nump">55,329,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">71,725,479<span></span>
</td>
<td class="nump">55,329,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540124771440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sybx_UnvestedRestrictedStockAwardsMember', window );">Unvested Restricted Common Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially Common Shares Excluded from Calculation of Net Loss Per share</a></td>
<td class="nump">826,265<span></span>
</td>
<td class="nump">299,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially Common Shares Excluded from Calculation of Net Loss Per share</a></td>
<td class="nump">7,247,695<span></span>
</td>
<td class="nump">4,500,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Potential Shares Issuable Under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially Common Shares Excluded from Calculation of Net Loss Per share</a></td>
<td class="nump">52,648<span></span>
</td>
<td class="nump">21,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sybx_UnvestedRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sybx_UnvestedRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120631984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 16, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits for the net operating losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">109,599,000<span></span>
</td>
<td class="nump">$ 90,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,791,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 302,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_CorporateMinimumTaxEffectPercentage', window );">corporate minimum tax effect percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ExciseTaxPercentage', window );">Excise tax percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Description of tax benefit likely to be realized upon settlement</a></td>
<td class="text">greater than 50%<span></span>
</td>
<td class="text">greater than 50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Interest or penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination description</a></td>
<td class="text">In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2019 to the present are open to examination under the statute.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 302,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards subject to expiration</a></td>
<td class="nump">79,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards not subject to expiration</a></td>
<td class="nump">$ 223,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 289,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_CorporateMinimumTaxEffectPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>corporate minimum tax effect percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_CorporateMinimumTaxEffectPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ExciseTaxPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excise tax percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ExciseTaxPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121825205&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125702128">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 81,803<span></span>
</td>
<td class="nump">$ 76,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,118<span></span>
</td>
<td class="nump">7,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">888<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,541<span></span>
</td>
<td class="nump">5,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,516<span></span>
</td>
<td class="nump">2,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Amortizable intangibles</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_DeferredTaxAssetsAmortizableResearchExpenditures', window );">Amortizable Research Expenditures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">363<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">113,521<span></span>
</td>
<td class="nump">94,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,922)<span></span>
</td>
<td class="num">(3,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,922)<span></span>
</td>
<td class="num">(3,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (109,599)<span></span>
</td>
<td class="num">$ (90,477)<span></span>
</td>
<td class="num">$ (72,791)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.365pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Under the Tax Cuts and Jobs Act (TCJA), research and experimental (R&amp;D) expenditures are capitalized and amortized under section 174 for tax years beginning after December 31, 2021. These costs are amortized for tax purposes over 5 years since the R&amp;D was performed in the U.S. The unamortized balance of these costs is presented as a deferred tax asset in the table above.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_DeferredTaxAssetsAmortizableResearchExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Amortizable Research Expenditures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_DeferredTaxAssetsAmortizableResearchExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540128591664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit, Tax Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other permanent differences, Tax Rate</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits, Tax Rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other items, Tax Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Net change in valuation allowance, Tax Rate</a></td>
<td class="num">(29.00%)<span></span>
</td>
<td class="num">(29.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540128643168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Valuation Allowance - (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at beginning of year</a></td>
<td class="num">$ (90,477)<span></span>
</td>
<td class="num">$ (72,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="num">(19,122)<span></span>
</td>
<td class="num">(17,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at end of year</a></td>
<td class="num">$ (109,599)<span></span>
</td>
<td class="num">$ (90,477)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540128998240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Repurchase (Additional Information) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 25, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_ShareRepurchaseAbstract', window );"><strong>Share Repurchase [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_RepurchaseOfCommonStock', window );">Repurchase Of Common Stock (In Share) | shares</a></td>
<td class="nump">4,196,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AggregatePurchase', window );">Aggregate Purchase | $</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AggregatePurchasePerShare', window );">Aggregate Purchase Per Share | $ / shares</a></td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_AggregatePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_AggregatePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_AggregatePurchasePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Purchase Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_AggregatePurchasePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_RepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_RepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_ShareRepurchaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_ShareRepurchaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120632704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 21, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_RentableSpaceUnderLeaseAgreement', window );">Laboratory and office space to be leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OperatingLeasesRentExpenseAnnualRentalPayments', window );">Operating lease annual rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_TenantImprovementInvestmentObligation', window );">Tenant improvement investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lessee, operating lease, existence of option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AgreementExpirationDate', window );">Agreement expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid included in operating cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sybx_MasterContractServicesAgreementMember', window );">Master Services Agreement | Azzur Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AccessAndUseOfSpaceUnderAgreement', window );">Access and use of space under agreement | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">44 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_RenovateAndUpgradeExpenses', window );">Renovate and upgrade expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sybx_NewAgreementMember', window );">New Agreement | Azzur Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">20 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_AgreementExpirationDate', window );">Agreement expiration date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_TenantImprovementInvestmentObligation', window );">Tenant improvement investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_AccessAndUseOfSpaceUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Access and Use of space under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_AccessAndUseOfSpaceUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_AgreementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_AgreementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_OperatingLeasesRentExpenseAnnualRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases rent expense annual rental payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_OperatingLeasesRentExpenseAnnualRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_RenovateAndUpgradeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Renovate And Upgrade Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_RenovateAndUpgradeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_RentableSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rentable Space Under Lease Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_RentableSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_TenantImprovementInvestmentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the lessee agrees to invest into a tenant improvement of a leased property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_TenantImprovementInvestmentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sybx_MasterContractServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sybx_MasterContractServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sybx_AzzurGroupLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sybx_AzzurGroupLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sybx_NewAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sybx_NewAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120578448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Cost for Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OperatingLeaseCostAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 4,812<span></span>
</td>
<td class="nump">$ 3,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_OperatingAndVariableLeaseCost', window );">Operating and variable lease cost</a></td>
<td class="nump">$ 6,221<span></span>
</td>
<td class="nump">$ 5,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_OperatingAndVariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and variable lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_OperatingAndVariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_OperatingLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_OperatingLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540125804032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted average discount rate</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted average remaining lease term (years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540124984464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 5,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">4,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">3,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">4,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">24,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">4,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">20,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">4,152<span></span>
</td>
<td class="nump">$ 3,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 16,129<span></span>
</td>
<td class="nump">$ 17,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540120526064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Eligible employees to contribute to 401(k) plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employee contribution, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum matching contributions as a percentage of eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employee contribution</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140540119293248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,736,251<span></span>
</td>
<td class="nump">69,698,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember', window );">Ginkgo Bioworks, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,340,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_PrepaymentToRelatedPartyForCollaborationAgreement', window );">Prepayment to related party for collaboration agreement</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm', window );">Related party transaction collaboration agreement, initial term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_CurrentPrePaidResearchAndDevelopment', window );">Current pre-paid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_NonCurrentPrePaidResearchAndDevelopment', window );">Non-current pre-paid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sybx_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_CurrentPrePaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Pre-Paid Research and Development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_CurrentPrePaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_NonCurrentPrePaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Current Pre-Paid Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_NonCurrentPrePaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_PrepaymentToRelatedPartyForCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment to related party for collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_PrepaymentToRelatedPartyForCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction collaboration agreement, initial term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sybx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sybx_GinkgoBioworksIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>sybx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:sybx="http://www.synlogictx.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sybx-20221231.xsd" xlink:type="simple"/>
    <context id="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_99fd2321-f1d7-43cf-b178-e7348f290f1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sybx:EmployeesAndNonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4516b6b5-54fe-44c6-ab9c-eee027b01c2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sybx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f9b859fc-2a96-4b54-97cb-88cba1858033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b99e72e-cd69-4ebb-a947-0d73db833415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a5e1f167-a526-4fc5-995f-8c2fa7bc03e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0abad65e-efe7-4687-9248-a9c45acb22de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_60a114fa-eeba-4606-ada0-5fecd8dae2ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_8e60fb3b-c7d3-4ac6-83b2-f6a6547f6e1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d79f3e7f-b5d8-44b8-8e74-072b254299d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_4a5c39e0-05a3-412d-9021-2ac827b89c7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e3e7babb-b939-40de-97da-4a92ec952e88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:NewAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sybx:AzzurGroupLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_3b826f3c-b239-4a65-b43d-e759471f2756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_769545e9-0aa1-4ec6-a368-611478b8ff27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_282387b9-90c8-4462-9a1a-f4e3a22907e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6c440647-2473-4161-b76b-146d516bb47b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_30a0f2b0-9a2a-4a96-a075-e5e89fb12427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_42df9a46-4a26-442d-8081-eac11aa26210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b9caf09-f6c8-47cf-a222-c8667dca98fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_37a703b8-c41b-42c8-9707-370b726139cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="C_0754e8dc-f387-45d7-8ad5-2f37ecf370c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bb7c3478-1f6c-45ea-b035-e3a9a00b30bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e08b8831-bd01-48c6-a8f9-50a61b822302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sybx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cd16f567-f183-4c6e-8b80-74f9c2966fb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_627e4d45-a0cb-4fa4-be83-89cafaf6b705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_698c1855-5f3d-4405-b9dd-9cbf05cddeda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_73d91fb1-2e62-48f7-92de-e383722c15e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_db9aee41-d847-4892-9d0a-5f6f3588bb50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_76fcaa28-0554-4900-bf7f-e8311ed88698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e8618276-8b30-4637-beb0-a8e46a028cc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_53c113d0-26f8-4751-aac3-06cad9a19780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_73945c68-b522-4635-afec-a62d38320354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cd0ccefb-dd51-4e98-b605-3e1a046f1576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_91376d3a-55e0-47d7-8f1d-b1e000c4da64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3d9937da-b5ee-4340-92e5-8a0477c4b960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_127f40d5-4261-4e87-a5a5-a06ab8251d92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7347bbee-a9f6-4c87-a6a2-eddd53ccfd0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_71a618da-156f-461d-a56d-61c9010a19f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0558df53-fc4c-4356-aa92-1218af4ad35e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8114c460-4d06-4e71-8f72-16758968f429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_125495a8-4ea5-4da7-b352-1c1c4f816a98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a326c280-7be6-41bc-88c6-584d5e7052d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_23b05112-0191-4539-844d-dcff33882fec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dc33945e-b2f0-4255-915f-8f700291d29e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3b538def-63ae-4f4b-9140-89b96b2a5ea7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_39ffddbf-7d15-4ff1-8e01-541286c83ab8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e617d399-c879-434f-a4fb-b4d8855f9c6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_261be9b1-a487-4761-8558-63f62fe17054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3545a731-60bf-461a-b2f6-a8fd246306f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d2ff957f-8810-4fc7-8b03-9624137f2f79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_13abf79b-a461-4ee1-8d29-6b819cbd08f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_97aff091-2a04-46a5-9057-7373ad98593b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_dd023e56-8402-47a8-bace-8ad6f1a75d5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sybx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4e5987d8-c576-4625-8759-66ebd0405f3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0091dbbf-6c21-4edd-9df7-2c4b934ef7d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sybx:EmployeesAndNonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4ce13154-7826-4547-a938-f6040b13872f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5c3d6c09-e07c-48fc-b6d8-d5ad92538a25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201708Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c5706570-7d04-4e8e-814e-029647b3f073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_df2e79da-2d09-4270-8ce2-2f9e4b85b0ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <startDate>2007-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a7af75ad-b1e6-4aef-851f-04fd45e648cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3ce653bf-490d-4819-8e5a-529c46c9a649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d97b6644-79ff-4699-9f6b-e83cf66bd673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_94ebd146-59d5-436b-8185-ff6c733be386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cee0ff06-3a82-48ed-bc1e-7798fb043a99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c959ef41-4848-4db3-9e53-0dd492572f29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b65842df-41e9-4ad0-b418-74bfc423b622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_df578021-db7b-44d1-8405-c09b71d9bf97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_794b0fde-85f9-4229-b743-26bedc55e777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_961a013f-154c-4b93-ac17-2c189db1fa4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7130c6be-123a-4941-b59a-2b8f5cdd887b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0dd3811-b7af-4902-afcd-ce7c054f5cb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_91268588-0fb2-48c3-8afe-0148ee56a770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:MasterContractServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sybx:AzzurGroupLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_92b7da2a-7418-436a-9524-56701b660c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0c9b51e6-d273-4c40-9880-9ef1e241ffbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_640feb28-ca33-4b33-8050-74bd8f92c9c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_99657c65-259d-41fd-986b-5c347fbc45d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5c13194e-33fe-40bd-90ef-6bbee6ee67f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a3f01399-c70d-4fc2-8fb9-042eab32457b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e13a3127-83d8-4882-9c9b-f8eadac41d7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_01e34769-71da-4fdd-af5a-ed9f45d058c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_29fed40c-524b-495e-b738-feab12394d3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_94afbb83-f2d7-4546-a4ae-0e428a53c728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6ad07922-17ac-4c18-97a9-21067c51ee17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_52001b96-65b6-4786-9e84-a405520ac86d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_406221e2-1ef7-4393-9e2d-3f9516e8e4c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8caafedd-e06d-4a10-aa7a-0b8fa55c8b9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <instant>2022-08-16</instant>
        </period>
    </context>
    <context id="C_5cb51fda-168e-4bf9-88e4-f2c1dde4f357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_83994bcc-897b-4ecf-9900-6f87c0a0397c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_fe7d4a4c-340f-4bfe-9353-91af7151de36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="C_44eb79d0-8fc4-42f7-a690-e5796a479806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e9cba784-5870-4180-9446-6bedd109f39c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_14cab79b-31e9-441e-9110-e4bc26c0833c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3d820518-ff46-4605-b3e8-6459f151a8a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_52f0109e-38a0-4183-afac-f6722c5543d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2a7a2cff-5d8f-4521-9e09-ba2479d086ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sybx:USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eaa3b6a1-b527-43fd-9863-6130ce0c85bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0897e117-252f-49bf-8a93-cb69564f1408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0aaf0697-e409-448d-ba6a-dc57c7587a33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_be0c663b-cd69-4808-83ec-81ad0fa98a39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <instant>2022-11-25</instant>
        </period>
    </context>
    <context id="C_dbe4b5e6-1273-43ae-8a7f-b8ea915f3ed1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_96b303f7-61a6-4679-becd-a1dd839a0a5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6edf54b0-befe-46f1-a01a-5d4ad86e422a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7c6943e9-6e4c-48b4-ac4a-76f2723a410c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b35d2ba3-ee9d-4986-b9f1-a7a0e81af1d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="C_9cb1f60e-ec3f-44d1-b1f6-3bcaa075be67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b910752-910d-4808-a82b-55cf3ff96bd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_80b6d2b4-7e32-4f90-a5bf-55d9ff118805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d77ddcfe-10f7-4a58-90fe-828bf55ff466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d4d75229-eaf1-4029-9ef7-4b3edaa0a833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3934f648-405d-4a5e-b610-f5dc014cbfd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_43b99e43-1090-41dc-af3b-41ef21ba7597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_a1266c6b-f79b-47ac-9d44-b00ab08b1491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_87720378-333d-485a-b610-abbe5ef1182d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6ad92b9f-963d-493a-a1e4-49542d62bb26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6fc8483b-ee81-4369-a735-5813ac304b5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8fa40dbc-7f7b-4478-86f2-ad847e50f5fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_83e56954-5a79-4d4a-a1b6-981f26235c7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2b98e403-528d-433b-81fb-64269d42e27a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_a3bc4242-7016-4d08-911e-e53fb03921c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9cedb62c-bc49-42b5-ab00-88dd9ea24194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7d6680fe-ccfc-4e24-8fd9-1fa014c4a0b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61230b0b-84df-43f0-a9b0-98509a23ed34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sybx:USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7d128f60-ec2d-4e7e-ad00-15156530da9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_17b056dc-d7fb-4fda-b280-76eec780b5fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_d15380e7-f98d-4b93-b4f8-739dab563868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_c1edfa35-041c-4e12-af32-4f8cfaf160b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f81bc0ea-4cc8-4008-8667-3a9f04ab0640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sybx:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2e56b967-590d-4bb7-93db-326ebc48a3e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sybx:GinkgoBioworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_654a16e2-8083-4d9a-92ce-ca57cab55a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_75851d76-14c4-43a0-8d91-11383d574278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="C_85363944-bc80-4236-b736-030f11ca6ff3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ae409a4f-4065-4a38-ac8d-81447767cd16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015And2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_92c74e7a-30c1-4b8a-9f5c-579a596fbd61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f9e9134b-680f-4e16-baa0-cd8a64b991b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_634cb392-9161-4709-9f2a-a13f53a4e68e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_427833e4-00a7-483a-9685-f0f6c211b01c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sybx:LongTermIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_eb6f0279-648d-4922-bffa-1e1ac712993d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sybx:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_02234d32-33f3-4416-bdc7-483f3c549a5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b16d8204-0369-41df-93d2-7ec43c203587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_967baf2d-6be3-4b7f-ae16-eff0641c22f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d51691b1-bfd1-4bf1-a65f-d5da006787a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5cec03e1-9dc1-4ffd-9623-0c876a46a0c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">sybx:OptionsExercisableToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9c420274-37ac-41c4-9722-54e874446423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3bc26f36-034f-4f53-93d9-b443f6b5e6c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e186ace1-c417-4554-ab06-b27470bd2ea0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5cc1a710-27f8-444c-90e6-5c3676f0f7bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_436ec13c-b090-47c3-b27f-abd9ac6ebda8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sybx:UnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_526bc3f6-6d8d-4822-b52e-24e5d384e725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sybx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3282432a-339d-4c93-9545-b3ee55a0a3ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:RocheCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_9404c746-39af-4f16-b76d-b8630bcb901d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_54406899-ec4d-4081-a75a-a534c1e59a14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4b914988-f15e-45d7-8299-f5e9f4596f51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sybx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_489afa5b-74fd-452f-b937-8e7dab8a46e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sybx:MasterContractServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sybx:AzzurGroupLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-21</instant>
        </period>
    </context>
    <context id="C_e59e7474-5287-48e3-b13c-7a4105517fbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20e586e5-e63b-4dc5-be33-c69ee29693d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3c4febd-5bb8-42c3-974f-1da160403289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c8434699-f20b-4949-8f3d-8de4ac28fe77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Security">
        <measure>sybx:Security</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>sybx:Segment</measure>
    </unit>
    <unit id="U_Vote">
        <measure>sybx:Vote</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_66a7420d-4ae6-4ebb-a5a4-555a6a7cbcad">false</dei:AmendmentFlag>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0"
      id="F_c5640fb7-a3ab-4596-a6cd-95b9bcaf8185">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <dei:EntityCentralIndexKey
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_7f387997-6c11-488d-a93d-d766b380d82b">0001527599</dei:EntityCentralIndexKey>
    <sybx:AgreementExpirationDate
      contextRef="C_e3e7babb-b939-40de-97da-4a92ec952e88"
      id="F_9ad71e03-2303-4ee4-883d-5ed6738ea62b">2022-12-31</sybx:AgreementExpirationDate>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0"
      id="F_05e3c282-5e7a-4d07-8c4f-40eddf5219a8">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_fc7e96aa-31ea-42d3-bcfb-bc7577c11e53">true</us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      id="F_cb04f5e1-07b2-4b27-b75e-4b304dd2e751"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_5c3d6c09-e07c-48fc-b6d8-d5ad92538a25"
      id="F_95ac8cfc-e3ce-469b-9f55-e96edd374653">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_5618cde7-2a4e-4e7a-bb47-0807b4054826">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_7eef8a2a-292f-43fe-97a4-d52a16e845a6">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      id="F_4b419055-80ef-43cc-a74a-f33b8a1e40f5">greater than 50%</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_825913e6-7f7b-4ea6-ba26-8a4ffd18af64">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:TreasuryStockValue
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      id="F_ee6be37b-9a01-4f47-82d0-a166404c555a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      id="F_02c6b8c4-1e53-4fc1-994a-906cacc53571"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      id="F_28c409d5-6a3b-428a-8521-04958db80cd2"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_5c3d6c09-e07c-48fc-b6d8-d5ad92538a25"
      id="F_cafdd680-6b10-4569-88ff-00aa7168f202">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <dei:DocumentType
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_8e48cf6d-f676-43fd-8717-b6ebf371131f">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_5f10e957-12af-444e-b564-d58682b3b6b6">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_2b64fa54-a2a8-4411-bed2-59975d95c997">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_b361ea5c-f669-4f95-945e-c2cc6fc58c30">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_9a12eb00-ab18-400c-8da6-bf0a8d84f5ec">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_cc32a7d4-e13f-4032-ba54-589bccf3d873">001-37566</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_dbf2f941-8d26-487e-99ef-0e2fa630a408">SYNLOGIC, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_16411f3d-25a4-427f-986a-857a3e80fd5e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_2eebe8ad-de28-4333-ad41-21f39dec349b">26-1824804</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_81c303b6-1c12-4fca-b1cf-781f2b07fc6e">301 Binney St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_47a877c4-f54a-4cc0-91e4-67c53a357d62">Suite 402</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_09122a29-1d3a-4346-ab50-4bd338055d4b">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_81e25f1a-14ed-4b69-98a6-15ca8259d68a">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_bb991efa-820b-4115-b128-8c734a7e2757">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_06dc931f-0aa3-418e-995f-abd45a1622e8">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_9851dfd2-1031-4e36-9c92-494baa81c9e4">401-9975</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_8d55c798-7f64-4db2-a83c-7d3f99091602">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_6d73e592-882d-4c8f-b548-c086797613c3">SYBX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_76534ec9-1f07-407c-b7a6-11a7746f7525">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_d95b44ba-2bf6-44c1-ab1d-431969b6087f">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_e3bdfc1d-ef63-49cf-b685-40d04f9b18b2">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_2ddbb4ab-b738-4bfc-b86e-7c24106d13e6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_04e1bb6a-4b42-4550-93b2-8b78d414a48e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_cb0ab9e7-3a40-4185-bac5-c4f128008550">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_5d28b42c-2387-4023-b938-8d1086ae36a5">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_3fc3ea9a-51a9-4478-adf3-320fc7af1a4d">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_8e6fb8bb-383a-43ad-a659-6b0559e105b8">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_31aae5b6-0026-4a9a-858b-a7cfd29d7926">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_2b98e403-528d-433b-81fb-64269d42e27a"
      decimals="-5"
      id="F_d502e9d7-75fc-49a5-961d-179110d907c7"
      unitRef="U_USD">41500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_75851d76-14c4-43a0-8d91-11383d574278"
      decimals="INF"
      id="F_348e6058-ae99-4e6a-a67b-b467c41d6e0e"
      unitRef="U_shares">67728025</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_ecf66e9f-524b-484c-9646-39b5199743e5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant&#x2019;s definitive proxy statement for the 2023 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_6a799ce8-5212-431a-9265-4cf83ea8ba5b">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_6d35eae9-cc52-4ee5-be80-a498ed30ab90">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_783cb9cb-9824-491e-b670-e189e8a461ff">Boston, Massachusetts, U.S.</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_d2a72505-0321-4da4-929f-7bc8abe30cf6"
      unitRef="U_USD">15861000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_90ba628a-2ef7-4147-a96b-4cfb1ab250a3"
      unitRef="U_USD">16438000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_492de647-1212-4827-a83a-3b719cd250f2"
      unitRef="U_USD">61768000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_75d8f88a-7cea-409e-adb2-4cb823b2ff26"
      unitRef="U_USD">112150000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_47f46b94-4419-45ad-a585-506f8771769d"
      unitRef="U_USD">2153000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_a4925532-f685-436c-ba9f-7cc797dfea05"
      unitRef="U_USD">4721000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_fb4a3e25-02ed-4488-821a-db2fedb0a743"
      unitRef="U_USD">79782000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_23fafdb6-a11c-4db2-9e41-96ce700de668"
      unitRef="U_USD">133309000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_72c96f68-23ba-41a9-bb5d-c0067b5b51f7"
      unitRef="U_USD">8041000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_01762bed-b042-411f-be7b-b0f5437085af"
      unitRef="U_USD">7323000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_7c12cc1a-d779-4246-9c6e-da1e0243f59e"
      unitRef="U_USD">9088000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_849a1642-45d7-440b-914f-2b91ea944319"
      unitRef="U_USD">14356000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_c3ee6d95-1abf-4648-86c9-81cf37c43245"
      unitRef="U_USD">13889000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_6d630182-2029-4b73-ae49-ea2034d11411"
      unitRef="U_USD">1097000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_57c0d1a7-beba-4d33-96ba-3f3defcef56a"
      unitRef="U_USD">1097000</us-gaap:RestrictedCashNoncurrent>
    <sybx:PrepaidResearchAndDevelopmentNoncurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_e6451e08-e0f1-468f-a6f4-4d7aaf26d94e"
      unitRef="U_USD">8300000</sybx:PrepaidResearchAndDevelopmentNoncurrent>
    <sybx:PrepaidResearchAndDevelopmentNoncurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_9d664419-90c3-4228-b292-7b845cc271fe"
      unitRef="U_USD">9309000</sybx:PrepaidResearchAndDevelopmentNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_2c046bb8-8681-4ac0-a31d-14f40e336931"
      unitRef="U_USD">7000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_84635ac4-acd8-4770-96f5-bd50814ceea2"
      unitRef="U_USD">3000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_f2e9d198-5c82-4321-be2b-2e550c88a071"
      unitRef="U_USD">110865000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_2f58d68e-12e4-4735-a7c9-d609245f06dd"
      unitRef="U_USD">174736000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_76f12012-b207-4c4a-8213-9c3047b4dcca"
      unitRef="U_USD">1785000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_f15d5d49-e955-4be8-9092-175889dcadfb"
      unitRef="U_USD">1944000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_408b6e08-5a83-4197-9605-ad45ddcacaca"
      unitRef="U_USD">5290000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_85a7f16b-fb46-4c4e-980f-51c06400199d"
      unitRef="U_USD">4402000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_8a345246-8be4-4a75-bed9-38167eafc411"
      unitRef="U_USD">882000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_4226e836-6cc7-4956-add0-ae5521bd53b0"
      unitRef="U_USD">531000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_70c92661-9f88-4f2d-8ee8-a57b5f146ca4"
      unitRef="U_USD">4152000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_4435eea6-de4a-4a34-9cf2-53cfe18c095d"
      unitRef="U_USD">3191000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_cdd70d2e-3ca5-4317-ba4e-bc3870ff67e9"
      unitRef="U_USD">13000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_40ebde16-18b2-466a-9350-f53ccae9d941"
      unitRef="U_USD">12000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_77baebcb-b45e-4a8f-9183-4a6b8985e847"
      unitRef="U_USD">12122000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_9e2584fc-4f92-4179-9f5b-84f87d33fcae"
      unitRef="U_USD">10080000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_d0bd26a1-aa41-4919-9f4a-640c83555ca5"
      unitRef="U_USD">16129000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_18e25103-657a-4ab9-92c3-05cfbb07958e"
      unitRef="U_USD">17372000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_ce0af1c6-658a-4f53-a31f-9e3249dfe833"
      unitRef="U_USD">4000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_fd142faa-90a3-4c47-b995-d27d1f05e2d9"
      unitRef="U_USD">18000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_84c83248-c791-4a1a-887f-ddc3599d029e"
      unitRef="U_USD">16133000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_f8d3e221-424d-4c20-9c90-5c0c75a0c0ce"
      unitRef="U_USD">17390000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_4e94a95b-6fc3-4aba-a5aa-543e301126ea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="INF"
      id="F_c8c37cec-02ee-481e-b33b-00d6cd7355c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_60ce85e3-7d70-402b-bab8-fba20ed63964"
      unitRef="U_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="INF"
      id="F_17a4f353-d68c-4f5c-95f6-eb02eca96c91"
      unitRef="U_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_b55632c8-da70-4d40-9ff3-77b29ae75bcb"
      unitRef="U_shares">70933140</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_d8a57625-fb63-4ca0-9113-380d6e764e9a"
      unitRef="U_shares">66736251</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="INF"
      id="F_4b198359-9eb2-4b0f-b9c5-561597f1b962"
      unitRef="U_shares">69698844</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="INF"
      id="F_8711b4c9-7b7c-445a-83bf-13b60ed18d0e"
      unitRef="U_shares">69698844</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_086aaf3b-179f-4a7e-88a5-b0e9a54d1e22"
      unitRef="U_USD">71000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_d4b6e17d-231e-42e1-82d5-9756dd22c1f8"
      unitRef="U_USD">70000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_083fa0b6-6905-4cbe-b652-4c7fe295b5f5"
      unitRef="U_USD">442237000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_c55c9da1-9ce2-454f-a4ba-34f1873ea5d0"
      unitRef="U_USD">438113000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_4b15c4c5-a693-4447-826b-56bfc84e462c"
      unitRef="U_USD">-161000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_49cc07b5-1ccb-4fb8-b120-7ea967760c19"
      unitRef="U_USD">-45000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_80fbb400-7f7d-4941-8665-0eb9d9c9b810"
      unitRef="U_USD">-357019000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_bf848d72-7f0f-47c9-8312-40b80f60a4d8"
      unitRef="U_USD">-290872000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_edad5b93-4bdf-4988-9a26-9969858ad70d"
      unitRef="U_shares">4196889</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="INF"
      id="F_137645d2-83b4-4b83-8f0b-f2b46b3453f0"
      unitRef="U_shares">0</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_7b73f814-0b58-40c8-9819-a69039123459"
      unitRef="U_USD">2518000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_ac99377e-6cde-4b80-be2b-533cf678a3a2"
      unitRef="U_USD">82610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_449325c6-f9d6-4e9e-a240-9531212c9978"
      unitRef="U_USD">147266000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_053c93f0-6f74-4037-9f31-980db7055e4d"
      unitRef="U_USD">110865000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_bcf61e76-ca22-4e91-95ca-ec4bb30eaf64"
      unitRef="U_USD">174736000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_383b5e38-0842-4731-9e9f-2cc1653c1640"
      unitRef="U_USD">1180000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_67470fa1-69e4-44fe-9d5e-f726d7fc0627"
      unitRef="U_USD">1754000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_8c7d00c1-3609-463a-a82d-fc2147ff72d5"
      unitRef="U_USD">52044000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_616dc689-51db-4d12-8e9c-4f624d4ec961"
      unitRef="U_USD">47127000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_a94b007d-b0f4-4c95-b03c-e061efa49290"
      unitRef="U_USD">16555000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_6968962a-3851-4ccb-9402-a5723cd5a912"
      unitRef="U_USD">15392000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_87f404fc-3f5e-4da3-b16c-93541118ab4d"
      unitRef="U_USD">68599000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_e0a7d2de-00be-440c-9873-523a71f730c9"
      unitRef="U_USD">62519000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_3a5b8d76-c7b7-4c09-9d97-e983cfce357c"
      unitRef="U_USD">-67419000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_12e0a993-a3bd-4b0f-b39b-3097f112db1a"
      unitRef="U_USD">-60765000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_169b6b68-279b-4c6e-9c57-2942ce75745d"
      unitRef="U_USD">1267000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_1986cc4e-debb-4067-9493-3148743d465c"
      unitRef="U_USD">210000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_fb16f518-cefe-401d-a32c-27d0f9c15ab7"
      unitRef="U_USD">2000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_8f022628-ca3f-4835-a005-756f7ce983cf"
      unitRef="U_USD">2000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_d54c21ad-7f9e-4ac2-b5b2-4b2e6ff3af2d"
      unitRef="U_USD">7000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_9ba5f300-0453-4587-8840-3c3fc334023b"
      unitRef="U_USD">-4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_79cab1b6-0767-4301-8dfa-ff2f0a078da2"
      unitRef="U_USD">1272000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_9dbf82f1-0cf2-4dae-9180-51a5781e551e"
      unitRef="U_USD">204000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_ccf60bff-6d28-41ab-a45b-c4119dbc22b6"
      unitRef="U_USD">-66147000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_3b3d44ab-0b78-4656-a926-ffb7295a4725"
      unitRef="U_USD">-60561000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_d557b26d-3ed9-4b29-aff6-12eb76a50856"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_e26ef360-bde0-4afb-ae0c-abb0e081ea11"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_1a345c2f-92ef-46ab-acf5-eecc31881606"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_dbb16380-b314-4ea1-9b05-94a5b464ba2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="0"
      id="F_7bfbb01c-b283-45a6-90f3-a2e770f2266e"
      unitRef="U_shares">71725479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="0"
      id="F_761e16e7-cac4-4458-86da-dadf4d703a8d"
      unitRef="U_shares">71725479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="0"
      id="F_f4232594-f44b-4856-884b-042b8bddd687"
      unitRef="U_shares">55329711</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="0"
      id="F_735a79ce-884d-4588-9909-e7749466fc46"
      unitRef="U_shares">55329711</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_cb0f1bc3-5209-4c76-b151-968065c25249"
      unitRef="U_USD">-66147000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_f8d35e4b-fd68-47c8-af06-f1b6d9c5389c"
      unitRef="U_USD">-60561000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_c20f03f8-342e-477e-b664-50c0b0b2b4ec"
      unitRef="U_USD">-116000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_5085d7e4-a5b4-4137-894b-f7e690450716"
      unitRef="U_USD">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_7617b89c-b8fe-4872-b6ae-a96e491eb2b7"
      unitRef="U_USD">-66263000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_262c6afb-afa7-4677-9443-fd34a5b13219"
      unitRef="U_USD">-60620000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_c1edfa35-041c-4e12-af32-4f8cfaf160b2"
      decimals="INF"
      id="F_2ca1ec81-e349-4349-a8ec-38d92c708542"
      unitRef="U_shares">38183273</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c1edfa35-041c-4e12-af32-4f8cfaf160b2"
      decimals="-3"
      id="F_d1092480-6988-49e2-91af-f2bb8cde78a9"
      unitRef="U_USD">38000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9cedb62c-bc49-42b5-ab00-88dd9ea24194"
      decimals="-3"
      id="F_21195120-cca1-44c7-a7d5-b95b92eb5905"
      unitRef="U_USD">345394000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_01e34769-71da-4fdd-af5a-ed9f45d058c8"
      decimals="-3"
      id="F_216ab10a-c169-41df-a017-db087495aff3"
      unitRef="U_USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0897e117-252f-49bf-8a93-cb69564f1408"
      decimals="-3"
      id="F_78a4688c-d2e2-4e07-b66b-84c316cf4543"
      unitRef="U_USD">-230311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4ce13154-7826-4547-a938-f6040b13872f"
      decimals="-3"
      id="F_b8f72903-7a5f-4b00-8705-84adfc1272cf"
      unitRef="U_USD">115135000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_eaa3b6a1-b527-43fd-9863-6130ce0c85bd"
      decimals="INF"
      id="F_ba36d9b8-1f3e-4df4-91a6-b4169a829ff8"
      unitRef="U_shares">2447211</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_eaa3b6a1-b527-43fd-9863-6130ce0c85bd"
      decimals="-3"
      id="F_3410fa3d-d330-453a-b435-71689d5ad68d"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5cc1a710-27f8-444c-90e6-5c3676f0f7bb"
      decimals="-3"
      id="F_31f57028-53b2-47ac-b957-bde7380927aa"
      unitRef="U_USD">8047000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e9cba784-5870-4180-9446-6bedd109f39c"
      decimals="-3"
      id="F_063b757e-4160-4e3d-994c-6f492d855242"
      unitRef="U_USD">8050000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a"
      decimals="INF"
      id="F_5e1b282d-ffc5-4a3b-99c1-4a907285a3a7"
      unitRef="U_shares">28750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a"
      decimals="-3"
      id="F_2d1f33e6-6818-4c0b-a4e3-d7aae4dd0189"
      unitRef="U_USD">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0"
      decimals="-3"
      id="F_a8eacc64-c47d-46a4-81d4-d73ab600e635"
      unitRef="U_USD">81010000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_8bb98c65-759a-4904-b178-057ae4a932b9"
      unitRef="U_USD">81039000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a"
      decimals="INF"
      id="F_9c7518fe-cfee-406c-b290-2df1a6c04740"
      unitRef="U_shares">139772</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0"
      decimals="-3"
      id="F_f13c5518-f3e6-4c4b-8c34-355b420895f1"
      unitRef="U_USD">280000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_98ff8eea-dcb8-493d-9c9a-bb5a1789f160"
      unitRef="U_USD">280000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a"
      decimals="INF"
      id="F_abbc64d5-e549-43f0-a213-1577d43d66e6"
      unitRef="U_shares">242454</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a"
      decimals="INF"
      id="F_b942c067-efb2-440d-a24b-e5ceef0312c2"
      unitRef="U_shares">42653</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0"
      decimals="-3"
      id="F_d75b1703-1ed5-4423-a34e-64c84407849c"
      unitRef="U_USD">94000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_4db84fc5-6340-42d2-adb6-1efb5d9eb814"
      unitRef="U_USD">94000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <sybx:StockIssuedDuringPeriodSharesWithholding
      contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a"
      decimals="INF"
      id="F_d35e6618-8a58-4b86-915f-53a16bc18256"
      unitRef="U_shares">28725</sybx:StockIssuedDuringPeriodSharesWithholding>
    <sybx:StockIssuedDuringPeriodValueSharesWithholding
      contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0"
      decimals="-3"
      id="F_e66db553-a0e1-4a33-9bcc-62938e686c12"
      unitRef="U_USD">73000</sybx:StockIssuedDuringPeriodValueSharesWithholding>
    <sybx:StockIssuedDuringPeriodValueSharesWithholding
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_fc4e354f-aaef-47d6-afb0-f487c0a8f9d3"
      unitRef="U_USD">73000</sybx:StockIssuedDuringPeriodValueSharesWithholding>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_96b303f7-61a6-4679-becd-a1dd839a0a5a"
      decimals="INF"
      id="F_17e36ad7-9c60-4845-a707-da74c854ab5f"
      unitRef="U_shares">77794</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3b910752-910d-4808-a82b-55cf3ff96bd0"
      decimals="-3"
      id="F_8512a62b-f8eb-4d21-9e5f-64489a923f33"
      unitRef="U_USD">3361000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_396a8e80-3de6-46de-b0a6-d430593c69f4"
      unitRef="U_USD">3361000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_71a618da-156f-461d-a56d-61c9010a19f5"
      decimals="-3"
      id="F_c07ffe96-0176-4bab-848d-369efb7c5114"
      unitRef="U_USD">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_ca887e33-bec6-4ebb-907a-dec3a12134a8"
      unitRef="U_USD">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_406221e2-1ef7-4393-9e2d-3f9516e8e4c3"
      decimals="-3"
      id="F_c5d53baf-b912-4cf4-9042-47dca5e0c4b2"
      unitRef="U_USD">-60561000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_017bb629-6dcc-4cb7-9a52-ce4c334be842"
      unitRef="U_USD">-60561000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e59e7474-5287-48e3-b13c-7a4105517fbc"
      decimals="INF"
      id="F_ef8afb95-5c90-4bbf-9bee-c928545ebfe9"
      unitRef="U_shares">69698844</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e59e7474-5287-48e3-b13c-7a4105517fbc"
      decimals="-3"
      id="F_4951cb0d-a0e7-41cf-8b18-a07d693eb405"
      unitRef="U_USD">70000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_282387b9-90c8-4462-9a1a-f4e3a22907e2"
      decimals="-3"
      id="F_0104a438-eaa9-43da-9468-f2bfc0ed8a98"
      unitRef="U_USD">438113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a3bc4242-7016-4d08-911e-e53fb03921c0"
      decimals="-3"
      id="F_e958cddd-20bb-47a3-8268-8704922a4703"
      unitRef="U_USD">-45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_52001b96-65b6-4786-9e84-a405520ac86d"
      decimals="-3"
      id="F_8657088c-d118-4318-a6b4-c3eb92ea6aaa"
      unitRef="U_USD">-290872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_ad9da325-1b40-44cc-a7ee-fdc725e21e74"
      unitRef="U_USD">147266000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6c440647-2473-4161-b76b-146d516bb47b"
      decimals="INF"
      id="F_2fa36664-961a-4076-adc1-1acb21ad1745"
      unitRef="U_shares">481451</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0c9b51e6-d273-4c40-9880-9ef1e241ffbd"
      decimals="-3"
      id="F_467fa90c-424b-400c-bfeb-3e279fe9fc73"
      unitRef="U_USD">287000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0aaf0697-e409-448d-ba6a-dc57c7587a33"
      decimals="-3"
      id="F_d056f89d-3d0f-4edb-b7f6-6ca4911d1707"
      unitRef="U_USD">287000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_30a0f2b0-9a2a-4a96-a075-e5e89fb12427"
      decimals="INF"
      id="F_5f821a6f-90c2-44b7-882d-6f1413b0504e"
      unitRef="U_shares">4196889</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_30a0f2b0-9a2a-4a96-a075-e5e89fb12427"
      decimals="-3"
      id="F_3d98f72a-cf59-4471-a2a9-558e3f67300b"
      unitRef="U_USD">2518000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_4ea84886-aad5-4a6d-afd2-8bb3c14e4661"
      unitRef="U_USD">2518000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f"
      decimals="INF"
      id="F_a404a76c-b161-4ff6-a00c-6f3980259c57"
      unitRef="U_shares">35562</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4a5c39e0-05a3-412d-9021-2ac827b89c7f"
      decimals="-3"
      id="F_6cd11d71-3c0c-4ecf-8477-84d74e4c5c43"
      unitRef="U_USD">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_12384b38-6e49-4eee-9628-9909a5b030ff"
      unitRef="U_USD">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f"
      decimals="INF"
      id="F_5f62e6cf-55bb-4c35-8f10-217922d4fc62"
      unitRef="U_shares">762772</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f"
      decimals="-3"
      id="F_783a169c-0c21-44ab-af4b-6ba647abe241"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_1666ae9c-05db-4d97-8a84-60b47329cf5d"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f"
      decimals="INF"
      id="F_f3c7709a-af87-475f-9a51-d31085c9f9f5"
      unitRef="U_shares">106629</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_4a5c39e0-05a3-412d-9021-2ac827b89c7f"
      decimals="-3"
      id="F_d280dd45-0220-4fd2-8d43-97760d584893"
      unitRef="U_USD">137000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_2c7b587d-4404-41f2-b659-698c73d9325f"
      unitRef="U_USD">137000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_ec422f4a-1b79-47e6-b4af-a2a497baef1f"
      decimals="INF"
      id="F_fe469d8e-b3f1-4367-a8ef-d664c04ad8c2"
      unitRef="U_shares">152118</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4a5c39e0-05a3-412d-9021-2ac827b89c7f"
      decimals="-3"
      id="F_66e416da-6ee5-47f3-9a9b-7e0eb963836a"
      unitRef="U_USD">3639000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_7bbbf434-ae71-4429-a630-b566949d25c1"
      unitRef="U_USD">3639000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_94afbb83-f2d7-4546-a4ae-0e428a53c728"
      decimals="-3"
      id="F_c35046db-aca6-438d-beef-df94635fd26d"
      unitRef="U_USD">-116000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_a988e87d-693e-4011-b612-5a9281365bb0"
      unitRef="U_USD">-116000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_4e5987d8-c576-4625-8759-66ebd0405f3d"
      decimals="-3"
      id="F_cf408ff2-f997-4ef8-a3ff-627f0213129c"
      unitRef="U_USD">-66147000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_4308d543-1e12-49fa-8220-11306e96a5e1"
      unitRef="U_USD">-66147000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20e586e5-e63b-4dc5-be33-c69ee29693d1"
      decimals="INF"
      id="F_003620ff-f537-4db5-bb9e-61ca40237790"
      unitRef="U_shares">70933140</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20e586e5-e63b-4dc5-be33-c69ee29693d1"
      decimals="-3"
      id="F_b21ab97d-ec5a-4af5-8f9f-c38615165daa"
      unitRef="U_USD">71000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f9b859fc-2a96-4b54-97cb-88cba1858033"
      decimals="-3"
      id="F_0b7c42b7-a978-4b04-9355-ec2daec9bf2c"
      unitRef="U_USD">442237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_db9aee41-d847-4892-9d0a-5f6f3588bb50"
      decimals="-3"
      id="F_49392669-f2a5-4d52-84d6-98028205e17d"
      unitRef="U_USD">-161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9cb1f60e-ec3f-44d1-b1f6-3bcaa075be67"
      decimals="-3"
      id="F_1726beda-7b52-4bbb-b9b6-7ef01375e948"
      unitRef="U_USD">-357019000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockShares
      contextRef="C_e13a3127-83d8-4882-9c9b-f8eadac41d7a"
      decimals="INF"
      id="F_73e00466-2808-4719-b665-6b61010555d0"
      unitRef="U_shares">-4196889</us-gaap:TreasuryStockShares>
    <us-gaap:StockholdersEquity
      contextRef="C_e13a3127-83d8-4882-9c9b-f8eadac41d7a"
      decimals="-3"
      id="F_13089165-5e7a-4e96-a87d-139a352bc24e"
      unitRef="U_USD">-2518000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_6c2e3a0d-0d29-4629-9ecc-cee5e869952f"
      unitRef="U_USD">82610000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_07583c8b-ad0a-41a1-97f6-334fb24086f8"
      unitRef="U_USD">-66147000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_c3d7dea5-762e-4244-86ac-784039a1ffec"
      unitRef="U_USD">-60561000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_0d582f75-9eaa-4f14-a4d4-0daebc5a5bb8"
      unitRef="U_USD">2520000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_b71d5f3c-2bf7-4d2b-9b94-6367604f8442"
      unitRef="U_USD">2443000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_5b1d8507-c7bb-4914-97fe-dc7af9aef1c7"
      unitRef="U_USD">3639000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_99c48f9a-33f1-4254-ad8b-2443a5070769"
      unitRef="U_USD">3361000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_bca1c73b-b08e-4571-b17f-806514e75b0a"
      unitRef="U_USD">772000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_e4b78289-73f4-4e42-b1e8-6f66c603f20e"
      unitRef="U_USD">-261000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sybx:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_b5243093-5f0c-46bd-bf61-1cb4aa57d75d"
      unitRef="U_USD">3149000</sybx:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset>
    <sybx:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_cfd0458a-1369-401a-b278-6556726168bd"
      unitRef="U_USD">2098000</sybx:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_c01033f1-13ed-4381-b7bb-b9f31f5f8177"
      unitRef="U_USD">-2568000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_86b04685-35e9-4224-ada7-ee8c840b180b"
      unitRef="U_USD">-1681000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sybx:IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_f6919da2-4ca7-4157-a747-f72f070bdee6"
      unitRef="U_USD">1009000</sybx:IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion>
    <sybx:IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_3d4bb67f-f9ce-4b84-9dbd-5d56aa0c905c"
      unitRef="U_USD">281000</sybx:IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_a24c6310-6fc3-4d33-b395-82da4e49a36a"
      unitRef="U_USD">4000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_945ce0a2-cf4f-48dd-9999-cfb7e01a0688"
      unitRef="U_USD">-1000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_09305e01-09c5-4c1c-8aed-592b1c9dbfdc"
      unitRef="U_USD">697000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_17f728e9-afd3-44c5-9ef3-a4f26629a34f"
      unitRef="U_USD">538000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_a2cec352-24bb-4da5-8777-334ff19a464a"
      unitRef="U_USD">351000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_17eb35dc-f26a-4ed3-9ecc-6d49f2f7df34"
      unitRef="U_USD">531000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_a19e2363-549d-420a-86ee-411606640f2d"
      unitRef="U_USD">-3898000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_36b76539-e389-434e-8de7-6709b38fad96"
      unitRef="U_USD">-2701000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_a0f8062d-46f0-4aae-94bf-0789446b643d"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_3b5e67ca-0379-4e09-b5dc-d6fd58cec81d"
      unitRef="U_USD">-131000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_8bed814b-2a24-41cd-9b1f-8d72cef5569d"
      unitRef="U_USD">-56888000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_022cc223-722f-4476-865d-d0fc0dd8ee8a"
      unitRef="U_USD">-52198000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_984667dd-f468-4c86-82e6-99366e7d446b"
      unitRef="U_USD">82787000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_dfd158c6-75cb-41fc-914f-85c72be0f9e8"
      unitRef="U_USD">167866000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_f133060b-a54d-44c5-a47b-6b38dea74f2b"
      unitRef="U_USD">141866000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_897aa3f9-9abb-4a79-b270-b5708cea5093"
      unitRef="U_USD">114022000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_624f985d-c4cf-4cc1-887c-c26fb28bf947"
      unitRef="U_USD">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_cab687e6-6709-4844-b669-3e820efaec97"
      unitRef="U_USD">1270000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_2442b0fa-3bed-4d55-86c7-48d1c1ae0d9f"
      unitRef="U_USD">728000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_900f04b2-a628-4bdf-8dd8-214b32ed91a2"
      unitRef="U_USD">679000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_c7cba684-c09a-44dc-8856-ba03a633cc25"
      unitRef="U_USD">58351000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_309197bb-2169-43c9-8a3f-570f4a73d4e6"
      unitRef="U_USD">-53253000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_be12b5d8-7fe2-4d84-b665-b58afc20f6c2"
      unitRef="U_USD">13000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_c174bd65-657a-4f53-addd-d75fd0cfe7d2"
      unitRef="U_USD">8000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_97546da2-e0a6-48cd-a084-81977cef0f0d"
      unitRef="U_USD">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_8c96dd53-f08a-4b55-b90d-d8fa80122aa7"
      unitRef="U_USD">73000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0aaf0697-e409-448d-ba6a-dc57c7587a33"
      decimals="-3"
      id="F_39e7c335-367b-4c27-8e95-e38db9698f17"
      unitRef="U_USD">293000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e9cba784-5870-4180-9446-6bedd109f39c"
      decimals="-3"
      id="F_ca5e2357-bed0-4541-928c-4415b102977d"
      unitRef="U_USD">8047000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <sybx:ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_7a971e13-617d-4eb4-97b5-5a698ae5c364"
      unitRef="U_USD">198000</sybx:ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions>
    <sybx:ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_e1dd0b0d-577d-4368-a9f4-b01ddd51f7f0"
      unitRef="U_USD">374000</sybx:ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_ae690038-2ee6-40b4-99ff-bafbec4647f7"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_bc1942a5-5ed6-4cfe-8fe2-80a7e0281ebd"
      unitRef="U_USD">81042000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_a1f7b39b-48f4-4c32-bad3-628abfe95778"
      unitRef="U_USD">2518000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_20b76bf5-614b-44de-8148-965a379c040d"
      unitRef="U_USD">0</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_438a1d7c-5340-44a6-ba07-7f40b2ac41f2"
      unitRef="U_USD">-2040000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_32af10a6-e95d-4adf-8aad-4d3a4bed8c27"
      unitRef="U_USD">89382000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_4a56b638-7097-4713-b083-8d7088107057"
      unitRef="U_USD">-577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_56d93959-b75e-476b-beb5-22dfb5faeb0f"
      unitRef="U_USD">-16069000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_409d8a31-c040-4c01-be67-7d3df6486d22"
      unitRef="U_USD">17535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4ce13154-7826-4547-a938-f6040b13872f"
      decimals="-3"
      id="F_91f39f86-d650-4366-a1e9-9284f576c853"
      unitRef="U_USD">33604000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_d260c9b9-3a08-4981-8337-821149d180c8"
      unitRef="U_USD">16958000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_2954dfbf-7bba-4403-bc82-56383c10ca27"
      unitRef="U_USD">17535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <sybx:NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_a0b5cb97-f206-470f-9591-7ef2efe166d8"
      unitRef="U_USD">27000</sybx:NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments>
    <sybx:NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_e38f30e1-f002-44fd-ae2c-2631449e80ec"
      unitRef="U_USD">40000</sybx:NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments>
    <sybx:AssetsAcquiredUnderOperatingLeaseObligation
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_cba4b91e-80a1-421c-839a-e4956ef5b1c5"
      unitRef="U_USD">3616000</sybx:AssetsAcquiredUnderOperatingLeaseObligation>
    <sybx:AssetsAcquiredUnderOperatingLeaseObligation
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_f8f52305-9028-412d-a5c7-5883e1ad8702"
      unitRef="U_USD">460000</sybx:AssetsAcquiredUnderOperatingLeaseObligation>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_006beaf2-39b0-473f-8c36-1a97efc4d5a3"
      unitRef="U_USD">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_d8c3f708-b7f5-45ce-92da-21909dacbe81"
      unitRef="U_USD">36000</us-gaap:CapitalLeaseObligationsIncurred>
    <sybx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_cf8bc26e-956b-48ce-aa81-ebfa5041ec35"
      unitRef="U_USD">6000</sybx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses>
    <sybx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_5c246bf5-a60b-4ea5-80f0-a15cf732d1dd"
      unitRef="U_USD">0</sybx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:InterestPaidNet
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_99b4d02e-5431-446c-8d39-d12613c67261"
      unitRef="U_USD">2000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_68926ad5-c488-49fd-94ea-b59eeaa2ebbf"
      unitRef="U_USD">2000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f1b55057-1107-4c97-acd7-1ce1145a2caf">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Nature of Business &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (Synlogic or the Company), is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of Synthetic Biotics. Synthetic Biotics are generated from Synlogic&#x2019;s proprietary platform, leveraging a reproducible, modular approach to the generation of novel drug candidates that perform or deliver critical therapeutic functions. Synthetic Biotics are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways or deliver combinations of therapeutic factors. Synlogic&#x2019;s goal is to discover, develop and ultimately commercialize Synthetic Biotics. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;The Company&#x2019;s consolidated financial statements have been prepared on the basis of continuity of operations, and the realization of assets and the satisfaction of liabilities in the ordinary course of business. At December 31, 2022, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash, cash equivalents and short-term marketable securities. The Company has historically generated negative cash flows from operations and has an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at December 31, 2022. In the absence of positive cash flows from operations, the Company is highly dependent on its ability to secure additional sources of funding in the form of debt or equity financings, or through the execution of additional collaboration agreements. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance date of these financial statements. If the Company cannot secure additional funding, it may be required to undertake further organizational changes, including reducing research and development spending on certain clinical stage and preclinical research programs and implementing additional reductions to its workforce. &lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), the regulatory approval process, market acceptance of the Company&#x2019;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company&#x2019;s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or alliances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;COVID-19&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;While the Company is not aware of a material impact from the continuation of the COVID-19 pandemic through December 31, 2022, the full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations, and financial condition, including expenses and manufacturing, clinical trials, and research and development costs, depends on future developments that are uncertain at this time.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-5"
      id="F_31f4b194-1fa9-479a-8dfc-c3bbbddbf808"
      unitRef="U_USD">77600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-5"
      id="F_eb7e24f2-953f-4eb9-a7ce-9e9fc7509ea9"
      unitRef="U_USD">-357000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_bdf00752-5557-455f-88f5-e721a797fc2f">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP or GAAP).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, the Company&#x2019;s management evaluates its estimates, including those related to research and development accruals and prepaids, accrued expenses, contingencies, and investments. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investment instruments with a remaining maturity when purchased of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months or less&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company held cash of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at December 31, 2022 and 2021 in a letter of credit to secure its lease at the 301 Binney Street facility. The Company has classified this deposit as long-term restricted cash on its balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.102%;"/&gt;
          &lt;td style="width:1.483%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.466000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.483%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.466000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash shown in&lt;br/&gt;&#160;&#160;&#160;the consolidated statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. Accounting Standards Codification (ASC) Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 &#x2013; Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 &#x2013; Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 &#x2013; Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates transfers between levels at the end of each reporting period. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company classifies all of its investments as available-for-sale based upon its intent with regard to such investments. The Company classifies investments as short-term when their&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;remaining contractual maturities are one year or less from the balance sheet date, and as long-term when the investment has a remaining contractual maturity of more than one year from the balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight&#x2011;line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.077%;"/&gt;
          &lt;td style="width:48.955%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lesser of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long&#x2011;Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long&#x2011;lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairments have been recognized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (ROU) assets, current operating lease&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations in our consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets represent the right-to-use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease term includes &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;options to extend the lease when it is reasonably certain that option will be exercised&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leases with a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months or less are not recorded on the Company&#x2019;s consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When third-party service providers&#x2019; billing terms do not coincide with the Company&#x2019;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company generates revenue through a collaboration and option agreement with Roche for the development and commercialization of product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full-time equivalent time as a measure of satisfaction of performance obligations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Services&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an arrangement is determined to contain a promise or obligation for us to perform research and development services, we must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, we consider the capabilities of the customer to perform these same services. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The estimates we use to record revenue relating to the combined performance obligation on an over time basis, include input methods such as full-time equivalent time incurred compared to the full-time equivalent time expected to be incurred in the future to satisfy the performance obligation, which require management judgment. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. With this method, we must estimate total inputs required to satisfy a performance obligation and measure efforts expended to date to determine revenue recognition. This estimate of remaining inputs is subjective, as the research is novel, and therefore efforts to be successful may be different than the estimated efforts at the balance sheet date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Customer Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Milestone Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contract Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (ESPP) is estimated on the date of grant using the Black&#x2011;Scholes option&#x2011;pricing model. Expected volatility for the Company&#x2019;s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer&#x2011;group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The risk&#x2011;free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipients&#x2019; service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company&#x2019;s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;greater than 50%&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company&#x2019;s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company&#x2019;s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Treasury Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, recently issued pronouncements that are or will be applicable to the Company did not have, or are not expected to have, a material impact on its present or future consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_e52517af-7c1b-4e55-9b17-01337d251981">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP or GAAP).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_c4bcbfd4-eb02-45e0-9dc2-70dd14084a24">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_9838492b-2b20-4589-9be8-c6cd3ba26216">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, the Company&#x2019;s management evaluates its estimates, including those related to research and development accruals and prepaids, accrued expenses, contingencies, and investments. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_47fa7ae5-b90f-4333-a36d-b757f1cdf0c7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investment instruments with a remaining maturity when purchased of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months or less&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:AdditionalCashAndCashEquivalentRelatedText
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_24808f0f-1eca-43e4-800f-5160190ce820">three months or less</us-gaap:AdditionalCashAndCashEquivalentRelatedText>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-5"
      id="F_b145fd8e-7fcc-461d-bf7b-90c31989329e"
      unitRef="U_USD">15900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-5"
      id="F_39e0a7ce-ef80-49f4-ad03-f480f847ab03"
      unitRef="U_USD">16400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f9b34f75-e35f-44ac-985c-7c2283796076">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_b800a7b0-4b9e-4a2b-b725-9a56d9503c48">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company held cash of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at December 31, 2022 and 2021 in a letter of credit to secure its lease at the 301 Binney Street facility. The Company has classified this deposit as long-term restricted cash on its balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.102%;"/&gt;
          &lt;td style="width:1.483%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.466000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.483%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.466000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash shown in&lt;br/&gt;&#160;&#160;&#160;the consolidated statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:Cash
      contextRef="C_5c13194e-33fe-40bd-90ef-6bbee6ee67f1"
      decimals="-5"
      id="F_7914cf67-f7e5-41f5-a3f1-557ed9de9d93"
      unitRef="U_USD">1100000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_42df9a46-4a26-442d-8081-eac11aa26210"
      decimals="-5"
      id="F_34ed262a-c330-4dd4-86ec-2ebe81eb9af9"
      unitRef="U_USD">1100000</us-gaap:Cash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_945db849-5f03-4e42-8b12-da5cb0eac755">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.102%;"/&gt;
          &lt;td style="width:1.483%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.466000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.483%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.466000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash shown in&lt;br/&gt;&#160;&#160;&#160;the consolidated statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_efc5a682-62b5-4a29-81b4-38de960b6d47"
      unitRef="U_USD">15861000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_9d8f6ced-93d2-4638-aab6-137b91fb2b93"
      unitRef="U_USD">16438000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_d1ce1d53-7273-4758-a03f-209a1f89cd28"
      unitRef="U_USD">1097000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_868ae4cc-d27a-4d9c-8253-6eff8faacd27"
      unitRef="U_USD">1097000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_8332cd0f-e562-4958-b45b-3d00f21117fa"
      unitRef="U_USD">16958000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_04c6e5f6-24dc-428f-b0bc-b9465af2b2e6"
      unitRef="U_USD">17535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_00e971c9-972e-4485-9c93-37c227b86ff3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. Accounting Standards Codification (ASC) Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 &#x2013; Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 &#x2013; Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5108231948175064%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 &#x2013; Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates transfers between levels at the end of each reporting period. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <sybx:FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="INF"
      id="F_b3ea4a92-866c-4237-b489-d0be7a4c0ce4"
      unitRef="U_USD">0</sybx:FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount>
    <sybx:FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="INF"
      id="F_d1a02450-2439-4320-b468-ec373cee3f72"
      unitRef="U_USD">0</sybx:FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_92365ba2-c21a-4acf-bbcd-ab7934eb2f2b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company classifies all of its investments as available-for-sale based upon its intent with regard to such investments. The Company classifies investments as short-term when their&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;remaining contractual maturities are one year or less from the balance sheet date, and as long-term when the investment has a remaining contractual maturity of more than one year from the balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_4ae23102-921a-41d9-a91f-747aa51a002c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight&#x2011;line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.077%;"/&gt;
          &lt;td style="width:48.955%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lesser of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <sybx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_08a94873-b0b7-42a1-8fd5-ebc2407dd17b">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.077%;"/&gt;
          &lt;td style="width:48.955%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lesser of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</sybx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e08b8831-bd01-48c6-a8f9-50a61b822302"
      id="F_5fca0e4d-cfe0-4b78-8ef5-b0761d12c99a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_df578021-db7b-44d1-8405-c09b71d9bf97"
      id="F_0e01a487-83a7-4927-9353-9842e01052d7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_13abf79b-a461-4ee1-8d29-6b819cbd08f8"
      id="F_db39496b-a5b4-4d52-abee-496dfd9e58e6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_c959ef41-4848-4db3-9e53-0dd492572f29"
      id="F_8c1379dd-55a0-4010-a92b-8e6b7bca7310">Lesser of useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_7e9e53c1-9a2e-4cfc-9437-d8606ef96a0e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long&#x2011;Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long&#x2011;lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairments have been recognized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="INF"
      id="F_fe86b117-65a1-47eb-a012-3dee0c894aff"
      unitRef="U_USD">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_84b8256c-fe02-4cec-a8c8-ce145fc1eac3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (ROU) assets, current operating lease&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations in our consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets represent the right-to-use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease term includes &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;options to extend the lease when it is reasonably certain that option will be exercised&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leases with a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months or less are not recorded on the Company&#x2019;s consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_e6764cf7-329e-4600-bea9-fac6d92fb5b9">options to extend the lease when it is reasonably certain that option will be exercised</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      id="F_574e5c1f-7cc2-4af7-a911-d898fa3f640b">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_08f204b6-3f03-43d9-a1d5-8e8dd2255e92">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When third-party service providers&#x2019; billing terms do not coincide with the Company&#x2019;s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f6f06d4c-5e53-488f-98ff-89a6944ed3ee">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company generates revenue through a collaboration and option agreement with Roche for the development and commercialization of product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full-time equivalent time as a measure of satisfaction of performance obligations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Services&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an arrangement is determined to contain a promise or obligation for us to perform research and development services, we must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, we consider the capabilities of the customer to perform these same services. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The estimates we use to record revenue relating to the combined performance obligation on an over time basis, include input methods such as full-time equivalent time incurred compared to the full-time equivalent time expected to be incurred in the future to satisfy the performance obligation, which require management judgment. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. With this method, we must estimate total inputs required to satisfy a performance obligation and measure efforts expended to date to determine revenue recognition. This estimate of remaining inputs is subjective, as the research is novel, and therefore efforts to be successful may be different than the estimated efforts at the balance sheet date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Customer Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Milestone Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contract Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePracticalExpedientRemainingPerformanceObligationDescription
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f764276d-decf-4f3c-9935-d579fcbf62f4">The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer</us-gaap:RevenuePracticalExpedientRemainingPerformanceObligationDescription>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_232384b9-d35f-4645-bd4b-c19edcba38ed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (ESPP) is estimated on the date of grant using the Black&#x2011;Scholes option&#x2011;pricing model. Expected volatility for the Company&#x2019;s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer&#x2011;group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The risk&#x2011;free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipients&#x2019; service payments are classified.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f73670f9-8d37-45b0-a9aa-d76ee978de84">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company&#x2019;s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;greater than 50%&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_d7928ed2-a345-4b59-8f3b-fb2d3c5fd7cb">greater than 50%</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_3d075423-0017-4d68-8877-cfeca94ee672">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_d5524fc9-4432-4136-9981-0b25240549e1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company&#x2019;s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company&#x2019;s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="INF"
      id="F_c739f27c-2697-4d9e-9a95-f89d94187ec7"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <sybx:TreasuryStockPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_090b0e30-3978-4a65-bc6d-6a071e6b2ec0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Treasury Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.&lt;/span&gt;&lt;/p&gt;</sybx:TreasuryStockPolicyTextBlock>
    <sybx:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_47e78922-4a8d-4510-b267-4fe57cad6b26">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, recently issued pronouncements that are or will be applicable to the Company did not have, or are not expected to have, a material impact on its present or future consolidated financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;</sybx:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_483b9051-dc9c-4b11-b4f9-49f47f559d62">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(3)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tables below present information about the Company&#x2019;s assets that are measured at fair value on a recurring basis as of December 31, 2022 and 2021 and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s investment portfolio includes many fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations. In addition, model processes were used to assess interest rate impact and develop prepayment scenarios. These models take into consideration relevant&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;credit information, perceived market movements, sector news and economic events. The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022 and 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.134%;"/&gt;
        &lt;td style="width:0.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.048%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.029%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.8%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.212%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;136,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at December 31, 2022 and December 31, 2021 are carried at amounts that approximate fair value due to their short-term maturities. Finance lease obligations at December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; approximate fair value as they bear interest at a rate approximating a market interest rate.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_7874ee02-75f4-41cc-b2a9-7d2bd2b58290">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022 and 2021, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.134%;"/&gt;
        &lt;td style="width:0.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.048%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.029%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.8%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.212%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;136,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3934f648-405d-4a5e-b610-f5dc014cbfd7"
      decimals="-3"
      id="F_2c0a1675-0828-409c-ad44-ed7a9cbe64f0"
      unitRef="U_USD">15861000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_29fed40c-524b-495e-b738-feab12394d3c"
      decimals="-3"
      id="F_0b790626-1990-454a-bfd9-41f862d0d036"
      unitRef="U_USD">15861000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_92b7da2a-7418-436a-9524-56701b660c25"
      decimals="0"
      id="F_3bd3cbac-ccf2-48a6-a841-27fa65c5fce0"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3bc26f36-034f-4f53-93d9-b443f6b5e6c4"
      decimals="0"
      id="F_dc5ed1ee-d6de-4c64-a680-41a403b9ed63"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_127f40d5-4261-4e87-a5a5-a06ab8251d92"
      decimals="-3"
      id="F_6c43a074-4807-4738-8630-3f60958c353a"
      unitRef="U_USD">44375000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b65842df-41e9-4ad0-b418-74bfc423b622"
      decimals="-3"
      id="F_2e9d8e6b-d57f-4dae-8885-2a681c151bd3"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2a7a2cff-5d8f-4521-9e09-ba2479d086ca"
      decimals="-3"
      id="F_b3da6b54-b2cd-4f96-a56e-bda57dd163ee"
      unitRef="U_USD">44375000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d77ddcfe-10f7-4a58-90fe-828bf55ff466"
      decimals="-3"
      id="F_9603af96-b856-47b5-88f9-b8a27dd12942"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_52f0109e-38a0-4183-afac-f6722c5543d4"
      decimals="-3"
      id="F_4d4029f0-d54e-40c9-af21-fa83458781b0"
      unitRef="U_USD">17393000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3b538def-63ae-4f4b-9140-89b96b2a5ea7"
      decimals="-3"
      id="F_b7612db2-2a8e-4674-97bc-02cc660a375c"
      unitRef="U_USD">17393000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_cd16f567-f183-4c6e-8b80-74f9c2966fb5"
      decimals="-3"
      id="F_d1742483-75d9-4496-8c68-bb3027b849be"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_c8434699-f20b-4949-8f3d-8de4ac28fe77"
      decimals="-3"
      id="F_7a84f826-f125-40b3-a4b2-d0622903443f"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d4d75229-eaf1-4029-9ef7-4b3edaa0a833"
      decimals="-3"
      id="F_1273d446-1779-40b8-996a-d0dd611bdf58"
      unitRef="U_USD">77629000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0abad65e-efe7-4687-9248-a9c45acb22de"
      decimals="-3"
      id="F_c6c80019-492d-4c19-b0f5-ea78f4b8bd97"
      unitRef="U_USD">33254000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_967baf2d-6be3-4b7f-ae16-eff0641c22f0"
      decimals="-3"
      id="F_7212a272-aa67-40a9-9bf6-456e1f4c6d93"
      unitRef="U_USD">44375000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6fc8483b-ee81-4369-a735-5813ac304b5a"
      decimals="-3"
      id="F_f47f57a7-6b1a-483d-88f0-8a670b02e6d3"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_91376d3a-55e0-47d7-8f1d-b1e000c4da64"
      decimals="-3"
      id="F_2759e29d-207f-471a-9e76-e660de22be93"
      unitRef="U_USD">16437000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8b9caf09-f6c8-47cf-a222-c8667dca98fd"
      decimals="-3"
      id="F_eba7a38d-5a83-42a0-9e76-74ec72ce08a9"
      unitRef="U_USD">16437000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_39ffddbf-7d15-4ff1-8e01-541286c83ab8"
      decimals="0"
      id="F_745271b1-70dd-4eac-82e6-dc87794508fe"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_02234d32-33f3-4416-bdc7-483f3c549a5f"
      decimals="0"
      id="F_8ae11435-d385-4004-b6d2-dcdbc5024180"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cd0ccefb-dd51-4e98-b605-3e1a046f1576"
      decimals="-3"
      id="F_859c1bc2-baf8-43b8-ad29-c35a0a628054"
      unitRef="U_USD">106277000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8e60fb3b-c7d3-4ac6-83b2-f6a6547f6e1a"
      decimals="-3"
      id="F_d316f1f6-881b-44ee-8649-ea3bc0a76bad"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_76fcaa28-0554-4900-bf7f-e8311ed88698"
      decimals="-3"
      id="F_06bac7e7-b3aa-45ef-ac00-63d751868715"
      unitRef="U_USD">106277000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cee0ff06-3a82-48ed-bc1e-7798fb043a99"
      decimals="-3"
      id="F_2a632914-37cb-4c3a-be04-c668c8e4d088"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_94ebd146-59d5-436b-8185-ff6c733be386"
      decimals="-3"
      id="F_c46fc2da-bb8f-4a2f-a881-e66a95b69d1e"
      unitRef="U_USD">5873000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e186ace1-c417-4554-ab06-b27470bd2ea0"
      decimals="-3"
      id="F_760b2283-1328-469a-8e03-5c399cd7acc5"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_dbe4b5e6-1273-43ae-8a7f-b8ea915f3ed1"
      decimals="-3"
      id="F_d1d445f2-de77-4589-b33e-a6c2716c5e32"
      unitRef="U_USD">5873000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_99657c65-259d-41fd-986b-5c347fbc45d5"
      decimals="-3"
      id="F_a442a111-b33c-49ae-89c5-821650bc8dbf"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_9c420274-37ac-41c4-9722-54e874446423"
      decimals="-3"
      id="F_1904bf0f-0047-4ac7-8306-e60345d0124d"
      unitRef="U_USD">8041000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_0091dbbf-6c21-4edd-9df7-2c4b934ef7d5"
      decimals="-3"
      id="F_7749222a-e1ba-41b8-8958-418999dc52d3"
      unitRef="U_USD">8041000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3b826f3c-b239-4a65-b43d-e759471f2756"
      decimals="-3"
      id="F_808d1712-077b-492f-834a-d2ac1aa02119"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_7347bbee-a9f6-4c87-a6a2-eddd53ccfd0e"
      decimals="-3"
      id="F_4cff09b4-0fd3-4518-9a3f-3b6e6296de55"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_85363944-bc80-4236-b736-030f11ca6ff3"
      decimals="-3"
      id="F_fc31236a-51e9-4ebb-b722-efeacaf70a33"
      unitRef="U_USD">136628000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a326c280-7be6-41bc-88c6-584d5e7052d8"
      decimals="-3"
      id="F_442d0889-9210-415a-ad7f-dc8281fd35c3"
      unitRef="U_USD">24478000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b16d8204-0369-41df-93d2-7ec43c203587"
      decimals="-3"
      id="F_05b04583-9389-4a42-9f63-30aba215415d"
      unitRef="U_USD">112150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_92c74e7a-30c1-4b8a-9f5c-579a596fbd61"
      decimals="-3"
      id="F_ecca7e90-b65d-4569-8cc1-16dd357a4ed1"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <sybx:AvailableForSaleSecuritiesDisclosureTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_8ad1fc08-07b8-4e62-865c-cf369e7ebd93">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(4)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the available-for-sale securities held at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.836%;"/&gt;
        &lt;td style="width:1.447%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.417%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.322%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.322%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.322%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The contractual maturity of all securities held at December 31, 2022 was six months or less. There were fifteen investments in an unrealized loss position at December 31, 2022. The aggregate fair value of the securities in an unrealized loss position at December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until maturity or a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t hold any securities with an other-than-temporary impairment at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross realized gains and losses on the sales of investments have not been material to the Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;</sybx:AvailableForSaleSecuritiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_d793947c-64b1-4e33-a41c-9fad2991d7f0">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the available-for-sale securities held at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.836%;"/&gt;
        &lt;td style="width:1.447%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.417%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.322%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.322%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.322%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0"
      decimals="-3"
      id="F_8fb183ac-9fe7-4da8-9045-651788e24013"
      unitRef="U_USD">44437000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0"
      decimals="-3"
      id="F_4d087323-873b-4322-95a6-6f7d52fa83ce"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0"
      decimals="-3"
      id="F_b7b45648-1617-4f03-b7f2-de25dfc213e7"
      unitRef="U_USD">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9a9704bb-1f5a-48e3-9c76-aa09512231f0"
      decimals="-3"
      id="F_7fcea62b-7434-4bbf-a8ef-bc5e69ac6c5f"
      unitRef="U_USD">44375000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c"
      decimals="-3"
      id="F_d5f26402-d8b5-46da-92c0-6f1c8b9ffe8b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c"
      decimals="-3"
      id="F_3e524593-a4c5-4528-8311-0622c26fb347"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c"
      decimals="-3"
      id="F_352fd678-451a-4d43-84f6-dd0c0e3c9c89"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4d25c59a-d1d5-4b64-8d29-dbcdb7946d8c"
      decimals="-3"
      id="F_2d858a18-3466-403d-8238-9276ca4169e8"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb"
      decimals="-3"
      id="F_de60b63c-b7dc-437d-abdb-98162dbe9d2e"
      unitRef="U_USD">17492000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb"
      decimals="-3"
      id="F_30960a0b-5955-42b9-a806-5ce51237517a"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb"
      decimals="-3"
      id="F_c4bdff62-cadd-4405-92e8-afee46387d4d"
      unitRef="U_USD">99000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fdfcb2fc-ceed-4d0c-a2f2-86f0908287bb"
      decimals="-3"
      id="F_9803420a-cbb0-40d9-8a0c-912f5b4477ad"
      unitRef="U_USD">17393000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_8668fe20-946d-4ccc-98d6-a7df1a058cb6"
      unitRef="U_USD">61929000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_7eb604be-bb5a-4aab-b4fd-30481e379779"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_3d0a37b4-448f-406f-959c-df90c7a73b95"
      unitRef="U_USD">169000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_b6dff15a-36dc-4a2a-a186-a665004970bb"
      unitRef="U_USD">61768000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e617d399-c879-434f-a4fb-b4d8855f9c6d"
      decimals="-3"
      id="F_3131b2cb-5e67-48f0-a95d-c85a0892dcb1"
      unitRef="U_USD">106298000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e617d399-c879-434f-a4fb-b4d8855f9c6d"
      decimals="-3"
      id="F_9888e2d4-57b8-4852-b2ab-5775b8250392"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e617d399-c879-434f-a4fb-b4d8855f9c6d"
      decimals="-3"
      id="F_d486dbcc-8625-4ee5-a5eb-f6288cb8a18d"
      unitRef="U_USD">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e617d399-c879-434f-a4fb-b4d8855f9c6d"
      decimals="-3"
      id="F_d5409415-02b9-4531-961f-c78d5f7a0b65"
      unitRef="U_USD">106277000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c"
      decimals="-3"
      id="F_8927d325-0f50-4bc0-bed9-efd1850b886c"
      unitRef="U_USD">5876000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c"
      decimals="-3"
      id="F_9d8784db-9ba3-4878-bac4-6faa45cdc4cf"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c"
      decimals="-3"
      id="F_3308b54d-0dea-4225-a5bb-74db0d264dd2"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d94bcfcb-0b07-4214-ba76-a5e2a672342c"
      decimals="-3"
      id="F_8152cb90-6640-4fbb-be1d-15aad0feca5c"
      unitRef="U_USD">5873000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_61230b0b-84df-43f0-a9b0-98509a23ed34"
      decimals="-3"
      id="F_ed5a6cf9-20f3-4530-98f9-fe66e5ff79af"
      unitRef="U_USD">8062000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_61230b0b-84df-43f0-a9b0-98509a23ed34"
      decimals="-3"
      id="F_9ca2e864-70a0-4af7-b3e8-54eaeccea7e3"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_61230b0b-84df-43f0-a9b0-98509a23ed34"
      decimals="-3"
      id="F_599e42b8-805b-40f4-82ae-5b9886e0a65a"
      unitRef="U_USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_61230b0b-84df-43f0-a9b0-98509a23ed34"
      decimals="-3"
      id="F_e88dc892-8708-4260-a4f4-7eb785fa86a7"
      unitRef="U_USD">8041000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_0a806696-e588-420e-a306-1f5b6712cd51"
      unitRef="U_USD">120236000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_3a6f44ae-eb7b-4d8d-97c8-bdfd4ddaa906"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_ee0699de-7d89-473b-8047-adf4d55b6822"
      unitRef="U_USD">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_fa16b1ff-b399-4314-beee-1e3a716b9779"
      unitRef="U_USD">120191000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-5"
      id="F_04d21350-7cd4-45b8-a7b0-0e28ed7e7e93"
      unitRef="U_USD">36600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-5"
      id="F_7bf5cd84-5f72-46ff-a2bc-bbf0670a490a"
      unitRef="U_USD">72200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <sybx:OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_2afa986b-3ca5-430f-8afc-5577d9377a71"
      unitRef="U_Security">0</sybx:OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale>
    <sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_70117a94-8bb3-43d4-a974-b73fcdec8e2e">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(5)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.102%;"/&gt;
        &lt;td style="width:1.483%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.466000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.483%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.466000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_04ad664a-084d-41b1-8085-802e217380e6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.102%;"/&gt;
        &lt;td style="width:1.483%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.466000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.483%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.466000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_5daa234f-1b8d-4cff-ae7a-3aaabf9b7460"
      unitRef="U_USD">887000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_b180542e-54d1-4bc1-856f-58b659705d5a"
      unitRef="U_USD">979000</us-gaap:PrepaidInsurance>
    <sybx:PrepaidResearchAndDevelopmentCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_030ca9f0-c564-4eaa-b925-0568f15881fd"
      unitRef="U_USD">320000</sybx:PrepaidResearchAndDevelopmentCurrent>
    <sybx:PrepaidResearchAndDevelopmentCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_21d143d9-ca24-429d-ba86-da997371b643"
      unitRef="U_USD">2721000</sybx:PrepaidResearchAndDevelopmentCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_c9cac654-22c1-4a3b-bc51-e945314dcb8c"
      unitRef="U_USD">771000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_27404a4c-6f8f-46c3-acfe-d0e3b77cc907"
      unitRef="U_USD">710000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_85a490eb-5cd6-4ebc-a3ce-69eeba1fdde2"
      unitRef="U_USD">175000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_f0953304-75d3-405e-b452-39718565c6e1"
      unitRef="U_USD">311000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_27259bca-c23a-425a-9c64-68cc8e3825f2"
      unitRef="U_USD">2153000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_2176ea6b-4873-476c-8a30-939b699a72ef"
      unitRef="U_USD">4721000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_dc817454-bb6d-46a5-90c3-8e9a48a2555d">&lt;div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(6)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.751%;"/&gt;
        &lt;td style="width:1.389%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.735%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.389%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.735%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense on property and equipment was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_5d62e52c-51b4-46d8-845e-50b2eed6fa70">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.751%;"/&gt;
        &lt;td style="width:1.389%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.735%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.389%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.735%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a7af75ad-b1e6-4aef-851f-04fd45e648cd"
      decimals="-3"
      id="F_0ba28103-c488-486a-afd6-22a92cf5880b"
      unitRef="U_USD">9313000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3545a731-60bf-461a-b2f6-a8fd246306f2"
      decimals="-3"
      id="F_76ea80bc-0a00-4021-8d73-7538146f0006"
      unitRef="U_USD">8274000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dd023e56-8402-47a8-bace-8ad6f1a75d5d"
      decimals="-3"
      id="F_84e35c7c-4159-4f2e-bac6-4ceda42d9798"
      unitRef="U_USD">793000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_eb6f0279-648d-4922-bffa-1e1ac712993d"
      decimals="-3"
      id="F_1a79b6f8-296c-4af4-bc47-d92923a89b2f"
      unitRef="U_USD">756000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7d6680fe-ccfc-4e24-8fd9-1fa014c4a0b7"
      decimals="-3"
      id="F_88c036f4-b79e-4dfa-8ac1-cd62e4d6ca1f"
      unitRef="U_USD">500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f9e9134b-680f-4e16-baa0-cd8a64b991b8"
      decimals="-3"
      id="F_cd29522c-8252-46eb-b765-ec212e5a617c"
      unitRef="U_USD">500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3d820518-ff46-4605-b3e8-6459f151a8a3"
      decimals="-3"
      id="F_13e16928-0007-445a-8591-4137b56b6408"
      unitRef="U_USD">9820000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3b99e72e-cd69-4ebb-a947-0d73db833415"
      decimals="-3"
      id="F_0f6bbf8e-a01f-4fe5-baa7-1809ed0cc409"
      unitRef="U_USD">9561000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6ad07922-17ac-4c18-97a9-21067c51ee17"
      decimals="-3"
      id="F_507fea92-dba7-45d6-986b-39e7441caad4"
      unitRef="U_USD">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_54406899-ec4d-4081-a75a-a534c1e59a14"
      decimals="-3"
      id="F_29a4cb4c-16f6-4465-8635-e410285cc6d9"
      unitRef="U_USD">623000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_3a94e368-eb9e-4f66-988e-8a26b1b70a41"
      unitRef="U_USD">20463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_c9ca01b5-5f7d-40a4-9dbe-bbb4a72878f2"
      unitRef="U_USD">19714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_82094622-f51b-47c8-a1c1-41f698659b55"
      unitRef="U_USD">13140000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_c1752202-9bc1-4c25-a4fc-083e8b3fecd8"
      unitRef="U_USD">10626000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_ae1216f8-b284-4e68-98f0-89407595ef48"
      unitRef="U_USD">7323000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_b577ccca-0df2-45fb-b8bc-d724c97e2425"
      unitRef="U_USD">9088000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-5"
      id="F_d9181779-b640-4be9-b813-ea99145ccd94"
      unitRef="U_USD">2500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-5"
      id="F_72cbb75d-dee3-422a-979f-e3c4427064a8"
      unitRef="U_USD">2400000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_9088d6d1-f1d6-42f3-a84a-59c40e89d36f">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(7)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.902%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payroll related&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_32e45de6-17c1-4d79-872f-33faf6c41365">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.902%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payroll related&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_cae13549-a605-41bc-9a9e-91290e1de2cf"
      unitRef="U_USD">3401000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_52881085-9272-4d1d-83e0-1e14e00116a5"
      unitRef="U_USD">3495000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_b5b8eb0b-8f16-42d5-92c7-f76658358381"
      unitRef="U_USD">152000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_d2bb92d9-a17d-46b6-a27e-34b7b4ffb16f"
      unitRef="U_USD">298000</us-gaap:AccruedProfessionalFeesCurrent>
    <sybx:AccruedResearchAndDevelopmentCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_a47e991d-224d-458d-810c-99e5d8bfd62e"
      unitRef="U_USD">1624000</sybx:AccruedResearchAndDevelopmentCurrent>
    <sybx:AccruedResearchAndDevelopmentCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_302dd3b0-9167-4291-8dcd-ddc3f00b5384"
      unitRef="U_USD">336000</sybx:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_9b37df92-5afc-4814-9c0e-3a121137bedf"
      unitRef="U_USD">113000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_38b3f5f0-9554-4b0c-a0fb-c01239bb9326"
      unitRef="U_USD">273000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_3d8590ce-6979-4ece-92fd-0bf1c3fda4a3"
      unitRef="U_USD">5290000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_697fe0f3-478c-4e53-8b88-69aec36ac2f3"
      unitRef="U_USD">4402000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_532dffea-d760-4d6c-9307-4e7b863eed30">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s common stock has the following characteristics:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:12.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.810754261802134%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of shares of common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; vote for each share of common stock held at all meetings of stockholders.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:12.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.810754261802134%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of shares of common stock are entitled to receive dividends, if and when, declared by the Company&#x2019;s board of directors. Since inception, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; cash dividends have been declared.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2019, the Company issued to Ginkgo Bioworks, Inc. (Ginkgo) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,340,771&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock and accompanying Pre-Funded Warrants (the Pre-Funded Warrants) to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,548,117&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, at a combined purchase price per share and Pre-Funded Warrant of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Pre-Funded Warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, with $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of such exercise price paid at the closing of the offering. The proceeds, net of issuance costs, were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to the proceeds from sale of the common stock and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to the proceeds from sale of the Pre-Funded Warrants. The Pre-Funded Warrants may be exercised at any time until all of the Pre-Funded Warrants are exercised in full to the extent that, after giving effect to such issuance after exercise, Ginkgo would not beneficially own in excess of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding immediately after giving effect to the issuance. The Pre-Funded Warrants were classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, such warrants do not provide any guarantee of value or return. In addition, in connection with the issuance to Ginkgo of common stock and Pre-Funded Warrants, the Company expanded its existing collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the Pre-Funded Warrants have been exercised as of December 31, 2022. (See Note 10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Ginkgo Collaboration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 13, 2017, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) with respect to an at-the-market (ATM) offering program. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the year ended December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,447,211&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. This sales agreement with Cowen was terminated in July 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2021, the Company entered into a new sales agreement with Jefferies, LLC (Jefferies) with respect to an ATM, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having aggregate sales proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Jefferies is not required to sell any specific amount but acts as the Company&#x2019;s sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481,451&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were sold pursuant to the sales agreement with Jefferies, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2021, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share pursuant to an underwritten public offering. The net proceeds to the Company from the offering, after deducting the underwriting discounts and commissions and offering expenses payable by the Company, were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. All shares of common stock sold in the offering were sold by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2021, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share pursuant to an underwritten public offering. The net proceeds to the Company from the offering, after deducting the underwriting discounts and commissions and offering expenses payable by the Company, were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. All shares of common stock sold in the offering were sold by the Company.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has  reserved for future issuance the following shares of common stock related to the potential exercise of Pre-Funded Warrants, exercise of stock options, and the employee stock purchase plan:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.27%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:29.73%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock issuable under pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,548,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,328,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,928,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <sybx:NumberOfVotesEntitledToEachShareOfCommonStock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="INF"
      id="F_8df3eb6a-bcf9-409a-9ed0-38fc371669fe"
      unitRef="U_Vote">1</sybx:NumberOfVotesEntitledToEachShareOfCommonStock>
    <us-gaap:DividendsCommonStockCash
      contextRef="C_df2e79da-2d09-4270-8ce2-2f9e4b85b0ff"
      decimals="INF"
      id="F_b4644746-97ed-40a0-b3ca-71f9b3826a5d"
      unitRef="U_USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_73d91fb1-2e62-48f7-92de-e383722c15e2"
      decimals="INF"
      id="F_600ead77-3c3a-452a-b502-52af8cbdad52"
      unitRef="U_shares">6340771</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2e56b967-590d-4bb7-93db-326ebc48a3e5"
      decimals="INF"
      id="F_7a2a90af-e7ba-4503-925c-43f10c6034d4"
      unitRef="U_shares">2548117</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sybx:SaleOfCommonStockAndPrefundedWarrantPricePerShare
      contextRef="C_627e4d45-a0cb-4fa4-be83-89cafaf6b705"
      decimals="INF"
      id="F_ba80db4c-433a-45a2-bdb1-837037612e20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.00</sybx:SaleOfCommonStockAndPrefundedWarrantPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_7d128f60-ec2d-4e7e-ad00-15156530da9e"
      decimals="INF"
      id="F_59be5194-026d-49b0-a645-f5ff083ff9c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sybx:ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering
      contextRef="C_7d128f60-ec2d-4e7e-ad00-15156530da9e"
      decimals="INF"
      id="F_9c954b24-571c-47a4-bfa8-e47e619ead9a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.99</sybx:ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering>
    <sybx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
      contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597"
      decimals="-5"
      id="F_e4b8d6df-e205-4a77-81c3-353381d411fb"
      unitRef="U_USD">79900000</sybx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597"
      decimals="-5"
      id="F_83aa0be1-3008-43ba-b1b0-41baaf398ba5"
      unitRef="U_USD">57000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_97aff091-2a04-46a5-9057-7373ad98593b"
      decimals="-5"
      id="F_170256d9-3177-4809-930a-b1a2d3002514"
      unitRef="U_USD">22900000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <sybx:UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance
      contextRef="C_5cb51fda-168e-4bf9-88e4-f2c1dde4f357"
      decimals="INF"
      id="F_1dd4bab2-48d4-4384-bf92-b15cdecdc652"
      unitRef="U_pure">0.1999</sybx:UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance>
    <sybx:WarrantsExercised
      contextRef="C_7130c6be-123a-4941-b59a-2b8f5cdd887b"
      decimals="INF"
      id="F_0aa72205-e1c3-43ff-8db2-52425a47e7ec"
      unitRef="U_shares">0</sybx:WarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_73945c68-b522-4635-afec-a62d38320354"
      decimals="INF"
      id="F_fc928adb-8772-4b84-864e-58871d9147ef"
      unitRef="U_shares">2447211</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_73945c68-b522-4635-afec-a62d38320354"
      decimals="-5"
      id="F_81667de4-c388-4dbe-a557-9cf6ef0b34c9"
      unitRef="U_USD">8000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_17b056dc-d7fb-4fda-b280-76eec780b5fc"
      decimals="-5"
      id="F_6ad2f960-04b2-4d82-b620-29c8a29948d3"
      unitRef="U_USD">50000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_44eb79d0-8fc4-42f7-a690-e5796a479806"
      decimals="0"
      id="F_e8ebc65c-707f-4006-a109-ab46103a53c0"
      unitRef="U_shares">481451</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_44eb79d0-8fc4-42f7-a690-e5796a479806"
      decimals="-5"
      id="F_02375f02-2a25-4d11-b909-d3a1363ff75d"
      unitRef="U_USD">300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a1266c6b-f79b-47ac-9d44-b00ab08b1491"
      decimals="0"
      id="F_f8e35b03-3622-4e79-8e57-ac51f3285b12"
      unitRef="U_shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_4b914988-f15e-45d7-8299-f5e9f4596f51"
      decimals="2"
      id="F_a35777b5-91a4-4117-8d95-ae80b718fc98"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6edf54b0-befe-46f1-a01a-5d4ad86e422a"
      decimals="-5"
      id="F_2454ae03-8138-4662-91a9-e1de67444c64"
      unitRef="U_USD">32600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_769545e9-0aa1-4ec6-a368-611478b8ff27"
      decimals="0"
      id="F_7add6260-954a-4e66-83c5-ce94b0f81f21"
      unitRef="U_shares">17250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_d79f3e7f-b5d8-44b8-8e74-072b254299d5"
      decimals="2"
      id="F_796c66fa-bc39-4d1e-ab94-52ae6e173fcd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_769545e9-0aa1-4ec6-a368-611478b8ff27"
      decimals="-5"
      id="F_14b692d5-78b9-46b2-a209-53874ab9255d"
      unitRef="U_USD">48400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_2e77a90d-fd45-4591-ae1d-110df7cc2d2c">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has  reserved for future issuance the following shares of common stock related to the potential exercise of Pre-Funded Warrants, exercise of stock options, and the employee stock purchase plan:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.27%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:29.73%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock issuable under pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,548,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,328,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,928,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_526bc3f6-6d8d-4822-b52e-24e5d384e725"
      decimals="INF"
      id="F_513ea67b-2909-4aaf-8526-e5c82f171082"
      unitRef="U_shares">2548117</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5cec03e1-9dc1-4ffd-9623-0c876a46a0c9"
      decimals="INF"
      id="F_77342450-5f14-4cc1-a789-b5590e95ee81"
      unitRef="U_shares">3328011</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_125495a8-4ea5-4da7-b352-1c1c4f816a98"
      decimals="INF"
      id="F_383e1188-e1ad-4af2-9f25-e5b6fda9eb6a"
      unitRef="U_shares">52648</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_ae42d8d4-1b9e-4838-ac7b-ef5539355978"
      unitRef="U_shares">5928776</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f23192e9-3f6e-4020-9937-e795161cb5e1">&lt;div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(9)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity&#x2011;based Compensation and Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company currently has three active equity plans.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2015 Equity Incentive Award Plan (2015 Plan) functions as the primary equity plan for the Company. The 2015 Plan includes an &#x201c;evergreen provision&#x201d; that allows for an annual increase in the number of shares of common stock available for issuance under the 2015 Plan, which annual increase will be added on the first day of each fiscal year from 2016 through 2025, inclusive, and will be equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; percent of the shares outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board of Directors. On January 1, 2022, the Company added &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,484,942&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares to the 2015 Plan pursuant to the &#x201c;evergreen provision&#x201d;. The 2015 Plan provides for the granting of a variety of stock&#x2011;based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, deferred stock awards, dividend equivalent awards, stock payment awards, performance awards and other stock&#x2011;based awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2017 Stock Incentive Plan (the 2017 Plan) provides for the grant of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2015 Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their eligible compensation, subject to any plan limitations. The ESPP generally provides for set offering periods, and at the end of each offering period, employees are able to purchase shares at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. The Company suspended the ESPP in 2017. In December 2019, the Board reactivated the 2015 ESPP and approved an amendment to the ESPP to (i) reduce the permitted payroll deduction and number of shares of the Company&#x2019;s common stock that a participant may purchase per calendar year and offering period under the ESPP and (ii) establish a period for enrollment for eligible participants. The reactivation of the 2015 ESPP was effective immediately. The Company&#x2019;s executive officers are eligible to participate in the 2015 ESPP. The ESPP includes an &#x201c;evergreen provision,&#x201d; allowing for an annual increase in the number of shares of common stock available for issuance. On January 1, 2022, the Company added &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;696,988&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares to the ESPP pursuant to the &#x201c;evergreen provision&#x201d;. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,629&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock purchased under the ESPP during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021 were:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.931%;"/&gt;
        &lt;td style="width:1.701%;"/&gt;
        &lt;td style="width:14.525%;"/&gt;
        &lt;td style="width:1.701%;"/&gt;
        &lt;td style="width:14.525%;"/&gt;
        &lt;td style="width:2.616%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employees:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average, risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock option activity under the 2015 and 2017 Plans.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.377%;"/&gt;
        &lt;td style="width:0.651%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.47%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.17%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.126%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.651%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.046%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.846%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;&#160;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,500,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,738,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;956,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,247,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested or expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,247,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,328,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.03pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(a)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2022 and 2021. &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,210,026&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options were in the money at December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average grant date fair value per share of options granted during the years ended December 31, 2022 and 2021 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.16&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The total fair value of awards that vested during the years ended December 31, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of unrecognized share-based compensation for unvested stock option grants which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;762,772&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242,454&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of restricted common stock were granted, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table shows restricted common stock activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.195%;"/&gt;
        &lt;td style="width:1.429%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.458%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.444%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.474%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;299,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;762,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;826,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total fair value of shares that vested during the years ended December 31, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The ESPP is considered a compensatory plan with the related compensation expense recognized over the six-month offering periods. The compensation expense for the years ended December 31, 2022 and December 31, 2021 was less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in both years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has recorded total equity&#x2011;based compensation expense of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, during the years ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021, respectively. Equity compensation during the years ended December 31, 2022 and 2021 is derived from stock options, restricted stock awards, and the ESPP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes equity&#x2011;based compensation expense within the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.667%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.143%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.289%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes equity&#x2011;based compensation expense by type of award for the years ended December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.548%;"/&gt;
        &lt;td style="width:1.504%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.155999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.491%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.302%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <sybx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding
      contextRef="C_ae409a4f-4065-4a38-ac8d-81447767cd16"
      decimals="2"
      id="F_9d5aef23-2d49-4daf-833e-2cb3ce1da02a"
      unitRef="U_pure">0.05</sybx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_427833e4-00a7-483a-9685-f0f6c211b01c"
      decimals="INF"
      id="F_2116f387-e3f3-46f6-bcfe-a0b7ccdd92e5"
      unitRef="U_shares">3484942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="C_9404c746-39af-4f16-b76d-b8630bcb901d"
      decimals="INF"
      id="F_faff9135-6df1-4fc6-a447-cb0e7f793804"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_9404c746-39af-4f16-b76d-b8630bcb901d"
      decimals="INF"
      id="F_749e2a9d-b58f-4981-8d18-208ec2e95cbc"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_d15380e7-f98d-4b93-b4f8-739dab563868"
      decimals="INF"
      id="F_af80030a-83ab-4278-9cfa-cb154c255c95"
      unitRef="U_shares">696988</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_961a013f-154c-4b93-ac17-2c189db1fa4f"
      decimals="INF"
      id="F_013a7350-c277-4905-ad07-278ae0c05146"
      unitRef="U_shares">106629</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      id="F_f8e51b6e-43b7-4e38-bfaa-a398c53b84b9">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021 were:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.931%;"/&gt;
        &lt;td style="width:1.701%;"/&gt;
        &lt;td style="width:14.525%;"/&gt;
        &lt;td style="width:1.701%;"/&gt;
        &lt;td style="width:14.525%;"/&gt;
        &lt;td style="width:2.616%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employees:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average, risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_99fd2321-f1d7-43cf-b178-e7348f290f1f"
      id="F_3a8cd0c8-d8a9-4fd5-8cb8-3147e4af5191">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6"
      id="F_08aae4b9-3da8-442c-896f-547e6411a1e3">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_99fd2321-f1d7-43cf-b178-e7348f290f1f"
      decimals="3"
      id="F_36956048-49b4-4a20-97ea-ff16528fe4c2"
      unitRef="U_pure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6"
      decimals="3"
      id="F_004a5627-f9ba-45d4-8cc3-0c9ba866b0d6"
      unitRef="U_pure">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_99fd2321-f1d7-43cf-b178-e7348f290f1f"
      decimals="3"
      id="F_f763ca9e-e71c-42d3-97b7-7baf369054fa"
      unitRef="U_pure">0.825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6"
      decimals="3"
      id="F_664319e7-ee36-4d8b-94bb-fb9302901b69"
      unitRef="U_pure">0.849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_99fd2321-f1d7-43cf-b178-e7348f290f1f"
      decimals="2"
      id="F_988a8900-30b6-468d-8dc2-728df1e94684"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_ae3bcde6-2f3e-426c-a6af-49310dabd4d6"
      decimals="2"
      id="F_daf8d09d-2eb4-4d13-9760-cb3769902d99"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      id="F_503af8cb-24b8-4ee8-bc61-9ca184d58ec9">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock option activity under the 2015 and 2017 Plans.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.377%;"/&gt;
        &lt;td style="width:0.651%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.47%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.17%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.126%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.651%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.046%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.665%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.846%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;&#160;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,500,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,738,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;956,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,247,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested or expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,247,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,328,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2022 and 2021. &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,210,026&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options were in the money at December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, respectively.&lt;/span&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_698c1855-5f3d-4405-b9dd-9cbf05cddeda"
      decimals="INF"
      id="F_bee0887b-5164-43f2-b485-dfc3d0ea107d"
      unitRef="U_shares">4500913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_698c1855-5f3d-4405-b9dd-9cbf05cddeda"
      decimals="2"
      id="F_0770fcfe-866f-4842-a876-6012c3a5b440"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_83e56954-5a79-4d4a-a1b6-981f26235c7f"
      id="F_a0deb5af-d914-4c2f-8880-1188dce3211d">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_698c1855-5f3d-4405-b9dd-9cbf05cddeda"
      decimals="-3"
      id="F_d1032556-0ebf-460d-a9d5-bdc2dea4963c"
      unitRef="U_USD">588000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      decimals="INF"
      id="F_03a8a716-9720-488a-885b-852f4950ad55"
      unitRef="U_shares">3738999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      decimals="2"
      id="F_e593a120-e312-4ac9-9865-8e7b3c507106"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      decimals="INF"
      id="F_f10c1942-3871-4a96-aed3-9a1213e1eadc"
      unitRef="U_shares">35562</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      decimals="2"
      id="F_c7cd07e8-aa5f-4b7a-ba16-1d94f059921d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      decimals="-3"
      id="F_5ede5bf8-c13b-45c3-b935-a81ebf162c80"
      unitRef="U_USD">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      decimals="INF"
      id="F_17af17c5-c886-4dad-aeb2-62637cb5873e"
      unitRef="U_shares">956655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      decimals="2"
      id="F_fef5d456-35b1-42c2-8d6b-7483b0e41b27"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="INF"
      id="F_d8722bd3-d090-4b8f-9eff-4704347451c8"
      unitRef="U_shares">7247695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="2"
      id="F_1e51a5d1-8a03-468a-8d5d-535f43cc40f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      id="F_2b268de9-e60a-400f-b542-babce8658213">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="-3"
      id="F_ee0a6b3f-22e2-41c4-897e-2e391afc1d73"
      unitRef="U_USD">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="INF"
      id="F_eb965bf5-0397-49ea-acd6-b3b62d84a7ac"
      unitRef="U_shares">7247695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="2"
      id="F_3c1bc8da-fd09-4428-9a0b-f979bf69aa7f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      id="F_646c0771-5579-4eac-b8d7-398e78363f1e">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="-3"
      id="F_79d5efdf-fa1e-48a5-9bca-ffbebf320c93"
      unitRef="U_USD">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="INF"
      id="F_489851c4-1373-4c41-9837-c555d13237de"
      unitRef="U_shares">3328011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="2"
      id="F_923b3461-1225-40ae-b124-6a880968de77"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_74611fb1-0792-41e9-a2a7-b97cac4d7f12"
      id="F_bdb32d24-cd6b-4845-886b-8dc19f5e8e26">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_c5706570-7d04-4e8e-814e-029647b3f073"
      decimals="-3"
      id="F_dc0d55fa-cf54-4799-a778-9bdb142c28e8"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_cb9389f4-0cd8-477e-9fe4-86e199597e63"
      unitRef="U_shares">185500</sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue>
    <sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="INF"
      id="F_38447786-f731-455e-98ea-d8b495eacd86"
      unitRef="U_shares">1210026</sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_6041538e-c838-4aae-b721-c57e646119bc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_1e16b184-6efc-49ab-bf85-1c5fc4f28ecf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-5"
      id="F_dbdb20ed-3ea9-452e-bac6-b7fc05670618"
      unitRef="U_USD">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-5"
      id="F_3a7e5c03-d40a-4bee-9482-8cc8a4a61a0f"
      unitRef="U_USD">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-5"
      id="F_6ff2641b-30c0-4f4c-b972-5ebafad0109a"
      unitRef="U_USD">4900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_6377048a-3238-4164-8bc2-9eead9d134ac">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="INF"
      id="F_7507b254-abdd-42d4-8cdd-8739928b5472"
      unitRef="U_shares">762772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_654a16e2-8083-4d9a-92ce-ca57cab55a7c"
      decimals="INF"
      id="F_ec99894c-69e7-4a9e-b922-a35cf643d669"
      unitRef="U_shares">242454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_c27007ad-ebb6-44be-807f-d03ae3fa80f8">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table shows restricted common stock activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.195%;"/&gt;
        &lt;td style="width:1.429%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.458%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.444%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.474%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;299,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;762,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;826,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_6ad92b9f-963d-493a-a1e4-49542d62bb26"
      decimals="INF"
      id="F_757cc1b4-6d8f-4dc5-9865-781d73172ed1"
      unitRef="U_shares">299248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_6ad92b9f-963d-493a-a1e4-49542d62bb26"
      decimals="2"
      id="F_e7fd0174-3f76-455b-8cfc-552eb2021f94"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="INF"
      id="F_697ff864-06d1-46e8-b372-256d42712658"
      unitRef="U_shares">762772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="2"
      id="F_0586f781-0a9e-4b86-98fa-76908db79dc9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="INF"
      id="F_6b2806f6-0dc3-443f-ba61-919eb7d5724b"
      unitRef="U_shares">83637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="2"
      id="F_3ac08a19-cce9-4351-9418-f3c9221cd92e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="INF"
      id="F_6ff7ef97-6800-4083-a5c0-18273f0c47eb"
      unitRef="U_shares">152118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="2"
      id="F_674a0491-4420-4927-b0bd-b144b5c72bc9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_14cab79b-31e9-441e-9110-e4bc26c0833c"
      decimals="INF"
      id="F_1fd111a9-c84b-4fc1-9bfe-045118ea0361"
      unitRef="U_shares">826265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_14cab79b-31e9-441e-9110-e4bc26c0833c"
      decimals="2"
      id="F_93d5324b-66a6-4a07-8f0e-0b4b22e3b6ea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="-5"
      id="F_303745bf-d96e-483f-b8fd-6909fb5a863f"
      unitRef="U_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_654a16e2-8083-4d9a-92ce-ca57cab55a7c"
      decimals="-5"
      id="F_40f02bf2-c492-49ed-a17c-e7b108ffb18c"
      unitRef="U_USD">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_14cab79b-31e9-441e-9110-e4bc26c0833c"
      decimals="-5"
      id="F_db8735ff-1d3e-49f5-a319-92e858a4b5e4"
      unitRef="U_USD">1200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      id="F_2930781f-ef58-4155-872f-2dd1b63fe188">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9404c746-39af-4f16-b76d-b8630bcb901d"
      decimals="-5"
      id="F_623a59e1-9284-4b61-a069-2558b3120467"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8fa40dbc-7f7b-4478-86f2-ad847e50f5fd"
      decimals="-5"
      id="F_cfbdf3d3-a29f-4c76-9736-964d6250cf23"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-5"
      id="F_4936fb73-2ab5-40c2-b77e-eb6927cd3feb"
      unitRef="U_USD">3600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-5"
      id="F_ea3c0538-d29a-4e49-8157-e0786f33f8a4"
      unitRef="U_USD">3400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_78e357e7-2fa3-4bf9-b9cc-0cb489b11c8c">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes equity&#x2011;based compensation expense within the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.667%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.143%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.451%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.289%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8114c460-4d06-4e71-8f72-16758968f429"
      decimals="-3"
      id="F_5f813732-f084-4356-a794-a61ca0eb52f6"
      unitRef="U_USD">1565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0754e8dc-f387-45d7-8ad5-2f37ecf370c9"
      decimals="-3"
      id="F_7c08d166-6551-47d5-ab87-ce0209adee8f"
      unitRef="U_USD">1373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_80b6d2b4-7e32-4f90-a5bf-55d9ff118805"
      decimals="-3"
      id="F_0b91141a-885c-430c-9807-15f65d0e647b"
      unitRef="U_USD">2074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7c6943e9-6e4c-48b4-ac4a-76f2723a410c"
      decimals="-3"
      id="F_f58a5cdd-057c-4d92-89ec-4cac67797608"
      unitRef="U_USD">1988000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_c374c748-33c5-41ca-ba29-6aaf36fe3f6e"
      unitRef="U_USD">3639000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_19e64af8-c793-4eee-8b26-c8d1d0c38c28"
      unitRef="U_USD">3361000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_8c0120b4-4e1e-4215-854d-b33dc684459b">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes equity&#x2011;based compensation expense by type of award for the years ended December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.548%;"/&gt;
        &lt;td style="width:1.504%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.155999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.491%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.302%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_fe7d4a4c-340f-4bfe-9353-91af7151de36"
      decimals="-3"
      id="F_fd8fb8a1-ba26-4e95-bd86-e45f2508aeff"
      unitRef="U_USD">3168000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_87720378-333d-485a-b610-abbe5ef1182d"
      decimals="-3"
      id="F_7e368374-129a-408b-9ca1-e1c84ee4b3ad"
      unitRef="U_USD">2969000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3ce653bf-490d-4819-8e5a-529c46c9a649"
      decimals="-3"
      id="F_a20833ca-71e9-4466-8a88-bafba27d449d"
      unitRef="U_USD">396000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_654a16e2-8083-4d9a-92ce-ca57cab55a7c"
      decimals="-3"
      id="F_47f00c78-b69c-4bf7-aa86-4c07159a71e8"
      unitRef="U_USD">334000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9404c746-39af-4f16-b76d-b8630bcb901d"
      decimals="-3"
      id="F_aa9c853f-0e7d-41a0-a6f8-1b77b53ccdc4"
      unitRef="U_USD">75000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8fa40dbc-7f7b-4478-86f2-ad847e50f5fd"
      decimals="-3"
      id="F_5eb19ed1-7f0a-419a-b12e-331a93b81e35"
      unitRef="U_USD">58000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_06262b22-3616-40b2-bf91-1b2aab1fac9d"
      unitRef="U_USD">3639000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_0e656356-8249-478b-8c8a-2d37c780ff58"
      unitRef="U_USD">3361000</us-gaap:ShareBasedCompensation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_e3206c20-69cd-4d6c-8f04-3cd0a2c2a86a">&lt;div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(10)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Roche Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2021, the Company entered into a Pilot Collaboration and Option Agreement (the Roche Collaboration and Option Agreement) with F. Hoffmann-La Roche Ltd (Roche Basel) and Hoffmann-La Roche Inc. (Roche US, and together with Roche Basel, Roche). Under the terms of the Roche Collaboration and Option Agreement, the Company and Roche will seek to collaborate to research and pre-clinically develop Synthetic Biotics for addressing an undisclosed novel target for the treatment of inflammatory bowel disease (the Product Candidate).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the Roche Collaboration and Option Agreement, Roche agreed to pay the Company, an upfront, nonrefundable technology access fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which the Company received in July 2021. In addition, the Company is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in milestone payments upon the achievement of certain success criteria. Following the research period, Roche holds an exclusive option right (the Option) to negotiate a definitive Collaboration and License Agreement (CLA) for further development and commercialization of the Product Candidate.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the Roche Collaboration and Option Agreement, during the term of such agreement, each party has granted to the other party a non-exclusive, non-transferrable, non-sublicensable, royalty-free right and license to certain intellectual property and know-how controlled by such party, solely as necessary for the party to perform its obligations under the Roche Collaboration and Option Agreement. The parties will establish a Joint Research Committee (JRC) to oversee and manage the execution of the underlying study plan for the Roche Collaboration and Option Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Roche Collaboration and Option Agreement includes various representations, warranties, covenants, indemnities, and other customary provisions. Roche may terminate the Roche Collaboration and Option Agreement without cause immediately upon written notice where certain success criteria have been met for parts of the study plan, or upon ninety (90) days&#x2019; prior written notice to the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company. Either party may terminate the Roche Collaboration and Option Agreement in the event of an uncured material breach of the other party.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The research and development will be performed by the Company for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;s according to three phases of research as defined in the research plan. The Company is eligible to receive milestone payments from Roche upon the achievement of success criteria for respective milestones.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed this arrangement in accordance with ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and concluded that the contract counterparty, Roche, is a customer. The Company identified the following material promises made by the Company to Roche at the outset of the arrangement: (1) a non-exclusive royalty-free research and development license; (2) research and development services for pre-clinical activities under the research plan; (3) implicit renewal options created by Roche&#x2019;s decision not to terminate the contract; (4) the Company&#x2019;s participation on the JRC; and (5) an exclusive right to negotiate a definitive CLA for further development and commercialization of the Product Candidate. The Company determined that the license and research and development activities were not distinct from one another, as the license has limited value without the performance of research and development activities. The Company&#x2019;s participation on the JRC was determined to be quantitatively and qualitatively immaterial and therefore is excluded from performance obligations. As such, the Company determined that the promises associated with the license and research and development services should be combined into a single performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company next evaluated the milestone payments relating to the three phases of research as defined in the research plan and the option to negotiate and enter into the CLA, to determine whether they provide Roche with any material rights. The Company concluded that the option was not issued at a significant and incremental discount, and therefore do not provide material rights. As such, they were excluded as performance obligations at the outset of the arrangement. If Roche elects to exercise the options, the additional consideration will be added to the transaction price and allocated to the resulting performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on these assessments, the Company identified one performance obligation at the outset of the Roche Collaboration and Option Agreement, which consists of: (1) the non-exclusive license and (2) the research and development activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the outset of the arrangement, the transaction price included only the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million up-front consideration received and which was allocated to the single performance obligation. The milestone payments that may be received are excluded from the transaction price until each respective milestone has been achieved. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2021, the Company began work on the research and development services for the first phase of the research plan and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upfront payment was recognized over the time of the first phase of the research plan. In September 2021, the Company completed the research and development services for the first phase of the research plan and achieved a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which was paid by Roche in November 2021. At this time, the milestone payment was allocated to a new performance obligation consisting of the underlying research and development services to be performed over the second phase of the research plan. In August 2022, the Company completed the research and development services for the second phase of the research plan and achieved a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which was paid by Roche in October 2022. At this time, the milestone payment was allocated to a new performance obligation consisting of the underlying research and development services to be performed over the third phase of the research plan. Upon the Company&#x2019;s completion of these activities and subject to Roche&#x2019;s termination right, the additional milestone payments based on the achievement of specific events outlined in the Roche Collaboration and Option Agreement will become due.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue associated with performance obligations under the Roche Collaboration and Option Agreement are recognized as the research and development services are provided using an input method, according to the full-time equivalents incurred. The transfer of control occurs over time and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#x2019;s consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022 and 2021, respectively, as collaboration revenue in the Company&#x2019;s consolidated statements of operations and comprehensive loss. Deferred revenue from the collaboration amounted to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022, all of which is included in current liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Ginkgo Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2017, the Company established a technology collaboration with Ginkgo. In June 2019, in connection with the issuance to Ginkgo of an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,340,771&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock and Pre-Funded Warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,548,117&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common stock (See Note 8), the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for its foundry services that will be provided to the Company over an initial term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The current and non-current balances relating to the prepayment of foundry services is recorded in prepaid expenses and other current assets and prepaid research and development, net of current portion, respectively, on the December 31, 2022 consolidated balance sheet. At December 31, 2022, the Company had remaining balances of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of current and non-current pre-paid research and development costs related to this transaction, respectively. Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <sybx:CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee
      contextRef="C_e8618276-8b30-4637-beb0-a8e46a028cc2"
      decimals="-5"
      id="F_995010e6-1ac4-4944-82ec-f6b2be19ace6"
      unitRef="U_USD">1000000.0</sybx:CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee>
    <sybx:PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria
      contextRef="C_e8618276-8b30-4637-beb0-a8e46a028cc2"
      decimals="-5"
      id="F_43065f2d-6e89-41e3-aeec-b04ec2ba82bb"
      unitRef="U_USD">5000000.0</sybx:PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria>
    <sybx:AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_a85a9217-f514-4770-b4de-172402868a5b">P2Y</sybx:AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod>
    <sybx:UpfrontPayments
      contextRef="C_e8618276-8b30-4637-beb0-a8e46a028cc2"
      decimals="-5"
      id="F_a2c78482-f505-4e7d-9219-0f21b6fc5c30"
      unitRef="U_USD">1000000.0</sybx:UpfrontPayments>
    <sybx:UpfrontPayments
      contextRef="C_e8618276-8b30-4637-beb0-a8e46a028cc2"
      decimals="-5"
      id="F_9c13a8f2-fd37-49a7-a318-a61aa0fad903"
      unitRef="U_USD">1000000.0</sybx:UpfrontPayments>
    <sybx:MilestonePayments
      contextRef="C_3282432a-339d-4c93-9545-b3ee55a0a3ee"
      decimals="-5"
      id="F_a7efdd48-40bb-4e2c-8a47-4e60a79f27c7"
      unitRef="U_USD">1000000.0</sybx:MilestonePayments>
    <sybx:MilestonePayments
      contextRef="C_83994bcc-897b-4ecf-9900-6f87c0a0397c"
      decimals="-5"
      id="F_b9e00254-169a-41e6-9b67-bcdb26aa18a5"
      unitRef="U_USD">1500000</sybx:MilestonePayments>
    <us-gaap:Revenues
      contextRef="C_a5e1f167-a526-4fc5-995f-8c2fa7bc03e0"
      decimals="-5"
      id="F_aaf20ca0-ace7-48f0-be92-e915ccc5e9c8"
      unitRef="U_USD">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_3d9937da-b5ee-4340-92e5-8a0477c4b960"
      decimals="-5"
      id="F_86a280aa-84c9-4e0f-b252-bc6ea7f7e387"
      unitRef="U_USD">1500000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4516b6b5-54fe-44c6-ab9c-eee027b01c2d"
      decimals="-5"
      id="F_709077db-54b0-4a0e-9c6f-663db03e4f62"
      unitRef="U_USD">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_73d91fb1-2e62-48f7-92de-e383722c15e2"
      decimals="INF"
      id="F_4a2f3616-bef4-4b59-a2f6-35ad6e291536"
      unitRef="U_shares">6340771</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7d128f60-ec2d-4e7e-ad00-15156530da9e"
      decimals="INF"
      id="F_b49bbeb6-1343-4e42-be8e-5cbd437b48f1"
      unitRef="U_shares">2548117</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <sybx:PrepaymentToRelatedPartyForCollaborationAgreement
      contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597"
      decimals="-5"
      id="F_291e8d99-006c-41f6-a014-878519db2c9b"
      unitRef="U_USD">30000000.0</sybx:PrepaymentToRelatedPartyForCollaborationAgreement>
    <sybx:RelatedPartyTransactionCollaborationAgreementInitialTerm
      contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597"
      id="F_120861f7-bb43-49eb-bbbf-e294d8161c68">P5Y</sybx:RelatedPartyTransactionCollaborationAgreementInitialTerm>
    <sybx:CurrentPrePaidResearchAndDevelopment
      contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72"
      decimals="-5"
      id="F_1c39d2d9-df46-4dd2-96b5-d7f15afd17ba"
      unitRef="U_USD">100000</sybx:CurrentPrePaidResearchAndDevelopment>
    <sybx:NonCurrentPrePaidResearchAndDevelopment
      contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72"
      decimals="-5"
      id="F_7c9a0507-0e73-446f-9eb7-423ffe8c65ce"
      unitRef="U_USD">8200000</sybx:NonCurrentPrePaidResearchAndDevelopment>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_c437b5a6-8c9d-48b2-9f6e-81fbefe833d2">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(11)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.517%;"/&gt;
        &lt;td style="width:1.069%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.334000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.747%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.334000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,725,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,329,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s potentially dilutive shares, which include outstanding stock options, unvested restricted common stock and potential shares issuable under the ESPP, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.669%;"/&gt;
        &lt;td style="width:1.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.609%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.737%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.854%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted common stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;826,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;299,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,247,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,500,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potential shares issuable under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f4283d2e-7ae0-40df-9c82-c9744cc8bbc5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.517%;"/&gt;
        &lt;td style="width:1.069%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.334000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.747%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.334000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,725,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,329,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_68b9bd3b-14ec-4511-a64a-538a9559f818"
      unitRef="U_USD">-66147000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_398dc519-db5a-4b00-9881-67b8dfa43c17"
      unitRef="U_USD">-60561000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="0"
      id="F_0aea2cb7-c071-45ec-ab52-81da3faefacb"
      unitRef="U_shares">71725479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="0"
      id="F_2b2d4d97-c70d-4d21-b406-02acdf74a864"
      unitRef="U_shares">71725479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="0"
      id="F_194760ed-302b-4559-9aa3-63145e6a54fb"
      unitRef="U_shares">55329711</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="0"
      id="F_a5924677-b584-490a-bd9b-4c68c1e858ae"
      unitRef="U_shares">55329711</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_62e48655-fc4e-4a27-8e51-43f45fbf29b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_33137879-9b14-44aa-bacb-e9b7487f6255"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_4a439428-8386-478b-be1f-d9184f923c51"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_9fbd87a0-c3bb-402b-b9d6-216b01a5ec36"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_403e1410-e07d-49c2-835d-83f3f5a43ada">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.669%;"/&gt;
        &lt;td style="width:1.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.609%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.737%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.854%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted common stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;826,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;299,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,247,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,500,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potential shares issuable under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_436ec13c-b090-47c3-b27f-abd9ac6ebda8"
      decimals="0"
      id="F_e35fb19a-111d-4215-8f8e-bec0b2c9dcf9"
      unitRef="U_shares">826265</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f81bc0ea-4cc8-4008-8667-3a9f04ab0640"
      decimals="0"
      id="F_5643a044-ffa7-45b6-b9b9-dfe4c58d700d"
      unitRef="U_shares">299248</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_640feb28-ca33-4b33-8050-74bd8f92c9c0"
      decimals="0"
      id="F_d5f729f6-6b39-4c46-9af2-baa96615a015"
      unitRef="U_shares">7247695</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bb7c3478-1f6c-45ea-b035-e3a9a00b30bd"
      decimals="0"
      id="F_7f1a671e-960c-4cb6-8a0c-25aee31ee8d5"
      unitRef="U_shares">4500913</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_634cb392-9161-4709-9f2a-a13f53a4e68e"
      decimals="0"
      id="F_7c3251e5-f12e-4239-bd5c-8f9befa44cfc"
      unitRef="U_shares">52648</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d51691b1-bfd1-4bf1-a65f-d5da006787a0"
      decimals="0"
      id="F_a7ca3a12-b3cf-4149-b1db-107075cdd2d0"
      unitRef="U_shares">21569</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_e234146c-4eef-4e76-9e83-75d02e6c13a7">&lt;div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(12)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, the Company recorded &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; income tax benefits for the net operating losses incurred due to its uncertainty of reclaiming a benefit for those losses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Deferred tax assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.101%;"/&gt;
        &lt;td style="width:1.721%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.721%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.222999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortizable intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortizable research expenditures &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right of use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.365pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.365pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Under the Tax Cuts and Jobs Act (TCJA), research and experimental (R&amp;amp;D) expenditures are capitalized and amortized under section 174 for tax years beginning after December 31, 2021. These costs are amortized for tax purposes over 5 years since the R&amp;amp;D was performed in the U.S. The unamortized balance of these costs is presented as a deferred tax asset in the table above.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s deferred tax assets, which are comprised principally of net operating loss carryforwards, and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance of approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was established at December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.802%;"/&gt;
        &lt;td style="width:0.969%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.863%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.982%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.385%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A roll-forward of the valuation allowance for the years ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.421%;"/&gt;
        &lt;td style="width:1.592%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.203999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increase in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had federal net operating loss carryforwards that may be available to reduce future taxable income of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal net operating loss &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;carryforwards, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million will expire on various dates from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. T&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;he remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;223.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of federal net operating loss carryforwards do not expire. The Company also had state net operating loss carryforwards that may be available to reduce future taxable income &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;289.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;illion for the period ended December 31, 2022. The state net operating loss carryforwards begin to expire i&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;n &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In a&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ddition, as of December 31, 2022, the Company had federal and state research and development tax credit carryforwards available to reduce future tax liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law which contained provisions that include a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% corporate minimum tax effective for taxable years beginning after December 31, 2022 and a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% excise tax on certain stock buybacks after December 31, 2022. The Company expects the impact of these provisions to be immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to Section 382 of the Internal Revenue Code of 1986 (IRC), certain substantial changes in the Company&#x2019;s ownership may result in a limitation on the amount of net operating loss (NOL) carryforwards and research and development credit (R&amp;amp;D credit) carryforwards that may be used in future years. Utilization of the NOL and R&amp;amp;D credit carryforwards may be subject to a substantial annual limitation under Section 382 of the IRC due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&amp;amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax. The Company has not completed a study to assess whether an ownership change has occurred, or whether there have been multiple ownership changes since its formation, due to the significant complexity and related costs associated with such a study. There could be additional ownership changes in the future that may result in additional limitations on the utilization of NOL carryforwards and credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognized any liability for unrecognized tax benefits as of December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company&#x2019;s policy is to record interest and penalties related to unrecognized tax benefits on the income tax expense line in the consolidated statement of operations. There are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; interest or penalties accrued at December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company files tax returns, on an entity-level basis, as prescribed by the tax laws of the jurisdictions in which it operates. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2019 to the present are open to examination under the statute.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company&#x2019;s net operating losses and other attributes generated in a closed tax year may still be adjusted to determine the amount of carryforward deduction available in an open year under examination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="INF"
      id="F_9335d409-115a-4f04-ab0e-074850985c51"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="INF"
      id="F_b017e75b-af46-409b-99ba-ab58971125be"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_eb1b94e0-b868-4402-91ff-76af2fbaf0a6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Deferred tax assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.101%;"/&gt;
        &lt;td style="width:1.721%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.721%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.222999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortizable intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortizable research expenditures &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right of use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.365pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.365pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Under the Tax Cuts and Jobs Act (TCJA), research and experimental (R&amp;amp;D) expenditures are capitalized and amortized under section 174 for tax years beginning after December 31, 2021. These costs are amortized for tax purposes over 5 years since the R&amp;amp;D was performed in the U.S. The unamortized balance of these costs is presented as a deferred tax asset in the table above.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_980fb483-5862-445a-afd4-016100e02b15"
      unitRef="U_USD">81803000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_a1bea7dc-2197-4092-b5a3-50ff3daa6ebb"
      unitRef="U_USD">76802000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_4d075375-f19c-4673-90c0-ac1748549d03"
      unitRef="U_USD">9118000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_a60f16a9-6f6e-4091-abab-94b57e118f62"
      unitRef="U_USD">7248000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_2e7cc162-79bb-4f7a-b7e0-5d08255e036c"
      unitRef="U_USD">127000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_363957bc-8312-42a6-86bd-5d734c662cc9"
      unitRef="U_USD">181000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_4b235969-9d35-493c-a41f-b16cc90207ad"
      unitRef="U_USD">888000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_45ca3f79-3751-4a24-bbfb-8d005bb192e8"
      unitRef="U_USD">591000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <sybx:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_9e3dceec-b8df-452b-9d35-f0328e1c12d1"
      unitRef="U_USD">5541000</sybx:DeferredTaxAssetsLeaseLiabilities>
    <sybx:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_f390e730-924a-49fd-a51a-45d43de8e95a"
      unitRef="U_USD">5618000</sybx:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_efd02e60-c1da-4560-a9ca-ac86c59557fe"
      unitRef="U_USD">2516000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_62c211c1-b153-4f46-8672-928e82aa9fac"
      unitRef="U_USD">2396000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_3bb16854-a60b-4bed-940f-17d3667daf92"
      unitRef="U_USD">1165000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_d435ebc5-7c65-43e0-91e4-6b010b2473c4"
      unitRef="U_USD">1197000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <sybx:DeferredTaxAssetsAmortizableResearchExpenditures
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_5154fc7b-67d1-47e6-ad1b-f94da79478e2"
      unitRef="U_USD">12000000</sybx:DeferredTaxAssetsAmortizableResearchExpenditures>
    <sybx:DeferredTaxAssetsAmortizableResearchExpenditures
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_b1376be1-f20e-47e5-bdac-d1d9dcc329ea"
      unitRef="U_USD">0</sybx:DeferredTaxAssetsAmortizableResearchExpenditures>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_60f53285-19f4-4c0f-893d-f3eb699a7e8b"
      unitRef="U_USD">363000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_0dcfc23e-1e54-4c50-9212-e41306c89435"
      unitRef="U_USD">238000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_b275234d-2b46-421f-a2d5-621bdeb95c14"
      unitRef="U_USD">113521000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_3ea5c7a2-2548-4f68-abc7-770a097f0041"
      unitRef="U_USD">94271000</us-gaap:DeferredTaxAssetsGross>
    <sybx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_53ead05f-a55b-4b5e-9269-ca90409b2c48"
      unitRef="U_USD">3922000</sybx:DeferredTaxLiabilitiesRightOfUseAssets>
    <sybx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_f3712324-022a-47ad-9884-73671d8086f9"
      unitRef="U_USD">3794000</sybx:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_2308abf7-764f-4650-bab5-054ff4493be6"
      unitRef="U_USD">3922000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_e8e2b991-ccec-448c-aaba-9e436df7cc07"
      unitRef="U_USD">3794000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_32a33a6c-a2c4-49e6-8124-d5ae77149901"
      unitRef="U_USD">109599000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_04d003fb-89a9-4ae9-ae9f-12b7f34c32d2"
      unitRef="U_USD">90477000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-5"
      id="F_f1b0ed9d-076f-4934-841c-fd9475db9ce1"
      unitRef="U_USD">109600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-5"
      id="F_298e8b7f-575f-4cbe-a89d-1bb60c2e9178"
      unitRef="U_USD">90500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_6eb58073-bca2-40d5-bb4d-f144726518c0">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.802%;"/&gt;
        &lt;td style="width:0.969%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.863%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.982%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.385%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_f94c4de7-2de0-4245-8919-eb2d237d468c"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_af5573ea-c01b-4772-9bc4-c3040d22eca6"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_ccaa02e6-e950-4f9e-979d-83e22c577349"
      unitRef="U_pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_3f6fb0b2-ad97-414d-a94f-efeae9ea461a"
      unitRef="U_pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_14514c74-1ebe-4121-9543-9d6e4f216c90"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_b5f21c40-0a94-4f9f-b6b4-180352228fc0"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_6f46e020-9b6a-4c6f-a263-d6a5aad02537"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_48b5dbbb-1d8d-4de4-9bd1-20a9c6658eb6"
      unitRef="U_pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_afd42e8a-6cac-465b-942e-0ce9b0f75328"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_707e8879-302a-461c-b05f-653760a7d079"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="2"
      id="F_2170fa76-9d2b-41e2-9556-a4bc3c53d26a"
      unitRef="U_pure">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_0db105f6-c45b-4e11-951d-2bbce8e4402f"
      unitRef="U_pure">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_deefaeac-ec0e-46b0-8311-eb19f0d137d4">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A roll-forward of the valuation allowance for the years ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.421%;"/&gt;
        &lt;td style="width:1.592%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.203999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.557%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increase in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_e011b182-2551-43d6-a123-7236839743a2"
      unitRef="U_USD">90477000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4ce13154-7826-4547-a938-f6040b13872f"
      decimals="-3"
      id="F_2da51c3b-8821-4102-ac75-1a8301882e7d"
      unitRef="U_USD">72791000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_442e4b88-e4a7-493f-873f-e27b64d443c3"
      unitRef="U_USD">-19122000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_a44801d1-b1d7-4634-9874-ef35f0ebd592"
      unitRef="U_USD">-17686000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_7b379277-dc72-46cf-b85e-3c83c9972104"
      unitRef="U_USD">109599000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="-3"
      id="F_25364eab-ff61-4a65-bda5-56705a12b87a"
      unitRef="U_USD">90477000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_d2ff957f-8810-4fc7-8b03-9624137f2f79"
      decimals="-5"
      id="F_f724a3d9-6e2d-461b-81d3-0875d9a3f097"
      unitRef="U_USD">302500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-5"
      id="F_e145490b-dcaf-4aa8-b93e-a0b7e1764cdb"
      unitRef="U_USD">302500000</us-gaap:OperatingLossCarryforwards>
    <sybx:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_d2ff957f-8810-4fc7-8b03-9624137f2f79"
      decimals="-5"
      id="F_97cee7bb-f4a8-4e00-84e5-31053f05d866"
      unitRef="U_USD">79400000</sybx:OperatingLossCarryforwardsSubjectToExpiration>
    <sybx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_23b05112-0191-4539-844d-dcff33882fec"
      id="F_6f520fb0-1c75-4baf-bd42-c0757cbc0c68">2034</sybx:OperatingLossCarryforwardsExpirationYear>
    <sybx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_261be9b1-a487-4761-8558-63f62fe17054"
      id="F_3766db4b-a0d4-4385-964b-a2789408dc95">2037</sybx:OperatingLossCarryforwardsExpirationYear>
    <sybx:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_d2ff957f-8810-4fc7-8b03-9624137f2f79"
      decimals="-5"
      id="F_41fe09d5-9239-4fa7-897b-d75ca7a3db7b"
      unitRef="U_USD">223100000</sybx:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e0dd3811-b7af-4902-afcd-ce7c054f5cb5"
      decimals="-5"
      id="F_1c4cde17-d25b-4537-aa56-366cb72feb0e"
      unitRef="U_USD">289200000</us-gaap:OperatingLossCarryforwards>
    <sybx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_d97b6644-79ff-4699-9f6b-e83cf66bd673"
      id="F_9391e572-a6a6-4787-b800-4dee1174ea0a">2029</sybx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_794b0fde-85f9-4229-b743-26bedc55e777"
      decimals="-5"
      id="F_76d43021-7601-4fb6-a0cb-bfc29a503c48"
      unitRef="U_USD">5900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0558df53-fc4c-4356-aa92-1218af4ad35e"
      decimals="-5"
      id="F_f69b5424-f94c-4b3c-a8ac-7f99243426c1"
      unitRef="U_USD">3600000</us-gaap:TaxCreditCarryforwardAmount>
    <sybx:CorporateMinimumTaxEffectPercentage
      contextRef="C_8caafedd-e06d-4a10-aa7a-0b8fa55c8b9c"
      decimals="2"
      id="F_259c8512-2c23-42db-a787-3b0dbe1b8903"
      unitRef="U_pure">0.15</sybx:CorporateMinimumTaxEffectPercentage>
    <sybx:ExciseTaxPercentage
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="2"
      id="F_a5650328-22c9-43c3-b29a-47084d00dd85"
      unitRef="U_pure">0.01</sybx:ExciseTaxPercentage>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_b6910963-f588-4252-af89-97c3c3539461"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="INF"
      id="F_f0ffd8ac-55c6-4328-bfad-2787576c242c"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="INF"
      id="F_8f1b368a-fd97-46b2-b556-aa29f164bb08"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_da8109a1-72c4-4670-96f8-c0b906b48ea8">In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2019 to the present are open to examination under the statute.</us-gaap:IncomeTaxExaminationDescription>
    <sybx:ShareRepurchaseTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f33a15f1-1874-4e6f-b3f2-41aeb20d6d59">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(13)   Share Repurchase&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 25, 2022, the Company entered into a definitive share repurchase agreement with a stockholder, as part of a privately negotiated transaction, to repurchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,196,889&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock held by them for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, or $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. This repurchase was completed on November 28, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Repurchased shares are held as treasury stock at cost until they are retired or re-issued.  There were no retirements or re-issuances of treasury stock during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</sybx:ShareRepurchaseTextBlock>
    <sybx:RepurchaseOfCommonStock
      contextRef="C_be0c663b-cd69-4808-83ec-81ad0fa98a39"
      decimals="INF"
      id="F_11092bb3-3b4a-4dd3-b33d-13178a4a6bb0"
      unitRef="U_shares">4196889</sybx:RepurchaseOfCommonStock>
    <sybx:AggregatePurchase
      contextRef="C_be0c663b-cd69-4808-83ec-81ad0fa98a39"
      decimals="-5"
      id="F_6645b6f1-d3fc-4b8b-8e45-067a4c08ffba"
      unitRef="U_USD">2500000</sybx:AggregatePurchase>
    <sybx:AggregatePurchasePerShare
      contextRef="C_be0c663b-cd69-4808-83ec-81ad0fa98a39"
      decimals="2"
      id="F_8d56a8c3-65cb-4516-8ae6-2f51dccf244e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.60</sybx:AggregatePurchasePerShare>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_c636d8bc-6ab8-4537-bf72-e51d4bcb4308">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(14)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2017, the Company entered into an agreement to lease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,346&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts. Annual rent is approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; lease commenced in January 2018 and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company has paid for tenant improvements of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Additionally, the Company has capitalized approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of landlord-funded tenant improvements. The Company was deemed to be the accounting owner of the tenant improvements primarily because it was responsible for project cost overruns, and as such, the amounts were recorded as a leasehold improvement. The landlord-funded tenant improvement allowance is being amortized as a reduction to lease expense ratably over the lease term. In conjunction with the lease, the Company established a letter of credit of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;secured by cash balances included&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;restricted cash. Variable payments based on our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. The Company has an option to extend the term by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and an option to terminate the agreement if a similar agreement is executed with the landlord or an affiliate of the landlord. Neither option is reasonably certain of exercise and both are excluded from the lease liability calculation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2018, the Company entered into an agreement (the First SOW) with Azzur Group, LLC (Azzur) whereby Azzur agreed to provide the Company with access to, and the use of, an approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square foot cleanroom space to be constructed in Waltham, Massachusetts (the Azzur Suite), for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months, from May 1, 2019 to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the Initial Term). In April 2021, Synlogic entered into a new agreement (the Second SOW) with Azzur which replaced the First SOW. Pursuant to the Second SOW, Synlogic was granted access to, and use of, the Azzur Suite for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, from May 2021 to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9ad71e03-2303-4ee4-883d-5ed6738ea62b;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the Second Term). On January 21, 2022, the Company entered into two agreements with Azzur. Pursuant to the first of the agreements (the Third SOW), the Company has agreed to pay Azzur $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to renovate and upgrade the cleanroom space at Azzur for the Company&#x2019;s expanded use. The second of the agreements (the Fourth SOW) replaces the Second SOW that the Company entered into with Azzur in April 2021. The Fourth SOW extends the term of the lease, for the period beginning January 2022 through March 2023 (the Third Term). In November 2022, the Company entered into a new agreement (the Fifth SOW) with Azzur that extended the term of the lease, for the period beginning April 2023 through December 2023 (the Fourth Term). The Fifth SOW contains two options to extend the lease, the first option goes through June 2024, and the second option goes through December 2024. The Company determined that the agreement contained an embedded lease because the Company controls the use of the Azzur Suite. Accordingly, the fixed and in-substance fixed consideration under the agreement was used to measure the ROU asset and lease liability at the effective date. The ROU asset and lease liability are subsequently remeasured to reflect the impact of each subsequent modification. As of December 31, 2022, the Company determined that it was reasonably certain to exercise the first option to extend the lease under the Fifth SOW, and thus was included in the lease liability calculation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases classified as operating leases are included in operating lease ROU assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheets. The operating lease right-of-use asset and operating lease liability represents the Binney Street lease and the Azzur Suite lease. Cash paid for amounts included in the present value of operating lease liabilities was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended December 31, 2022 and 2021, respectively, which is included in operating cash flows.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease cost for operating leases for the years ended December 31, 2022 and 2021 were (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.501%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:23.987000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.285%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The right-of-use asset for the operating lease is disclosed on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average remaining lease term and the weighted average discount rate for operating leases were:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.375%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.341%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.864%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.419%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2022 to the operating lease liabilities recorded on the balance sheet: December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.945%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:32.056%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease cost for finance leases during the years ended December 31, 2022 and 2021, and the finance lease liability at December 31, 2022, were not material.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sybx:RentableSpaceUnderLeaseAgreement
      contextRef="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0"
      decimals="INF"
      id="F_db05eacd-c2a3-44d7-9ec8-471eece86607"
      unitRef="U_sqft">41346</sybx:RentableSpaceUnderLeaseAgreement>
    <sybx:OperatingLeasesRentExpenseAnnualRentalPayments
      contextRef="C_e8fe0938-f51a-46c8-a3ca-196ff94642c0"
      decimals="-5"
      id="F_a2c2d959-6539-4c6b-a418-688f82e08410"
      unitRef="U_USD">3400000</sybx:OperatingLeasesRentExpenseAnnualRentalPayments>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_37a703b8-c41b-42c8-9707-370b726139cb"
      id="F_b833da7e-e17e-4915-8c2b-84d1b7946314">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <sybx:TenantImprovementInvestmentObligation
      contextRef="C_37a703b8-c41b-42c8-9707-370b726139cb"
      decimals="-5"
      id="F_58d88c28-da03-4672-923c-09737f8d2a90"
      unitRef="U_USD">2900000</sybx:TenantImprovementInvestmentObligation>
    <sybx:TenantImprovementInvestmentObligation
      contextRef="C_b35d2ba3-ee9d-4986-b9f1-a7a0e81af1d8"
      decimals="INF"
      id="F_e458ca5e-4f90-430a-a3a1-e8c87feb251c"
      unitRef="U_USD">6600000</sybx:TenantImprovementInvestmentObligation>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_37a703b8-c41b-42c8-9707-370b726139cb"
      decimals="INF"
      id="F_45b96467-0040-4d0e-852c-c5331817b51f"
      unitRef="U_USD">1000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_37a703b8-c41b-42c8-9707-370b726139cb"
      id="F_39d36217-ed9f-4dbc-b52a-985b5093a6ce">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <sybx:AccessAndUseOfSpaceUnderAgreement
      contextRef="C_91268588-0fb2-48c3-8afe-0148ee56a770"
      decimals="0"
      id="F_9d1e0f1a-6dde-4ba0-8964-98ebf16647ad"
      unitRef="U_sqft">700</sybx:AccessAndUseOfSpaceUnderAgreement>
    <sybx:TermOfAgreement
      contextRef="C_91268588-0fb2-48c3-8afe-0148ee56a770"
      id="F_660b11c4-b5f6-4a2f-88b8-7210739ff464">P44M</sybx:TermOfAgreement>
    <sybx:AgreementExpirationDate
      contextRef="C_60a114fa-eeba-4606-ada0-5fecd8dae2ac"
      id="F_ed0778e4-0699-45f3-a459-673440397135">2022-12-31</sybx:AgreementExpirationDate>
    <sybx:TermOfAgreement
      contextRef="C_e3e7babb-b939-40de-97da-4a92ec952e88"
      id="F_fc072a4d-5a06-48b7-9738-6410aa472f06">P20M</sybx:TermOfAgreement>
    <sybx:RenovateAndUpgradeExpenses
      contextRef="C_489afa5b-74fd-452f-b937-8e7dab8a46e6"
      decimals="-5"
      id="F_4a27e323-6641-4f59-938d-363469c734f8"
      unitRef="U_USD">700000</sybx:RenovateAndUpgradeExpenses>
    <us-gaap:OperatingLeasePayments
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-5"
      id="F_a6f20e79-0423-44b0-a225-006d6814b678"
      unitRef="U_USD">5500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-5"
      id="F_938e2a6d-1f0b-4dd6-b5ba-7577885995ee"
      unitRef="U_USD">4400000</us-gaap:OperatingLeasePayments>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_3e0f8696-39dc-4d95-8d2e-25c26688e082">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease cost for operating leases for the years ended December 31, 2022 and 2021 were (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.501%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:23.987000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.285%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_97a2c0a3-520c-41eb-9a79-9442492f64f7"
      unitRef="U_USD">4812000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_a0e8c57b-ec5d-427a-be11-78278f47938e"
      unitRef="U_USD">3824000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_562fa081-821e-40c4-942d-24cce741aa0a"
      unitRef="U_USD">1409000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_7ac88890-b5c9-4058-8a0a-962da42cab61"
      unitRef="U_USD">1500000</us-gaap:VariableLeaseCost>
    <sybx:OperatingAndVariableLeaseCost
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-3"
      id="F_47e1062f-aec0-4450-b195-7535aee598d6"
      unitRef="U_USD">6221000</sybx:OperatingAndVariableLeaseCost>
    <sybx:OperatingAndVariableLeaseCost
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-3"
      id="F_4d452a31-375d-47b6-8301-5fc50062d203"
      unitRef="U_USD">5324000</sybx:OperatingAndVariableLeaseCost>
    <sybx:LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_174de797-254d-4e4b-989c-29f3c14923b7">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average remaining lease term and the weighted average discount rate for operating leases were:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.375%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.341%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.864%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.419%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sybx:LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="3"
      id="F_8f0ba1f3-0d7b-4af7-a84c-a18cbc15c4a6"
      unitRef="U_pure">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      decimals="3"
      id="F_8759ee92-61f1-460d-8968-b67e04653a23"
      unitRef="U_pure">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      id="F_a660a9db-ce13-4457-9106-94b72bdef448">P5Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_81e01642-a38b-4bc0-a42d-3b02ce2dc640"
      id="F_982ec5f3-ef9b-497e-b3ab-1d2a1d1f3697">P6Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <sybx:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_f17d4353-8c87-46e3-aa6f-1a2e618aa0fc">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2022 to the operating lease liabilities recorded on the balance sheet: December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.945%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:32.056%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sybx:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_8c835392-6aa2-4029-af61-8b1890cedf85"
      unitRef="U_USD">5626000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_7adacbc9-18d0-46dd-a1d6-ec67b0b4a138"
      unitRef="U_USD">4749000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_e3cfc9a4-91fd-4460-aac9-aea2c7dc3795"
      unitRef="U_USD">3792000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_21866b66-e101-4319-9b9a-6bfb97beea14"
      unitRef="U_USD">3905000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_c6f40df2-24dd-41f0-804b-47fd7b8f9503"
      unitRef="U_USD">4022000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_c18012df-d6bd-421c-8071-caa28f3f2f1e"
      unitRef="U_USD">2667000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_65dbd057-8756-423e-9779-4fd5c6beec99"
      unitRef="U_USD">24761000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_06792c8e-f9f0-4cda-800e-1c60935dfc0e"
      unitRef="U_USD">4480000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_c2f4221e-9beb-4fd8-b606-9bbce11c8d21"
      unitRef="U_USD">20281000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_2c2596dc-a5ed-404c-82d2-4ef047d0e756"
      unitRef="U_USD">4152000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0aacc6bd-0d04-44b8-8186-fe720001fc8e"
      decimals="-3"
      id="F_ccbf4886-0f01-43e3-9508-6f80187299b0"
      unitRef="U_USD">16129000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_6dae8846-ace5-4c33-9e34-dfa19606c019">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(15)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_217f23cb-6a58-4444-8451-2da1c7a39139">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(16)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee Benefits&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a defined contribution 401(k) plan for eligible employees. Employees are eligible to participate in the plan beginning on their date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation. The Company started to match employee contributions effective January 1, 2019. The Company matched &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the employee contributions to the 401(k) plan up to a maximum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the participating employee&#x2019;s eligible earnings, resulting in a maximum company match of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the participating employee&#x2019;s eligible earnings, and subject to certain additional statutory dollar limitations. In 2021, the Company increased the match to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the employee contributions up to a maximum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the participating employee&#x2019;s eligible earnings, resulting in a maximum company match of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the participating employee&#x2019;s eligible earnings, and subject to certain additional statutory dollar limitations. For the years ended December 31, 2022 and 2021, the Company made &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million contributions to the plan, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_c3c4febd-5bb8-42c3-974f-1da160403289"
      decimals="2"
      id="F_51cb5903-c87a-4569-b5bd-6cd3597dca52"
      unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_c3c4febd-5bb8-42c3-974f-1da160403289"
      decimals="INF"
      id="F_aa556252-3745-4201-8dfd-6f4e44f9314c"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_c3c4febd-5bb8-42c3-974f-1da160403289"
      decimals="INF"
      id="F_3bf159f1-001b-48f4-a1ad-6731a9992010"
      unitRef="U_pure">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="2"
      id="F_492143f5-ac48-4313-88a4-161d21ef8e80"
      unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="INF"
      id="F_5d3e21d5-fb01-43eb-9299-23fab04a9fc2"
      unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="INF"
      id="F_0b15f1e3-39e4-4197-9df3-7a67cd056a30"
      unitRef="U_pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      decimals="-5"
      id="F_a580f165-011c-495b-8ed2-1d60eba21f66"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_dc33945e-b2f0-4255-915f-8f700291d29e"
      decimals="-5"
      id="F_44f5daf0-85d2-440f-8bfb-b34f83b7f128"
      unitRef="U_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_53c113d0-26f8-4751-aac3-06cad9a19780"
      id="F_59aaaa3b-437f-4e79-aa34-29703c46f5b1">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;(17)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Related-Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of December 31, 2022, Ginkgo owns &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,340,771&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s outstanding common stock.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;See Note 10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreements&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Ginkgo Collaboration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the agreement the Company made a prepayment to Ginkgo of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for its foundry services that will be provided to the Company over an initial term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. At December 31, 2022, the Company had remaining balances of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of current and non-current pre-paid research and development costs related to this transaction, respectively. For the year ended December 31, 2022, the Company used $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the pre-paid research and development expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72"
      decimals="INF"
      id="F_629dc26d-2575-4b8d-a14f-39b360b614b8"
      unitRef="U_shares">6340771</us-gaap:CommonStockSharesOutstanding>
    <sybx:PrepaymentToRelatedPartyForCollaborationAgreement
      contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597"
      decimals="-5"
      id="F_ef86328b-1c6d-4c6b-a166-b329d0067d7a"
      unitRef="U_USD">30000000.0</sybx:PrepaymentToRelatedPartyForCollaborationAgreement>
    <sybx:RelatedPartyTransactionCollaborationAgreementInitialTerm
      contextRef="C_43b99e43-1090-41dc-af3b-41ef21ba7597"
      id="F_78d5c825-e4a3-4226-9964-e0118eb8b067">P5Y</sybx:RelatedPartyTransactionCollaborationAgreementInitialTerm>
    <sybx:CurrentPrePaidResearchAndDevelopment
      contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72"
      decimals="-5"
      id="F_5cf99ec0-deeb-46d5-819a-1a1fe4640ec0"
      unitRef="U_USD">100000</sybx:CurrentPrePaidResearchAndDevelopment>
    <sybx:NonCurrentPrePaidResearchAndDevelopment
      contextRef="C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72"
      decimals="-5"
      id="F_e6a1c667-6163-4804-a799-70db579bc3a6"
      unitRef="U_USD">8200000</sybx:NonCurrentPrePaidResearchAndDevelopment>
    <sybx:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_a3f01399-c70d-4fc2-8fb9-042eab32457b"
      decimals="-5"
      id="F_19d50bf5-9820-49c7-96b7-34dfed6744d5"
      unitRef="U_USD">2900000</sybx:PrepaidResearchAndDevelopmentExpenses>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_5154fc7b-67d1-47e6-ad1b-f94da79478e2"
          xlink:label="F_5154fc7b-67d1-47e6-ad1b-f94da79478e2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b1376be1-f20e-47e5-bdac-d1d9dcc329ea"
          xlink:label="F_b1376be1-f20e-47e5-bdac-d1d9dcc329ea"
          xlink:type="locator"/>
        <link:footnote id="FNT_4518ba34-7fe5-4a26-958e-210cdeeec538" xlink:label="FNT_4518ba34-7fe5-4a26-958e-210cdeeec538" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.365pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Under the Tax Cuts and Jobs Act (TCJA), research and experimental (R&amp;D) expenditures are capitalized and amortized under section 174 for tax years beginning after December 31, 2021. These costs are amortized for tax purposes over 5 years since the R&amp;D was performed in the U.S. The unamortized balance of these costs is presented as a deferred tax asset in the table above.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5154fc7b-67d1-47e6-ad1b-f94da79478e2"
          xlink:to="FNT_4518ba34-7fe5-4a26-958e-210cdeeec538"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b1376be1-f20e-47e5-bdac-d1d9dcc329ea"
          xlink:to="FNT_4518ba34-7fe5-4a26-958e-210cdeeec538"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>97
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MN(SZ?U-J55RE_[>/\O^3V*,, E-ZLSQ+(Q/T2S"Y%&(!DU<[7QG9#ZB/QDJ
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M+GAM;*U:;7/;-A+^*QA=YRZ9B2("H"C*9VO&<=JY?FCCL=OK9YB$)%Y(0@5
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M%^#^RH.@^C]\P/BZ\_I_4$L#!!0    ( .$S?58^K"< ^R$  &EQ   8
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M5E*@29W-]EI=>Q&8!%73##25ML2X8TQE!M/ACO!IO*AUP$+;1G]!6U<F"5<
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MSQYRR,Q_Z$U'+]/;F+XW!_H3>]<HBP/@]ZT!/I(/N$!XN^)/_P-02P,$%
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M0N/I?!: 'IAT$*SJ/'MME24N],N&?CZHG0/9:Z7LL^ 2C+^S];]02P,$%
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M'@#,#**0*;?N3&IC6<;7N*#@,&TF30K3UH)K-M.J0,$C](.JY@N,N&'D4#
M=40N#I(!1YAI%4G.A3'.HA,)V*-?ED*CB_ 9C@B65M98$"/+>= JYQNE\%X6
MA<@DMP)8 0Q,!0UN:HIJG$A8R%1@@RD =%A\#U5P?":LT)!, 8.'-4F_54@7
M&/1!@FRK-)#K4\G^R@$_8(?/,U&3%A[$?C28#*+I( GRO>T;OBPKC9ZRX<V+
MG-DE'+U'P@5BSB$O6<)JQCA[Y%H*2T 13[9B,=V*10P*XWU'^#EBJ27%1!1X
MMD2 I9NCL:S!*S#-:IE:D.E'>6%[+ZI2VOHM%$@!P;P[*9-H$3@,X^Z1YTB)
M\,Z-7/HD')X"<:@%0<:[9^1P!7CH W:[(3628W9/4K=3$#NQX;5+#X>11F1E
M/7$'LE*59\AY.9.UE?7+!C:H;%4>07'7E+.#1D":*Y:Y6D,V=-;<53I=8%P[
M8S[>W]V=AEPC<CF7F"N$GT/,7(89FQ33H#0B&(\OS$[: 2> PTRJ*B2QSP+@
M'ZT@YB$&*I]205BUQ%5 T^^]:*DWFC2Y"&ZN'OZ 4,/Q&$V4>7-92$OOO=5H
M$IN+4F@P:[WM'R/0,T O)#+00RKD"2+)+5F%_ HI;6=@U( %@&"450_@ Y(F
M&V,8(.MR">5-#L9!\?@">@"%*_$J-+>2+G04%(:-/+>C* -#FQGQY1F=K5)J
M*@.88Z*R 4XH-TCY#@0#@S9*4'Z$)].HD0JA7F#!Y=;/=/3#Z03P$CU!K&8<
MPC2C4/7YC4;!->9\C>P0KM)BRK4H;X\Z)/-0^7L135==0:*V,I5+#-8"D*G=
M"(NR%--+!@6BKA*[&&\J:&TA%1((5B"&- M<P@U%XHD2U2>3Z3;PNZ&%IV^-
M(AKI[=D@N8)2)$ 5U]DT"MR6"VO#Q9-(*QH*^LM4:$?=>GFD;]# UEU%O5PC
MH%[7P42AA:&,0M7VO]&_O+;0CJ:C:#J9[)19LN?K*BQ@M\(_<6\4C9+I,:T#
ME_9HDE7$(;PG9KDPJR,J;$XZ/EE_<D6!O+"BS2+&#Z@(>U]H2F!7[ =4N);'
M]#;G4 WNTX7*434:<08]:XHK%RH3N4N%S;)#R&+8JF:2PPB#N9LG!]I&&K55
M$J-=*\TQ,VDN7,0$ZGGK'X<A:8429L[=-)S2^OBT%%04L2]CHT[BUZJO6K][
MQ,X\8E!;I?ER-L.M@2QA&L0JT\C[I#. A!UW>NS[C=Q'E4,0YMCB3Y(.9O3)
MH#.%$1]"([*6(L^(.7%R$7Y;Z*R9"ORW1%YW?B'_#1@V<7<[%%QA!UD'C ?4
M=%KW6\YJM+ZUD2UO9/T $@D>L* .-W.@]!P,#8. K27M3%U,0GM1&IFV_E9'
M(^0-G4J(4P+75:H3?MH*&B"=X DPCJ ^I4N[4)4!M<QIZU.C.8=LN^OYF VB
M8:\73>,^>\>&'3!T FZ#R\FD]1/V3]0EC_N3:#J=@F-&20WO1Z\:Y%O6'T9#
M>'4*(\9]%@]:[S$[0 ^?=7]4>B:DI6'3(43K< CCDLYT(^D%)1,VCI+!.!I-
MAZS?&0U!Q1A4[/=:OP%Q!)5949-0L4>DTPMRWNU(\L801PY.[4?]9!+UXIAP
M@JEC(.F[FG/@$TH./'AXXTWO-6FPF*553F79[V SB=5,8%_\(.P*TQTU/\'K
MSKVA5_ ^#X%^M(<A#N=KA',K&X;&. BB DQIU&<L&"K6A^T/&:+#XLD0.4-/
MXBB)>U$O&=4RWRB.VNREJZ*A=NXE6-?(9X@JV>R,Q?: TCZ:'9:?>\Y^1>8#
MEU!K]"0+MU-]!VR&K3..>(>9*6&'M+7*0NPV],)]G=L8$+Z/CJ-?IQ#2-&$%
M[,]#IX6:3,*377UNJ +NRZ22C"7S@(V82L,"N F ;4ZJYB6DR,S!>W9@,XI,
MJDIOVE8B)0<8?X0AS59@/F!350N''A0ZDGUOA]YY!I:.'%A-I%^G8*H@!VQ.
M3/ZH2%/J@5RRG;FT5/E3!< '>O(TK72'?=[L\]Z[\'%9_\-;71BQ\2B)QF/_
M9)!$@^&@T:HT-I1;<4HQY)E\B')[16V!F\9CTD)I.V]]/KR!W92N3=W9\+GE
M]3VIX^VT]6MP_<&2DDRGD&<GCJK]NHP$+*"(U)G[A$WZT:@_IHHPCEO-8A$/
MDRB.)U14)O&S:R;0&(RB9#2DF)U,CP9FZ#^_06#V]@*S]VT#,VXL\.K U,+5
M%XBV8\<5-;&^48Q._A\Q^NQARF:OA#M.J,%0#E'YS?)*^T.+E;0+\GT ;DM#
M!*8T^XC0Z:=\.BOPN\C>.89#XJ"@4(%?9MI^6"%'\% 6V5L2W>*:'U!P'Q2H
MXCWA3]2WSO*;!PMX,H\V:3I;()>)_4\!!RW ZK9#5.BD=B*A#VU\'0EO#K#=
MX/'6;*GS]JB5>'2L)1Y\T+'X\=.^[=/.T&UMMN'/["E>BR+2SC=)^T<DI5&Y
MS+A3!7[PL,*X)@>B;],#HF0M%OB1]1&/MXQY [\(D^W-@MOW'9K6VNSVH(;
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MW)=/MB! VF#S6G%3M%[5]860#CI0>> 7D(<#8=[Z(BB-"EF%\NCJ]EJ\&+U
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M1P+Q >D4E+)BRAE0K'>7IH*CT,B,V/=.%HUJ&9VS=B =#J4>8>R5H:?4@SY
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MH81+7[RI^:=04^.]*?GC0B& +0W ^YD!2\4OM$'[V[C+_P)02P,$%     @
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M&O[+^(N&S^8.JR5:2 ];90= )<*YJ6JA-X":T&(.4I,!X2^VU-)7#+@ 9A_
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M&!RM2MH7%N]TJ^P&$99HL);!S]) 6%Y,RRUBV2/R)Q#C'#Y8$QH/[TR%U6-
M2O8,1N4[HY;Y2>);+$<P&9]!GN7Y"=YD<'(2>9,G>'<8I$.Z2F%P$[Y<%SXX
MNA1_'O.XYTV/\SA1KGPK2IPGE D>W0,FB^?/QA?9FQ/63@=KIZ?HWW<D)Q''
M#7PQOG@)W\#A]P;AQNI6F TTPH/@2TV\"DHZ52>++J;/-!N_N'\)K1(&J!8
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MH\+HC0JNE$C@2):1N3I<VDUZ2C(I2%EEHWCX\@K6V6<"C>3TXNP%!NLSC!<
M<KV%&CA&##4K5ZA008Q# $#Q!]*<K*-14(H479$HK%U@B0P[*62V?KG!Q/;I
M=+<BCG-9+DPGK4^%T5\YBA<5;8QF'J1-S(2LH!Q:S#=<=.#1X9]F R&NHRJ
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M=V]R:W-H965T<R]S:&5E=#(V+GAM;,5636_C-A"]^U<,M(OM!A"L3UO>K&W
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M 95UH.];2=5O!W:!_N=C^1=02P,$%     @ X3-]5@;;[D$L P  8@<  !D
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MH@=:&EE"*%(AJ3C^^PY)674 QQ>+R\Q;2,YXMA/R214 FKQ6C*NY5VA=3X-
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MOA8:N"XI(_ *,BV5-;R2<''3F*=#'JF4E&OEOPEP6*(V)8U;E&<6#:J:B3U
MNU\W,D75R,(HG_;P#4&U =F]H][R6)GU@0^>&&))\! N<J=AUVH@L3\<3/PH
M&O=^.NJ#*)N'ECK&-Y[[?C^>^&$4]:X/ MT-K@[A*Q1(AK$_&DQZ#T+C<0S]
MKY@S'H_(J<<4')5Z!7)K&YI"UH9K5_7=:M<SKURK^!_N&NX=E=L2G3#(,36\
M' \](ET3<Q,M:MLX-D)C&[+# OL^2!. ^[G .VPGAJ#[)TG^ 5!+ P04
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M$T96N:.]R!^%,5X'T]B;9TI;\9V&'/-JN=P(FG<6^F$\HNMT_$2&NIKK9%O
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M<!IC(E5/TGIC9.F&T5(:'&UNF>/'!Y0-P/N5E.9I8^=;^SE+_@)02P,$%
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MU[NL.#H.!\V.C8B'5<1#;\3O),W4 J0R:9@J!;A@:!83SNB<<4RYN _GH#<
M&7D-:^ $4T+Q$)Z8:2R>^RZFO",?RU0!=K9#P&.*AE]0M(>;\XJ;<R\WMVE.
MF33IDT0)E4MP!>F%.#;(<T\(19 M#=?@XZ+BX\++QVO<L0 XZSE(:E,U!ZQ[
M3@C<,Z4AB\ L(I';DUD+;,9&U]%ZXQ]'RY6+ZLF3K*9>JR<R]K)B[.73&/L:
MDKS0QZXLOY^%.ZKVA^@$"E_))L&MSS1A"HMMJK $F_,'$H'$P@LC2*C>1K-A
MG&.R0 B0$5/.JFK:4E2-Z0AZ=<G9\Z<[D*E9I#8T9]'HMP]ZY &H=!T,DT.F
M87GXN5CQVSZ5EIU*//#Z]A:3>+;"=9E+HX8BK++A/H>88>X[(2R+))@TB,V1
M4-KN\KF9?K.B(PS*6)$/9@=V%Y0K<)9K?A^.7= '(MJ7#=IRHDET6!,=?@/1
MR'))*N8+*W)L3IUSMK1RYP1EI8HDL]O-2;%W]*,I]L?R#E/$1. 9F3V@YY'
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MQP1H#-)TP-\70NCMBQF@NI$>_P=02P,$%     @ X3-]5F(&AG7< @  <P@
M !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULK59=3]LP%/TK5H8FD#J2
M)DT+K(T$S:;M85)%87N8]F"2V\;"L8OMM.S?[]H)60NAJA OC3_..?6Y]^8Z
MXXU4][H ,.2QY$)/O,*8U87OZZR DNI3N0*!.PNI2FIPJI:^7BF@N2.5W ^#
M8.B7E DO&;NUF4K&LC*<"9@IHJNRI.KO%7"YF7A][VGAFBT+8Q?\9+RB2YB#
MN5W-%,[\5B5G)0C-I" *%A/OLG^1QA;O #\9;/36F%@G=U+>V\GW?.(%]D#
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M[?Y"LDWQ,.H]DY*EQ<LU)0O*<P'U^9(Q^?TB?[[U\#SSY']02P,$%     @
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M7 >HYVO&Y,N%/ORI#_L6_P-02P,$%     @ X3-]5CD;;)%L @  S@4  !D
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MP 7M O#[4BF[W;@+AA&>_P902P,$%     @ X3-]5F*6[ "R @  B@<  !D
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M8 Z$*"7)<=>(&JU/9=@=/ZJ?Z>!E,"O,84[)31:+=&;X!HHAP1415W1[#DU
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MCV[)HVOET2_&'=JG@@5\DT9_ZP$9U*L1^V:V61^A5NRAA+H=KJ;+#J&0+?I
M8 WBYR7Q\_]*?,"E.C*5(^*A&=]%G#G6)X:UO:%BV#M/T!VC0J(Y2O+U@:L+
MWEU?[?(@>^4#@34$6Y2"+>R"U9=P3YT@5LBAFBRZ%<=UEJT)D@?-ZD&.BUL5
M!ZA;#1Z7)8]+*X\?='D64:#R18\>/^A*\>!+'WM6H*'L08)YD& ^$%A##3RI
MG,GDA5>A10> = 1%\T#1?"BTII0UDXGA%T5VS,'JX$[]Z:Z*BJ!Z)>NNBJ#Z
MU>225%R29UP8V<$'DTHZ?.$>5B';]*'0FO17UAA;3=LS+(_L#0Z6Q-[]^P72
M\GZ!A!</KI! .^9#H35UJ]PPMMOA7W)+VRL J(TMT.J%9NZ2^9RT9T4WCDS)
M=#9MEYOG<+.XLK/8[F>_:W5IQQS,:(^C7;9O#/0%.1TNG\/1XLK28KNG?6Q9
M:4\?3!LDF@>*YD.A-86H+"Z>O_32$M3T@J)YH&@^%%I3RLK\8KO[O91R3],@
M6U(&^?R29G[IZW/(1'G[LMBYVXM@J^5$NYBF1[F^O7<V[:T.UJ]K?O'$=4G;
M(_?$38D[<]IE[#EL,JY\,K8;9?]JO>[E#-06@Z)YH&@^%%KS457EC,E+.V,"
MZHQ!T3Q0-!\*K2EEY8R)W1E?IH%@IB!%*4KWR;4N6;J0%0],Z8%&,;V.&;KA
M D7WE>ZUCLTCWO1JUW6Z[M)=+A;-*G)A[]E@52#1?"BTIBJ5QR9VC[UFPCSQ
M-D_-M!IA) .^UW/'J% ^#RLN, \50WL+@V=0CH9Q3=3),9ZUKA^@C?I0:$T1
M*J=-[%9U75ZK1:1'/=7SP9CJFC"U&TJ/B %JL0NTEAB+CAB@]AD*K2E&99^)
MW3Y_EPVT8PZF?=IQ>/,.Y]V86:ON^5"]:C)9&6KRB*'68Q3]\^@C!CO*8.X@
MT3Q0-!\*K:E'9<J)^]*+*5!;#XKF@:+Y4&A-*2M;3^Q/?Y_)"]I;':S?_&E>
M$+15'PJMJ4SETHG=I9OW!LW;:;->?D&]-BB:!XKF0Z$U5:B,.UF^=*D#O04
MBN:!HOE0:,T7-*M; ([5E[8<2N$7^5Y)1=,P2C>]+UV"FGI0- \4S2_06BOT
M2;5:;+)>N77G?W?K3M>M.]/%=-E^J?'"WK7!?(/:=2BT7)9Q[77VA(E-]AV!
M1)D'S]_H+O>6WRJ<9V_HM_9?X!,__^*@@LD_@'A/Q29*)8K9C8:<',\U_R+_
MIB#_H?@N>VG^FBO%DVQSRZA>19@ ??R&<W7_PS10?MFQ^A=02P,$%     @
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M*(XL:MM#*V9ATIM.LK%[/IVD&QF%"=YS$)LX9OSI&J-T=]DCO>>!S^%R)?6
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M#>KZ(DWE\XD.4/YW,OT/4$L#!!0    ( .$S?5;P:R2;H (  .0%   9
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M$#N.FF,51!BGWZ:"&"O*6B%8,8V%@*3Y4!J%T@(H+4313+&XE5C<ES%*E>U
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MC!67,:O5"]22AM)\*(U":0&4%KJ'YGOOJ%Z\RH_V['YTV9ELQ%*[8K<CF@H
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M%V&J9?TRJ"=:E/9R?10:KVH[S/ Q!=(8X/Y2"/TR,1]HGV>3OU!+ P04
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M=Y^_[WQGWW MU2^= B!YS+C0(R=%S"]=5T<I9%1W9 ["?$FDRBB:J5JX.E=
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M9*!L .XOI32[B?U <S4FOP%02P,$%     @ X3-]5B4)]V=A @  ?@4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULE911;YLP$,>_RHE54RI5@= D
M2SN"E+::EH=N4:-L#],>'+B 58.9[22=U ^_LR&(3K3:7O"=[?O?[XS/T5&J
M1YTC&G@J1*GG7FY,=>W[.LFQ8'HH*RQI92=5P0RY*O-UI9"E+J@0?A@$4[]@
MO/3BR,VM5!S)O1&\Q)4"O2\*IG[?H)#'N3?R3A,//,N-G?#CJ&(9KM%LJI4B
MSV]54EY@J;DL0>%N[BU&US<3N]]M^,;QJ#LVV$JV4CY:9YG.O< "H<#$6 5&
MPP%O40@K1!B_&DVO36D#N_9)_9.KG6K9,HVW4GSGJ<GGWLR#%'=L+\R#/'[&
MIAX'F$BAW1>.S=[ @V2OC2R:8"(H>%F/[*DYAT[ ^+6 L D('7>=R%'>,</B
M2,DC*+N;U*SA2G71!,=+^U/61M$JIS@3KW.F$!ZPVJLDI^I@L$A3;@^,"5B6
M]5\G[QP&=V@8%_H<SL ';>,T\!(V)3?Z@B;)ON="T&8=^8;8; 8_:3AN:H[P
M%8XO\C"$<'(!81"&L%G?P>#L1:9Z>"GL4[%MQ6%;<>@R7?YKQ3\66VT478^?
M?=BUV+A?S+;,M:Y8@G./>D*C.J 7OW\WF@8?WT"];%$OWU*/.Y!?=W KBX+N
M\=K(Y!$&2[)L)>?PW'LV-7VM/W'ZMC\/\7AT-9W-KB+_T ,V;L'&;X(MLDQA
MQ@S"Z@3X#&=] +7.M ,0#B?]R2=M\LG_)E^AJD_#8K1WIH^GEK[J\ 3#Z5\\
M?J>=[,MTSU3&2PT"=Q05##^0B*J[O7:,K%R';:6A?G5F3@\D*KN!UG=2FI-C
MF[9]<N,_4$L#!!0    ( .$S?58 [Q5U<08  !DW   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8T+GAM;+6;76_;-A2&_PKA#4,+9+$E?Z698\"Q/M8AV8ID
MW2Z&73#2L2U4$E62LM.B/WZ4Y$A60M/1<-J+1I)U'I(Z+ZC#5])LQ_@GL0&0
MY#&)4W'5VTB97?;[(MA 0L4YRR!5OZP83ZA4NWS=%QD'&I9!2=RW!X-)/Z%1
MVIO/RF,?^'S&<AE'*7S@1.1)0OF7:XC9[JIG]9X.W$7KC2P.].>SC*[A'N3'
M[ -7>_V:$D8)I")B*>&PNNHMK$O?'A<!Y1E_1; 3!]ND&,H#8Y^*G??A56]0
M] AB"&2!H.K/%I80QP5)]>/S'MJKVRP"#[>?Z%XY>#68!RI@R>*_HU!NKGH7
M/1+"BN:QO&.[7V$_H+*# 8M%^3_95>>.U<E!+B1+]L&J!TF45G_IX_Y"' 0H
MCC[ W@?8SP+LR9& X3Y@^#S /A(PV@>,7ALPW@>,GX_AV* G^X#):UN8[@.F
M9;*JJUNFQJ&2SF><[0@OSE:T8J/,;QFM,A*EA13O)5>_1BI.SF] Y5&0G\DB
M#*-"'#0F[]-*XH54WC@@:12_G?6E:JV(Z0=[\G5%MH^0+7++4KD1Q$U#"#7Q
MSHEXVP#HJV'68[6?QGIM&XF+C)^3X>",V /;TG1H:0[_+8]5N%6$6U/R\=XA
M;WY\2U;RIQ^LZ<4ON@&:>0X$3SS;?N)I,.[K,98!X[T:8UV81N6?N$HT/2>V
M<52MY UKH0Y+[O"H4(4 (*5>B0,BX%%6*O2?&W4F>2\A$?_J5%IA1WIL,=-?
MBHP&<-534[D OH7>7(U],M"-?8D)<S!A+B;,PX3Y2+"6:D:U:D8F^OR&/C!.
M)>-?"$U#PE:K* !2MD<D(P] XD)0(?EFDORUL9&N&JI@XQ)65 K;^<@:CB:S
M_O90')A-NI@P#Q/F(\%:XAC7XA@;Q?%'!DH;4;JN1* 4DN;J]L<AE3H1&&%=
M15#!I@<B&(X&Q;]G,L!LU,6$>9@P'PG6DL&DEL'$*(,_@2=J9JA$H$N\,;QK
MXLU]L0;D"U N=+>+$Y$V2<IR29=XS!%XF# ?"=9*_+1._/1$XE.:2A(E&6=;
M4.LKM9UN0<CDR Q@Q'45PO3%#&"_T\T F(VZF# /$^8CP5I"N*B%<&&N$D!*
MX,4<$'!0RR!=[HV$KKF_>)%[:Z#+/6:C+B;,PX3Y2+!6[M_5N7]W(O?%NN*,
ML'8Q<$;@,1(24E4H*EVP:JVA2D9X5 =UR]EK8SM=%6+NM.2Y[D[E_*\H%[/C
M'B;,1X*UA&$-&FMD8+Q>=Y#"3A6$\E2!8.9T3?V)7HV/5PBH_7!1:1XJS<>B
MM95Q8)I9J)-&H: HI5*O'F-;G=5C[OFQF0.U$RXJS4.E^5BTMG3L1CJV,0&+
M-8>JUH3'+.*5RQH>DX:1U5D:F#0'E>:BTKP3.:B]SM*DU(H$J3MMD31>IV4T
MQ>9+*C8DHU&H%B1!G(=0;!S,-D'Q^RIF.]UMX-H,[ZP:5,]S3SLL?<=C3>GK
M:DX<Z1P2#[5_/A:MG?C&KK3,?N4M%<5*Y%Z!HP $:6:+;V3Q]6O.B<]9GIV1
MFYNE-O6H3B4JS4&EN:@T#Y7F8]':(FIL36O\?1Z56*@6)RK-0:6YJ#0/E>9C
MT=KJ:=Q0RVPD+@(U\8CR<4DNRCJV>ER2IZ&:F>C!A&1Z8F)NI+.4,&D.*LU%
MI7E[VN'3H>GS6YZ/U61;(8UM:IWR3:OU<*T%K0!0S5)4FH-*<U%IWHEK/QH=
MM_E]K)ZT==&XJ);91KV#E&W52J::.[(UIR$4JQQ(!>@+5513%97FH-)<5)J'
M2O.MEV[TM%UHM_70.*N6V6_\'7;="UA4%Q65YJ#27%2:ATKSL6CMU[0:X]4>
M?)\"UD8U8E%I#BK-1:5YJ#0?B]963V/.VF:+\U7ER0F&/3A^FUV:8SOK M5Y
M1:5YJ#0?B];61>.\VHC.ZPG620=Q:09T%@FJV8I*\U!I/A:M+9+&>;7-SNLM
M?8R2/-%* M561:4YJ#07E>:ATGPL6EL?C4%KC[Y3:8+JS*+2'%2:BTKS4&D^
M%JVMGL:9M<UOG'9^X\S,ZZR:EV^=3B:Z]XY0FW51:1XJS<>B58+H'WR(DP!?
ME]]8"1*P/)75IP[UT?H[KD7Y]=*SX]?6Y=+2''>L2Z_Z2JO!5Q^-W5*^CE)!
M8EBII@;G4S4P7GV'5>U(EI6? 3TP*5E2;FZ AL"+$]3O*\;DTT[10/TUW/P_
M4$L#!!0    ( .$S?5811^VHD@(   8'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;*U576_3,!3]*U:8T";!\MFLE#;2VC*!Q,2TL?'L)K>-M<0.
MMMN.?\^UDV;]2,L>>$GLZWN.S[F)KX=K(9]5#J#)2UEP-7)RK:N!ZZHTAY*J
M2U$!QY6YD"75.)4+5U42:&9!9>$&GA>[)67<288V=B>3H5CJ@G&XDT0MRY+*
M/V,HQ'KD^,XF<,\6N38!-QE6= $/H!^K.XDSMV7)6 E<,<&)A/G(N?8'D]CD
MVX0G!FNU-2;&R4R(9S/YEHT<SPB" E)M&"B^5C"!HC!$*.-WP^FT6QK@]GC#
M?F.]HY<953 1Q2^6Z7SD]!V2P9PN"WTOUE^A\=,S?*DHE'V2=9/K.21=*BW*
M!HP*2L;K-WUIZK %\.,C@* !!/N Z @@; "A-5HKL[:F5--D*,6:2).-;&9@
M:V/1Z(9Q\Q4?M,15ACB=? >L@2(?R424E># M2)B3FP88TH3_%/(CPHDU8PO
M2)-_/@5-67&!P,>'*3D_NR!GA''R,Q=+17FFAJY&=68/-VV4C&LEP1$E?D!N
M!=>Y(E]X!MDN@8NV6F_!QMLX.,DXA?22A/X'$GA!T"%H\G:X?T).V)8ZM'SA
M$;[7(A:VB%TEJAFB;@9SH@>JHBF,'#RR"N0*G.3].S_V/G?9^T]D.V:CUFQT
MBGW?+$GQ5^HR7+-<61;3<59)U/?Q8ZVVC1PFA?T@:I-V!/9:@;V3 I^H9'16
MP#_TU22]K:W]R/NTIZ\CJ>=YW?KB5E_\Q@+B<2*KMZF-#PH5!^;?W5%[F-0+
M#ZKI;K64$N3"=EJ%&R^YKD]@&VV;^;7M87OQ,3;YNB>_TM0WQ"V5"\856IHC
MI7=YA064==>M)UI4MG'-A,8V:(<Y7E0@30*NSX70FXG9H+WZDK]02P,$%
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MAR2PI&NN'\3V!]1Z^H8O%ER5_V1;Q0Y"A\1KI456@W$&&<NK+WVI?=@#^*<
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M!B-\[8DRHRXO%,^+'/.1*\Q8B^(6: Q"5\#G:\[5ZX5NH/Y?8_X/4$L#!!0
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MU7MPYWT4KMY3X?J_E\/?4$L#!!0    ( .$S?5:7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ X3-]5OP3-"Y2!0
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MB&@VXTV,25DH8[;0QP5%L=?[/#$F9:&,V4(_I[8V&\_&7L*,LE#V.3-PP]9
MMEKOW&J+H0QC4A;*F"WT+R::I?E;Z<=EL^EL]HPQR5UFS!;:AOE7,YG8##;L
M F-2%LJ8+;2QD-O_3#$F9:&,V4+_O:S;\F),RD)9:Z%1>[$_.2[@B2M57,(M
M/)3GTN373C1_NDU-2=KL2UC4QIQ!V55U866QWHV\WDE]\@-02P,$%     @
MX3-]5I=W<N0L @  ]B@  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<\W:2T[C0!2%X:U$7@"5NJ] BS#J"5/$!JQ0>8@DCEQN ;OO* R28_6@)\AG
M9)4M7_^C3U;9CR]EWPZ[[EBWNU.=?1[VQ[ILML-P^I5276W+H:UWW:D<SU?6
M77]HA_.RWZ13NWIO-R7)?!ZIOYW1/#W>SIR]?IW*_TSLUNO=JOSN5G\.Y3C\
M8W#ZZ/KWNBUE:&:O;;\IP[))G_OKZ9HNAWQWGMS,GM^63?_\EILT=9! D$P?
MI!"DTP<9!-GT00Y!/GU00%!,'[2 H,7T0?<0=#]]T ,$/4P?E.<HXYP@:80U
M@=89N<X$7F<$.Q.(G9'L3&!V1K0S@=H9V<X$;F>$.Q/(G9'N3&!W1KPS@=Z"
M>@N!WH)Z"X'>,GK9)M!;4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;
M4&\AT%M1;R706U%O)=!;46\ET%M'FR4$>BOJK01Z*^JM!'HKZJT$>BOJK01Z
M*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01ZVVBSFT!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0&\??:PD
MT-M1;R?0VU%O)]#;46\GT-M1;R?0.U#O(- [4.\@T#M0[R#0.U#O(- [4.\@
MT#M0[R#0.T8_FQ#H':AW$.@=J'<0Z!VH=_RDWG7XVI=Z[?E>XT]!/TGU<+ZW
M7!]_67Z?1)P7%YS3;45]^@M02P,$%     @ X3-]5M9((R[W 0  *R@  !,
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M;%!+ 0(4 Q0    ( .$S?59IV@J5[@   "L"   1              "  :\
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M2P$"% ,4    " #A,WU6Y6X#OK("  "[!P  &               @('!%P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ X3-]5MWCHS3%
M!   =A,  !@              ("!J1H  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( .$S?587_%96]PD  (]J   8              "
M@:0?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #A,WU6
MS>&@_AH(  #%)0  &               @('1*0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ X3-]5J8;Z8N;"   ^A0  !@
M     ("!(3(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M .$S?58^K"< ^R$  &EQ   8              " @?(Z  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #A,WU6?34<MLH%   @#@  &
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M970Q,RYX;6Q02P$"% ,4    " #A,WU6W?7PS*L(  #!%P  &0
M    @($H<0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M .$S?59NS 98T@H  * @   9              " @0IZ  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ X3-]5HA*C\SL#   )R<  !D
M             ("!$X4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #A,WU615ML=Q0$  !0"0  &0              @($VD@  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .$S?591E?OF7@L
M +X=   9              " @8&6  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ X3-]5O"5<!$% P  L 8  !D              ("!
M%J(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #A,WU6
M([3FO[X)  !C&@  &0              @(%2I0  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( .$S?5;F[L]+Y (  +P&   9
M      " @4>O  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ X3-]5IBI58Y_ P  '@D  !D              ("!8K(  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #A,WU6IA;/:H8#   -"
M&0              @($8M@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( .$S?58(!F11/R,  %-[   9              " @=6Y  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ X3-]5G\Q(\&W
M P  G0@  !D              ("!2]T  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #A,WU6>=;)>'\#  "("   &0
M@($YX0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .$S
M?58&V^Y!+ ,  &('   9              " @>_D  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ X3-]5@+2/MBM @  ' 8  !D
M         ("!4N@  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #A,WU6>[$7&.\"  !<!@  &0              @($VZP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .$S?5;&SF/ZG@(  *D%
M   9              " @5SN  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ X3-]5D7LC#3F @  508  !D              ("!,?$
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #A,WU6S68Q
MCRH&  #D$   &0              @(%.]   >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( .$S?5;<J)[\Z@,  /H(   9
M  " @:_Z  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MX3-]5AB)8[VL!0  Y@T  !D              ("!T/X  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #A,WU6/9V(+=<#  !:"@  &0
M            @(&S! $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( .$S?59(CN'FN (  -H&   9              " @<$( 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ X3-]5K'LUG\X!@
MG1X  !D              ("!L L! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #A,WU68@:&==P"  !S"   &0              @($?
M$@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .$S?58;
M[MOX" ,  (0+   9              " @3(5 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ X3-]5D"<[0X/!P  VSP  !D
M     ("!<1@! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .$S?58Y&VR1; (  ,X%   9              "
M@0\N 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ X3-]
M5F*6[ "R @  B@<  !D              ("!LC ! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #A,WU6O5&VYU4)   *9P  &0
M        @(&;,P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( .$S?59GESY-Z (  (X*   9              " @2<] 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ X3-]5J^#QZG'!@  Y3$
M !D              ("!1D ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #A,WU6>N?LS3P#  #."   &0              @(%$1P$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( .$S?59(J-AU
M.04  $<9   9              " @;=* 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ X3-]5O!K))N@ @  Y 4  !D
M ("!)U ! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #A
M,WU6$<6NRFH#  "6#   &0              @('^4@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .$S?59U.^'E+P,  !X,   9
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M970U."YX;6Q02P$"% ,4    " #A,WU6HN )=;T&   <,   &0
M    @('#; $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M .$S?5;6;""<9P4  (D5   9              " @;=S 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ X3-]5AB<M <A P  E@D  !D
M             ("!57D! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " #A,WU6K)",P+L"   F!P  &0              @(&M? $ >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( .$S?58E"?=G80(
M 'X%   9              " @9]_ 0!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ X3-]5@#O%75Q!@  &3<  !D              ("!
M-X(! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #A,WU6
M$4?MJ)("   &!P  &0              @('?B $ >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( .$S?59&RJ>><P(  &<&   9
M      " @:B+ 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ X3-]5IDOF$TY P  H0P  !D              ("!4HX! 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #A,WU6BM\G]04#  #K"0
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M+G)E;'-02P$"% ,4    " #A,WU6_!,T+E(%  #-+0  #P
M@ %:G0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ X3-]5I=W<N0L @
M]B@  !H              ( !V:(! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ X3-]5M9((R[W 0  *R@  !,              ( !
M/:4! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $T 30 2%0  9:<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>167</ContextCount>
  <ElementCount>353</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Available-for-Sale Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities</Role>
      <ShortName>Available-for-Sale Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Equity-based Compensation and Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Share Repurchase</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchase</Role>
      <ShortName>Share Repurchase</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Available-for-Sale Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Equity-based Compensation and Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Available-for-Sale Securities - Summary of Available-for-Sale Securities Held (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail</Role>
      <ShortName>Available-for-Sale Securities - Summary of Available-for-Sale Securities Held (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Available-for-Sale Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Available-for-Sale Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail</Role>
      <ShortName>Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Schedule of Valuation Allowance - (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail</Role>
      <ShortName>Income Taxes - Schedule of Valuation Allowance - (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Share Repurchase (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails</Role>
      <ShortName>Share Repurchase (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchase</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Leases - Components of Lease Cost for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail</Role>
      <ShortName>Leases - Components of Lease Cost for Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail</Role>
      <ShortName>Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail</Role>
      <ShortName>Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Employee Benefits - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail</Role>
      <ShortName>Employee Benefits - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sybx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Related-Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related-Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. sybx-20221231.htm 4566, 5745</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. sybx-20221231.htm 5430, 5434, 5745, 5749</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. sybx-20221231.htm 6330</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, sybx:AgreementExpirationDate, us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted, us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect, us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement, us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend, us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate, us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract -  sybx-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="sybx-20221231.htm">sybx-20221231.htm</File>
    <File>sybx-20221231.xsd</File>
    <File>sybx-20221231_cal.xml</File>
    <File>sybx-20221231_def.xml</File>
    <File>sybx-20221231_lab.xml</File>
    <File>sybx-20221231_pre.xml</File>
    <File>sybx-ex10_32.htm</File>
    <File>sybx-ex21_1.htm</File>
    <File>sybx-ex23_1.htm</File>
    <File>sybx-ex31_1.htm</File>
    <File>sybx-ex31_2.htm</File>
    <File>sybx-ex32_1.htm</File>
    <File>sybx-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img119790510_0.jpg</File>
    <File>img119790510_1.jpg</File>
    <File>img119790510_10.jpg</File>
    <File>img119790510_2.jpg</File>
    <File>img119790510_3.jpg</File>
    <File>img119790510_4.jpg</File>
    <File>img119790510_5.jpg</File>
    <File>img119790510_6.jpg</File>
    <File>img119790510_7.jpg</File>
    <File>img119790510_8.jpg</File>
    <File>img119790510_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="599">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sybx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 599,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 167,
   "dts": {
    "calculationLink": {
     "local": [
      "sybx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sybx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sybx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sybx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sybx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sybx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 555,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 11,
    "http://www.synlogictx.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 16
   },
   "keyCustom": 60,
   "keyStandard": 293,
   "memberCustom": 20,
   "memberStandard": 29,
   "nsprefix": "sybx",
   "nsuri": "http://www.synlogictx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:AvailableForSaleSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Available-for-Sale Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities",
     "shortName": "Available-for-Sale Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:AvailableForSaleSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Equity-based Compensation and Equity Incentive Plans",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans",
     "shortName": "Equity-based Compensation and Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Collaboration Agreements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:ShareRepurchaseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Share Repurchase",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchase",
     "shortName": "Share Repurchase",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:ShareRepurchaseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Employee Benefits",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Related-Party Transactions",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "sybx:AvailableForSaleSecuritiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Available-for-Sale Securities (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables",
     "shortName": "Available-for-Sale Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "sybx:AvailableForSaleSecuritiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Equity-based Compensation and Equity Incentive Plans (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables",
     "shortName": "Equity-based Compensation and Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Nature of Business - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalCashAndCashEquivalentRelatedText",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalCashAndCashEquivalentRelatedText",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_e08b8831-bd01-48c6-a8f9-50a61b822302",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_e08b8831-bd01-48c6-a8f9-50a61b822302",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_d4d75229-eaf1-4029-9ef7-4b3edaa0a833",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_d4d75229-eaf1-4029-9ef7-4b3edaa0a833",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "sybx:AvailableForSaleSecuritiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Available-for-Sale Securities - Summary of Available-for-Sale Securities Held (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail",
     "shortName": "Available-for-Sale Securities - Summary of Available-for-Sale Securities Held (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "sybx:AvailableForSaleSecuritiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "sybx:AvailableForSaleSecuritiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Available-for-Sale Securities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail",
     "shortName": "Available-for-Sale Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "sybx:AvailableForSaleSecuritiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Prepaid Expenses and Other Current Assets (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sybx:NumberOfVotesEntitledToEachShareOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Vote",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sybx:NumberOfVotesEntitledToEachShareOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Vote",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail",
     "shortName": "Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
     "shortName": "Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_4ce13154-7826-4547-a938-f6040b13872f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_4ce13154-7826-4547-a938-f6040b13872f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_99fd2321-f1d7-43cf-b178-e7348f290f1f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail",
     "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_99fd2321-f1d7-43cf-b178-e7348f290f1f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_698c1855-5f3d-4405-b9dd-9cbf05cddeda",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail",
     "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_74611fb1-0792-41e9-a2a7-b97cac4d7f12",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail",
     "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_6ad92b9f-963d-493a-a1e4-49542d62bb26",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail",
     "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_3ce653bf-490d-4819-8e5a-529c46c9a649",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail",
     "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
     "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_fe7d4a4c-340f-4bfe-9353-91af7151de36",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Collaboration Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sybx:AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail",
     "shortName": "Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_436ec13c-b090-47c3-b27f-abd9ac6ebda8",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail",
     "shortName": "Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_436ec13c-b090-47c3-b27f-abd9ac6ebda8",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail",
     "shortName": "Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail",
     "shortName": "Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_81e01642-a38b-4bc0-a42d-3b02ce2dc640",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Income Taxes - Schedule of Valuation Allowance - (Detail)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail",
     "shortName": "Income Taxes - Schedule of Valuation Allowance - (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "sybx:ShareRepurchaseTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_be0c663b-cd69-4808-83ec-81ad0fa98a39",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sybx:RepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Share Repurchase (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails",
     "shortName": "Share Repurchase (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "sybx:ShareRepurchaseTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_be0c663b-cd69-4808-83ec-81ad0fa98a39",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sybx:RepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_e8fe0938-f51a-46c8-a3ca-196ff94642c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sybx:RentableSpaceUnderLeaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Leases - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_e8fe0938-f51a-46c8-a3ca-196ff94642c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sybx:RentableSpaceUnderLeaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_sqft",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Leases - Components of Lease Cost for Operating Leases (Detail)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail",
     "shortName": "Leases - Components of Lease Cost for Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail",
     "shortName": "Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail",
     "shortName": "Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sybx:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_dc33945e-b2f0-4255-915f-8f700291d29e",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Employee Benefits - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail",
     "shortName": "Employee Benefits - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_dc33945e-b2f0-4255-915f-8f700291d29e",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_0aacc6bd-0d04-44b8-8186-fe720001fc8e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Related-Party Transactions - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related-Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_5ab9195b-e60a-4319-ab94-9fb60b8ecb72",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Nature of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sybx-20221231.htm",
      "contextRef": "C_53c113d0-26f8-4751-aac3-06cad9a19780",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r303",
      "r308",
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r346",
      "r537",
      "r564",
      "r599",
      "r600",
      "r614",
      "r619",
      "r626",
      "r669",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r346",
      "r537",
      "r564",
      "r599",
      "r600",
      "r614",
      "r619",
      "r626",
      "r669",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r249",
      "r539",
      "r615",
      "r625",
      "r664",
      "r665",
      "r670",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r249",
      "r539",
      "r615",
      "r625",
      "r664",
      "r665",
      "r670",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r338",
      "r346",
      "r376",
      "r377",
      "r378",
      "r513",
      "r537",
      "r564",
      "r599",
      "r600",
      "r614",
      "r619",
      "r626",
      "r663",
      "r669",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r338",
      "r346",
      "r376",
      "r377",
      "r378",
      "r513",
      "r537",
      "r564",
      "r599",
      "r600",
      "r614",
      "r619",
      "r626",
      "r663",
      "r669",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r303",
      "r308",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r656",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_AbbVieAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abb Vie agreement.",
        "label": "Abb Vie Agreement [Member]",
        "terseLabel": "Abb Vie Agreement"
       }
      }
     },
     "localname": "AbbVieAgreementMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_AccessAndUseOfSpaceUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Access and Use of space under agreement.",
        "label": "Access And Use Of Space Under Agreement",
        "terseLabel": "Access and use of space under agreement"
       }
      }
     },
     "localname": "AccessAndUseOfSpaceUnderAgreement",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sybx_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development, current.",
        "label": "Accrued Research And Development Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_AggregatePurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Purchase",
        "label": "Aggregate Purchase"
       }
      }
     },
     "localname": "AggregatePurchase",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_AggregatePurchasePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Purchase Per Share",
        "label": "Aggregate Purchase Per Share"
       }
      }
     },
     "localname": "AggregatePurchasePerShare",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sybx_AgreedToPayRenovationAndUpgradationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed to pay renovation and upgradation fee.",
        "label": "Agreed To Pay Renovation And Upgradation Fee",
        "terseLabel": "Agreed to pay renovation and upgradation fee"
       }
      }
     },
     "localname": "AgreedToPayRenovationAndUpgradationFee",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_AgreementExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration date.",
        "label": "Agreement Expiration Date",
        "terseLabel": "Agreement expiration date"
       }
      }
     },
     "localname": "AgreementExpirationDate",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anticipated completion period for research and development projects.",
        "label": "Anticipated Completion Of Research And Development Projects Period",
        "terseLabel": "Collaboration in research and development"
       }
      }
     },
     "localname": "AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sybx_AssetsAcquiredUnderOperatingLeaseObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets acquired under operating lease obligation.",
        "label": "Assets Acquired Under Operating Lease Obligation",
        "terseLabel": "Assets acquired under operating lease obligation"
       }
      }
     },
     "localname": "AssetsAcquiredUnderOperatingLeaseObligation",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_AtTheMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "at the market.",
        "label": "At The Market [Member]",
        "terseLabel": "ATM"
       }
      }
     },
     "localname": "AtTheMarketMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market offering,",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-the-market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_AvailableForSaleSecuritiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities disclosure.",
        "label": "Available For Sale Securities Disclosure [Text Block]",
        "terseLabel": "Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDisclosureTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_AzzurGroupLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Azzur Group Limited Liability Company.",
        "label": "Azzur Group Limited Liability Company [Member]",
        "terseLabel": "Azzur Group, LLC"
       }
      }
     },
     "localname": "AzzurGroupLimitedLiabilityCompanyMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_AzzurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Azzur.",
        "label": "Azzur [Member]",
        "terseLabel": "Azzur"
       }
      }
     },
     "localname": "AzzurMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right exercise price of warrants paid at closing of offering.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Paid At Closing Of Offering",
        "terseLabel": "Warrants exercise price per share paid at closing of offering"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sybx_CollaborationAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement description.",
        "label": "Collaboration Agreement Description",
        "terseLabel": "Collaboration agreement description"
       }
      }
     },
     "localname": "CollaborationAgreementDescription",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement upfront, nonrefundable technology access fee.",
        "label": "Collaboration Agreement Upfront Nonrefundable Technology Access Fee",
        "terseLabel": "Upfront, nonrefundable technology access fee"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontNonrefundableTechnologyAccessFee",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_ComputerAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer and office equipment.",
        "label": "Computer And Office Equipment [Member]",
        "terseLabel": "Computer and Office Equipment"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipmentMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_CorporateMinimumTaxEffectPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "corporate minimum tax effect percentage",
        "label": "corporate minimum tax effect percentage"
       }
      }
     },
     "localname": "CorporateMinimumTaxEffectPercentage",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sybx_CowenAndCompanyLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen and company LLC.",
        "label": "Cowen And Company L L C [Member]",
        "terseLabel": "Cowen and Company, LLC"
       }
      }
     },
     "localname": "CowenAndCompanyLLCMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_CurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current liabilities.",
        "label": "Current Liabilities [Member]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_CurrentPrePaidResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Pre-Paid Research and Development.",
        "label": "Current Pre Paid Research And Development",
        "verboseLabel": "Current pre-paid research and development"
       }
      }
     },
     "localname": "CurrentPrePaidResearchAndDevelopment",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_DeferredTaxAssetsAmortizableResearchExpenditures": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Amortizable Research Expenditures",
        "label": "Deferred Tax Assets Amortizable Research Expenditures",
        "terseLabel": "Amortizable Research Expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortizableResearchExpenditures",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "Right of use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_EmployeesAndNonemployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and nonemployees.",
        "label": "Employees And Nonemployees [Member]",
        "terseLabel": "Employees and Nonemployees"
       }
      }
     },
     "localname": "EmployeesAndNonemployeesMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated project cost in access and use of renovated and upgraded under agreement.",
        "label": "Estimated Project Cost In Access And Use Of Renovated And Upgraded Under Agreement",
        "terseLabel": "Estimated project cost"
       }
      }
     },
     "localname": "EstimatedProjectCostInAccessAndUseOfRenovatedAndUpgradedUnderAgreement",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_ExciseTaxPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excise tax percentage",
        "label": "Excise tax percentage"
       }
      }
     },
     "localname": "ExciseTaxPercentage",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents net transfers in and out of assets and liabilities measured at fair value on a recurring basis using Level 1, Level 2 and Level 3 inputs.",
        "label": "Fair Value Asset Liability Transfers Between Level1 Level2 And Level3 Amount",
        "terseLabel": "Transfers of assets and liabilities between Level 1, Level 2, or Level 3"
       }
      }
     },
     "localname": "FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_FairValueAssetMeasuredOnRecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Asset Measured On Recurring Basis [Line Items]",
        "label": "Fair Value Asset Measured On Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Asset Measured On Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetMeasuredOnRecurringBasisLineItems",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_FairValueAssetMeasuredOnRecurringBasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Asset Measured On Recurring Basis [Table]",
        "label": "Fair Value Asset Measured On Recurring Basis [Table]",
        "terseLabel": "Fair Value Asset Measured On Recurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetMeasuredOnRecurringBasisTable",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_FirstSOWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First SOW.",
        "label": "First S O W [Member]",
        "terseLabel": "First SOW"
       }
      }
     },
     "localname": "FirstSOWMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_FourthSOWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth SOW.",
        "label": "Fourth S O W [Member]",
        "terseLabel": "Fourth SOW"
       }
      }
     },
     "localname": "FourthSOWMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_GinkgoBioworksIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ginkgo Bioworks, Inc.",
        "label": "Ginkgo Bioworks Inc [Member]",
        "terseLabel": "Ginkgo Bioworks, Inc.",
        "verboseLabel": "Ginkgo Collaboration"
       }
      }
     },
     "localname": "GinkgoBioworksIncMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in prepaid research and development net of current portion.",
        "label": "Increase Decrease In Prepaid Research And Development Net Of Current Portion",
        "terseLabel": "Prepaid research and development, net of current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs included in accounts payable and accrued expenses.",
        "label": "Issuance Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Issuance costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies, LLC",
        "label": "Jefferies L L C [Member]",
        "terseLabel": "Jefferies, LLC"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating and finance lease, liability, maturity.",
        "label": "Lessee Operating And Finance Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Maturity of Lease Liabilities for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee weighted average remaining lease term and weighted average discount rate.",
        "label": "Lessee Weighted Average Remaining Lease Term And Weighted Average Discount Rate Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases"
       }
      }
     },
     "localname": "LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_LongTermIncentivePlan2015And2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term incentive plan 2015 and 2017.",
        "label": "Long Term Incentive Plan2015 And2017 [Member]",
        "terseLabel": "2015 and 2017 Plan"
       }
      }
     },
     "localname": "LongTermIncentivePlan2015And2017Member",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_LongTermIncentivePlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Incentive Plan 2015.",
        "label": "Long Term Incentive Plan2015 [Member]",
        "terseLabel": "Plan 2015"
       }
      }
     },
     "localname": "LongTermIncentivePlan2015Member",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_MasterContractServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master contract services agreement.",
        "label": "Master Contract Services Agreement [Member]",
        "terseLabel": "Master Services Agreement"
       }
      }
     },
     "localname": "MasterContractServicesAgreementMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_NewAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New accounting pronouncements.",
        "label": "New Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_NewAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Agreement.",
        "label": "New Agreement [Member]",
        "terseLabel": "New Agreement"
       }
      }
     },
     "localname": "NewAgreementMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_NonCurrentPrePaidResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Current Pre-Paid Research and Development",
        "label": "Non Current Pre Paid Research And Development",
        "terseLabel": "Non-current pre-paid research and development"
       }
      }
     },
     "localname": "NonCurrentPrePaidResearchAndDevelopment",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_NoncashFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash financing items.",
        "label": "Noncash Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "NoncashFinancingItemsAbstract",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_NoncashInvestingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash investing items.",
        "label": "Noncash Investing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingItemsAbstract",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash purchase of property, plant and equipment in accounts payable and accrued liabilities adjustments.",
        "label": "Noncash Purchase Of Property Plant And Equipment In Accounts Payable And Accrued Liabilities Adjustments",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_NumberOfVotesEntitledToEachShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes entitled to each share of common stock.",
        "label": "Number Of Votes Entitled To Each Share Of Common Stock",
        "terseLabel": "Number of votes entitled to each share of common stock"
       }
      }
     },
     "localname": "NumberOfVotesEntitledToEachShareOfCommonStock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sybx_OperatingAndVariableLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and variable lease cost.",
        "label": "Operating And Variable Lease Cost",
        "totalLabel": "Operating and variable lease cost"
       }
      }
     },
     "localname": "OperatingAndVariableLeaseCost",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_OperatingLeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease cost.",
        "label": "Operating Lease Cost [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseCostAbstract",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_OperatingLeasesRentExpenseAnnualRentalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases rent expense annual rental payments.",
        "label": "Operating Leases Rent Expense Annual Rental Payments",
        "terseLabel": "Operating lease annual rent"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseAnnualRentalPayments",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "sybx_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards not subject to expiration.",
        "label": "Operating Loss Carryforwards Not Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards subject to expiration.",
        "label": "Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_OptionsExercisableToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options exercisable to purchase common stock.",
        "label": "Options Exercisable To Purchase Common Stock [Member]",
        "terseLabel": "Options Exercisable to Purchase Common Stock",
        "verboseLabel": "Options Exercisable to Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsExercisableToPurchaseCommonStockMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than temporary impairment losses investments number debt securities available for sale.",
        "label": "Other Than Temporary Impairment Losses Investments Number Debt Securities Available For Sale",
        "terseLabel": "Number of securities with other than temporary impairment"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sybx_PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestones payment upon achievement of certain success criteria.",
        "label": "Potential Milestones Payment Upon Achievement Of Certain Success Criteria",
        "terseLabel": "Milestones payment upon achievement of certain success criteria"
       }
      }
     },
     "localname": "PotentialMilestonesPaymentUponAchievementOfCertainSuccessCriteria",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants.",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants",
        "verboseLabel": "Common Stock Issuable Under Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_PrepaidResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development, current.",
        "label": "Prepaid Research And Development Current",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCurrent",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_PrepaidResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development expenses.",
        "label": "Prepaid Research And Development Expenses",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_PrepaidResearchAndDevelopmentNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development noncurrent.",
        "label": "Prepaid Research And Development Noncurrent",
        "terseLabel": "Prepaid research and development, net of current portion"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentNoncurrent",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_PrepaymentToRelatedPartyForCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment to related party for collaboration agreement.",
        "label": "Prepayment To Related Party For Collaboration Agreement",
        "terseLabel": "Prepayment to related party for collaboration agreement",
        "verboseLabel": "Prepayment to related party for collaboration agreement"
       }
      }
     },
     "localname": "PrepaymentToRelatedPartyForCollaborationAgreement",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from employee stock purchases and exercise of stock options.",
        "label": "Proceeds From Employee Stock Purchases And Exercise Of Stock Options",
        "terseLabel": "Proceeds from employee stock purchases and exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre funded warrants.",
        "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants",
        "terseLabel": "Proceeds, net of issuance costs, from issuance of common stock and pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently adopted accounting pronouncements.",
        "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in carrying amount of operating lease right-of-use asset.",
        "label": "Reduction In Carrying Amount Of Operating Lease Right Of Use Asset",
        "terseLabel": "Reduction in carrying amount of operating lease right of use asset"
       }
      }
     },
     "localname": "ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction collaboration agreement, initial term.",
        "label": "Related Party Transaction Collaboration Agreement Initial Term",
        "terseLabel": "Related party transaction collaboration agreement, initial term",
        "verboseLabel": "Related party transaction collaboration agreement, initial term"
       }
      }
     },
     "localname": "RelatedPartyTransactionCollaborationAgreementInitialTerm",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sybx_RenovateAndUpgradeExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Renovate And Upgrade Expenses",
        "label": "Renovate And Upgrade Expenses",
        "terseLabel": "Renovate and upgrade expenses"
       }
      }
     },
     "localname": "RenovateAndUpgradeExpenses",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_RentableSpaceUnderLeaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rentable Space Under Lease Agreement",
        "label": "Rentable Space Under Lease Agreement",
        "terseLabel": "Laboratory and office space to be leased"
       }
      }
     },
     "localname": "RentableSpaceUnderLeaseAgreement",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sybx_RepurchaseOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of common stock",
        "label": "Repurchase of common stock",
        "terseLabel": "Repurchase Of Common Stock (In Share)"
       }
      }
     },
     "localname": "RepurchaseOfCommonStock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sybx_RocheCollaborationAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche collaboration and option agreement.",
        "label": "Roche Collaboration And Option Agreement [Member]",
        "terseLabel": "Roche Collaboration and Option Agreement"
       }
      }
     },
     "localname": "RocheCollaborationAndOptionAgreementMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of common stock and prefunded warrant price per share.",
        "label": "Sale Of Common Stock And Prefunded Warrant Price Per Share",
        "terseLabel": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfCommonStockAndPrefundedWarrantPricePerShare",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prepaid expenses and other current assets.",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule Of Property Plant And Equipment Useful Life Table [Text Block]",
        "terseLabel": "Schedule of Useful Life of Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of shares of common stock reserved for future issuance.",
        "label": "Schedule Of Shares Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of Shares of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options forfeitures and expirations in period intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value",
        "terseLabel": "Cancelled/Forfeited, Aggregate Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options grants in period intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value",
        "terseLabel": "Granted, Aggregate Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options outstanding, weighted average exercise price, and additional disclosures.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract",
     "nsuri": "http://www.synlogictx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award percentage of shares outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based arrangement award, options available for aggregate intrinsic value.",
        "label": "Share Based Compensation By Share Based Arrangement Award Options Available For Aggregate Intrinsic Value",
        "terseLabel": "Number of options in money"
       }
      }
     },
     "localname": "ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sybx_ShareRepurchaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Abstract]",
        "label": "Share Repurchase [Abstract]"
       }
      }
     },
     "localname": "ShareRepurchaseAbstract",
     "nsuri": "http://www.synlogictx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sybx_ShareRepurchaseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Text Block]",
        "label": "Share Repurchase [Text Block]",
        "terseLabel": "Share Repurchase"
       }
      }
     },
     "localname": "ShareRepurchaseTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchase"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_StockIssuedDuringPeriodSharesWithholding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares withholding.",
        "label": "Stock Issued During Period Shares Withholding",
        "negatedLabel": "Share withholding, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWithholding",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "sybx_StockIssuedDuringPeriodValueSharesWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value shares withholding.",
        "label": "Stock Issued During Period Value Shares Withholding",
        "negatedLabel": "Share withholding"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSharesWithholding",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sybx_TenantImprovementInvestmentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the lessee agrees to invest into a tenant improvement of a leased property.",
        "label": "Tenant Improvement Investment Obligation",
        "terseLabel": "Tenant improvement investment"
       }
      }
     },
     "localname": "TenantImprovementInvestmentObligation",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sybx_TreasuryStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire policy disclosure for treasury stock",
        "label": "Treasury Stock [Policy Text Block]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockPolicyTextBlock",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sybx_USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US government agencies debt securities and treasuries.",
        "label": "U S Government Agencies Debt Securities And Treasuries [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesAndTreasuriesMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US treasury and government long-term debt securities.",
        "label": "U S Treasury And Government Long Term Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities and Treasuries"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentLongTermDebtSecuritiesMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance.",
        "label": "Unbeneficial Percentage Of Ownership After Exercise Of Common Stock Outstanding Effect To Issuance",
        "terseLabel": "Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance"
       }
      }
     },
     "localname": "UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sybx_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_UnvestedRestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock Awards [Member]",
        "label": "Unvested Restricted Stock Awards [Member]",
        "terseLabel": "Unvested Restricted Common Stock Awards"
       }
      }
     },
     "localname": "UnvestedRestrictedStockAwardsMember",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sybx_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sybx_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised.",
        "label": "Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://www.synlogictx.com/20221231",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201708Member": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2017-08 Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities.",
        "label": "Accounting Standards Update 2017-08 [Member]",
        "terseLabel": "ASU 2017-08"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201708Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r624"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion/amortization of investment securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63",
      "r155"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r161",
      "r560",
      "r572",
      "r576"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r27",
      "r114",
      "r497",
      "r567",
      "r568",
      "r642",
      "r643",
      "r644",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashAndCashEquivalentRelatedText": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Additional Cash and Cash Equivalent Related Text",
        "terseLabel": "Cash equivalents maturity"
       }
      }
     },
     "localname": "AdditionalCashAndCashEquivalentRelatedText",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r649",
      "r650",
      "r651",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r197",
      "r198",
      "r199",
      "r200",
      "r210",
      "r253",
      "r254",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r385",
      "r386",
      "r387",
      "r406",
      "r407",
      "r408",
      "r409",
      "r419",
      "r420",
      "r421",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r540",
      "r541",
      "r542",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r100",
      "r101",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation expense",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially Common Shares Excluded from Calculation of Net Loss Per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r127",
      "r136",
      "r157",
      "r188",
      "r234",
      "r243",
      "r247",
      "r263",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r426",
      "r430",
      "r453",
      "r624",
      "r667",
      "r668",
      "r712"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r150",
      "r163",
      "r188",
      "r263",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r426",
      "r430",
      "r453",
      "r624",
      "r667",
      "r668",
      "r712"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r257",
      "r279"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r57",
      "r256",
      "r279",
      "r555"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r56",
      "r279"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r56",
      "r153",
      "r279"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r45",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Lease Obligation Incurred",
        "terseLabel": "Purchase under finance lease"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r577",
      "r578",
      "r624",
      "r638"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r43",
      "r152",
      "r601"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      },
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r44",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r641"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r38",
      "r43",
      "r47"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r38",
      "r122"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r638"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r144",
      "r145",
      "r196",
      "r253",
      "r254",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r406",
      "r419",
      "r420",
      "r432",
      "r435",
      "r436",
      "r446",
      "r454",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r492",
      "r493",
      "r540",
      "r541",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r144",
      "r145",
      "r253",
      "r254",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r406",
      "r419",
      "r420",
      "r421",
      "r432",
      "r435",
      "r436",
      "r437",
      "r440",
      "r446",
      "r454",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r492",
      "r493",
      "r540",
      "r541",
      "r565",
      "r566",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r197",
      "r209",
      "r255",
      "r271",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r84",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r130",
      "r141"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r288",
      "r289",
      "r595",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total Shares of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r649",
      "r650",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock $0.001 Par Value"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10",
      "r624"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2022 and December 31, 2021. 70,933,140 shares issued and 66,736,251 shares outstanding as of December 31, 2022 and 69,698,844 shares issued and outstanding as of December 31, 2021."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefits"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r167",
      "r169",
      "r176",
      "r556",
      "r561"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r134",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r324",
      "r325",
      "r336"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r616",
      "r618",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of investments in unrealized loss position, more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r260",
      "r280",
      "r610"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Aggregate fair value of securities in unrealized loss position",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r261",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r7",
      "r8",
      "r128",
      "r135",
      "r399"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Amortizable intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r701"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r112",
      "r702"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r112",
      "r702"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r110",
      "r112",
      "r702"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r112",
      "r702"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Equity compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r112",
      "r702"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "negatedPeriodEndLabel": "Balance at end of year",
        "negatedPeriodStartLabel": "Balance at beginning of year",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employee contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Maximum matching contributions as a percentage of eligible compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Eligible employees to contribute to 401(k) plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Employee contribution, percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r41",
      "r61"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r350",
      "r381",
      "r382",
      "r384",
      "r389",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-based Compensation and Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r90",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Equity-based Compensation Expenses by Award Type"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Cash dividends"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r177",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r211",
      "r213",
      "r215",
      "r216",
      "r217",
      "r221",
      "r444",
      "r445",
      "r557",
      "r562",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic and diluted",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net loss per share - basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r177",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r213",
      "r215",
      "r216",
      "r217",
      "r221",
      "r444",
      "r445",
      "r557",
      "r562",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - basic and diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per share - diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r189",
      "r394",
      "r413"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r699",
      "r703"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Net change in valuation allowance, Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r699",
      "r703"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other permanent differences, Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r699",
      "r703"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other items, Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r699",
      "r703"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit, Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r699",
      "r703"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits, Tax Rate",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll related",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Employee unrecognized compensation cost, period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r698"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r74",
      "r146",
      "r171",
      "r172",
      "r173",
      "r193",
      "r194",
      "r195",
      "r198",
      "r206",
      "r208",
      "r223",
      "r270",
      "r323",
      "r385",
      "r386",
      "r387",
      "r408",
      "r409",
      "r443",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r497",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r304",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r448",
      "r510",
      "r511",
      "r512",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r304",
      "r339",
      "r344",
      "r448",
      "r510",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r304",
      "r339",
      "r344",
      "r448",
      "r511",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r304",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r448",
      "r512",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r304",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r510",
      "r511",
      "r512",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease obligations, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r480",
      "r487"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r282",
      "r283",
      "r284",
      "r305",
      "r319",
      "r433",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r610",
      "r657",
      "r658",
      "r659",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r395",
      "r397",
      "r404",
      "r411",
      "r414",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income Tax Examination, Description",
        "terseLabel": "Income tax examination description"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "auth_ref": [
      "r104",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.",
        "label": "Income Tax Examination, Likelihood of Unfavorable Settlement",
        "terseLabel": "Description of tax benefit likely to be realized upon settlement"
       }
      }
     },
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r700"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Interest or penalties accrued",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r190",
      "r207",
      "r208",
      "r233",
      "r393",
      "r412",
      "r415",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "verboseLabel": "Income tax benefits for the net operating losses"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r391",
      "r392",
      "r397",
      "r398",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r538",
      "r645"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r645",
      "r708"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r123",
      "r132",
      "r174",
      "r232",
      "r472"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r181",
      "r184",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Interest and investment income",
        "totalLabel": "Investment Income, Nonoperating, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Short-term investments",
        "totalLabel": "Investments, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Cost for Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, operating lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "verboseLabel": "Lessee, operating lease, existence of option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r129",
      "r139",
      "r624",
      "r648",
      "r660",
      "r706"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r151",
      "r188",
      "r263",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r427",
      "r430",
      "r431",
      "r453",
      "r624",
      "r667",
      "r712",
      "r713"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r188",
      "r263",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r427",
      "r430",
      "r431",
      "r453",
      "r667",
      "r712",
      "r713"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Available-for-Sale Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r38",
      "r39",
      "r42"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r42",
      "r131",
      "r142",
      "r149",
      "r166",
      "r168",
      "r173",
      "r188",
      "r197",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r214",
      "r234",
      "r242",
      "r246",
      "r248",
      "r263",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r445",
      "r453",
      "r609",
      "r667"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "negatedLabel": "NetIncome Loss",
        "negatedTotalLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Common Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r234",
      "r242",
      "r246",
      "r248",
      "r609"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r485",
      "r623"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail": {
       "order": 0.0,
       "parentTag": "sybx_OperatingAndVariableLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability - operating lease",
        "verboseLabel": "Current lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability - operating lease, net of current portion",
        "verboseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r481",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid included in operating cash flows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset - operating lease"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r489",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r488",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r70",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r162",
      "r624"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized loss on marketable securities",
        "verboseLabel": "Unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r640",
      "r662"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "terseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfEquity": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common and preferred stock.",
        "label": "Payments for Repurchase of Equity",
        "negatedLabel": "Repurchase of Common Stock (Treasury Stock)",
        "totalLabel": "Payments for Repurchase of Equity, Total"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Restricted stock awards withheld for payment of employees' withholding tax liability"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r34",
      "r55",
      "r178"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r602",
      "r611",
      "r662"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from sale of pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r55",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r149",
      "r166",
      "r168",
      "r182",
      "r188",
      "r197",
      "r207",
      "r208",
      "r234",
      "r242",
      "r246",
      "r248",
      "r263",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r425",
      "r428",
      "r429",
      "r445",
      "r453",
      "r558",
      "r609",
      "r621",
      "r622",
      "r644",
      "r667"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r62",
      "r154"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r64",
      "r140",
      "r559",
      "r624"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r345",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r345",
      "r500",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r498",
      "r499",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r103",
      "r143",
      "r720"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development."
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r638",
      "r646",
      "r721",
      "r722"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r594",
      "r639",
      "r646"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Common Stock",
        "verboseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r81",
      "r138",
      "r571",
      "r576",
      "r624"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r146",
      "r193",
      "r194",
      "r195",
      "r198",
      "r206",
      "r208",
      "r270",
      "r385",
      "r386",
      "r387",
      "r408",
      "r409",
      "r443",
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract": {
     "auth_ref": [
      "r285",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient was elected to recognize incremental cost of obtaining contract as expense when incurred if amortization period would have been one year or less.",
        "label": "Revenue, Practical Expedient, Incremental Cost of Obtaining Contract [true false]",
        "terseLabel": "Revenue, practical expedient, incremental cost of obtaining contract [true/false]"
       }
      }
     },
     "localname": "RevenuePracticalExpedientIncrementalCostOfObtainingContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of consideration that is not included in transaction price and not allocated to remaining performance obligation. Includes, but is not limited to, variable consideration that is constrained.",
        "label": "Revenue, Practical Expedient, Remaining Performance Obligation, Description",
        "terseLabel": "Revenue, practical expedient, remaining performance obligation, description"
       }
      }
     },
     "localname": "RevenuePracticalExpedientRemainingPerformanceObligationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r175",
      "r188",
      "r230",
      "r231",
      "r241",
      "r244",
      "r245",
      "r249",
      "r250",
      "r251",
      "r263",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r453",
      "r558",
      "r667"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "totalLabel": "Revenues, Total",
        "verboseLabel": "Recognition of revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Securities Held"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity-based Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r47",
      "r126",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r347",
      "r349",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r158",
      "r159",
      "r160",
      "r224",
      "r306",
      "r307",
      "r308",
      "r310",
      "r314",
      "r319",
      "r321",
      "r614",
      "r637",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Percentage of discount for employees under ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited, Number of shares/units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "verboseLabel": "Granted, Number of shares/units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance, Number of unvested shares/units",
        "periodStartLabel": "Beginning balance, Number of unvested shares/units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance, Unvested Grant date fair value",
        "periodStartLabel": "Beginning balance, Unvested Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested, Number of shares/units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted-average, risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised, Aggregate Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled/Forfeited, Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted, Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of options granted to employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance, Aggregate Intrinsic value",
        "periodStartLabel": "Beginning balance, Aggregate Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding Ending balance, Number of options",
        "periodStartLabel": "Outstanding Beginning balance, Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, Weighted-average price",
        "periodStartLabel": "Beginning balance, Weighted-average price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic value, Vested or expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average price Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted-average price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/Forfeited, Weighted-average price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted-average price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r354",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic value, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted average remaining contractual term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as a percentage of fair value under ESPP"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r48",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r74",
      "r146",
      "r171",
      "r172",
      "r173",
      "r193",
      "r194",
      "r195",
      "r198",
      "r206",
      "r208",
      "r223",
      "r270",
      "r323",
      "r385",
      "r386",
      "r387",
      "r408",
      "r409",
      "r443",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r497",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r223",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansTables",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Potential Shares Issuable Under ESPP"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs, Shares",
        "verboseLabel": "Sale of common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Cancellation of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised, Number of options",
        "terseLabel": "Exercise of options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Repurchase Outstanding Shares Of Common Stock"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureShareRepurchaseAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase Of Common Stock (In Share)",
        "terseLabel": "Repurchase Of Common Stock (In Share)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r54",
      "r624",
      "r648",
      "r660",
      "r706"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r187",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r469",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r469",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r469",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r469",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r504",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r0",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment charge",
        "totalLabel": "Tangible Asset Impairment Charges, Total"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r258",
      "r259",
      "r305",
      "r319",
      "r433",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r657",
      "r658",
      "r659",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r22",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r22",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "periodEndLabel": "Treasury Stock, shares",
        "terseLabel": "Treasury stock, shares",
        "totalLabel": "Treasury Stock, Shares, Total"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r22",
      "r82",
      "r83"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury Stock, at cost (4,196,889 shares at December 31, 2022 and no shares at December 31, 2021)",
        "totalLabel": "Treasury Stock, Value, Total"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r197",
      "r198",
      "r199",
      "r200",
      "r210",
      "r253",
      "r254",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r385",
      "r386",
      "r387",
      "r406",
      "r407",
      "r408",
      "r409",
      "r419",
      "r420",
      "r421",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r540",
      "r541",
      "r542",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r390",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r225",
      "r226",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r486",
      "r623"
     ],
     "calculation": {
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail": {
       "order": 1.0,
       "parentTag": "sybx_OperatingAndVariableLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r212",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common stock outstanding - basic and diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted-average common shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r211",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common stock outstanding - basic and diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average common shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.synlogictx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL109123557-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL51790836-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130569-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r628": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r631": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r632": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r633": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r634": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r635": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r636": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0000950170-23-010428-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-010428-xbrl.zip
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M!7S$VKTV\3B,1=6).ADP&]5:I+J=;<^KU6Z8P5)ZN'/"H9Z]M!VCB8.W[3#
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M=DQ6HFZ=-8EA9*B'868-S0TN+:[IY@*ZBMEU%GK?*J$'9?M89CT+^^=Z:LR
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M848Z#RLS,6,GC=S;B$S0P%8FX<M8F5-7X7K,BX"\R8#BG^4B'_D.C'D3],B
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MW3H)3S.P:I0SC\KAS&E,*^U"#AM,S^[0ZDN)^I?]Y$H^'@U4(K2C28PE-F2
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M"2'%#5/0?D7UWJKO]MAZ[*9HX%[9!ATJ 2(KUE<V2=)U!&QQH8;S=@KK!KN
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MJ$6"&T-\@FYX/%_4JX@1TY*)D*/X.JBN0,D-F8'S5 ;'I,A4_F#.T94>=M2
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MS^7+"B5'XNT=-Z-;JEDBYG?>DD0B#'&51Z@)KX&UO:!N9VI'0QZS%*XR1$Z
M^\PGWB\K.<LP[VY4_>IJ0*"=Z!YS;=510T-)7B?>+SUT1FB@26P*EO0XL2]
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MO>V44X0T<HI.G$5AM,R-^@[<B#%_\,:.OTZ+IYSB;CI??*$6AQR;B[:@:>J
MG,]$L696R<BU*!V+CE882^_O:;H5GS^U=UQ4,QSW+EQ['_(Z2U[P>7A-*8NG
MB2*,F+TR5*]XE *$9ESU>TOY B%&:;;X>*9"Q<KCOZSE>KY]X=XT4]_&ZG%'
M.[+*H>K:LD9FK>8)3O[RU4#=I,HKFF#RT:LS7QM=T'$ZD$TKB?6U_MV<BKW&
M(J93E/F.&::P5SCW[3@1;ZO'+SZ_HFG<A1^$D_N#=7+A<6QDC2KTA-:L1EUU
M*$@!IGV>0^IVH%K:R]OT>3(+M'-##41^$B+03]^F8+JMP *>6#09,#"E]FCK
M?GF ]5.;G>(07:7"Y5=]VYX#ARP^Z^,9J<52O4IO.SGG\%T!]\E!$_!9/3)?
ML$P?LJ5U*;=+!I?=*]0XQ?P$-RUONC][LSKJ\C)AVIJ"GIGT,L0Z$P<\[F16
M5 01@\8[_H@_NCTKB,S+T2\%6Y8<ZK[QOU:$2KOBTM24+X$6>[,ZCUQ^,G3^
M19>  L<SA2YT/%5N!@IJJ;^'Y7[H$")1>T>U@"W%XUP]3.:M3>Q'0?H6![IB
MD;PA/RDBRN1W?0X"-L-=YV".+6='DM(??IGS3TW;]][WK-"0;)?4'?XS^?'%
M_!B_VJB3;$I.5-U.T>"$^:^@)[F/SM_5>$B_9)SLA.X)K(,O65\_Y\]//"&0
M*!:UM DXPB3FUXB5I5:FUJTK03^^E&U>.@8P!226>.12WHGZL1"/]$%QN)YG
M9![2XVK+PZ<SP]TV<])571U/L;Y"$U;XS@/%CM9/UA!":$+%GI90G&"4BZ#Z
MJ[=CC9KK&@JHK\L]GQ[RF^^/F^/<,RY0(F:,HFOR+?-"RNN$]<< U78O6V59
M00H3'70RK1/BA43^4,4'Y3BN+1JSF+/4]]"1+IV+7H8VE?<7]EY&GO9W,RS8
M>M-"&'=;F20FO[T>8SZ_G<%K"N&3QOG)G-;971/GR/W2N<]IRVF96^\Y@F^U
MXB)M<UGN?D\Q>>^A?P5$T!*+SG06+*FTVQ_,[>_FB&F1&?5C'7:/XI]%M'+S
M,N^@WWPK+]U'_NXO"=^L^7ATVSWAN5?#=M@:-]CT@"'\=A%CWW\G?B/2[0<]
MH4%"'0.(NSM.FQG<)XS399N_NQ@YUV_#D"CH:&O&'OJ((^!:@LG#=ZO5ELO+
MYAYUS6D?K[#L;)A(;N+Y20O/MD3MRVRV'H\G+T)*BQ5$E'BU)D_PR1.;_TD,
M_F]"6[I_D2_K_J42_M=2ZG]IFO]E]-\:<])_KP8[W:=XFO8+Q,[OZ0,N?-@Q
MX*\$BTY5X1/ \6\9%B?#AHC_<I_P1\YNG=D@:/7@YO]=#^[LAOP/">]_G!.T
M&A.9L:FW@]A[?@Q08R4W_//-0B--]Z<5BBO_D1P-SVL58VHEA'74\<VV5!HL
M#=\*OL]=6&@C2G\_)N& ;V?-$TA>@)W,%[_/4%+NT2%]Q[4FW&#>6#GB 84Y
MA0MN< S 9%=5#\EP[NA4S>G!A!.?N,40>4@J!=7XIM1%/VC!2CU_[?#K&%/W
M.-KTBQ)V;DOX-*?*!=X8'A,TYBW_-=43DT[D1<6OQ.OMF10;XMK;661:YRZE
MYRM<-VI_GE".C9L]CWH*R0BIOS[H9X= P76L*X=O8&NS"LPMS3^R^ #J;=5*
M[DI&)SJM$)&HO"EXI<&0C"]\ S/^0=BV%L/<4B'??/\^LC>ZKLR,D+>F23H&
MZ) JWLUP1QFJ#\M4(0G8I',.+-?WL^QX0M?"G8,/G\/I+$FRE3,_=SA1Y6M\
M+A!O7FR-IJ*V'JLLG^MDB.5W K4>=-7'UP)-S B\[UBRV*_Z/12B:V_YVE%L
M9MSYXC>U:SI4D3ZG6@0  RS+"TUM_59[+KF9 J;I'VBU(E\&=ATUCJIBHM !
M6%4.,NR]'PC\=3DE.=0C74H?\L5YHQS'_YI^O>S.NB_#R#$@-(T4%D@%$FOT
MKZYX<16C?;-RL^/-QR0AK8T]WR4>^<Q\Q_I"%G67J-$1SRGW8-OZ_"< FV"'
M(-ZN!@4> F>G3YU3H:VY C$5$?D98]0E+@\4+K,99'K+U]1O*+;@5+8M3^+L
M)Y'<Y-UTTC7$9?=IKN(LZ0/[G!M!0^=?2KA)9Q5!..9^;!>8[,:3!/P4$)P5
M68(^KR?\H[[&L;$#'9?F]BV]#@UC,)'Q+F,T@60!7>%JU0 *\'<Z:$8(':'*
M.[V4A":M;S9*XD7+.WXD6"[\:?1C%V!=YJ,_^K(#8Z* 6LWY"M'@RD_68$.P
M<3P!##XS6'A:N8O'M3<:.PRBC5B=4J6K)K](KF13M$LDF$ZVN;P9[(6*9"0H
M.WQB=*V.Z9A4:E>5)9T:4#9PRURJ)*151#EXY-VC80D-C1V9)ZL3I&V4/9F8
MO!PY FX3J2E=3SX4BU(=)JK7K$"E ^BCGTQP-,R2%#^Y+>'*E"\<WK&@*I%_
M5 UA4*K6%R_NCK!U;SW5<H[]G"19U)$Y-V>,Q:^ED[J'C4'T(\651W7E8W9L
MJ#\/[T%_>BW>]S%.;I4@9#4B&'=Z)J6>5]7]1+;+Q.WJ<!NG*#UKN2OXJCE^
M?,7 Y]!L9<ZR .8?*8^P1SW7(>-C)+;[63[XR<V>MSWT3):I7] :\PPSV>:A
M><2['=Z<6JKG)''#(6TQ692&9MD-"*SP,YVFLIZ6K?OV?'T@J?(C5-F2>,AH
MW_A4=.,UB_I"NXU_7NZ+31$0RF8M%_GG\+844Y./7N$WBG-W#P@;7?G]\6<D
MI5U@"X1W7 )MA[XSK;/L34KAR8BN%X;;$--1F(Z/.Q'^?-S)DLU[9P)7S[V]
M)]*I*D$;FKZ$V0BA"0^O^KUZY>;E\DK4Y5&DZZHFP$7_Z ?0P1^V&SK@?I&7
MC=;=KJNZE!>+/G7CG<7+EUS[PFT9)'T$)URNQ1Q9Z5&\N#F^1))IZ>#Z8<]P
M_\$LRD?>YX5M0IZ(5#A&NP##,<F3O&HRR\O>R,\MN@.[XG05[.-CIL/Y,W4]
M]/I+D\4@&C;CPEBB9E3YC&D(G9L',"3 G,I-T<FGOB4GJ'(,.:-6B_^$Y#%/
MTOVXN\/CA?YJ<\(D'2G+"D0$Y8F[LF#XPEQ *_\ZWO-N^H6^S<0O/6$%QG<'
MHP8/@)>Z/!ATN)VCU2\5*07=9]1]49YJ7#(L)I861&J.C5-DOL:T9 )I5'F7
MYC.T92U#=:1\(9\#QI@SM330+YM[)O(59/? \28_O$-E'WGS')JD(5J,J(]^
M4BR)2JDRPZ#6/3[!Y);*YUI\T(6[;TN9],T7H_D,M0J=7JYHB.4-'"S0KD@P
M27R(KI7VE2SBJPRZ+JALH["SE^]QEH0.ZTO.G4;8C^[CN8N@N834W#XWKHR9
M?F63OOJ;E#"R"8UEC9MHGXY>\J0)Q^@DFXY@NE (C^MG$L.E5Y58K*QG]3^F
M['4PROV.+N$B@*=$8UKCEVB^N=#W2YO[7WU<THQCL^Z8;PX?E*05JEOU/%]M
M8':DG2&]2;82PJ&DTT6[[DH3HH;NSC^-RHZ?EI^O5M(5T(F;^O,54^DHPS35
M9W3*;(^I=JJ*E>P062\/+ZEG]3,8\'L.RZ*$F9&BRR"0W0*Q,NC;./GK"?U3
MG,7H-FO.^AOPB#;DC4$_%M^<1>, QL'K(\6T\7.S\/E[[?>D-G//W=YEJ2"N
M9?G'Y&X#3U/<FDOO#)5'J*C\Z+XD>?8-7Y8J$AM#] <VWIF)<L4_"-;2]>%/
M-@S%FO3J4HF-2RG[$JW6S,IN9,B,1&.4ESKV]\"P59GO!]&Y1X-M]^>>6C@L
M7**GP[B;YW7X3H?0!"D+A0@;<.DRU[VRT#M?@VTF=*\S<-GWWV62]KVP=^(W
MTX/'-2LR2.+^FOPML$OJF1..2]],BY.50\%B9]1Z'(!MT1U+)M+' 'I''TM4
M(BHW&7*V+OZ+6)9I^TV;)KMMF58J4PDEL%HT)2:*JI:W\HAV>QV:65*YV5;_
MI\MR;#],II$B/",<4R\+WP"-*,L5FL(13:K\6,9WX;X(6<A1V%Z17H#!DJFK
M5N6&8Y1W)BIWH=32E*+61D@JS.F_G/K=^GK,VFX1ZX3-NG?P>(53;W++-*,I
MV"O%H^*C'6/4 M4/5*1FV[!Q>8?4%S\;PT.!&9)AK6A&RR72&"6FO61)!ZJL
M-%]#:+K'9$<GL]C W."HSV^):&XBLX? MGN%6Y 7W,ON3:G-:^5;5M!)6 %L
M.H8JW84]>L2 SR4@W)99R]S680'<)0,.@R\'16>''!22^KO/R:EF&\4P430U
M2.5O4O2^0/)$;AL?*K_2HOLJ7.?7/[,1F7&EW)H=SOX4*^-K?6')/"D=*K?[
M"W<+XMO3T>3(L[#GQR?R6C_"2N;$!4;#+D*X4)4ATB&QB#*H\YN]CB*UROOW
M==/HMZVP?.W^U.[='ZO^%W(I99HX&:B:3LD(JAC#JQQ2@PE_,/1 _T$+YHT[
M.MQDIC\BB\04Z>=+[&7KPV[X&0B%X IM;.;UST9J0O0ZF3;.JZPL]0?[_.GX
M6,\+5DSL:P#/>%;I+A6,M?T1[$)>GNI=V3#K2PVJ>OL]=U7JGZ/@?%\!]1J&
M_P"^=>;_$6$IS*N2&FW.#!?YVCA&2OIVE%H,*I&/5OM3.6N%L>+\67"I]IX"
MZRH7(VFD/!42Z&UWJCXKV'3$4O?K 9>[@?I+I_M5^ER(3E +8H<*W#Y77/QW
MW2(1/WZO^>A((%E5?U,1>YB9%!NPF(/J<Q/#]"H=/@.'TD:=?.4B]!7\)ANF
MQM)F"N&IK4D!5P=@'J#=S36HC7A'U3;=!)Y)8O7HJX7?&^N/,1Z^1Z4_S@?T
MS],60@B75=,+'6;Y0\2I8-*&\5#1$SG7ZXX)V_:&'$P=K/U6ST/NR#L->>XL
MNK_*8D@D<D4/0F\=BBR[IFAV?,P9D2XI@CNO: SMF%PE6&D3WPFOA]*MS]>=
M@_$YLNWUV-TJ?%,)%8Z[,27GW.X23EI[M&%)28<0,QAC&*W KN ]21U_C[>I
M!F?@AV'U+I9,@51V&71TK5O!Y&+;>I+ZX9GA/*;W0/?#%)+C#%G.@!(/,48-
M;>@++$MR\-R,2*CK$CP:&:XO$/::=/)QSB!?;"'T9<F$1*.A;KX<"J%R9\AX
MOH80;U#  -=WBJ?_ W#%AK3/P/ CF/R=&NYZ3 O%09-\&36+OK3,SB6&3<#M
MW<\9B!Y5OW0].##;M7'O5F8=J;CJ!,GZC"ZQ0UWL9EAKW4V[[C\";0BC7CWG
M_?B].#X*73H-X2W?K&7EW.S6-ODSB9(!T\*&WU)JM)(N5G'1SAZ>YW?JB9E(
M<YC?1HFH:$_M]HJ_2K1]A_?IK&,XP/=.,TO[9E!T4:+2<V/0V?-$G4X?18[N
MI-?U*[@Z?ZI0T9)B;'4I+IO6$\18LMC#\!Y:$%A3AM03&<Z*+#0TU&,W&!SO
M!R$O"YS2B'PE8]BGO004XQKNVY79GOY@Q8>3T1PNPD @J2-]KZ(?Z/.ZK%!,
M1,@BLS)AP6O4]/LS_<^P23.W;<O!"D8V0?!UD0ZJQ(F!-Z6\(T9I^'/-MYLZ
MY^K$\OX(YSAEW&BH\&HXW@P?P(J%EJ]IJB<W[R4K#N",ES"LNMV#7Z1J$,,8
M[^%?)<RY(Z_L-QP<_D"5EGU?;/KQB&@B\^YKR1975Z1/I8BXK_M+Y/MID-;#
MFU4TC3'EG^^R16L![$3E9[++R>O!!=.ZKVP*QBVF-?F_S&4%N437FGR@Q#2:
M^&2$*_N[R,8(=<7K1+WY8]NW=/K$--?)M5C1U0WM](=Y70$S$ZK!PV+;-??4
M/I/H,LS'5T:+(:XB5I,PR#CM0M=1:M!<0[D?KD''"G\,"/3I>$^[(3K%K]-_
M=6HI*:[+3?#V[M:\+ '.>6+X,^-;K:^BYDE1NP7$PB/578C7A7KOBM8\^1LQ
M3J0>ZU,K+'#^Y@JW13R]PX><%$<SU57U\?E7B^J69+G '25_B1FC]- H1=!$
M_QO<0!L_LPUW.$/_RBA2Q]5]&C2%EZ/U-OGJ;*%VAW"&.G@'MRGQ6O_,Q96\
MED*GI H\WB#K?")%\-WPN(J4V0&L[>CB,S(&'QKW3/R;^AU)EU(-%0/_-O@Q
M($K:=U*J%<>>HI'H+_MS%T?JNH9KUC$;.=O9=1@"L9.^L&T=:?X^?M'U#59T
M$ J[$>'^MK=R7O 8P*2R/*7$/!>G)3CDHY*R,34/'/NI3B]\:SP"\@*CZ[YF
M,PI5]OIJ!3$$WW.J&%HVB$DY^XF-8UFE]RIEZT'&,Y#\#@@L_KGT@_$#D,A>
MJ=+K>G>*[V\5;2 SF.!9R)8#RS>UTI)W7&MZ/Q=?VY/V2=V]_@(%ZNM![.<M
M&=9%UKAYO*U(9B[&W_:!JKRC85Z0*2E)1Y.5&X/",$/('_A=,=I.>=P:ED!+
M=U?)T"3C@M%3%N9+!SD8;"O_BD!4DP O+;&-4C9K%YTXP\CR=# 7,[)04\^6
MK%UJVWI^61*?LKD1BKPPXBR!FG4?*<+X7N1\.2[T(YK5W@)ZGV[+=ELF]2O%
MS4#L=YV,WQUO,")[V1>]3N"YTP6479_Y :<^_7;M6_?XM D6_&=+<3;A=P$V
M?C>M6P224^U35UP.\E+-QBMKY5(<=.4(.7.R;%_?S3\E/A3^RI='R+?P>T2:
MS V^C!$O@_ E2X[S-L6'P1Y.9#@1:9)FNI 9Z[.4H)6GJ68#TE7SAW;EDONA
MM]R;=<LH@<#$UQ3DP9 ^*T6S7;-ESPVN3>!.]:PXY.\]TQ=@%JGZWM:!<[X^
M]\1EE])D!VR&H!@3;%%[^EL7UL&$-VZ1O_FM%%_X6,?X*:%,6[SLBLPM0+TN
MNR]B;3GN'P/<5CJT2;Z(L]/+YO;)D@/.-X9@?K8>(OZ*IL> $4*"O+T^\<Q6
M^,2(*I^5$WL&BR%>#V(HCO)@E(R5S>IE7A>2G)B%S;Z@+[>"9VD/$W:</2["
MN?HDQ3KC'BAGJUSTL2\8I1RVI"1%$U#U98X'KL"DO7,/6+E_O-D&FI.@D.9Z
M ;)UBR^:53?7TLR)@"R!Y5N.?C^'5)(/G1:]<3@JX#FUGX-5OHF\3HHN\<]-
MUS'W5WO^ _3!^4U 7XA!J':[Y("'ZLBI-7;KJ^63SUM\L!NA.V)*AM7#(Z$L
M^J6" >/C/_8*3:: @[5 :.XQ +J<Y.,_.>?4PYD<](13X"@-F5N;/,,># -6
MT 2*T[-*"5-PY]N9('A0]E#HX=?+16=?PU-;*@D.$<5YV+D1J#3JN3JFO#)N
MJ-'R99&O[8?@/>Y;@2HKEI1@8@,CHO.Y:5F9$IMNJ;84IEI61679TJ:=P!ZV
M_5-&3,T84U'RLR->ZHFDN(;&M)6*2)=[1AA-/UJB96EHF>T>Q5Q$!U+8&2PE
MR_UG@5)M(D>L$U]I&J0"<53U;U;68+84BUW]*X&_<,^_7+@T> PHKW7  'S;
M\T[<68IXAH._;Y'Y.,'JTGCWT*4G*IH89\)DBS^,AZ0=__!FF-:5/Z9\[[GV
MISMDD^_#5_3)(IKY8"17S5! %VQN:<:S,MY%R%SB]\3YIM-U\<2D,/I0*E/V
M*$C'0_IJ6P*D;5S\0M_Y-7P.P"/A?ZL6Y,J,Z-*.^2>I[.M_W:#_7T4.C:_5
MXPL51?PS'O\W2@:<H)B>AG^:R/[?K1A@><(*^3R/ 3N]B$^%,N8=-.6UDQFE
M' -N&#MI<Z]8WP_ \I^A:LWJ<\,UVY$\%?$F_IRV00LZ01NK9<HPJD'7*'ZX
M/%7=2*':=?ZQ'H-+F:KBSZ-T#R+Q&/!^T'&*D\L07"\4;XI==4:_7V.H4(6.
M[G_LT)Y7E?13Q"HS$F.BS),P#K"SZ(]^:C;BX5.P^_=>A?+&OEO49]TST4M,
MGI%@7 JX.S0_?&*5_#6Z80TP%PX/58K*RG?Y DLWZ#'@W#SS-V[PD:.?.C'Q
M)]DXGJQ$7.52S7$AL[0J/K+4R;>VUG2YMOSU[HW8<R.-2U;)1. [FN@P[:Z?
M/$Y">L4MSY%V!2I._O4MTDOH">&< M_.-E,PC9?BT'BOAS]L&Z0K^M3M1N6'
M<XB"977W6@-E/70B^!APNCF*M^H+*9767:\:1@2&C+VYBIEFH@1M'I5_ABF7
MJ=2B/]E\8DHDFT\)'B7+3%_UNU&>K#D@-*"L!BD^!KS1R9I<MG*;C 3HI\<D
M]LG+HRL<"PZPC^K1=#-1#KL>9.$/J@R4N'%=TOMJX$>9J-=],[Z6FB_8Q90-
M[@F-D9MVT?J4'%),J^)>*SK8'!G_ZM2PLI("],''T]XB/Y@27?IEMF7!=ZUN
M0J?Q9/[2CV3&O57L;%<](V7KL>7-D>6#O B\4;FU2H"ORRTOM@YZWL)/%+2@
M)-68$K<Y-FD-=\(I2:R-J\@>B=$&R!H7F$4BJ[J/ 8P!80A&EY2]INFS\"QS
MKOI"(DIQ[WGGK1G34_8=NE,-4=!+QI4IM/)CP$TA-5U.&#$O7)0*_LU[$32\
M9E]24EL>_42LF)U9XW.C(9!A&9XOMC9;&7+S(YO\I[,O# *_N@,\"T@B'PD'
MO#JO'#/#U9A_ J-C:S/HJ58?H@3295^R:FCM^S)LL.=HWA3M-DJXCV3XT2D]
MLV]NVV4I'6 9T.AC>92Q=O;UUJAE$_^N7XO?P'V)AQ/A1UJ]1F&Z%950,JCE
MY+7T%@!@JZ>O@L;U4W#WL_3'-/ _#=19^YS].LA9NU[8>A':0  OSFX+Y2<&
MR]&!N/C;>,Q-=-P0/N4R&FPY1.M!GHUHIET;N%'V,ZBC)7F:()MJMS\U6].)
M^)"R>U7=:;FO^\ZJPRK1<ZWJ3P,;T*'ADI]5?>D(1L WSVDWMEQR6=&N*<B&
MQ7]Q-/J[OXB<^5%B[84BBG5+ /^A$#8I@[CG_2:@2R$*I\'3"2IXLY6R:ZZ=
M: P61#:[_Q[WG" K68\I-58T7,;HTW-L.)1BQ7&[!^N0(+S<_4);-C<\1T'
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M=SVN!?YUGB XT$!+'2!V[<NU9Z<'U85.OOWGY-O_7YWV/U2G_?/H9OCMXF!
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M-81#[[EI<U _QJHNTNWHNYAD3F^U3MKZQ:.[1_U-O)>7@<QM(A-/JE>#P)7
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M /=I7XYRJP)>9EP'B\ "N*.=M1X-Q?M'G0\!>0[C3RGWOK.8Y)(I>YD;7>>
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M37LS\;=Z;XWN&XW.D]F)V:WW$0+:9D>;&WDABKDF;&\>>T 2X2#"!Z? W3/
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M/1RJGC[CI&.NCY&769@*AG+U-K4=</W@K1IY.BJ\?6B=-O^ (ZX>TX7+]#8
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MYQJQ!%5^VSIS)8]A1/GY#AG.2A(5@9*#4J#D"]3O\$):L^$GYS."0U'ISI;
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MQ2L ?I FK'97NS5W_J5/W*2[<0JDR9]*,V[5D;^AL:;ZF[^T5D3AFTWG\:]
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ME5,WF=]"VS,'EB97YYWD:C.L3H;,H4$'M^+7PGP5M,E7[[SV3%W1=Y1:.'A
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M(-G+K5:H=#GJT0;R#\4Z/J^XF!Q'EXO[,[&"[4+(YV8 BTH>QL_+@6LF&1^
M_:[7U\ 07P-K^1*8JZ^Y,LH;^(W7-U[?>'WC]7=YN;-< E7QO\EK1 #X,Q-0
MX+9;VA&9@:NP7/[Y\4\.5Z<!0"\RXL/-HZ>LA>H?=X]&(1^F =84B/R-8AYP
M/+.!1!A9OT?5SZ-R&%'5B#2I,W C=.Q8BT')CWFOT3'N2Q5B)'5VL12YG!O\
MDF('= R$)]:4,5_=8(*YD"&CZY6C3(!_#:#=[<:.FA?I5!0TOS+0Z:!F:DF$
ML.I._(TGX9$_\%B"F/W_!5!+ P04    " #A,WU6TMC;'4!2  ".90  $@
M &EM9S$Q.3<Y,#4Q,%\Q+FIP9^R[!U14R[8VNA"4#(+D+" YY]PB0H-(E)P1
MR9*S@*T@($B0+#E+SCE+3@*2<XXV.>?NU^Y[]]9]WC[[O'ON'?_[_S?>8M08
MJU97S9IS5LVOYE=K 9^$+P)WG\C(R0!(MP  "?$'P&< *0#MSAW4.[?14%%1
MT='1,+ (L+$P,;%(\>_A$E"245-1DE%0T-!S,-+0LM%14# ),K-Q<?/Q\5$S
M"HL+\8AQ\/+Q_!""A(Z.CH6)18*-3<)SG^(^SW_Y@G\!\-"0^&^9("/1 K?P
MD)#QD.#M #5"S]M(OUW ?UY(MY!1;M]!14/'P$0TJ+P+W$)"1KZ%@GS[-@H*
MXE=OQ.\ "MYM_/O<DG?NJ1BCTCH0\+P-3T.C>U3:0J@ZM$_/^]S1!QV#B)B$
ME.P! R,3,PL?OX"@D+"(U&-I&;"LW)-G:NH:FEK:.B8O3,W,+2RMG)Q=7-W<
M/5[YOO/S#W@?&!01&14=$_LI+CX](S/K<W9.;EY9>45E575-;5UK6WM'9U=W
M3^_PR.C8^,3DU/32\LKJVOK&YG?HP>'1\<GIV?G%Y0^[D !DI-^OO[0+#V'7
M+1049!34'W8AW7+[T0 /Y?9][COXDBJHQ@[W:'G>HA$\"D\K;4&GXU7=)WSN
M.(1!1,^W].#@AVF_6?;_S#"??\NR/PS[:=<T@(6,A)@\9#P !)Q=,J6_P?B;
M0G;81:J\FZ>UH]]%*N&39."]PA[?6>Y@48W7>2D=7A?@Z0<'Y$RBMC9S('MY
M4PT'3\LL+OGJU%3Z/ L(=1V81>DNW'@%A%N#]UDN^!X?42(U59'Y3)+&[BB0
M1DG/I@HQ'N43MCVN^_I:'-/]U'$>F\J05E8E6NO"ESPJ,M0;]TDC'$!7.SHW
M?-)8Y<^Y0WXQ//GH8CK"MCUNSV^Z:S^MK8393:2.-?* HSKO.[8#G]LE?X,*
MP[G-+B:I+1</&,5F]PY2MKY[/,QL__*[ZS>BL64W."#['$7KX=1*$8_[WHY\
M> "/2!YK1.4!_WK232-.'4V$ @-]2G^E:OIC4WHL?'M'M"U-9TLO>>?QB5@X
M,#4TK9@P/<T/X:&1T5P?(+G<9W*P$ Y)T.VSW@RNBL53(GGNEV'TA4N(+G0Y
MNXB*&E_)=.E>CO;W<4OFT>E)29+)D+@@\\D4G:&*,9=\)8*9[SHE91&BD_0Q
M1%4:S\CODSZ+[&[9ZA"\@P%6DK9WDV":,'R<8E IXN4J[V@D;VEB%FD1V3<K
M:WQDGE3S?;Y>;X[='^)\]ASD(N/UFAYKV,'"<C8Y@3X0WS]\#$FHC\))SR8[
MB#/MX$%H@J=WED'ADC.K2;U+_=N/Z/2K]F"39]=25:%';>/C9:OT$Z<'$2+!
M33SB'1+ZJL_7AS>A\X^#;^WFH0.V0CW'V9I)T%?OSEX1)OE=#&1E6Q.5Z$&J
M!*\C<,WTJ(NL#9\=\+=95^N8AL!BC=C&GI8;5E]V&7_,JP\ 3!CG0V4HNK<L
MBL *!\YG(Q8OOWVI.ML1;_@:K$5_L$&NF_:LLO1<S76>/[S0Y>K#>SJU,IGD
M0=*;8P]3E!MMT5=!>L'"X5-JN)Z6E*TSC:.LHMZ3\0]);E!UOHZZL#:"6JK)
M$G-\#LGI>%G"HF3O"5V:E3L;HFZ6G;^>*BY(;ZBK#3%+AAK7:;HB!2Z,.KJW
MI#VP+ETH'<;<,LGA?Q/W>K04/5B_U9STTJQ DQT-\T#$7@2;$H #S9]S%LZS
MGPWSDQM[>F3T1N@5X$_IQO!T%MB3.XB%M]"\58JYPHR?26HD[)[;FLYL8JH;
MMN%PWF*H1GL>>J+K,K\4H>;#A:K(XR2?9WT9<1[UG>A,Q-N7#9W>[E6!] C%
MFK(/UQUAJ,?WWQ;?-$O2VOZ(<V!Q,?<']Z=E%]Y"I$*#W_7JSWW;15['VA5#
MN;3@@%FO2E;5>\$$%-N'V#6)W*2D) 1,50+;SK'3NPF?YW6G]>?8W(BIH1G3
MV@F)Y@ %UIF8>D^V_YR4 HM,YB*Q$>J6WDOYW)2@6+8('0]#H^#$#-M#MV14
MD"?(#]2U?(\SH&G(;"(<6]:V6JLM#C7F^K88F5?>=\P$F8$FYN4D-RD6V4:>
M8+0;YICJF(DA4AL.VF2N#DR9EC=&]F#*#@<RTG(EJK#2[V6;X?P)S%7QG*P[
M"C64O1EK%S(>6_U:%0>\T^<6"I;9.H5K UD/DBKPL,/++][9VGW!M[#?Q@#;
M*+AIK5A2^$FCE(J_*;*BU-09.<FWX=044$W8G)V>U<V@P6?JD5%5(EF]:\W8
M.E@@;UPL/CL>9LM1-/XP:.:ZY68V\?;I%IA1>5W44[Z&LY"VKC+:U$<=E[Q8
M!K51P< N SJ]^V&Q_YXR]V02NP:: >ZG7I7W^E=UR ,.89U5)TKX RXS21R]
M5T]+B-Y_MBR>V:O'\E.?%>KD\>[ P;F\%5$Z/J2GZ]Y[ZDT'KBFKJ(J!GIYL
M9RIQ?6K+L=?6@N!H@IX,-]5.L#G/.$ED9,STQ!SM9FNH45RG$;LQ4GV.9<5Y
MX:RFB4<=PC'H<T*I#+;F7PL9G.H)3F&QBWMHNHN$?:X^Q6_C*3?F/#86TRDO
M_LBN_.W+ C)TM <R<A=O.WG?@NEP7KBH:6([K6#6KHXREC8-[>QL9[H/S^\^
ME7=\M@>Y.XF.@H-M/7D><H+MIECEST\4&V\^\Q;DA=\+''=BXV"C\HBP^$ /
MISOY(Z#+3'BS,H5TMV^' 4ZS$]0%UCK19P$-NA0@\_>3<O1([U]^NDY5DCIK
M,O$=CO'LN\)%MU2U4K8\\Y=/T%IY1GI?/>A-%^->:&UV-T67C;23(%E5::YU
M=9U9X*FL20D:!P='=(IS, ^>&MY,;K]D@?5T5FC&Y^_%$DG&[.UWY#AV">.)
M/MX5JUAU&O 09W8L60?K2DN:V2HDRNRWVF+ ]EN2WEV9)ZJ=/+A-H/+POU,H
MQN.6Y$T>G,Q76IIZ>+HY'^Y:G+U3O,7$)LI$'6)6_(Y?5%2(J'=Y4N$S%%_/
M$KI616(H''B^DDM*NJ/?2*BWG:SFA B]@K[E3R>-2MLJ3.76QBA87]5BL2/:
ML8XE/IWE;(NQ.U@O]]@E6^@JR-'75+XS?Z7 A-2S0K)4"CLHR@L2_N28$1S;
M5O?UE7_EJ>E($K^ &7%Y#$][EL#V3.C#G>XMC>UK03<;3K^IK'<A#*A!+^\=
MW2-1J0Y362 <50&+XJ@Y:4H06]\HM>.ZT'I'JE4&S3VZU_C$'R5YKI-%@0IT
M3Y?<6G1MQ&#Z]N09TUZ3.C(R>C#S]V0%9SZ5KUV]#AFMF@O[P0P)&[H7?;DW
M)56*<\FNU\Y;8>-5G!5QNV+J6="\@_?L]^/H5167]3BXNRIM5,"\.&H>KU-0
MMHQ!@<1R(\6%[4<&#]K/PLBYL&09Q BP4)$W12=L/"B2&?>=/[S<,V=(L\ @
MWJ):&\ !T2G:85AP.MOJ/JGB*=\#,=YN?'(\N*1+R=RK.8:?81)2M0\KY5\/
M8#N]U ^IBF,VN9UKTLRD2;.(-)&]I6M /VP^SE9H7.T^EM[@[\HA>UOE+5WH
M2:DTA[EG=&^A2<R!H)_96*4^2+DT7L@TR (V6IPH3R9Q\,U[\96W@@ <>-A4
M/5%4J2 RH=08>O)LH+KAXHE(\!V-:7>ZG"XKZ&::PH=HBO'2M 6H!'FU_\*V
M1EUA0ZX#WGL\#%E<6][@>],YAN<L'I'2/N,6JICN$?/G DYL5KUP@)/2C7GK
M9D4_BX"Y H?YXYRNM*<E?\%6'>G'SBTH6DN1P4!;Q[1ZA*5 I&7YS&.Q&DY;
MS$ ZR1%')'\:S^ )?6GZ;8$BIV&+"3BP'P.Q9"LE,1MIZF'U41]J(\+*2!OP
M=B] :WA0E'1G1H8YJX6PXN#)&9I6XW@7=LU!BU#/@,=Q\</T^(1':V#&904Z
MG?'TNA*!^*?C90>WOQ:TRGN%-093E(CYH&6-.X>8'?94M%AG08EL,#HCYLK1
MZ6QJ.-R%A3>"R:";&7$!S-%4085++D,<&QZCTS?Q<DKS=K&6_&\9WBZS2\E7
M?^-'+Y!)P)..@=+.OSQ(0^%HY<I<?+%ZI6DIC:& W4$R9'FO:P7]Q/O@)EF>
MOEH=91>+HLJ;VU?Y/.')*#\I7WZ(Z':G-7ES!6&-J[IQ92PI<#E^0U";M$LD
MG.,<8J(R\=*%W4R>*:-D_INDA7:U*'96W"<<8/OV,R4T \Z B%&]-JHTFYS&
MFXI4HH<=?<#<OF1+46>0U[9>SKI-1:&ARD3!B8*%SL,8EN7Y^:FIPVTN_4]O
M9]Z(?X\W"\FW'(&.Z]H8*C7$6[]?/R*1+:2YRG((Q?6:>"9-\5584=$.RZ!G
MD9P=31YU.O7N'4?%MM(6H17Q1N9I_[>>=YJ=\KZ/UWE#YUG0=_8D5 LRD,)+
M/.UE1#75I2FVA57ZYRS<JC^DUK-'X6O->Z>[+W8_M3%^MQ)YA%/S>2M>(@/T
M_F6E-=/+W7$T,NKRN5)U&7IJ;EG49.Z1+.?1'P$8)CI1X;G#^@5&:SU5N!I_
M>,*!_"B3J:^3VW<37&@K$%UD==GXKJYKTKA\9.UHB#WITR 3"K,PL@4I(\6$
MM(NEG??+\3/ES&]5@G3!OK[AET'Q*1(^:T)C^[M9608&'"FFF?/3>@,C:0V]
M#5A=;#@$NWJ'(E1C3HATQ>*D$:0Y'-&SYC]6:%8='<_'(DN3"ZR@.'<]^9Z3
M-= 639&5XK?77'8M;>WM@JR0+UH304C#L-EZ+/'NM3I%'4=UKONKSM8#-J/X
M >A<&YB5ITY&DG%W7U&(NM#E6.5'__9+C=+/UF=U,4'LC$'7]Y/GUZ8$NC.0
MQMZ(X8VJ34<W-3I8$W":9BRT[_LEDWZ@#11>?2&@.1D\(25-T;;&TR"8)9_N
M_GI$*=Z8[V-N']8.*?V2T\ =>W$_JR%IAMU=O@("%6F:OV,C_Y\NO(E7*@H&
MA2>P* #ZRW/ D8?I<_8L 11@2@_ZK:!_Z4F/AP/V(SE >I#/\N'T-[-ETV"C
M*JU3%"S8B]?.2.*$JOJ*O>B/'6=I2^F-3CM%DN? &QJ;0&HB5CQS\1DV(!+$
ME'KK]_(&,4"F4DWS$T#GUV&=AH.LG$'/%'\V_)\J\8VZ6S?,HV/0!</O#W'2
M:S\QC++OV%*1K,7L?WT-EL/1='*S%:((:;1'?27':;<;[SZ6&<'_,?_VNZ(O
M137"N[(#X$I-IB+G8TT0Y7HQ7SH7J:!LVF0++#_R(ZB!"U4"=D*V8!6IY_/X
MH+6\6,N#)N"V$B4/<7BB>2&'<NVPBA;1A$YE3ZA8&:KI JON2I^H5MGB"?"&
M=T_S."'_0Y];C MF /<;5)>EL&\E0J=IJ;4>$HO9SY[M8FQ\%2EPG-=OWZV)
M'L/[(+$O"^R( <)BRA\'@H(VDL\TY8KN!M/;$KM%:;WKIC("C XB@U.RZ.0A
M%+'X#R.Z+\S %C,-#F\<3N:Z2M-;:X=4](YFK1QD.Z)AS]8JEO%E]3?6,808
M27;V%&H;FN/7936$^^NV11O2L^]_7#5RIJFFFLM9PTS"O&E3_-P\RP>5PA@8
M/6[+X?'J);@OHT':S18 !TQ!25(%#;ENSXG LG(0KGR1T,DU"%D^1VZN]+UR
M&O(6[G#T"S1'0.P,<-I3BYQ5"(6UUBGQXZ\+R*G*?I#-+,NPZ1I]PZVK++4*
M+O_J1ODA,7Q'KQ5*%AQ(0RNY+DNY<CC))W](X7\\( /Z,I:RP_Z$9%J)_;%*
MHHWS<T6IQ-W!AP^O-RV#-C>_(]:8\E#Q@\9R2]-P4M^/MXJ&,Y"1_!6Q#2$U
M5MI2.>DYT"W>[T552\%^WX ",'FG!\7;X&^WH:PIH92*O=O5<?0Y8JG=!#4L
M^H=(8M>IH:_C/DOF6H64QC-C>'RY?2AKKHI*R<4E-ZA43%&/L0&6?JXS9ZB4
M.2_G2DD_Z?I^R#?#Y*/0!FH:Z>5XDF]%G7=]T\TZ_URCK'"7,&IR!1\QFRKC
MK&$6.ZUWQZ4J284:<3VLS6'-]DCL\TQUD4,G:PI17669%(L\PP%6*!UY%N!G
M&!6S0>][N1RO23B0'+1A-EH)$MCJ"Y4.L==TIO\H993SI8LN/!%&:-6[>^F9
MG^9"+HV1;RQ N>A*AXP2GKP1ST8LP%0P1S@O+^AZ],42_7&BP+$!%[JM4O%*
MZ%B6K,FSM,MX%WX1ZMR</<&;( BG6]Q:U5RC4RCWPWLJ>E\JQPJ7J\,??!0*
MF:698U*]ZY7M)LP(!PI5%7*MDEVZ0X7Q^0&?;Q&2V#X9R#7?)_;SU@@'0H.Z
M2NN;DP\7]3J'6O/L_=!>.O@(=<H.>(B-UC%'M=G3\Y2AA\4,VZ[9B]A>U&T4
M>ZT$:6#&.ZM(W_?[;Z;>OQ7^5]43E\]R\\>:*@"HM/33'>5:82&2GI.L_T"6
M6T@H>!\M<\D>!X6GIS-]42>YE20-\/\69'[9RDC2!+\59,-=,A?^"RG%5(R)
M,P53LZ,"F4>9]KR=BCSVZ%^@[GDE6\IR/.U026,J>J4XDB9[9+?OFAM^MK3<
MY2(;2=T=LM?2JK#VLFE"#6F <^ZC;_0#7V]')8GC,;]<K,MCS+4+C.$[(%["
M^VHV9JN7!R/S,0I.2A:K069S[RY&.=0V@+!K]]<N3-^V"8KH[/. F74*BENU
M=&*)^+Q*9-)Y%TV&<211QC["R-6@+'%DU8X*KC:T0[K)PB,3BI1"V1_0;.PO
MZD[G_V"&PHH0G$JPL88MVZ4B30#\7GZN0.5;0[\\']U\_3E)P2  :CD*_-H>
M49 2\CO+,9D,W6+.:+@T6,,KPZP,M]E%8>[--S#(0;:5X58%'+B\I+[$5+]T
M^Z;!VUQ2L7>Q# ?.+N! 9]C/EH5D3/68=*)7F(IP()D3#D!2KBU@K2/-&Q_@
MP,(&'" ;2O]04O9?Z6[U.3M+1V=2;)\^D(6'T)CWX CWU6S!C1U,DM?[&1QX
M1##B=N?CG#%*Z?3CM2HYQZ 6K2(97%*"YDD=M^L#R-4U'%B1S_/>HKZ\4EJU
MZN@XR<J@G9V3Q 3-X<L2NXV(6UI_XV.%&%LN''7 @;TC.!!"_4M/C96ZZGB/
MU- 7'L8SZ[153UZ\>.':G9OS+TS,"WA6<N\3]BJ51=2C9^Z#GV06:TZZA-*W
MV=Y#_JG=5G4U#TBX4'PD!VD1#F+ZIQKI\*FX$LFXG1(EP0$Q0Q@< )T/W?AE
M0P:)X4#S((S?;L<5#MA<$2>F6!Y>+[""!+ZNN(KS=HAX+%?YR*V'FP3QL^UV
M(3V$*A ;OU#]D]J@7W4K8$@SI5^^7?]FX"$M)Y=M)^](\1/#ZJD=C2L]<FWM
MJ M?%,YYNDFWX_3MO_,>P^C+PA&O:N7T)=T'73)"J)MRR/QF_\7Y_^\NGPQ=
M=P_2Z"(:#504\C(TT-F8K69?W;+M <?GO/I/\U\!9/JD]8ILJM>9BGJ-N&E>
M83AP8'"4^IP$<IXG]FOEHK:0$3PY/IS_(N0S#P[88"Z'*)+71M=2WMQVB'3@
MU0K)ELX5+B_(>M6;;M7=#?8Z%0Y\:8,#'2I_JFGVVV R&PV515U]R25_W135
M;![I8/C@[/9<2(#0R:7*MEC;] 6UW 45)1Q(R0'M<\&! S6/7VOJ1R_LQ0K2
MA;3[*/,(Y7J.J4[8B+Y5."DX-*K2YJD#LW(#(L>;%J<2QCM>81D-OQG0WPR[
M0PUC":-K:SXZ0?WMOLD1#@0:P<B;^T&M8><Q$->](Z7]C,F+@,I#B9!#,5'$
MLE*&+!K#@>6</]7R-Y3*IQ6P"FW-<?'W:)4S\3[B*EZ/*61\4]GV^J&YO,??
M::XXM,DT+7Z;JNVK>''X<77XTL+%1?4_<9,H.#7#XIC $Y?KM D\/ \.@&Q
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M!EZX=6@J!52!S 6.#/3D4</%ZXH([D8TP5)=4.PM/7W/0L/D1Y?&"CI&\?3
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MLQVC7H9\)08W\</K\^2Z[XVM4WLB!KH?^1EO7E]JS(<4R14,N@YI5;AR=1^
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MR.O/)P0J^AMM_^X_'1+R*UW<UH<#$T0P=3/0B?4QH:X: M#4%VX<[-8T3."
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M\[RTXN@^()*E[:ESX 7J1DU+$PX9]F)D:&#=PLUH"\>+H96GY!1H:_G.LV3
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M*.$9]H]?]?P_;, CXK\!4$L#!!0    ( .$S?5;2V-L=0%(  (YE   3
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M::XXM,DT+7Z;JNVK>''X<77XTL+%1?4_<9,H.#7#XIC $Y?KM D\/ \.@&Q
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M!EZX=6@J!52!S 6.#/3D4</%ZXH([D8TP5)=4.PM/7W/0L/D1Y?&"CI&\?3
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MLQVC7H9\)08W\</K\^2Z[XVM4WLB!KH?^1EO7E]JS(<4R14,N@YI5;AR=1^
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MR.O/)P0J^AMM_^X_'1+R*UW<UH<#$T0P=3/0B?4QH:X: M#4%VX<[-8T3."
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M\[RTXN@^()*E[:ESX 7J1DU+$PX9]F)D:&#=PLUH"\>+H96GY!1H:_G.LV3
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M*.$9]H]?]?P_;, CXK\!4$L#!!0    ( .$S?5:M=^[VX'H! ).U 0 2
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M"@G^-0@>,0D)&2D9'3DYG2 ;$YO@_VW!M@&T)-=2".GQ\;B!:[1X^+1XV"Z
M$P#P"/'^)O]:)N!=PR<@)"(F(24CQW6HH0&NX>'C7R/ )R0D(,"]^QSW/D!
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M%\21F#']CQ&ZCZF#A[&K&%98G\PP;'L!"SA)C1FZ#;9]',=%ASS<4> '_@O
M?XGN+=8NN%3X>-,N/EC<XCJHT><'B"8O5,IW*2J,*')1FRA!BI%Q6/C'H?V:
M7:<@]4\:L>/CTH7X9^+6(4JN]H8+#HT)SWIMHQYA >1QW<&^R6O3 Z)425WF
MI3#W5?SB1LI"D"4^>F+A<%MWS>;P8-.*06.*5_];)T6I.,E1Z<)UJX%"J)Y)
M<Q5,,!C"G!]3&U&3)J[2COQ<)M^-BAD*DQJ1XYRJXSP7*.'?<SD14Z:'1ABA
M^"+F3\T;+G3:&J&=9VYP?F,NVWOL _KHEN6/]AWG'IDBD8$GX"QG,^JWB?4
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MG9'8A;B>2+$EG?$L>[W?64:02E\[ON1M*%[OIM7+5@YTC:(H72O?"(L<78E
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M398]GB^K3(G=D4Z73X-K47K1W.$/7_G8!JH9.(CD\M*H$3$JLDQA.M$XPO=
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M-[/X 9*^F\>&?TST19E\WLJ59:)R2<>80H86KF3G3 RA$ J+BWCS&+7Y"-V
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M\[AD5VWH49W$EHS^S$-0 IB,>GVB_KD]DNBU@[F2(&D-,S$*5I+XFP>4[\O
M2=&LO2R46(M./BZK.WRTX_@VL< +=*,W/\!<M%.4RI75:E?GLA-C;O6Q$W-V
M@<@N;2C16S)1HBY9-04A=<;3739:L0 :Q!.6TALJ@WH4SQ#]]*!'EZ3JY8?G
MENN<U@('(2(HDQI^N#5"0W/+X[:$!NA.XD1+ENP(TX1LD@&=K;$:<"DPAJF
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M>2B<,QO)NXT]5 ZE5G18N0J:6M5I8X#L$AW\<W',2]\/BLM9GI<X3:T\'VX
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M[Z\I5A^]N<Q4'8N:CH0;GN50LI]QJ7M6.GK?_:&?K^6!Q$"U%O3U9C9G/M6
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MT.?_1HCVM?([0B>YRKCISS_@+V@*JPT0[)B4I;YA[X67PZO),I_X-AD20NU
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M$W33)]6&K;EVXUC'KN>O6.>>ODHY2LMR@]MU-IZ\+QVK1#RV9.).MJOJ,!&
MAG%]U( _2X359"2NU(S4HYY840UC4EI%4N211I;F*A(^!@O2/S86<OE95MQ6
M;73NRU"FLI68'NR4A+-:7%?Z^ 0LE!7? $P6+5UO .8GL$HN'U2#SR+W=Z<P
MAM.M#@N4F$"IV,7;;!X90;'H-^HJVW);NHB0C0@8!49_D%J+Z_Y68F<VV=_/
M^IY,:01&2*Y*C]\ =L8+]<T//)A@XVC<#U>GQ1O 78L11>-/T8?:+[,L)E^_
M?4:>_\\3M(-6"@,R?4IA<GGZ.C._A4C$"KYEY/.OS^!CEG=( ZH3ZDTTCK99
MI,YK_BY]VR.@EI&2?]#U?D\[G=ETS/OS1'S]XXP\*ZKJD OR;3*?=19A,;:=
M280MNWB62+R!O*)03=\!JQ=WP,SVGHT/CE\$:M<NX"D8:#H>5CI (S7D^T9%
M].O/@OF>+NMQT7#8U8?W-0U#+N+L;/J:\1\<A$P4YQ*/D5U31.C72PJ1?O7;
MG^)/0G5ZPI@^<S.X<_2;UA&L6S/5\I>5:&O.N%/+X%$U-3\4/,R./?XJ;(H0
M%MJ&;D.SDY%1]2W#\!<DNG4S2 4M<7#_OAT_,:?(,Z[?;O>+3);$CG_<P\G]
MVJ92L$A0= /4_/P60PLV)K,'"/_I08A/%E>1**--!RKM-R<?<,@.5(JTN$K!
M#RC4E]*F!Z'W-<9.=9IX6ZBK:XXU$]?'GYN$*KORM,5_[A5T%-Y@.E,JG%0,
M,XP?<<C-D?341=YZF_M$_#F)CE)]@Y<.Y$JKA/R@C:%W$/GYL;3I%*;K4],1
MY7XL5_'GV<1X6HD1^-ZCI34USWP @WG,3!F_'O&GH4:M98WAW<P*L]KHEQ8!
MQ"5M;4 T-MW2F9%#03E8XB6IL5GQG<KH*1HUFIZP?9.5L.JW($_A#>?&&X!"
M=&FMG2E[<E6?2]7!8!;.0W<GHAC.>5@.N5)Q5;I?E^3=]B^QT%[>=8^;[_BU
M@TQ.VGQI 2%+M"?1B4Z:I/*0SVBAGM96\GKTQ;I9$PAHY1\:P3M\Z'67=TL/
M&8)<59Q [K3"<%3C*BF6<ZW59'^G\3^8B:FZ/D5FZ"6Y,LIWHC=G=19T^D1^
M_6R/+GRC&B9P9U"8X6K4Q@4J@'7[WO>YJC9.XM2^OZ3O#'"D2P7/_I-Y_>)*
M(]*&P0U,]1.7NP%L-'',.6Z+%F\@XD.26(466$Q&@9:]9(T2111R^0I?'RWM
M?U8FC4,9*%5)C(#ENT!C;_93X2B3%/GS>0X\JXM 7?;L75M^4:'OW48O%7[H
M"FTWIF>-I&.KTQC'-$8,9HK;6VC0EK&\&[D/'"%!(V+"V=NPP_@%*RH5W4%^
M^L2X;-JIW^K-!A]BQIPTBY=Q;X'?;P S/5;PS\<CALX>49JR%%_/:588V;SD
M[.RVJ!F0CU:S4!P+/--V+^!Z":KCM@?%?!COG:L\F\Q!P8&GTJBQ<3VI*UC@
M1N,(PCKVTC2S+OU3BWC?X_$!3%UFXQ%_=0;D]_1V<IAK@/W%L1%-%F=DPS6(
M^;#$398+22IF?$=@]GFR8KY%Q^\O:B;/Q/;@[.$"0;\3.M6RU)OL&/FF&]R0
MBY#T.)+KSUHS-P!+_1G.]E*[U^7WM03RN'IB>L,VQ'TI7\1GF>;+H.#Z.O.9
MJ;SOV6L)AY8F*0LLXY.;RY9"%:6X1>:+S<W"H@F,7G4/BIH\9E\(-H3D7"N-
MVU1N,E?[[C[_V4&VIS@;-$AX-SFEJ1[6\C:=+*'<<=U[PG%6D07MTKD_;SLQ
M#@_2%4G05 C?S<HGGF0Z_;F@HZO(]T97^G7IW^690IRTX@1W1H]*[#IRG/?<
MVK#3[/DDPU5)D1<O=$VN[MZYAL1^Q]O<G8#:ZFUC\2D.]H 5WH?$H*ZK:-+>
M8+4U5^.LA"LK>7O/IB;;_>8U6++H;+B,3O@'>1&EK-RJG+:>]<*>N@TB$>F(
MAS3"IWFOO8US]3$A%_+4&GDV_0J/,BQ5SP/L'0O$U;X]YNW9T\S/O:W!$(E[
MI9UT?^VKWP 6CB7L)ODL1#3B,\B\/S%U#F@36+XH?9/'$T,[U]-%:VT2<5J7
MX[*#I<,9D.ZNSL]GSM3@O-<FFS,"NT>&&N6 "04"#?DZ;6M6-51#M///+RF^
M%8B8 ].<[1P>N:Y[O A_1ES;W7_7=R<]L81 ^G A)N\/.F5>JE<T:3#'@ZXR
MRRW^3O<L;O0VX+3:BU$_Q)Y \NOP_>G0&IU9HG9SH[+3G<LOZBSQN7'V?%;C
MWN&%HN+4QS7PN<D4<:Z^+V5C6>:C",[]827:7W&Z!!@Z;[?J\BZ^*-W6+8*W
M\GU/GPL8--*<,]>*<X2F]RF-2+RPB,)XOK)9JPTQ;:JI:<T/>JF>!")(3Z^T
MN(B?P#,<^::[KTSG+^S/M1B+2THL5,EG-27UO7ZDJ[8TGZQH65*,&%5:GVA:
M(1&5'MVSC?:"Q-7'D;VI82=X)F1.F.I_@..PG=A?P$[;OH:'H D'IXWLMZ>$
MA)C]NI\WEI^/3!CX-U.E>[GKQ>]36#+>>48LL!QSS1H6$;>M$3\QX5IH9WSO
M\[LD8H97E.#4U#LM&WQ27V(FNWD2K?C87M"?.,D9#$\E_R.]_F6&+4?LT/7#
M!^'HV7G[A1ZW%]TVF>KT48EK$2#"T5\'>GJ47&R5BQ\\W4,JLU[]F9;3PM+4
M3_[@D_S;9%O;VXX-N#-D'8/',F1T\;<I'EI\*-)1A&]+%TV86AHG&DF_\YCI
M^R/Y#:&:F:GVFU-;I/0RG9N$2=O)=:_^!N![#'CSS\[PV$F$*-JUT=G@+P4*
M[NIUS.7#B-^REZBU+C1'"Z0:4UB<IMI)"J$W(Q'WCNMRV]XX6<$3Z"IZ" 6?
M* _A%)ZW0G7N4UW$(S9JEBA4I)W2E_[?]Y^X^#P^I+P!A*R3,\Q:]DYY!0"]
MQI[N0[&D(P4\CJXRE$<4I:?S\B4]-%CJP#/@D^V[*(5OW3@]U$.:,^,I<-E6
M/7=@,ZW%#<!V[ 790OT>+V5?-ZR![ARXFLQO WN/L<LAX96KD>/J796"1SM<
MK-H=0]]P=/-#S6ZE"Q(RH.2:K+%).O]^,ZL4D=UW#.=0\H+IP)(NE: =Y A/
M/N=(NY-;0&R<.#(/KR*EF*.,"J-BGXZ85@9JG$GV53FIJ1BH_R63ZF%4%(DR
M%U9+X$N;4I&F-/EO?<R>P%9QIUW/U9E/ T$(L+.'.(L*3@;V3-]#=5IOP!!Z
M?[[")OGAO2#HGP%C[>1"Q3]G_%DJ(WFY]<#/X&AOXV'%IK7X)BNB!(E/18V&
M@:\6=4U\[C:!/B$CU4:*[7[= , .9-V$N2#EMAQS3(,,W0W WZ[H[CHXK%+R
M ,&!#?/A/XK+KY/NRL<^4 _5M%9C7YSWE 3A=&-:L=V3U[S&>:O4\3SKOM-=
M)%@_[?$UR0?\?J$X*HTKY!;/74]G,!!+NJ-?+!][N918(<8]SN.47=V<'JEV
M^\&M//[\9Q].JE7IT2M/OL;W%<SD] MW:W0_Q7X7)MP"6V2/6/7G#7Z.CM5+
MYG6V([74!_K?"O[H:1-AQX=F=ODL,:J6R>KQD5836&>)3XK,LF O :WZ=+G"
MV,^9\=UU&OD"<]GS%Y.P+XASF_SQ /@:+/<ODMH8AUMG-[CRI+K0#O)JL(2;
M!F?]--6E--PF$0EQ?=:K-.E%:7W:)TK"R;>C>5=;)H _*+K-<ONMH[)V_@W@
MK\$H7$"]Z/3K>"+'TN[=*P_4O6B0?E?(>&8"^ZYVL;IHOO@!4A_?;"80OLQ(
MW';"-R.3_E.^S?)G@ZCQZ&LE-C'C>Y/Z).-?JX/7XQ5<U2+X7_=# 8P0?2WC
M[]3)'E1"65\&]Z?4":+EQ.^K*YI_BMZS,1ZSH5MN,?4W_[)+^M0W-3F!)J>W
M4B#<:J2@L/<8HF=[?L+C+'G?0L"H[PO=)X?%(MF.%+?>*QFE5OO'T/KQ/9U6
M$:H&#\:)0CC(0<S8PK$_._+#=U[,^)7>E]9SRV?ES=6U\=QGP12]NQF?22D2
MM)M3C$7>>^5IS_;> %R%<]7,L'<]<OH>ZU@:Y01U]"($^>J:]$9N ,\Y;NEA
M^>C^:QOKE8B)M:2<'R:%5#1B3'X$O]#Y.NX<;>>N9A.SRD]:1UG6/@XZ[EPH
MN9E'*L4A7-QLC.^DGZ,YW!.*HFNE@<$E;LJ3N4B,KX.IC0=C9R+?6CHW!X3-
MYDKA 4/Z2LFKA.>6?"+*E$*#*BER5F>>LV?\_!DD%OAG:G0=86XO)6O;XTS/
MY[(9O%3!K3/L%CLYH*_!)N4//\KVU]D[TOQT5";(WU,:LBU9'Y;N+/0P=+Q*
M3=I-X;&Y=R&1^!3'/AX/-\P[P*.:JQN.!X'=209VDX0AKJ$3LS%L:#:$6?8>
M]7 #*_:A6ZZV@9ZV[OR'9H@@-X$ML_&3[_:D8I[C"HO$%C,!%8\+W8P0T#L:
M$5]WLRF%"0'?' XT5L8KMQ#AL=K^A?./UN\G*82Y7#HE]U:/[:]B_*"Y8M.5
M(9W"7\2S E^_%^Z$:0.Y/V>7$>V_=5@+OX HG)XA?\%;%NAL5*_>;?T-A;M>
MKU7O[Z0ES6(UQN>+!"><M/5>8EC#LZ(<9=8,O[\59J#K.1(,WO/FM[&]>, :
M[1'-'[S^)"U[.2.]#7E:?._VGSP+T3PC!D=\W2,OZOWHZW-$*+9"*+0EM:J8
M32E1)213- O):O!RW96-UQC>VC%ZIE&MV2[%2N_[CL<OO=%S0BEM*>/QELBW
MYM'36G0M0V&\V>SIO9^21,/XR5'I;\TB_HCIARVU)Y-]J-Q=-+RJH::I1FMW
M_WFM?[T<>: JYM:A)NR)(0YQ*7*;%Y-CWV?ERRLB]CB7IVJB&T?#=]T: #3'
M[MT$.5(+3".SMYI@*AR2)FJAS-IO^VV#OB*]^4R\NABN/R?>E/X;XL!GS$VA
MRO$6]TZ8,L%XA?'M13NX_G-]U0=;(TV3*_F,2EZ_.)7M;(!#NK(5V-<A@FV^
M$[^7LC@LV2756;%L0]U.+LU5]C7AK=2;"*U8WZTX9N:ID8YE*!V)Q'$G,67$
MQ$4P6N8K_3=1)B&"7/;VF?48ZX>U8[MHXF=!25Q/[%<*CCTCY;VV9YS=5'3D
M8%8UY #CX-S/J/1$VI[,H:;V J-8"M6X^#X=MQO =[XMJI?KG4M_KN;%Z43-
M%A8;-.[([J  +@/"?'VR9Y8N?('4T>W//029/C/XAJV<YG,=V%@_/4'L&U:'
M"IV\_/E\8_1E,C\'N>'YL)?=N?(EY@3<MQ/9E.J"SJ@W]1PPT+&9;-J[V+%=
M<1'G0FF-KI:-_3XI7OUC,@<6$F;X_M>J.N2 9$LDKCBM:2\QGN-Y[KQ;Z;2O
M[]!)E[&&\;CSEEUR+\<5N$%WOT8KMIMG<FT0\L+;-!?6JBX1^F*@R.>3E?=Z
MG4J]5,>G=S!W3W.)L91 52N5#ALE_'Z3\Y:3_HIB53VRLBF=<Y+*M)^T-CPE
M 6+_^#&H6+7IL#H\#_)FN\:5_6*(TF+]<>][U9_V?Q$RG15+JX9X9?TU44AB
M_+*R&B?J2;'G7,CQRC:S.M!(K_?DDV#9PL%%)&O8E9KD8:0E2$J1=C?J]%2O
MD#BZQ2D]>T/B<L!2!<2^RS23<]!_=3#N\M;9@'AS@>DM(],?SIGW@=#^75"N
M9DRD5<#*'Q^F^O%9U=H1=/3>X+JKV1^)!J<:"4QQ+YNCS$093!LQN#&X?^'F
M9F:,<9*+>:='I< /%5=C;^WO C#@=C<0WF-8C1C33,L=TYP_JSJ_7WSFL2:?
MC+X%%=4UN85V^2HMZ8Z>Z8:#220B\9_FE^\AKWZ1BF)2T.%2O6C4^R&]D?/#
M!ZY!RX=*X^KBP<(;,W6T_$!Z;\DQSMQQ>#K$(^*3JJ['<#>A^J#2*$H%.XP>
ML#I0P!1SE7&&BFCWDE&DT:JWELSYG?7<4S>@PQQY&YL;$DX-)$0Q\]5!EU8!
M?RUY3:9\L:P3W:Z6E&I96B-2LV17B1/F&&C0/S!H,VX>PW-O4H6&_K7//1=V
MG;^6=_ZB[MJWI$%JS&3\E%Y1RD)B<)(G^)Y.C0TA7(BQ3%<PP-DN8+32TE2,
MNN;1.Q6O9X^[AIB_DI]2;FX&4T 8K/)"[A;DM0!<[]9O"3>93'9?ZG;2R,M]
M^:TD=^8XC$RXOC.NH#FF*CMLQ__07F.&*H80$\1 VGX$AJ#P;ZR0QH>I&J_L
M+T8!H +6?IA>58Z<XY_NE99E?$6P/]/!X0Z&B4UL1'=.3FR@7DZWH6Q?KH>?
MD0(<Y-,:+=]]2VP?_-MCQ/]I^V6RY)*_:VU;Q=&]]_JIQ\;/9>/WT3!4L1?0
MOY$PUUT$=05IKVB]4"G9K</-UYWC3[SP^E55[&\+]LC[^IWD::$25I'ZH=AI
MCT2)AQC="R-QY?9>HYJK'@MW<R8$;GAO<DL[G1L3\R"%W)*)XLE^F+4@CV_Y
MLTV_WQ(XB2H49A3-/X%<U]SR*G;>78ZP/XF$O=^[Q())# Q]>U?DG-0,_N5B
MRE'1BB0B,K\YX_OI#8#GN(_EN+)"5(XYM:*NQWA;\6T(QYR$[JT'OO[[U7F!
M6L4-]M+I4Y2B*EZ$(5^A#B69S^:Q8)@^Y6&-J@"30 "5-<B#7FHAJ7,-!P:&
M>Q5[=TIDO'"SK<]0\,U'O?>P< ]#'LEXFS^24+"TY=U;ZYL\O)=QM=Y4WYBR
MHI$4S#>@3OAYXA@([T<.% Y[\]]2'FMW8V4D*R<?D>X-H/H!_=F#QA")W372
MI'-:^)4,.6GHCBUX&YEK=<N51[PW_[/[W__]'= 8-.*2W 6!/<RX 4A7V7M.
M!O"%V@$V576FL\'DRI!U758RP<0'NS7Z-X! J]/9!DV[HO7*>L5#97K0\]7P
MWK9[)HY"_!HK'T?W*W<@M'L7L]KE?&Q- 2,9;C\='0ZTE#)XMK\>+6JH@&&4
M\PW:73P"P7 +@[\;A?A"9??N'>J!7@49NZM]X=UV]$Q>Y]OC4)]\.6$*,2"9
M4S[/UUC:-E(5>\?@>E5 *,6C#Y=(@3CE:2\J4NVDO$$3SLD,+#U8$1(&N!0-
M*/_19YJP:Y[.VW+HLW=(>-33L%,9AN<GRU[H4GPTR*,P(^BE?=60+SAO:59_
M*DP.)SPB]:^T(T>1S!=I/.XYB:$X]O/MZ3Q(L#/8 9_2BXMTH2?@#V(HWK37
M.R9$/+H/7GC[1HBQMB3KR^%$9.'6X=0VU1,%FP=BV;3*W 0T7VJ9(^5MXY:A
M]!]KR;<TV&RX8U;W-8QCYQL(66/2-S(\*042<Q)5T]A>SL]8S3CN<"S"1M<]
MSI=\:#"N"ULSX@(K:A8'J3P&\Y<C#.13)C[?&\Q*#R?\[3P\S"TA!#E^C:$V
MWP[NAL7X3M9(*D&DQ D40C_BNW7X(*0I%X\5(C3+5J,]HZVJ$Y9)"*7)PT45
M0[@KG\DI4#GV>I9HIHOG=Z9\G.CZ4I!3E-#$:EJAN*CG#/-83RB3LV,*A-ID
M68J(-R;\%,\/,;JPS;XPO @066\HY+T!4!M_ 9X]"KT!?. W6FQAHJDR&K+D
MR:(&SZ\+/_W^UQ_.EFZ&QQP:BM3*"3JA8*^O=LMA[3$/GOH++WVS]TS/C+7L
MH3-R(J($O[:K3%@8U>DYGS209$[$I%A"N!)RE<4;N?KR6L.9?[$\8[7OP9-W
M@N3M@BL5!7;:TRE&.BH=II)L*^X1/1&*=*!A#&; KDYJY6_%>W;\B->.)7:P
M>RG(3";B*,P0V5J@Y6X &FWN..>0Y-@E8=8Q HD2A_&LGD3M).>KVBH/=HD_
M<K8<";.]S!J V!Q(9U\,PU<=TME&5V\ /V851BIG]1@YF<LM.8M=*$QKWM(^
MQA6D4G4^)F5(+C,W90UP!I+-0XXL$>;LN3N,+^:>"Q"5MD%;W5B5Y7==P@D_
M3>[%D^@/BB:.K;F94$JT?XUL&1/0IQYVQK';"(PJ^7-R/7@1MM:(NM5@ET>J
MNQF\%M-F;YR9E< CDR>5".>#K$N[L9/VFKK2([> ^=,F5M )UYLH+;EZ5QE]
MMZBV1VX7)7[O1RHK,3'HK^<"5D/T<IR^_N_#$@?7E83ZC%G<B@N!!!@GQ6BV
MUY6UZ&BVC]U7<Z5?_V*(275TW]K3L//FS+*BZQ<IG@]I.KVO+>Q7_E-ME>'N
MG:ZF5R/1DZA3KFICF1QT:K3#6A.R,;MRW2?E3%B<N2U9"7X#>&BS_MN4LG]%
MI2Y8^WU:"*7.VJFP.(@_9 $X^@S#C2N*+W AY7Q)#4JB_.$K0VH8P3/2)/6_
M2EE/<1$9+U^ME_ J'=?P&?1P:N"\K!U\7@?< %0PH3;F#-J?NJM%]WZ/UR2F
MA2Z'^&]?W_&;4M=3D$&.2 #=?^E7)P?SMO?9Y%9<?JXU)6F#COBH1J[IX<N6
M<1SM?[-H=\2ZL?\7YMXR**XN:A?LO!!< L$] 8(%".X2$CQ @. 6 @2:QJ%Q
MZ 1W @2WX-(T'=PA. 1WZ$8;=X<.TDS>[[LS]\[,G:J9.U.WYL?^<^KLJGW.
M7GNM9]=:S[/".56?I>[\"I*3#.+'MW.Q<[<[V=UEC-F@M=+_:!I$RIO=_^/X
M32'2N5%G>+<K6WS_J'')I*9MJOT!P)\^"EJFG_3@@1,-%1DI.PONC7?9:)\W
M5]=[B>F/XAJK:_"_<XXV+FVJJF4]2!@-4C$X3J%U3;BNF;X<\31H=JS,=XS=
M,+>LRW9Z]B<"^7P#JW.[;/7T0YT6H5WSS(581G;4F"O@'PFQZF^/!G:4?"[+
M/2Z;!4K2.)B,JY,7C9V]H,U_@P5H0I&R:OV_QQ G2N'<CND7!CT7TP,/R(6Z
M(^*[CXGL?82 V@K;Z,-S*KG'O^YZ@7OFSR:%/9%E>Z*SHTH*TL&N3"V^4\+'
M3^V::Y?UL\N-%]41(M^<Y,*-(]U4%^8/"OXNX>I[4^)19<+0;@>!\!)'CWY&
M=O9EM[(C1_K&N[QJU_YA@1@&IO BK^_:;RUI_#FSE/C:N<KTDQ'C/#V! O9R
MP%-K436W>L]UUHG<+;EBQ-7>'VB?V I"5G#&Z?7ONB'N7#W=VL O!K+<^J$M
M.0\ (NWMWN;X WCO[A_3WOPHGF$YQ?\A#53$R4IH'3^%183P3H=GH4]-8]=;
MF3%X@_'BB4$W=(Q<VBMU[5!X>#OPU;D??\.MQ6@+_(EWA_()7^9][-K.<[_&
M/FSUWV\#3*^=G=H;*^_X2(J?J[+Y5X)[/KB0N10?RW5",L]NAYYTKHV%-G-]
M=A8]L[GM9P)W7F"A#>3"I^>2T9F]&?%1SMBI\&ILN>:&-V<<Z%S?D6DP3YOQ
MC?J(DE>.#^GP >3UCDPY+*#X*9862>M87]6?6 ='9:ZVKBA.N/RYPO^.(+ \
M?D==Z?T5.X7*6AZRV=K_B3E/!D(T$W'WN$(5%>E!*?H L(_BE\@:\'1<SUJ7
M^;5KV#P]!1RTLR^=!HI0EPU/F/ANAX#AI/Z(Y,R7$K\RA)I(49*!XA5JDX(Q
M,ZBCB.\VN$">OV;T0=56JS5 3K>^-?H8^;L:/J,)VFW\K![!FL':Q/;^=\!K
M6LJSI0#259.Q!F]Z]50)'M+OD%5L.&;(7!1(ZBGTAZG=0,[W_9_OF!>[#P#G
M$\HK'/,5A_W#VK_(+2ZE8BRXX0$ / F9C0D$J:< ?'D W9=+9NUY=@TWCB-9
MN6XHZLB:G5_Q^^:J)Y]W87>ORX!G_L4J6,ERRTK]F%'05LG1;/11P!7U]8*&
M?<#'Z=0QK7.9N"C.RJ1MA?]!VL7_;T>5M!5,=>VOUUVQ?V(U&OM/;T*6T),?
M&-JQ-1-P\+H9E<43;Z6K+B23'Z?W5QDCE8]R#%:G9=E_S!HD77+&]I]<=1#/
MW/.7;<E2H,'NJ%O1V<L 191Z^*="OC_L+*M5'"4L-S/9?FO$HYE6[$>1I2)3
M\F)I9J*RN!(ZI!S(*/CJ2B3IFCKS@:-]%_#95R0P_A^5:K</97T^'(V]CB (
MS8'-Y&:X8G7S[;O2#ZHNE/K2<8W8&_&:/$'<P6$MN2!CHVG7E$(XX6X#;X=,
MQRJ]'*&_ACM\1\ADCUQX3I^OW,9)O0"K-FGQI/N$<M$@]^[Y>*5P!^FBA5E>
M;!VN?JSAQS_V)*0H0PS-)5R^\K?8%2CMS[L%G3C)_(*3%0SS:1/QYJ_:JIQ-
MS(% ;?@.#F@S[-/1\/;+?K:;C!OEO@;FSR>R\!>NF09:MSN.F+IS&[=/RV7,
MNEVUAVH5M[7MQVB7_(K=JZ=[&<EML?EA.:C7=/^X"((,>IE(IUO9V:OW'+&B
MO_6)?1TB3:5E^.(7M;[I:)%WF0A7$Z'DX/<YB*$S=<V93M[1_QN]PCN9F*-O
M=4;%8V]$BS[_\JG>>D?%44K0=!C#5+O.!$K_Y,K4J;S4MM2!\Q<OC47T&ZM=
M1,?BK/3F4BKF[WE>SQ(^2<X8?VR(,D\@;L*.*1WUPU#*PE#.V/,K9CO=7=^&
ML!^A;M6XH35P&ESZJH3K!EM$[95)_8$K!%B_3N>Q6#B9I)X?6#\W< X_&#HO
MR3RU<;UZY>+D7WQVGA5P8 6GU&^3P9.K.9BG88)@35VC?EY88.]*-B\H2!LX
MI%XG'*L;'B(T2FBY1Q*"#R!$DQ[9DV;:'\XYW::3'2FLU_.=G2H'LVPHYX',
MI/S.EVWZ75='4L*37\2>8@M:/U%+U@YR>R1"X"VZ\OZ4."S]!RCE)G$I+Z&8
M3-"'6_)(-\=UW%:V<5_W8'-^!S/>[2XR4MTRL<!CX6?BZ"7QD? 5 3[;ZJ-E
MV)ZD!B9!4+%L803$6GEI]+Y2&>;D'=QM[/F5(M'(.XZG90C8H^5XY1FE:+EH
MG?4UKDUF_\=I:BCX7KFW^7.J*S3;>,O;L# >$&KYWH>-3WE]^D2&NRVSYNC3
M.8'_B;VJ8IG,AZ0)CJ+9Y0[6D9W*DAY9JDEA*;_0Z)XJ<POD *O?VWH;J7A3
M495U7-ELR=FX]),'@/K,AHDZ*97Q6*FTK%V0E"=/C,=*3GL!+5.R[*A!5<&P
MRVG)H8E_VQ^;Z\.&G'YFY^(5,Z2&*]#&5?H)T=!+;:&75K1#3UZ);V= S0M6
MH48._H3K)NI?Z^V>9W#A^ KVK&+RJRZ6W'CDPIX"KW4-57E[)^E5"#;'PQ_G
M:%UYK\_E%$1U?*[(#""BLA33<8UQ!BHZ3T!7-O\PB%#.^RO/LLQ<0K6X#HL;
M&^H,CVSK'@#Z9]:)%-=8,NYFU*%A"45WG(US_!=2O)J&?'@]$R^V'L^X-I;M
MM@@G"V^L!T25Q2=+2_.H9;9FZ'<8U%?VITR8%Z$<^=].2_,4>(>-J<:KYJ".
MQ$?:?^4KOGQ-K_1H]YOK0&6X_HEL8@Z7Y,Q(:*ND4NXG1MB/KPHC++8<W+CB
M-#<GDE@&ESXRZ;_/?PNHCO**#<.VZ7E\EK?#M,WC5Y6G[K1.Z<[48Y_W\A)#
MTV"/JWWLL#AQ:3H=GHXUE?H3%\\OW;V?=G0Z@&TW:-4ZAADF)[BL$G'1H/)T
MVBJN;37>#>I>1;G,DNE 9,-SM8UE62*?G8J64'!6]:4FEC\G>OQH%, 8:JNO
M831_L<;G7>9%P EMUD_R@]G_9R7NX#C)%]^D>;_Q)-]GO[5#3 L/$K3)"A-T
M1%X>N)07L.6J73KC^/.ID(&UJ,J_%/@:-:TIFPY KBS&)NL]2/'M.DAK:Z"@
MFEY>5)RM91?S49]DTK\%MVO^5NNW*T]59J^0,.%5[Q#F#"TOUC\>-Y=P$%:*
M9LU62O^VQ#6E$OY$5T>NP>Z"SY$'DR Z^[NC6-?89E\'ZU)I/U/"#2ED:+:U
M-ZV&ZI/ZTT35?57%@%BZ)P5,AJQGOV>VC4VG+!4I]+>>_;>Y'K.Y;@B.,GQ9
MMJ#LQ3[A9P2KS(O 1MGNCFF_.4*+-VBJD9?^I$6%5DS6_WR6+<(X[YL'RM:6
MZ5Q[V7KBQ-C/7-<KW3SOBTHHU=,.U:,!^!I0 A\ [.6WF,[HN]D6>Y2CW$:=
M!61> )(Q%_X&>",W?LUS3*IWDYTUWN]*V"T-8G,2K18?L-Q1]+;MD</C#ZM[
MF].K=14P\4)@;LAI_^)([F;F:.:WOUJU^M@_YJG,(DU&WVZ>_&(>SYAZ;/RA
MO&ABQS:F@.Y[YEX\UE]0MT>:3G"5&T*=XQ7*QYMV[NSFBMD'0') O=#I=L*Q
M\[VKC4LR<>;K<;G)1B&\%9*["J^/[ X*YS+ZK09_+PVG+]!K(HTH";Z2>.:#
MGR\[;GG]]+SA41THD]-FQ/81=!&I$IBF)S<P-_!)>#/U<V!LPNU1&_-6,*;C
M*:(T/VI7UOL_RF3+22MWR1;O<S3T!SEP<5XTRB_<V(H$9FHXL4W]VVOYS7^%
MDZ7;.3QV?]VY#LTWFXV$H/)X'2TU0&)4%&*+< B<,VFW'8HY2!"W<5HDZRRS
MFQ<CX*Q8\C.O.=E*<;YD%OJ]_ 1OSIT<<J^4]6GCH(&B,+_R2KBTO-F\P!FZ
MZV*QD/)J-#/)I?-.T3BO.#OM14;SW^FETLI6[BCU6!)2D2/8.KE*IV!P">WE
MAJZV6ULS_J#2W)[]A)XC6(IPMS#J]PT"I=(QRZ8#K?;<P.IE;X>5F"W)U,'N
M*Z[)MOVUAROV@X._D2@+NPW]=%=N<HKB+./\KX7"4(L]JF8;.(*_V-!JX+T*
M6Y4, "LQ(%0XTU/!D=W3*+]T?E]4,K0GY6JR,4=D<7R$L)>%J<44*]Y?#T*&
MCIKJIONT8M$OG" <].K9>Q.VIXMQXN7ODU)YZ]A'N:7GQF?SH?/FRJ6[]7,_
M<0R/+%6_B7<#?I%E>6U5UXW1  .9IV$.8"RQ;'!0N[$U)P<MQ_YN!BN^FFF9
M/7F6%=/G"S&[_*B@KB@NVB NVV=Z2JH<  * ,3>AU+Z&PE.1T&DQ;1R$.2U6
M98"@U/0% J3$-C7SF$)/PT"W8>*BZ9)PL@N/VOW0-*=Q-4 #7_3@:VWR@E/4
MR#@8*4<&!$%*_N1H?TI+</D5-9FO[>KI%V)=6!D4Q5GX*O^GOSKJEI10]7-S
MB)@@?767W+,/ZTZ+VR_E6GE\R[K4N#7L!G6CDZ)\?^1'<:L1<)9G5!;AQ!>-
M03S8[#Z:C;*:C<3<Z*HV6+^8-+!IYJ[/+C79:W:@GG5LQQ^7?#JW$]"O5O-&
M0^J5AH@'A;;BL_\92E^TD@VAM1K@AG_70?[WOXJVRX@1,<^6&=[)G;1GNW#4
M3SX_I]B@-2O$.OFD*+J/H@ZM.*:;#3"7$S !.<0NO7X ^+QFAGE0S;TR-^YW
M!7)K$$4WL;WYUCT_ZUG"490I@Z_%J) 1D[5.7;\K-YX2Q0DCE=YHYQC:O).:
M=G$Q[>GX0P;:1ESG1K\S^*7S]4ZWCW0[=]><V/PS#SJ7]<*)1K]3;%GK[&W]
MG)#1DJ([B%51^!TCHQ:W\AN#2SC9WO+S1"Z1S+XFN]=DFWH*VW "P($<]U!^
MD].AU2ZCN$19(Q26^SX_BHN.D?FKOR)SF+\>\>' BX7I;@'MOT&16>%198/N
M27\0/Y@'9G-G0.%9<Y2&?+MG3;)X(N'@?NVYO=S:'C4KPLND7^E3=\)7Y.RH
M61"245-79R'2D;Y+91R6Z77R^58E7J<^ZHB6=I8G$MOQ>216;$$3R\='*U&[
M%S!WA2F8L&[^'D(Q++>6<" KOE;J"0#;<R-[V->JDJ>'$QKKV<R07&VGIZ/I
M-*JI/^59\0!8]91YOR>!#J_<H^./\D!2.7,J-?#1$>;]M.4=_QA7P %C8FV;
M./:WS!\IVO<-3"]3?EJWG.<@]I;9#B$T4>U%HO5FS-+<0)'?X1!$49U65N9^
MR&26"@(5MQT<7S.5K&<;:+2=J!5#_0KWZ$Z^XWV>,@FD]F++6>'7GA+O!>T'
M"DY</  BFLWVEI&+")%,Y AO:]!KJBWLIPTRO^YX>NU*#C?]D VK"H- MU(U
MC:*1!T 26^TAR,XSA_/D*IWR$ .GCKC8;V1O.M=!+'\\%VS9#),BR^UGA$Y4
M7-Z3=^M6F0D933A<O,%9>4;[%L8AYW<+C6'(8CA=;J6*8C5)7GI^2JLU"^S+
M-HY%[-O,L#> '>_&],=% OB TJ[%0V4($]D"F?Z%XIR/5>(!>WA.(6ZDXZ<9
M9\6/#<OZ7O?CRL'8*;.*-Q(//-=^NG9KND5WB'0\_@C7^(O;(E/?HN7 ][EE
M)LB],M>T?+[8%T01^'@+8T,Y,UL?M/$;12<,6]D$7&,XJH$WR(*SSYMCD6 S
M+X/J5),.GUFN[['S'[32K%<!N+-M4F;H:)+L]39)0C\DJ(U.W=^TEJ22,CUB
MD.4!0#(C?L$Q;1 UH4<W&3OJH*07WB-^SL-9G*BNX7L7KUS;,G'W]%3:;,$<
M:6IW;=<=4)MOP2(F_DQUYU<@TV6')75(JP"*4;EG$*7NER#9PEZH&?/;](@%
MX.:SZB*P,MOZ.:K(>(G(?E-VSC?^0P%OVT8'QY;1M-,(I@SL;0!L3-_DV6V*
M[-_7*X7+GVAU\\0ZVV#JV>I^KA8&L&5!#J#'TU>7%07X'SR5 UDIWSQ6SX%6
M6\PD?%W3PMF3?=F*M&_7*/\O3"09K8;MJ$N_Z#&2._[QWK:*3R:#. K_2"_$
M7Z==69P]UCG5BJ]] ! BB)F[3KNF>EH$@Z\]'P!WNI"D77-%L)?,Y72J6&+K
ME HR1UGB)6A/\ YZ."W'-N:=4<FGF2S#BKR[[>BD8V(Y9<I#:<@OV0MND+!&
M>JOT_V">*ZO(X(07QWS0RZ^5I=-Q\TI94Z30P_L_45AVY,)O@NQE<:<62(SQ
M[L*90L4QAG*Q_G_,G+^T6OOSE@E[F>1J-;&.8"6&UWR]ZR^9;'2=9K0W/]HY
M[-3_8'^+%%J&AIBD\<H*6JA[2;LHWV<4^%=2@,VW:ME/L=N?S\I5^PMY1O[S
MML;,'@_KN_Y.!"E]?-GN)<R/GP3H*>@SY,#1).>[M?JGNNKZ\_89JI43$>5_
M6U=U]/LR8V-!II^4#*B!*3^UN8XTZL=($KOG/A$I93_1VVQ+37\Y]]B*X/E'
M^45\Z;@TRGG3)9,%D]IK=V5L3EG;A*#2.PW7.<@38\Q:12MC\1#4E(2H5ZTK
M9^,!<%.:1[551'.X7;+!?:9&(IB",<;8AG][W4DCG'PPX2_=.@=/U3XM0J>8
MNCK:Y5$JYSE ^$<;.YB]&;R-[2HK"H$O^6C*PV\G&LP*KVE&2>O\+DZ_EVLE
MWF!P@W5Q];,D#DM0KG4[<KCL/*C,@1:9=.<>24@D7+9R>XW^\!0:?VPL?O_A
M :!68=R&[_LTQ!/.K(N$]K;S/0 *O/?Z-B!C%8[H2/H' ,Q\RESB%"8  \8O
M(G_>93X X!;4D1C:&P.2CJN+EI(_3/VS46&##?,F3=L>:A"UC&:M1U"IQY^]
M$WD66H5*E8O(^1 X9.MEXCLRIUE^L]DZLVS3K)-\],JA+]KP;[\G! 5!F&3V
MUDZ?<U08H8P)O-\A5$O0Y8BSL??G>+>&G__(1%WU-V=<,II\:#RY#CT@#:TP
MT/E2&B=!YU#.)_[)+XY4 F#PM/+O">[)L+CRS%MMD(SD?GS3-=3 A/XU=CM_
M52:ML:81.-7I2QRBK>%'67D.=G9,D4IO(,%Q [#9,@2*'$QKEW&>M[>8[SN.
MT64FBP\E>"S/^ATX>+NCF K J(A:QT!$GVCFIJK#)DGY_ !VV$?W*3AMZ5%K
M  H+M7]/JC8)@[/%*:D B JMT&DI?0(7-W-B^=Y>N@VG?4F>.4PM4P=WFQ\K
MF#2^,*G7B\N]E_U^.>U<"X\VABVGEX@6<*MR@CS8!,P%E1YMEUB]R5,=.2N\
M7TD^WK\)@NF]=A=M.\Z&[=XP>H7>^?B5F]G3.=784E86 >D'*!\1>%[JX'.P
MW)X;28KU\%-Y!RVA)H5-U*-+5P0'PPP3\.B5^:^KZ3O&=5M9?^Q3^RY7H63,
M?ZN+-H;I12U]APJ)W7)D 03&=.RWN\Q$;S6F+MFG'2IY:3<5\KW3"8F8TAEF
MA6+QN ;9$ TKT[-94(TNWMILS%%(!CSN,K)5531R38:/9S_:-+(P5<I-W(&X
M&\ DJ&6<VXV1S=2?$K%NJ54W,] (4C7F\Q0=]P/3B&/;MGTR-=S'$)TNYT%W
M$6\SZBI_F%7AL<4>MC!SLCT)^*F\XPV1G[%J.!6+N&QQ!_(>9G<5OGRU(FJ8
MY<D $!HAR6:VK:Y/\9II_U&N?Y71$. $RS?#KD%'HY:4E7-NNM_6IO"\JQM>
M,_G(Z()SL$&BB7]#D-1CSMM^2MK]HOUG3:RE[2M[J3C_@N2^924W0T_QL773
MZ]"Z ,^YSN:P[,(=MY5.'YX2!*N^,V\ZI>$3W&*\W;DVL#X3\;1C.[D%4(OY
M)@!Y7S(XQOU:@5JV\34Z8[:02R?#D1W(XPMN2I:8@>(D.9UZ7>Y^/,&I*M]=
MICB_C%:Q'(<YFJLX/0EF"Y%3$(.T2I+,9*Q07H8M^1"'9;S4.]V4&3@?&"N^
MPTBY&D@+D%25HQ6VNXSCXEU+RDW$H\[L%O0R Q6^*3=M, 4U96J1+@,G5*U*
MT50!"@<"^![5PV5S[=VU\7D4ZP2"96+"<$AW^QK73*PXIQ@H4*9>BI_L3CE3
M'=/;/ 5;RQA['Z'!/5 RC,7*7?CDT9X$;@:\PCNSYYNW_M&UQ7@M&@7\9.+G
MEQ;S=:;!UF5IVM+WZUR1]FE)^!%F8JVQ%L:T:]D0X1Q% 0S!_LFN3G2QG36G
M<2KY>^\!T+E%3PBLM+E58.:C&:J7V/[G9U1^6X:J_0- %R@YAA!=CKX0$HEG
M6-G)(1X'$TJILX.F[S?,3;#E 6OREO&S4*U35HNI2T):L",YO88H^BB:+5W-
MVGI;? ";@9)1&6:+ABK-\,DRH^V75S1:4[S?1WY2H<V0Q5T&6 >*0%"RR:4K
M)MX.1H9FIFG:=Q-$+S$69)>_UO/V=XT5*.BC@/;_"K9'CE;K -LH(*LY*4=5
M?:/;!#\2 QZ[6! DP'G! ?;K6SE7)T']E8"E/S9__>$Q>^SG4)3_(9C;=0<4
MC%9_%JXT73NHQ%'3)M5?+,\\0NRBBWFL[L,X(Q=/^">+N"/R\\GA=81BRF9S
M:W)^W%_\_++O:B@@0+;IT#QZ]5!PKKN#=&NFPE@J\^^#S2V6;RHZ"I[BV!]O
MMW[ZLZX^ !J\D\PD,:DNWSK2?JH*OPO>^D3(Q8J]G@=EHO@Y6YLRZ\_E9^LV
MF]3/C5CV>?F)Z$-\6PQ B;2*Z7('Q8Y?0M.FEWEN<4(J14K;6:9J=Y2:]  (
MLM_)$9T&\X??%+=(BT+!MJP5=A&=> 2%UE1CITR7N:[K]V!I0EMX-^C3"/M0
MMV3:BGW\&NOVF%5.FZ+[C5Y'U($_3QG:B9G4]-,:PJ Q@>8QO;R-^:N>4)K.
MX^7F7&)OSZWK->D;Q<O:^FOR= )E08J/R.H2W$6"R*D"C29AV'#[NLH'F#9G
M\?$0.N7.8!T$$QQ3_+NY/I5@4TFV7_44H?V N*+P#> RYZE<1&WT1>V4QY"R
M!9=9Y5$1_E.F59OO)*]7JT2&O%G?SO+?:16KPG;G1&<1BE5DF1%&6(P]E8(2
M+.V05>$<D?'+Z'C&(7=PH;G]%=\/DT*BS@^.6-A?/%>W983VU83M^O)+"JJ=
MY\PD*X.3[:N+]^PK)R^FS./+)M!6_>?[&7R5UZ(GBI"27U./:%]( '3'S+_$
MFZ.J>-O9O?-OE7*NQI1J$WAE09DQKV*5/^(<;,\E790O$X^+.$JTJC)NI;HZ
M64]MQHF<I4$%=LI]EM!/#5J%"O=$'P#XX"&)B]O2RJ*4-PRDA+@NVH"NA*1Q
MC)Y.B0)Y<J(OO-^-5?(\Q@DQ@:%GA(>T_C49?+%PRVFZ9Q2A46K!/RQW#\=G
M(7'"+2WS+(VU7Q9?OC?M.OTQA/72C_+7GHOO>M;3+R#2;G)0#CW:ZF5*\]M)
M"]@094/&"VRN_I&&(.7)9CC._ADZM=MEC_I)A1"5-?C=(1M3@0PTSL6C7/+;
M@A3CMPSH8TV_.O?4$TCXT2$8JF_(INXG89-<:1VY1AX>^9Y%24_ZB2K+QU4O
M*(0:LJ$>C>EX^@!X;7\$C4$767F5>JN)._!^;OYNQDH1)G@8"QO%M?> 2J9%
MJ"E %76[?PM(0"T8O9->CPNG'WF(&RB3*?^CUG/\C?OK-_<^>38;B.3LJ46T
M=*Q[]P/ 9NJ ;ZTM3J(@Y8CX3(DVC"#KKH1RS!Z(6G*6G_+GYP@O"C'^S@SD
M1M)P_[W;!P>/R:6J=: > *3V9/LY-$&_1[>.Z.F]+7WR0].59K'8OO9CB2 '
MU;-%$WT/;CS$_^R="6>"-.;,BZ^CI%W]+%%X%\PDP/V TI^/0](13;18@+C%
MI&^ HI.&.'X1QD SW!Y1?)LR%O:W/HAY6E;LG,5M-C*C0(Y)<!LUBL"[1&4*
MJ1,YC1OV2IUKX6<,B2]1</ ($_6D",P6A9W#->O K!E+$;'V[4G/P3P."2E@
MFPU<(9/-;!4@NGQS[BEZE=Q65[<" @XMPHOOWIQ^KG;*FZPU42];94]/,.3F
MEWGMI-I/(]-,5\<<!^9_@B;4S>GK(X/8%3F-YWY[^WL!/(3U[=%Z3O9^\HEF
M0X5=XMYQ@=U8.3X!/K9E9&SUK28%N3+O'S#E#)JU2S*V).2R=YKUC ]LER$<
MBN86_8E]8]VTCJB':29+-5!4S'28I$V4Z>>KJK:40"9[F4.]FJ>I3!X7=5P]
M25'.V4US5L(C$6@I(;R3V6E&0\L631?5"XQV47WDKE>#,S:N>Q3-N;^P=+SQ
M0,;^0MZV.N.5:_5-0/7E[Q^K-@7BTJ2_COK-R5"'PH7IH=$:!IWGH'3GQ<77
M+\O;^[GZI%:_!.QE =5J%R<#6N<"KMG5*NPZ7]>M#%XAK>"S@6RF;U;OI8PF
M'0_OAM(SN/*SA/ 6E%D^QL/')X=0'61+=KXI9>!\X]>%A+KL/YMTMDRKO] X
M[7Q(&M=7CFJ5\7H X)'$.Q?OB%&=TR*,8"RD C')?;Y5@%6PM$=E1P]5JI"_
M0,HLO8]UHZAV:>B35#;' >2<2/"'3P6_4V#PY-&0?=6A]#;RVP/+-^OJ0Z1A
M3_9%]27]R>\+NUBBR'^6#N[D-6-$-/=1!I&.%[=F>A=2WK6#:4IL;@L)5:,K
MF5]<7+_Y@L7+J^T0>6@QXF]3SL3S;8L?S^B'L3BR&T>YMR-KLY76U_C";7%R
MP;S3.GW67Y]]VOE'7.*]H&3\:-W[O)%RS3/0AO6F2:K23'[N\ 54ZGM;5= >
MBX(6W4#3?A@M\VCK/89EOWD4YNZ\>LA$/\!;TVQ4<TYJT?K#EH%$M7)%(7;M
MY"B;H73PN7%/1<RK#R&TV)XB6\;"3"_0?N462.,=7?OZ.6R'1/9/)$)UU3_6
MX2QS3$Q/G'Q?S YF>T>.<-I/^M7R]PP>\SFT\HN6.-7/Z> ;&W[8>#;L#[EL
M,;#Z>_#(0+["LZ=V"&NABG*C2B<V0KHG@;N#[Z48$GDR3C?#FN!HOS?3F@FO
M6K_FCM5'>E53(8._)L4GG8R)J/>E2"[75.PV9_=%0\"6[,T"51$_[4R8!<DI
MDB6.XY1W9_ 47(N+'"4ZY'13W++8M?MNSC#FX>JKN8R+Z/ /39.7)GYV3GD*
M>U=CWUWPL$DT?2^QKRO\+"(P;#-'Q4EO)AR=>"W]::*3!!@;%_'O*%!EWM0*
M,Q>Y#.HR?=$R%1:?/6-=^EZI/-8=EJ ]G*L$\>M/BL0J[43<,;K:E-,VT$,5
M]LFVIQZ[8\8M]4O'KV!L,)LYIWM5,/26#>G5LMOA%.Z,6F&P]^4K*-G-",QU
MOMHOI3*@%KR+4&5U<BLHE=X@28:O(4=,+":.GYV*IM0KUI .K+S\;9#X:(SA
M<A!7=N:W=R52W[L6&:#;30SK)\Y@2WTEY+/LA(.B=9,?*V6YA#X B"[N#90F
M+VG!:5NU-2^9\#@X!+XV5O4[+37UNFMFBX1OQ<+_[$]9C.^$JL63#?$@SZ8J
M<TN/0^8T/0B79-^T'!B\*W>_XVC8PK\#M59BK;WD0R@5!2I--[=(/;K @F-D
MXKM:;K9[D<C?_4KDF"XQ L[\)LT?_U^W7/H_CDJO_KG$>6_2#SE+48.;V$22
ML<,4F+!F[N[3G&Q7J+>4=G5UQ)!T53SO(RQ7(M) J0^:=Y7]^L2]GX!-A\/P
M7??1._J3,8U3W.#U:;B3$SEJHR-U\Q4AC3ZW(-YV0L8$6L)'&H*X>7MDQ&MM
M\/I^4E7_ 3"NO&]ZF!K<_AR)8*^#FB%,BCW[,H+R*S6U"#"%$\XG_7WJK,VJ
M#,1<0PV($Y/]N+IN^M[>/M(WAZY,OUMY=&%1T3I><65G"P^ E/#&"5/;[C%"
M>PQMW!U(C.R=$]%G.3XE-X$6B0&F_!;)XV@W _O^GD] A5@# O<M]?(]EP<
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M)HE;BCPTL/O[+97\AW&E'FL<-SI=' *'<BY5[]VG2J7!/P@I]&2DM.GB$:Y
M+]"5#X+Y(JW>IQ$C?*D[CTEV^T)0  ..0'<:C'T791H0K +I[ZU+9;RO&0)%
M?*. C2UYPADUG'89[^BHHAU+3,BMOHH>L3Z.UX&0JT(OM-\X:1Z0:^O__0LZ
M-/]3ZOE-.>(PSW.)S%]D%YOTN_I_D$IWTWGE2_0//@?,"NV.JKO+F!9EXJB.
MPF[\"!5D5;+BR'L6.3 6*&#8/*ZS:0O3XNC[D'>XSL@;< D:OY3\5^L]*1T=
M39I[<JMG:DOVKT@Z7\F-P>C,Q7$$+!"Y%JN)I!5$J!7LUZY?PM.@H[UP'Z$+
M$JKLD\MG"RO'%B?_1+45J-N0--F^@-*F#+[0E7R45>ES<\]3B XM15N\;ZJ2
M?1K&><5ZGY?7\ KJ@7@EO^&_N-[F5KK,NWBC.O<=U!<5#%PQCYY>!S5/8<CW
MFU/200&/E[.J3+N26'P87A$]HNT";S4:7_ 'RYU)F#T YH(? #L#>[N<OTVK
ME?F ^FT,PE#MY"8PXOH!P$K8RX0SW<KN["Q:)%,(==FDD#]08;'-*JVT;UXA
MV+>8MR"G6D,ZD"^V/O5U_-RG]5-<+M3+W1#218D;<_G]=_J2SOAZGFM6_,=)
MR'J=6D8.]*V[UBMHJ'VRWLB+)"U0 X\Q C%G=N3=9K=#MNNVGS(('V*3].$8
M]>Y\B3,5]R6G\= \U:?2#.VWAO,UH/B/NINU88HJ*\G[)QOK,O@(W"D1:+FQ
M";PG%]^>ZY]NL ]#WRIGGUIO7P#FD]#AA]*#8^2I0%FF:IEBU^!YX71=Z].
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MB6=8#GW\FU2M,!.1;DKNU[9]A-L2Q'-9VPR?OT@0$FOUT#%'%9_$((+LJQX
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MFBT)A+X+T:JKA(&Z:R=M3*SO5Q-?EU&@,_M\EEB_'>=P<VRS['-W04FXYY'
MRGA@LT9>_DYU&MWQ7:;##\4Y*+<W\%"M.$<9R1^'P_!6&8T#_=N&M3O^*"=P
MDOY4LVS>SF4\Z@=^CE19JS6579SOUZR?3-YSZ3'X+NDG?1V3DW=X!;N?=VX+
MF^L:$6O&V<UU2=8=).^>ND0'I)SW:"IZ+5/C#$JR%4P*R\H,*,51CW^6.C9>
M#[SU][Z #NJ.W@T9LC[;P*PR@F]HUI?7>R$<9=&B+(D=4K<Z1TE-][@F-#_H
M*/0#0E[CG%O3/!4Y?_"8!SM1_WB@M:\T,;N/6]FW(AK="#T=&1]!=-SH&\H
MQO>%[@U'1.&)M#KZ6LP_^9_9HFL)IJ>?98(L%<97Q]R_U^SYAH=_S^E3:OP\
MA'GE"ECVA&H1:YT>W*2LN8#M$2[9L"-V9D<9DLPTI[H_9Y#0T1)3,!IP*GOR
MLI/$B)NV8F;R(/G5KR3O]?.>^0\UYRV0KK=@.FTR!WB<^1ONOK!NQP0%F>.O
M"[W2KFH1!#[S5<<8&5">'+R$PSS2@CO=7N;D9 I]%3ZU8@L* )^6-NV>;F=G
M'9D,E3D.:'Z&RY'2I(\YX0<KTY.].9(<+7OF#53:ATJ4:?S/2;W-. AV&W>M
MT=%66THGV*KK@;,1Z8YL#M5IJ6RAR!J>".9_3?&T/(Y=,K3)*KI<$0_2Z[.1
MF./F5NCP"'"LKVM\?M)1&%U5]"P2QDD[%R7YV:W3R"4/]6I:H2D$*&UD:/>.
MZT--XIX[>_H65O1KB-3%9M'H<=.;3,ED360!;6U7R/M/20!%DN#H#",GP:_U
MZ<?:E<0K1HG]#RPG/39MQFX_R;GC4']#2W)VM@+EA^<CK:>#@N52<QOM.WM\
MM*F%5'-EV6"(S#?(0L2<M#47IWS?3C5KNJS!U-\@/+X?O*^M!$;S'^CTO=23
M5)*(6S@%L-*6YB"E7D!!Q,9#5Z)U22+\WU<::Y*9TES&TND#DG<=[*18;3!:
MW$KO<W?52TOE[5FN=+%7E(Z:KEKE#Z;#*FPYVRPVZ2TZQ91V9(S%\E<SFZ>U
M1[7NG1<R/5L%3YSO7AZ#(VLE(1S4M76^[QT:LU#A@I[GO]>BP,+5J]$4>]RK
MG7G;D$^!8@PF^;Z<Z$T)@P!O0P;T)U]&84Z0W_ )R KI0_NMXM&,S/AEY"UB
M:"'"2M(E^C=LCPX'4>O[A[=UW/N][U-OD(>-:!(C#W_@9_^ 6ID1&"R@IX(Z
M2:)Y/FSQHF7*T7'08[K"UVS=0YL"G#O]6T)X*+8VI(#Y:&83&.Z8^P[S62GN
M%_ (_Q+%CE'-L%Z7_9JC0B?YS<2\I,EUC'GX&\N7Q_BOHYO%I5Z,8&J!/*\Z
M1"1"DJRLO'TA'#.:6_D5?/:T\(PA_:TX3: VK@EK>/X)82*DMI_\Y]NJ:W [
M+7_ZR9Y!O^31W -6<&6RK"U;$6<M;U4]W&4):'KC%R6[@M=RNY-DY%BT.33?
M![-=YQ5X3Y#25J$E<@ZCM0(B:WGI"7"WO<9W0+AT[M.:3P>&>SZ3-O0R+E5,
MU)YK8QBC(/JI1QI-K5'L*2EE0^WM6$?UE'V]F.)04";!KVGAYQX8F:>_;YC_
M\)1]/,WG'!W0(J#)\G$@UI]4+8WHU.\9J:G5M#^$T:O#,EIM27FC/>I1_OZN
M+"JUTC(GW)FK8I,_Y(]J @4[MF4YQNM/,+^[MU':7:;6WHE>S@Y9V,;3-D3O
M=S?^CNU'^QKG37DT+-DC0Q*MCOHTJQU:5LY#,$NLI*_'%"?J)48+IJTT?: [
M5@S)\ *5:G-?3*U[[L9RK\]U_^I=D(_X(J"$[_(V3R^%\U)BU["=@[@H%\;*
ME)!P:3@-WJM8=B4"QW?7PUD:BQ5@W4_M17')!.TB$.P,CJP4@"<]&*JLK(7"
M+"=1U>468%^U":9PC<8I[@"$]. ;IC\8^]\,UU#4%47KKB#9WP_/)-HN?^]!
M9NOXI7=DU"K#)'^.*&TP;@+.&9%-CL".5,-29^LOFE;,7W! TNF99K%L^P12
M+@^N]DK"-,Z0W4? 5^,2%+:!-XW!U(6.H5%4TH.SKSEDF2;ZCL5G_6\Y(5PP
M/"!3D LO\QKORAO"T&SDC,Q^H+U74@.IKJHOA1A1U>65YT1MSHIKIGO:D3!:
M1=Z[RNME]KZ")S=CY7>N#"Z\I%N'G3DWPNW1-#F=%N*ZK,XO#E5A(F-E^<<3
MVWJ8B<..R+E-Y^22+T_ZCMIE3=ML16"L8QO@.V[Q8IU %")@=X;9UQ)4,ZON
MS#C*X\'MVTF/=;ZW9V[E.S3V77G&BNZ-#=9,GR0<7UMX3/:[,/^)NM8$^N@-
M+E+F4ZPWZ$QF6GQ$\(]7J>KQK>;?4L'5D=CW0&ES?,:47V@E AW2>+KLL1/(
MH<G;[O,Q 09T&%^P'/5^YD@9MPGAZWO.X-2WCX_!QX>.3?K"DB>O.*Q#2]#5
M*'ZK'EX+-VM-O+L0"S[1#B^78B\!V<,4:7P<Q\(';IEL"G '^+3X //\7^/C
M,Z?J/6#FYJBSWY]*GT&<?ITEWV=0QE3Q7YL%MONB 5W :.KAG:DA8?7D(;,/
M[X7*S;U*GT(W_J:$GQX89=&8]FL&$QY/A$?3\N?"P>2N!S;82L"-]>7+;F8M
MJ-'<&4^AZ-/Y] ])70FYB5'LO'>IM_LNF1B_D"PGSC]>[Q4*XO5';22.8S4Z
M+W*T2;$\'\&0WU%I%9Y>DM=D,UOK@LRVO;>7RK]MO)USJ9^#MGCR@T5Z$%T(
M4)V7UV6UQH/UL0+;::'4ENMR?'K\=/%JXP*.4A(0E>2R:B]4"I,88:(SM5#<
M:*[:QVFR+<3:FJ8]^];/5D "NB@3>>4&$RO\^6%JPN+4<.-,^U0]5QJ/I,RA
MK+L/0/;)IF5$K" W;$]&_[^ZC^5_Z6F)UZ1MYA4ZY=+)'I1,1Z?+1^Q]0U7G
MCQ:!E0]$1JXKXX?BA*U"%3J8O'HQ_WS,=74)M]O]K1/I<US [EIXX-:H;$)D
M3B'PJX]AG4C=3/OW$B&>U>\?]H*;6]I=7%CKT&/ZP6@4GN?D"C-;\<L/OTX[
MC1(H#U.4@1,YR'/U%I&U0S,E/;%;:)%S^_(#Z1GW0?ZL__EEDFJ5'1,__(;P
M,V@W[&\I&T%'=<K[<OI [\IME3,=/PIS8.D[Q1TFS'6U>%%J,.?<3SCJTB"3
M3EO5<>\1@!X0FJRC2+J9E?.?5A"P!T/,X,>'M1AYU@'@Z*'@DU>9)0&U:8I"
MLUYOM(B*R;%*"WTO&ZU :\XX':7VF$,I>G[&NYVH/)GEK9.;Z11">88(HDF#
MK)  _H?V*4AUQ3JC=O,[ 1_%E\NB8^>R7P_,+:.;12\EXTMF"AE2*@6BE]V6
MMB%9R-8DM!]ZT9RR=".GC>] -:WDU:>/ .')U=+28XPH8;Q/"T.-(4-..QUN
M8Q!!%/8&9^V$E(E--DK^9:7Y39"*R=3D0;^TVWE[^<W\?%VT7B?4"=17OQJ-
M[9!:'T:V*C8V.]#W;>PT?#[V>JJ"$N5@?S[W9OP3(Z?3<PCOD[Y>&B_8 0[0
MWU)!(C@Q&E_TO?Q"&VWO6K=+*/"$)0T+6>!!5B^*BU[6%2>^C:F#J"]PE9]T
MY.G5^$G<YA89)QJB%*5O[2%F\SZ08"+%(DKX"!^5(C-:81HN69Z6OT:O?(!"
M?H0=GVXR"VXCN.>-^R*_XZ'H0L_+"TPL$./)$MK@71=W_7JR,].A#XT_5F-]
M2LN?%Y5:O=!3/4&_C/WYM:ONJ"L1@3?><-3K_+N@\?CPZZI??^X 7"1WP9%%
M/%#A81!"@#@EC53$/O$;\WS/3%EN4II';3CN08M_/.=05P7LOY,,'7C8]2$Z
M+R'=3K1@3OCTT%$FEUJ8.4_A)&YS9;A+<$U1DM2*43V5!ZK 6+@NP]A"E!MS
M%3_L;'?>K:?N0<. ^HA1Z!U:8"$>S'YO8_H!J].HXN[EF&9=FDO92+)OWH9"
M[". JV/]@?41(%\A,B$E[5V,BL.C78G#6M10JWII&.D3)[_SU5)QUK33R@8/
M5O(LA.1YF"2 W^PZTH." U2Q[ISTUC6MZ"; >FK3DM*CC5&]9CS7.7.C>4?N
M8?5^'%4O>TQUWNL1)>)-P5$TR"_UQ((6RNBG@"J:)BX&L:V?/6?\BOVY%)5N
M>[]FR6^AG13K--K<S]8[I_Y";Z6PXFS;Q^N+D/8^+\9,^UZ==])HVK2;6] Y
M!?TW]Y\Z0"4.=B;PQ9Y:BXE!XL'\WW201_A?S8CWWV6%ZL3:.)T"H5&*'+L^
MA$K/H>-R%K-YG>XSUBB7$_&#<HIP<F?N/^=VE@G.G1'WSRM<GQ$^%\?,(6V_
M,SKNO:P+%%;7'T9F8KW#Y"4_"3 /2"D.( -GW8(ZEV:N!#Z>:3\1EVJ&_(;@
M9WVY*#>%-*457F[[\[Q+E,7$=0]@NZV^I[]8ZCMTR(05S.V9:O9D^33E-+R&
M[?L2'>(3K!BQE2>6EXVF1Q1@L2O.Y&T<V*HVCEV$9TB<N' 1U(NMA'ZDZWHW
M175Y%!9 ]# ]\0BHW;<:/D@-.-%WXS)_!)#NG8_6@B.]2>WAKI4W/4;149+X
M)?X%>1>/@$ 2'<4//E__75GI_\0LIHZ7NO\B,85X.>3SN,WG=>5G0^/N=[W:
M?3?385.P?WA,//Z#QP3_7SPF0-VBG8'M,T&I5HH[R<*K[;M'0/^%9 6A7=RV
M1$UBE4V>K) NT=7TG2_58(6VF^W)BX[*A9D#8,&S(M;D K1-A7U(^W3*X(L.
MP6Z.G[$4I>PT@1)A-_/2-H;DLN1=8YET><%3J9+\:RM6!?:7<,UL/>PG?/$)
M8A0,_MKB,!#D!1C2U8\K,?1ZT6Y>@ MV:CO3UM,\$D;[7+K&FF-BUR<*ML(T
MZ:$^K+LS/*F)><@0'DB!C^'["+C8M7RRXV4:$,VXF*)3"$FDQ+H&K.7L9!U7
MR$[XJ9?8#:%G=/#;)EM?QSS0MF$?NK=]AWL,H$_F^:I*R\V'GJX;DK)/Z6PL
M4+]VGZ^H%I8RRNDNVZYV_"X\J6)*AK;9M^6\-M$<:,=<EY+;$)G[-[=%$%GD
M![RTR_IDK*!A)?WQ]#CO>.]&/^ E%?D/Q[RZ<-T:]2H%11:W1\ 3UAO=/''$
ME74-=FS$1?CDZ2PGT/!X$9I7*>JYWCUK_& C&^W07[Z.,%)FU)3D@_8R=K[J
M?U$ED5[*WH&YIP$[PK+#*]_=93:\99(5&I*\X5V[JWZ3GUO>2S)7)8WVF]/+
M*[^C"(1#DZ11\#ZYYUFF3B]ZRTG60!6PU\CG8[UP72-42F1C-%'?;Z E.H^@
MP',@1Y_C"X "@)\ ?(OX=*%NA7Z')61;N#)P&S1)7^#W\%*_^$@O(6O9MT%U
MO ",C!: ^)PIXYTP]GA6@E4=:\+S$\W5^0\5!I1D+GT#73$(BDMEL9O%[Z-7
MLNKG67AJ:53[-JSHW0/$64_H$I)6>4-.NV \R3)S /%3^OL/]])_M\BZ&EZZ
M.=6Z4=/OQD-9#)\;HJ.Z( 2G-T:XG,+ ^QS7UHS6LZ62W-,CJ\"K>*\D"+/S
MGE5-;BRMM=S)+YOW,0.NSPLJ-*X__W?GH/]B>T)I,%GZ9:#S&5&,(MBIVM[M
M&+&*:U0'2&-7!2=5]VB/TD]"3EA:1G[Y6:TD-^NM7'^:P_J<U5P?$PU?NZ$+
M?03 C)&%6]2P\;T-XS\KI6(&R/3SN/L I=K(?:K$+/2#M!\,&6AY^,N/ --*
M"^GCP:XS.Y^:3 ID-;94P0=BC[!/R]"Q1X LS!?/0"+,I3'$*C 1NZGP @A=
M0 <K=V5AT!,X9#G_^AXILM. EL\[63%V0?_]P.+(0%B3!V&"8/DU^8I87F E
MU&5;.0<S-;5F2N4/@G.(]4LY]-)B;_!N_'2!M':U L\<# 3&#:R31=R-:48Q
M:UM6%)69GE+9SV25ZI9BCQDP'/Y%?R213_^3&J3XI>TRW! <4-#H1PG_?JS/
M02A_&M_HC=1S9SJ4/TLP*!5LJ)LW.M/W?J9'UK)].G0:=L=QXKH S,)S*"M[
MG565]"!\1'GC03=#6SK>\8%6?":+LJM1K4)[3Q]9"M%Z!/"T6H2R*SJA*CJ'
MLW<+K' =609?]]:7W"NC#$G]WUCGET</,:6;_P-<W_S3!46=:A0N+,W^YH..
MB_-8I^Q0P^5YT<6"LOID<W'-'D95^M;(DU:%<])HM2<? )2L7S!]HE2@0^&;
MGI7"&?G35[&FLX77-HXEM?NS&)'XW_)[[<DH'\ZKGES--99!T,%6MW2(@Z0B
MF3F^9;I*7NCDU5UI284LD5'&*2P*+G1ML+BB2&+$/D8:"T-9:4Z_32NJTX[@
M.CGNW-N5C@2-ZX@I@1+5MB<R5">2A&A3XE>&"1Z([KEF_7/*L6(:/_!A^#[)
MY#0-8_]-%*QO586=P&SHY.;S*S>,(^+W?[?.['^Q$0B@H,O(Q@A4J%HT.6'$
MPBL/&UH:WZB');5IE,N:_*HT[[[1J:U>K666]$>MKP\MT5N+3;IH[+A/GKT+
M6FPVZ@F@;C[F_9X[W2P-YQ2)=R5=?]U;0G^I+797FICK7G# 6*^W\\O@9?+*
M0Y[)+&@9 KVX89S=+I/% N=.=YMR6,@'IP0 O[O%4T.^[H-<X7JZ1LHC4P42
MPK028<,4BVS'4UEA[EY5S=1F?F-#F,,O?**==19;P4AWWV%,@S3MR0^GF]\O
M]M>JT>:I;@(;C\A1KT>[4VT39%XU1;Q ;Z?).9<I\0W;JE">Y82-^C(/+V('
M#)37+*UL/=B."!D<6*JTC%V(?Q)FT]#K@6#0)M,MWTQ1G<[^798%2CKI^KG_
M6I5A_RDN@L3%5:!Z\B%WOEWACZ"\X@Y=<8S<W*]"J=729\J3CC*,8*ZR.=U+
M+JX\^MT"M!"ZWCMEA[/20=4R7N9:N&9<5[>Q(>__MEUT+X!_?'FZ!ER[P/ C
MY0.^&L%%Y<7H)"32'Q^-U&.0\32 8< "OUY:^%"Z;7 #T7?FPY;;DK?QKX_<
M@M-!1\R??.&H)26Z6/\C5/MR]/QNEQ<#Q=>D7+Q[XI?E\YS"_TCI_<ZV;/\Y
MQW*7T2V1Q/;$K>[?^31H_<K-AK?55&([.V77$V2TNG\5]1?4J)\2NFV4:E+?
MLU^ZK=0H@S#8S\RNPKEU%$5,GKUMCHPC4J?QU:78Y>1\?4(*_?XA59UM4QX'
MW5E8;L2?3],!8=\]\T-H:NRO;T-(=$QFD8WVV;/,W5?)!DL?OD\SI=O^3WV^
MCY&DI+6_S6<5W/ UW%[UI5 L1X0EQOP.VSR44G7!+_MP&M->-B,GXQHV5#97
M[S(@2JVR+?KT-URM6+'753_^#UO9O2"P9JH0'C7JZY^H&=4=8"AU+GUC^(TE
MU=-*4_KM_WC__VS?,"&C8ZR9%!Z$<5!LF1P$D=N^)3EX!\44W_5G+ZK_E:;N
M9A'6/]ZL^KY\6,J317/,RO.\1_Y0E@.9T]T]$VA?FIT;QH[[K^.)L@S)KD2J
M3)@;U/0Z!/2Y.YR%9/F+"RH568@PY6?)[%#4G[Q@$\J0 ,ZU+.H;CXS'N<I1
MW&TCA-F$'24XYS07]1M[5@+Y5,3OBJIK?^]><H__,TP]EE1.L"GP!S';I$W&
M'S9Z78>6'JB]<T%_$66BNO7KVU7)(()/'M"/W>[ W"*[F^ZZ1JO+)NY5OHWG
ML9_EZ1_@;?^N:4B:!8*9FN].FW[R16Y./MW=^X<]3YP^&8;M*-P0K_WN_YW*
M_\^, V>.TU^I!Z3^)]&813<J0NP5-/=KX>IAO13GVTJD#!FXV&D_I:#R9TQ$
MP'[_ OWX7W!@YF-4"8985IVPQ-,^9%XKK8S=;\_!LWS2C"8^70P+ /&47G(1
M1RE[2'^7_EY!GDKKMJ+](S@F7CJB-Q"L'GPN$R&K[6*6.N9U*QM[P8X8*78=
M&&@V>GC6-GHSY^R16RTENXI#3VROZE_8WZA-0'D[7N_Q?L_48S+58?LZ[.>6
MEM8+0[NN$^5O0G\+'OM'@&VK>3R#C.;OZ%3!>^6BBB<GY"$7!+B[FO;%BE^\
MHPQNXRJ*9!%%%84.415Y?_;@;C,.G[G&VBH,9+(OA;\Y8!>6NLT-5*<FD_=+
MOY^KAU[3\^J8AT;(T.W247@V!'ELIFN_*#FCKXY:LLC22NB=3F)K:!(\CY!Y
ME<B26JQFI/'7A?'9_QE_<TX\D(![]T45Y":MNYL/T@R=EV,> 03_@DO>!1R5
MAKCY(9@,01,U4%$L-\9HZF!H1/;V:,7R;6;EFC,^Q&J7WJ%6PV1>1([^=/BV
M M'P"-@SXK8(7UX(6.H-($G2G%(!_2%DFME=0_U'F\Y:N91TD4*%3#P-'G>[
M<Y+=2E*U+_9-,\]+@Y"MU3_[M!K,7FH@@_L E@_%'[&SX[0 :# ?\N!F_/?6
M;<@UZMYATFH(09/OK2$T1(K2.7<?WCSGXA]%<-S]<-36XD&:\4GQ_@^15F3M
M/_SM71ZXB?J!Y(D?L6@<3)(O =:I P@_;>BN;C-H<TX FIR[(=6R<[^Q%6NZ
M7[*M,RGPJT-7X'F)1$AHX6XI\=(L4RYOXY3GK4N4=$G>X&32\-A:Z\MY>5_;
MO-%G@2K,MAQK.?3<'\&Y<V\0AV59O\^B:X[ZR<XH 3M!Z9EN1\!%&01K8ZAZ
MV.\1D[P?*6H=E._"3[\BH&J+E<?EX5 S6'=!(%.):]G(:,U-9->TOH,28?C%
M0\K(\@;K*1MH]K 6.HHK8NK?Y!0A."KUU0H3OA[S9/EJ,WM,RH"EQ;X(:*%
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M70S.N#!7[PH:&:]P$KI5Q<[7Z5FQZ36<)[EX,+#J,J)*;%O15QPKA]%1U^
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MRJ,/X:OJ;M5(ZX:.O0"/J^=2MV2-INLX5^1ZOG^B,UXE?/?B8#FN2-=!FSY
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M++2.\\ _[Y*FA^V ?IEPTIXNR^*E8PG)Y[^1\NBD+YKB22<G6:B\''*%!A>
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M>_8:BBRWW+VPTRJ(;^__7KPB[$? 9Y&1J D4^7PM=JODW=PX=_3[J^WU8/<
M_3*.6G9*%N1$3^+T.MFE68%_R2]/NTD8^R[ZG(NL=-3)\1@\^4_0YG7*$+6M
M/X%+HKD_P"@LT6K=MW:VHI116'7VY%M."R>M"*<&2@9V]%"/M2>5)^Q&QYH*
M/G#68GG/8,A>D<O6-7Q,U_;1MG\LI_^;9EJO==[P-N[.Y+TB?(W7Y[ I1>IW
M]I&H#6G[WWD@=+1[Z*-;S./98=KVDM3TYO.TYN05*H>=G6D"2SF&TM%LGQMO
MC01UG'B'?7PXLR*(!V&I\_U21QQ,MXQ1V=3-34S#6%9T>XZ[M-0@?!'W]T?]
MT1V\:[;S#%]U^OB-YF9;SS7UZ>(84 G/5:W'5OR0;KT$7< Z0)IHU$D6!JC,
ME)?],Y,;(W3K/<;4$]_43 /K;FJ*&_0-\>>4HKTMI%++3/NDN>B[S^UXN:X!
M>9X^14XACMZ8$19!1 CDU5W*YT=$\OZ#D&WLO*\G4A1>O/#%F>P3P8/!H[?P
M)$\U!ZG#Z'8-P %!6%WK55>)3]C4Q_6AI=) O5+UD>P\L D8.1.DR=QZ :8@
MV9*^,Y0>L87D>BAQX)C?(KL.>3OK+QB-]\WEHU55?OY _KZGW/)@PHH>)(*T
M.8CH(U+L1UI&83BYP/:6R)E>E*!/95NNLP\>R,XNB<!B67$]=0GFP-EPF7>C
M5#>-].:<XQ-H^&_?!7;=](X22H:G2PZZ;S;.L\'FI*A?EWW*79T+,!HSGG\:
MZ/50@SZEEQ/XKOLWVON@.GD39GEN7'_'^#F\5TZP7#N-O75;4AQ,)-C]B,I<
M^*M^AB$#?1UW *8 L/Y?DN]7NVDOC&<,8W_S1J?Q =@8)T4Y9'$71HO.R%!3
MP>C+ F'V^ JNHF+(A=!)W"6]*952T/LH0-<L>,_"K7Y&D9@'1BNSTHPDCTQ"
M$V21J6PNX@V*\P%7;OJ0"_,";UK5I][;$Z)'<7''-D<OC-F8)_W2(ZG5P&B/
M=D&KQM*UCM.OF;)-MTE!7E4';&,BZ&;)_,/0GP"N\/7H.+1/5(E.V>@6O0#8
M$N.GC?QYG.J:T(HL5;2:E"(O1=S5&Z=<RD]$CZ<YT\3HYNQ(P3L_$<=RR^^K
M_A.)/-&*)&-5L@) 3+L(LJ3%],>=CF ],6RJ&W+1),LF\,8YQK,VQ'TZ!/L_
M#FJJF_E8EVKWN1LYDO>VY#/1?B,&G15MT36]I;UFR(O(K3CT] NMG6V?91<=
MLXK"+Y@?"51$>8]:NFQVS\+LX[OVC*WMNL(KP+%. -O$BY8!BQ,#WG!Q7SZR
ML'10<*7#TH1O_NY7&ANE#*%XF"9&G3H(N@!UJ^8(N5ICRB(82XE4))5G75O%
MNA>M#0X)*2WJI-Y/VIAW,B &(TTT$/XKN_=YJB\OEO Q8DBW=0C8\BET9SH)
M"F3N_:]:6X.\.*J6] 1;/E=GS2/M)^O!J0<7.O[#&J=>BP]X\23R4@Q#%]19
MN>:3)A_W37Z[^;BS[[2T3_]*M^KZ=V-2E:W*=U=;:X7QBI'9:@_\ H$.,"EI
M; ZY[#5^2O[M0S?)U7K=Y!7$K,$D.'HFWURTLV-L0SZISNOMS)$+:^YT.6!0
MZAU-($O F5A7-+<&AW,^U_Z<PH"XF,O>_J-8*,7,VH3V('9:;?Q<2.]<EU)6
M5,4+H'(,(_3[679W^"Q:_ZH\V8:J[@ :UK66SUHQQ6;S"=:CRGA=9KQ>XY2=
M$BD[5K_2W\O'UW$XWNN,]L611!XWBDLP1(-B?0ZE^I%VXHIM"HRY:+.7F6,7
MEGWC&=OQC!_ZMU1IW5TO%?[DCA#[2E*AM"^ -"'ON4>!-184Y?XO+.B!F!)X
M=1M[2F=[_EKI7WB2+9V^B;7]B%4M3KI?UWB./,M"?=-7/<^CL&IMD.J'+QP[
M/,/ZU1[\;]AJV_7.IXA$KL ;^A"KDO>G-AO/LFDS]JA5"G7Y!3 DLF3P?,<O
M5F@UNU]4%8M9*#"5PCJE-,R8%V&*Q^'"QJ Z,,VS))_@%Z&E'KL7-8L_U\WQ
M7L_T/YN#K'X1Q'I^W[8NJ_Y$A+YKG9A2(@PK?!2,]N3U>-4IR"UB]-_X-$^S
ME3B)?,N?K**RD8[&[BO-75\ GA_\2JJ5\G+'B^[))T;_OH.K/V-=2/_,#F19
M,A"[17D!+(RW(WVG3#>@]=+>^D^H:HV\E)E]-Y[GU>'VO;T-RG-AF%B@F_CS
M@U:#T?,P<_OTS#]1C%M/+G0HWP7%^F .Y8#S_5R.BH)R41.QO. P7:OF+4?_
MCJTOR:WJ'!)8G@7S?/ DNR/#-ZG5+'^_R8'2< IN6[-*I.X75_Y3(P([IG^C
M/*)'XYEVZ<HV&$_ENW,PWG\BI5LDS6!+R7-V4$8[+?;U5&. $5+@[;:__(:$
M)-I? !0/[97?"HF.1_YM'!K3#<FQ*PV0ZWV?=@5A4,\O6[D[ZO0N%-A8_!-,
MO*RFF_9EL;Z??@&8GJZ$+@R=MND0%XDI?A*CN2K:;T<7EMQ$RZZ_3;NJA)Y_
M&]D=EI[BIPS?FOSM>E=;5.7E.*#^=BRFI+1J:>C^843L@[>QWHC]1J0:#<7;
MD:ZS%P""8O'98SFEXBE'A# 8 L3"7AZR17/>U8W-B/T:&YU_3JESV8YU2_/E
M=%[C3QV.+B:4^_'<%R7GD5,/@\.$Z5#E,91U-@2;W^SRZ 60>O "6/?3(?(E
M/PV)W0AS+%I"Y"3R"O<%DY[!+XGP&R7Q)Q,B_@B_K[/22,^4=GMXM=6WX?_G
M&5]_ZQF>1MKXI'%-2TN+M:-#J5UY8'K$TZXA,N=RS/P ?TE5BQH2S@HM+Q_4
MVCAG5=:N1&,Y/K.8E>^#P$<^DS.\(,7_DA+&58SE/REA0'?IH?=C//6<&9<G
M41JL610--3- $_K,D@,-Z!1P6*I/S=H!#4!,CEXB&-O"'>>Q'P'XQ^XM"\:;
MC=/^(IKO[$&8C<>;Z[QC\F3$/EC6BL*0(,6M'AI5(5;#4<=7WR)SQ!Y<,"%L
M18N#$Q303(0L,>I%9A$UJ<!\(7GV-KFP:%]5R>+I5S('F.R?&711GAT]"A'3
M[>G$UYIB2K%U3IAN<TGKH]:)Z:R^>G !DIT!W;7=?G8*\7[6[:Z_$/@*PG8U
MI, T^45DV4DF"K#XQD1 8-2#O!Q%[HP@LPCBRCY\7[?-?<!F17*(^XVL1A?0
MDM2_CIYME61;IR<-2S,O%?UUK9$\>]'3I9T/1N1=E5&5POST279]&Y,[R7JC
M54<,<W^V&AR>.S=[+GF!N_/C&\C-.2:4_Q N3D[[3 TRLL>[MSU8T^-^9R/]
M<_*WKMD?LAR5K,+@3[=5 S;H<(R.3+O>^+_,;9896;@GMMMD>V[+SFF%FWKO
M=_<,?L_ <QN:9*B]/.#PJL55U0H)] IBB4ZRP [*KEQ;"LJCR)+V#;SF!OFA
M.#NJIG9M>M?W*&G$!89$+H@0?MUM!T;$@JF3M#NS"QN[BH+P^EIWYD9AQ+A!
M;2WG^2PG#,,O5?OW<I!8Y>2M[PTQ@]ML/<Y_FF"0S8]9A+MD)(T;D7J*<_!7
M_*0$Q\S*WFAW>C@PI-'U?<P@Z&?(6780FD4N?*W]UI>SX!:-],+IJA_)Y;M4
M%X1H8_J"% TYF,EK/0XCY9W%(R9>EC<R)[9T/48:AJT.B 1J01F?U&)FI+_-
M7#YQ2$^S4YRH-,K4$=N>N:W:5+/#VW3%79&>)DY&F4<KB_7T(,W=-[\EFU:'
MESU.&C#2MQ9;<!,3]W6G!8&POQM/"C:-#;5GY+W3CG>5A.GU7WZNMI1296#_
M)S'2D#TV:$!DF'#VAL1F=OPI=ZMI85AO&<]<%?F31W_)T:/L]099\J)HT>Q%
M.;"U,_K--P MA8'3,>(..QY93&I%]JVTR?3FM)&@1K$16V_0$MW*<^YU4(C
M(N&(-[J_ESM^8;[>P82$B9%7[@CASZSO<]2;-!\6/Q&+V_:08;Z/LECT9X:
M>E*@;8363ZJPJT5NS@M5_K61GHI<?!JZ< #"8 #,R7,V,ZLMA01Z;383/9OM
M,GXW43B6_+4,$W,RIIMJBVK]0O>I*GT330G)P-(M^<^2?L\4L'51,8 >@].;
M"<6I1H,*)Q\E(T)/J/M"<@M$KCCU1="VP.%;8LN4U(4LC>&Q4T7OW\0!8XA
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MORZG$7ZWV' >S4B_+K&SSX=/9B/WB(<E9<\!^V(;.I YY<W[YT]8!K7Z0B\
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MS/Y"OQC;I<E'NOU,H$7S1XJ,J1W"PB5JKV-[_!ROL[S/^&>,5L!R.RSP:X2
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MN[Y,O24KY^D!%I]^@2N^S5+0'_[.@K!7SV<OQWH'7+:Z25<BZ><?250O\/O
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MP><RSSQB&LW1/,A+LR.8J0QL'9X#SL8Q74[H*0+N91P\(-"@"KDL: J($.L
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MTHSZ..A>!*G!=B)/?P%DQPUU-;%.01XOAZLH3FP$858L@HY7S9%JTO;0M E
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M$4IAY(S("',&J6QO?W =SJ%@@I<Y[/_[;KS_B_\Z,/Q=^F]02P,$%     @
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M%W_P!W_P!W_P!_]G@Y>;ET^4FT^45X"61_@OA4_P/SWVP$0 <\ 5\ %H 5G
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M[7KA'1/PY X="]+A&CK+Y:1+,0Z\04/%:'&1,CO/^2;9Z6%C#:H^VY8?:GT
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MVF_-7G)XP?%':PC63(R)A5PBZ![?D1!\P\AUY&8MM\^XP9R=\LDIVNB*#J2
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MO:B=VA0INJ-OGL;R'"GNFKJ FV1G+C4HH3EWKYI4HYX[UB(/?4U5;<]X3XT
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MB@(QI4FP[L1[Z_MU.P>;.;KD8*):3UX3U5;:&P8&%RL'51A7=;3[$SLJ2WQ
M20H(]TGM*"1W.J:EJXU[$^_WSNL%J=;+%SF2>3156M OY:IN$+F7,[G*6:\;
M:\-4^/>4?YZX*F^H2R.Y<GMCS.?6J:LL&6Z=-U"IQ]/$P0G3CF3W2U]D#.:
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MU(0J,VR[_G"D99&(P-C-W)7DW)_TMC:8\M<N4$AKBG%I-&-!>T(0@DGS,O0
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M)0T7W*JV"3<V.1S[EBW/GM)+AH50F#Y8/U)<P,+*+6_DFP;]D9\<SZ=6D-B
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MP@+=PD"+UOZ1G#)QR0H$70@-SF(!5L]3:\7RY]<9 B3%]?(GR _ &$6U"BS
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M>9I.WC(#G*Z,!1 L(*3B*PWL8Y_!+(^"$C3O=V%6E=FO. O1?OLQVW+PQ_!
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MGF(.">DM[5D-O(U_L?2V+,4(_E6,!5@R9V(&3=+=,N^WKNE@ 17Q@UB ;>D
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M#PY_1$D.KWOLNX#[\U4EK" _0JUW9!G+606P9G\Z&M7XJS=Q$8>+*LL!X+#
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M^@6 7CS/^_(OEM%AK690[Z:4VO%Q!2[_TE9&()*R88#/W]/F?"::L<M'5_.
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M286W*"OGFQRF]';*4ZAXQ'F"/JH-%B1-+^5D[ECL'==@%4 R=L5))9[Q@:V
MLTI&OJ:Y_I.Z'VN26#@C'@%PVCGWBI<S*TY(5MG2@3'*3;% I;RC T6>K2O/
MM#XHSI@"7[U+I3DV$;3()5DBP7DGSKNYCRI<*NSM.0!,C;B4S*V-:)+Y\O:"
M"3^P!1.)Q@*>3I1P?- H @!> \1T-*,7GF6(94?I,+?L&+)E-Z@S_>^[43HH
MF::NV\W?CGD5V_R[RT,:2"<E_G3.2W^>& N(>RB-!90[M6(@AE/91N5&N$"L
M8&X\HHCJUUK;N>H4)]T #FX;U1[Y40<>$A>%,9B.]^.AG CCVD4PX"N'^?CA
MJMC[7%K(PMC">:M^UV (,-&#*5Z1E>E$,+^XM\.-Y#3:1J]0U8#^IKVH FYR
M0QW_56=U1T=L+X8JL ![,-1S4YQ&.: :"S!R7#*:U2,'L29XT9S3,N1YG?OL
M42!P ;%/H9=!TW@\6;N1B.587']6D;KAL.0:V=; T+>CZO"J<;ZP?2Q@6S?:
M3TO76RKTP1KD(XY30_Y1O9MSSD#6\[-;R"2<"3Y!'?C%^-,@96E,W+")4EW/
M5\)&56D6@&A;<;._KM=NO,87)S7)(AHGZ247;K=8*  TK!*CD^@>)G#^VTS8
M2Q$"3^W'4P-<3=ZQ#FG@4:86QZ*DUV#(K/NLDJJZY;#;6:E8P(3>?QJL_YL#
M-EU.@2?',D?[#?\)49^[]H=DR2P\9S;H+4F29L_$FW.Y/A_]M)UGTO9!L30?
M4/M-4LRU9_P<Y$%IL,DC,"DZ9J;]_.5Y'DHI_V=<X>KDL28F"-3!@V'TK3)N
MX;3VX&JH\38RD.]A,*80Q.&Z:HIXE!C%IWWQ)@;[UXLQ82Y]5Z!(-+O@I90H
M$4A 8\I/A<=0D5&EM&N:;_9JQ[5EJLPEK-)8B@'OJ2E+2KI\T,Z(<O:<":9&
M]!FZ=ZRD4#M!\U P\-I!N\ZPRZ/R _Z[<\]20<KE=U[W7DPQ^/J'##8'/?00
M3$:!Y@<>*%N%_S+FWOE*U7.":&$<>YH_"J/:V1W7]37.*:IS)1E[0+)D9NBK
M>[<Q-H1"=X11<G23WC!K2S'J T,2)WR 5\2.32E-2UV9"[I9T?L!JEF3>_)H
MI,EHB>&^J0S(EGF\N?.7C;)5QASBXL7;>,NGO L?S$8<!9 6(WUZ'XUE\-:M
MFU>"M==%VJ\'-?B4LLH-7TJ7&*"%E3/;3PVM3.G-!?M7IV3G=13N4-Z(ISQ'
MU)\%DB-(O_IZTVDKM\0/</$%^#UZ-\YM59/^S;+14@S)K- >$@<Y*+(2M5;<
M25#O/45:[5EG3=!ZLW#Z7.F?*L""I$PLG%@X/_>?-(&8/A(708?.O8LY);CS
MXE]9X]L_?DMU7/:8GK1IY%+3RXLA-'^<M7[H@7A X8_8X[>DG!$*+HF?S=5(
M1+?GZR]<;H%.#4VA^"BB?FCSYNCD3+=C35^]U=7:F)[C:]NU 86U1@J"J)I"
MZWSGQI,-2V1NRZ#' MPW79FIX.<M1<+;US.(Y61]6V,".3PSR3=3&$(ME4V
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M7^8=!PTYDQL>;\?D9C%R%51*%;HW[KE*TT)VHY:!'S)4-M52J\??9T,X?OV
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M@!EY+T?QE2C3<!BCRV-<625]!GZQ7^FZ^7S85B:#?6^6B3),GFY4KN%VTMO
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M>@E&#LM+UQ?7#>?C<D3#["A0UM!MSE_I.:ZU*!@K1LC*ZMH&*%>-RJH$+[$
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MKA#YW]"NLO&#RJ.I59\%*ON]^\:N34]PA^/'P30&$D:ND)P>ZR^4]HENG7>
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M/K9N^,^I [69?H<[5GG> 5S_/=PQZ!\8[O@_"/[[SPI.F*9DM:_\,$Z8[+>
MP9G:G%&>?OQ);Y3A [EAY7<)$IY$U"\![O2"V+@A568<[84!$BN25[A?C'B%
M;H>WZ@Q'^S[[]IK/ZE?^0OD:\35^5;AX31-KU'P,_#KAR?2::5"R]?W]%,IK
M3YAR'VT2A(GAX?W\O/DAM&&FD'++*43;3YWVG*O7TH3?S+ZT._KT$$S?*):9
ML,X81<8M;++:[\S;-GM1K,E9ZEXJ'=1'1&:FY_*V3;8]7V=^ZH'MJG-X9*];
M+:R+<\!?)>ZPEK^_.GE@*K0!GA!8]W@*_$9+%*/&B5I&P .O:>,T/FR8\HK*
M)N-7_<$C\\LQY46PECG9[-/\4'JK=[ILN!A6#!6^M2*.4!=S2U8:A2*K2DJR
MRAT-ITRQ<H:WD?'A5T%Y-IUIX$W[>^3AZJ?R]Z2B2*_=&"ASZOY+W2?8@]\$
MYDHT1<Z<9 :@UE7[3JC,<PP^0CW*GY"2<Y'_/#7]RQ&8 !&P;74"OO0EC\T-
M!G ,88HXYJJ,LR%.=NJ*K:->2.:F9($_D6I^2'^B1(2!)4*&Y":-'1(ORPHS
M?1=F*IHSFJ%61B&BO','&$%/9=A^@X\3/YF\+*7KPB#,Z6XBL'*":*=.2SN*
M&8V4Q 1(B')PF0S_D_-FL+3;DI\4'[3ZFENP8B[S0M13>8/K@'G)B_7F$>_K
M]V]KF./RWWVI\BD266\JI=\%(MSM-0B:!8F;U$K)(9]CL)>;K-)792RM=S2/
MV=$^9VUTJ33\M-N?'<VSGCY*8I$)$$=%R92Q36M5]L$+-L\3BN,MK]2)XL$
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MZOR2\W0K,C/M+4YU;2U2N25$)W%^-YPCRRB'GY%AMDNYS.Q)#+,RKOY9D7>
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M2RLQ3R).5D,DT6*V.VRKG.")J$TAO5S6H<9'(9J\O(KH(\.T+BQDE(\=NN-
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M4VHF3OY&/Y*'<&S.[(S(!>-^YY=EJGO-SN,&3F%AW#L##>("?))7C<9=KOK
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MN1^25#A/#^OKI]$*X>S9V$9C*&]E7^_[:Z(;"6(+P52+VT.66I'L"''C5'H
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M&X.6,FK[>M+MH7DI=S9$>-C@0I4+P?S9AK.YQ+2W7#^#4]<WZ)V7+F-?GCF
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M1(7B.@S--G+ZL_D54FR@[K5,!3 A") \K]N37]4TOQVS?-*\\/:6VRBX^^O
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ML^(-V8LA;'CAPTH3NUCE$_VL6')-_51R37G <FRMC7*^5_7S@FD?8^XVO<(
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M1J?$M_*82T"#VHO-L.@N"<5. XH*?O,ES]"81"U,[A>L-E;I^FFE,PFNO4"
M63/"4,W>T2:"I9^A]6= H;K"@I?V<J&/<,&&O_XI"^G237>KBR$:2$Z:"$K$
M@*2&*JM*?$TX7[$/PADS1&-VC\R)6D2\3]3O56$[2^08<-5E=)BE._$PG('1
M0"<)\GA&=J] =FAOEB<$:;X2J-JE<QEE7PO]X9PNF&/C[>AT)_-0<T^%]Z&R
MWUWE$PX+!Q,6A&STM:_OJ@NA<66:DP7= 94Q_4&G97;^IAC@L2SSJ9T?:4R9
MN"IY8_@:P7#^V0O'/WG$K.PH03:B6O;EC-R:;!BT&>&8S0HWJ6+,\G7[\6LD
MH0"1G$#'#&,CC4$E#L-[C!#T@J)Q4B\OW"-F#?L<FZ(X6;$&NT/BQ #;Z08M
ME6EO!77>I6TH4LD-7JO,^>[JZ(;^3-$0J5IH3U55B@RZA,FW)1R1V"]_8SM)
MP".X)F"<^I8/EN 5ZB1:=8B>LXD>3A)M>N_+]_R;P  GDS_#B5%HQ]O6P-53
MD6PJA"->KQN]C[U[R,];<?BK4>]O-B>JG?Q+GTAV,W(@&!-A)RL=%$8<N:,Q
MTQ?/CUP+^S5<7S.VABPU2^OV>$LT#JC>\/1J+QCV^&VL)'&^>=0G)Y>*8UER
MB3 )73D*]]B&GK8S(RB+O-1,Y+GIL1ND8LANKV>Z_03$^DP08SU7_#0]Y$4V
MM9-._0]:Y+*%LKY(QISL<G]8*RRV\+6"E;Y# X2L/4PG-^60Y>T.Y**7S#VX
M0L9*B7/^>%'+!V/!VHPT'59GM]@R:35W ;#BVGO7:%GD2U[Y*@VAU#0F;<:C
M:[]O543;R6!_N6B-IDF;22L%&]#FKBI]CG9,\F1ZY!!T5)>;R]2!]NP[^&B
MLIUD'&5<N^N#3=F0GS10M(F-E+N^)'$N4D-I_Y8,&"EV/OQTD&./*$9:PN:D
M5+Q^>P4R&BL&G:7J^!#X.^E$O(M;<--6D^_P31$9_[D31(_D/NQ><[D/SJUK
MV3C7>Y1EIGW],4Y@UFW/)-3$]B8<X8,*R^)$W?"C >K*K9ZO]N=0W#H3MI:P
M(VWC)<^?,:P!O94R;[:;&/!5O(1]'%]-J-)ZK<L20-;],"G62_92>&^FO*\
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M)<UP_"0LZ39N66P[41,:N'%<(H1-T,CP=P:43(5A7(B8#&N[IUYMIK;QDT[
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M<SI,$K<8N[G>>M!$'_-&Y8M)=ZPX[QAIVJM6^)OWMPL=+F4CGO@6+36\+'^
M7[D5&[8]QB!7&0)C+!*N(@3K:NNE/_".%TU=[FE^!5O>,S;NZ.(G?.['Z0$1
MQ!M+9(/93H3>B>__*B/](@'4@O,JK\"MKBPJ'^LI 4"AF6DM;&%D32V9(N52
M"=;96F7\9%FH9G-A_T"@YQ[=FIF,>T_95H+'C/0>JU'M)"ORSNI%X+(M58W2
M\,V4Q=7M\STT$$AB<%A7%=).V1PVH/7)>>P3L;MT8Z94$;N<=*,E"M<DQ*-(
MWWC'J6@!VL>>K,#RF.*W=UP(0_6[^)>O_97ZAWSX$X=UP&?3WU9UD'<8<^C/
M.YR.->4;Y#YH-#D'>#&,'JD+@K*IHC#,SS8VL(B83+G KG81XBV&!M[A59;*
M$"#57%ZL+]>9;>UONGV]LG4^FFZY>=Z3CED-8>P_;PE7Q"02/)M?57EX.LC:
M6'BW0">ZK>N98?M 1L"CB2_+JS*-KN>_ZFII8(ES[OHOS-Z=XB2_;B>LR <[
M]!&5BL6-).+LJP//DIS%+VW:^'M0=R:NQ5>_Q9+U.WSB_1_<O6=84VVW+AH5
M1$5!>B]*E=![CZAT >D=1$ $I$IO$9 >0+H@1>DM1*3WWGOOO?<$*0%"<N*[
MUOK.Y[O7_O9USCYK[WV='\^OS)GYE#'N<=_C&<^<)?A)GLG*D;NDRT&WOIT4
MIM,B73,];%7&.1FO9 \JOY&JT:T! VX[0=A/LW=9<S:%;A=[S EXJ"FGG[>F
MLX^YTG%OC"OGS6<FIWI)<A,XS8=/(X.*AU8=@M)I)V+'#9K9/'+#>=V ^1QU
MOHTZ77E*^^O(1ROR]0) &Z).59^@U/?T\P4.DW5L\+,XMI#.X#,^.D%&B.'R
M >##Z:#GD-$OK=W.G4QM,?VL%BI7%<,61P,C9%^;^DYHH<Y <Y1>-V#-IJU)
M.MM*.K>AKR5%ZY(MT&5!_-##GB6 DXKQC;H_,X3XMMR=$AU0 #VI<HN \#=$
M8,:C/!K"*ORZ4]C3BLK@WE&@H051V[T[:T_]=OT_@CC"XS1T9,<B5/<3L7'M
MP<L![W8OW6!.XE]&M5=<];&A":A*GU(<_R"<$TTC+,[\'2(+1.>TKWW;&^TA
M:_\GH^G>^R/&<4ZN(\ZE_JKJ,,LPN-R&V6='3UKZTZ0UG@LBH:.KV_/@[=RL
MEJ;CQ^] 9P^J,( 1997\XX6;SIMEPOF9X?T_8&F-PN">%PZ7)Q&74R-"OZHZ
MAR[8(S$ DQBPP78;ZJU0(\D0EG4=B?X]6A%TK;BFY_BN\1%$%F( ED;7:4.S
MTOUEB$ZYR;4,@S,P4LX'.PNR>!@ ^P]PI*=:"^B"_??&72Q6V%ZR5A?U%&!Q
M6;Q 5A0[9TS2V!G(#,0 XO5 G=%_WNGFHD,_<N';/14#5DD=C/GN43BD'>RK
MVPF:U0FKZZ] ]X4S"' \O1A??_T9?%]719:,JU)#!RM!/O_5X7J0$2(OZE":
MV=0#W*9[]<5(W'#N@I> 3)FH9FJ8/K>AM=%IHH).31&Y /;^-G-=BP86^!2!
MGV0OQ3.B"F5$-=3H$QI(O[X5,HX5IP&'+@K!HT.Y#B3=[9FKOJ"NLF1?U[18
MOD-K1JN""2H^K'96%>XL2H_8G5RK'H_>?02I?V7$#\P0C'HJ*NFD3X@-0-2H
MEPB6;#3+V)Q*6>"&.?.#>YE6S!RE\]C%)$A@ZT0N.M!9$SV;8_;6UGZ_AM,[
M+?13?<NX?RX)*)5TY:Z 'KG".\M)FA.QNQ*9)>G_JXC8,UE=6>Q>(;^B*$!W
M$$Q4C^NPK%>>O.]0PLU:O;19_H72==:=6YS B_9DSYBGDY!XB9!@V^N-4G?2
M9.OJ3E*T2%#KM4"L_&CIF>)<PJ'U 77#9%>Q_MZL]'=GNWTA0YJ"+KWO-?)F
MR%LIP[!XV ;\( V:C::JF=35#)I(5\Y?>[&6UE.*506.'TYA>>7 &2$>@IVI
ML?N*KK:D@WP0\J=J#)$<\1="SS]=E/.,R)*%Y:O+D@)T>$)=!CZH7X'."$/!
MI?4-BPZ7Q$:>-9W2B NGP+$2WR*;<.N9>15C/:SO42&:KDD94)DM:$%PJ\ :
M^)(=="$;B+(MRRR:!?'4D'0WY0X*H(DRL"XQ(H,!]'(RK,G_:4Y8)SJ+[CN4
M^5]TI::/]'B%\;,V_0BCIBO?SHRB(8NR"R#YQM-O/H6\8LSG>Y.ULVO2M.#^
M*0S G&4+W:,],$#A9#"J(R'^'_D:R34%>EZ$%+J.*P/K,&5V^Z[>$>S?T/W!
M[SD>RO<[>@F+#:E68+WGSA#63[>_80 ;Y(2(K)4NU #XC-\$O)\P,SD6I_&S
M:AZ213JQM/D_' N'5-;Q58Q1Q.7[?SGAT>]0C>NT_Y57">5]VT8SC1TM&G_H
M ,V>'1!I!UY)BPI7RCRH454#0+RO=&5D">Q@R#LV3\!M/XK5J'8_O%O$GW X
M4)U9J3*G ;M& ] XFY5[(NT&3Z?J1< Y9>^OM!Y0EZ+)N_#@H@61)24BWN\\
MV5J:;N]X;20<UD#GNOSVG-9E:=>< T@%^/""V1SWMFW'3V!WMZ49FFK'!:'2
M-&+VI'>I1+5O#;NH[T$(<#VZ GRL/\![+S& %PCZ-$<S:_>?\I&(1EX%G(_-
M'\6&S(S/@Z69V**%(J[IEY2KJ\ILW\XXJRJM/W1?"QKTV*IJHB,S%Y[;-E?I
M8*Y-;5AJ=Z#RJ&L7(?<#!/95?23.EJ<1R =Y0C+8A\Q0>^XK4^V^RGI3+/"M
M<#.]4\ISG,^LK?U-GE1>-P%L$!>A-@^!=A5X6?ML3G1H^<5<_ZO(#?;Y>W$5
M26[\>=*-(2FCR ]D2^&-W$;(3 F=@,$G+ D]ZS>WNPO2MQYDM):\BDQ/<7_,
M[VZP:S1>#UX3;63:K66-J,0 SJ,?0(N>9=1)TLT 2#X2:D8;#%4A$]8.*-J=
MMR\[:DU-2X]C1U9E@4PW?@12TH0PU71+>4] \="J2K_0=4;@[3)UCPRT*G\?
MNA$*.B'+>[<XN>-8#_4^92U%!JW9X761>[E#*D/MC6\UC\@),Z7>UE%3<_8B
MFDQ&S/3[L8\LR"G-Q>+!AEXB.[ Q5$T. X#I@4Y\$MBZ^-LZO)Z\X&XE()/G
M=#_)%-Z,4'9,N+ (=>5A0"G"3P=*<DH,.<EUY?GF%&_B,%W5,(BG>J5.:2)(
MN@PBDP)<C&W;=.7&KF1:WG=&N<6S6<_?Z99.3^A /4=&XD65]SU@4QPK,7=R
M9'%BQ(TXX"![%I=1[[FV8P F$2QP40N2IAPK 4_),.KC99$R1S>G:FSH1DY\
M^2 A(9"+" D_A?*LL$9 ]4PN#()&#:ERCV.J*$++?+(?\OOB.DV9@)#1KBO=
MIW-Z'25)-[.=C8J),H2J-=9YV7";:@%4'>]13['Q'W]EZ'++"NN7#PQK,( X
M&X;3S8Q+48UH#F75'(G*TVT7$RJ$7P[,1\#7?G%0(E*5<ET3T%M<DIZA'AAM
M ARH4*-'*8Q-73V[]+:]HWS?0+R9)CVP[WU?^ C\=#'+_$IREV0'=W+%GI8"
MDM8=%,]'>38D53N5W@4*66K]\.)]!7[TP^Z.R#;18_-7,\P 9]5AF>Y#59OO
MN.YY&I9LEK#G4Z[19+:+K$CQE*Z0K(?S&U/J^&5W[V5=?'(X.%=C$)'4)8%G
MH8DQ@ -2K ;Z@)8!V85<R5^KS0^!P)M7-5=-@W4,(3H_EWP>3'!QQ=>/=;G3
MVHB7\;\F[)\"PN,ZSZ2I4GR!KP*<+X/&E6EC_"ON2JCN?WY*-42570Z)?>Y5
M73GX\ZC3X,243K>MQS>2O8_Z.J,G^OM'OHO*PZLN*6L_1A^%B?<^"NG4\$^/
MCHZ+F.MNI>WS$VDAA@,4T0E!8 R 3;3I=);GFM6@:(W]L/X!(AQ$-&3S:T9%
M)(/&/+C7SK5GF;>G:]F:O7-/]>/Z_K4*G<BJ?(0/SZJ'8%/HP^!PY[K4SO"1
M E&"'&D=JKT3*"B<7GQ*DFWUFI^.>QE?SO]MRG3G)^6K3AQ[QIC/?"TE AU>
M?3XZB,HTNV_Z:K2VE*%43^=OO"^KO NX<32W1%:&B$,K"6,1V,@<"\P#:HF2
MO=M&0PDS"16FH2"B>@E?*^^2]L3)*G!]^,0R!)C?J<O$G1?3(K;9,#BZXL"Y
M4@-Y&"?WDUWJ*9/0>@8#!K#6]QP#*(D#,\,T_JC2T.9<SDZ(-'-E+3$IL=(=
MKM?V+!R03EACV)^3G]N8Q=*V#I&D( !JW]E9!A0%S,TL5<F2*W'*@$.02^AP
M0K3Z:RQG^0.A9T:T#QB2YL/63<>LJ/X>@OZ,,UAQ[RV_<<[XGUU:J-ZS"L7K
M6J0;<S4EP0!L#6PRK'\QH8?"'S0:&88 X\:CUO(:O'"=TEFQGI&W#+["KN#(
MS1)^9S<_7XHWEJ0)4TFZ\_O;F>'MX__\LC@@!!F- ?#G74,2P5=2;JZ=/O(8
M0+(FNE,9=)U>DM$>FM&*)>"R,F9_)9#^52.+6TUS1Q/![B_:8*7>E=J,MF'O
M4IF;'H\1K>M);L+"9Q'+#P8%N]1R7XLX'NBJ5300Q;XR:OYI-V1DCT<'[ DY
MN,DOL%),@&S">H3KD@=/EY=#I!V++8NW]Q>^+<->&0["9W=VL:I14KOV0WC=
MBR>=!DPY48+A0E$L6B]N:&N]9J<#D.ZR%_?= WXI0QPF^:Y9HWCNBX#M AVM
MJ2AZ)>14"?;1"6-CUM#V%&]<4G6%?S6BVSR0IO474TW[-$Y8>$F)QLJ+[C#L
M0DP++V%I-A<]/P800V*" ?RPZT*'VTABE_ Q*]8T7\^!KTDKP.:;\G._I4)
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MZ-JMW!L[IA+JFOM*9R$_D$"YL0J'NS;2C!'RI9/U,EQSR5SV\YRO['U.S"$
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M/N,?B*36N0:2I]6>KC2^+,0*/KD:E*S"@1#:A"ZJ70[C-*'O2KM9O"5H?H_
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M1UH,"(_H0Z(G,$>EK-"[GHP$Y7;>T',A@87>E$>Q'HA+$FL*CKE#F@W/2'=
MF]L-1S<*ZZL(_1L.V'Y"QJ<@:[CZ7E[).!>3M $K9RG(9275]P@,WN5LN+H?
MJ5CS#W&'\,SO$C!E>Q%9>?NLI_MBPY"C$V@:!:EL7CV[LLY^4>/4/1 JS!ET
M@L'.DF7NQVZ$'RX!2PY%F,6GG+/EC^>O'T#G0(:#0,(6T"Z&(-Q&37Q8A)[=
MYVC83D&'Z!S</KX$4$,ZOGA= C">_LAH/%SSIBW*:?V\9'Q^]U0;$HB6P?#9
M_?ZTVZ<;>Y2G&^?X"=NH!M4E!!2M#YF:3<48[6X*PU^<P%^D@"LG\)=9B9I
MOW TP]\+-W#^A1[N[.0DQO1"[.Z?.9E"PU;O1S6#NP5'TTPS8[K=7]UTY#MK
M<]Z$<D6V_PS'YDEP?F[3L?&HD _9.EFK(72GK#[BMG5\IU?,87]<^KW"%:/.
MQ)#74./MH(*4NQSLGJ(68_%O%6 _-SBR$C023I7EOOQLK=[&\_W0+[I1Q<#N
MZ.*T,EL*1(6GW,5L?07Z<ZN^YL=:";$Z<]=XOV*=V?53)6L':MLJ/':"9;$
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M 9HW3. 4P?BLAZ9_AH1@ W&#AE]<ZUSO)2"L#J3ACA)%;W+L@SHQ&V0@>/3
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M.&@HI^^..\US8"6$QON746A56L#Z-4]M;6TN 7T89U5+4)ZLCR[^D#V?\?Z
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M"?-I%N'EO[D+Z\?B;FNGTE8+*HMN($.;X82!EE[^6=+!9=W!.H[ZK1&0_4\
ML.[Z2\7Z\S\JUL_K?9F0$(Z1LZL.HUC#D],US-9YK'9B_[MG^%<3A=3;YTU
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M.><ZIJ[;X\OWZ>911?8-=!0]S!W-D?9'L$<NV5H0%;[ZFFA0CH'2R(DD^1W
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M ^U)&W_I$3#E797".E-[)W*-;E.!6<3J1"CN92OFK>?\O1Q-UVR?!#%5:F?
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M,G A ];XD9%YGVMB!PKQ1^+(S$64D?P&9Z_TI[.[<%ZG&*EHIZ;2$POV]7A
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M,XTQJS<B*C,^""7F@T3NN]IO'" Q%<B8E0$JU4?D_1B[U6P[OHBS775[^/F
M FRQUCVWAX,O*!Y$,V(&?A(YZD>@,Y >$-5S7.8OT13W[EL)BRE*I?:<!&,
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M T*LA^<.:VQN;S=W#VMMM[62Y7T))5MKZZ,[%Y_5RS@>SVDO'08&L?HUBDM
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M_:B"^U$#]Z-8MX%P\OM1^!+73UM^=O1Q_-G1AZ@5G@Q<1H?UW* FR]\"NNX
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M^HO^HK_H+_J+_L\F07Y!(0E^(0E!$2:!QQ+\J%_1_W(.A40 "\ =\ 68@*>
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M?='FVMBU9WW:9-_"%K/%LAI&9'''Y1XO-S_8FORF5*%E9KSN#.UI8X '9SV
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M^O-GI<?Z[73O\1OAJ*B!K88L9<'3P>VTV,T!CD13>C5];QH? ]01?.CZ3W@
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M-DC-R)%P;^U\'UO*IC[ T==WPSSB!/XTT/ LD]<"?YO6/C/RJ%\KJX,P@X'
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M+A/-FL00 R68>FK]C#.%<[O[$^\6J"(=DAZD3V59'_SX58QEI CV^Q T77P
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M$.6,[B&?AP-:A#15]W[WNH3:VW%'1$VM7CM:ZL5,T8M)[>7U UX>&^_<"XH
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MU4W9M?RUHDI1AF4:0GH#/4Q0.BLY\!P+Y3_[8)K2YFFV]R>1HN-CI%I_<*;
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MP81'G46-E%$/4H3E%V1Q[4N$9+^MR.MBJ2B,PB,:3H2*&7>>23H&12.33KT
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M;?6:7 A,9=Y)^=&OLO5^7&LCP$V14;*]HA-SODAN$XCR/JR^7(#S>06*>6A
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M8V1\[+03PN'G[MGW)9YSP03LIU2&?DC4Z7)T-!'H;:)C(" 2Z6%Y)3T:.AM
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M0[2;C6!R,BO\;J5 *$S")(!M2\0ZCQST4K9$:,-;*RLF;X@US/G^H.XTKM,
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M#&G5L#>SZTVS9#%75.[3DG&;Z#I,!!2HUNH:H7YPP1ZW%CR-*%[>@<,'%?2
M//_L I5YB,8_6MCLO0$U(:1S$! 5N#D%=1)C=W*)52XE\.18 0T%H:![IU'2
M!2M#N?^<M-&E;)F FBW+AHJ[@<BP45K,N.JQ>J,[<"U@^</L=%H7GPX8MZCW
M[GXT"3SF_;J=!A&'$H?67Q?7(=BJUT!Y/7N@=R'\ZIYNW8I.O1E.OJ&G76T,
MK,(,F&=[M>@WN(GE<=%')V1S.MB=).E_[WS=Z"=''A;9CV&/M]0?_T+VV>$G
MNS0YY=R]$8%>-=;ROG6P)%9R9>WBLJ-@* R[N^:4Z2BU? *Y,LM:'?A /3#W
MK!WY+N7\1B,1,;A!>$_32M PWE;>VK\3*^2R*##<I,N]/,<^20X>;UMW0/#?
M@0]]P;[9AW<V47>EK0W+$5[U^:T?$:0R,YX@CV(=G9Z7&2;HNJ]AB@)32O'J
M?2MKMNX1N>#,/([)S?C4B/0.1B&"''I8/D]_"XU+R\6D%8>0768(&EVIX,&H
M$.+6H'WA9?H:=N".<EL0S7CMG=Y%D_V:U7*Y%QK1L;W'9/,[.$@>?CE]_'O!
M0T<J*@%'!B:>Q+@6T]ZQ:>PP6U" 9/P[Y@F:P9"T&<2UY2>.Q+DA.:/TE1^$
MT[[->W:4@WG\"?O\>0NQ=*>=[]P]$DK"LT3N:640SFT# CX==;Q6.E<13_8-
M!W#>EU63UN=@S2FOY;X7:&-0P: R\*0E1[H_!%L?YMH!=HT[S@Z7N-GB(1J]
MZT,9T^"$FZLU>ZQY_CS7_W87P<4P@U@Z;,/,>6-+LDVULO$TMTP</AHO<\ T
M>*I7N5,I_R(>Z>S,C&#OO37M3F5#+FS(GVE3$7AH_98I#4\A6S/-&"73"$"4
M==CO/@)PDKMJM3XZ\*%S.4P#J9B]?T4JW/&6)J_AE0I80=X*4YL/#;%.!5.C
M/(E>SBG7$OPVLS*,391D3@'H>F[?&3[+=?5D_#6?.:336:B$01@;%-<\T3"U
MLK3;]OK^91EF[6XFB"3SF^!07H-0'FK,'!8:42["IIM$LD?XU3+-=GJEX(K<
M<'$QI7FO&,@.0?;\U56IS<8=)>++Q?2A3:7D_;.VWDJ(::Z0<VM+R&+,33^2
M,X]?S2M=; 2*RSYH K6ZDUVY/I=%OMY*HQT'GNX$EUTDZMC5Q!;67<>>Y<&5
M,4UFO> Y^$*T>OB*Z!TXAF@JY1C(SQHHNN]T*\WNPL@U=##?1"]G/\F=S! &
M^:PY(70$8E&7SO_2'&('@OSYVW?,*[R/#*QK(^_Q2/74(XO *P)^_;O;$1>[
M5D#^JJP 2>Y:[MK6^59?IGVETS.YALQSS>O0_5/'O=21'L(B03<,84TU.,WK
M99$T?G*PNG-SFZJ&IZ07V.__?X>ADSWI+;23/T*%D-$#S;@:F.1+&-XQH7#B
M(^! G<E-K2UHU!3['@@PGG&!"@"=K#CF@IL3VW$[6,E 1D1"R^*6FGT[!J)I
MI>P7PQ:NC;3(0?.LD4M)I0B][(BM+]]=>9U9%F52S?*KMB+*?]/:.1\(A/1(
MD-J?VJ5[3E7OW'4]3"-%L]P(.!EWGA??_NT1QW?"^([F#1968,+OB_VU;H"R
MMW<[5<?]+%3V_4(A_Q6^Q,JZ&*&HMC0I0U'_TPI56%.BDP19V@G+%Q#I@_6V
MOMMH_M+(:U0(PYYCVS.=FNY9C16]@<3?/2WV62FG_.GNYS88" 5-N-Q:/*_V
MQ +!4,+G%$FH+;;S%65PF6>U?TDQTYHSXW@O"KL370'=2JCN>K=&=3KUTK:3
M :86AY#N57GL=W_'SSD0BND=ZHXZ;B'F")G:>)Y$*!QT^@;+'LT!.GVXD";4
M.8\\[7$[KG&OI> <WU$)?EOP?3^G'")JH0_MRN*5QV[8Y\,*B&_\7%-+-U@5
MZ.M><7![!O:'XP_6P%,K*GYG>KR@43C0[\C0\9_43+^QZ#O;0W)NZ@M5>@E&
M98W&<92^0F[^,D:B_D2$[&58R+/?W#<BT7XE=ZO&<<\<;,^D!X^R^%<WW069
MA, 4SXL(@NW\;?G>S1%L(%%9]=?7"K(:QB9@^&^B/WR7/(5/GI81CI56H2:\
M*B18X7(;L6ODIC+V\(NYT2CR_%3/YNKMFES,S49_:TUWMEU;,DJFDL=]6F<C
M67B/H<<'4;V*G;EJ*U/Y1^R+V##;O72&#B*Y*R%)?+%2W#'9I4R-*D#EQ/=9
MCT,C1<1&DW#EWFU\7E9_KK:$X3EUB$3:.F AX]PGCXB7O(^_H;05SKRR%"[D
M^BV9&EN 5JT/$LN6/M,@JV?43<B'50,1W/(-%RRC4@OHGPX5KP<%F&MB?>9A
M\&+057'A,X>9OK%."[<I;$F;E13.]F2;<;RC1!?C' [EBLCO=[)5EGP?E2B%
M?F;OK3*+7U?JJJ ?V$=Y&NLJ<:"@DWCD/>A@4P"Z,1%!?:N2OJ[/LS>U@U^Q
M_@C T]R/GR$XLA_UL+, +HWQ 7O47 [M,TA1S_!2'/:4138PL784XF])9[AL
M^UJ.,7 9C2*Y D"^\U26E%SRK"J'L+CPK=^SL3=;UD56Y,NK,/ND0%]/%3N8
M7_'\/HFNBH&YG\(4R1?G^927T30 X]-7&)_1_**&52H1X-*]6X5?W83:#OJ[
M&BJ#'YIXH5^BNFQ%=ZBP?I.[SSJWTD]@QFU-+C5+&S8=*X/=J*,Y>\6(YL76
MKG@Z.OK$E""=1IFD$>^M<\Q#3J"<-;'5!^DM;]'OID]BEUA'Y<T]Z%>V& <:
M0T)J$A)B#&+,SL&COX2H6V?"+U>R\G0'$C)-FI*TALYZ2?V_V1?YO 10S/<X
MH73P];1!G4+OM Z!XY=3."O9.3.NL^8J6VOXH[S]]TTS\5FP.=R[KCIUC:;J
MP1LZ+2Y1K9R%0 O_Q39G>/@?TR>F;E$6XOACTK2-.X.J%L+\'6@=3?T(<.QM
MY]J8,Z*K>1.FN)-D^*.$M@1L]:02.(IMU0TP[D7'S/EH2PK-3_[L$?[8)JR3
M)&2[[_9IOR^ZCA"U2[L<=U7IFG05$L;5/U!9) 4W]=N(?=&J%>_G_ZDTPH\Q
M\] 6Y-B4[%'0,QM=Z\K]89OK9P:J,8$&P$=25 +;PE] +5NP9+A+5_:-=L=5
M\)>KB>Y.EA-_$XS!/D5,3GE6ER]J0R#UT+ CTY:XQM43R_-'@'\2(Z$0[51-
M\CM@$E.RM$TV>Z_BVV.M 5\TA2;$['=8"7</]RP]Q\=JG7!!&.MHWO[,X7C#
MW_?!NO$7?0"/JUH!\PR.3IJFJ&R355RFXNR1AEY#4H@[_Q9[GR!O(5]$J-7,
M>=>L.G?#I(UI$F]MMZQT+>U"LETSU^G+,38%HJ,OYCD42NI]\CD0*QN0("1O
MYM;"=N$ZL+CYW6DO$TBI!?? A7#5NES652MP042DDC6B"<K;ZS!98PWI?%U0
MUV7%+E47*).VV=#0&JH:/M!/[9?"YCDPV$2L2X'&\U<P!)$G8<4'NUAQLUT4
M3O@4SRV-<_<QW,>JK[Q7P7+&)4A ,?TT$,R=1#/8XV%$(#.((@G\:BO"^O?/
M&O17&$FZ"6G2('LAK.F<EWMGLY'F9M^^TI-M5L&W>A!_ZG!SJOI(\B@2F"MF
M0V(7Y$=6.QYV<2S9PMZ]BL'I!=$*U$WDT"G:*XGG7]1)9,9]$66+TCL>^0 @
MLDZY'"4?2JI6YSO.O6X<0->1U=R*'B^YN@'$G-^D]S2A6E'XP3U<JR2@*UK'
MS&DS/,907J%I&^ +])2/[Z?>YMTM\PC %>8ZBE ==+^:#"6UMO ?MZDD30J@
MN.6Y9G5QPTGI2QQ#/U(ET:>)RM9[J]@*F)P/JO/=L\P$=EV/#4\'+NAHW;E"
M6*_</#[W.INZK$>X'V.'<W">QY4R$^C8-6IBAL%4=4W=(GZLI1\9F?W=B=)1
MO\;16^BQL_HPB/&7@ELE<D!"A-*?8@!8//@V]63QU II%?T$Y@NV_?\E%8SL
M7P*4_BUG?4JLK& Q]!&0 %D7$<=32_F'W0KMWT.V#_XCL<YF_4M9\-/DBHK_
MJ/3W/P_[-AQ/K2<^D_!KJ]&G;-%42"Y?\#=4AZ*+[B!"VYSK\->"S.%Y6YB^
MH$=HH@![]F 0==^BL<KU(M+M 0WBS:^>WJD0:& 8(HP#CH1D2[&;HX8B2R"M
M(L<>[MAE9#:=JVAUH9Y?9V^C$RT9EV1YO3WWL-\KE!5<W<Z.MX!RLV.I#V'?
M7XS<S#WMR8#C_Y0R]U^-9\]B XC1?+'=X2PAE.A&%0%Z'EV?<)YOE9:\M2,Z
MWA5NVN=W(G.\6GCUMV-3K=,::S=17%HK#70: ^.._7XZT_0))SU^ "9VK6 6
M?('<.YJ<I)@VX+_7/&5P-5*7DY4)_9'HVK>IU(WK!#K$5D) I_>%T9M-'P&O
M#0*Z-:*MIPX_0S?H$M%.^Q$70FNW(3/%*KIPMCS:="!T)82^U,'VOPI.^_^X
M*RA*GO:-"HPE&#M$P,K#-:)Q@?:,J=SU;&J-LGNKC>26$,9<[4@)V$^(JIU/
M8J&E3G-I&WAU:YS>V:I<2J9:&WRERQF@CWQ_RS*,_"F.IX%S]?T?AE$9Z'AC
MLZ5:[):6_"NAZEC%#Y?(AB*+**![6IZ;&YDI?0(A-I7*X6N>TJ+UDRZW>SO\
MRZZE!^C,LF=U+* GEYK*: Q+8<JHE<=]<JQ9NLC5XOI(F^8POI(,#7V@GCQ1
M 0U>%*H[&Y_'_"%50[P+8\ID4@ZK5]A7B,E*R\HD9)ZISG/6UXD>+=^@6:$6
M--?LE:^-<%E/RR+O3C]@7!AYV\=$76E)[GZ;_@W<K[$Q&A(OF#LK:_1PCK)S
MX>D=UX.(Z''O"SE1W]%I-A\PEB0B5?X$:<SZ>;EORP:&F,OC>"97=<:C4(:5
MO#9<4OV^6%"U1AGHXLV7M)?5+ O2T<O8-KN.[N-Y9L\^F>;%0$F!>'/0WNC?
MS+Y4LMPRP2[&ESL4U[NF08=J['*BX4VPCZ2O@+^N.BW^R+>"KQ.7] $N\>P1
MH#E'341\S#X9$W(H;$8N3V!%+2NAGBC0OPDX\UECH4#8#.1(8"5PJ^2ZIJBR
M2XTWVD8O%DZZS#JT5">Q!$'0W_0P,";Y1P6/*N&U?]O9[3HKE5T7[K(R[:*@
M:IKFW(225W"\[8U&8XE';2-_2>CCMO.GC/:T+KRF#6WD)$O7'ZJ22!7G(K$S
M!>U;^C8K77!O!?^197P%3P:1;[S4T?S-0]&36'&)GUDBMZ"\3(8[4%$=]U6(
MO,R4>]91%]$#*Q.&X2>95V8] @S]NYY%TBTW!+9^RMK'=&\+.C1$!)_.?)GX
MH7"QJPQV,6K_)F8EE.*;-]&J_</4<$26G2Q:7IISTE4%AM6V=NE:7?3+PY0_
M:6&=NZ]IROZ5L"C#>RT'(:O$^9 !DT-S1O[KO2/O%@C[+/(M DWU-/W*_[B)
M1,S.GH!^70-+3008+4*=)LRP)F"U(;6XP<'7DGP3?ZM:(5I&*628,>0'9X05
M'D"(!=1*Y@33[G1>;;[0G>\=&,)6:O@=A3"L9U IH% C<@2A)<S$N<'LXK>C
M:^)GA-(0H>NU\)V?1G($FMN)>LQ'.MZX2KZL:2E%9!ZP@GNZ4[T=/P[0O%,&
M&7="-(B/\><O,Y\U7)X1K49<P8/>>R8X>[<^;O4=;3H'-X%/=.VUE)YB6I.M
M".576!Z<KB?BG6NR@@=IHM7A40ZI"73XC9O?6+1T7ZU;B5<-__FBR@BROZ]0
M 8V8Q7CY9/;VP3W16W"6&DX(K9&36:X3 3:]YUW+!/A$Y.LB.4>5Q.UJ%YN$
M:N-X)O)([.9!7AWB>,H<;RXH_?1IK-[UPN>&:1?E%%^1O6N/B2&^W0$] IZ7
M">5U<<2?]W$P*DO-\7W:SR;S4WO-T\_A8)@OB2.AFC--:::DM4(YK:)[>A20
M1XRJIY/]"VM(DOJ4E]+?;+8\=7JTWX3P-<^@(YZ2.)MH" -I0W.HM,EQH=3M
M5?9R7&_<<M3@_OG-;6PVF3^_Y+IJ/AVC](FXZYGGR$X3T5D/M9A8A'<!,7*7
M[J)DV(*5-HY>8 /MLK@,B];&&/*%^A*_JO M1W_5P^J!7G7"L<'0^8'P:EG4
M64 %X95SCHL-'>6/N*S;M37OW\6[3.'+-2,9KL/D<?FD\Q*RK#RJ2LO!CP"2
M?6]:LUFTOC>.=^:FT4@\)RA-ORGE1Z38>=$ML&!MF/=[R^L"@Z(38^ KIDWD
M_C>3.=,738[X0XNU@3-\-1:3869%_;_5VS"<O$P?F)U(U++;B?ZD*4^\Z%,N
M9).^[A&"8)@)H0>^TUX!$TYDF W]$G\>-<;FUT1\77K>E284H=4:/[#]M\.%
MY.0]I6N4ETB?C4PO?/Q<M8EV8HX*!_J:<]?DXGM0:<$H6+B#@L!<O_5-(#\B
M)F1V..?!PK$-NZ: LPV=\5Q;9^$WG9DZR&21Q+^/RIMS4B/=DZ45NMCID%5$
M<&>9%X' U(93AF]7)9986DV5$YFZ4),Y$MW.DEK0%0@P;NDKYC9694XSBY7[
M8XFF5%R7T3=%(K)@G"4UP6PO$HTP6IY_'*3<!IO*P>FN:K.9K+^#G>>&QK(3
MWV$XTY75'^@9^'%8,?>>'>_(5TF%'BG1\J+<94U4;2\G3^4Q"E!&'=RZ'TZN
MD;/Y(#UG$SQ5:NF^)ILO5FX*"4J/"*>ZIV8,QP(=SV9O-)+O-5Y8SN.@$P,E
M@(Y*8<:S>F9U<O2/ &U*3I\D* VORX,"X\1V?)_R%]>07ZD$FJ,2!I^L*?W>
M7$8$.HSF&0BE.ZIEQ6VI?OND-K56Y W .4HZ/]"1:/)3/)^+JY>H#Y#DI<G:
M:KADV+DH;1.=]JFO:EKHV 8H1$VH$>%B&_EBCVG(<ZUL;C0S$9[I($V48Z)3
M>8^4SPSX=]V7\:;L@!8'XSX?4K^>^3: !4F0+&\0(2-2K()'P^?MR;,[6L0A
M9#LHO.3N+J6Y(8!M0JE60F]<![3!O"\'CBYEQ_U^WTY&A_N("]^Z.J@J!-XR
ME46V+9#H=6O\F-X$R"CUS]<;/Q=9NQAA/]"KP7O6>;# 7 9[,<,2(^\A&2,#
M1@=KY83ULQ-@:<89%K[\)&1Y.<)3$I.S NDTS36X$=X=,Y_HH#ZF!,6+OF2/
MN5809'@X+KL2]/@ZZ?F$XVS>4;)["[0QB>Q!'=*5E##M=9;?6I#0IM*<DP8$
M]IL34/^*[3V*MOM9'<F7QJ>(QFJ2"=8V'R]]^7NR)N[A8O)+3"^I<<Y5I.RW
M:"(R8P]8NL/ZD?[9]HX^@2$HJZ##C2#IG'D;BD>/PD,C5@MK-_[IWW\ /0X!
MK%^F8^ZGT2>H-)EAQ4_,]X!M,,["CY6_?S0U&WQ!?"/Q6B"F[WFB4X8<)'/?
M$!-%M6[*=)*F3IJEAM7VM57>H/(/3V,?>]&+Z])!Y;3]6?DD*Z'1HUGZ!NB2
M#/4Y=NY&>\'&#]>XU#>LBC+O4O,F0P [;95ED'6&L1.!]"7MO7,Q]A-*4%W"
MS[#-A\G)B0HF1T&P0K)LHQYG'E=2R>50%' \@%6&["-J+9L+%IL@?*9I/Z_(
MPG;W5G?V6N8(CV>)&E#1#S "NG \ZUMVA6BVMC;.^D<&;-Q)+.PS\4DG.$:U
MA_W^@9KOO"*U^?3&>0>-6"4P^IK!Z0HN985<=%*P5K88,)O5?D@MI(S.C#3"
MWDYO&._97WUS;A>^VCHWN\R:Y9*K="O<A7X^:BD1K[W(/C#]-Y$1-A[!_;!;
MX2 6RRV__J8[,G?_[-K:Z_,>(+RPOU%9EW4 ^HDXL?Y60R-O_Q%@/<.I@TT]
MB!R)Y[D^&4ULY?3<(#-RYK\H80#L"/]S,V99GC9#S_RT"_V$DKTL,2ILTVM]
M=J8(87]\+2F'TN62Y#R+'%IE['024J%]IIPE8"]DN0%\,VVE?2S\5L1(T#>G
MI<,.;]7LI:B2O68O&OHB?W _,0KG.PLKM%#EO^97ZZ4:F&Q?,>[PM?PJ7\ $
MYS_+>FWW\O[!; 1]V##0;!8'YW19_\"5,DJS16CJ=I\Q;%"R,OR*ZGVFLJ3>
M\F\NZW^M] '^MSP+):S6/&L6I-X347Y"YNIV_Z0V_UY$J_3?TT^GV_QQ6VF?
M9A7YIT=>=R?D7L%E_:9ZT8M;&CG5.$5CEA5Z]('L;<.^".5 (]^ZT >=Y67P
M"EZ@7,O=B\D5&>J&LU^M6F>W1P(D]<"M C8K)LQE- TX5H8+T'TG %*QKGD-
M;+.!>AU%G:U+2!+S7I6\JFEA\+BJ\%.IBCZ2QK1.>&.,ZC3@E[3M!%; W6U%
MG<UIGEW4;+IC_<2G!7SY]MF2Q&1_QV@M*&'FP@;=_ GV6W'*T3!E3.'2&U<W
M^P>FG-\WD 8R.J24V8B$Y.#-"PR33^PG!,(<]H1<;E^-SVR*5T.*V=F.1]C'
MC(A[+$9+S)UG]XP<"K2Z7-X_8]I,59<8_?J1EW-H7J ,;H7Y%YW?U9K]PRUW
MFL/M;+IKQ,"T 'OA 8E&8#68B4LK&P3Q8.6VKW>(_KTE+4B8MRXG(AW<G^T>
M$21@GN?JH37I>-=0XJ<OI:X>O65TQV<%Y$>9BX+:79:X77IQS?3R+Y:(SI!*
M?V9=DN8KMG[U]WUPQ]_MYKON> *-A4> 3RDGJ:Q'0-. ;C^'S(K+<6QA!?7V
M9@K*TK0!KN;*ZOW74/F*FC&@[ZI\Q"%!8Z-P5!V/D#8=ZNE+UC$,QZPH?C1V
M#4&9A6WT0<?ZZB3>]4@38' 7"-N0AS,&-BRZW24A=3'O672P^+N$*=W,JOB0
M;8X*BL>ZZ5P\"MAU#PA\F4?QY]8P>U9GHW:2?$B1:XSXL[4&#QK%0^'PTU\C
M/VCI0+]/,&GO?\7XR=@ _019^R"F9)RMMBC16Y$/,3;COHU(V/&"+DC?MRRZ
M'"K/C?",\,'J-^#8.E63AM,U$2^'P=F-V>%.F/<.>!*]I-\ UQ1Q$_]:':QH
ME!/[I8[./7_-=.F];,'?#U70+<9+TC:VZ3FJ[T014'8?@'"J+I[VE+)]:V")
MQ $C&&AJ7XZ1-T7BY##N6HM?-49R-K+W8T;Y0ZLJL ^=S[J+MYV\E^].];J5
M-J3S*-J+7Y&@@$V,YCJ: .\'%58Q45@D-T/<3IFNZ<#@ML0TGI+RI[(4;T9$
MB *.Z_JAE73TJ@+M IZ^BW1Z2H3]$J1=W&,UF--Q3( ]WR(BXL*,>(KB:%P2
MUHW=VXRR+A&Y<-TMZW;,_D'KN#DNN0GE#,D?)/RS-.DC</N62,VE6NE8'^T4
MAM#IY'(W1QE%W];]=$)M#V%&&WNS2Y_9L&BUG$QC\BTSY"/&_]MJ.R.SU;(*
M.&8N?/I_&@+6N3:=Q*8^7:.];+4=XR0=#33 05LX$^KGK6M2&P&&I> *NG9A
M_RG+!W6W\B%LQ3Q,8>B.G4N0K*6WPF$8&?>J.(^ 9_CCHMIG@HGA:GELNQZZ
M]L"*XJAR8UMB38I7@IA\]<)^MW=@?=20%9=EH91'P _+-)EGL<)?R=M.24Y
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M?I0VAHCFNHSG[_S2T1;,KZC2=_W]YVBI_5MEOLCKW'2ST.=@!M<GP3F,(=N
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MP8Y>#4O+^+P*)*YV*'13/CL@O'ZG77S/L/.2(J$R=\#HU+8VP!^V'KL!/"9
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M2H\_ONX1$!D^Z$YN37L9RL(4G_S63,+PJ?MO+6(%]=8AKXLEFED9Z$R9"^*
M=/4PT<76TY>_9S'=^V \)C>!;.XS@"$VAVQ@WYMWZ Y+,'G?(SX^HYLMI2=Y
MK)@!U;@H_?+N#7E(^SW@<]-IJ,^@TJ)X?FWE-@TU*C -82NG43V94P^:V"#\
M<%(<X*@$ &'%2DA/X4^W&& >)TI-N=@_,]37M;[45#!VP4KDEJL/&V\9F>TB
M.(P9.6KV)?,"H0A4IVZTO3'W=!)BC*W9>AZ !Q)L<\/KCHC+>:>0$T7CS64O
MWI58+J4O(2+DU"::19W<L\%;JBWA!)R+#]S,OJC@,&.F/C%\NK)+41!XP,6?
M0FSLR1K'T8!E\SN8BD;V+0Y.OO4 WSV TEHDHV.%D \>T+? MV.D9:\ZY/C=
M_9.CU B47G@;H@X-,IA>0Q.OW;ZCUKP0G:\0&'!,Q&> 7!_B6C X2+Y4FA?5
M'?(9-[B3JU$UP$&(KE! K97'Q11<$.Z;<1^[_<?)O\F_(9<BA\_CI$L2S]3X
M,-^\G3*:*7,.HQR,X)QJC],#6@E^4 K_(FP Z(,D&_34EO8=J.FDCVI?753@
M^V4:6"6*]5D3>C=<]U7=,6.B*EC0ZDCE=Z<]$]MU%&F;):9\[,>#'O7QY Z^
MS8NF])115ML20GK-M 3(B,</$%=""XNVKG=6+)X"^=E]HU!A>H.NWFK=&_ZH
M'A^&ZA,_#=? (3M&[4X6C."]:$AZ?/5GA*C2/>!QU+,NJD%+6SC2]/6I0"%#
MN 4Y<J:A(B2AQ/38[FJ<NW:9TC)0Q/ASN*\B@B]-'4'D):#K28T+C).Y?A[*
MJ2.UZ:YE.QS%YXCM&W1<_%$-I-^]CCA8]ZC[UJQKBN1@TI?^$(IXG9/:KKFF
MH>N@87,,)#/6C4=(8**>M[Y ,Y?NNA;2K/&_D/_Z],M0#  X*7S#!NI8ID%%
M-ED70&./>D&0W),0G;$7K*986^$' WW*]1TW+(K)RDWS6!;.3>G5GUR:2IJH
MGUSL*?MQ<F8%Y(8R,^#065"!TK2MX$&!$GQ+.QZU>2X"B87O)A9PDY8FZ'P@
MX7'A)"XWQ:.=*0>@;I' !@3N]5X1^V8]MXZN B\9DGS1M4B([.';&["G*%M4
M^F&?[NH*$7.8&)MU<3&[8ST+GQ54X?EJ5 %D7\;NK((;S=?[6$RYH%?>?^'C
MD'4ZMAO!NG\+S=72X=EU&#3OC=@XG_5K\CEY.@%19-D'Q/=D*DI(PTE!6(UI
M.;3KTY2;G78YY:#D/D&\+VJ,#=C1^@+E<I%G7PBU@WN:1U0E1EW7]YD.7'>5
MOQV=:.EZBS9>\R4XB&7#<'=H.UD^):)M]QX_Q^2?]?/S:R\/ 2GHO.Y1=6M.
MTE6YMK^PH86W2C7/B2'M,]CK'!NV2,Q#V:)W_J,W+N[F_T0G;_GW9=<EUUBW
M.>9_%Q%/VH(S'AG/P/5!76S4K9GS8-O6?3><!MHET]^T=LI0_J6TW@QWCK)]
M(MW%]PMFH3+P7]X]WBEZ*V%>N-GHWEF[ NS!>++00SJL$/0E36\#Z]I43>36
MY$;2_O&.6K<US2WH=\[&$S88RK=SR;,S_/2W(9P"NJZOFR4J=VT][:MZI*?O
MH,C).73MP;\#"A)GT?_#@>7_1L\3V?(:4)*L&>-;;D4XMR-0I:^G,$Y/+3ZP
MC=. :++'N:&=N7FOMJ6.EZ=%13U1<61&NU]@7]2'-#A=:WNR0_/\YXM&_N*>
M:+$!((^BMW;3/8!UNR#H^[D'_=;ITY- $B&URSPT%^B*JJYK)<#5@/C3%/^K
MNN0&*@D)>=YY;^"U88+H%=YS4 Y980G]:B59<GUR9![(]2_&//+?*BRH3H)M
MUZ/O 0_BU#0X#(=$S+(9V?LP 9Y3 W".^(?##)%:O3K8/S*0"^?W +%/^E8'
MNY2>4([@E^V<R,6+FR\E5[+1L=UUI'3GORI,Q)7=0U.^-ZCN*Y8:TYB#=P0V
M5Y0CM(Q3-B6C[@$ZY:HR'C%Z10S0D[CO*>:T(<1LF%=VM+]^/D.L86PO@I01
MSY<*2@C6?+>MXW_L?[P'+!KY/EDM;O/RX-/?!H]50@5D?5^J3L&CKH(7G<T-
MMSY.S4:QR3>+-<09:_"+BWCK*M57P8 \[J8O2>G,SG>MEJR@WDY%%M>%P+.[
MFG"3 D;2J>W4Q5?KC62U";TCOW#-R2Q-M/K/Z##4-=)D!*QXHRX&;JUJF$KW
M^7['_[F(Y;XI3^PJJNU8N)[PE=*;=DEFM9G(&=5DN*N9##3X/1#FFF]8.NRZ
M.%QP9%"9MA+D,9EK1*[XLY\>B^9\1>A4)F?X6P-#KD.-R1M;^/(J35E&-^T]
M0,-P^BR^1HK_I\FWF_;4@^(95$J:A%8T,8/R)D D9NP/ S_Y3?79HF&O.";5
M/:%/Y]%G+&>Q4-:6P*-]M%B[M U@LQ14G#8]2EXB^L??/OS[H)(/Z<_KZV+)
M_;C[\\@>R$J1B47*2(0"1L;.\'B[/-SFG'55;6V;!ZH]);3.A4V QI_^;.5#
MM&_W)2&P'%SDPLY60SOD_-(I];-\_X 8K<Y2=DDRJ.6<.8%#!TXNX$,ZOL^_
MXY*B^Z[QVU@PC1-;Y>L'7]XH8'XS@*1+U*A)8J#MJ&DNE:)47HW<27$,^5K&
M\;RA\]=U]8C\,BLM0W5R2!6S;Z('%95JU&>T^(G?*+'RLR)Y52:B?I4VY;!B
M>50QS8L_MR)$U_!%!HK7\B9'.&9T,-R(TS42)\]*3;044MW?H2JK_6,58T^.
MKRF(W9/,-?W)\6UDC'?> KC#YOR!SJ9 _,(0<ZL2D>0#-B6E20X^6QYJ2>7P
M'FO  @6I!9PW]7.(^*U5/8KSFVF@5!FXA]GV9QU\DH@*^<1I8#1/BZ(V%9YX
MX;C[(O^:_/IUDM>BQ\$(N-6M/O'57&?B6MTWB^;&QL3W ?F->)NUEX##W;<C
MSZ_+\70:CN6"[-GY]MC*^!EK)YTNM-+E6)-Z'7E/G>_89_+*"XR](9"'\0<M
M0S-E5="U>/TLFYA P$T!W;$WWHN_RM,H!_*7%Y89;"OARQK1;!Y$!#CP#+'K
M2L>N*EX8+8XE#7FL I\XSS_$IS0I/V)Q?B)*#&_$C\L+2FH+O'.D.!9JM[R'
M2$:+/KK&G5--Z5A$2-;XT.WZ4/AW$8+'[3U'18\$!T_V%W:[7>Z(%?*A\RZ2
MU%9WM+HOJ2CT=-=;P&C3DW7;A3[UD:.UXII/"R=,9\E*HRA^_C;<[5;ZRM!1
M[9]*85"5[6A>IA'N#K5'R!KI/#1OUQ5G/C\>VX=(^(;Q"6:.P ,/VQ'>/CV+
MY?H_F!U^'-;DEPGUN 15U4BV-8=_EZ%>"!#S3-5<"?9Y)9<#]J!>*D_B&-Q3
M>QCX.+6]'U]8DN6PZW0/.#^C(%??L".P,3=EB(F&B,G=MM D%Q6Y!P+%&2$)
MXBIC"XZ.3GW\;7IMX5[F7BR0W(6N@I3K"#5D?RBW8&+DV]$EX8T@FO,I3<?-
M*D>^* YXR#]I*<K9[JQ';P<-KUWTRTSQ6PNR_M?V3/TW ^$ACAY:_;F-1WI)
MELX/6R7 S2J;!]E^NN*^=H(]I#L6C=$?)E&-"VLD5BCA#46GK"Y)]WJ(IY4G
M\L/4I(1C(@9Y_ 5B>J<E:@Q[VO!INW4,XACS=N>MKO18J)S"O]MF0M)SL,QH
M)R=;LI-3X\O&$K&.G(;.? .O#E;".%R.J/:>61%KVY[0?Z$B*F#+B'\+.&U?
M/R^!<_FYB LB\G,0X"V8-5L64__X7+^@*?E#R,),TRY+8ZQQ?R1EI\23*6<"
M*O17[>;DZ8,:83.H)K/)+H4:TH$5L'K!5"W&?%R[I3+1+%< #?0$VY[[D4E;
M[6L+D J+?G?$9:'V .6KRL&B'=^CD,<EO3@?:&CMB1:H 0I-@_"%NPN?PQ4#
M2!-Y>53W"B[[N?WCG62#),B%;@2+?%U2KYM%PE*4^HB<M/[Y\]O2"HBG4*K<
M-Q@!Y9PU+@0112CE":9B8JP+4;(_,W&M&.*>6K\X,G!!M/"JH( ]:/8;84_J
MI=:"#?$]78%U_8(M82K:>*FK#)W+(E/M+&@NN9Q:*6_X5RTXP5<8P=,!AF2F
M%&I8+%X9TZ8K_:03T=N+ HH$V_/G62XFB>%BDN56M9I*:[9F8)[Y2J,?+QF0
M "+>=G(DEI.6P5.T6_&. 7M*MP_CE*T=E_X3K.HH*Z*WE%&_<C*W25N=]K9A
MGUA@I8:L=EN).[[XS:IK%61 S[5A\PEQSMTULW1RJ654X-+/B&\6L3R/Q-+C
MF8J.D8:3-^HN96@"G2"@YPR'F"#F!E9JJE?IHU$A^M"S7RS7V@:("XB0TA$.
M.DX=;5UHZ5%>:>];M-0?6=U/K@J((2M_RQ#U';E!#=&&MW5%&'Y$@W*AYI0I
MC"V5#:=F,4O=9CZG60NI-\B?1P9),D]RHQV9W&<C6FFM6AF.TP/RYA:U^R32
M*$K+>']JOGQP4Z_F$;GZJ94=[>1>O R^&O$K+$\KT^ZL),=WE1C_XH@MM1X9
M]*KE02B) MUZF+#D(\L[SLJ6A@:4:Q-V)D/X*RDLZ">ZV_V#CT+]O<O>T.(,
M4N<B?F"0FSG)XH5=G1!UY[K@>BEP3;]%0'[",EWXDXA(_&?C:*E=%I96.^.3
MZUJAICWM9M]C'S9O'BU-SSW+1^ ? 9IR:JO1CW?#15S*J)F[$EUI\1*[)A5P
M]<-8."Y+:+F<L %;Y'T2\96YEA<4+])K192K%G1?,LCFI@/58Q5*8,+.N@^B
M--VW B4H!BV.C]2.1X.9_(8W!C]4P2N-:7_Y 8=P7L8)G97>$K0;B(]3P#L7
M>C0K=P1.'S]X:&Z#&=ND&$D@K(_>;%$)]9G0"9O/Z;L3 N8K-OK.<YF*+)7>
M:=>%5--%S(KY3:(AZ4WUY4>=C3823]&^UGB;KU[4]GKFGYD(MLU21766^G82
MKTTB7LS2?H@X?P%YF2QG_COHW?.T3-2<9MEM1&V!*7_\#9MX\V"M_$+.$SMP
MSWM%KJ3^58FG\W^HU*.[G#(]SIEI>PH9LMUB^=';,RT?DNWSA_'QK6FF>&GA
M;'C-CXB$9K/]U*<4]28:5/6*.V2>?_K^=P_1_Q,UW_\,?(0(WV_+%"AZOCT[
MY[W>]5'+!X&2!\S25[0>!]M%WS_%)[50R>B)->PH%*Q[#2.YOEW-?K/)G_+:
MYH+-*1ZFX?=^U'K]B]81!^N\G'-W9+-WK>RH;*,V2<AR\UUXVT?WBGP)KGO
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M:$V<?NTBQ9:I"&S++6H1L$)$KOU3P:!^9_0M][ :.L3;WA[EUBFG^4.Z8(%
M=,@I0&[9?71:K0G7-_".L&:J-PL_R*X.HRZ\^CG.U$M1N0T=G:- /GMBW5R1
MC6]NUN2,N$2E#7N!:H]N=KUS250^>]NCX_<W=TZ:P/;MIR5[U_84-Y#QG(E\
MW29J&F*^ZFZW?%1"/[T_[T;XK?5,";/4<6W8V@^S*.E))(R(-LV/??C<G"'F
M('FF=%=9\9<HO2($TI2P__>=5AK69J?.*O]'"A#_R8J3$PK N5HU2S>M>HKO
MPEG,S9DQWE+% HW?OM@N;>(P5RHIS*P?/Z?D$L:5/>T-+R!;_3%?2^,;1GXP
M;/7_.4"FNQ3-%^FLX[#^"5Z\$SV^TO9#&ITBLBW:;J=H<&-O):1@#\[XG852
MKE"9P3$1JRK@79>]1$ZK):;5OTN06?.+"KMRP8(B 6.N@7!>^F^ 2H S.7TR
MH$Z&A_S]L1SK@Q<R3S'V_'D_[H)08 _]Z=M^4Y)2#MZ 7L1S"TRAK5! M8P%
ML%#_!^RW\Y)P.:(Q1FR&E]W\T9Q9 \Z1Z74VS/+_U63G44^?6O/J*A3L5\E_
ME7/?8CFE;=S?Y=Y[2VKYCUQ2!0-:'5%FH8NRR\(N\.;HYM'E0P@*/^J8PFO]
M^A1*LN?\W\U/_L4P(OX^YLO]9P)IPSGF TJ^?_1H_5NU'<KW3D&E\AY@(WGF
MY?+'<?[Y]Q17Q!77U$'&=:ID#]<OC'\0L_^2&DW/M8 @IG HK<[,1VS65.\R
M>'5!S FCBY-@RO=J+X68LO,VLIFA3&UIR),W0KX"_*IOW??J'(O>TEFR<U]2
M[QZ@XU$[N.=ZR?8[ZJZ&O61CE[C"O"OJ]+<FUW)7!3WTNCZA*4R?*\@7V7$/
MV"LX(QD&R:VUH4\2[QI]I52#[E[FLZ%E:)]EH).X;IUHAV8TK*!?[@'=@W</
MV#BK2U#5.I)=?[Y(TSP_,(@@I2AK_\M?O=[T0""M=*JOA$K<=_0PWXQ?M7L3
M7;UCYV*IGQJ*=?]2L8TY!OS-8 N2"A=*#GYZ;]F3Y7$S" 7?23&VZ;@LD#GR
M^Z"^H7)K8P)\\&--?3J-62CY]+Q$)E7HJ6^8+(=ZCP31&)-#I9[^[[B-VHB\
M>(^M<L$9LV?:VE[VZ;ZXNN\2=&33Z/7RJOS(C8GQ&J@L('J7_1+GDQ0LG9<S
ML\(;VD5PN$%?V:(UQ>>T===$CXA<4IY[0$F@]K3^7:B*LBGT:U\R4]!: S_T
MJ(PKD=$X%/<[DRO6@V)9IXCV#,437*D\O1NVV1ME!";>85VA'NQ-<Q]GQ G2
MZ(Z(!TC]A9H52 1V@-^\.99(.'Z?2'I*[G6AVJ(Q FDJQ!GZLT.-XFPR0:%@
MP9E>("&GYL2.TU2%UX?&V:[9*3Y;^P\3%<R1;ZJ!SA'4L(A [FIGO#KZ?*D#
MG1G08 [:;N!&J50[J3F/R$ LC,JQ5L3?0;*W^1)1GO$9KR)(C",;K@N7*]P5
M3::TG,:@?QP7=7F5 ;0::@GZA!+L:3%8)H.)^N7+;>AJ[[T",M(#/L>0%ATZ
M[9UU%ZM^MZ^:O@L0B0TO:QKW*?@Y4+)3"<Y13?Q8HT0<KL^W^TI8B%8 ,AMJ
MX[$9QW&B+5,TW[)0ON%G]ZR_B[Q?;SW<R8 %84MT#^@R?&H#PPT+T]Z</H^2
MX*ILXGO'\_5) P#I2H#4:4P,.MOCBJ!Y,7ZF9!:T'QURR/@G.DF9#]9I,G"I
MW^ZK77#7'*T<T];&7QR@T_+S4/3RD\U@VTR^F5SY4CM[F@,U44W]%7H+=%5]
MK]0Z2-JM?$?$:[S'MUA;9X#N(9'UMW>K9^W,R2='N& 1S2943H_:,GC&<0&^
MR><O_RG_]E?>14QX;-EH":W.+Y1+LPY7*->-LHM]/CI#:BK_A('C-8_NS]U@
MJ5\_X6_IQ? AP+F. 1E7TMKDL+A#S_QSPB-V 5/1ZEYQ)P/C-5J2O5:Z8]_@
M<]T6._B 3$<0L*%9"Q&Z4C_0/KJB.N)>7M<#<K!LPSLG/Z!_)H/WE>$1]E*2
M?B'W E8D6[\+6?+@JF'06;\O$JD]]?0;/M()XQX VU'UAYQ;W_3IV$J^OP?T
M[YU7/$/'*0(?;H]9.^CMBGQOVP%%RT;&=NN_BU9$4NH6DHLZ+;?04.NJU$\Q
M_/SZL2;AA.L\88<GB7@W<QT4##VO :*U72\DR$/R,J0FIM5-_EP1'_#TW 8_
MK;]<T,Q)7GB/QN4L6[OP/<!3E F].PCA"627CE@*,KZ[\$B=B<W-(VN]!Q2E
M6M7_4JK;]GPNLASOY#,C<)666F>=-H-:I)?GGMW X?=HMNZZPYPN:#X>7F?N
M>C&FW>SF8Y<^<9N]^08$,6D_/-O'$+JH^%QN%1UN$+FE+/Q+\4#K?U?HW6BV
M_R%9R?\XY)HD(8^JCIGJU6JAT_YCVC07OO"LJ9(OO[JP"*-E * 4U>JOOXCT
M>EK-+ ($(R8"R!EQ4$9./>Z%W/''FTV?;0MV5FRG3;3B<17<>$2-A^)>/*R.
MBW]9V3=L$/8Y:T?$IE=?5*D:%AU.ZK_T+&8GFH5^S!EJ#LZ>*%73A-"++-"9
MM*\+0*9HG/;>4M6$C\,-T'L'/.Q29B#&D3<4M-_OQ(MK(A/@%8%>3*^\)78.
M]KLC\G;QKANF"A\>8X@F"N& ,=VL#O(GG!=2IIKK)P\^-[Y] &1@'<F9#^[?
MM1(^HWZU2Y;=,%%J'DF"2Z1@$UZ(\Q:#BB /X%"UPI1GL>;I22WR&M84PDF?
MT'FXD_ BC6"0W*&4W V'E?OKES?<H7%:M5,P23PK<.-R%S#YXN$;+3W>,*&Y
M*%&L['T<NM6G>'WY[D=FD_OYDSWA,]$*YL_IZBS]PE_W8B^:8F)BPI.L<\&U
M B=2GPO@"UVONV-ZGF2WV;TEX\,8&,[?$3'LEL23R5E86,"N:[2(7 'P['\L
M?7O^N]6N@%J%U9Y"VA:" .)*>W[%2G3,81,8FX_" !8R8U*?1CJ%;A_P*;-V
M3.\[#XJ:OU.$"6P'*) Q&+EADO!/!Z0=JWJ"'[9_[/#:[EI]TX7O+8<S]1'G
M.9PQ/PM!\,Q21"V7PFFN=X)!$<OUTEU4^^V:RE@NLIS5%ONV61N!)[&YX3Z^
M/U#_X2D'LO(=]SYA5.V:OHYV?E)!LPYU0.Y[ZH$'=P@>H)IB4=^Z5470F>M$
MF1W-1H[GPCQ\<R.;3/_@ABU=\0L Z[P7.O(:D[1;P/7R'D#(A^O9WSW&7S,
M_9%6$1'T5#+8S%E,\[D.9QIG")*;L9AG#@BY8!1>L [NNMMV!J9D))(C)UI>
M'MBN-T9NRM.#$0]-XZ-?O/7XXA$^^3 @.:^3(Q?#+H2W,-S$1/:Q_9$99!@
MF9E4$ QK?NGDV)..5(C;,KU<,>&^\9S11\!W:4A0BUDF#3+-L?(+&.W&1%[M
M5Y'N)-L@$94T3VN2FLT,:X@]OEA]7H V,28F(!Q?J.A5)<Q?F A7RU3!=X95
M%N#SX#2R&2#A_T686A&/9T5A#%;"\>J7^12M,W?_LD8MZ@7BA#5<8>&)G$0.
M>:DL+!SJVZ=CC2OZ@_UM D/M5QM5A?6-T)?F<U(X8L=2.Q,M *BO[ NF?K#
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MDLK=9X_0SW6T&*O*8LY&DS+1.0ZS5LSP%GX[W?DQ/Z$[^<;_BON]YM5I .9
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M9KE'UHNV[/<#353%>4X3Y<D*T[&$Q<C?&6GT.?90L;"YMR9-^#LO.VI9R$>
M['2BZA+U<O*M[DGC3^40Z=,R0@&,6V_O8GR.=:6X8DN76O]!]1J%:59S9U>K
M*LI887JS'3&)FQFQ1\#3M]!"MPSXMWV.JKE]A#6L@8L5R]J?*W,3+]*!)?$'
M$!N2;]GHL-_Z-/!;=8KC_EX),5D1HX'QTL->QP40;SV13?C#=MI0>3BIZ[M,
M<*-S\YD$39Y7PGF-.09<8N">P%>^#X%3 4.6E&HC3>RJ=D>[*DNW?F_+!:%]
ME1&.?&J=OA)2LD*!E]TESG>'T3:O4/UG>&EV0^ H.58$N]N0$1EE"CUH!.KR
MIF?8GMHHP)*.^;'(%ENPAQ8)N ^Z(EHREIE.TY:AQ?,6R8KPO,(^T]HZQ>$.
M.5$_M'VY)PU-'"%76K7\K@K95M%06&$3+N]O(R&.D]=+-0CN?O*CY*\C?C41
M+R0F$SOG\9MGM.S=%3&'NH,$M00[WO=B1S[M%=@DD#;R\^(N!R=?'AAH]^?L
M$N*HCW]K);5J3I??R#Q(/7-<J6$DT!RTU:IL8>JF9N1)>_7 S+Y#,9G-JFWR
MB<MVF&!5&RV@8W,*=R7LEBU^.<?F/J-$7R[_SYC^S:N.3DP!=J5#S#ZX$B',
M@083@6I#5+/SS/C6@-/)DUWK!/LT?_EEWB% 4XK6>DA)?06[$)9I 1L332NB
M'::3H#W"ZU:C9M$KH:FS#F$N]_S11P E2KJ^&H:X[ W&W(DIE(WC*;(N8PR/
MQ9-T\74_%&DH72$]J"SOCGIJ]4)[Y6,^MK'%U<X1.:.?8@ RM!U]47T^RM_K
MXR. T(L#'QHKFI<SLCWX;8)NZ?Q%E[E=@<\C(-!R97?^ ;:Q@FLUL;L]+*R]
M:"AM:^I+MU7!13B43HC>PMM7>_YBV_=[0Z[;WS4Y=9&F>F/< GOH-^%@.V;K
M2WAO'EN2(4VSH 3Y//9 ![ZM;:.)X$LKWM.:D#8+8I.>&>#ZGGJT>87Q@-60
M L)!YD\B;Q4P^?B%\CH'"Y2J"[G0&,+M)0:(2P%,9&Q'.J)DB%<M!<B%3U/Y
MHZ(]^(WUS8X^U?WO4RBY^(>B?M>A>9AFZ*9K6Q7>%&0MZ'G)CY<[VU7I[-VV
M=-."[S@6UJO9[+9-\U<=;STOMA,UD/&Y8(^(J>*Y?==^LX_+!CKS)T%S51($
M<V3T5!MBZ5(.F@_$IQ^1\/ESA;$77;E+B:W-L$G)A<6>^EI@>D,OV2JQ!X=E
M8AL^A],C@,C2@3_0^)0W;Q'*6[,R_VTN<U%NOLM^"4G86^%5<\P.GKU,@6H^
M;1;A*T?'L1F?*E,)EE%.^8Z2<M_^6587\$ DMVX%G=$-*N+6)W&U@;)6XL+=
MT,29J"%1\L>Y8Z-(+D6*:33K*)/I?L+?^C*_6.L@FQLB5D%C3A(;OOZ5%ND6
M=2U5+C].]JC&*CMKA4GH19-&>#EAL&/]<F]A2A_:BM,_L>#YA*)U5CFZC.M$
M(?=*Y3?2&(%:^L1=WT?0X\Y-L2-:3A-#:-5/S5&:+K>J>_S$;'FIM17<^H"1
M'ZK2AQ&9YO@SR8<\(I*](?,N:;YK@P(F?B''=LLW\@-AG/%2@ZPTA(*TGT\'
MQ'Y<'BAZ]KP0\V?CK;]42**97E_?Q_S@;X2';G9>3U/LABKC:VII>T)]"/7M
MGCHEC 3*Y'OQCEV^LTGH56[S9=E>6V/0PTL5[5KT(R!L(ZE><VJ=>6^W/@G4
M,5]G8]\&A%V-AC"%UV_R=9U!9B/FQ+K"*2B^?5_WQ44!*\>A3O=B!G%#WYJK
M&U)PM[C-X"E!$Y.QVJN.@=93=MANJG=RIT$%ZY[W7(3XLV3DOM7K]<2183K]
M1K\X,#;"/2 #7K4N%"U30U&!B1,C:^0\=PUXL7ND#MJV(O+Y? _B&XBR\7K?
MP%?'7ISN10/A&?/SX3/@^B^'#&B]4Z =@YZO:NO?HI$JWS<(L?<>N,9T>Y4I
M&3[#6CJCDDDO:7(F75$A-U?#U]UB.,U@!MO?7^D4<)@&FGX"G_L":3(W/<)N
M/< Y==^WTZ7"F">KFU(QT8N8*LI3'IC<UKP@91)?<_6P:V ."6=/SQD.W?J.
MT39P5XHNJ 0"2<!L(R5]YKHE"30JV[G7K8,/M'5_-GPF'%TYYJQ_Y"Z:B+$
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M57<T:!_EQ?5C2F*9%'\L>WH31>V^.ITV= E-"UA>7)2A+GY[E92RA7N0;#A
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M9,$\>]*YL0=2-'YA+4M^H2(A&W*Z3+(K]<[IGIF7B:D[C);B3VD3ODX@@PO
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MU2)<VV/ 9R1FZ;#TY)IB4E,I8#V"M'L4V/@JBWH>;K\FH6GTN00@LZ6^TOM
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M9>PECR7OX[J$VC)%TG/?0(+MFQ;*QM(+ GK4ZJ>A1\T2X%PA>5OV=7<5/TJ
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M+#T_S5*C>ELM-V]%,YQ=18:&JA38>NIAB>Z,AG1R\UH%FB)-H]C<C/%'B5%
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M<@**8*Y>.PWW( 5SW3_JHLF3_4JI,F&WX3-HECR+K)2<O*IX!L#O(7RY;=U
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M"'\#KL=)Q!2::EMTSK0_3DDU'U2P2FY9>A2U0.*M% HJ?K9+O>[YB/U0G;2
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MA(5P"AN2*3G:!Y9UT,>,U ?\J>G6,6([PB'R_$^+%*B=>-9O_0_LD>Y@I>U
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MNAIB"/S0@O'7LMP.-?C;P<TLH;HR']P^MS?79S%\BQ')_>Y!%6&_(C4NI'8
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MF3WX.'CB<Y#\*4WA>K-FG2B7B9)X?,.15M=321'>[L$"L^VA(3[U/^C82<E
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M85&-S2@BYQ"$_#<8CFD4ZYK MT-,Z84]<CZ$ J4/G4KK,"^C:4+K?V/@MSA
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MTC=HO/ 99,#(;"MG;VP<'@UCMXZ@LQ<R:I&L(MXH%>$.H9;AY)D="SL$ 'E
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MN1<P(8XY(+R:$JI.2/D8=<#/K@>E*ZOJ.SL9-_K^KZ==WL;BPG$<&Y$B5_\
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M9<$9E+$J,)M+-D;3M&,BG>)AX>FFMXM?:;<4:,>4\RJ(Y"JL)3'P(V(4?/\
M*<>QI>[<>MAW_"862WSPRVUW%;I,T!O75!%O6(RD?>W_ ' 3G;C/&<\4S1==
MNM6\1W$;VUQ:6@L()X8;@1[F+O)\_P C-P0%&"01CH.[5D\+RWTUDVW?;S27
M3^<)%C+JGER$.WR-M5L, 2!GD9JO8W/A31].34;*>Y\B]ML+-ON9V6!,\\[F
MCC7<>?E SVS196V"[[BQ^-3>R:=_9VE73I<WK6TJLT)9,0N^.)<*PVY*M\P
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;<%.P MC@$X!/UKSMO
M&I-I[0(FGPQ+<B46J.C)*-A7YV>W()&006C=^N7)P1Z(S*BEG(55&22< "N*
M\)ZA#:ZI=02:W'JD#I&1>&XEPDKNRB$K)*ZASQPNT]BO2M(MI.Q$K-ZDT/@V
MZ010+=+!;?9E=B'\R1+M8C$) 0JAL @[L*=R*<#M3T?P#);PV]OJD%I+;)=K
M--"'1HY0L,J9V+!&,EG4G.[(').,'3UO7]7L;G5VLHK>6#3;>*01F)FDD:3<
M,[MZA57&XYZC/*]:H6?C'5)M/BG9+*8W3O:VSPE&5KC*^7N\N:0 $,V1NR/+
M)SSQ7O6)]VX3>#4AFAN]0LK.\AC@NX9RJ,TL:23-(K1!8V9F 9A@8QDX)K2\
M.C4K2"S?4+5IKS4F9[R=E*&)43"$C&.<+\I((+L<'#8P]1\8ZEHZ[(8K<![F
M[W3W,H$;LDNT1AIIT"9'/!; Z)@5<O/&6IVMY<6AM(#-!*UN<HPS+(&:U[]"
M% ;DY+#&.E#4F@3BF1:CX,U:]UW5+U)+.);RVN;=6#_-(LD>U _[O=@$+P78
M<?*%P!5BY\%O#<R#3;/39=-^TI.-,G)2&4B%HV+X1AG)5NC9*Y/."*DOCG5K
M?4]5MY+6U/V)9ML)*+(NPC;*5\TR,A'S8\M<*1ACU,^D:@TMIXNODOK3464!
MUN;(-'$^VW'W2'8C&,$ALY!Z=G[U@]TM'PO>+X-T[2C'8W+VLXDFM)686]P@
M9CL)VG@%E8?*>5'%4X_!=\FCBU>'3W!MYXC LS)&N^Y\U0#Y9& .,%2,C!!&
M:MP:_JJ:A$#]D.GK>06)C*.9F+VZ2;MY?'#..H)([@\F7Q!>I)X<L)I-<M(U
MDE5VN([A[6"Z4*?E\Y&8Q*3@@Y.2 O.:F\AZ&5_PA6KM>:-(?[.B2P>)BT9
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MQ&3?[&'S),3!9%GR*VSE&5]DFX6E>-Y=#(<:GJZT//_&^5=PC Z+H-G*V=A
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M^T/.RM7TSNEA]PTK43I'2F=V9'K6/LA_8G#OD*'?;9>)J6ZB/D=EU9NQ3<@
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MVRQ!.8+'UKQ=-]1"/ XN."R:\N3-/[^107Y._4-DP4+9]F1(#O*0<+?G52@
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M9>=":\VF \9,&/L<UXN/]:?67\ PO+\2%7,=KG)HZ>!&M,1'W'D%?Z(,N9/
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MZQ^FMGEK4(<SD)F7[:>O>@6=2''+QQI9F6WRN0(V/B7H".QG;V_=\32(XB_
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M_C:.0T.)\%3MN8_";E@DG5L*66U/L:'F7JKJ?D6K&KW_VPW>P:=4BQ&8Q;^
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MP8< A\1[1UL^7(!$3\Y<&&@+ND7'CM.A87OK",(=?%&968GO!6S\/P78J$^
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M=6QIY>KE*</LY>5@(_G&\HV(E8V-"(^5I9 -CX" C26/I8V0 (^-D)"-F(B
MN. ; 2OF?]';6/\[^SLO][?_X+:QYK-]:^MLZ^+I<=,; GS,?/]S.6^ZZ-])
M_]ONO_'QIHZDO+NMI:>MPDV1_2O4//Q"/((BK_XMU+SBHOS2?/]#/6F^_Z&A
M_Q_TEJRTC;6D]5]M<G7_)[VNK=O_NVB_=9#]+P+[GZ[>7/FG<<-Q,P#OW+DC
MS?>?Z?]K?_#]:_S=6/\^6F_N?/2_ '^3_$WR-\G?)'^3_$WR-\G_OTC^0_':
MNMS(7)\;/7L]#\@#!/CXM_'Q"&[CWR8D(""\2TYTHS'N4I'=(R9_2$5+\Y#J
M(34=(\=C.@8V!NJ'S+S,;)Q/N)]RTS[B$^+C$N3@XN;ZZR$X!(2$=^_<I20B
MHN2B?TC/]7\;UQT .>&M"#P?7!QFX!8Y#BXYSG4/P 0 ./@X_\"_I0DXMW#Q
M\&\3$-ZY2W13H>X>< L'%_<6'BX^/A[>S=7 F^L 'CG^_<<"<K<IM"T)F-TH
M!4,2<@E9GE=U4NF,(EF%K-Q#[]Q]0/V0AI:-G8/S"9>PB*B8N(2DO(*BDK**
MJIKN*SU] T,C8VL;VS=V]@Z.'IY>WCY@7[^P#^$?(SY%1B4F):>DIGWYFIZ7
M_[W@1V%1<4EU36U=/:2AL:FKNZ>W#_JK__?8^,3DU/3,[-P*'+&ZMKZQN;6-
M.CPZ/CD]0Y]?_.47#H"+\V_X;_TBO_'K%AX>+A[!7W[AW/+YJP(Y'OYC@=OW
MY;0)+-THF 5#""F?)^16==YA$=)!4EFYC]Y]P"J\PH;ZR[5_>/9_S;'0_T>>
M_;MC_^'7'$",BW,3/%QR  1<*$5Q9Z+B8VN7;AOV\ASVR_2LECT8#=P2F+C$
M21AN%<[P?N[,YNWI:9"NBK+0JXDQW8;=GN1YVO3UC")D6^X9P8:).0\*C<R<
M>P6AM1XN=,0C:*)PYC_F6)US?^<Q87>[=/;W*4>V:./,J$I<M5(EW6TE&GW=
MS\KE[D$/42,H@T@O#5FH%C-4ZUSQ&LA*X';IP/%&90H,:>'""A3KW#-4=NPK
MQ<;;!(P6T7\V??RLC15<C&=Y!SM>&](35XR^UVKL<QI[\IM7*E)5_75>HP4N
M>@8\1'>.'U)S2=_UU!?V!BMY-1J7Q4WV$EU0) \OEU<8DW[B5J)JU2,E_\[]
M6<?02 0NQU1.3<HN+WAN(U_;W,L:Y6 ]]7B\17?E<A!_0SQ.-=+V(K,DTS]F
M.N\^E:H5@,N:/5% S=#W/;MKU-P#SA33I)14PA:7Y.)EMU1MI&.64'A9'M:,
M1,!::2.HJ;SOJNY2&I!4!*B;,'@',LF-5-8USUM'?@!*<H^'[EP):*,]X%EM
MY7"<W!U)C:'H(HFYA*'Y$-?]S/!'V0L>6K._IW\V(OP9]JC"$7P49(1H1V?#
MN:O* 4]MZJ\U4G&2R]< URH"G0;WS5-E1OL424I^U#>:"263QY:$WQ'Q%&/-
M^KHEK&_P\<1DT4Y)?5!+-4TU*RMY_L7\%P L0V!1X)YV#5!^K3/)("-&N[Z<
M9IS\XZ%ZCS,DI+/S[E(193+KXF<)U@H_?*H>L#+<-B>RSF>,3_C\N%Q#CAEF
MG35#8YF)FS"-1\H-R=-V\[;6$/&DU%94Z8HZ')2"8RO+H*Q-H)#] \O8T[2/
MJ_5D;2SBXN7#1!C-JNF3L'Q'46I:V>)?#\Y /<^&%I;ON<V$&$MZF!'J,0_!
MHCC+!NYREBT2]4A:1+XU/U)HNM1K4K&R.YSE[[BE]!!W)'XHZPOM*VW%1W<Y
M\][?U!PX(-\R]JZS^PY;/#> M*,.J%.AP?#;!'!%X8P94>'-DKF4S?':TF8$
MQ6^>;[XQ#F<YCDDA^VZ&V+LH*_" G+.FE,33KC\CN]Z+F8 [Z6UE4&[>T#35
MY*ZGL+;BXW JJ"FX#<L7K=]&;>B,[14I_OJ="_;:N0PLT2>K/==,Z\+CPCI^
MEUO,#$6:ME)*V3*UWS: E_@I!5,?4(47$HYWK'NNG_+ ^J:MG_$I]4'1TL^D
M>5;\!VW+!W_5W[G\=BGVP$M[B%3VK."ON>;R>[V7JA=-!A=F%$W?7BRCTVJ"
M*'Y6&#O/&+D&[DDI0US@S6KNT=$U>.,&<HKO&,70Q00?1!)^=/X0S1=48,N,
MQ%3=XW@?I)LT@F5N=A9%.DKJ%6SGRGG<?7$O<V_A&^(DM[? FXUU,>%-%&<Q
M)V=>%,!9=N5J-MXB54AW]69C=ZHSE'IFN'^3_UMZ,_'H@@E4F*=)@E)25#)4
MD$1*IB.0TB '/ XO"R)%,3NX?I>9.U?G_@/!$0W54ISS&)_0C3'-^ES 1N7M
M1T*%'[O75E#8Z6_W*)'H4T]"P_YW&P/Q;%$R%)?6G<#WH9_/VQV/FC A536N
M[:9CVF_I5+:+\J+D_QG1F\+]&9T"GS^XC799>CG^&))JQ#MU"W*WUSO9>QC/
MXS!J9VNVP,W,O%-1V<.-H: ,0I%5U16^< $(.@UZ!M.CEWH9W^2N')#-R"8G
M^3IR)$>:DC:PO1\BW(LO%^_M-]549<Q2I'R5?#-> 4IM4]<>LD^X':6%UT!/
M[5+=5A+N\.'IVWEL_S",$D'-8<,^9F!GJV@+=NH1S>9$7K656J>H?J05E>[K
M#BW<#,XMJ[P'GK$WYQ^M97EMAYUX+7T-2+FFI,Z?>6=BK7*X73K_E'N4Y$5Q
M*?V3[5_%( N&,:VM08V.D&8.ODU3=V([RWD?!P;QPMZO>NUJ^+&]RD,T<MVL
M'MJ*JG**E"]Q_DNA2H''ZCA3=#7%%3HFM$S]%/Y4?>O59ZGEL/B^= -O@MQ2
M14NTD$D#BCIL5\1D(DIB7SNZ[%'X0RMQO*3Y*0BGXU"7YO:*(M77,G2\&O(:
MF&VOY\4.GQ9+%P5[#S:VRKYTFVZ](_;S5'@S+^K9/YL,0EA07@-=3"M3DT'0
MTS]J5>?FKFF99T-DA05.6VGM<Y(:!9M:3TT[DMX.>>^_=,N^<KC9?YI:H_\Q
MC2BUG^'_YT(UB%[JN[/<RDBW]=2VY?X?YKG86EXY"0Z",<C;"L6]\-81I1BM
M^[_(FRJ4W@6>%]HY16V?<N1%/2'^QZ#-*W*2A.6L7 F<D)@C=D^+GM=FT/Q4
M[5B1$W;!O^"2<OI4R6/56!^(_!/-ZASCHB-()MO7F(SZ&1RI U;?Q7L;,7AI
MD#6]2A*;$7BQGA[M?Z<VKB2*.P49'!L1+2+C.&)(I[7;F,J#];X&Q-CZW&JM
M]_U/<MDGN[:D&/0HM54L_W,@S#50;[A;.7KG"*+"<YNKJKFJB^B?D#7GO CK
M/*':$9YE4<VW7U/TM/RH3X/G1VYPQ[TYB?.(^V$V RH['/XE9(PO86T^%1*<
MJG=1C+5F3NK+IM>B NL<O'@M/65VNAO\47%-Z_B"PI2ZIS(B73\^7PON2KH_
MMK\[R_H$ETII ">%J<MW#UKGTT8X6>$UC+?E%WLF1B%_V1WC\BAE$8T Q>JJ
MLHDG9KBF*G\QQ,BG0U?PAS($;*><;;"#L62PNW+=@7KR?).*?GS=P\1D=]&R
M<V,*1#[\1_MQ$K#N?2PN+E)DH^ECM#7''HN3RP@9EQ5OEA0-WHOS:Z MF0(]
M7:?WRH&;MRE)0VIG7'ZC5:J;H^<B./;!Z)T)STN4AVNM^Y)PH]P)[M&M5HL5
M2-0UL,*-3!8<.F^KZZ%^EJV.TWT-=$2 3*?YD/Y8)5?:X.G5X OZ2?V3X!6C
M *.X$Y!/KE/AV_R\GIZC:R"@:A&[0VX \FVXZH$NJBE6AK2C-BJ#I^'7 (O1
M!6GS#WLFV@!MMS*8L@-ER*CYB^7Z$W'$#.T(FNX:8/0[NPKB.Q0QZ*8U^UB*
MJNG5=DP5G:XJ:>8R?5X-^'S[14PF+.6AMEPY0'<O0&6J]N 3=9-LR(J#_L7F
MD-FZWF,6'8$)Q+;;UHYY>?$F<OL";TYC89RP,/IWHL);"<9&B=5I7)1RIR1)
M95B%5ZQ@'XGH84\^E*V$,,RV:SDD9"ELFKGIX):CCR0TQ+-TYY3/[:EXPK#!
MHY2%H(9AA-'OA4AHKALZW2XS0!^)_;HR2-9]ZB?SW7N4J*:AZ#QSV1U:##(^
M]3NLC+- ;7R[!J81P8_-2]6<&Y2PUG&);Q@+X2!2L/EF=Q',>.O(=-V]F=]F
MF"Z.@".N;7)#C(*OQS7:6#-W9=.L=O%QOL/!U[NER8%HFHUL@,&7H\ O"QO^
MW;&Z+/U'FJT_,^^D?[3GYZ)C_!!X2S1</][I9ETP'A,YN+.AE6U$8TXXLQO8
M("-#^DY9,^55V6+JZD1KQ:D464S[H89+^TZMQ<7#$C^Q/K([W85&QJ:FIEVC
M70G-=8U<A"_)7N2,M5(X+IB$2,N3?JMUP8%6%8G(\'8;5/L[ZTS1?:%1X>;"
MC3FCV0S<ILQWT8]V\VEBL@QV*)[I]2U<4/9PY?RM2F?#=+1E.(WE1D(^\C)V
M'5Y,=2DR.CTK4H9MB&M/G%2P+)M6$XI<*B1\KPZ%"^%PQ&0M)Z"YIO,MT!X*
MD^P.=3S,??MOS'X8E2<L,69\&KP?%9/^.B/9)5YPE,65/L#:@F++^U#QNV'%
M4FV3\]',$^WX8M#G#:HE]+3^E*<%:48[J4/[G%BV8V72FO 7W<RL$CF9=LDC
M$*6A//(([AWMMN)\BK*HCMR=[->GZTH(FPGK\R/O];<UTQC??"%944!"NGUX
M*5?=-+'7-N KS'4D%RHJ0!_#J#PR><%91J+%A;YS#3 /W6Q %F'7P#,J=:CN
M_'8[38N8<YY*9:#KTV"'Q,?-;YB\R2HFB56.12*0[1VTKM''3O-9SX]>0NSM
MR$OF?I=\=R;(+-Y(/VDG!I/)(9.$T_5JZ"+HC.%OEMAEA$;(OE%-BCT<;"N4
MUDW6$6IQ0.%BR0>?SRN//:73G7)Y+]!1^($@]ZU'4ABTD#6JJQW5WL-'^DR$
MC!QLU;.UK9SN;".5CW?V>)[)U.K;J*'8'D/I5;NL?3WSDDR;"BH>?7O[6(O"
MEPD9N=WN-+\:&&=V>6%M671F;6MUDK+XI[GRGF/3](>R$U><;@<?GN[0?C\5
MPB_.W1^9^%\36!@?\85/FXN&=5,3K:B3\,)_P01\6MZ0LLY\Q246[X/!ZF8P
MY*2RC%GG<ZZL3W)>\&E!12R6E3&?(#FG]X.OJ*CT$W04,)I/-Z6=$1^0E;-O
M=W?G7TY69CC7E=#;9=J<[70P[.2TH>)[F,CF2+1Z&.G'YS5UB+NFY-<5"AO/
MYX_ZN"GZ!'8H,."J>)7L.;JEZOBJUDUV?E$)&9QKP)7>JWQ/7@Z=4[P%$15+
MKXR $7U)?T+M%%-*S!C0)CFF':5V2L ^7S7A:,ZIA38X8V0=K7^1-[+PG$TW
MU&WTO4P\GEV=6[I!3_ #=%[7XQ57TOF%!86P/1\A 17<:\ +QW+^*B^PRB"G
M>SK[ 9JN>,LX9E1#6'1<U-+JY6VK=X(X!UO&U\#=4=V5[(2ZY_O*'+C%1W3I
MYKM6BY7%YD<.SKD&'6V@)A1IL7^>TRE1X?;IZQJEKW/+]TAQ./!L?"0(1+K
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M\U4!+<[0 <@/SC$!S>D&IR<B@7&@3G-I1OZ:%L@EY\^IIYWW3=1438\)JOK
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M&LBE!B')]0;HCCQ_-F8U^F5_;Z[GQ3R BM._28WBSISYZXTC=R1**\RK>3'
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M%4HJP:2]969+F;=@-C*G8919&"Y<26VB <*P&]=EY^(^9XY[2!&SD6I=Y9$
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M7[$&,]5/0?GF\N<?H-BMI7;N,2Y^Y5IA6:95KTRZ:05FD^65<RF-S#NW&OK
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MU%^'<)>O:C@C+WI6.Z3>:?F5O==A9@=:_XY/1@@#GQ$LADT7>C4J93$EY)N
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MQQ77"IHP7_HE>MSF3O-(Z3HP1@U35F&07629!O^I=.@G(MH_2V2AE3/JZ;>
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MWH!X@C%_LFEK6I]^!U%4_-F['RT4ME.P%*Q?6@PR,-%,9<JR D0A!=NM>8T
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M<#HU74]+FJ&&IYI0KN E !E+]]L15'1B@EAL2UW1.WCF'SD!*IF7I9KGD16
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MV='6=W07"EG&4J?T0>'>44.LG/+@$,/ J70ZCY EE8.K>5 Z!*P5%[@Z$%!
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MF.][QLIAAYO[H+R/[_<K+5PWA9+_#][>.JJMKUL;#846*U#<I46+NQ-*6[Q
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MK/SRE^MES72=>I16:LE,DH'XIVIZ+2C6X\_J:_7OCO1OV(*8#*O?(-HCSC
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M&8\"'F<0%P/(=29D1._'[<%_]S%@R?$H\(FZ)_C&^IZD)?XS(?_* ?=6.MK
MN?)V&(!95^1_4?SE^=?"]'[-OY# <@OLJZ""V\);+QGI_XHQ_F-ETFU1Q0Y0
MWS]S?*Q-$#;Q_G$<;QPW$LX$@Y)\2Z%:>?Q/0?3!<$:Z3M!Z8W]&D7(\4"3Z
MB'-FSAO-(X ;V'P(_OO6]^>81-L(!M#8[+QKID=I.G7$K_?WM6*LF,H,-U=7
M631 CH?0'*$<WJ+ES3C76'Q;]BG_9+)EEYPPT3744CK)9$9'H_*M:-8V3W&
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MLE,V"CD,1;?FB"\M]$FL.[GW&P^VH[(+[+*D YE.3K@.X)!G1K(11G/;/@^
MCX1JDS*L5^K$\(%?1IFVW145 KT9P[)=?>5)37JFVN2;<I+0Y:GU;7,5=W3
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M^(>"C&3LG DIN5__CX3P_U/MX_](EVZN_U%=!EGSXYS.J&DKZ[/\AP:-R.A
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MDU!-&.V+9\I2Q)1-\ -4I2@<RRGJ#5TF0XF\,+?!;Z)\ M"<?A=S-8LZ+D4
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MHW4!?VC,A5EUCFFQT:]_[$365M^FX-,?+7LA[YXPFEM\F%K@N-AT&7.XL%D
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M69=M]S[O>L:*U*LH1X00Q22F;3H-9H@6\5$$A^G[H2W[.,*>FOK$G3KN==4
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M4^;;1+5,^J5%=C\&O)6F@XD Z1%7.\OKG 'Y@'F_K12 ?/')_73H)W!J2XL
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MCNC_OYW_5W9FI)"F91Y0-J7NU0L]TS;XSF:[4C[!0GYZ%.X\X7:ONQ[5$[\
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M,4L\%+7+GMDIHVD]TR%+_&.E-F4DGY<'P::X&0\""5NF=$_B^UW'JQ,?MQ<
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M054CX1L!DO&*TJ17G7QX76$V>T54Y=343I#]MORGN@L=9$WO'A!+@/ZOB'(
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MEI=E7 <&@]("5+#JT&'<-NR7TB#MGR)EW/EE<[5TEQ?G^G*)!C!UAX#:LA>
M@L_0^N8 :1;@%C4^-5.<-H)@2.X Q2BF%,$P;[!R9-:T=MD7K7U<M>"9??VZ
MQ#<6V0S$?.)^[BL]&8&062QWVU4(.RINUR:GNIJ=/?^1ECO*N7\'>1*"-_S'
M@#<PC\R@^72S'IW3I81"GVV[C%.<T*U\5,*_*!F*7?62@?R>VY'"VWR>A87[
MBOM"EA@#]$I:8W]DB+/>J@'>NU,'@,$"2>J96B,>Z-^=RYSW4[XW5)32,VSK
M-H7WVFJQ!O,? >T<D;U6 ;QA,D7TWJ;K/.6%D<O3#$>4L9HZM'08Y)2Q]MSO
M[A4V#)2:)B<D(ZO%*XC>BA.H*4=+E#&8:?SK?.!_DA# Z>:9.IY#LW8)72I3
MK:D>L)BT*9G[/28Z?VZUGJ=SG,1!%]ZA4O]U%Q*46%F"H;_9H0<#K6&*H6P4
M'^Q98X.&=#"Z=L5Y\$M#FUA=&:4V-(!_.)!O*AM#=[[278\05%9_>4?&*2ZB
MVV0@ 0>K2UOI@E)(VT,>>17V%)]W$'R@7)^F,U \]Q2Q3(U*-)#0M=$Q)J&5
MNQ9AH?W(*S,JU>&1WT7)I7G0C%+J2VWK1T@H:T&Y=$75>O9=+<%S='*!/WI/
MG06*AX:0<E3C*L!Y0A93@(ZKIX\7U[, /U-H%JY^Y.MLG]?(+:BWD4#Z"#LW
M*P"VC.TY%5RG&V.L^.Z&1]V1S+X_>F<[L*87 K+#R0>KS>QB?E*@^+1;\A90
MXEW\IL64!$NG8=9FV=HY@>!#=(^#'>]1+ &"JN%M8$P7'.'(*4%_H+N\_)',
MRA/II47/R.W/=14]G+6:Z*CK^N:=<\4[=8'K9) OMONWLL6\6/VE;C!O1;*C
MLM#M%7$;7G3%+&07KV]6*XSOUDFD:9H!:-1A?9$;S(/XE\*)I+<#;986&>0-
M,[UG8#8M/:U*[52^>"CEE_#P#?+ N0"1TFO7Z#F-+DNK &Z#".,(X=5/^&^:
MCA3%,GLCD+:9XBO*CAFH!LYHOU&8[XKZK8@72N30J19;JYS1U$T+55^F\_JH
M*ZA@RF#+%473[.K.K9I7;F9*Y_$[$+LI:*Q8-N!ZAB<J:K>!?S<A?R"7!K.2
M.+(,^#86NK_S?L(]4?$UAU0<4\6TK$HJ(ORAA5'U=BL4XRQ> XD"9.W HOAV
MJMZ;OE:%IR72_(O@U!:=7>H97'3,!<NWN PN=O3KNHN?/@?BWZS<JQ ._(B3
M;0V3KZW)5((4B%)H::_B"#NTS?] :MJ@+MY+R?=[ 7P4?8T7*T&SSR&HU-]5
M=*TR**8I[PH3E;P,!FZ-O\.IWIL[/%IJ:FVTM/T$/RI27^<1NK;DC>?IZ&(R
MI$AA:A08L-7R9A 1KVYPKS<3CL[6FLRR;]5;?D4G/M,18RV7YN4VD-B*ZJ\M
MT6W&+L?I]5:\C;,\W>DYX).XCA _<9R'IAT9L208SXM+-(T)#-CITS__(<.@
M.&,$\[-8FDPP1GF0)U@B4FDBC)QOY%S=G^TIL?'UZ1,\*I[A"8?T)"Q\=9"B
M^Y V%^)!;>".U-'-%LES/^,6V*J^@?[]_E=*_':8.\AV((;>\[M2?[G(^'"O
M?4^F7F'H:YX1] ) &7A5PRN5)\7C"MF]/R\N_H[XC1,!;!:]" +/ZDXXZ8Y>
MW23CI4S2HP0..,5"=BJLDK\R-RWME.5 F%3SM&(CZZR\C>IGQ4*?J0]?C482
MJR+DC2OQSC8 *R,$VE$Y1"&*-40']T7I=^\I8-]Z(X*LWY/)OYU-U]J7H,ZZ
M#?5C[*<<:A0CPZA?#< ,<8\!A#(?D*6#W;H?4H]]*:7K0GZT?5G$<"R5PU6/
M @*&Y1E1'^]17LI D#>VW>5'5PQ9COT^@<GB+HN-KHW \ QKWXU^1^CMAN3I
MPUX9 <3YCHE@,QKA>]9#D+B(0#7ZCIZ34'"KOOGJG#>!RYIUA,+>UI3L-)A#
MT9H -;V,XM41\ =&.]S.BN3=LNE/M1JNWIU@'2GNI1#/)"8:*4BD2<#&->[,
M8L,8=V;BTS]:9NTGHII>,\C(!1VCILHTRF &AJAU#@Z^:G)5;'!;ACN.*.MG
MBI/?\ /$R%B8?"RH+18JL-,PFMG=1"0?I+7O33F95Q/RP-=W+[U8PG@EZ,TJ
MN95MA(9(.T_ CP6ERG0XK5 X>YMZ>B(]6[NG-B!7U12F?+ZC:D$0;;-)ZFO
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M+?EZ]5:VZ&GN_&&<9C#ZR!.1]<EL>5' W.7D3]&^#SJDMA&!O4AWKP>M'0E
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MZ20P89OKF/6*Y=+I7OVD>+!\<>B46?DD$HE/I$422;J$[&Y6IAZXL(T87S
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MP/1?@HU]YZT/K8Z9&5@OJ=OHPOBZ$]:OPIF&;4GUONN.EXH;NYJ3?AXOTBZ
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M8QUQ>,H/Z+1-HF[&'X$G%72R8#O/3,B,Y0H'%-H,RYW[1/'X7L5-J:*.O8L
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M0PP-9W3I*949H]/BH&$7?)^!A+/0#[ZOY8US87JC+'$^2(5";T7);,='BR4
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M#S"B^6[X'XO&J.+-D+IH@ODV"\#=95VV)2#5%9"]4$;I[QV"$",X<LIXRC.
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M1 ,5'TC4D#*%%"PM2EI,_V\IJ/]*':9!A$(L:]NZGOBWAEBCU!V<XO$;5V?
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MZ6A;85Z96_.P9NMTEESP;YA,@#RM+>TXE6YT["]KI3S4&%GZL&#%U]W%M\\
MI1FN2#K8^>!13A1Z4^0'I&[N-:1!TG=C3.5_4>V1%E]<GF7F&",E*U9'2D:U
MWUQ?,^R%<W[@QFS\HQXL2]2OL%#Q"5=/5W$]Y0J8P:W'ORF3P7I,L",S/Z1)
M\>EDH::#^=<X CO[L+1M+,/471!W>6%QG*7.)D#62,,B+4HMMFO-Z;)HW+6X
MR6DB;SV26_Y3-W1BV=&5DF.9QR553._B</C=)3*D.+>@I26A7OH_=OK_UF.1
MSP#VJL>()-][(1=GQ76Q_XS&__]KH WB.5+)QIJHSFJ9:,C/_? 2\,Z"6.AX
M_7@&O(/*KV9R /%4Y2N"3,;X=]>E UEK@5):\S=A[N\I_*Q]$F.=SP1^7VPM
MCA8#R1?I-"ANS^/OYO*5U4KEG>GC/N5LSGT'&%BGL?A(7&I7!/KDA)S_3SJ\
MX=N?65(T(K)?>"F2FWH3QCCK7IE_ST#!H^=%@HAL]VHA9/4]3!SR/>K1X!KW
M$]2V?&KHOCE^!NCFL/ON\565%I=IA3K3STO<WNU^G6&NNQ[&2/-ROC T?3(J
MG5MPECH4G[*MNUYF'?K+ZQ>=O)Z,*HP\<[U#S+R"-"J<AN\WPYE(TJ+O-C%$
MSO&O,J"A!=J;1ZFFZ83[V\#<S7-\SP)LW 7TZI/QQ H?BMO:4W+-D--@#_<:
M=]\[@K_D:6TWPN;E!;,A%+VUX6/_X[F\-XVD>(]<C?YO^D"=![2Y[V@7JM/K
MU]&>L7>OYZ&W*(!G0/2HC_1UV,RG ZVYZDFEP]$KIH4O%Z#O_NV$(6B>D6)K
M-YB,Q8]X%# HN!WOEGWN9&^8ZBK)DN*2)>SH+Y>@NTO(P9_H@YZ%A# CKL$8
M"F+\/ LQ62,1L'JE?F3K8,Y(W^8P0-&DRJ)GHLG?!<___Y):^=\FO=+TB=@-
M]PD78YE]\UYGH_L(Y_TBSLGR )]J+.1_\/:>05%U4;1@*P@B24!R5)*203)T
M(R)90)"<E4R3<],$14')24"RY-@@L:%I<LXY-$W.N8E-AN?W9^K-U$S5S%2]
M]^/^O/?<N\_9>ZUUSZYUZJ[G;KEA17;ZOG.6XXK.N/'JNPR:1=Y>XD\ O1P5
M>WXJ(OAP'X](-8>#5 >Q\B>73A+/PT*$N-)<# !K-K3/F@3'RSP#\>QKJ5C%
M*-!"7?5=J]/,48(7$Z(@@5&GY9J@V8.7Y?D=JN:RKV4Y2#17<=P>L00I 7R/
MN>+&5IP__LE&9@SO91Y&&_@G,1^FW=9(8RZO3Z2'%R#)FWW')]-K7<!BM8]J
M5<Y/?(9UH![@:Q,5+WC=IZ0O10J/"*Y_@'X/^TU"980@P]K92$P'&)0,LS>D
M_/FRB>OQ)W,!UIA8QM:K2ZC1;LK0Q)YCO.D4SUG_+:=RE,B[<;,/U3:"1J7F
MKVH#11XF.*R]'-JSD=;ZT*Q9GU&B?9JN16SS/NIJTE(_UT:''$#:UZGQ%OK-
M.#$^V^XJ,^(L;W+EF^XQ+\_;QC9\179F_NIU-]?IPE[ ,1A?M?9PZ5"D\?OY
ME6F\;]+B]NC@P[_N#)6.4>L//E:-0W"D7"" M)_& V?6YC\'?%_V%E/-3L(F
MOT_;-6HQ8(CP?/W!K*UP@;D+P\#*&31*CN&X*WOL(SLRESEYF8TTIM8%@"-Q
M-6E$3Q_*R^N79^'L(1/P9LG!?7I'@#NQ>IT Q3CCZU*$_TKJWX+ /Y9,I9_!
M[%.M/.V+4'K018K_S'11\=/#?H'/I<L S2$UM_?6=QU_YZ,K,8&O _;KY[OV
MD>/YM8O+%YO6!G%2:=P<-VR6;A*;M)V?SD+=MFHJQL_$W><;^9VWTW7S JF2
M\DQVJ!^DT"N90AX25>AH=3-=4 J3EV*/!KX$Q\H!?)<BID56&KC5Y);+"B@3
M$',=/&L^3_-7:&59OD!Z@%+34@WMY9 _R5&9]X#'S2C+.0H;U*,#ZELOD E:
MS,+["#KMIR?L!''WJ[0]330/T]\$6"Y9WKVMX/7[2#2;D)>^D%IHMW$A@[)L
MB*2TYA+2>Q#^JIM%_.,7Z)&V-.7+;RJ3[.$#=UU1QPKC4;3-+I3*,Y*_YAN<
MI#Q6*=^JJ?=K'45%>N;8A\-4CI53W\I*^EF_1ACSC7UG+'[WIV*^FE)B\.7.
MJ/0LA[>V'L7J2Y'GRS,4NHWPM*8":[+2)>CG;T/&)QN"PUFX9-H:(:<6*\/D
M^O< :S2A^.F6M:HFS=/<[TI$03((YB=X2T(2K6OK+_/+7=R\@>1%<_8Q1O98
M0X_PYRE';#X].+9D^T.0?WI%[[<<&]SUPDOCZ8+=Z/9P=ON::JEA:KA79OKE
MP,]LM3_FM?\ T1?A<?MD6.LP80CF66"O&VC3\'-'CZPPZNV3W[^J$J]S7(PK
MMEQU]L:H)19L$=W8NF:08CQ6"N4(NMN_?GR)(+(!<JL@RS^,.W0'2QN57#[Q
M)'0TM8'72R.)*I\_(CUD..MZO2A2 #,<MBN;O["?I'7T4Y,<HI7ML&#>MI#9
MY_HV71KRXY$_3O+,EE'GWS<BW8C:V,]C?.14@G^MD]RR<'$BW"YV9\MJ*Z(I
M\\/7_*\Y&D[@I^W%CNAH;%7:'>7F['Y":8IS%&]N;? @;+VF[:T%;B=-E( Q
MO_DS\9[]AH6:U7$DL.3BN(M>G(?O-'=TW789/CNU=KF;F1"@NQ8?1$(*5+ [
M+@DT^9:<'CDYN"89_$L42^SJ+.CJZL*N<RV.P^658<09)>E9DK !8N#C0W(_
ML_Q,V*A%(^>A8[*LMX6'/U:,NHV_(]OEKUR]H\BL+4B_!\@$V"1?#[^6OC0U
M];WYW5W#;\VP6:IIJNG];U6>R*Z<32"3IDBR!/Y&Q#E)MX6N7^*4K5Q<9Z"6
MGJ#&/.+]5]*-=Z9&YNU%$8Y?-5UPLH<KW]>2TL-)Z LW\>,3>JU<3TS2SRC7
MJ9@_W76--E?)K+E=6P8ZW ,R8>A[0.!F('42W'OA,N! ZB-?\U\CM2.M(0OG
MIX%V<\02.E4>['/2.8^OVS>[5'P93@OV.H=\)ZVWK[K19S##]I[C>T"5593,
MZP"_P:.239I5^HK%/->4O!IL)I0C!.?5D5:'R0J#_,L'3L,,[DPT'FMT5ON#
MB?'>*[MVCB]22*MGNG@S/CZS(PMC(UJS_/F51OKI&Y8(BK=?+J.5LI%.7OJG
MF=2&J+F97LNI*??"L3\":&<A1^L()W.-G@=6T@G=N'0[W2$>5A>16+("6:SB
MV+LQ=,* NU)E#)/\UAZ.V !*>E-8G'U"Q5L2'9[:<Z:JZL-#!S:02SY 3FH^
MP%FGU^"M6W,=*]-+]3%)SC\4][9!X671)7Y6TK'2H05]>7"AH\:I5E5]^"/8
MTPCJH29[9JM9]N-J+)*;E>.@025.]!2;U7YUW9YVIC(\5:.QERXSK!0P*AV7
M*R#7X)S,^E>'MK5EDVUIZ2%X"#0$ETS,33F YVY+-F/C:?(0U<XUQ9!O?0)]
M8^4'/0! 2833\,<,=,<E7>8/QGO !%\A3K0[41;I[:GBBCR?]N_+LO"D@.>U
M574^&T&[G\45?[_U>@6Z!T3Y^K\V_!/T )_E]$6]#-D\VJ0B3*(L>$V].#&2
M%O5JV*1NL_P>8 C_+%G4$(&89<_2K ]P%F!$1JLWYT&J2WHG?IF6J#5!XVGA
M'#_W:G:E=NG#"V\Z5/V22 #B7?[VS!?*CH-Q\^SI:S'I*,N?C+]W,WS*W-^/
M']A4U1IY6CQ:%IRC9/;@/NB]$8<!Q3)Q%OS9RPQ]BD]4KFP7U^X!'#9T\> U
M6U(*H]O0@]FQH^?&GU)8<"Q7OZ71Z1P!TI0I\WZM''98!A'&KA/\I 6(B6]/
M4R;Y_R,B=Z39@9+CXQZA\H.-M_N[QKT,LI_,>%C>*,)-:V"2D^M:@H9;J9>8
M>P# _J/CB[OD0KGB;5TX%G5<]MG@&5,.JSAH->N\%)U)96#HTS?=[BU@W.D)
M(51U?LUUJ65.KLV(FF]="FL927UKPMD^6%K+EW&W7=UD%C<. F&87<H75HK]
M'*K,+F23]()GZ?>%EID6+,6M%MX*_"NTS"UZ)>S6CM0>=J@;A6B]N)FM .;)
M<IC5!%WOP90(V1_32DO!2S>]^&KS##=!DW2?>\!/X09_*IG@*2H+,OE ZAN"
M4 6+,[;XBVGBXD P/*J\N8;?84_ZC0@95C6\PGLS>/X[V:7]Z*7/&6V7O0KP
MY/V18PAL)?WC&WC8LE/UWWR;6&U6I^WJ(.7=N2>!P=(Z5JO$M#6\0MP_LPQ2
MR.%/BE'&-EFL#%?3R=L+_Y;1]_!5F?#5NYG)ZF;./L<KJ^FXX00&P=8>&.:K
MA7,[G):3^H0HXQ[@]07X(NQ8ALA@VS#X()IW[^JAZ6S_ZRH-(9&SM8Z8(%N4
M6RG!7("U! [-D+TS$;J3MROE*@.>-[,[NA"""-VG%2$PX_1PV#"N%$HC37(2
M_-H",Y'R?/VQ?F="[U=W@:'BX9W))Q:S?6Y_VTLQF^07S$Y/=/2/2T*<?[DF
M<M*RC9\IL=9-BXRN\%JHC#E3^:'F[*E*;:*(_W1@CR'%>"0^LNDM!T.VV(!/
M0[[ISV8F$]D,F*'!#U)IYOQ=U4LC_]>;@12"#3<RE_<%SX@_K^YA"UL-U2(N
MV)9<_F34!-3Q1S(?OR^7V:V6N:(I2DO[/"OI\BO'B.R)%JHZJA9M.LXO+7,+
M=_8JS[]4$YL5C1'E<W-1\&E=I2T\)26W,WWY%SK_9'=?]ZCOL\WQO,#20P4:
MG-$?FZ;,-H5FAA=.F.4YH\Y!;-9#-,6$T8!8_"F-\3V@"9Q]8>?J:',8W4$A
M6CC[CJ"PO_8,[X2ZE^HQ/L:+9L>]6^0[6'0,Z'OY_I76KWCO#1699:B856!#
M%3"L?E"J@ZYQ,=+Y-#S](=11$B4F7U@AQ2[M(MXZI/'6-0K<Y[%(-3_C<_+&
MA-KP""^K8(>: '=3?SB);_/)>\B>F$VM^&;*MG#YTQVJ>P"MGP%CY_X$5E32
M([[;=EPP4N52<=UXB4E#=FX<6X2>^)$P%)<DDMG@B0!KUV)V?&&4RXG>&6S3
MT@]*?!8T*':HIA.KXA_E(>O@3_+<GGA?S]F,IVV47I1T(=8QP7X4)=O3<?KS
M"^]7/M%7=K.6<-WT@8[C"%J'\3)K=1M_WO44;OS)A[M"M\::3X=5CD(:B[?H
M+,7H.'Z(5@G'/YY]Z?[+F/GW$L7^Q61#)KE=+5U(>L'.:WKPOE+ RER.H$67
M@O93P8PUO22?J_X.TR<7OM'\86?T:'2Z#D&]LNF+T'70![_N]9XA/'QU\>(
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MZKJH,8%!RI4$FE]X7>L<^]T#*M^.71IA,2W;:0P!.D9M3"_^*8[RMD3?:51
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ME9\\G*>4@5%NOKB7[ZFM2=$=V/Q&W18:'1V,S(I+F!H_32'A-4U4CVEG28"
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M#BIV[HH>]V/%;#0>$.R2?Z:#P^O5%[&)CYB7"P6A$3IF:E)L"N)"I4^RIJA
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MA,T6]2)AYW:0"'13]#]9(5D(.<"[M_=R6U?:N D\@F-N/U[K4;V<)R PWN8
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M+YFL?WO@Q^\Y :B+^VCKS=YS)M'J;K;>,,-OLG[1/*TI+T%^2O^XVK7>X_U
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MD4V1"CO2TGCJW_!4I8$_P,BK_WR[LS-.V98CS%#@U3(A*TRL^&8P$OS%?./
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MK*P8+_NK8$SE0R><TQZ('__(:?M<D&5@A":JY3*KNB21%@&.-KZ;*=J 346
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MBPT%6D73W7C"[6V.G#*YO9"$^.BB\^W5E5*D&(B"BRTH 4[Y(\7QDNC+;O2
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M3/KUB'7FLXKY@I?P@4B.O(542D_E(&OJRHMZCYYLL!"<YN288#F+CRBG>#'
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M @])Y11Z8A2Z[6R)X2$XID+%C0Z:*GW024JV@S8TD!Z<?@R:](6' T3WEK%
M-H;5(!!S:*^*5K3U$!HP"F.O<8SV&'J/PH?^]%;V;>N;V6$?2Z5QX<[R/4V/
M-*/O.1E LN]L7_KETWPLE8MG1(,!^Z;-S-O[FL^?G5PT5A3DS?Y/UW^[BVS^
M;YR:^7_8B-"#_P!02P,$%     @ X3-]5LV%2CGF[@  44\! !(   !I;6<Q
M,3DW.3 U,3!?."YJ<&?LNW54'-^V+EH$ET!PER A0(#@3B<0/$"0 $%#D$:"
M6^,)#B%H@ "!#NX:W%V3X'2"NTLWVECWY;?/.?OL?<[^XSZY[[XQ;B9CCIZK
M:E5]-==:<ZYO4J/0O]!+P#U5115%  ,# XB[_0/0RZ2  L36&@#4U0%N  #P
M "P,*>#.K45VVU -MP6P;FV,6]OX2\9?OP [ -R;W&$ <&^/$=VV96\58-CY
MV[5_Y(_\D3_R1_[('_D_5-3-7;U9Y*S<;5ATS-V];"U\   [#O-OG(+BECL4
MQV']W6Y+B/^;C2DD#@ )"?]I_R>_P,O\ZYY_^,4?^2-_Y(_\D3_R?[8(/A84
MDGPL)"DHPB(@+BD@*"GP^%\>NV4B@#G@"G@#+( <8 6X S:WEL[M,7? "[ %
M+(!;9@*@EPG9;=S=G27Y^1W=^,PMG=Y8\5DX.?!#S)WY!?@>\P/2((BSN86]
ME3O+&RNPK:,,YV%S.R>+K:4,I[Z(^F-U9WDK&UME'U<K'1\-70L?>PL)2TZ0
M[%T":8@DQ,'9P<K=G 7B\-;131(BP_JWNTO>VG\=YF>5E7:UM);4?J;X[SUN
M6S*L__XL7EY>?%Y"?$ZN8'X!"0D)_L>"_(*"O+<]>-V\'=W-(;R.;FS_?H-G
M5FX6KK;.[K9.CBQ_M<W?.'FXR[!Z>-A:2EJ;6XN\L;04X7UC+F3)*R!@:<YK
M;BDDP&LI)&0I)B(@+F@M\(;UW^$M+?Z.[NSA^O9OV)86_%9OK1RL'-W=;D=#
M@)^5__]=S-LA^COHOQS^6Q]O^TC*NUJ9NUL]NU79OZ::][$0KZ"([G],-9^0
MN+ T_W_I)\W_7Q[T?\-HR4I;6DA:_/5,3J[_!J]CY?+_;+;?VLK^-X+];Z[>
MGODWXQ;C=@'BX^-+\_\C_'\?#_Y_7W^WUM]7Z^V5+/\?R!^0/R!_0/Z _ 'Y
M _('Y/]?(/_)>*T<;VFNURV?1<\"\@ N-C8.-A8N#C8.'BXN'@$IX2W'(* D
MN4=$2D-)1TM#24--S\1YGYZ1@Y&:AI6/E>,A%\\C'CH6?B%^;D%.;A[NOVZ"
M@8N'1X!/0$%(2,'-0,/ _7]9T!T *=Z='*P7F!BLP!U2#$Q2#'0/P P &-@8
M?Y/_*!,P[F!B8>/@XN$3$-YVJ+T'W,' Q+R#A8F-C85U>];_]CR 18I-=E_@
M*0ZYECDNJPN%X/OX+#PVN:I.2NTQ.+O0&]<@? (J:AI:.HX'G ^YN(5%1,7$
M)23EGRDH*BFKJ.KHOM33-WAE:&%I90VVL;5S<_?P]()X^P2'A(:%1T1&)21^
M2DI.^9R:EIV3FY=?4%A47/VMIK:NOJ&QJ:N[I[>O?V!P:'QB<FH:]NOWS/+*
MZMKZQN;6]@[BZ/CD].P<>7'YEU\8 ";&?\B_](OTUJ\[6%B86+A_^85QQ^NO
M#J18V/<%<,B>:N&:NY"S"K['HY"+SZKJQ&<3TH93OG$=(Z!B%U[F0/SEVM\\
M^Y]S+.C_EF=_=^P__9H!B# Q;B</DQ0  9>*45S5RO&*XZI#$>^^"3%@8Q8]
M>,>HX*KCIPVWI&92VZVB_BD8K[R+!ORYXR]A*@4[>H:U:?/;*5HF1NTJK*^[
MMT_/BET2YO%59#X(Z_'%K^R3F$R6N]_P7?ULKAW)((T<S2>>./\$QHWAL4M4
M=\0OJ-0RF %_<%<'&S2-GPPOUIC,.!['OW$N"IL)>".:Z4\B/*Q)NT6]P)HB
M5S=)6?LP=>JK@.11.^2.(K'$EJ_6T!6NH-C#[.K 9:XQ-+#\  V$^.Y#$<*S
MS7LHG9/9YD,+)PV?,>LSPEQ[+5V1#"=-."KM,JS"Y<Q7]W79@SX_,F?Q%^IN
M@?"Z:U(T\+3]^E,Z&HC(S^&LQF6O!X,5WFRU\8]*/]N0H=<-VG@BM'[G)6*W
M]ATHST';MJQ3^(R ^R.J/L_V;4G1CJ>G5:.6BW/5YC%K04UK;?L[30NWN]^?
M+:D0O8>!M!0^'V@J4*;R1]8\Y%-ON9S.8%A:ZCFWH0?)N2FD8VI$*5AY$(4(
M5@ZPK)&JL$=2.+"7%T8)?N\'2+1M@1T>V8D>.M$L9X<]$5_ZHG"#Y48EIP&&
MZ5 JFSM1!8&EMFEZB_OJBN/#7O-7SW:9 E)9<ZLG']4^]-N7/"!L:'(*>K%[
M$:SQG<\@.^IMPB,!Z00&5BYK\2UL%D8%%^@_.U[2Y-3CA&]73XB=7(^1])/2
M2N\#YZC3G8H$D\B-6+?\[*BB(KLZ.IG4IBG'Y9IW#$Y)74'^N$5GA0_K%5RY
M$#J=KNKK?(TT;U=YL8K;S\>, VHG9XT[O1U3J!*5I 6)<N/%K<QW\)8F7.S=
MV2=^)4?QT!LB/(.7IPE+=^*,)&A)$U[=CJYKH"J9TVL'WA]I/)EC+=[+T'LF
M_NDJ4UEI;N=O/&Q^M[WO&%DVN7M7I.%!9J<"948Y)/@Y?"&3O[8DR][16)$A
M1]1@[7THUIEPZ4+WK['LPJW+'V'M^4J%MM1W-J;EY!JT6X*#\%A(!PZX3^D!
M+04*0,LX,%+:%PW@G7\4_HAY);;//*-.=X$*&.'W2Y<]F/CBL<-3F;\RWDQF
M&TJA+U*.O'H*/VATR-UQ&T@1"I4P&#3H%,>.=<P\85_HF#'*X*704C97H'B!
M\4_J:BJ*@%W?AZ4]8_Z]^!8U'C_A!5V_\%4ENIF MN^/-\TX")?SY.]1Z%+#
M0&\FRAWKG(Y8;44WZ2OQ^P()-J6Q5YV0&L+#)>U[:*#R)M.)!YRQX;C$L&G3
M;RAAI$]8\FNG,#M*GN!A]CN"A\5T/^L+D('J_O+Z#5<RQ8_U$BUD\<49'C[X
MV-&NH#]QN%]K(DFXBR\]:Q]"0K_/TZCIQT"J]Q#(COI76E%H-KOMX]%[NI=I
MTMIBK4)/V_4^L1<PR*YLX5^]R]E[EJB9,WC_GK@*F>[,<&;XEG?9K2=[/6D^
M7[.CN(@>9D<!_ZD-L31^:K7PO@JJ>'"!>HF=-J#>PEOOZ$.TE*!IC/&2IE'J
MOFA"LY0/#Q0>'LEWK58PXA*8/6=S),__R;R!DWV)X:C8-V:JUML+!VHALSY[
MX7F&J*ENPY\I%M3 Y7P_DZ@N=<>V)%'K51-SA/ (F>W&N4+CE7I#7)_9L.7%
M.ZSHQ[@-9=QT]BX'%'H:H2L9S#WMMJB>EBO-WP:/%IO<9S1<SM^-R(_7%MJ6
MT21JOLZ.VLA#G 631%-W:VNRM%OC0Q_M$2O*'9RN^;Y(],6T=72OT5*X'TJA
M]03[ORJEIN[4R0W5Z-P.+&Y&_@M.4L?@"5/!+WTIZEX0]@_0I[0U\V_1+8+<
M:&!1X<F-W2?+,SE7-4^/25UG8WD/Q\2988;1 3'V^,J_A<ID$MN_3>NM<B=_
M*PRTW-*_C$W:](^94;ENG?7:T_[UDU@HIJ$4B@FI1Y&#2.H*SOBK'#*RCJX7
MA;[B2G2<GA0,[;N8F/8K*5!HTV@IZ'YX.;$YR5$9A)I1&U#<YDVP$F193?BZ
MYL'\^2NANY8"0/$OE'(=Q%C+TR"<P:,1)D]9NU<.?NU,_*/YZ=E%Y#6V3^T;
M9$G73."'&OV)4PZV#,1SJ \G"H[*:361>#@H^FS"Q9;A)Q3NU(G8+DSLY#V)
M?G=3."=X('XU1/$^]F<I4FEY""G5D^*5%E#B?.DWYF"DU+\PHB=#C"O?N8:2
M?C>*8KN6P;PB6[,W-/9G =JH)X9!@FB@XZ[' @XRU79E-GFB?#]=<XI-^_DC
MUVJ+\G'O@1/I&Q?#X<P?!>[/O!T3]<"\JQ#F#BAYS2&UX7TJL9'J??W\/7,T
M('(1WI1V*.VVX@[?#'*L5?.F&&;%VS=@"/-BYF)JH'7J*H6,=!>M0/$7;,/O
MZ)O !5"TU$EH@"1+9%667C(E]M0!MYLN^W'UZ%3:%E-I\2\ 1:]S+*S E;OX
M5*JWIBDS'A[;K20']S$USJ)N2B4?,BK47&*.'[DF:*G0_]9VNU$=]M+]C/O.
M=V*_ZBXP\3HN#!3.'&:_M72GD   7F/,M,1V5.6B 5H_"ZPA)BXJ*W<9&MHG
MG=?XV>1>GSYK< ]QYD+ 9O4(L7 '$:/GV!FR[C^?.XI;@>0O7\,R G_\")QM
M1\U.2/,(0XD#V.>0IJ>S5SRZYAR?/HX9W"R.'# [UZ"!B\:**R\T,.M#X6U4
M-XW+DQ>P<=YG=O&@WNQTAO^&2+<-%UX??G!-F#-G8F/X]EC%+OI(!4POQ.#!
M'IWV897_.M&HXG*?&A7&DPKOBT6(!A)LC]LLL$XX[#%A/U9@MW#E?*V9X'VM
M3JI?T%I+CSQ[>*T'1Z4O[<LK3K4(,)_YKZHN-H?&X!O?Z_#<#8XAMH>=IE_4
M'!(N[G#1O-HO7?NBJ.$\%%IU.%!!T3;AT4Z(3(.9(N/!LO7V#%%LF3QQ@_1@
M-I[808U1_]W9P%KWV0H2-& GC9!-9V>R5T4#SGV*&D_/=D $W Y,67<7Y8<"
M&"'DJHB8>+&(%MUC.R]]G0;N"<'0?K>:8&@_32__V1.D&\))J6X4G'(%TN]2
M<V [Z--8[,<*PM\L+"V[ R*?6;23;.\F5$O\FJHQZ]N59\U6/L5.'NV!ZRD^
M*%*PY&_(?\]/(Q,-]+G*U#7C'96^M8KH9[# 90%GS'W!W-&4J?%J]IJH(IA6
M*QKWLX8YN3OA]%-!V;I@WR(LDXCQU'/C2-XN!=#F;R_B^#UL8G<QZ>>=&NXC
M-.7HQDR0+&3FDQ&\:^_WO&'T#?PM I+BIL35V^(26&;K2W'../+<W\74J\#L
M6@,>'O8RN?/ _2SB0L[]V++6M!\XH&&,8/$A^$GM?&X2E?2I5E^2.>2<N@D<
M(8(&"#1=8:)-;T,ZUC:=OC_%G)!F\)0HSI3*/.R#DI5>DSLXPPWDL%)"21:D
MO!+\G1LPYZ;K.[MS5+X:SQDLR$R7N+ D:@D1B;LEX$A5<&:N96;@: 9_4KMZ
M@DS*O4AE^50DTP8)/Q(OOG+U#SW3/M!<60Q)DXD-LVZ'#XW8%OY2!.N3"]%Z
M'OEDTF,&"0R4IW0PL38CP-TGC4*/?*+-]S.MU3N4OYH/K$I3LNN_A,0/6D@^
MG[6P^27E0^1J/QR T0PEV2D,6&K2ELV30,E]:_Y$[T]8'3W5E%)C%J)7S_L@
M:[4D4L1?U9.C(S6)PG/M-724^'.Y?8\AZ)H;2K]-!PW/3W6_VN02:6[;>Z>X
M+OLU# N<1;E_NMJ4V[WBU6LOQ7/'<JQ&OLD6=M XP!N,&GN1\XO\)?Z0^J*Y
M!A>OF$Q4B1WHB+ 9#93SHX&O:=]>UC)?8,^C 1@U&AA5?UTO*JV_S!S4 EKQ
M)T:M&E=>Z5;.A2@>YS[G&W4YJBP;H?=CA=_4AQV>\I(^J,[\B?-%:2-%$:^1
M;6-PBR2@=NA:$.%9MCS/='27OZN^:<[U)V->'7_$SU'1C,)%PVT1!_M^E$1U
MHG(5O"6-MVS@MS#,Z-/>@6 G1'9(W6,X0^-\=#V6+;2L:.R:8SI_,H"AER^'
MRZE*&>Y=[NKY$ N\10PB6!*^(CR,SA1K;FYK2%Y4K!97,"T,N2YL7'7!9#^^
M#O61@WCX<<!3M,;WF;\G\\HN+SR1O0X394?YD;SF(5E2[9(FAPS&"B]6)L(.
M'H!(4*U*@JHZD9Y.R8_&H$NPX/6JQPI@:<'5#Z$-KA>79/HGY4)=,+K8;OY(
MM>4,N>7\\</Y9V\5*0[$58 ]5U%H?SFVKS^DOV^T9"666 4##:ATNS,&ER].
MINFN;5Q83;I%16TH??630ZC 4T+ ;<',]O$A5!W1[_8S-4?O!!(L29/"RT&D
M!A41?E8RO3WUBVW*?EV$7&M2]:8^[Z0LMAY=!X#I3*-R;EZE:2^:E,1NV$^]
MI6*?<$C^M4$9B06F&5JR.,GS(K MSZG^-'_)Y%]V335ZP/9*6HI]1F'.D99!
M>9R?62?.'T]D*WE,F"JNF[U,2#&JC.=FD\7"Y5S&SI"'DTOE57)V<J>I$0(K
MEMQ/#;X9JNN=C!";*9^H8E0&P;%!Y_,^'QZ_?-2#C<F>.-[BU"%YD%1XZP])
ME$B&QM#$=UGU['EC]K<O,O&(E!04:,]+\NM3WH#'Z +Q-OV9#1 D(8X&R=4-
MMEGGQOL6)U?AB KM"FK8Z0]^)>14WNZ,7A[8R][O ^7ONE1+ LT!-0=IE]OT
MWF$_[N=2 0IKH2VTBW,X7GE2>8"ZNO=UM4WHBZ].$=4:U.5I;MH>R A1$-XB
MP9]4NE,Y.QQ]\83:66;J*6M&%K+["8)-T*;IBYC@P\%8;&:F9@/,6#]]#'AW
MAV1 7G9%Q+7:G1W]E)_CK'/7.]0N]!'2 NSD/R&]7E296/#U\(B<Z5+W7V7E
M.7+%E1^K@@(C6)88+%UV555))PI7UD[%22*9CPRE[Z,!$][VDZ\PKV*_9_#\
MCS[3:6'?"#3"B>-S!FLN&=\MW=C_1/'.#/HCE+KKG(U%:E($>@F^0WT$)P0/
MF)_# L'PB:YD'\U?Q+%.SK3.Q]_?YUGLMA>"GK\<3DF6[BEW!%L$/I]ZY)&.
MU3I^D--4']C,#F:3S>R?:822*RUY(0)2F2/??*Q-]>3];+,N=81\X?FQ8 -U
MKKK:1C!P)LN&8(J.&7$B/#!9*%X70D8'R&4@V%!J2B&@W;QZU"<Z5:J,<F*O
MT)'7Y6!=Y(=E&29$F=/I9STK<<N/3"8%HWNX.-4!?,CDU6[4W:,]=@'CQ>&U
M1U'. PT<$>=+)'V-3G?-_!Z,U4#>M&;.H! Y3'XP/;+AE'YQ[,<X/F\^V2Y(
MC\"Y=;Y5RQ@IP]Q_!(S.;9U7SO<0T_3-%9VP%5[;U4(_")O(]U#3<90=[*O^
M$DC&B1S]F(L9] 2W<$N3X:3BP;A'+,EV('4-#"XR)NF8FTU8XIS 79+PI,-9
M:E]V;KH@5@=%ROQ!DC/* INW B]J.[SP@AX-,)C'>A3L3>WQV^R[P>S9%!%Z
M'U<(FYL=F([W!5_5_4:0%V<-,D/>D<B/GA7ZV9<'=DDMS2MIZ<T^<J$,_Q*
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MN'LT]5!Q6^97X[HU3'Y<^ ;\?*IE9*],<?QJJ#_US'9:/?6G4,T7,.Y12>V
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M8+&1LH^WZ:+;$?#I!U(Q E>]D9^@_0!*Y&!JT+;][HDZ9Q_)BA1U4\QZZN(
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MJ A/?J9P<^4C5^WQ%]0@1;W^9<,%&J3W;:&-/W+V4?3W6E/GG97E^J9@& ,
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M5T]3,>5E.']_K;-\I7EGZ^S<\" =:VPFN\755+&T@!&/D[5)39-LRS!TW,C
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M5J]H[#3Y,#LJ*"CJX=<[_[OUFY]\WDB9#;6A?]Y)FM]$(:$;W7I.-V:<H(S
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MQN#YUPE*FO MHZ+V#47:@+2H>".$=G]R[EQ;@6X'V>OZ$%)N+4285[[[II_
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M\2G7M$>K&_#E(__;A]< E\OC'T14SJS)NB>-U/1[X3E'JDVDR&O)N:D(T ,
M/DK%\VK!\R01)SM%Q2UKYC1:#JDGDX9-$5;]TF1;E6?L06C=$^48%9OK7Z97
M;*.>B]I*\3]B3^LN9M&H%6ED$"&3^SH)IJGLLKI\OQ:HP]RXX-#,-)PWHIE4
M_6GV1:&W!*3 XLSHB]TQ8?>+<@"3V,RJV&:DP;G.Z^#E5!*WB.,B01L-B=
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MA=D^FYXI,?GG*W=SF(!/F=&.1IYRSIX<+F(7F74I"5@ X4([%G"XG(D%+"1
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MT\DNL+5H2),CS^ZT-(.=(6Q&=&_/.CT!NG)U]-85"PR%#ZMI&%<T#;7S*\#
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MYVD4+ [CU:3]&=T5MWWF'/FI3HYQZN0%3B,,E8 2)G[!\\)\-%$MA%8*$_*
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M7?VKDN-Q8CV\WV8-;!:_.*E9ORXU<20/V;KTP(&?__ZF(Y=C0FSI;G)[V-Z
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MZ0A^5-(_4/<#V@A'W+H&?",U.$>(GV-/2.J>^J),'AR.*T_:JUM6:25U/=>
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M)VP\B*DE@27I]SR^PX(^WTV0=YI.!HH<O;3$U+/JJL8OZI)3=2WZ7@BUZT]
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MM<BD]34[]^;U' /%V/DAI91GJ[^MQ7_=OZ41@.Q?.UP;G]O"L@%BAWQ0>3J
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MJ8,3.EI=VNHL[!NH!8[Z?S(X]Y><___78W/_(^T@_RF#,WR;@KONEAKY8T4
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M@*5\*RB>N;;_R,S\1JWS6-NG^<?C'_:^DY$SF!P <L$_W_TX'M:^]TQ%XAJ
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MAM%'>+&<<=+H\425T4O3^<9='B_>7 =0?P>VVE@RPJJ23T!,P7.'6K;L-&/
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MRC*(D!ZUOE0#YDWJ?,=Q&5DJ39EY,?3AIJ!UQ\T[K;A/,6TEON7[M6BT+C9
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ML%M)!65M>*@I$5N<WM&S3%AH?5I+-=ZH:^]>9LM6)WR[%=>%:;O=V.T9LG]
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M^'B_-OS/^VG_/_Z?P-^Y_P)02P,$%     @ X3-]5M=!60P,[0  '!@! !(
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MON\4 +OX4OJXCU;=,$@T>-"?_V45?4&EC>8TZK3_J>UO62\G2FESG:!VFS%
MQN#S1&Y\?TC#0X0=7O[[-E-9]V.4CC^#&CL  +[RM,W%;O.N2FF(<CROG>A$
MPJ#56LG>,KBX[[;H2L#:LCNT1270PP%' 313 )P->H7PCL[4'%+:JFG8TK,7
MNOMJJBYKD-/DH6E6?%Z+C0,V**KI2QH019P!B3Z@]SCZ2N]J/4O"3#?QD-[O
M%*6Z[ 61,HLE,ASJ@T"J55UGW,Z;3;SL>WJZ0P,7,+?_6N7Z$3MA K.[L=.#
M7=NOM;(!7>-"&PF4<IZ[ D#[.'!V/)\K)V ]V(0XJX:S*M=1]<?>Y:![;J55
M=.,QV6$ZC8KT184+3XU1'6M_5)>L@>OX$HM4.2P\'<[9=7*69?C#"R7YI6 F
M4B/QS%P_MU,3<&#'@,4VZN;&D_O#' 8=B$](:F&?;]>WT4WZY;B?%5@#PN7#
MIBC>:L,?A"2KHN62%KOY@I:'M(;%=]-S@B2/1,E#Z:<-V@RH"9I#II6#*K>,
M^5169*W*&Q)]6X):GOKP^\3-)&T7+50ZMN9H:_2A/ :)HE[^/&W,2C6YJ$&P
M224A]<C)EP,3$U':<"4!C0R'UU^LV^,[\7U2,N.GX)-9YDGO?OF!92B<]E6@
M <[=G!#_97(*XJA\1T]HMU ](I]N3J3+8+J%MO3T)B0=R.AU%HI)[W1_JZQ0
MA%<",;OX*,9>W?</31'6G9F^SE!+ZWBQFGJPPA8V"PT]5'P-M9^)J>M\B6?L
M07HK1\4)M2<H])_TL!:10"ZNO9_[T.%B)=Z*BC2=FH@)<G?9*=^JN,Q9&.LZ
MH1?@9+>,.$6>2&=2\9N#T!*L-%QOKMW%"UYV_)!)]81L?K^";U+IM/Y@RB/_
ML0&7%$^((+1%,5 F6W&= G OEOK\V$O'2S=COY--CJ^839/XZ+Y'1]#3HLJ'
M#0RM46*<GXVR4K-S\X+YC3^RYDJR&MGZU?R^Z$!I^1/L.A4Y@N5(^0T:F$8K
M)'=ZV%6AQ_8)U]NX-:KD+]X0=NR&U5( = 1@^WN"PM)> U[%5C7 "#/59W]D
M$J]'-EZ?YUV2;Y3*F\$%VFW(&#M5%505Q[F8E@?IS^SYXB'A3YJ4G&W9A@)U
MO.9B:":R#Y*BVCBTO\H6EP;\/'C*R&2Y2J:Q]?6C !R9@+G),)?$PSB_7.R0
MX1VKMBI#QLY)G_NX:YQ<, F">K[%>/ P\SA1/&W+@*:; @!^*)T[U1OF<5!_
MJA/EMX.%!9Z%UPQ#'8$1"0GG3]8GC!X(/-DJM@< OX>/(SU7/57XE!KNDGD&
M7X\+!]O[R+L";20"M,*A+ILG?=VMZU$; L.[*T^Z.>2<O#NULUO: L>7@(F-
M7FAA9 P=(0XSG3DG*;MJU2AG$-GM=2)72J"Y;_2FK_S6_GH%GJ45<>:)BDLV
M87QN<#=&3JKZ0^I688$)9]?\4G702#Q.2ZO1/03,N;M3'1!T:JL7]:,&7=I<
M-C?F>.%QSM"[Q8>^+E1Z=V,DLKM6<B[O%'P?V<A-7GG<[]U J@$!K<;'K3L8
M2YY7;(LA77H1@H"#:Y,>[ZGF3:-<]H8) =G35DB65>6HRI=W$KT3VCO8,:E?
MXO9?K-(*--@UF[%[!K<UB=:X^-I"0%IRKCS5XOFTH*QW5X_ A >G?VI4@MS1
MQ!E%QRE$7Z?G6K3HT34^XZYGCL-/Y]/B&Q,[Z]9ZJ_5GWNT:1#;).H(8<&[I
M6+^0Q9S<588(%U*RVV,_W5?F ._F4I/C) ;7"E%QP.:KJ$J6YF6L5JM8M15:
M?7J3]Y5V>&\7=@8/[(AA#E0E)8,XK1Q-* "'W!PN';@=Y_OFC#0.)<"6P8"'
M-7^)0M(,7P/-Y?2YZS">BBG+Y*C;"^4G0PWO>*0U,_!Z]][.XY%+IFG]X5RY
M6GA,?T^?Q64RTLM%.KE^.2A@S@#MTC)-A0_-P4S9;TJ6KDN&#,?Y*46]!(28
MI"0H-;-MYVUHX>F&L+? ]"KJ7TBYTZV'.I;7E@YX']Z%?**.'BF8"U) 6I'J
M=HXD;TZ+USML661\/&5L=D)3*UC3&3)1/B6QVP]0>U1FD?+M:XAA84GC%8_=
M/,Z.JU[S!\&TM#'-FDF!NQ>_3_B+=^Q4!_FH+MTE9:I<SR'>@.-4&YLRBUU0
M8K0Q!F^TW\<J38\?/%4"Q4.PBAN2&/<PVPOD%E_X64_+6S/R:?%NCQW-N0[P
M W/PP".<CV7RG@]A.W^9_YKVY70;]. :2EKHTX*5!_F4TDEO@5K.4GC,":(O
M/E(Y+#+L!0PF9?]!7KP(HBHEX"!1\Y#QU.3]G3F^@J-KV[S#!#L:"?6H@TQN
M9YTI='8 _!%:MU"G:>D'/S<I0T44VP]8G988RJV-'=+1#)C0C.$X]U[NU6=B
M43IN;,-I%L;A,LV'NCK2%&<XFE)LU'##C[-?EA>?PLOHTJG"--LHIT7PQ$.M
M4$0/>^PF?&6#;^9'AHS$LY2FN31&3W1]S ^3&T,0S!UT1GF5J]KN&=8ISI8X
M.@"UCU%XV.D.!;\?Q7EBK1B/>_&]4CKY2*M HZ9J\\$#\?0;OB@];R"]<PPF
M?S;=]IY.1?0R]G+<5W?G ZUFD!SA<RYYZ- ]I.$!UKS105V^(ZK@Q+#;VZ^F
MG!LD\?72$?S/+ST4P-F#)U36I%20<0 I97AHS;,/4WLS1\*>:RB"-+S@73ID
M!D]77V?CW,\SEBZ1O!^H_8<=V?_/<M>SA6]85EU6HDP[AX_SD>R'5Z=W.G0T
M )YD9D( )@9@-6E%<&@[= ^;K?40'%RI*CC1U7Q?CH9:D,FR%Q_6DDY%O#%\
M"8&7?EVIYWUXY<3DS ^DQ">^4UC9&SORXT8W>*?+<&.MP1=P&U4O"WQ==)H&
M2CY;GI4-N(9&"]2BS51<.;N7KP\6!LKC$FHQR1#&57XNE/MS>KW<F3MI?8K5
M88X7O34U1SKUKUP?.U;*8PQRBG@F@/\#'_)UI=*0EDW2L^X'//3R4_7,CP)?
M^Z@\A#D#SQ)%BWRS)MJKFWA1/XGJ+M5=(Y<K-6MCW*<F+O*$ROIS+U=[PQ@(
M!4=.@>($W<+N'&?+N57_!JTG59:W+B]@0=%M"R8;*:,[CJ;MNK$?K8)OU8K\
M[#<>!O$2S._A-6#OI!N4<J8(H<,BK^\F#7(O2M9.5-U49'BTH[J6Z<40^<7M
MY/W7?2[SFP0_2"OT8!O/008PD:5B"'X._U"MHP J9!#;*Z3V(^TT>WP1^8QJ
MEN]$IWG=YDNB.05P.H5CZ/,2RJV8/'CR#E+JX<6/^8*QK/-TA_1[IJ3W@9)'
MXH[5^!5S$Q?;"\-[$1N/5TY<+]PJRXIFIEKBC?4?8Z, F"0)1A0 *%C@>/%&
M10%T#!Z?DOCCJ1'H8SOHTA"3$\N:F'@GF9D\BF!HNFH;!58;"^XOJIX:DA?I
M;=@DS[KQD$_H!;!C4GQ*Z2H+#1.%[HT??/R2\W55)*M<1.3WZQW_@[)4',Q/
ML-/#"R'?2EX]JSQF4S.UN&HX(3"I4[]IW]S=)S(0S$>P:T7G+.9D+W-[)^;;
MGG=S*Y%,4+K<XW;]$T-*7%K F+H&I#)Y*B+>6VF#'K,4JB)=9.N<! [;V9 S
M;NBJK:^LTEY(%O:8;'XTO]WO7^"!2VPQ#[[,+Y#<FJ12M^QQ89C[FYP"?K#:
M;C-@M[0\/!CE@Y#CD C@!/'A@&$J0/GY.OZP!U]T_2=^6GZ;>BAWI8]^]IF?
M:I"+;,\L!?!B9\-LTPB."WWGGF\C_F6,^4<G7UOD-4'&V93#Q7I^+$(1_,@F
MP+215*-BXN)1"+%&%R>53OB5VLQQ)D:*7L,V,DCQYPJP%79ZSYL'/V83YG:3
MJ5HGT>,V7^^ 3Z\(ZPY>C5 5UI/H<Y68O8<5:L*+G5(JIH>\/&;VB=>7D9(&
MEHR6 L$T9VOD ^ZZ&J7):[-+-:73X=LC.D5PX0*$V/HSLA3!!L,$U&%-NX3K
M2RSI.8>.M45_B<X>D.%"PL'Z!">,ZJ6V:LNS,:$[]7KGEYD]\MJ<(QB:<3[Y
MG.Z==98B>W'E,7)?GQ5-=YJ'$L6S?17O<'N'Y*"=V.DV+L#+0QY&RJQZ1\NZ
MF(6+\;A.11Y3JOZW:S'S<-B;)@8\>Z8D.0^3*KNW95*GLUAEYJ,JJZ]46A7N
MXV)G:5IH%#C\!4M,C2QA:O67#I7\SJT9[Y!["RE1];[X04Q!\^+G7(+BS<%=
MW:C;;5KE%<-2<DLV:B>^Q#Z:_WE?]IE?2;A(/4^)4=5D6OT:HJ!W#7$V4!P;
MT5$_TG ]=U51EP*0+)7\,(,7]+3,NS'$&(NV^%I-[GVT%97W424+,341^1"&
M4@@P\F9LM!#B4+2O@AFH<\^T@(#P@87!!X/%#U!"1WLRS5GL_=:E5UQXV@<)
M]"W!''K7(>26P4!0'YNDUZEP'N^'OE16@)1#'U@"](F-UAX<97F<.(MR>C 7
MGL$PGWQ6\U\X+%D\@W*N;7EVI F-!3H4&OAA]2!&HUZ7O;<O#Y?R6[!5]$^K
MG OP")=";A12 ->GCQJ/#M,':9"O E6A&<BL_JP?O=F=@.CN#!.ZZ :I*V)P
M1!OXC*5D4ANF44KF\;1]U<1=4L\COAXD[07/#5N+HW/$^T!NZ./CQ;'S]IUR
MYZHK%("],WV]H-[I,W$_>^"UY-V #@Z[>^&#9B;>NX]5FA@'<L<X+..T*X(>
M^$,^F?=Q<AX1^O5%QE3X,GV3[@F-[$2HZNL&/W#)-U,'7B#6\CYG*]/@>'3D
M_"[WR\^JX;:QAK.8&58]AKK.=W8%/70;43\W1F^^5FH6]- ;(U)C^MG4&92;
MPNSRD:<G.&M>6F?LG(RF<3?2^#'WMH3^6F^1:]'00,M0(#6F$:A;._3DN20(
MU;KLFC;-XW7WX_.#%T#%.?/G8,:58*Z*(_X/>59.5?41!PIEIX<\5I]>'XUB
MM0DW+>Q;-78[6JLQ4_<%J\?9<$\X*;@6O:R$<)KW=<I$$?IOCV5]8$[)##9W
M>7M*U#'KU8EPD8S_;;FSY=@+D&0=O=]XCZF@.+F?P]$_H'QR3>&<,FDA=H$*
M&.K\T5[RO%R\MEI '_)%\'0ZEQ?X#05 BZT:*.7NM\2?[?\A4*?9UL*.0I4?
M*ES)V)N")#"W7CS)>"\EP2X662M<"ZL'S^8T20T&:F%FJ#IR5A/JWGQ=Y3@K
M,/&--U^F] P2U<0.0VTIBT6?!5DI3/6;B-XM^N9EHH^60CRM-#:RW>W/6[ )
MR8H-5YQ4,K]O%LN55?/*O+HNY,W[?A8VWQ^\H2>?7QA;RUOWP@?OSQDTDX3-
M1])[1XNG=HY6/&(4M/'O0,4Y.ON]P1ICRXI$%B06'!IX"6=@7#'J5:^GL (O
MF&?6/[)RTL9!U2&J:89>N$*CJ 7V$G>Y!3D?+7ICMD?#[@$[.Z"IK!H(P19T
M@@+(A.F#]T9C"+:VORI%^A0  HX#WFV']M<&?<=1 )57H-N'8,)Y"D"N[C>A
MO[>KA+9NX3A(9RU]2*2<W3M:Q*/$R;8C=5H* )Q- ;R4WKY>*!Y" 80LS$H?
M<E=N'AUI$:6!5-"!D3SH#!KZUR' E4__\P#N)%+VZJ>8@WWIVK"]4"8R5(L"
M. %9]+EK3D\!T/<T0W;D5V;V]V+^"NDOPD$FS,=3[L+^%?) "P70OTP!S.H2
M^U;#,5",+X&>'%IRG4P>_%W<:69_*Z;P(7AILFD1B.8$'Y" Q#/0SU-&UM)$
M:>G?E09C_'Q_22H>2_X;P'/_##"HX"T%D/[LZ!/4\3X%L+0#Q0F1';PTGB)P
M#0TT%("Z62H% '7\@[E&9(#;/R&>3!L,0"(YAGP2\?UG?BD'F2/Q!6+9>0BQ
MN0'\@^QA[B5R4,_/!Z3,U\<C'4-K3CQ('6%KI0#^SE/V/TK_>PI@?^;X/U'@
M]!<*;/\K"GXS9..?*-A+_%>08_ZJ],(?(#N1_L, ?^9X[[_A^._>\5\ZM?3_
M@F/>_\L<_SF.0?\89OA?LO[_BF/3@]0C/@J@>Y=01*YSGCE4:-J'1(.H)6B)
M0O['H0GKEQ[7[4A2"#ER)"2;(X;O5PX)!IG8#Y>\<44M/ WJ"&*T""WA!8G>
M/FNK^KG;BBLT!2,RK"=<6J2^R_^OF6H*^*LJJ5#TM3]R!?Q3/#;^7^-*Y'\2
MC]G_!5?0_\@53.\75X0F><+YAVR!YKD.>7(OB2M!YK\B8&82^0>/:&3KLR3>
MPC5B%YF8G6)C7+Y0 -QH^'")>_9YJ\DV%0="UM.V;;;(@CXPJZ7R1=MX@U=.
MA[*]K%/3H:&J+Q<K%$'!I!HRF&E\?U:AK&#<^G2#3A&TO4+;**K5 7CUTXY&
MC\,8/WQ+>)WEB)Y@CMUOF7+HH #.5];".AME8K0?7.^XRGSQXD_6R,"^@Q8E
M3MN4,8XC/=\X(U(-U%7R$F8LS,W2@-&)0S*G33EPL#"S=V&,K\DX@P(H5W79
M]6DE<P\1^3 ;<NHHU]&A.T.NV955(?Z"CIDWB"$ 7^EUV)'(%/D;>C^\N!+*
MJE [&^324_NJ\Y"OVCM1_+W^[H'-[?=R+X*-(%I+5_^7-W'_5"XIH"TUYPU/
M+%T-^2IWURO(N4>M+';;L#[TVZA,0I(/739>?I:L0BI]WJCX'8YK_#R2QQM4
M/LLY"U3;3]XI79>B98Y,E.2<V3KJ%^=+NK^UO/W066AA[.?D(7/NO3DII'-T
M,1)@3H/MC^&GP[GMU(\^K*V%''B7D[9)(%M:K,N<.U>@)=XA>HH"@'N]BZJ'
M]I34;F52#SFN$19K<!D.U##+HSO2=-.H]OYY1&]Z\ES-RAHO&S@%T0W]O#/V
M#OHDX;'O#A/3[',+^!FP3019?C%I:>/2W(9K-W?=2EGZ@8,=7=[J,Y?OCFL0
M(W6AY@=D;B>$*E0.4Z:BE?1P!F&1,^YTP%V7&"'?^. S#)YZ<[VL>]O-.J9'
M/O8;W[L'M3'&2,$QO2]$.;Q;+7=C3)@\UURPZ7<:UIBB^V8*\"_3OM"[=4/P
MTV<;-RJ>) BHB7FD>*R[#.1(R$\IZ]D\-R,Q"53*>._%#Q<?UJ]MJT#GOH64
M#>!DCO97R,LP$5@PJ4"%7O'-#I#.1J]HQ?^US23H0EG-]J.(>5JIZU[$M6:7
MA)Q[9I4%]=F'D!>.PYGQ-:9F/L=;H7*P_F\;HCWWE_>AK9<\D<0F'6*([TA
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MDZH5ANYL6=1]0IM3-<!/+BD=^&'+=MU?@>0))>#P!AVLK@\*?O^%$_METTN
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M&DS,W6B,MZ"^CAL%\$%5#E7=CN32,(E<4N2@G[)I\AF<R%JNDLO"P9463K>
M7"S0DZDCA_NKS]'[&[0%J\ 3+!UH6;6\->9II(,'ZULAC2?$'[1EG)?DWQ4%
MWB$T-=%4X2?!X]YH]G9H^>G]8];Y[0)8^JAFN0OPXIALHB0I23/QZ0HH4R&'
M=5]68]^'95_M)P#PN&+=')L>WG1NF7Q^B'C='101X J,+Q3, %Y2HAL'B_+U
M*;&U6+%$[:5U5N;UKP]50I/[D#9BG+8:QDDQTM?-$[<.K-/WWN#;H<Q-9PA@
MZWLAM;4-7DD7GIW7T&2@K=):,_&-P*9W $/]#4+A43<EY:_2YV='B[/:K#,;
M/MT8EK%])JZ%#6MN]!Z;[0]ID,E$0Y] +"8;]C79Z11E%;"*S)W:; C\-F;I
M+=$"AVSU=_N0T[B[FYZXU!J=D2M Y_]>&=_A9,+TR7.L7<K>Z"8/Q'PLMTH@
M]8FPI!C_VNN/^\MU#'A89PRSKQ;6($2WQVV:8<PN]-'9T]ML5E2AQ%V:CZ2S
MMM6$'"SD7/! A:_)[:1)7_^VY-$M=04V-8]ZE<!V28? 0-Q4(9%F$%&9&V$P
MLO/6%4WS(73OO8AY5)"!;?I4$; \[(V;ZPZ?;@<Z=VG8JP"D(PB4NX7HH !.
M/$EOK9\SX9'HO*;O\VU#<;ZD.+"T3Y%!MD7%0*RN06%J1FO-;H9C+<E+WC/=
MV2MH"V1XO.>]_T^?)TP.4T&-4>%]L-.IN IUN?ZJ)9,4MLIRVL4/B(8@5A]Y
M.+<<3%X_J=Y!09A9E_ZV:=%U#:_+A *\@P[!*CLH=Y=X=*!V)!_INOTM*.BC
MCSP>&-UTP07,[)4W[!41=['[W$2F@ C'42$89G(W4 \;9="I/-)94C0)'UE?
M$HJ94AN_ZVVT8F%Z.&T29](SUZ_J[+.Q# 4O36I8*2:'*,SI/*D_^%I4DK7*
MO"*S&F6OO%*NLR T<9&Y8N[GZ^DJ%6KAD-F1G%J\Y92UA57[H]"^<>C<HMH@
MYYZ)F4H07NXNGM2N<R6Z3;OZP/5JO5$5Y]WGLUY/?(A%8_'.J.*"5M#J%&*H
M'A3,*J+%N#J2WK 7/C.R!WF7C9F).$^0;L4BV]!ZI:G%/376:ZY'W>,!)VE_
M>EAK[)+Z"KR$>A?:J\UE^?JO]EE\.HHS-,L+"Y0I]"TE6#IYQWA)XZ]PWN(O
MG@+D<;->Z3-U?;SK2@%\EH6]Z\PW',G)TB4F0E2_U_W [;^13V>[<PFU<U :
M^O01-3-L).9$8WT+ O"\5T2HK_["B%0-V,'Z+>LA_X9M@:O[V90S#,R"YS):
MD=PA1@3SD(C^B_KXMJ*#'5";-$89'D2TKC6W1Q"IVU6N'UWK^E;NXI^>./!)
MHM-@H);\JA%XBV".<:51>ZT3:D%+A->2UH!]==]N'R2-AUY&(%69ZEOG?_ *
MD*:NSO@4$6]%F;%-<!>[#(B)4._D>>IH^&WL.I1G);P#"D);U!'S5CA%$G02
MN@R'111M2!-$GJ43- ,9?USCV([<HP#,X'BOH%P(>0V8OAA4JN[N<'W_?+@(
M[-9AQJ]_&8 U@N^##P0.8TBACRF @?--]+_.W-!J"5(?.GKL3J(2__X=,04I
M!&F!CR<NB-S*;9&LIJL$7,Z7O_[@VO+VO_T; RJGO_XRFSWV;R=ROM"&!@\#
MX6:OCY1]H3VDT9(Y^J[NKX-MI '?[<=(L==#1<_YX4M0G $8Z))^OD$1S]1N
M*SP\83RR*9^/UK&_?R)&Y &SOQA5\XDF"Q(<<:PX!_$*OC-[CG[B:(;-U]VB
M1JINI$52OKX,RX6HCP[7^G8#R99\)$ON;A(@938H%CO7*49L$!49T[VKRM7$
M;@=VBM8__='\_!I,#CV\-UJ%+"PPV;N^.4QRW68A^PN3]D3^\KDCOCU&YDN<
M@QV*F4'V5Y<H@(CLW^O0O]1+TYU,#AC=[74/^@=@,N"E+.C,S9B_?#Y$J$(Q
MX\'*%$!6SO%&,+@42J@#_W["_J\G5',,YIG^4?KA/Y&V_[.TP[^2_FWL+]#]
M'[!^",$;$HU8+K XW@\7I?]Z4N1/]6/%J<>-R9X[PM\-#E: I#U14M#:%NU>
M&BF%J'<DUY9! 3CY]ASY'#TR6"!%Y49\V]I;NOYIZ3KB-LF,8-8KW$H!T,K)
M/';E'Q),B0V,+\HS[=.7M/A@%O[F;ESC=VCD#,USIJAI#F6S,N ''T;+'N-W
M6LDNEY5C3%6'<2Y8=QIR!TA^%'39QC? .N9(^M97^X!49W"2$A;LTT7>OL)'
MWO0_JNY,9U?AP:TS$714=/-6I/S5KV9\@\Y22QZ:LS!MO,1%.S6D$^Y<N@-E
M3=@J#*9U#>)G8HG*U.O\:&70O;+\]/:5N)&TJ%D$S3*"*5#1*6.97?1!+KKT
MO/Q\A8\/N!U9*U]]C\R!3W@]Y\(<@"$][K&HNN3SV4&VB;9F%<QLQ38WO+@8
MN(_X7/Y#U$FDN/F?Y'%J.AQXPFK.CR"-,R..6_O9"HSY.-4%,XG60@.DB31G
M6G8%&O=7;_!U+ZNN;3-AJ_)\CES(/[Q![*A<;UQ3LIR%EMC6.Q>6QXO!X"8U
M  50;SV2.\<C.3YXDW>KH4JKD@)H4:$ ')+Y%#%1FU&!6KD=/@%8]?*^Z_'=
MT8-,#')=4N-*.R>:7HTA'&:85JF2]1+F=!*_FBQJI6<N;<FO<+LE.V6M5"4%
MO1%WM7.BLVJAV]$>IC$%WA#K\'G@8MHJ6*"3W8.\_W7\37*[FN[AST $UOU5
MDQ!NM:%LHK3 N>'SDZWV().2IT^*H[N^F0[/%C$P[[+M'2=B9 2(=QDD&Q5%
MBLWI UG50V.-=B_!YB &H?V/&M%X1-X!D#X:(Z*C]$#(8?PX_6YI<2*=UXE<
M>"LKG&MQ%=V@<]W5;V8VTH80!9;T&\&;&'.B!PYB@8OM]G1F+,F%@9Z+'[4#
M-X1W><W37JFZK(#'*^B"!!&P)!"C8:>]_)/-,U"(7QD&0;\:K# J5(:2-,/B
M/RR=*SI)I24H!070/+:Q[+7SE(1_EW;W8'&-%54S4U]66]%U"/+(L]'P<E))
M&).YXKL8$EZ>;JCAPR]%B'>:ZV=HKYN.A6'KO>_&W*L6 "M(D9VC\XB.*6NH
MPH_F5_F3W!J(@U=7,(4#<2FUC^%CC^O]Y%Z9/;*W?QB=)_;MJ=HN?_P.LKD?
M;119-<V/]^I<?Y^ +@[#G1&E ,81R@?)M(#9V9UKF1\53S[R-_,ETC"T)@II
M+!]FYTGT>BCIV5M&#!4>[Y1*EU;*M<M%[.]_TU2CO3!4--\_OKWW*HC1!<I
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M!"\\XGWAVQLP%9WI6H#.Z8UO-S=#,7P9J/%RSV3CY/62"!(R2[=-U>UXX/Q
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MA.K@7YZ4#/1U)!"DJR^^/_,\<.VWBR]I*G*^;G0>^!/(!'\PS&$4OUV6]@P
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MN(36R1=->",>!+](>?S^(2+OO/ 6!]VYJIX[]> 30Y+:RSX/=AZCQ?1I#H0
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MN9T22O/XQ+23=1,Y"K[695,(C" 3:2U3%Z;GMWKJ+UU.M<&(0K*W<LW=E:F
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M&(2R(@S\K40<3_4.)#1, ^_2ILF=?_OA5P*Z%QG)_7,TX)9WPB8O>I);"%2
MN@8F;@4$6G95C/QXW$[/+8WZPH7N=GJRL563O=7CM@(13"*5RA["A9\<%!CX
M7]%8@ON8#=WJ;]C"5+,-L3\#_!8$J'3#B#^:%)&!!R&#LH\6HO<Z-<-;L&TC
M7+RD(7[>:*XZM6RAKOQSI;41W;$/@PUG+@J2GM= (DE3_#>(:6BKB9Y*N1##
M:"Z;9QUZNJ>"%*/%=H2,$&910KCQ2J+Y 5@DF-OEG.C6\=1OR>I92-5\X1KZ
M+4F?-BK,7U# NOJD%9OU4Q/@>/BO6?<3L4T$W5A)&E:%>]S8/A'&*3#K<+,.
M3LH5YVSTL!]Y'<7_RF =\QTC;15^"QT,-J'U2F#P_Y/,TT9>'Y0UL[W!JO4C
MY=T/&,4T?SP4:IWN#/Y#;V>*=.IWIEKA.<]-1X#)V_.:J^>\O=K!DU>Q*S^S
MDSL(5,"Q7\M+IFD.;5L?MEH?]*$-T +U\@BVP+&%6D!/T+>T_P2?D]EZ,-"Q
M%JE.F/:<M9)X;>Y%_A8Q>^_@1CW/')!\-5$5UQM3 M=)@T.*2Z_RW10&VWQ
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MPNJ=OF#Q(W398?\W@[S"-O_X!\WS*F#1DVO9?(47==^7CZ>QH!56#S2:@!?
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MX"MTJGA%MF>@_OTG;$T'$Y  WU'&8_5K5$"P&F[U;,]P)(#N<8NT?L 0%+^
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M3K*QED!?RH+*29;?_AS(FH%)^0%Q%/448I6UV';: $V1UILGF("O?C=&=0*
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MX.5*<T1C[HKB'E7=R'HB@ 9=6GX*.@0>QSQ=7)RZ*F/:9F:A(G]8G:6).T[
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M]8Q;'K#;@U$50W3*19WM]$[63ASQ;XWC?RJW(VZ(BP-NN%SC;\[HLD1<4S9
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M@?;7G^-P1Q>OHE4&PVL^+!*7?.K*XBI>#3?+UC^H05+-;/9:1RD0%"/,*G^
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M4=^E.53M*X8D;87^74XWRSM^HM1X"4:*$;]/#-/N>!^,T(Z<$P9O]J)"]SA
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MZQZDM=(!S)2CN;*%P1@V)3J@PS3/RDV$NB4Y;=&L!K!Q!+$32"\:%I,Y$K.
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MR68^_.+&^"O[PU]G0_.+3\U+<1D(;P3W;'A9E6\ ['6N;W_,M/73]G)BG\)
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M^ 0SC%3*G,3$RDABFAJE1%D3D42(+#$BT?#OJICA.W_W_J*++;G"#7<,AL[
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M)UWZZ]&\0V:I4JD$I9M%A"5)2$2L(L)5Q@VC3#*^LKXW<_@A^'I%?-2\-Y7
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M$EZ+!'[L)M9W<F6LYTI.JU J83,22Q9B0X2$P.$G1#-'(QZ&/$G"U5S)^;2
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MW#/76;#DC1!G4#N^5X;<=PR/ZVL*+&+9YA6Q0:_U8<8MQF;GY750 -I5-:K
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M1:;+GO/-^_I>#G*^GZYJ:F](+++E@/-8K^&#4GDY-QNZ-A ^Q:]W%7G-:Q8
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M,EZY!5QRC(T=O]0[L=:RL$U-M+];<RP_?5OEIQ?=)?E$ER0VU.]^60HSPZV
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MLG,1RJ_,CAT4TG#KX.<L2ZM]@P9P8YT2<2E7>E6/L=EL:B;F ?CE[P4\%A]
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M^0)NOWY+#EH9Z\BP0;AS[XXP 5V[?/(7M;KC=+\HZ6GR71/O0*24JW*&:[&
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M?&*U9P2545(E>P>4::1NL$[SM(FZU.TB=3NMFZQIV2&HN9.>6?;E1:(G#V5
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M:5<E5U&<:LOJ%!B*K"E+H06H_0DR#>>+%5.VO6$NQ<#+->0?!JSQP"0DJ3*
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M50-#_FIGL6LOS=%>'KF?UZP?FO# ES?KK^08U*+U[]&)\]*RJM^,>1^VW%R
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MWS!QY%K3YI[$ZH-Q.G[8G=D* 28<\7CAFYCU5ZG-9^5Z$QII.8Q!"BP*FB8
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MBP4SP'8!A!K0H6$%DK8!UI%W)<WZS%6%YZ$:N+^(^UU!RN5)/ H5>;.6FI7
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M)@3[5ZZ\HFDPCP!SCF,EJI1*;IL; TV%8&C@Z 8L+*/NVPJX4G/-G/1\+/U
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MND21IX,&VYS_Q!D=#L/Z)=@8GDM;PMI?91HZ+4_ D1<*S$I]<PFK"X<</&O
MJ4\'SW#JN,[^3M"Z@C1OBW0V<^N&&98E2<VQY&GRADZ#'+T-OEP_XP3_T(-T
M626W'BICIS)4]K-!>ASK3G"*@@YI[S[*L?-E.Y,I;O_YY2L,3* %T:$JK!O#
ML; '!J=U7<X8<RXWB7!]!O<#2X! OS0-GUQZ_QKS)/W_ _%[R>E$NLFVU@)>
M[AH3%Z">[*GSL*_2(OLS0+A]@X8: )A/H0.2W$34HR!J#0R95KJ2T^2I,Y5"
MO .ZP8P>J$'I@^V(C$1.3TL[WBRE'2F-U!I6 #601;C!'5+H-@)"QQ,W6[K9
MVV1=9MS+S1V=);\^QMV7/ES@04=1"/L96H6:Z \7 KK8]I2T1A+ X1$JD&P1
M[K5H<T4#<KIF8[8,"1M%]R/M ?3C[6!Z>VH4MF61]\4FC,&$3.K3H',:ZYMZ
M!]X8,R8A0. N&,[ML4_?%O"2D.N"F^O//VWGL!TE>\[2 ;H#-9W@*8;JP"XJ
MQ$:"CA;[P:?ZHKOY/+88Y*-Q/\]I\M)QG,%P*44G\?SH/7'^<OG7AK2RS\.*
M:/(10X@?<M&SG!CR4O*?_8XSGE"<(E<I;B[V3%B7["HL E^&>\V%UU@)83HW
MBIMS.&8#%BVEH$XT2+51C@R"=6[11$6ODXREO;P 1T$F<GM>;1YXN%D]:Z4A
M*:O\!_Q!9]VBW5<NA2'%S>E7V?GV#V4AXW",Z1V&C?$XBS]O$62?**O?YV4+
MEJ*1A<8?F[5,B#P.KZ[9K.4NA8X31,N"W0R-BAV <#1S7'1';ZB$5I?,N</S
M?O3FU>6Q]N6U%=P6W$<[0.NA-]69*WUM8I_L>7;,2M1)R)_V#;9(@/.4\2PI
MV)WW%!U@&\V0RV[RY8)9GF:KT:Z,=N5S*HT61ALK'+)=KW-BW.XN1I*(ER29
MBY 8[LF->H3<U*<FY,#T)T.W=T3/P?<W"'?ZKY5RB[86$X?1"4_A.STMZ.=]
MPY'GT#49\IPF4>HZ[$T*%7;<QAW[]P)7-2X]<JW1N<Y,$]O1!(<-6TU3O8O;
M;7TG5;KFLXQ&"[0M<#X,!)(!<(@6XBKCS)VF#4U"_=["W!#BES\=QN,TNV4S
M;TR_; #4.^:C^U;TO3::11:U\?8CFYC#D-;\V_2*77"9C"':DGW<,\G8@_*)
M>U#.QQZ4K]Z#\L%)&TVFS*DTJ&KKH&)3&=A!A[10NIL)W&Z792P6G<MTD$H]
M4X.F[2-\7CK)8S'8Y*KL9M@XLY*5AF] 50")F'H)[@=@54>O<?0:/]\6^.<R
MRYVGIJ# )55&D"C6]Z(B]+]2UMS=++W5T!2U3TND?5/ADTJ+])&]U[?NN^:D
M=*<#&W&A5H0T4:[40.)6V4:OVZLK=9A2;@1&O0LU.Z3 &;8-6'8=Y\RE@UV*
M>+6DR(4 M7\G=:N1>U:6QT!P>[O;3C0*#5UKP-^O,'LI=W?-*I<*/<T,OIXJ
M,/I9VCTMBKZR)\)KS&K?.>-"-,RC#V\AF9(;O"0/5*O"_-;UA6(Y4?P/DA8&
MQ'8HZMG!1.S, XQ5J=[(HOB#R:>2UW*IHZ=O_GA]'")].4&91]*J&.2NTRKE
M'$AIU#27,AZ]B+ ?U9(XJWL5 ?%YG_V1'#UKR;-U=(4_H(1US%][#@>ML)0'
MQ5H+ /UG7)7Y):V09__3A-Z?_'*\UX?V 1Y3_\]8GOP\Y4F<[_A_[(K.?KB"
M*U)8X"@;F@M%"\_TLU778M8T*[R8M*JD+)&A%%KIREUQ(P_PK6\B",RJ1 ]M
MGS"(D0,GVE3JYJ&I!Z..**3ULDXRMT@\YD@.ABI/O[08,<F%4T6&B%:=ZY3.
M<0;^-T:H)%QVIS0QIS$1G5>/55.@(YP, H%]KKB31)UTY$"V#5T0KDWY_-[!
M5\894/0IK=*YL^GNL9_H[!N!F,V_7P,E?>G*'F<G46$V@*9F7&(02A#DA[X(
M:)OX <B%A+%*8!FNSY4.R]ZN>49ORF3CTLINH%E^3;/$J@Q1W? )_8%^SW.'
MO)4DWH??;Z\CFC&2**;F;G[E>G0GWO_I)OOE]^F*%O1/=%G67RJ-7B:L2QKO
M-=<E>ECOJ!+3Z*]LDM(Z]&<OQ&_ .$#QCOF[@J=6@>T$E=3L.LM1\'4-TM!K
M1X9*A*C,ZM$1<ZTE@@X-5\,K9"-."M.D73.1>XO,DD*6%L ;A *M$;+**2$5
M#]C_7Y__$A ]/W'^Z'6;LY7<WD:=Q:A('SMFNAS@;@;_*C"[T3S0/1YH28JV
M!F[,_Y 6])FDWJ8.W-(.;W@F[["L>^BJ%"^\;GKST6^$UVTR-K1_<OZ6[0AQ
M3TWQM,SG?WE"Y?NWX7_^X_3-*;FMGOWATE+MKR3M[.K]78M?Q!.Z/[J7^^Y>
M7M9UNY+HUC X S;;.W';W*7;CD='+\)B=O8[^]6N%+RH4LX1)CM/X15Y;9%@
MQ9;4X2YRX$E'/W$2DH6AE&+4P=I5Q?E NA]"\PY1GN?)M!ZJ2>3JX0O7:8^S
M!7[:ATCN4I&RTH)ZW!O"F!'&@W=2E<S%&U$,AHX.X][MHD0B[(<1M//E(J'9
M3@[#I&:3(X9]OTNQ! 25\=/_ 6!>G+-8G1:?=N]FSI'3\;<[IQ<)K<4<P?CC
M0%_L4=1H^ ?B&%_2,F4Y!0;&LQH:)L:Z?F=9-6M7OD$EH"A%GZM3;?1PP C5
MQGRZ-%_DSA><Z^ER%$OQWS/'Z72Q#Q;-&:.;.3VA_B,>8&+:G_E&7D:#6_SM
MSB/:TV=GP*K9IPU& PW?'N])R -9%DZ\<??.K=:!/5^FSP-T@D_<G;3.9"5'
MGE X!K%+N1 \QD);P%T(\0L-BQ: 1X4V;OAP6 'Y/FWKC"D?A=C!CY/7ILRS
MA7Z?++GR/3EB8Z[IHT';TK]1<V,&;>$>=[4K.D*[&SV: ?C)9/MZ=(7TT4RQ
M@SAZ45*OP#0FR4P.WE?\Z47F.VI]ZX@'2 VC*JI4X0%IH=>+%,+M>MS(1$<1
MQX%B7_$1R[O#UMHC>MS4\/UD;/$7XMTN_.P="]%]:&^V],FSIC-.%I1KNI8G
M3OJ&SX;N0J:$K@5,?3*GSRT')OTT^<.3[(:FHG69XZW5 AOCUQM19 =:WE=5
MU'OT%$?<'S!M/SE61^->K5=/__CI<J+'5G;%$3 63Q@G[ GJ'Q2I-\LXI!:R
MW;ERJZEV=!F6D6#FI>\S"$VF"?.$,_(Z?@,<3<,@>3=!_\SM5BAR9N_>.P9E
M=8\O*KW;J%9F7+7I]C?Y.J<4]@6=BD'SG/!T\Y4C5F]]#(/2^(;NR'L D8:U
M=]-+,89PIK$7W;W![0"<>YY6?)&@C['==62WYA7JIXMM7%; ,=4\I30^B2D=
M&+F:T'BD]K[%/()[+!JJ3CR_WJ+.L," _>T]0=9E-4I[C^130WHW_X+9NYC/
MI0.QZ'#)SYT<4+--+,G8&6Z>ES>>]MG6<-B(>VU]O_?0<WMHAS*IG]:&_QB7
MKJ6JRD&1K7*&[FX1!3*8T(4V?;(G:V4PU_"S"P&DGQ#Y92Y K0LY%/AJ';H>
MZYO9OLK:,CH"; S7C"FL 4FLPUE[(]J)39?65.^KJA99$VY?!X#*+6\N(/LM
MBL\M:*0<K$8/$DN9&P;2QA5-HXU4^W%\"L :3*/@DT/FP7=2JR0)8A#X:/'@
M>YU;YNB$4RP.^O",%/\633_07X"N;1FJ3N])!/A*OE>BS5STOKP*APY_J]<@
MCK__ Y'XK3?2+#]",3[D$13#KP8]7CTN]@3Z>DEF!K<0N+T%Q2O68Y^X-S=L
M0E[39*M /Z0P?;55EN01YX _-^ -VQM@P]EQ5#-9*EVO0AJ"C?*GJ]P=/6IG
M1H#GT*T4=37B!27S;,Z/9T?)4'EN4)VAPX\AGJ-/D83C(W2WN(+Y=[W1[@XC
M2"ZQW@(7CLR[LPZ%B,0([0PN*C*IQS%2:HQL]9\;*7PQ(H6_.E)X]"@_.BLD
MJ9B%$_)X3NV&'OQ@-L0C+,@Y"0URD::=AO?6M#?/<"2W>9-(SEZUZQ4>"8N@
M1_;$$L?SZZR&VKUOYHXH1R:12)PF F))1"1OZ2JQ0]K)U'H+XA/8 JY$D,HT
M()Z+"0Z.F>_)CF$A;9/0JW>YP%Y"G[LVM7<\,;9E65K$F)>:$VK,.^*_PB98
M$W3^<=5+4&/&3#)__<&Y+[PN)SLG8&FJF=)[CD5MIKEW>RT+;,V1DJ0T/A=0
M2P*BKV1Y(]@>5GZ4WIPYN<NUK)8B,(!]4]TW>^IB?-(<P'A@?Z8#VT>-488Q
MY[ZW3110^-,W)":CD[X5>)4%VEK][,0)J)DI1)$WMM<WTY"GI@U<<Z)-^YZ-
M BR*7KP;[PF_V-T/*AX:C3R[=DR7PB?$T$>Z->(N^QX](X4 C>/P!PCQD!;
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M5>(-Q8G128DNF.Y6EB2).DS"-!(-0FSOLEA6O!Z('ZVU2[)OFHJ$!;4XY=\
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M1.=GJ? !(RT)O:)[*1H)[?1-./6L^\CN6(P7;%E,,ER$I:90CGK<:27/H#C
M1,W=+%HZ/W7"^"I\1CUQZ2$ P'[W%FS&B4]6$K.+"'LNWIK32",-5)&*1 V3
M"!6(&4K-3AXH/#N^[[@E&1% L(2MD20ZG5ER-F._EYCQ09[5@+$D:S3(T1%O
M:+U/\NI?M)618,YS7M\X&>.I5RM^?+MIZF2=6!IWOW07WA)=,*8K72:D8U K
M!-V%@B!LI')GTR1XUT*HJW@ZO"<Q3%;.9!,PY< >L4)0W0HIU[&&]COKB4X0
MH-OOBSY\-$& OC@$:.K0_XT=^F<Y%21^\GX=(JB^,3P6,8OPZB/7/'U<=6=M
MZ>V-ZN]N#\D?K"D0DN+D>L"I8.FF693.)$=0<N5*K)1$?\TV\-:Q)A7_BI@H
M-K388Y^3GSR215Z2H'J04B9_#1N"&J$H^HS=<Q1/G7DWQP6"'AW7H;V$P,H/
MX^3I-X^S>P.)1%SR->B3LU_RC^@Y/@W>V'WV]0[\E4(QSLSR;5MS1QH]2AW$
M/K1$P"3T0UQ2]T\5767[Q!7HJXH AV>E4>-26<A#DBBT?63'V>OF"DKUL^3:
M=H#>_82'SIUFXBRO\Y*C1*=\>O+MN=LUU/?64\4<4_E8GL>@P@=%S; FD%_A
MF3PT&)9.01#&L'1$Z>AD6.754E<AXJ[^"F$V?A%KM\KB%$0GU"N/F8OP$:X>
M;;PE';_JH>]8\(/)<N1]6C-_5\NXY3D-K$?\>LW#$YH##;1V ]!SZ8*/#Q+W
M@/;7TG6Y?746-3C<QTW9)K$H#X.G_N?SLY_>S;@5IP85AFG%E/4TB_7VNM"Q
M[O5L2'9D=V"?$GHTO%EI%79" C53! [GR3@1LTR_THEB:+AV%+=;LK:0$AL<
M-5<U%]_]V/SM@^WHI'%1+P/Z6UW#/;.."<.]F3.6^-@K"P8J4,9[$5_8"%\=
M!T' "( L3*IQD:"2^V%#5"K1]>>V1]S*TWQB(+CUQWE,EKGH/C*26J554'^2
M71+S@?;3EN&.5N_/-9W2YWUHP:8TFN0^"2@7D--JU?*^SQ>KP.J2P+!,_SC8
M&\,@P!0K39.2WPC'4HU>[K(3@K=P!MIADU'HHCO12?^6O]L1W2WYM+@C\@RD
MX%5G/[X\_2<U^PU$.Z,^7)JDIO-@F9<ML?6%'O \,!6'!)<>F=K6'3!6HE).
MV,6&,FB:Q.E4AM,TA<X'5':#'% L)G FIW@NY ZSPS)Y!5)6C!78>Q 9<3S@
MY7D$_&& =?'-D?B;),7?+ -!<[.,,DYC.;@A.Q&=1TK:8"" DO&EH]NOQRTM
M SK5R9DD1)A__9=$S*Q_I^,F+!IV/6A(@_4CV\(\#?>(VK> D=IF_;B89;T)
MG#\?/RT#8C^\QT!3T,E1,1BHNH:Q-D38 G;F K:X%I;/P:D=$:_>_?AGU%NB
M='37;?- ]#Q<LJ&*$G$OB9@6>>>DFLKX0P7M#(Y*?RO5TKIR#/#@BQ*TJ.!7
MH^L"VYQ><CJ6*9DXL2?^6;F9;V6+= ?BS4'MSF^=AP\>/+VSZW-*T-QVCPZ6
M^DP04F?Q8")FS^42+>'PU%[@6"(FH0B[T&/S-2OQTD?PM5?^'),5+!=@!/1[
M!\":__=@>9\\R.Y)U8B.JUEV^@+5:H4A"K:10&B_;O?<^_;L!16^K=C]V>MS
M GZ#B*[GOHOY'&%J+EQ1TI?C'9NKG&-)/=>BYI2VVK=$QZ?:"OZJU.+OCV0N
MI-'<44"<DQSY40@K*65$-/W[%T=-SUS50#4 PZ^9Y:^I!2KJ?[WR"P4J!G$8
MN;F!?M^?BQA*(-SQ*X+@9DOY(*%2HGJ#WTM2EP\L%$+%88$DPM)>-U;W8>UR
M9'W JFDO;_,B^T]MJ)>&(R\Y^Q6P-HS%F:DH&!-E,9!]B,X]K??>AYG/?&R>
M&8#+). A5N=:K_^[BS[/GOIEWAU^ /@>8,6N QZ1XAQ*U@7F> $L4%EUC9:H
M3>5$JY33/8!$^$!HRP#I@;#/X0E4'L6*I2+8+^K\:EB 0X3A-IP=$]P)"+FA
MRP&H@AV4(D"%QY'J\**44G8?J'@K_X#&YEI92@*O W.;7CK.+FG3E0&Y7K<O
MPMT9^ED%W8OX-,?9ST@S\S8#7C2Z]H(22]>">?TR1\3,!O%O%Z57]R=41\*(
M#7]-T-:9/)FHDR^P-R1V9>B,MEJY Z]J<D6G[,V? +&D@W%&D"VKU)CO#$!J
M<"PF<5_<8!3<!1X!/9%NXE"DZ/?:LQK1<2VA,PRV5E/2T2R0^8U\PT1LY$/0
MQ8>*CQ+" L+PUQV'S]3HB0Q.QIF*Q7-@A/C?Q7-&QKNT=8UP@]5. 7*X(P7A
M ;J3I#W4VFK-)2;+(_IQ?VZ8,<  .AG+;Y&=_-"?95.>'#]Y\O5D52:K\CNL
MRG6;<Z9NG^[$R DI K'72!:F%B4%G%'N\][)?>:,ZI.N6.0XN4%'+CCN5N_[
MSZ-G\_/LWD/<)I$@OF? D,W'<N$=4E"!^QU\[]']:\C3NJ%.XS5.K7<?[86L
MP.U^&UR*\Q[Q1;M0-*1:FJ990\>=?2N2)-Z?/29O&5R[XP1<<)#7#A:_[#C'
MODBRAOL#;U1"9NZ\=WL Q3M3%#"C1[6A55U?0^@7.F_I08CR]=HV6IV?P^]A
M\LTF*WICDWIZ?>@3RQ[9R4,!2B#&@@6T5890":*:A?\$<]\G_IK9*''G\.<,
MY<)>H,1.1XR P(T?*UQ Q9MQ2&TAX%5@OS!J"3:Y"9[O&9ODD#H@ITR*.^-U
M'']I0*>%_6FLB,-=@:@E2*B99[](RO^]K3"=/#RB,8T,7!\OE&*4='JLS/C7
MXC6:/,$)-_U;<=./)]ST%\=-3X?NY]-1#-W?M/U=Q"KJD78VXPJ/9#?TD R1
MRB=3F]SXN 2L]9"HY(&3?#^%&-(4WZ7?"!F+V+B(3'UG^LX86BE0O[8']Y@)
ME2BW [*JJ[R+"+DQ% ^Q<(V..M3]M3G-/F+R</=8&(%XRX,W,8 =T6L*>"+_
M:NZC53'T_%Z3P>77B&PO/(*Z3]\Q]92)1T&A3.!2:-.4V:&7D-T+63*&5+K"
M 4?+V@FT7JAEMHV:6A0V,U?/?1D>+ZGL7MKYEGNWHXBM<2KTW;=;&I2.:7^5
MW<^$G9++%:A*[#5:7A=W4;H?)8,M44#;=LS"56B3\T'TKNN=_47A+E&JHP[#
M5A"/K3S?;WP.?@R#(,'S\./(C*%I,XWC4&>1, [HE)8Z+F?DETK^8<B'GR>4
M^:9E]9.CSFW])"))[>"3=_ 9@S;=Z):2:L\:)$/&8(?[CX/YMKRX0'NT]G6/
M;K#C[)<P%>,;A7!?&C,010VB@2Z%^[%]":G3 S8IR2.G@4]X-61*<U(=.9KO
MCDA]Q)M8_Q%6TTNYXW7[\LZ=@O<I>+]1$ 655"*_X4=FMP-W&X>2W/0K5)$2
MO)9K.:B2^'60EF/18"-H++E^Y! IW]9!=%"DK$*%6F/;_9-I/]H]SM[U(QK>
M4B12I#PG%8D4<^UGNH^?22^)<F?'G%4T/.)3FIN&"!+>(L#F@K'TRH9TG)TR
M-W)'E*?XN/*"RCUG<<IB[Y# #9)A#S2^$M''6LA!/I/L;HJ')[/P&\V"0E,U
MM "^(E)X9_5V/6<?,H83HD'F_^1:E 3-7PQ_F:5&?;7UYL!PMM!-6.8.K)]^
MC)>LB+XM6=^C:!9;(3P@5@BR3'T7"!BB*%[@F@EJ178X3-]Y"%#Q>:C::7/=
M?@=D'\O[%YZ+OP#&^!T3"E%7Z\O(*G1[YWP"$=_Q@RY" .S:([RP'GWP&YD.
MS(A3)Z175*?A-E8#XND!TX53B-)/478D5=X84LX %+:MO@8HFX]^2_"[U"33
M94MWI0JU#Q^PGG5$6G:C&:Y9*,?_JJ^-(FB9*@J RJ:F4Y1AIWD<*%?,F6--
M>K?U;!;9C>N[ZG1F.1_F[Z?=>J-SH\4OR'Q<$NZ3RHH^XG 'GHJOBZ0,D92^
M._"*HYROMN0(\Y5$[4$/<4B>?\%YA0-+AU>9$EUK'- ;'K;\0CO=B4B>&+N9
MFYTN"/B!/K2?D47%2*KMW)M9OYIB:/:<4Z.-$.7B*^QJ"1.^21YI0[9_LR"
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MD39T[,4&NBZ[5QZ[XUEH1&F6RZ,JG[L*7]+^D_O2@N//Q3S<U^\;-"[NCN3
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M Q\V()TX+_T,YJT680:#PZ_@?A+E.9+CG50ECE)R"?VA=9W+6R(?')G6(?V
M):(SPU6VD.EXFJ*S&YM4.*!(7K_0I?L3^_$Q-3#+[KWZ^7[V8Y-]]>C)/Q\^
M.'FLE<>^:3X8%GY5XGYT,A/Q\;Q<=[S T70M9:T.0B9KG*UI<_9(E#:Z>Y0%
M!YP5JQR:X/X!O>^]"(3)IB8I+<+/H,\0[ELHSR&7$Y7F.;LL<WP./!Q(7L/!
M%*E!7%69/E_]/!AGMB$]20X2\SX'BD<90)_'"W:.(A;E9:&)F9.^@(_>I#;
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MB9>-K;=$P >S=E$7)5OFEPW7,IM-61O-DF#UWW*BT-_I%/F\77:/_OSV]'[
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MCWS;?>2S?>_P,(K^ ';>.*=4/?!7*]S:V]F>**"':KFH$*Q=WE'&4WHKI;2
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MK$B/CC)?A2.8"4]=J+8_)VB-D";=R^^+!I/^6=+(2#^;!I8EJW-F)WZ5/'@
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M2PCB^&;;9:]^'IYD!%:#87/4*^^-Y)R \MF]O)V7/7EN2IS@+=L132]'@5@
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M\/K-3Z]>O.8?*;H #%=[^;@^%G G,W:AU<[&J"))(:[!!B$B&]S5#=<:?(L
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MX"5L IJ$G=0@TBW(T#A'IL[0.LUP_%'1[Y2$O#U.\AWU]@(@@=**I]L+8#>
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M=&0V):D],.I_.U#%WZE!?O+)/GM2!U!09MD8W;(#U&;2A3@ D7$!B0F6&?I
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MRE1>NIHH1U7^U]X_$H>>\;^B<<^EW.172R&Z#30J_]_>+<)AT+G%MBWQ8/Y
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MOS2E_E77,.2S_"=7Y29Z PT%[-M:,(-!KZOK >ZV&3A_< E*4> N>RD'[]=
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M.UL]((7 16-DLE'T=K<L*GJ+7:]N<9-T35:UV5QC7&[X-PT0&SA?+^[PN(]
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M2-OP1?+<B#+0W+0T7=0;/S95A4][Y/EL!@Z/*,\!QNM "_E\-0J\.+-TUCP
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MR0W W8LV:SN2FB@P9_/RHL"<I'F0'J@7!@1P_%46K'QZPBX$7G ,.Q\8NXO
MVY\*O/U-!-Z^I0Z:2>#MJ/JCZO\25/_/+R^]0O_MXNT%_@6Z"#I7 VHQ!1 7
M8@\8B%[PN]E,2/M@]*/.YL5&83J%,+T-B98&C<(4=@C3-#IC=ZE2WIEYSWVT
M-8A^C8ZWY45CY@X>?]ST/D!9C@)W-B\_"MQ)K)<,%CD:.1!?8:@H)#FR'&,!
MV1%)8Q^C_O-YD5%X3B$\?Z4ER\R?D+P84,J0S.0R#]'D//VGU+!*'!,:M2A
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M),_^EC:JM0WR[ %(.,ON$"L!3B*(1H;RV0O:V3_IF\9*/PD!\+N@.ZP?$KA
M^$2!Y,8!:N4 5]%_Z^*&7.*8E;('<W"@PD,D[NC$84KWCI)K@<JFCCG;-CTB
MTR<N/7K>_.7W[,\1F>%3_(&/:,(-WE(H2DB1]FO&49O5?<?9&BMQ"R7()LN5
M!RNS &VPT&WJH)1M/DJ=O-V(YKLT62Z$AG#_'C#(G4]RD?B0)[6&QU&CWR6#
M@YO"GWS%+O>CARD%%X^?I,E;,H6T^N0?]"QD\YYGU3M^HK?_>)XFVPSIJ5K;
M]W'W%W2"Z=U519:\Y$$8P6Q:)#^[O7HMK"%6%G^I*O*-)76I@'J;30T/1_))
M/YN<H?#H<C4%#O3YELPPCL:+NMDHFE1J7\G/+W]YD0KJWMP@R71!3\#[QV_"
M/=]C_WQ+'CLP_&B\(GID^N(2IOZ%0NGB5A>20C,9?;_=FDTG>%7V1NVJH(]<
MEAVY3\L5YP+5][![,]P0_.;OY,72T^S2P9.^,3A.QF74\$QRM5P/? G/C;>C
MEIPBO0U-KO'QR,0/17Q$'Y6;%? ^*P.-"N>XKE )(Z_4Z<]<,$OP/FD[4L7X
MLV#=;;(RG!,D5Z_ *S"Y70-N!ZD:N(&@+@,!+2V/-B<X>H%5X:?C[*UIC@F3
M>X=)04(*+Y2?LIZS1<A#:?#F+!>@<?SA\<.'WS^@6/EA:!!(G(H[Y$,E-Y6Q
MB>;)%4T69>9= I)T3GDWC'J),U5P=$(:%EZ_GKE26<3H[", <9K8%A207N1X
M"LPN0 TE*>/D?!YB: 79?<YZC.XT(P.W=>Z.Z_,(/Q-H&MR>^X.'^L7K%M8?
M>,:Q@GE>4T2D&D-APA#$Z)2O\-/45[ <_0;_^C^/GR84&I6:I2_K3-)-!WP]
M?DJ-[D0K:.2S.K 7K&$.^XZP9E+^D/0M#")OM:,=(-75^FEEY$#<'7$ELKR&
MU12L84MO*(,.HP.32QUL3MJFIM"+7TK>9%M%G1$[[%48<EFL=@\L%-<J*(;+
M"RS5?X_3$^_G1BT;,E9S+3GQ&G7CN:[5,-!R52?+/@/(FM&,R*>^;4[&V=?J
M[817ZJ+LA\Z$#<FO MNE=H)]:-Z?&=E/WJY#CAB;:'F$G5HK26.%/):+C QI
M7=T=Q7PSP6V<IW+S5$_C/-7GG*>*?L2GAKG6$&^!IWE5H&^F%W4H/6;B92 ^
M:.&8;E&5*9F,RM.\&9D\\ K9$N2T].NY"7/2Y*'D<+JE/+#6X#K)UNR#4YQL
M?I<*IS7,'$1KZI@>_T@N1=7]5$K%(Z?3JV.H4,[BPB$OU,@/4N,:E/?*9''
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M04:;G2*D)YI^TZ5>6BP?M)D<*QJ<>=3JR8$M)*_&4N$J/9-IL7",7@B9LF8
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M.@O%F]3Y_$&VI3TZ(0^P?<&>:C@3O*3[Y97&0/[Z&_K<"+Z!8-!T'@>+3&C
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M536158\P-3?77&&-#[WD#9#0U$Z5NQ"PX'H!ZL$7-PU9P]C;96NV,#FA?C_
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M8.R;+6BY2 KHOWQWM$\"*F9RQVSSM&MI7&@_X9'-8Q@#?W%&]#3\);<_C'K
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M7[DYB-UW;D,M*OOOB2XCB_6OC:@\4B;XLA-M<H5@?(3T[GZ^:&VR:CA*-AN
M!^++LS^T$AD"-WU7S ^MBDNC0]KY."=R1\3CMMG83R,.?MQN+!.6 D_'IKB_
M618UM2+MA-X_X8S$7,J,I-@RQC HL]T'16UJX;!L/,:>)96! :<?C5JS*NA^
M&%S(3EI:$6P%B,>\QR"+\;@0MHF3QT'; QL_.2?V412<]A,#19"L,1#+V#<'
MF1/"UA-M2I6>E(/-KM)KR 4LD@8*[+CI=+ OTNU_!7 F:> 8+HN=@0S8U%=U
M>34:IQ&O JC4/*3,X*DZB8EAY[QEE%/#AQ3M*=+)NV3X*)[%Y6%5+&]J,"<,
M-NUP*Z_Z.A1NZ"#:^YBVD7)S]/394LAH=*EN-#=TA$MU0I]C$G<-41AN8]UW
M;:'(MJ.'G,1=P6&8C0;#Z-2L9SUY4^S$S@S.$89W\7K&GVVS4C>5I#I<"B^0
M8<CF%/HJ8,F&(GZO 620G7W.%>E>WY(^U#$Z<V'AFH*N]/O9P1H#KH_'R>,<
MZU"1^@RLDR"GF]B,J*3;KOJ!M%PD;PY*X[3 J68<3OPI$,IH9B'4\I,8D2$#
M#4NHQF0\ANZI"?"@3N^.M(,W\]8*3,+GZQ1!.)(T85<&3S!N,0_C41D22#WF
M=&'L35I]^+X-PE*QS]Q)R=V7O(4%AL;L$,1PGI7W?VX:]@X"2W.X W'4'SD>
MTF1$.P$(<&,'O, _L1Z429F@BW%B$U->8 <%9D]@,/9!JT9!0$/9( @FV\0A
M+W>-]J6]>0"]<7B4UUX>(-Q!H!OCQ]L(0'YQ7&[TGMQTH?7AQ*Z]_>E%,$4<
M9("XG[5PXS2K@J''Z%/%X#"L.$W'>1P^VN^,P F1"[DJ-N& ,OVFKBI3IDYD
M*L&C\#D3($3RI"0WZLX,#_A(RD5:[P8YEUS UI!)*G>6(\?R4VP+I(J<;#(Y
MAWTBH;D5!'_<0C2](SO!9OGLOA\(<SE^>[[=%X2J!?!X\FG9,NM]E]S1G&DV
MR7XIAK5W16H_!^V4)P6R$18K6C>3:P.>@<A8KU;3AO#$,X0IA5%^(3IS=3,(
M$@(!G_7YTMC(6+1#"5F#OWU<OITHR](X$! G.=M9,*>>'CI9&$N5 Z"!'G8L
M)/F0/S'3EN6[0NQ%*P1MA#Y]QWNJD#O:9,_.R:+L@5^FH0HL'MUY9[*F%4!)
ML?,CW)_@^>U#ZYY_6!$Z93 L^ 72[_=9- Z'"[@/%D,KP]0&$Q7Y\4-,4%ZI
M@]:&$8* 6:$D. ^AO&4%C*7%8]?(7--.%&*I Y:ITL38XDM5*2^+MNDWFIWH
M!I.W<KS=F6:$,X2G;5EO!9(-A1G/) .' 4I'(#F%(U8D4YS#/[FH0!20_^:$
M" TYQR:++<X\#O-/#%8MG#<45/!<$TD%2[OX,;]=O+T(;[D"(/6J!^C]MG)?
M4&4"+UY=\?$$#Z_2SE>-\:!)1Z2B?%8"F+CHFY+'=H%MRX+*CM5!76+H:>J=
MT36T=&C]-[TF$/JT>=V0:W]5-!1WT'',S;J8\V-)!FRO:H05WBN)C_.P'S$/
M^S3.P][24;U!5I9HH'13 ^^)W*^C-H-3))P 9G3%//P,%#SK]WH^[]G1[33V
M&I;V-?SJ#GK:&D,&#K<MB C7NK,1'H^K'09[6G&Q/&-^--=57D;6K6]@'%*;
M,9YX*AMZ!\%CX)AG7(\5-Y$[(L(<D"U)^9V=9QO$=0/,!WI&>@^E^R.2.I+A
M8E0@,W)T1ZXT<E624"+31%_3N#I@AZRT[F!Q.8!M(=MA'8U2 ^X!\ KS'&35
MQ[V-F$JZU:#_SR8KN]4<Z%P.B(43Q R Y>C_@MKC-25AFEF64YA3Q+(Q:7)'
MSN?M4XM.U D[AB[PW# #92:Q2Y94_7IFF-,E/,D%7:G@'UL+C 8%NO+GG@L!
MH["$/O&*P_K'#Q\]E$#D-5T$6OQU4W?&$\Y<+DA2<L[$O\#5+@&! &=^+8C8
MRL@@<B8?P==^RGM%]WUC:$WH$99_7@J&).Z;?*7<P)QKE%5(7_'\V>4+Q0+.
MGWV=,N+0!GANN35> 6>/XQR76&<+4?9/7[0JJ+)61I+T-DOA)#=-<24E]9:[
MFS7W,V&+]28<M6U0#*"#U$L<1,+0MUVSDRB('F *-B&UJ1(L9XHDJ [*$6JI
MA.IGEU"D:YH'>)WX:EO06>0P4E&E$-=RR+LVW:K.<>T=OB8;UI@9%S+JK6S$
M$&*OMTGRY!6#C1<Y\_S0R\.W<"8 ],P@A[1<8&=W6HV6^!K;91]'<<]X\ZM5
M5N*E%14&//B'MBM*^1T=1<'F9M JV90T@*_B)@DZW^M^[9=U,\\!-+'WBNDN
M]2K^NP):,T,2J?2K(N]1LS-5@X/*^3IW7;IQAC/'IZQNEN0U_*_MI#<M$EE%
MN^)< ^,4+FSPW&7O)2<W7#F 236TGS49+VS3,,_V1MIZ]O=93NF<6R[LNY?E
M-1#GIDM>)@S2@JSD,ML(:$OO@;M9#\CQ&"Y&&E:8LP9M0NCS2+Y[^._)5_[E
ML,_TE'ZW(0>VSRJ7^WM>,+YZ2VKZN61JO<A_GZHUY1I?J[_]X>N$*;D>U(L'
MW-Q@UXD/P,M>UE!QO"-<91&H.EL@Y.V:/H>U9YH22# RUUR,SBUT)JI"@SV2
M[A91<8%AM_6G<)\\6'G==QM5GWL4,#;YQ'<!8A\?T=%[BBG/+]4AT'AJ8-.E
M;.&B!:TP!,J-C(O%+=_4%$?,8--A\CBG5S#RD05CVG(N']XN6I<X0V@OB!1H
MM0N:X;OLG1&MLJJ9T6"[,KRZ0NCY@BB(CO<!^_?_L_>N36X;2=;P7V$\S[L;
M=@34:\MS74<\$1K9'FO6'BLL>?T9),%N6"3 P:5;G%__5IZ\5!8N[&Y;LEH2
M(C9VK"8)% I567DY>0YOG9NK>@] 8%)P%"P8QXZ@:V3P/1\9?EQ;Y:44LX+S
M-!IV<3/,&HM%<SE0O5AP$.H;V>S&(>VB5D+'ETT8P_X430W3,[*Y$3,KEVN[
MXH#BJPL:G;LQ""SH* C/QUZ*,'9?Y@URL.Y7'!-;2,'T4W6Z+DBLH7+'$G-@
MM]F=XWAZ?KXGGUGVOA2@]V*Q0A^K%4H2)/7((.GBCQ$*I6#J5G V^;8&HC)L
M\DUA!HJ<]J*"SWRQ^B$*PV1TYG_.FUD\A*<ULU9'3^%S_)P\<+A=Q(>;WXCS
M/^U7<]RM154!,\%\F,60,F\K.222*67/Z_%_T+D?ME^[D>J,57RXJ8@\"=M(
M+(#S.9[C"YJ +/@3\)0H*@%;79?:<XJ5[,Y@M459F50HG 1%^+]"#2R3JC[^
M[(LP77VU)]OI<+)AOBY!)(M_B3QHL/EDORM,]C^"GT+I,Y[M+WBVGQS"(J ,
MU<O\=9B+\,0_DCC,SLW[XU\Q[PRXFIQEK5_9;/M:\U7=(GUG2.0-7=:4E;C&
MH2K0250@TX=8V-$DL^]FOEIJY$G0@(IQ]/^F%X*P[(G7NZ,WAT(=R,KSBA_;
M0FBZP^//'G].+Z.M]\");1F '=:'C(@F=C"9M(*^*C8%@OG'?Z;W\_@S3$O=
M'&MFST5LTM( W"&!@;:&W$X7E>GAACNDZ&H/P)/(#-"W0? Q]I]]6'K.>?V;
MTBL[F'ITC7/QK<FQ;_E$!0_CDQ?/P:[\[;<O/'K <Q!>E[F0,X5E!_B&T#+=
M*6>ZF/][.Z&N7'T<E:LM2=7R"7"%D1554MD@MV33!(>0&D;T6H)PLUAS[#JF
MJ[$E3"9'>K*52V7@+XRNV\H8-"!O^W702-&DAK*L0+59&.]W/,+DH)H0&?$.
M&(M;H5-TVABN$59"'+$+86E+"E\$_&$[ U I/9DHK#!.".D'Z4TEZ*&*.LL7
M1_(3*PTUH\_+ 0,\3V?T-)N1-A?$[% I$RR^KE)DO^1MO'85)VFBD^)3"S@7
M.D^KL,S)^ ,+!0C"0>AN].6HPQ#37F0&@Q.\)Z]BOR^"8V%A@4Q^\&B#.6E/
MY&MG"F(H'?.\E98JEXT;9DMDR1SW^:9P 1$>D'QN*@F4KZA\I@$Z)URW#KY$
M]QX,EE!:;;WAA 1<>DID86XERF@U#&@%BW'BQ!FW=(7[%14;<G*,AFG9?_3A
M"W2N9*OGX8D@U+WZ&_T/EZ,HT=/>L"I/^&&QZ>%B<&V,*>RI<8A('%SV4";8
M' #*R=:'$Y\'?%@H[2YO1T8]'SDCA><29%>Z<1$J)C%%"'MRT7ZGZ,+0Z#D2
M:&$H9/!Q'.^A+I]CG$UQ)0<>Y00%4;XFO?1@9"9>+9L'7JOV!XB6[%& V[.O
ML#[A=N'I7U#/#Q^Y=&;[EFUYLN%<'H(O17U&1=Y$Z3Q^$4]<7U1=J6Q>>-!+
M-C;D\FVTT4&U')LR\OYK8.F.:8U297IB),HR#2T<M.'!2S/[%1_=++:*X->W
M!ZCG+GXF-[<7)8S64)V MP'GV6GJU'A"+R(<*W1@M/V!>[:2SK#\37>\+O'C
M^^5 ?$\+E*&LC"?U,J!C2^9=8@;'\3GXK-KMM6JD[2@6F]"%Q+-_]B/)NT^<
MO_(AG((#-<,$L^H=9VQDH>I69$5,*B<'8:QBH&847'PWX!CLN(J"1&UUWTUU
M-[T@LA3I'PH/\T6&;(T[UM& BB%,"HB;#QYV9F('VF (PB^^XJS]D=)T6L^0
MT4YDO<K=M+O.[8(:;;6J?DK]G.RIY!QVE?JFR :7K56%)!"%A!)5$),YA:QH
M\N^\+5M#*0:'JF<0MBO)H,YSYCG:F+W;%L36 1PW#_:ZWO>'PDVLWI>//:HI
MEAPNSLUI6&46==/";MU+5- X><?T1O^4K9Y^_X(M;9I(_*#,XH)NO >Z\4\+
MNG%!-[XWRU5.0JY8BW@XB9L31L/!3\B/#<<JTQ]IH9GS1Q0/T?D'\J-R(R>9
M0!5\1'(1;25@X9.5E[D!B/?+MS23#&VR@4W^BZ P$^M/_2JXI+BY82#<+<!#
M8.U1?"TR0VD @,:\OC!V)RF$P^_&3?!(VX+/3PY0-'.\N\V_&6+,[&3T>!97
MM>%![%G$FQZZ6R4A+N>5J1JW1[-_/& I:D=H!X%)JDC-5\A<+H^2FSFA':D?
M^A7BK30>=-E;M!\C$Y)'"!&_(Z0OEFCAH[4S3SK+XA?<NY=9( HX)M)&XH22
ML3EI5)J(Z57;F'HIK&(./]\EZDP2=2)U,>%E6WHNQN;L$\>5.TBH450< N$2
MTCH&7<E&=)L*[]$["1":TWLF0$>!%%UD7T.R#Q; 9Q)C91F%IS)E_/#/';X>
MC GEWDF7J.$B28IU5FX&S$6_?T5@GLT5YGR0F7H:%F#8O%5I]81V.*%I$I=R
M&#511L;GYFL/BT"</5+D';/(N'8H_IC2.F@)H\1.M_K39ZLM22,*40J #9NK
M8%(9I,7&U\3X"(D 7%&^"2-O.2.&B?[DYR=//\TDXBACX[]$1W:EXO6F*+;M
MZO,__4<FC:>,VKCS7(239)\C \Z BEPR,\"^'="&)OR%"=L/X^!+IK9@9$-E
MPPHQ)1^L%)G\;]&$>+B[^XADD146\IGR=KI8AQ@T2<A:X8Q?LS!_^/IF0=.H
MS!)<BM*&/!4&"]./JN=KEUT>0=@$0-%)[$@%NC:\TBU@_;&2ABJ:98-?]$<J
M>:V>(I4,%^.JV&^A,U8>6*Z,NUSEO*,4A%%GA=\6AZ.S4I'O-N&3@,$9)455
M?9(1@K3<PTM^_K?O9>IX\QTP;'MH#P:AVD1Z1;!> PA45AF6 .]H\']LD-N0
M=,7QR+4:I/*(ST!RM[I@86VP9V*NLJ#S.1S6P1?BA^556$+4.F<?YAN9II<-
M1?9/22V9U=V),ZS</H+[@FG>Y\&Y(."C9:D33LXV)E&BP+1,0IBCZ-\P(@C8
M%GH.2:5J!?Q,G0897(^?XD(/!'E!&4)CPEZBE#W5$^WE>C9D>04$"NINZN85
MO\8(^L^;AC:PR%F_<#E7G4]F6:)-/GJXO$7+3ZP(4/EV1L-^ +RB03>C->=7
MB+F-YD=2+P)>?TL( =H\ RL\+LDI?4583%0E6?7A(;^C2@A35FPC'E,/6!QR
MZH"SJ]DR/+QLMH\(%$K'^*ENVHAN2LY(!3(UAT&GQ61+Q70#AA3V( 0^;/P)
M2X(7C]]LCFB(<0:&KW+PA&;@C?0M3]IV.U!6!]5JB.:#YU,P\FXPK0EMB$+9
M"<OJA<ZM(,/K 0?3L (2+4D*$4!%4)-RPAM$  TL",J('A!DH?/IC" U*R!+
M?S0K+_:PBZPD+('*R&F:H1&9Z)/^#6]U<<??2D_*USVUU84G">:'MHM&[58-
MS:1L&.+Z 4+5$4,D]FK0^A=>8;AS" 1/9TB(DTVK_GM9];S3XOJS9 5376GG
MB]2XU4GVIT(R2HGGTX>F=?[U3W(V^_A$N#*F"+C<H9107='6HAZ5#>%>8MU!
M74K7HBAN_[*PWP)5W88P"C!<Q"["Q28J^I=7-:'\*P2<$#\ER!5R(R[ZB"%E
M?(-Y0PQ-"*.D!=8'I8 N)[517%M+R[D0-0Z SV<=&U]?'_8M&J.K(# 3?'6V
M2K 8XDL17LZ56]K4#8ZWC=,@MZ'*$AT8?CR3+%CI,1!W#6X-67K!A+$5\;$T
M_X4!A=-G%+EAA"](SJ:$0E2  &(JE@;;M]L@*G20D24TBP4Y]'7IOX#VFUO=
M6$R[)N\%4+PF.2"&,NZ"!Q;V<8B>#ZW\R:%.?-B*+K[-2=9B<*[IV*%?*%LA
MW20$@,)^S)R%6#_(-Y&=(%K D_ SHMF0XE3$"GSGFT)6]8Y 1:X)<0*<N+3Z
M/O"=\O:5T\-R$4(#L/$H">E.&F_FZ2:1D O'2I4X2I&@RY-S3O033Q!]I32^
M1+96]^W$?IS>A!8I9E;BB<#K+"D</ G[X='_E)M7],HP(@#=_5>^P99^REN:
M&XJ1\SBUU*!'@"I"0E9\<^]K,IO#2T#L\%F$<DSC,65Z&><)"+(CVN;;%M:I
M'*.G)&R\&5HXN+*&P62;XSP%[3*>02QH<!Y3+48\*QS6 \:-EU?RL-$%F?2N
M^85;]+@(M"]:48M6U(.=<^;/O,5HLF4(=NFJ7)?D^D[9.&:UE/85JO]RC@H)
MIN"WLTO3 J#="?"<2);QGVCMEG[#X-^SSL^AK^3H..O+43)3FCD IPTA!_JD
MA7=>JCV<B\4I1DE#566J5K3QH.C(48,% G#/N,\DM_D9Y[A2LKOS3:&+ .2#
M6?:+J7DG_3W:6(%N*F:-$*W[47C%'UO;54==A!S<G#0(2JS2M%'R]!F4 9%*
MR]!(493.C1.P(YN<,^N"1.</*0Z3\7F(#ZZD^SZS39_%XL)$X<$PO?S85- A
M?[??TSS=2Z-O@4'> P;YYP4&^7O"()=C;3G6/H9CS7O00D#VS!K0GA- 0J)C
M$)EM@'?2/PGL\O.__O5/JT^^??;\R9-/+6\MC$J$5K&61#TOI?5<CA(]!#7%
M#Y0+09$.!=>"-9V2<)(I0,0WCPB>DL\EY 8X]<ZMH7PFNDL<\HZ:XQ?/]L$L
MQ\4$O L3@)U[AI#PF:L/O"PV5Q73XM&.>ZH2<O)52T26E%?U/;TN^VA"!I!4
M;QF<MBL!/W7%7[]KI<>,TH29U26RB.Q4)!6ZJM1K)L)!6DKAV@B(Q^6.9>L_
MF&6X;/UW??K'VH%1NU@1(=F80PXU;HB>9D,A.+44M ><BP<$FWN%;K6,!@4)
MBC7/R,[G_O-HA& 9&*!M0XU8+AB$G0R"5;CIB_IT;3:)^5)J'9B4(M]<)>PZ
M@CJ]J9RT%4,R!7$<'(F"T(< R ;S&6\WBS(3QIQ(S5 >:$Y00,*+-7RKB  I
M62.ML:.#F:?,F5_BZXM=>R![;+%K[\*NO6#867ZS(NL4C ##R78KVMD*E<[7
MI*KEP.N.^9 0"8]>:3$!&)I1DB_6$H$;IG0^+7B7D&\C-(<5NJH)*.^T1->
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MIQ6N8YF;,]TM?!5.K6^+=? ."I63=D>:\HX1A!D1R(NOG[(QHIOS54#7$2[
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M;.@EM3$61A0G ?.4YGR4-(RA,)T2PO8/F.F19!0VC,"F2HEOK.07-C.)53
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M>U\"^QD1  L3GH1]]KVCA*5^V3%@["OIG/VA B1M7R)=#UNB0O+/J4EOVR/
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MU\3&RZWI-\$0=D0B .K3HQ#<A--3GHCZ"U&LP84'SU!-S#&F)4I'N8<1.B"
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MYPU2$NB-E;_6#2$,1A*(@R3I3/\R0ZC&6=,G%*GL\NNZX0R4&->1VH1M/5"
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MZ P9$54M+/(NBD'.I=-IH@F N#7R.K*,.ZD#Z%2J.&&<6XQ@710DN]N4<#)
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M8&@8]0.7$ZL72B,-E!&S^]V,9,AIRB&T:_LOK%RPB^&63%04_N-B]80ZISG
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M8$:EG^KF KO!Q X'P<]XL& G&-G[^G:\!K27+/='\A<FG&!J'08K^4U7 DS
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MNCH><%O#2'LN 7^[DL55(J][IOMTA8(]O6Z)7I_+_]EA96KCR+IEEN:7212
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M_Z$3-N4M884?6;_E"H@,A 9!< $KB2)-9$%<HK#Q>ORH$G.YPE8TESH9G84
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M,$X N\7-4ME,C#DL-JM.5_MH2>H85BL5.,(4WP2?,RSX 0T<P2',7D'REN*
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M_:)8 DH.5>(<G\PT8KV"7] 7=2&94+/ZVUI7_T5B(=QN^9CNP F^WF&R.ZR
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MZV&Z#Z3%';[+YXWT/^8E9/D-[+!CM_  BGI"XOGVF<EF7835,N2Y;I$R1G:
M,8["T=G04^3:5>X$"WPDG? 1KN!!2F&/;Z9/I."%DQ=.SR6<3H^//$5V0#AM
MT3!^#E]B=SGE<Y.8KCC(+FVIU*L>^8CWT$A^MDAI]R5<EZ[)7XV_&F]C>=[F
M"<A?3>]4]*;MY,)8K[0][<XM[1LY\/:*_/VKB%M+T;=B/N\A"G2$JKVGH_\
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M1WNFR6S5I]FQ6]@)@/MTOZ=G<B].3L.C!ZL>NTQ2W6X-T_/6F][0WBM:V@F
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M(NO#X]/!T!#V(#![F2894F!,G\^!60C\O$+JBV$-AR[+&4#[<D8L1@%EXZH
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M@82(-@BPL4AB__H7D0F H$3MH 2 T=/3MDD02,3-6/)F1"1.XA[#>27]'+Z
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M;6H;C&X^\C9W5$>-'U<<57.]Y$/W'L9-4,.;Y%]'JE:?FK==/RI/2MM^25P
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M)MS*;_#3XG?R,'-UEG@,#P@S0<<0-U[K(19[C-8;C]5Z?75F>N]1&F[>;2Q
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MW"S-&_.K-E;EZ4"K0X%4(A+.!+X0&=BCXKBRY-H)(#C55\4#/5QAJ^@=#P.
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M 8F((N$W1_BTL"8X" Z"@^#H#!S$ G:1!:3C0&ZP@#MP&L@M+. G/^2AX_.
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M"&"W(X"Q/;0&W+$U[KACS1Z-=&TR] ;:U!WH8\-VA.!F+15#6XL FMG=C"*
MQF325*5)IPXWU3RI4X>?11'1?EU3 \0M'NAN]DVTK6Z4X4%-C0X1GZ"5+ZB
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MD,!T)$XHR1BS/ER="WN;+-''"UIG(K"?JY;:3I5S31XD0@6VCV?MXQ0T #1
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M1ENW=L9*%W<]@.V+>[E>>IVYWIIK )*&#$EM&1P\O'\?C,'<V,QA,X=X HF
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MN2V/09/LWP=C,#=2' -+<2">AAQ/;1D<)+)_'XS!W" 1D CB"20"$L&B!XF
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M%E=(%%8SQ;1*WO>B%C;+^,_#Y;RNG_7SWT]FFP_?GFNZ230PB 6(!8B%=KT
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MK:.FHG":^TA,[9KDOZ6Y T=GAS81"C5"#SI_]7-.)V>8M)A$OUI]V+9;..J
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M<>"_Z,.S/Q[:D;_=_X8\K!Z=V&:<H!Q[J[4-$KJ&9=QBH8=%M8)15E6PNL*
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MB^#E*OA12WTM0&3'T2R@(:7;,E(YQ?6AD[O_M<]^]S?,K4D>1X:)J& D,KP
M\[K@)%=&$AD+(902)@]W6D2'8(#+5"@2JI 1QD1.\BA/B=$9#<,P,C+?4TZB
MN<+_QS:0-WR.!PZ,\;=7H*O^U/7UZ\6-_E2[QW3C\CGYZ.5SEET<3A0\<28'
M=#.?6PHN JRJ/K/_!GK86<MO#>XM6<'F!B#\_M+VNA>&ENO:,MQ%\.<6MK@J
M&P Z"-. ;09<N=!8^P-D@ROA/J_>-PYK#OQO7XA#<%LB8'T- !*_JK0I96G!
MAF?#C[&A%IFFS%!2)+$A3(N"\ Q+N^C"R"P)"\V+8[#A'W ,0):JGWB] (#<
MO!R(]:.CU>>S'V)S^.GC%5Z2[.)P(XYS842^1RU=@#5J-1,7C49@#SRPK)KR
M$YRTJ<U*9,K+*V!'I<&^41:X+RQP=XK3&I.6I^%%"N 4C(%:'72GU%9E@Y&E
MT!1JU:LSS R,)U9H *'4@%'ZQ@PP 6OX B4NK^PW] <8OM?GPSN (G.PJ%J+
MD%_6NKW"#W[E"S"YK)4AP+X"HZ,U#+>-F69M\,SA@W9'8"TX7;N^D7#I9@,C
M8"U9&.>]GL,N7@,EKMH=Q*'+KFX)@IS6B@,$L3?.('AM-J8#]L^B6NW9RG;_
MP/Q?@1R]A14!QFF[E<)\;:G;%?\+7K.NK=>A&KEY<)NN^.)2P[:Z,BI("OCJ
M6KH?#AAG#1+;&K @XG%\%/6MYR%PG@?\"ASZ_M-^+, ^ES6_=C*YO&Y[<EA#
M?UB5G4*[NY7SD53U7W XI+X('(H\$R8]EAT7>4-N_P;_439_N</V;M&>5807
MQS#KOCUTY4SLNI<660%_SV];QV/K9MQ1%\U:_%O+%7(U#T 9HTH"25A;(J$+
M"DVZ*JBLJ)J7!A A"F#9C5ANB*H9V%XK#.&"1Z_+E15YLZ#F9;,E3Z2K%C?;
MD&+BUDH6ZYM;E>A#LXY#6/I*RZM%99UIZ$ #T7O3J3^<J=5;O)RC*"X7&V+.
M>F\'20BSQ DWW.B5\Z-J5"E<WAYV< 5C8;JJ03&T6K=[=:V=YQ:V"DZ2KG&!
M8 ];*[59H[BVYO0*X<P@=\=ROPF>OOKC3?.L<S:[1X'<:S1^ 8!;W^3F\[_"
M\^T\]"5"LJJ^=:;L#;Z_KD"APT0=ED>4K9?6^=DJNEV+OUTY;#H^Y4;2:A;,
MX?SCE]Q(EI!H+@#(ZTR VUF/-W#\1?"7OD6O;E,M%GK>JIX*B-C!@K&/N:?M
M[8:%,<QK[%L=E!60VE867*P [2"/#?Y2H"^,@'AUY#/O0(%EBHUCA]-[#\BL
MT],6J)9X*O"/8QUX0/NV+M2QRL9SL&@0NAT\C'"R^LW<0\$9?+-$:%5M>(('
M3\GB=I\S%K<0,$SGU=V[I&M7DFT+GG4<R15\!P%13T!<F*D!2-5K/(S:>6^&
M)2+#SDL\6Z362W@O+@O&ZWTU=E9(,!!*@(<6%?IYUK4]C=M ;Z#[P?VVQ()Q
M@+?PC)OUW+G+ ;JL\,#:(8=E#"?/;-[1#*_"Y.3Y')Y:.]:!I8-XZ-Y3"6<$
M=2,/.]]T\]+M$7*/@LS"B>'IWL>;=A;M0!V;#2-V;QVH#JN[*=$:OPA^NM$
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M,.,T\T3N(?**)4KDK"")"6/"-*,D%Q$EBB=2A,!369(<)7M67FFUGNLWYE,
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MZQKO T]?*,7]P=[V;)_%%;-C7AM.Y9OE/6KM^_.Z7I2K=:VM^C7 R.-"(U-
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MV<UW=17G6+D$?9=2=TD_-C34]I%H0Y5MF0ST=G8I]#;PJ*O_>LBVL:MHNRT
MZ,("/#!3'KA(3^LFQF1\&^'D+@)@-F5SA:,,W9RO@!VU:Z?7[7'G7KH(?J]P
MO7C*7#\/NUVWAR:$+VG#3.$0WW97#YUUM[6]0&%3CLL MWUG^Y:TRWIM"ROA
MYT;#F;:!M/ ZO.%8N.X >' O2^W+7#].*?MNT350L>>B:DKGZAQRVS8_'SI5
MX)]KY-_!LA\QR):,&;LNUMTK5[?6_3KV9.SZ!C[=ZE>X3IJW+BID];YR?32!
M.VSGX9V*\Z-NBRCJVP)HV_6J+P"HU4T;=S/>@SY.?N#4G5?LBM%>8C;P[;;S
MR]+ZH6VB&D;Z\+XG@KCMWFK7M%Y=577I^O&TV8D;$QK"1?>+Q&KCO7M65%KA
MWQ6TV[>@8<\.[=?'?#GMK=9&E\M^')MZX,H>;08/N?A4D*VPW>-FO%<V=7*?
MN+HCY[7*"IIK10F/64*82 J2FU@0(ZB*96)4)L51G=<_#6?AE_XDO3'O%H;?
M5#:-XJU>K>9V<T]?!%V"ZEW9*WE81A+^[;SCM\:RH4\5ZL"'DPD8GFPS/YJ>
MRHZ##D.Z(5G-@BR+01V M=&"7<2S@]!.;MN([O5BQ',C<=BE5[>)W%V2TT9+
M)"S'!S*MKWGF+NZQ G]_8VSC+P FV]#T25Q$ 4MF":/ B&&4$:;2G.1YEA$)
M.\8+IG6:T6/P\D]MPLSONK9!;/X^ZE[OHWZ#4_@+WLW"_@>6 /Y6ZG@R[ <P
M):3E='O_O<0F2;C'+MGO>KG>C.#9B;$9&D;9KS4N]7X4W80%#U;8EA #5US9
MT"'K#(S_<K[N9,UGS:!9]_$_1YZ,%7$E6',XI;[:P$=>LNP-POVO&V<1K1<8
MC60K:(*A5EH;;_/9\=S:V2Z'6(6==Y5-L[:FXQ $AT%*DY#,*DDH,[(@C,64
ML"A.25'D$0D%A3^$"2MT=)288FWS3__HG#Y.,GOY?*_RN25"\'IA<TM\X/!Q
M!?0;%[.$0L%M=.<A-=;RY$Y(5HLNQ@ES0A"S ;3#''6!%;[;)+ZN0@T6R*GU
M:FS@E0/Q;.>XWEV'Z%0/3K36G,44Z3Z<"F6IE@[,7O._M$LP[#XB;4ZY#32=
M.2^H+*V4N\+BF%6?.(BBL5K7L@UQ+L=5V4<)BION"#<'YUZ]"SOR!$],*Y)_
MKMO,<B>39187AF82Y&N!:+G0I.!%0DQ>J()%>:9E=@R9_)M5CV],?VY;^= \
M 4U5NI'?_4_[X1-[&& SFG\\>?W;ST\"=PK_\:0$-FZT? [*]GU5JT8OGGP/
M9[S3:-W:SL:2K+:Y_+DK8V4]S-LUZ1'?W"Z #U>@<44)Z[FT; F3UH!<Y!#9
MLT)[O/M.#7(#&1 -RK):-Z/2$? NS9NMZX11N+IE=_U!2PN,,-*YE,CGO/FD
M*' 5S-W+AHI- ZMW5::&T,SM>AZ89NW*,<GV(WNG<Q&\G&\7_QA%3_]G7;:]
MH>>XM*L*HZZOT>QN?8W#ZDWYP4I2=Q^#K6VO;INV%7:7TSRJ._(.CC%\8J]\
MVXQOO*48]0"V\=&V+[=K^-N)[(7-^EXY#YN-M5;8'[AN^A:A[VVAC06 O6D$
M>X9%*$(=AR0&7B>,IPD1,E4DY6$6Z510+<-OD1K-K?CPO LX?XNHUZ.W>T5O
M?;"_W7P/W(X8[]GM[&9*DI,%[2T*WH-8UUW?,@9K-K6M-JPL: $7VGYU^^>^
M&73;1:'/(AIW)UUMO'T2LH1E.LL+"@8ASQ5A210205/ (D8G&8@&D";I-\N2
M/S1&',UO7RJPGK5ZV7?,_KVN%A7>5UD1[:7,O4J9CBK!ZZ99M[?;+86"@43!
M)HVF%3WU^8L]RJVVEZ)MO+ MT%FZ$F:N,]$"1N##H5EN')K >0[M*6MEYQ"E
M-SIJ;]'59O-A?Z@P&>?ISR_?_O!L:.4^>D'3/FKO</ #4:E2M['P&ZF7>*)M
ML8E61#=+ ,,V \A=XR!VMEU= $-B#851W05$^VM[86N[NL]L/3G+,NUBMI;9
M7^G@)7Y['XU7YP!;;61(M3$S5;KJ:7B_;ZWSKNK=.&+)_7%4HA3@,M9DJ%Q>
M51=$@.5V7?#*I^_S*VM:R'EE\YT_0POM_?3_"8+[4$]Y+(H0%(R2A21,1!$1
MS!2$%89E)DD*E1[E.NEG7M;_P@SG'X>=.:R(1NO>446PM<LYOWUNYOK#'C6$
MQ=Q*<]LQDWT,)!B8)"^LB"!8>ZIYCC%;MA[0/H$RL"7*K.QO)ZNK]LN7C2WM
M][-<X'X0NZT??>^V2/[(CN]LY)/OG\9]@/"(RIN3./']!?F-"?W_ZA+Z!U'\
M&FLGKC=+XCH)8/_U:O/;D\TP@ MC,E&?]-)[[.AUSN&][I/6&=)KF3:!6V&.
M][A& _IF0%.M:WN7YF)MG?[[$?27O2B+HUE 0THMZ(,?HM:[JTK9-; ;C7A5
MZAK[K?5U#0;?\TK+JT7YGW4;&='IMK;=XE:DDZVA.8QK757*5KH2MHPK&EP8
MU!_0$W,A?CX.G05OU]=PW.U6OAT56QTC;K2#1O4F3V03/EE1R4>^/C9IMR/"
M2GOC;IW?>#ULX*17HT+@*#J<X[<-OFI0C+D8?"OV5&41LDO;PU*]JI5WBL-T
M>Q]T8R4@1F7-VEA]5Q9FZ-C6#*9(;RD@4M>=_WFX;=N0SLT&H&^#U-M06#V4
MC!9Z(:^ SG^Y>AW-;/@$YP&\CV%JH^7A;F+M('<E9TL!VR:;?%67'_KY8W_B
M&F\,]>C^;[LOL:U],YK3>_1>K]NPT[;G[5;-$6=3C*XTW&MN7;==L'EX75;N
M(J+1[@68+_*7+5Y2;;5UJ/4<)K=8G23;^[QBGU>\)Z^8[>05^ZQBGU4\T21)
M?^1\5K'/*K[?K&(/^]O=E;56Y89+8X:!8FUK+P3 >@4(L@WXZ&'O0K]O.V'
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M1Q,>37@TX=&$1Q/?XIAB%"NA%J2@$2"#*.&$J\Q@FW6:1T;%B=Q!$SRFJ:0
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M(-H<)>_?11U\]_TE+Q=3J.[OY:^7OU[^3H#%O/R]5_D[AP\GT5[%"V O@+T
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M@ZU5R.-,( K*#6%A:DB1%)(H4X0RXUDLBN0AX=/Q0XZBU/MM'JM6^):H(X_
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M[Y]1OJ+&FD=[4Q&_^]&>5@E/I2D(#4V,P;DA*7+XU>@TU8DQ6<%W+I72B,8
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MI<5<EN]URU=@:XQ@#CCO": 8:Z"$"L 32RD6D%.].??=$J(H\\#@$)=\=.M
M(1: # )"K)##:B,/\P#+=_NQ@T-9OO6XPA#C;AG'']"@FOCVU,>7/?.C\^%5
MKYOE^ZPQH*L(3F1!?XW_NROK7"[V^;?,U[J*+-IQAT! CL=U&PC0DFK E*70
M2^4(WQC.=Q>H?FUM7&_3]K,^3Z0N_G,R\^[OM3;UJ)[6OHTQPJ?IL9^L_.IM
MW=I1T\XF_LUL,HER^QJ?X?=18_]\4?EH'J>)\L3;Q%=;$=0&'71U>SK2YT=A
MY'^LTA\D.SG^:]9.ZW"^T$UW&6BG>C)]U;$<$!?*27MD=.M']=A?R8DNM)QH
ME_CE*4B2:4;N@9;KFDB7\JS'21Z@$^NUWWN955XC\0U!OOCMI5CNA*]H>?TA
M]ER^+WZ;VT/UKF>?%WU>NU"G_^_#@P'!GC+G.4 B%=FXR."DP $0$G3@EB+"
M-Y(#=P&#+_;8N]G(?PJ;./ UP<-V0[]KK,-+K+.VT.9A3INTV=;MM&I"%>$W
MLHO1J/E>C[]5+Z.GG1XWLS9ZVO;7HY\&G,\Q]%YD*KI$Q>*1YF^1GO9(SZ;-
M(AF4'C(*-B)H=SF(\-7,(OK5/[Q[U7^=Z(0XOSXNGY$^;?U1ZT_U1$^7KJ?+
M</:W?G%5(=!9W=:=.9T?+>ZQI1RH_U;.A@KBA+5;<V;]A6A(I;C1=? F5Y$A
MXV1WM\OGX7Y2H26?KD#KGAMK,H]]-;G7VVI%-[O43=1$^NM_OL OBIX>F0/O
M5-=OO?4GQD\J@@;%&O?4&HMN\M5-0<J"E,]8R_E88PD/#D:513>9Z^;)G-X=
MSM)FJ<]]<XYI<S ?:[WU$<G<ET-FYEV@-U_=%.A]?M"+\K'6 KVE>V86E=1[
MN$O\69]/FM&HFOBN$T8^'6K*B;!\FSOMO]D]HH7=YYS7P]E4.;V5"P)OZ8*D
M/2*,*J Y9( B8X'2R@.%L((>.8_M1K7F74Z(OSLY'37GWO_1X_]*>=:\$G,W
MDV8'%*)LNQME!F<'XT.*A\]9._MD$L7#%P]_:!Z>82D1E PH+#"@#CD@B8<
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M,P*=5ANG5JYT+N_FRNHL8_G'I4=!Q4CNY&B6/F-0?:^GQ\4"KN\B9!6C!E/
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M^&DV;:<1N>/Z>-<MCZ_- C'6<.)TEN*H.5  ?)N0"JD#CJE^6=CIN-L<N*8
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M75ZO&:5#>VUD:/,4W-)=I#]?ZKG0)74OROO[-UGU#/T9@.(1KCTXHQT.BD,
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ME\8?T/ A5L[^Z?IJ,FF-(E(%"J!U<:$+X8$*G@+)/5***>'Y1C4RU-I:;AR
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MRK=6GR8:.9GY;>>*2B;W=J5-H1F-FN\=O>RZF[;'S?=VJT7IN6:.=D'OG^+
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M*%Z<(L_'\G+7<3ZV6#C^/H-HT40NFG@R=U8VM)_&[?5%J_E89]F_+E!;H+9
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M7V64/7O/]5G:S=&.N-$M(1W%6F($P\H1*QQ&R@J*K""9UCJS0J_U@)&9)8Z
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MC),,(-5:)76CTU2PS")%'48,^ 0)XIL N!QC*HBAZS55]HFS\"#CVX^#]E[
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M1JK@8/8P[+,#G$,YEXXZ)1V6:]W([M>SY(UUUJ-;,"U. :5.FM.1^:V4H;]
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M[$_<( *U.V(&6 O_[5^?T6?QE'F_ERHN3UR>*.>BG(N,%)?G:!!^;*UR>';
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MIG25G,,.ME]#P,YO8/@&N*B<E%]M8.*1_2+#'_9K"40';E# 5YY5I^.JW>.
M(X'IVQ,"5]<>WP)8\6IC>\5! F3Q0L8+#[B^+AOX'GZ,=#F6PV%XV B8J0)^
MA5' 2X?^4+^6=7T%_/M-U@8>XH=I+,@-F'R8@@3VFW@V!4ZVR;#\P\*CX.-1
M NS6?K],@6_E<!B^J:VNOHR ^.%K94<6B-C,9K1A B?)J6=_$ ;3X00&DK@I
M/.KK>F*T?X8<C^OJLKP .L-P'DW#[,E4C0'X3?5VB,+6"(-PSAUB I!KP8A&
MS@B69T8);1\]7Y&O!."S[^4KGO"M\?<#W\K'PI)P_S ('Q"+D3UO//0O"ENH
MW*$LSX ]M;)(%L"M1"F.-;6"Y&NU0Q\Z/^8N["GP27:TW#G;UAZ^V\;CZK(Y
M]P!\LFHN',E\P>JA@86]^1,,LK$WG[X"=E@Q),!2V!5?S]FDLT,Z+N%6907.
M4Z2TI(AADR&EF$&.,)93GI%"X^M<DJ6:D-1@1+DK$.@Z@D"MI0AS+8V01.3%
M&I><:5C.Z=!^<+\ZU\YU?@#U$X"F3X#. !@.R\ YG[UA]1G>^,NPTG\\@RT!
MYJ>W#^JIW>9RO(6]0*+!T.Z_TX"&%_2>H6#@O,ET4M57B;-@U,LA6+I^D0(J
M!I .OU2;#0 [6]6U.P"I U.[R@O#U9YAVSS'3\X GOF.6W_"!F^FA$69N>?]
M(,%8>HE?A<O14%Y5TPF\XM*:5^WKBD#$[GK8?T,Y;NS+QHZE7Y$9?4(8I7WT
MLTTI=E_+IFS-OI>S9VQ)M&O?RME)@>E/GK3;HACMA?A$<'&+ZXB?Q?>O@M?R
M=&>/@\$5MYG$K0>7%MD//NX[N8_%?5,?[QT_O&WTI^@##Q<'':G?4Q[%[E?F
MA](H'GIMYFW!^ .W!?N!\R2]7,]]8!Y5#<V^]L2_0KC  M',BD'1'PZ^\_F"
MOF^1_K!\U*-1CT8]>E3M-:,>?1P]ZAU7_>'6J#.CZ'VJ:Q-%[],3O:0_W!I%
M;S17HKGRV%P8F2KJS*@SM^\)GP?MH\O]X=BH-Z/X?:IK$\5O%+]1_!XKB\>2
M\$>>-!9.4<WRPA:98O7]&#S6.NUS08F=EM#K&0L>#=$/OI=1/+,P.U(DF&;&
MYH@:BQ&C+$.%( )910U-<\-XH7>1C7V;'.S3R=M6UI_-1/W*Q2MG&L;3VLX/
M-2"Z?*J!/OO9^ZU[6M6S9R*IWY5K?HHR[?8R+>KYOC#5T1#]X'DBZOE.STN7
M97EJ)=*8*-#9.45":89TBADVE%HMUQH2&YVF@F46*>H\-L@R)$CF4.%RC*D@
MAHJUH\-1S_=3)!VHGM][,>[HXGE<:>5%P/()/ML,VA(=;N[XZ0IG],>E&ST^
M_2TAVC../!JB1R1X>+)U,Q+46DI,+4=69(#JG+!(Y,*@(K64ZBS/4R8>RN,3
MI/_IR/Q6P8Z:7W>M*_3-$'![_9@HBHX! 499=NB>GF-FJJ,A^L'S1-3OLZ:V
MCCN%%46@F7/$"#-("N:0=59:827C1#Z4IR?J]ZC?'][#$Y-X^B2E/DS.;>TK
M),,=OEZL*4%PU+[TZWV:J<4DGCY#OF/VI!\-T0\>\AV@,(P-AF^"KH1EA.F<
M(6*5!>A*"1(92Y$PW#)'"==B)Z4A;P-=WU>^=,\4+E-#^ZOO3=#8H,INCUV3
M!K8N?/SLYQBF/ H0^R+F(QVME^J8N>IHB'[P/!%5?:?J50;Z7#.,L!3,1Z$<
M4ER!YB]PFE%*"[=>!7I?7JH=J/J?<=3PQZ#A8R+24W53^9.CNK:FG-S'+14S
MC?J,\8[9_7\T1(\8[_"$YV:,QQWC%E.,A.(2,<T=DI2GR'"926DPS=+\H=PY
M\.'K5KK? =2E,?9XU* N2J]#]]H<,U,=#=$/GB>B1N\T.BM49I12B)C"(&8L
M ]UN"*)8"LUY5ECU8*?(?DBCTZC1CUJCQVRB(W?3M-E$,(:+F#UTK&Z:8W9_
M'PW1(Z@[/.&YK32 8=06$G$M-6(\4TC !PAK*Q1V>9;2M;;%^W+3!/%^:OX]
M;287,.:[0+L8@3MN:!=EV*$[:XZ9J8Z&Z ?/$U&O=WH]Q[DMBER@%%,)>IUH
MI'#F$,_2G&.9&YRO'?3>E[,FZO6HUV-FS=-TV;RWDT2?R]$77^<G^2J'TR 2
M$CD<5M_D2/>H6'MTY/0W.G?;E@H]8]BC69S==[SH*8 \0!$;CY7=!(0IR;&3
M.4?"4(48L12)+.-(,J53G:6&\K6*"/MR<+T.BO#=Z(UUMJZM@8M.F\9.FO^;
MZ<73F5K\D8-F5/0VP'GG1B@]$^3]AM?W.IKVY!(Z(HR*,"K"J BC(HRZ XS"
M1A&<.8XTRP!&6>)/YQ.#J%+:%I8Q3-U#^1,CC(HPZF%A5,PL.W(WY5SL+%4C
MCZWFCMD]N=-@T*I<IB?4"V933=701F3=!^:Y_0)%;+V7[7!),6&'PZ^]1U)'
MS[@]Q#51P44%USL^B0HN*KBHX';%N,N&/OPN@5X_S[Q![Z<7\&0-?YORZW9B
M_=0[Q93MEWYS0G0C]R-\2=*3-$U_>O74B0-;95<[>NZ:[39BYYDUUCIII496
M8XL85Q@5*2'(*B(<-L3W<=Y%@/ML>@'4O_K@UKVLG^')OPPK_<>SQ#9:CCU3
MU%.[3:*PD\QOC9MV HU^J;"A3I.Z&@Z1J^IOLC:^,=[DW&Y*HTO@DO#=E95U
MDUA?U"YY8[6]4+9.4C)(-H4W#I B%%.:R)%)X!>2E$TB&YB[)T.3/"]'0(-J
MVL#WS8N7&X54[P72GM7=3+D%W;9)<LOII)KA!S_(<O3E)7X5+D=#>55-)_"*
M2PM@)+RN"$3LKH<-,Y3CQKYL[%AZ]^F,/@'GM8]^MLF1_K5L2E4.R\G5R]DS
MMKC3V[=R?L(H^<F3=AO,:B\D)YF@M[H.W^:J](3B5"S]M[M'GV19OM.!TA]]
MW'>B'<7CY63?,?>^Z ,_%[TR.^-*/-Q* -W]MW]]QI_U/H_D3B&EW:_FYHC2
M/N")JH9F7WOB7UNP5W_X]<X)!'W?(OUA^:@U#UE6QY7HRTK,M2:-6O-):$UO
MT?>'-Z.&/")!&]<FBMXH>F\4O:0_W!I%[V,9)S&!^=##(K_(80@#R4FB+,QW
M5(Z^^'"1#P?U)TNE9^O\A!.Z>K82_3X8\J?^<%#,WHI'__9&A\U'_RPF1)&"
M(@!>!+'4<"0)35%.4UZD(F>II-<33 H"=W%&D4P+A9C2&$E&#4H5IMI2HSE;
M2S"YZW&^W\_>S$_SI<N'^1#\Y3RE)G]]5EX"U:87IIITWS_[6> !R_-86.P8
M)/.+7DKF>#XKHIW#Y:F(=B+:>;IHAQJ9$9TJ5!04T [!@&%TGB$BBQ03^-#F
MYCK:8=J2E&0,Y07EB&4L1U*D!7(<,ZQ(6N2^.,+CH)V<#G)!(MHY!LF\%>W$
M,JI'[MY[-]) ]J;_151[MM2'A7ECK:\>']A\_)!GA, 1 C](HT=&+5-%@2R3
M.6(B=:C(X1]+<\6982S5Z2Y.E*TCWNN@>%;IZ_0"R#JY/1Z>U?*Z"1@3,2"T
MORTA8ZFOOOH->Y*C%/V&C\Z$$4-%#!4Q5,10F_HJ,E9@8@A2Q "&XBE#HL@9
MLB[-'+;*9&(M:/HC]5(?&4/E U[PB*$BAHK)AD_(&[F4;&A')J89'I43,M:-
MZ[_H[5&(/A:>BRB\!W38T@55I;F@>8Z,SBF@<.V0*@!@I[I(M1 Y)7BM-A:6
M4FNN#,(&,\28*E!!"HZ<S2G&F#A=K*'PAPKF$RP&F=AI?X)8=O" Y'Y,=SQ6
MMV5$7?WGOHBZ(NJ*J.L6*919RIF5"CG'"6*29T@9F:&,YSB3A*HB7VNY&0^,
M1-#54[%_*S_GT12+WC<N O+82SV<&ONC5"'W+@[\<,4;]KPUWZ)CJ>J;KI6H
M_<OY/' PEE]L*R"1=+!R+^7PF[QJ7CU+_OQHK/5H!4!V2_BS?[W_[</?WKT>
M)._>OSY)3M^_2<Y^_^7LW9MWIY_>_7H62RC?6/$^;KD?H.?[:@(W3:KD=34*
MT5@YL29Y6XX L)5RF)Q-X(,+N+9)GON[RM'4FA>;!%W_YI;T8)OTD&'^_%VM
M'WL"W+XG0.,CKBNU_9=+Z!WX[ :AB\'KZ@*F<96<2Y,X"^8-R(61G235&'Z=
M^-HVPZII$BWK^JIKC@ BY5Q.D@MYE2B;R*^R'(82]R!HP$:<^A8)T\FT#JT]
MPQ==IT^@Y9^B.7^#.>]RRF1J!.)@AR/&B4(%,2G"19X9(5.'1;Z6RD2=$UGN
M4%$0C)C3.2H43I'@E)$T=]3EXKHY_V&VMK_!TKY>7MFM5CQ?L>*S&ZWX%-.3
M;*L1?^!<D\ #AC"?D^1#VR(D;ND;2YH0EC&!%3):.L2D+) 2J442J]R2G#-M
MU"[B@G%+WW]+>P%]@PHXDMFN:+)!9-\;V5?DVMI<*>08<"ZS&*."V0RE!&>@
MCC)3<'X?C=1<J<L;>/=LJOYM]>1S]>OEN*R#PWDG[)R+$W;TW/P-?B;6$PZ@
MES_,7)?5M$F\$=@DKJXN-G+T?8>UI7<:=QG%3F%$?(D'ID 9*,,HTCC/<JTT
MUKRXOI%HJG!&"$68"()8E@K8?,R *G$N38N".JMON9$6^\=WCCA\RX3BE,W-
MONM^\./8QF!-/.#^3'/.C6(*@(D!S)$6&<@K_R?-"\%P8;3(UO8G '0K%$&2
M%3EB.2>HR+("\=1QV)LDQQE[NOLS/^[]>9)\/I*9@ U3VPM9AD*V$0[=>%Z;
M.(N% =E 01DQ)P':B!R,FSS3,@?37>5KULP.X=#[:K(O1$1I>K*]=M&![_!;
M&CBK/BY3):-JT@$HX/8E7QD0M H.L\8[T/?E+CL2XD>OWW>$"M%,&T +R-!,
M>9B;(RDSCE+.M<H!2"ALKPL5BXU)"T*0RKU;1?C::4X#)6RN 76X3*OL@5TD
MM! GVXL\'/@F3BZ.9"*=()SU,(8M459F4Q-C'^AHI=XMA5PHAN^%6F=RED="
ML=%#FB$B%<1F.7 SEQQ,"K K5($!-AAK"<F9E7@MH<\  N&<,90+![* "X&$
MXPK9(M6.<V5XGCY9,X2*8S=#WHT2>223,:;T>V_@.XUO"KQNCUCZ-N6MG*IM
M UM7GX>/C/UJA]78ISAX=)5H %SEY)K@NAF1)<-2AG[9I6UB!/.[Q\"X82FF
M!.4<$S!V%$<2:X64TU3(#*>:K;GY<L$4=L:B(G-@5%$J -6P%%&NK-%99O,\
MOXYE/LO+UV$ME\77=^HNW 7,9"?;CWX=.)/-C2'/('$WWQB/YT)EC#+D!-.(
MJ50C64B-<B<$92FC7).UX&66%<9E*7+:WY,"D)=24$0H*:1CTJ396O!RW[LY
M/=E>.>1(=O/ "_ZQA;F!Q+\ZV5D.V[Z'_]TLMEND:QUC'EM,7;L?13^,DM/I
MEVDS20B?@:>/P"*E)V3RB_\1Z@Z!V><QU;N1&[:5CC]Y !1^.]43#WC\O4DY
M FPTE-\2F!=@*_\>6?J;QW7UM6S@\L[+58Y"[F$B]V(U'>!";#NX)721$8JH
MIBE@'J.0],9>JK!1EJA"X+7"GX66$O"N019S@Y@D&#1++A%6A9-9I@LE5L.A
MKZMZ7($Y9_]1CLJ+Z06HF5^= QGYT=8^PUE^63VU-0;(.]<OB"XK&'KS8?FC
M38WY"=:@(R)HFD#%8!380$?0-:TGI7/<^MH\S5)7P'"$8MV,"<@K,LC-5=TR
M#M8"+1"E&HR"5*=(@06!6(X+9C VIEB+Q]XE;RPPR*^7NFPLL,7.&>)X^<$&
MF@4F@,72MO:* &94Z3\2-;WR<VJV;?S5*(J]]'BM"?JGA(]:=0-_P>.7U4KE
MPR;E!= :AB:')[N "?<_V78D..'CM&ZFTKM'JN3,MAR8%K1;"< %0/21' (L
M^&I'4[]X)B1R$U'PY/F[3Z]?#!:;8*J:"3S+'RW1H19BX[LH+/EL_O=_+BDF
MXE635-]&MF[.RW&(BP$PF0X]> "Q."PORDF+1:KV9ADL(?_6#4[HY^\__/;B
MND<'Y.M6/U#G WK^Z7_EQ?C5F^[OZX]8#ME-&P Z,+;.*12D_$GR^Z0<EO_M
M!MI2"X827K?ZZ&M/[A[:M(%<3W>Y0CDY&DWAQQ(98#\!$VU:G4^O$S,-?JL%
M/5O*+]W?3>9<@K:JM)[Z@]S 8/:K3P<;7B4A%  7Z&HZ-.T5LV5K9QS8%ICR
M^CO:N80775NG6Q&B?2EPCR=Q(":,JYT]C,K/R;D&%GQS=-0_'CY:%2GGL@E!
M6[AB/+3^L!/0=C(UX7&R:2QLF&_G%@9;PP/6B>;OGY%HX DSN]C_8UL2*@O0
M^0*V:PFOV$"3IO0%^TH0;*V"",9IMTJ>2AYUEZ[4GNG:<5Z6DZMNSP[#"2U=
M-7 [C+?29?C@6SDYATWB=W,[GS!M&%&[9CZLW/E.8>>L#VEE-1=;>XGK%G<O
M[YN._Z:K.]TO[CJ_M4O<1.F\2^F\O+?+!A;L/]/2<R]L)0/;NX;[[&)#!Z4\
MKIIR628MW7Y1U5XN_&$]>\'6"*S2JM<&+,76H)N.X5Y["4,?=7NW->F\P(4-
M4PVGLZ?[I\YVK!R/+> B_[%WE7]I-PMH<6T]UPT2)4&(]@\$G7I$,5\+.6K0
M+?TU_9G"CR5EM)P]L?I\Y.M<)#XH-FEFFV:VB4Z2MZUY,_\$=I&U0?OZZS;O
MJ'/8)^?5T+3A&G]WIQEJJRL0?O]MU6D02?.SJ,WB+&K8Z3X, Y+M*EPV!&ZW
MC6^X/K(N:)N@T$#R)%]JZX%A^WI7.A"EXQ;-MP,KSZLJ%$Y5MMW"LE4T89\'
MZ0:2W&-+H-AD,@Q#:.7M)"3&#>U7V4:/@D4WG9Q70*FK=;T3S;D;S#G%!<&"
MI\AE1>$+;OM\E4(@D6LP[;)4,+[N2?^!8T"_CQ9[#.RZ7]K]LCW!9:4XS;OW
M;U>L.I %VEMVODA,8T?/?AY5QVK7K?"FW]&SJ.=5<'!,E\@:&+ICQ&93I/9(
M2')$)WU7A-7"!AM7PU('9! "WQJVN7?T JX$4>LQW=@"(@R![YF>APNW[X5.
MH'8 /;C)P,0?-5Y%C.Q,Y.OE6@1SJ>]W46?9P?<S>"OKS6F04:[.(I38.>-#
MDEFF.6+>8::<-(CF19[E7%-&]2[DZKNPIMZ!O$"&'V>[XW1DWG7;YE3K>FK-
MNKR]@Y3=/-/"$97R0B)G1(X85Q2I+ 17J7"$,Z7P6F;!CY0Z>\B9;M0GQZE@
M%H(%U,E"KLB6BKZ^_68W.?Q"HDVY+YO2E4-?( 8D=6TGTWH$AEI(#$G@4M#]
M:.C]9MYV*YN0E 7C;71=J@4R#QE2\MO<<OCWM"X;4^K65@"1WP8,RYG?SH)L
M?\!\2B,+P)V2H)QJD'4\QTCXMGD:*X&Y8H65:U+C1QKL;9(:;P*MQN&(QL'O
MFG>M\F[?XMU.=1/\P&K:@&YOFL%U9\.2?W/)F^"WS7K.WLJF&7B'AM?]XS'
M$^_R6T8#P3<WFH"].:J\' E^B19JS%_BX0-\TD;CPD%7#WAF_C>_ASW@\$^#
M/3FZ/L+6VSKI$I^G$WMRW!FDF['ANJ?=MGZ^JO4U328@!J;^)/$7@']U '/!
M?:_AV@X8^@4(CL9FXH\B!R_EOZ?-Y+H#:]5WO.Q:A(MFV0B++,TR2*BP=.$-
M[8(M+>%A9O]L+&?Y_R3)7^#GGJ6D2U-),D<0\8VSF.4.J=11Q(BTBF+#32;N
M(R5#L/7L'#CNDQU/:WTN&_L9'O7+L-)_/$M 3LJQU^@ !6ZHE_H=_5X<BG[?
M:UFTYR1]D21)(':RH/8N$!0_% +O/[7J??6UQ:HTVY29'JH'!H$8HGL&S&,P
M$GRV2!/6I9ZO2R*_U';)YRC;2+KWGMJZA5RR#F)1@N(JOX*<]:K/?JDF;61H
M4LM1TYH*@]:,GS\Z&LXW';H#6$B52L$69!(Q8U(0>:E!)"5Y(9GD8$]>%WG*
M8LUYJI V7"!68#"<4ZO!>I8&.RD*F:Z>Y%WPWP<'>^.B&IU-@L1;LAG#CFAN
M,ANO)Y>P 1%\4!3'FZ'>TB2 @4"U+KWDW YG=L=%<$O"+.478* O'D3.]SWP
MB8[%YK[+ 9RS3'%0^B9U/KF]4*BP+ ,%GDNF<>&<6CMJ=F<..)TMS\=N=79S
MU/3X:W&%[(.X@6_:P(7)N"P <O),^W/3A*-"6HZHRXC1VE'&ULY-WW\#?[1U
M %>K&QE^M2:4TVT^N-. K>6;:C@$"[2[NMOF^/9)A/B$XZ/=YF!:MF+>&_<A
MX#N7W]\ ]2P2>*IEM%5T>80':>!%S^4]J;F 4V8&$3R:#K  ]LRDMK*9UE<=
M6@@9;<T$V'12#CUFN$I:[#T)*30@7F$*9=-,K3E).@_3-__/J.HN:K,1%A?Z
M-B>MHW/U369:SQ(B@D-BVVGZGEC[FJ?<%$HC+E71UIM0+J?(@MAD2BN6KD=2
M?L0G^IM/_;&+P^9 ,]ML-_N7)KYF^)NR&0_EU4LWM)<;C'[O5"K=U6RKA,M0
M,P'+Z55@  3[]J)YZ7.0?"1R([LL-IUGR?RG(_,,K)!T3L]RY.F! EEO?.]U
M@7,#Q=<(Z9T2;%Y5?FF95T=QX 1^]G.[P>=,'KK1W*<GS<'X6_9*U;G\2*[1
M-WJR=A'4^?MT>.7#(_E-'JS1DIO*GP.TP7,U'M?594B=@T=$2^4&2\4HG%GI
MRS-1F2+&3(Z$U5Z/$@LHH> <K]5UMX4O-9<6"*P9Z1OJ%DBF6B(BN'."<48U
MON9L&H7&6&=^\K_[F$A@F-/9RJUZG?[C)G?R.9%!RH[W$'GSGZG'AL[:X&L=
M2N6/_%5UFY9?.><]2F%\'E:FF"2_E*,1(,HS@((VI-"_EA>J+LT7.TC^(9M&
MZO.I3RAM3I+3]D"'#UOZP.@JWT03_\93@%13(S(!)KZOMZBY0I*1 O&B< 6U
MN&!DS4M[9\:YAE ]'_W:YJVU*Q<8:_A17@5[8$<%&8Z^_'2;<_B J1ZJ2%,C
M<XLL@7^8(!DJ-%6H8(:H'!8^)6L=R--<YC@%*T@SHA#LC *)'.<HS;'**2>I
MT.HV9LUG6U]X%_]HXE=S/>D++,1%>MN!+S#\0-[,/?*LB!;D^/B#'>DVN>'O
M$L1!'>!2T9YYJD(9A&;YN&J(2R0.U (*$K^ML#>8'>MKM<!(UT'6M"?! 5[-
MNJBVQ\GMR!\Y*"_\8ULOQ.IQ@^ O:\;PNM(G1+C@HH"'VS:=9B(O_9$;7](W
M/$K;P5+JQB*KH\O.;992;69),F'VX93@1=G89OVTPUB69MM@0[@R:KE;:[FL
M, 6(J@(9B5.?I$9]?6&-L,C3W!6&2K&FY>XBN8*6^QS6Z=UBF=Z-OL)^\;]]
M4,/NQ-:.HC/'&YF<*[?3^8G)X=7ULG2^,N:XG'0'C2(GW*%;$,L*+3-0WTY@
MQ%(L ;M)@FRAB]Q913.RELZNTLQ0!7:5M<* WB\X4L(1)'.);4&D(Z;8%R=\
MSVSBQU]XJ[671F;H6VN[:7!]?U>!^1"/\6:IZ<Z?AA1 K7T.H-=,X0CS+*5X
MDX89UT#@&J8 -VL)EI;/,/9/O:X7X9Z0AAI" 7![74]]BFG0NTTX4CU8RC]L
MV@A >Q;&ADMDJPM]1L[R$-KY?'_B2ZJ];+HSB/"N>M+*!O_\>I[C./>MS,[-
M@*(&K7P5!K[0RXE/G R%/V$Y_CT=M3?/SRR&:ZZY<QK_G+(Y#R?BAV"7MN3M
MSN5'?7VW+@"9$AS4-,*8^=*\V)>NI!KI+$U)07*5$;<32Z,<^<2AL$9OI0['
M\?XA+WT1HE^JNJZ^P69Z+8$X\/ENY!4Y.=Z(\TQ>'<E\P*R<UNTY#"V;\T3)
M81N?["JP;3QLW\>)K,3(8\_Z'5+V>'K6LZ4]$GO6/USP+?:LCSWK8\_ZV+-^
MOPSS_9[UQY,KL>_V+D>#;_U9\;K4H1P:X-N3Y/_ W@\NZG$7B6MK2OD$T6H*
MAKZWJ1=EK]:]W*N%K*YYRX-#H!PUT[ISEZ]Y 6:=<CK+_-NY'?D'AE)QZ^[Q
M<$!Q9M/#+K,CT_DRZ@L/V1^RLZ4P*:<D1]8(!]:JTDAE5")19"K#(I5<KZ5)
M[RHN]LF.[#<Y].&QXPZ*.7^X*QPX/O*P6!>P6FSN]A!O8*3SY>-LI3^RUI3P
M0EDO?]P .X#I.J]J.%ERHR7=F1[GRJ$_WC9CYMGW)S#<L@MBM?X8[_"3334*
M7K)9'5*X"]Y1ASJU?KP@\\\#1W=*QK2'PA?^M$6Q(RV'>CI</44<<[=WL''>
MW"9'FA2WS4)[[B][6];-)#G[\,\7[58Z_>]_01'\#0@S'B2__?8Z>1X^>=$6
M% "IVUX0GA(<SR%L:^S*.]MCF-K7+81+6D]Q*!,7ZAT,PC!BYMNM^\<;8K$C
M$G%CK&_[C5$A. /E8Y4CG+-<FNO*1Q#*"U\F#CM%$?,G? KI+,*$%=9F7.;Y
M:@+/:5BMTY'YW1^T7.2_W2[U#=_<*1X?KT=TEO56^8JY( E'=05BL4US:\,R
MOE;7I)[JKKK#/^5P<BXOKF6XM<S8\M;9%.;T8M!E0728">3Q0W::YU@1HAF@
M',<1D]1WW@4HDU."\U0XQ_A:'M"=MUR;\+.TP3: FPMXQ?GA2VYV[(WFPSJ!
M>1! P3_D5=+J(O' '>BMP7E>6(:P[^#(,I<BR7SJ8YXRAE.1DW2MXP''DA#F
M)+)6^5Q'S)$T(&,S9[4IC+14ZFO'&;L=N^CT^ ;4V*H(]"Z70!0CK[RR/@:
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M=T'7Q>+S2YS:J/T H"X!U/;5L@8; U!T/W@]4(:WRC:S.=+97RBH6VZT8V'
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M)@@>@/FVP*RHU\")N=T6#>#LYJK- CBK60R>TG["\VQU^F)Q!_OZ]DC5&S>
M5@_<O UH)RLB>TJD3@<(=WK/;%N'VQIL#+#2XS]5M],.WK,M'R7,9T:&091C
MCAF$-IB;"]<+8>E3J%1WPJ8[]@80Z5&DDD.+>EYEU =Y3 =[(>U6U(_28X\#
MSKK%V9T?X,O!\KQ5M-*7H9G+5]L+'>I<<7^1^?+R>-H!]KIITH!'/2QEQ&.F
M7\GF0L6IXJZ1*?2-9+]$#=42OM!!(@:4=G,XM^UKL6'5>M1\KP>9<L=XA]??
M]A2>VH='NEC"VH.O+MSIE'(*RU=Q1H,72IE,I1]/+R@\Y]2!BBK+$5Y>F2\E
M-X-)]PT:P*4':0K@RAJCI$\DTRD2]2HZ4@!D<<>01YSQB:_0['>C!W!N#,[B
MH3_\5&<8^'QU11W*T=!$I/=60!_]^%C+)6@.'5,T5]X,GMMHT@!0/7I2 *A^
MK##I%8FZE:E"L&4,]*4':)+>:60#2#NTH'@(2>T//<]_*68*;<3! "$]5E%C
MXY)&2-(*4 Q(V/13#C4+(/WZJ195#;HON9^Y\ D(\J%\_93$DX8[.-:[(:7M
M:ME<RZ!KW7\>W:4R+)&WHF!\A?J,RL^-RR?GO@BN?#Z&S:R%YZP5F5'E[?@8
M0%!YH8[\;$74#AIZ^9A@4S(A*&DLN8!GP,8&V$C.JA:RTN[IPH(.1SI]I'P!
MNY8"#?+"D_JX!EL#3EMOVH! W76=(#!SA%9+9$NZ%R$3.RBW31IEW$FU2!W
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MM%GA-R;OR^K&C+5P,:%\//W-#ZBX9- K3UY-9]ESZ6_(71N:#$.[2MG!<%E
M9Y2_]TX_<5F!XGZSN(MLDA"D%IPL)^H-S(U*+B2]W2MO+9K[4\9"R\,'EE>T
MH6UK[>)X^$*<6YROIC['R*A(G=C_"_-:'PD3?78,9OBH-T#7NO[%#Q[""6Y!
M8.8F8IA%KJJW,R:O6K2UQF/'!P._'_(XMUAR^/1Z 6MJCE0H*A4JVT3.<67W
M+^@DR'SLIO 9G&3 NF?<[7NDBTUA<GU LMX4D3U\6N*=@',7%@7X)[P1875E
MN>PAE#O]<Y 1^F+%H]4!HYV!7.VNK1#T;T;[GR%Z<0?7D'AW7KOUVW78D;30
M?99\M]0O9_6CGTT]!@M7'C7*#46[BKV!A7D3!GM/FU)'X"TP<?*\W#K$VU-T
MC,8!U-RMJYFYL@&+W@Q5 P"E8L8.GMQF"Z0$K%R%S*%.'&,N&Z,6E7=G=.ZI
M$\K$^FLF5VBX<Y/^TO$TOY<I1"/B 5J__BZ-4>F)AW(K<HV9W9:'1^72,5JW
M?A_S7^) 2QIG*;Z$ZRAVYKTC=^K ,,T+E3#67C-FNCXFD::9O*7.JLKB7/Z)
MO/3KG7<3N,LI,<C3K$&6^4/%I,HU*O8TOVC3G'98$$VI2BN0+_QX1PZ;396'
M=\TPTTBXMHS =95*W[K9W7EA;#HTO\IEQ':'O[Z-_P=CG8;/D\]]I8<[-AYE
M _?NX_6=O!;*Q<W*F!$]BZ:LXRE)5V\#W*[:Z-\+"M\MZF,^%R$F;*H)IS#Q
MNQO,\0MP6<0UIN]4U&[@4]YWJ9JV E=5ZHUE,N_1'RD#]%POEMQ_CM;VL?=6
MSQ%O2-R7]7,3Z?EB/-76R]KC/NYQGMA$WD-@PTXL:\G'+XQR,7>7I]. \M0W
MDEE&9LR\RM=]]&/'03P$V^+>TY=*E,9=#)5JCW<'VK&C)U91<MBEI*!W+Z1\
M*MTM;%9A">Z,V3U&D=#^RDM3;UPF]S6)NEI7RPG>AX.AR06.F5MPBE+6T_1.
MI.3^G@=WQERP*)B(I%*/\$7J>V!CJ*[+UM5Z)_CI9/*;FSI9;BG&0I/C5N6%
M1?/H^'B[U7L+$CS.Z:W%O]*B$'I!WP6(3V)5"E(DZ*= ?_T5<MG:C;N AI*4
MO55T/V]!O*;D_16V1*!>=UI]$(/R4^8 HER;)HF7>4G,=#T5[X7B\><(/S<W
MYT6QJLK[*8X*.6<27POB5);W4IS"!XB33_'FA3)1]5*T*Y>+X&'\>UZ4XM-^
M=MT/>3#7^UY\W,O._^JRKS/_S/5??/X5SQWDA:@L[J4P_T/E2QZ6CT6[55;2
M2Q%N?#9#-T7N>W69[]/FQ6I*O5NB-I2QU\+=6@+>_N<^D_0/E#_#&D!4;!H:
M$O=2T"_TI4*JLI)>BA#Y^"/'B3SI[\=Y2!G_5UZZEI5Z*;B6/907L;*XE\+<
M^_:\\.5%%H5O*@#:ID8O198I'R_<#0+*[L*)Y]KEVV S74_%PRB$O$(L^J"T
M2I:0:?Q%"1N0]E/(AU_]9\J9C#C.*+/EMZIRB?7,>>32YZGM7]:LW-.!B#JZ
M@CZG8L6O_[Q8Q6%8HVHO!Z&9I_L1F;=SCD=5UG"F.L')?(7AG' B7;)OZ"+/
MR5E=WF.AFGF[<W*VJM)CT8OG@=(9F%$@?0W.O$SR7\M*Q3D<Q$7O'7>\H3 9
M:?9 JKK9F.;NE5G%GR!X5-=+%09C0R8]'YP-/T=2-V0=L^[M0.(.*[4,W&?P
MTY8T0MJ)E38^;6KT5NSHH%&<V(V+=CR\&#ESU85%FN0M*_56>'BMP]_>ZM3Q
MEPC?=OI?MW9OAR/SR>HF"BXU&IOQV(FAJ;@LY$G0:>C=N-,*<[H1BQT8F"@[
M-IOEA,<7^3-U8 %R%6*&>)SC9!JA37CU=ZCR5Z_KXE>6]U:D>*NHCAN6F\EZ
MFG<737U[0P#T%M8O_P=02P,$%     @ X3-]5G\4BUI-$0  U>X  !4   !S
M>6)X+3(P,C(Q,C,Q7V-A;"YX;6SM7=USX[81?^]?H;HOR;3R9]+F;G+)R/(Y
M\8SO[+%\:?J4H4G(1D,1*D#:5O[Z+D"*GP )4A\ [O*0BR5AE_M;+!:+!;#\
M_L?713AZ1I1A$KT[.#D\/ABAR"<!CA[?'7R:C2>SZ=75P8\__.7[OX['HXO+
MJX^CC^AE-/%C_(PN,/-#PA**1E_-/GP]^O7\[GITC:/?'SR&1A?$3Q8HBD?C
MT5,<+]\>';V\O!P&<QPQ$B8Q/) =^F1Q-!J/,_93BCS^_>C"B]'H[>GQZ=GX
M^&Q\^MW]Z>G;;]^\/3X^/#G[[MN_'Q_#GR4RLEQ1_/@4C[[ROQYQ*GAV%*$P
M7(TN<>1%/O;"T6S]T'^,KB+_<#0)P]$=IV*C.\00?4;!8<HS! 1OPS6,5X;?
M,O\)+;QKX@OQWAV4\+P^T/"0T,>CT^/CLZ.<2MF"?QJOFXWY5^.3T_'9R>$K
M"PY&T!L1$\_6>,BZ^6NC_<N9:'WRYLV;(_%KWI1A64-@>W+TZX?KF< YAAZ*
M06OHX(>_C$:I.B@)T1V:C_C_/]U=59BP51221^S'KZ(_H0-.3T[/3HYB[Y5$
M9+$ZXD1'=_#/;[,8>I8;Q91P*\ !? S.O9 _;?:$4,Q 4O' )XKF[P[8ZN%U
MO&;(5?2WGFSBU1(!&[Q8ANC@:)MX"N._1M 9;)8L%AY=W<P_>'%"<0Q_B1^N
ML?> 0QQCQ"X)O5DB"D84/:9$%RCV<'C:!7H7S]J=9M1=E'_);N:9=/#K) JF
M9+&DZ E%#-S*-6$;F$'_9YC6Q-1C3Y<A>=D2Z :['>,KC#,WRQE^C/ <^UX4
M3WR?)!&WPEL0U@?+Y$XF2$)T,[]#/@'G'&+11ZGD_+_W_TOPLQ=R.-!OX)UC
M"I*@@/^66K&6IDP*MC>=7WJ8_N*%"4B=SW57X+^IF'M+F+CY>]%J-@T]QD '
M*)@P!I[R S@'X!-,XH)5! I(* 7=G'L,LT$ZW[]@>]/YY!F>ZCV$")SL#,QA
MQH427C<W-'63GU$8#%+HEI^Z-VW=4K3T</#^=0FN%_&!<Q,_(3J%?@1#2/MZ
MD$+Z,]XC9@)33[P"F;C/6'*3_XCBPN@5#0;J81L/V]_H\7V:H+S;"C%K/PP;
M)(.8[PT[K#S( MU[KV71[M%B22@,X L\GR.P71^Q<Q2_(!0)+W<SOT#P/;A"
M($S-&GJR%.L-TM0^1#&AU_K<S4.C)"9T=8D"B ;#O.D=A$SW9#W[O >\8E%;
M^7U3S>Y0F+WI-ET]<-%(E$:8XILI8;%JD=%381L\8<]:V&#A-4@G6WB>2D.^
M%_I)*.R2IVPJK=%KC*( !6L>7"$[7/)SH21B3:A?D<JC_EH@^+,A4S5)DK4X
M8ER#G-L8@QAK^CDEBW<'"1L_>M[RMY(VP9O-8N+__D1"&*",3Y?Q*E<ED=)D
M <?!B%"@>7=P?#!Z03RS)!)J\"EA("E9<BF\,.T#2^#FHC<!9NLC=NNM>$3I
M&LAT<FK!Q]=L/"M06];%4X_2%8PEL>!P#*ZT'ZN*< 1/R48_P@RJ[L:J[UN3
MK<I$CD#6\SLP2RY()-JZ9:$;.EE)AYZX@[C=S_*%2<M\8CO.3E>K3DM<H(>X
M^.0F\$T0NVW5[9XYS?JA3K]L.V ]5S4) IQ*?.OAX"J:>DL<>V')73L#>(BG
MYCAQO,@RXQ#J\RD913RMGN,^=0=W6]P(V*CGQ__&\=,T83&LSVENWG4/9COD
M3M==S;&N4ZSRF-(-L'*4:8+T-N0;0]4LJ3/P-/V4[R<++AK*LN7E7=$TW<3W
M1@'XS?S>>W4&_1"G)6N5P3US!V[+Z%4LCNH#UW:PZH%;!2B.\]S,/X&CXA3.
MX-.SUCN>UHM0\-ZC$2!FI9%\@>;8Q^X UK->:0!9M]UO+(>JMMWJ\0%)8&P[
M-#VSO:=B'W\E25F4 (Y/K(/7[#F>M%]'1/S,('#C*<0+](Q"DL8+S5[\UO)>
M;'&N1:@GP?7/'KA"4@43\I.4A%:W1#@:!G $E+G''@2>3!BQQ7"$PIBMOQ&[
M)V+GI&\(  MS%/:(',Q"J3E(M?#KA@;$5>T52$56-#8AMFSU4Y>VTL: D)K[
M%%+A]6B-:;Y5Y8:'73.WI1YYI;8&A-;8 9$"Z*8S $;;:]OAIYN[,?)Q6&]F
MQD>K]AE4;EK1WH3P?7<0Y)!Z<K$8:.?H'L#( -S./0(IMBXJ$_VFD?Z7]U,W
MH2&_IDSG*UV<BL(( )TLO0*)!JD!2%JI>"DB'4HC@-JR[@HD+21F)M5^V735
M5-N+BSU!9KO==1 9A]'(%VN@J-,8 *&3")8BT2"T)09H-ZQ6$B,]HDKE*OI!
MT=R Z++TK%1H2</^XC://??+J58DZT5JPMG(\Z=R)R-MFQ[7/JKGAJ_A\UX/
M<F_U_K'IA+=B5MI@_[1\]-*Z_/[F<#O.;%F0^>_ J!>66"2XVV'5UE.0%GC
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MGL].F_<R<+$8:&W6V0ANE9?%H(LY97.'Q=FTKN.R[_D_#\#HA_\#4$L#!!0
M   ( .$S?58)U,>&P3$  +R8 P 5    <WEB>"TR,#(R,3(S,5]D968N>&UL
M[7W==^,VDN_[_A6^?5]VS]Y.?VTFZ9S)[)&_>KS';?O8[F3W*8<F(9G;%*F
MI&WEK[\%D)1("0!!"B0*LAXFX[8!L.J'0J%052C\_3]?YM'1$Z%IF,2_OOGP
MP_LW1R3VDR",9[^^^7;W=G)W<G'QYC__\2]__S]OWQZ=GE]<'5V1YZ.)GX5/
MY#1,_2A)<TJ._O7NZ[\=_??Q[>7191A_?_!2<G2:^/F<Q-G1VZ/'+%O\\N[=
M\_/S#\$TC-,DRC/X8/J#G\S?';U]6PY_0HG'?G]TZF7DZ)>/[S]^>OO^T]N/
M/]]__/C+CY]_>?_^AT]_>__YW]^_AQ]KW9+%DH:SQ^SH7_U_.V*]X-MQ3*)H
M>70>QE[LAUYT=%=]]/\=7<3^#T>3*#JZ9;W2HUN2$OI$@A^*,2/@X)>H8N,E
M#7])_4<R]RX3GY/WZYL:/R\/-/HAH;-W']^___1NU4O:@OWK;=7L+?O5VP\?
MWW[Z\,-+&KPY@MF(4_YMC8]4S=E?@VS5H=[XQW?%'U=-MX9^_L3;?OC\^?,[
M_M=5TS04-81!/[S[[Z^7=QR2MS"9&0!,WOSC7XZ."N0\ZM,D(K=D>E3^^.WV
M8INZ,,[>!>'\7=GFG1=%\&D^PB,E4RG_%4L,NQ\9:O^WUC-;+LBO;])POHC(
MFW<[TP0_DY@MC;<!F7IYE/6D4#K.</0F<R^,=R>W,8QI:OG@;^=D_D!H7U)%
M8QBF\Q&&HW[^0-ZN@.E)K6(D&<T5P9O4LH^ERSA*9J&?O7!%"IKOXX>/GSZ\
MR[R7)$[FRW><_%OXSQ]W&:A4IHU/$J9^PP#^&:Q^F5Y/[[+$__Z81 'L!6=_
MYF&V;/*8+A]>WE9?X,SL.JYMCD^\]/$\2IY3,XQN#3<P?^O-MX#U&':$X"29
M+T"N^#8UB8/B+[#= 8FP7]]$7IS>>P\1T>/9S"=&P^$NG\\]N@29"V=Q. U]
M+\XFOI_D0%D\NX%)\T.23H(@9+1[T44\3>B<,W)*,B^,.H)B['O($&);>Y!'
MY'KZ+273/+H,I_#S#4U >67+<LX73.P'A*TO$:-A>>Z%]#<ORH&JE9%Y =80
MY49OC7ZV8+QX>7<2>6D*_))@DJ8D2[\2CXT33++U4/$M\7-* 0=8:V':"]_Q
M"1L-\\D3?)4IE_.$WGD1N6-$P>H"<:F$2M[DGR0*>@%J^*NCH25:+%<D6PN
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MJ['TIO;G'82V]HK.H!AN?\=!L&HSOI%!6.DC?M=H^.U;^76,P$JM8)UK'$;
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MUHC3+WDV(OMGC69M^WL3<?&E;<ZNEI?&_B3$)=K]PR@\/[H=W1IW?=?)PNY
M9HSMEF_Z>13PV7^*6:#]:G4;KNVU,6(2<%5]\E;-(:K20];.WCR_2%AVA9!&
MK9G7'OJW0M>:E#)WJCH_I_JP[?[>"%NF]$TJWX.<ZDV&6?M8N=&2S[,WF2-Q
ME\Z#> UB6?22*HK.W1LB+QN-AV0MU17N?S]#OI+M61R4C<BN;XUF,NGX0<MN
MK'O:VBGP^>X#V)1)Q*D_4EARFI[3A^R.^IM$W0GW"=QK\$]:'<#J06A,F_7B
MU5N%$=\8YS3UDW!=87]W?6L,S29Y]*+P=T_H\E@W%@9"EX^"&SBL,&,*_[E8
MZCHOO9'2/ ^[31^U/HR]&^P1C!8L:M'.?QD?KKRV:A\>(X>;SQ0MAN":#9S&
M5\;P'WI<D4'5!76PQ=*P+)L3B]I?'%=W;EZ':5B638GBM7&Q Y+.ZVF-:LK%
M:=K%2]?PPD2\ ?I+5C';\PW]&^C5]S!FG6=\?SIC5JE\Y#>^N UN41? '=:M
M7*7IU5$4AXS"?:=J%VH5A>)38VHXW;*K:A^W=E$O5/X^#W!S>S96AXEA M<K
ME_L1&&?*4;6EYU3\]RI2&8>_A-G3V2;-8(H3_976K\1>5.QY/ X-MLF%N8R3
M)0TS7M47!;#U0V%PI2K*!E\%?+QIZ%>%_$9A881-(JV?+=^KPJ%0LQ&JGK1G
M\JV7"6RKFI2BRD<LG@3RUH(U^ME+0OR4^06&E1W57W[3"^/6_RK=2 2L:C8P
M8Q(88['$.MY',*44=@"*D#9F&3H9:VI.>+.P"9CUN^8N=B SD&OJ;N4Q=KI)
MPPA4LUI75/&I,<X?H+U8&D=J0WYN];.CW*PJU0%9.H/%?8P3Z8YH5",[O#B"
M.");H-G$+#XS1O0EB>%+ V,"#+T,;]-_;D+NWK^&O<N+;NHB,NTO3C@R  =J
MZ/<,"P@:T_$(Z-Q$65K 'Q,5MD)AJ@T)]"!HS\,'!Z<?KC&BCQ<=H^IRJXH]
MP>;[!_6S5/!9Z0/L0<[Y58* ,W/0^VK"&84_'U.^H-3/C6^DT1AP/Y[%')TH
M0XWJ;NWY]',4@&F&>HE.I:G.Q6EYQQYW,6B/Q1R?2$Y.A[*Y/=X^PLUH&(O*
M/'2T#:M&&B/;4<=A>-*!%D2F2W'K@,OQ8,C1!GW1DZCS$U5A+&JDMO-=H(KZ
MYT8M*FS//JQ^UMKIH9V"^2+7*7_MSX]2[<$3P'U190AW^2."NC7.:.,K$\E0
M5K^3WN7"F10%IS2BRU!^=#N'5H6+Q>E01W@O\.S_=+32A0.YF$@L"U0;^E*9
MA=SUK3'L\6<O9*B0P46-D>E2RLHJ3C)THN&&1M.NSO#=F\Q R?>WN.5J,N[S
MOXWA$<2BG"[.D(H'QT=/:?.#U#X^BE)1F?V?GF[-OS2X O<@,)I#K=&3-AJ*
M -R3UT"=_2>< VD0^JT^R[:WQM%"8/<&/! 9/G"0</3N??1>P]5F-8^B#<)R
MY7]$?XF*5C1[\VU0MH=%1%_,W-<X@A]]D7K0'$7?]^T)@*Z<AVQ3[_>K>WI<
MI%"8V0 9"9]I?J]>O/IL$]#@,HE7J&IM5"9B688]$$5M#63/!UI2+7*NVG,X
M#R PHJ'#'0:RIIY'+A.Z1O"#*#"4@)SGCNC1AU(=*'8HX<9O@$N/_9]PW9C-
M7OGP8'Z42Y@DCPFKY!)^5Q7JK']V=)"F5D<*?VC48ZX- JK[.=:=TA0\&VC'
MZA2&EP;PC2YOCJ&$!O_8B%AS>A_#1QHB1[#]X9RYBDR4D(>R5^ 6S(0P#3.5
MV2&^&)F]@0\T.1J<#SN4E:K1 W5L@5?IT&2-ID5M(>!^[XZ>]]*6_E?W]*3A
ML6MDV8/ F!AO1M$*7*I\Y[>H%9U>M:;\265%^F!3I;1(3XCTU38I?_L1&$CG
MN0R9S*"HU72,1\;='[B++^%J:0N&-;XR$0]M597 ? E')98*7(+%T[/BH$AK
MC*A/%:Z:SM71=L^9QQB>20IB33Y8=Y;UI3JDK[<ZHE_ZZ[A?U"["0/=/J^'=
MD;S"81!ZR=8H:FOPI-8_/U:L;$<QW(U2/92C5+H,3. 4&O47S?X^AP.. R>X
M3N@3B*';-8'.LUBB9=*\G;N\.11DX+5,&*^XA\M/V,/4C%\HAI!Q'KQH>WU]
M5I^&5/OL>"TOA ]PMRRG6['5GD2<[X-K^N@QZ5S:/;BJGAA%EY$%'YW:0]4]
M/592;N&Z^A1G;8[+EI?&CWZVJL)UCX]9AVHTGFO;0,WO'--5O5LW68=<I0ZC
MC4C%J(/!&H.3<0H@?$J#%(]IA</4J2-&ZWM3JN9H^PXZO#AR*FMKIE5:EVK5
M)KOM4>QYA. NB!"A\6/(*"@-$4WEB)_7P)3_%-)GY8> Q8-OZF[C8]./,[!2
M$=.^TDO4F^@X*9ZH_(OL]-LP_4T L.)/]1F>M6^,$37H%VL^W583:#! 78XX
M"FA+A,<K7\1+S^?N*)D^<AHG2?R"UXFWAK\T@!_N0<)E=G55'7#SL^-7_TOS
M&V[OBDJX*ED<C33.X5,/S-"<T=CIU>FEPOK^9K7A^7X?DCA-/T<)%0D5'^ Z
M.*7+&/?EZV'YL1UIVX<AV $& ML%J_[NXQQ!HFHC[T=@-/?_M4 3T3!UURUY
MJVUO.8!8[12@V@-:]0!Z8QP?7OI4RLA [-VG.,D$9+NJ7:^-270G,(9XA?NT
M$0ZN\M$)^#A:4VUJGQ_E-M*%FL_4-$Q@3V!GKYH_F]G<;4>#U2&F P(@LUO;
MM)=#J8S^[348 Q4/CK)U!3QO225HJ=1K>F<$(3[0"/8#@T]A'JS"*$PS\2'(
M6ZA1F&[OC@G[WX0YI)L<<34]Y1V9RY6 G^+L;S3+$8F,O@!U>W.8L<<)&Z[0
M!8I9>J!#MFSSJF=MYQ95HU_4]I'<ZU7WH!EB()%MC)DG]57>M8^.#FK4<$97
M/.A$!Z]Q]'Y.Z7+#KL/E7MT-]B=G$Y(C?A8U5)_7CXD7J&.TLFB]X6F+' 6J
MI)S;B9C[R-LO&VT1.W0/[T=KE!SO=4+A[&K 5"\\,@H>(^BF2YIPRXE?-+S#
MID[K-'K(X=>75O^IT;JQ.L0T[-2=RH+B+XPGKR+T*X/ YV&ZCE./?4CBS1HO
M"X3JPUJY#0WDQJU7!09E8:P<@3R+O0)LJRE/H/G%<0N[VWM15SX[;.&5_ _:
MIN6@=_.S%ML8)!1[H-]X6WDA"8@-<27Q?UWN@('O\^9@!6*B9A>V9)R4E[SV
ML5&J=52E3&5ME*QJ1^VDMNZF,X$IQ?NO5J"T)Q7(9/N\:3$-$".-\/U'P6*Y
M!"-/C]:4#MCRSNA%AJUG7NWCX[;"X6JO!/6IM46JGYX$W/I^E5;=WQ]S5;KW
MZ&E\90013CV&J4]W3Y1F*H&X44]N>&$T'4;TN>O<&*;EI3$N EF9<Q_/?3@G
M$UI[OM?=!]T)3.,[Z=1-K?J-,8RK0YONX<>QZ^2R1G9JZ,6?Z O_4Z,AU/ZR
M1<=IGN59V2!)=*#@F:ZJRJ?:W=V;W/@Y0)68=>[;?32.-T:P9+FD6-),]1F#
M?0@P[A!A?$TDU/$;(J_9KXM]'$+*GEHN[JL;..QK/?R5JGF7]\8L #C=ZA__
M(P1E#[C;7B-O#>[WCB]/!NE2 C1'\$%@NASL(;RI)0954TK_GI2&*D]#](8*
M1X+YUS&^]2Y%JQ.H3CTX;;T>N[J4_Z!N)5Z9N=?^<LC&-.Q1/*!SZ]XP"+J;
MI/4DQH0R$;<2YCW6&4(53TX$ $'L*,S-S&A4!X#7X<51<MWU\K?ZF*J?'1E[
MM-'^KWAP5,=P 4*IO>ZKPXOCNO=TS^H;"DS*;MRJ5:5T6K2[_3I1&28_I2FL
MW^W%48'>+&13=FL<9VT@>TBK<72HC='UU3&.#K'[P99?PO7!CX)+VN8R;'EI
ME*R-0EU&J6HCK\O 2UVA7M5F=QQ :BJ80<TIZPUO#(B@E9R)GG9EPZ[NJ:DH
M+2V&4_,[(Q>#X]:%P^:CE^&^WBZ6'[WD-RHZ.NF]7A]=W9../>^>QXIUZ# V
M'*'+31300.YC;CRI2L]*E]W>1$8Q4T1^7$!?,3."NWX5C 9F6#5^V!U?'M/Z
MJM%[ZI\;Z$"2=Y9(ZA#QA:P2(+CQ\>E$'KBKKZK+(2]0W"\0T4++^0I=^<M$
MNLSF609\B,P@YI6K7%H>/F[DDV*,8 " D_* $RCI-:#?"]I9BYJZ)Y7)!*6,
M2JPFCR$OO5$&O('Y4Z.H3(JUR8!:=4]6Z?[^)(3K+,5(9J>JG!=ESKO8@HTE
M1MW?'RR)%'.V57U?@#V&EA1.%;]V6^WW[KA=3&H/TF)TMQ/,76^R VF&]][K
M58 AQ&4H\KI:D)_KGA_-@:KA9U5B6F.]5OT;4PP!UMU2XD0S2E#XZ7#_Y$7%
MH!QBNKOIGWL !R.5<TIKN*E1P\YCH\1B$+>+!@K4R3CZL1.77YOWV^'%D8+P
M]=GB=4^-B7PM=C1^!G'$/? -0-&-[XQ1*@>TX:*168*-4U[YZ$BE:[M];[JA
M]'9[=RPDW#;\U=)# Z FY5A'6%A=92]U?M=>G(F^=.AS7_'4)/)'9*8NPC"B
MUH9VX$YJ>>=,DD[$!E('+U8T>81]\"&)7[(GB>M=JPQ6/ST%!VS+-UC__,@1
M#!ER@!7G8?*M"@9C]XJTR9;H$-4XG+9=EY'1$ZK-A5/QJ,4*-QU<!Y57G3(&
ML%IE'FWK2Z.:L%R'/=WR$&BW#(3=-T:Y-[,,@9H$YE&C_E+YZ#&YOG6F\CQ-
M-ROEEEY3G]>D.L#V;A]PS .[4- 7:F!CWJ^HXQG>A<3DDC6:OLXN;PZD#_P<
M,U!-O$0D*]1'#,O/C>-LK:Z>>O_VW9_?_J7-T=KAW7'*EWD*52/WI8=&:K>C
MCR0$_,C"1-R,78O_]J$PF+.;Y]F%HB-G"VK"SJ-C? $<JZ.B/T;=KJ]]_HMR
MAA:+T4KQ//Y'K*O4TS"XJW1?_D98G$]Q%!?K!J3A5#-9]<^/=S%H^WK'N%8H
MQ,:O\F]!ALW;?%*6!QGC \R;WC4EF[4^/B& W>Y1[WTHC!3("#-ML'-HK$<:
M^85-U"[C7D2F> >T%:.I[(Q1*^+V8V*::0GH!U9M#P]/3BA0&4'0JK3=QFK;
MAA>&RM3,8Y%MJ-<=7QK%]%U2N- "[)G)=<Q]H4WV(#!&<+/4>*>8Q]%6>=SM
M90=A(1YWNLV+K!30&]CM3/E,FH-#G2B,H9[2K+7NM?C,Y/Q!U14W"L%>_;M.
M.#NT)^,';&G1T_+2J!YXT]M*N:)E*/P?@5_0L8)%=(N+A3GHH$2$S1U4W(PQ
MG?K=9L=<XSMC"+%3I.E5UV4VB[4GE1'AR11<9@QW,?;$PJ1:V%-XM%0JRG6!
MR$/).4Y7-W5Y8U5,?=X\3N>/CPE]! D.Q5"R--X4E+KZI)&N6ET#!8L([XB0
MP[8\Y8D&)NQ:',&/OO@*FS./^E"R)LEEF*39W>*7^G29TA,#F2RW])&W18FR
M&D"@RL<FDW,VSQ1:?V..:*=WQP<HA[WXF'@KI=P)<W"^R9[B!!7 ^_C42*JH
M30ON17,"%EF;+E7__+CI&Y5N)1-2$+>9,!3S8/Z>VJ.5049##"IW/VR*HS>]
M,4HL]YE&]3B9^L^3<;SNY2"=%);ZIYT.+9U>L7958U[-8JGSPZKNZO(CQY3#
MI,X)T=XK"G0Z48R_JB^>O*58H8\]FV63W8W'G.0\V6=P,A]EET"$Z&X/K"$&
M!&QT5+@:H16<##5F-<=U2[_,B@>GN,)UL\[[XX#Q(=)Z,6;!@TF+)1A8V$ZG
M'G[:Z9 #U#)\BK/>3:!K:!S3!CCT@+,2 '7+E'.K53K*M^_>/]R'V8[V6/G(
MN,6+K7THB\]-QK3>Z0166;*UE\7=D>0X02CD!13,YS# ^O;/*5:_ZF-HCJCA
M(C[3'"$\@-!H,,NZ]K%1O:A^=DRX<1DEP:-+[)ANE8?=WY]"0Y%F9)@61WU7
M*@,Y&65S-ZZW+1+^;40[-UCKXQ,!.M8A2Z-4 <LK+^--?=W+GF1L(H+Z<!S)
MSI?1(]>6FRJWFE\8Z7(ZN$>E:F%1KMJ4G2LO7GW>T 6;0(C6$ W7V8!,#)<C
M#Q2;\N+QSZ/4[ K<8PP;UWN#RD_914?F'^5];*)GPQE:74)8]2'M3V24CXM'
MY 4.^P,+'T6OUBN!#5H786A[:Z!;Y>Z),M96Y5QXR&)<4D5,"JB=U8''ZD?'
M2']@G"X-JHW$YJJ CB_;"Y@6\F0:$V,JHZE[O#Z%>#QV3I._DU.)A6'),Z\]
MX 4)'DL[XQ18(S]>I.4&%8[0]QCR&X04$4VE?Q<NU&6<K+"K87[\U-=^6R0\
MF'M#*04U0?G*QQQ]>EI1U0W73VGV0FG$FS2]X__['M/8\(<?YBOT,[9_D0=1
M'0_"G)_9;7[IZF?'..CAZ@M"ML%ZF-SB@\T"&B<-T DLNOV*=E3+<D"]34YK
MY,=P(G##AA9-L-:N+VUOC>%]#A\CCN,7948R$SHR8"U:$PJZO3QI1UQO!]PH
MCC?5A!+NWA";\E;I4K"QGH4;GD<\[F/1[T;__2Q.LT]Q]C>:8?T!K.3O8%MP
M(Q.,"_DK?*XN,CLP$T<8'-\_R/S>413\$$ZF6N/8CB*P!XW1ZQWP ^A4X\ ?
M'&5-HA2.]$"TE>H&SM?TBC7]LN0.A<6NO%]5!X_&%#D+!,>X!CKTH56]IG=L
MN3S##TSR%V_7D^YJE(FD5YH'J9GY*&_VYOUBD? HVM%+<^9ZM\]\;S+C1M#;
M:FD[O3)2XS+*/Z$5MF+Y7=I#*ADG%4U^5N%FE5YQ9:NI=?6!Q,:,TUY%8 2F
MPI1OS()H>F/"K3WJ5JKKZ],QK\2.L9#GT$3(FOYP\8H)1W!3@;V!53V@#%=I
M!56/V8P179K=N:I+!AL?G9::OK]2/E[; %121 5+MFU-CVU\90H7F^AJU?5.
MDT_;8CQ-,H-I^%?.,/SC[Q_!PEQM5M6;>^?O]M(69+72SW%&4Q[(8YB)>.'Y
M3WP66J-N^Q&8S$9N;7]1^8*U:?\ 3SS&IV'\$B>_83RW_E"K>W1RV SBR-K$
MF[0:2>'=^X_PQ%.Z2*YC.-D2.Z@-_4<=MTBK(YA_TQM'F)%M=)@;(?6ZZ^BC
MH#_\8R,M"MC@#>9CPP&V'XTQ&G%XKP*8VJPW:!"H_OF1;,UB[+Y3?^R*Y\<J
M@RXT?&NQ/AI>F*@WCR>S8CP;.&#ZN5JUNQ?),;Z=A&?8;-LK'JJ>'$B9/</C
MAB9K3,.KT;9J'QLV4UK^YSJ,:#FPU/SL9*I'&L[-AA>.26?HVD4->XI.#[=X
M+^;&N,]T:6J#1E%X9HR]LWE(Z3\WB*GW3%O:I54_:\\G)F/Z$I&*JG_66W M
M;TPA*;*I(7C-P\=T@M1!SO)<BT:,JD&''B/2CJ?5OKCE+2]9^]1V*SEXKG\8
MJ%8.\$&=8P@C5M@4BZ54KF\P=%-=\6R!ZI2PY=O"!ZWOC=BOHSC3S9NN^9T)
MEZPU>G0ZO#Z*SU3%-<66,3=1K=>TX96)K(X DU%97'NL2^G%R>C^S17O3:_8
MPXO<K%9>LETL&S-=KVL2G0\B,0F%*8Z#EY QF&"XQ$$)"+&=!?]39S6J@<10
M,.H4=S2H(0%]_2]:7]M5?FZ$%=C-DBI/J$JPJBR,.)C,1(ZN"S"\,HKE,DNA
M4=['>"B%43V&S=YDK)T)\]]_WR3U]I#Y9VMCGL7)&@L]J0R4PG(*UUYSZD*7
MU\9KQF,<?RUJ7L,+H^H//!-' LAE6R.,URS.'@3LH2DIQ\T]6.BP)Y+MU0K,
M@H3C7X'%2\UT+Q%&; Y-5NTW^X.,FBM:GX%5=^,?1L/:(JO,(&6/E[-!:AX:
MM_W,.5TGU ]ED>2:4=G^STQ0W+=WB#7RH^Z_6K:ZM?5M>?V87%Q-_6M_CF&=
MN5UYZP#R;H^1![8Z:FO6]WE][$8M^GB\CXU,*AF2/<?B4!JTIY >2&_,I.;3
MK0$?=9EPE[Z_;8A2='ESHD'K3S&FK6[@,5@8Z=/BJD*/J'4]S3$,:%U7QA,"
M]?DB 5NP<BO=.5Y:JVO[4CVF [XS;&2WYAOC\S,*$C9W]%]%L&4:RKEV'AL_
MXMFHSU0].@++'VA$$P_]6?-@!>8TWB%X1C7[]=O>&B,HECQZD51\"X6:HO0G
M1;^ * J2Z&T>TTC);9:M'=KV7#4/#S^'5$-C-3AM*A\\P@-T7-3?@>!]^P)V
M !.P]=:U'0^[O6,7)ZXN0%N=?MG]O:G%/QN#.EW>'"<^$D:45RTEX<.&>PS
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M@5DIBJ.S3;]&RD++5%XC39D(TM,7AHTD1TLY+T\CSZ'.Q(&/>7\?DD,RL,R
MI%'0G.18:JG;F/,@8JJKNZ&(F0]8@/27-[O(J>3#NMFT5_XRD4G.\RRCJ;AG
M+YGWV&LUSRYOB<J=-N@2)#QU0=@H,A12A1_:BQD?:C*%93HM*O;%2L9>@.JU
M9;(S8@R(C3O.J<\Q+<D/[V;D_=OW[[Z&J5*?>(?\Z:[ITP9S,_=UM#H^4'*5
MYJ9AT:5J(>IQ]P1WF7"A#&R%.Q9R'\>PL_B(E<+HQ2;C,#IP5355&X#)EZ>/
MY6A$:4_WE+VZ=$..MOH#;DP;R7"&.$[]8L>\7E4U[R<=:]Y/*FK>9[KH/<X%
MFI$7M7*J:$>C67!+7X!Y>?G2Y3V0G:;.H*+V%+- F\.?XHQ:1M8T!_F#M(F/
M4"16+PW!(89'W]P5M;_!GQ;$HX,O5O^.=Q)\<_I,Y]WECH#EIMT/]D42/FR$
M#I1AWQBW:1-S'X[L#<_&YTE@>-\D] F.:HV#T;]]@#&(3#4K##-4S9(S6>6"
MSA=G5S4+Z+"Q@-E !CL1QLD:L_=H<+J]I4L*H_MV[AX]"#%'P0M<CW-DTK'.
M@@UU"^G4T7K3I @0P_,S[:@6FQ687SPDN&N@&/8+^0_*'%8&##T%ZC!6J<:M
MXA<'EQFR[K$6A ?XWGN]"A!'8AD*(.Q/F[Z'LW0M8Y%$D301M(] '#:6),5R
MECO5/EFAE/<%H9'WHJ8[ 'Z[14E8BQ C8<YTL**%+F;T&^?JPOV3%Q51&&B@
M,!CZX6\;@!1BI_*T!8YG^OTF"EWVR)KB'%GWI4K=VFP@;U0\E($J:)##5#C,
M9LPS)7J#6)X5@'__Q]OOWKY]1]:>RL-]_\>WL[=O^?^7NXIXF^PI3G@>JL<S
M(,O>^O<RG[[DP_^._/GM[,<??IB]^S=-*Q21+'S^3W^:_?F'/\W>__&=^J/A
MN&D<Z4\_SO[TXU]F?_FW?ZL@VT[DG4/'3M^58H5%NA.+) -](@KHLF([\\*(
M!A=>@JWH4\,$.J=P/>[1=*CRY#(MNT 0/ IA*GPVBCI1Y,D;4SHY@OO>5PZD
MK#'%CW#!V%YKY1:HRU)OQ6M1;1>#Z35  PH[312':)B8^]NDXBAN<50!XH@7
M4?;4KB?BE;(JG[$^F"ZD:3G7M3$M#TQVV3["BLNPKDO%M(5@K?P/D+U8V;)8
M@DY:<1:5&A4[-%"<B,(,*2KZ+B/&LH#0' 1*,X><XMT!>M9R<"+N0]0Y,A8<
MCV=>DFR7<8+F5GKQN@X%=-K?J-?K$/BTTY63^.9(F$@KAR);&.O(1)4K9@"!
MH82% 4@^ OG;\4E82@A8[+&6KAI1?*(O\\>$4CO*&S:;T>0FRS&K8-9UJ^O^
M7)>K_TWN'9K[NPB:\BY/;[PM^OHQ:V:GNV)/%*HJ0$TU+)'C"M2.J@Z,[N&H
MAIB17>TOQ70@+;H$I1J@>F(8@9F5U7<9GKE8T>01CNL/2?R2/:$UX44V*I45
M72(($TEY\J*P<:2H+>JQ4;^\V*E*<EB\;$V"'=5)$1R\9EF6TL*7R/&[M@K?
MZ<QC+&T*8MNK8TYH0%>B<F[<2N;!YH)534,^^HP8XTL##S@0@8/69&R7.;VW
M5/5ALY(3G9,;*">Y/_^5?;&&E,, .(LCK5">T]1/PG5?')P"<>)I93O(R1^+
M6*Q*HMQ\.#\^B<J-C-K7:A"D11X1/-UR,!JKD(FB=/!T2P3.S8# A[U%8B5I
M8B7-PV#27-,,)G:Q/(/K-;01Y^'T4!)!<=J<LVJFAXCW'%K,ISMFS=-TLU*5
M?6N*9;3W-%GUJGM4A C6J7T-PIMZ1K_L&Z/OF,'<C.@IO7<ZI<46#H;E+-E,
MSS<'*S/5AI1PP1^G1/J[KVE2H4;;SC"Y_4'"C0YA=#5#^?6^.$N&06X78%J8
M0$YR?N4X$)%52E=E]K@3+_?"_!RS#>A?B4"0LX'LH2D*)#FG[K">W+.!&3?*
M7F0H6D>B12#Z_=MW?W[[%PNQ^KO/!&F=O/W+D4G!"N[FRF"]%&P Q4<A&?=?
MD#I,9(?F3#_F68EO3.&7"J<9C1Q@$0IJ5Q3<TBQ,A-VI*U)[7JTY27)*([H,
M,[=.2[."BB/+\[)H@2!DHQR,Y$0E+M&T96##LZ_/,%"JLE2KZOF6ZE]K[''2
M1\"Z.G(YO8)QD-,\QG*'#P@U6->3D__Q'*X3/8%]OCQ.C7(X*(0W#(JPV_^:
MO/$K280\C=U.Q=JA6,8WX&[M/L61SJ02B:TR8M;GZ!&BAS)/5L8/OYV1B#H\
M1*U)(G>%24_G_$J2;HO1"QD%.^D$H'WP^35^E9^0$B[(2BZG2BIPA_ X#9F+
MRKY.K)A5Y]2@ZBSVM_%KXX[2D$U#E89[VK%^M C)MF5A13%D:95SO./<5JCN
MWV09\Z<F N<RY]J=8&Q'IE)KJL&1?[ N+\QTJD+,_0 T\@MGCZ6%U".)I 1S
MK&,5D'60;00XIS95-6U!4%,X:75*:0%'K5]@21 R=,03A6O&#^2O=9+V4-K3
M/;$T:;-J7@0"'!6/"//Q/]%LL;SW7OMHZGO5NLT(+[Q8HAO.>7*QZTFH*?B+
M^23XA4E0A@P;'8:JC\2LYXJ[$[RJKXFHK^JUJDUH/<<@C%RPRCXLPQ:B&>#U
M.>8!/U=-1%$;>/P%+ 0Q@@G.>BRBL9&ER@/'2PK&: "?KW"LWB3HT\BV-T Q
M ZU/%VSWS#KF1+F"1]W7JKN32L4 Y  \WJ0\TFH0^ F'X<(.49@OD0R4+5R$
M&>L9<](P"=HJWH$Q&ZY>E&?'W%+=-WL>11N/X2\\IC)8["3B,%Y7XW'ZQ"&\
MMEO96%DL6>*+5)73CHB!B!A)Z;^NVGBYE;>^:%3(S9UNTMEL+B[\1^7\.PQT
M@Z*4ZVC]P',T*5[X.VV6[PUC G5%-D&.Y?X!*^XA+M203YC9['CFM5R9/V%6
M6<[E0"@NAS0:%EA_BZ7Z=[\5T<"!8?1,4^F*.YJFR[WG0JMTO=IRY[.H&1DZ
MCW=[8+>1XK&G@E-"!6(NZX7=B%,LG3"%V)(3$Q4$_W8L0E6K<H6L:F>-8':K
M=,R: <J# T:H\R-PM@';:!'=XM>$7<I.O31,+0).&\4]LG;Z#ZFH[@F7(?IC
M.5M$<8)-I8QT(9ZO)3DCG+4O=,[8[G3ETS!3LX1FJAFIUK.V.T^#8%9K;Z?N
MPX*5 E?1F;<.0>6QD'6<-WA!RB=PU4G:1R(,:Y-C@'17,X@">_D3L)'_AF=&
M>CZ_!?NO5WW(ER-;&/\V,JH*+QWM-#!;,S  =)RRVF\I$W;?O??Z2Y@]8:,2
M.$%0B:L,&_8SA6]+G3Y%_Z>4O.#(E 4$E#?=&PH.0+I:LWA+:?H'\8A@CF3>
M:ZXF'/$<E6 .Q' S[J8TQIE5QSSS?31H=S(S5FSP8,:+35- -Y(L=ERT8P*I
MMF%PEJ[BB#K8"I.;"*4EU/7**_7',T^;8H^\8N%;5;]/1ZFJDYO22JB*BG9V
MJH6=_)O9W:[4QL[3<XOGF:?G-BSV4G7HOMR)J=1#__5Q955&5IJ #IWG&;@4
M? _(RJ,4L"E<UK2HCLX(,&?@VV);#M1+@[QZ[R:)(_C1%XJ<1;A;-2*10Q*C
M8K XZ%&+S/:55F<G.#4E!YR!TI&O9\*3,^'E,[$NC.L*KO0R3-+L;O%+?_N+
M4R) :I*<L@*39$%^<0U0VH_?TD;1D^M@'^2I*[?T,<0H?91]\E;]LDY%QDI.
MD"#%Z?+.AF6[&7Q\GO%;#@Z!PTP60T]J0"#W9.TSGC72U>=817(C;1DU'J7U
M\0<Z'GQ\3YG8_HOGLG\$W',Y@!Y<AX^)MU+Q-)&%-M?MGN[C4P/$;^^>7$6E
M2(/VF7W55=[;LI /]X7(KZQL[J,R)D".:@80Y3SD0TO '&/TX;+)K&C!:-MP
M)7_MOK;*F@#JYMC-@!NZI6MU*07?2M*'@2>%2/?+<;+<Q-MV:A[R$<EG=&*<
M,L__[01> 2JI] V=8#T*?N(?XP!F!5T8XD-0KB/1S0SW^87RS_+S\1.\JSVV
M7^I45X3I&DI2"A,GVL')LI:<GT'C= +QZUK GFL S-ZP6H*LB'.;F*%#X#=:
M$XB9LLQ4T'Y0:6[I,XTV_?H,*!H#M+ [C-EB"@MF*#]&H<*U3@31Z7%=U(DF
MRB0K;H&ABPK[;-N6(-<,KQ=N4,@<9.?;VY*(ICG.845.*F(+,L]YZL*PPY;*
M*2Q]=:D(*+%]-F-U#8QCR!.KPK06]!R1,*PH1V7)#J]M=.1#1.3:Q5)#,O19
M"R2%UYSGN)M43Y:9P2V8^*Y[7_7DMN2EW9ECE_CNAR(Y*P.%IACF@.]#H3C'
M^"O#TU(JMK^EF!D$OT?H!:SDVGBL-^RUMA,5)$&B1H%K2@_#0;'!B.$L$S +
MJ4;+C@DFH_]KFEV"DN56I%@ ?OP9*X"_GID^N@K, RT6,>1RC,Q]./X$_Y][
M& ,6#H]\C *(S+A>&:4\#P;)?MDRL[*X Z05ZB['UV%$K^#'7F:6ID9^17J$
M$YPT]VPDQ@^%;$3$'HQTB[9.B$S P5 6RR7%1'+$+>RE>=($(^MX\L!]',C!
MN$M1.PK))@IH0B[N;FZ^C@FR=R.<ZPD5C;&0/8%F _> Y)!C3SHO$"ZG'GV*
ML[O-PS_@;KJ/\]ZR+C.N2!1G)!5CXFV8]YD]4N'E-FEL&PPC$3D4N8^-+L)'
M*O,^C81KU]NUMG_(,7*H&FH-?ZP:=&P\7?YH)G%:^KMKS#),Y)%EM=MW[Q_N
MPZQ?7(@3P+O_W?LW#]^JBEU'+6#[,LX&YME$;I1018=EJ95J@HU\#/(_WG[W
M]NT[V(K.H:=[2U'&T'2?4]*;958QXP,TKZA,=LIKJZK_WA^"S:C>0MI?AH!J
M">N3O$IBUSPU)("; 9Z!C-PD\7,8T.!TBSD=5Y%6F^9^%CX+= 8+G<^XS$L6
MO\A&O+DV[NEQ'#:5=B\LRRT-+JL:"N_U-SQ=)HR^-2HA\A$'Z8PFHH>H?,01
M[+G^CC#9Y4!3G#CKK)KK ;Q:&@U 5MNC5B>^<XO%)T.TAW F""O+0(P1QCD<
M5?7N?3SW8<LDM+XO.:+)]"MLOI&YGND8K=D="5I9G9RBI2+'&:?+>EYK, \"
M>";ESM9%PD_KJ"=*MR@\D(0Q?0_+-L$Z5L2G+PX;39)B1EX-HH[1N_1OU$LN
M@5"?!7O_]OV?CE<2N5;[=6&=$1R.X'B.O'PR>^<RC+P($X%Y],*&!GFW6:\9
MOQ(\QJ,!LED G)E1')WPE*&E&M6M5FE?4*4]RM0G350$?]PCKUH5IN2(54+E
MBQ,B=8>>5E3 V^R_XB],2Y!#_E]%?B+2@L5_X=]L@WZUBU>XJZ-'>@M'XL5R
M20_8U"4XQT .@4@4.%&SG=(G;C4FN27I.S>@ISM[ALD]:[>W18^FLA%>M+TY
MQT2Q3-XHIK^=$<TW48P3Y)P(UAWWL(0'[?3>=)*LT)=5-@B7:D]?13 UL OP
M#NR9$,EWT!H[FF,D.I2$)\NZG&=%16H!L)WEQI8X8KSX3#TTJ_13.+IZ;A(J
M09ON8PF6=.,EV1;LCT)7JX,3_(H.[GPX5(L2,2"L)Z:XXH+ZA4Y:KC,MG0M?
M3.7]JD1G.U+?QT2.1/A0'+VHIG7:L4I=4KX.7'.GRAD_<+B5LGA@X2,?.H6K
M%E%->U4;*T>*S H2"B=U#?]J62!MU_&B:4V/*'HNO0AW3Y0QB;-JP17"R2G<
MUJGRS89D6<+4J.KNQ=*((MJJLR\6U9,W5Y%(+'" ;&Y3'+8C"5CVOI D=1/*
MM<G^#BK0<&)HA%+&8A_/]^HDF4.;.4^C!LV-<'+3M=:D.:M%$S!#!<#H1H1H
M.T$B@<R6XS\OZO"?G0$KN9-X-YKT!0M;AIB:A-"U:(/P@_J=_*!N:4J39][4
MFW?8]EBZV_&[9S]'WK>;.F]</I:TRI%2!;R(/^L_Z-)GQ8: E):,5+8X=UZC
M?H/^Y=#W&#(7A+"3=9'1#4W 0%FA!I]KP0:>@H42?&QG+L?G&X0S,#/JU]8Y
M#R363,Q(D+/Q)4T1*\V.'II<Y+.35X$9PQN&2@'TPFVNIG+*]D6Z4_1R+Z\[
MI#L;O+-AV:ZXQ'1PD0/?PP&3GM+LA=+H&O8.>\?_]STVOL ??IBOL-"D5RJP
M&H:7YN;=+(RF->1!<$#XF.3=3/[P?H:1:_'S#U_,Y-1I.7ILDD_9J3DQ[\1_
MWI,Y-@/A'!#!PA<S-[NF&/#'XV@1S%"FYR6,^!Z*-UG#KEH9G666.-O/JK.,
M!Q>%TJ@>N$:U247\O;C_1-L5L?]@S/7&:>]!WAMGL>0V[+6-.DI.$+T*,D/Y
M>HB:1"M2,%. >%@!YE$6!B';8$>./,E)A%UH@ 6!:+UNQ!Y=+,M0=E96SN3!
MR+0BB@N";!"##USE*A"\+WK&6,?)6I8G*QYQLD2B!BTF%6&B1?]&:I>FU]S0
M>E..^<*]6;)OW#I.W&K EJ5D10%W\Z1RT@X+V,+'*%R"4AUE!CXYIK;";K.#
MX;A9K;QDRT^\?+ "0+L<[MBD5'IOLU0#@79V+RGHFR#$TX$VHH2@LG#B&(5D
MN7Q[UDLXK#20L )W-'D.?5KM:89#XED4D?)28HXC9_[]+$ZS3W'V-YI)<,+?
M:2!RC"[CQ, K[(6YHSCEG5O5*$6/O!]C(L=:9#=Q;$0]]-<Z@UV]_9I!57V+
M'/%Z^2ULUYPIG3R&D?3;(>:W+Y31_IA%[_MLTT(]\DMWG"CR!M.4';9B/H)Y
MK-BL?6O'IP?OA '7,%,]%7%<&)]&>(V?ZQ3OGDG5QABB_-(<A>3##%*'5ZP'
MP'.EU_=5;'',S_PI\\[*;$L=_,PIW[#@*>B& ?]N+!;=W20A[*$U$X5;A5&.
M0QC]@1@DAZVWXQ["4J4,' 25AM]'+^/N;HMH][FEI(CCSR+URFR4C/=[:=.Z
M2H<==#+D!I  [(:R#<=DP4PV_,IZI@3P_ !MO0:=DI+S6)57&687S$TALW"6
MMY.=D95DPJ&'5Q0?A,]851&OZ+WWBC4)J'[":02L<!6:QX.NHIV@=-[3@+'X
MQ>M9\LBM4Q%Z M/T63<H\!1Q$8*^=8(B-I'YD-^0YH((-K3@I,@)7'9ZPBIB
M]F:7AWP2)13>L&TQ3&W3;(LA+7&;Y[#9#\-H>J&,?H?P.<,+WM4(%8/.]!P,
MVNGC$WUI[I[HHG&F; TS8-_,H<35SJZ7>NG& 3HP,EY%,RK#1MQ72N%KNH@4
MKH&9ABS[D)>-T O1#^S48Y[3LG+[8MYE7I)U%_24/H91='2R5L!JI4+*."=Z
M'**PCFOE,,+I^PGENL8*(V>_RTBF F)%#\A-0E?A9I5><0<D/Q?Z88OH,;_W
MC$'QH@WU$(, C3@6OA3,58.1-^9PWZ+<>D2NR:LQL=97CSH ALX5SP,1Z2[]
M$>_,B-@B>Z)@K3Y@CB=7&,10Y(U,1W'H5;4HG8K5ZORFF90C3ZMQCY77C(63
M_ZM/@*\##([S9D6NY"Q6W@Z!4>5*$M9YL0:/Q8ISRSE@7ZB&&16PSZ*PW0+0
M>L"A /NXQ^OB%7%Z[[W7' /_4+<$IT0R[Q5#P9+6=+DN>=^&Y!XT@4NL&PY^
M\= ,SU+K<+IHW_(;^3,O3X8!3\2(1 TY;=%*6 +'Q3S3?),2WPX5"9L"[!;V
MEQ? 959Q?9RVKTEIAF;]0FCVS:<XH^3=OSG46"W*Q:I%*M!TB1(C?=^REWBV
MM=/OR'!F:\HS1W4F+F1A;6(,@ "[X\40CDY[OAA!;_("-'I@7,F0)MG?/X91
MN-JL^M]ZDI#+&Z,ONVPP3CENX :I+Y8_PTF=<@@-ABTU+CS_B2^L-8 +,1#Z
M;YYQ*$+E6+Q["XQ&4IY]/PQDA%.I64'@Q9+P48@:AK?J08%%N4$)[>,8!2[#
M11ZTT@YUG^KK:/X:]E)]IG.Q'B))AVL5R;HZ=C[ +Q[CTS!^B9/?$&G)AJTF
MB!;QP*;-O[F?)/>*)L>N=/!1V&2?57*.C+N^MBP)4#JY!EJ"''#"]&B6/9_"
M[MC$F_1SE% !\(B-UV[B5"3/O_\(3SREB^0Z!O,D44>\^GNOPRT_P_,H$Z^W
MW6A>1%>VM1QM1E8Q'.K9DQ>1[(6R9PJ_0/:^FNGK[F&>D9PYDG,G6OS=Z E]
M]YX(%GGY.V<2CF:],)I1UPCH(EO28KZ(J_1+!VPSQ;%((A0TATWPZ-LP3S:-
MPQTX;'O!&3&&_NKF1^X<F]4?!J<C- ?4$;K@'QMY(<!1VY!XU5?!-A*M[C"U
M@_?]_+P.G.:B.I6.M0KF3.M6\H&F?Y;0(,S,_JU]5PK-!T&UT*'V"*1@C0(X
M7XU=\+"S ^O_C80$GFM O,%PT^P),0KLFS7V69%S@R H?,Y1"="'\A2S .90
M@'Q::=EB4/T#;VCA-)7;F@RLBGW9.FZ>94GXL!$=NK(8@<1Y'[DA>OAU*'3@
MK9H0/RGV/::?ZQ>E$^V?0N'KR9":A@)94I@<."X>:$2783:5<@];LR W0O?:
M#C%5'/ )AS:>I^D 91SW"4>KVEIJI*O(N6ZE:X%M5L6QXSC-&:IA-.%@^C9<
MPB8]5U!^EMAF-1P[4WEV.MW)_UR'$>T%45#N=2=_($B8W+_$$Q>%C25%<[OE
MWI]"7:_D8Q"$M<C@W"XXV*<A=)RK"%09[MA.>3+Y_9,722\"&+5+&F8;8*#D
M[?B *4CG</OI)/!>(&1B'(18X80)MVYS_,5_S9TK=Y%4<PTY9$4!]\UK9Y(A
M3(4S2:P92D0&R?I&UK&!6&^?$3?;W;8BZ\4L*_/I_BS9/*1@N<%&N'B&_[%0
MJZ()$DYQXJRS:JY=1R@5D!:F)7Z*(ZK^V7_^-65^-YFTCT(45I9B7I+BN%:F
MG/!>6)S((.\TD%P"1?B0Q&FOHB9.@ 0*W@#S]P6\\M2%D+NKLID")SA!Q:,8
MB*+I5210Z;@C]RK*DC!*0[^W2J;H@XXP?WQ,>)4IT>0GJY8YG!UW,3K*DR4$
MHS-CDAWK45S1@S--@]T(]]6AC:., T&HD"9IY1I[(ZE_Z[S*T;)T)@P;E\YY
M"RR[ K#.*^/H(MUM$LV;58;87)IZB8_6^#G6^L9K_%8^T6RQE(&0&X$\W;.
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MLL&D,I925SK"_/??-TE_M9R3F1Z+S.#.M6K=@\V2)L4IN8)&.(N3-6)'4 G
M Z>0J![HC>3H*\ID);%],*V"<N+NT1$=R%5:EM'D,RJY2KI[SSA#I5TR0'3!
M0+)&. %08452IX%VT$\P8P"\<!^$KTUFCAJ]DYWCI.H4VWNZPLV3;*]6:R],
MD#6$0Z FEKC /FB&?; #>I'CJ9.7,'LB<9Y FRE&2:@Y_5(G1^X6$3=$1HCF
MA.2L$,&+B;^N8"I*8!@Y%@:F'Q,W:,O3F+K2V;AHWD <2X7G#.53&(DI#' *
MC?WHZ2G$GF8IL.;079 WUZG'Y;;C##,:"!4!4U#"PI'DU"\TB.#:G]"*%#.$
M%TR!S^KTP%Y(( J2ERIJ4^6:E1B^F#K#I1-E=Z8=G@.@"&U6&X9M2<[I.J&^
M*)>%GYEH"1(%9IN.FP2MV&Q[P]"C*K07'B7OVY#(X(.8C* 2(UGAFHS)S(PH
M=N G9&BFE1V9)S94#Z-Q9]'L=^1F'@=LD3365)KQ=S>3Z+I3R- 35]G4"%T^
M&/G0\Q<8O'Q!PN^8D]8WS! J4.T\\'Z&5M2^Q5++*<3D":MZ(-DZ<1"%SZZT
M<NE+BUA<PP&D.[3X0M>SSM-TLU*5&&OJPQ[^.8:MS/.H;@]P_A8K4P1%\JQ)
M?E5S(3>)A3J4O%B7&%S.B)[AG%%'*"][1-;['Q][I!.X^L1<R\N^'E&GF##Q
MB<IL0/0::0/]/C;@TB7 U'G(-H@(8"%1_Q-,0^)E<>*V/]<P@LD-C 4G*E4?
MA_S6< 9F<0$#7XX+:I$8>1"?NS[=3[<?.001/VXO$UXS[F_[ A,8-(DF>E32
ML 9!G(,8=,$,^Q1C,Z4-/ 9[2J;C<[]K_YH9T-U67H0B!R%PDF!0.IT*5IHU
MN>4*=P=+*XR<5ZCPP0< 2\-&L"S&W<C;5VA]Z99R&^LL3K-T1Y5+K4!8BU#9
MR<.NKF8$TF#Z8$"<2%3Z72:_#3L1%>JJ5D,-3?77HX#'_IFF>+F!G2=5Y/L8
M?V7TD];%\O9*\6OK[V=$\(.0[U3I[' ]/O-ZB QK/'D&!?GAW8R\?_O^W;\F
MUD45OUP$_BT;JX"_+K6%KUI)QT7^LG;V*H(/'KVL-HJH0T5LNFRS(L=7[CDN
MP0]9,%?+$$3._3X6)&!C,?^!1@A-BT[9 #.*T 3 V]1"E:TD+;RM!>*#U=G:
MEL[L)&1(YQ6('XTXK.LZ.03K2!Z]2'KAS^!6B%D8>#)*<(.( =)1L5A>AA$<
M1*''.'BPZ [0SU@VQ^;=8O+1^5R8XZ-_1'- <A;<)V_-'QY^#ND<+D ^HH4L
MV8<' A2))CEEQED-S\[S:&TP7\ZHE4)XBJK+G**>>J6A?MGLU[(;),_#V0\B
MG)WC9!8;W7RE<Y6G9<@$BG]-DW/#I&![C-8"2%PWHL,6# 4WS]ICRJW0+S-
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MWPFG"/<WDB1+I#EU[IG)N*!&.+D!OI/J? _9+AR^57F 'M+=W0A_Y!D>>4]
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MNSCP:9TD[1?R0:[%XW@39FL_@C2T&_J74<*/).EQFCRWC5&=-0O1Z6?/75H
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M<#,NI991H;+[QJ'0X8 'L4@=^*N"NZ53[GA":>G8IUK$/=66P*$:KZDJP8X
M_>,553'"(_"GU(K"<B1/0<N$P;SZ:!?L!SY@&1GC7.!W_!W4/#?*W9J3N2B_
MP;DR%DVPMB<LH/693!+!?-VN N8P@GE*+G16 Z4&V&DP#*O,=@':RB%SOX^3
MPJZ4I'2JE98TSX*1J,:#*#<D068=L@*)9H^I#P%2#X?=<Q*-R^!EA#Q.:8:3
MC4XS3Z:"_8VP8H<D6RZOQJO5);4+C]*;[92CQFR])?W?E6MM=_R\&\KL2;ZV
MU8?Q-<Q?7GC@XCCO/0]*>*O(N7/.N.&JKU8J;TMEC#-CL;$).:LA9S7@K.Z%
M BZ* BK+ZL"6 OD/CV$.,3JW<1"^AD'A1\ ?RS 'G?\EW#\F4^5\LZ' A%(-
M=I8\149V'*8!LXW)ZYE3%95YMA_V_IJPTGYE.?1126&\5#GHJ 4W=64P@%>P
MXH%ET?-S82VJ<05VVR>.%,5HBY*(BW/CJG&%*&OV9%DSEW;8XCECB$/YAU?Z
MCRDJGU4D/4;3 Z*SYR"R3-YYI9"6!LGR.L8L B,P]PG;E%U'#/#J63*XBPTF
MX+>"57P/G@]XQQE\\G(*#!L%*Y07S).C>:O8*\<3>,UN\5].P7KT+\EULYS:
M?+B7Y_72CR 8[.&%D'PITG+&WO."IL>(>I+J_'F(;--W?M5KDO6.3D=48W)4
MLHZ+Z$S(0J2;?:.^#I@] ?#>_W;1JJQSYSLN.>_S:J?L'-_N]O1DPT&_HNK=
M=EP$7Z..:D7;$\2=>U0FYDV-/:V863-JY\)$U'-M9@BBHSYQQ8Z[_._#[/<;
MJD/(@E/@\!E5:XA ,1T2_.*_DM3?D@LOI2/\LJ%#>*$8PTN=>LMF]WVDWC ^
MA:,N-L@Y7G@P2\"%)67A,,<>2:J50GIL)I#!KXXL2Z-<=I*B)TB6N#S.+[F)
M>*G;63@O>TYR[G./.I;@=#6!ZE%M=$+%KF!0F"P2ND($@'?_DN7_#Y$HM-9U
M'DC>P&DX91TDMSP?41I)F0*/0%>A&)8L=T!@+SA%6M#@,8/"7X+]<3/ F#O'
M!,C, -LJ4$%I;W!\#TW,KW:S<]9XN,/9<-(/15N[: Y#RFA'*-,\5D4&.HZK
M5X^9:M28I7/EMTHJ-V K9Y>'VB]3IMX;<9<S[_+0^/6$Z?4.OT34^ B)[2-<
M@'AZHJ^@]?*-/6QX_LD19T_KA71\"ID:$?O1/7DE<2%1?&[O'R: *R$!O:.=
MOJ.3SKU\=CA53Y M<:%_HI1_=AT>4X=2!FRD*6(@J]<R K*NXDFFFWS4G#>C
MZ %)]_"MT['1< 8TEL%;4](._;G&8'CP8XZ/ 6'U99?A*W/6J4:RL^(HZF#&
M=1R(XCU5,H)9I>K5YBDC4R@#C!H\+! ,XDHG<,%-O_1I7M<;Q#H(G'"E#SCD
MSP3\V\AU!Q-K:R$=WA]*R#25 5?I0PY[BEDE):#3=#'@>S_U7AUG)$_/3U1C
M182"4^)0;9Z3%U;<$G/*99V4KR2*_AXG;_$#?5Z2F 0L\'&4$">JIP#E7WX'
MTIZDS0,['81E3,Y/A,:*8B?AZ3P?OOF[,/9YZ:#?212^)$E ;XYXX[\F*6A8
M#R2G6L#8 ,!KDJW3<"^AS^ B>6;% P')GXY[$.4R2FM?L6?XO7+L,_\4E05)
MYC<IHT'5$#D>?!QE1._A!%_@BY^&,%@I78Y9:$E,D2AG//.H,6E1Q>7*R:S9
M@_TYB0$#]:Z0=;N-(N1MW/"QR+*Z1*U.7X$0CS,&BEFP<$\BI^#)&N  V":0
M#,/8\QM>)M;)YU/SB#.LW[E]/[%YQ(P\.260^\K/R7-S%VINKG<;>TV'%VLA
M)E>3))7I_?@?M"%VR@^K%J+?EUG/^S+KN=JN77M3D5T]OYJGB_0'%J&=/[Z0
M3PQT?;SU:O'X::[3% =AD7M0^I%3<FV7&CWIQF;S<R^GD^<0^2YCVIT5HOI(
M2>39L86HZB45&*T?JT[7N,^CGD3Q<?[U/H)TV9RL6!F?[BG 8HV/WG59NG82
MC)B:G*7 =7Q&L5).P%Q4YTN+1N)5XWC_C0L=(Z%6 XF_\CH:<!811&8*;OHL
MX$4)41M4P#*OJ*&FF>D.U-YT,CATP6-#)=K471JN1YD,RW>R&7U*!54G-6?/
MX/L,>"6ROL#AS8>@^N">F'*)(.;=N?GR3.J4P,6L1LRM4(DM>I$L?#,)6#+8
M4N:CB)_J4T2-K\#&\^2 G<JTN])#)_T*#6UE[)Z8HX+#58W59A$$(73QHRD!
M?LK@/?J)XH92X_DR%M7;)"E#36 ?]R?:EK=P".8_H^\UG7Q?J8W5[$Z!2%1&
M.H\K"\-+<(V2\Y.<?H[0CZ*#)YUQG/U&21@_6A=161+F,\OVRWA)F,R->P[U
M&TE3T33U<F2Q-+>PS/3V;J!AE_DZE6(S&M6;UX&KXV.?(5]1!TNU5*)J&%=6
M0HE20=_=,&4[Z7IDGEE)$AY30=,+G.0\3<E"U)Q]1<Z[GOWLF] DIC6PRS6+
M=%V;N)^NY23HOW;,0[3X R!2DGW^"_^@HCM<5VJ@ 'WUZ%?)KNB_KM+'Y"TN
MOUAB;<:^RQ]./O$://0]D0Z7-D:TRD;O3LA,Z4.D%!A,'5.=G;!7JJIWV@NB
ME<JVI8E/NX@CZ"%_"LVCE=F6UM8>F966C&5AP]1V+JNAU"9[QSUTUL5H-Y_-
M"6O[N(><IZ[>V&Q:*@)\)F_LE\QX[7=U1&;NGF2$-@=)]QIV5K(7H@@803B4
MO8ZU'MV0&3-4+[X)8Y_>TFKU8ML5,IP*]F:=$F !UA-JKEU#:A.) WCFM!O=
M]:!('Y7)YTLJ?A+2,/_?$T@PD/DF4/.%GH1&&W@\0?4&!LS7H:LQT.\5EHEU
M!T<B7/L1K&H0LA"I=<KVA!^!17BU63WGG,VK)#:>PQ'DD#X$J# +.K$ )G<3
M^=NF?E/[\5QOC<YPBB\DR^'&Y$\?R](O#_VD5\FHF:#>+Z)H%-W)8 ]])>!=
M?O_KN_]%3SO]OS^W)<,!W;#W51O<DZ=F:9?>U!AS=42$Y6W\2K</O548TI].
M8NANC;P6]13)1OZ3;CVL'9"9$2<_NTG2RJZRVBCI0CJ.NGMA;K5//KV@4OEL
MB13FK#3D&>Z!7KV05XN+-_7])+6]PU,<""$&?+\,L)EY+'0+>!2AF5DL&@7(
M^A@N=#7+4%5&48M9[R+1_]5LX!A##_U.!='B-@[(-ZB S'/2,BZ*\'\"%H3^
M<NW3$_OYAG1(EJL-JH7>Q*&V0%\-[;T CS+'2NM^Y32=D)FZ>@')MXR7 2M2
M&L;K<!^1ZD]T&>* "L'9TQY\/+<["$1,0ZHG,5.UCN\IZ,YJO>7CWKW(LB7Z
MZ;+4.?FPVT?)@?"2HS+S"$3\(9;&+E*8TLY5Y&?9:O/5!]4N7Z5,OJQ%598_
M9G=^&"SRJRC)*&M4Q6?5@^)M2Q::@":VU5)$+)4;5A0:U:ZZL3'VE57)TU?^
M/LQEV!48C=-7$E#Q^Z;(BY3(&#WM_324"*:=IPC"G,XGI.IXT++SJ#]B7SG.
MK"OTO7QE!I:&@9*%)4,\ Y+5I_^\?MBEJ1N^9K8^ R>'^6(]DIA.YW:W3Y-7
MPK-]86O!OZV>HW#+(V^:;U*O7LA[KXQC$(&GLC27;BN8VLXGA(4#^I0U=Z_H
M@W_8)"EL1^TSVK/K+&W$0XW#J%HS@"_>I4E0K*EL)BQ53?W8U ;;B*/*T&93
MAJ89YK8Q8)->)1'MD?"@P-)2>!N'$(T-VZ:UGXXE-)-5$]-7 DRNS :!SDXS
M-*9F5G.BO<=,UH@=&2X4]#Q?:N-962(Z_?CONFT4W32PMZ&"9Q(';$&@5&II
MQ-1NQ(X^V$XE@<5M%G[J+3"O]BIZCJO%-2^644?N"$.9@BCF1Q&!A/K@-,V5
MW[L3\L9L7 ;2[B,6J<@S,--"-)HEDFTH#6P;TA'FZ460["F'4UF[!3E$NQ)/
M@0"-*]T+*8LY7*Y@PNGA*@EJVGK/+K-0-DO'D6W/&IIB7C%/#Q^I'I_&;#Y;
M0K<0R1I%8N+@,645(^E_&/2SHZC,8MWJ*) *9J755J#O@BVTI5L_#K_[7).)
MLR0* Z[)Q,$=O11E,M5J(\)]_:C<BID&%T8KU$T\!NKKNJ4:'F!4ESXD$9[0
M?E)-+;$S+]@W)G5/KT45M+7'-A?[3$P#P0P$TM5&4<LM(7:=O>:C55C6978Z
MN2W3P^A^'>#(M1/"OD=+Q37)LDYKJ[DU]M:SQ9;)D('K@OR#J@F/+RG1.DH&
M$\&^$:5C1=2X9O,K:USW2$JS]$.75WBU39&4I)=/:DW0)RRDI1X1@J:VF/+!
M2N;OL'@+9A1(Y#6EV!$,(O&@WO@KU:BA)^-OOX;YRU61Y71QTO+<&Q9P" E4
M4].QSE^QI#=)NB%ASI*(XZ!".2BAU>@QI+=&%JY;_F>,\9'WEM#Z#FRW<^N,
M;O]HFJ&JQ7OZ'W&NB\'3_8Y[3<E*EW'00L?77$N6UMA29X5(($5#[C UG)B(
MOA!"VP2P@FT,"%/\"#!P-G.4KXN!9B.U:MPM:EHEG?>Z5^QP-PUT4^+#SH^B
MRR(+8RJGZDV'M2;8=R&EOMHH-[TIFE[;$%U(D'$^,+LKN@NV@.GFVSV<W;V0
MV>(A,A;EO-8 VZ-G@@5>TNW-DO.T7K[.7F?B#Z(W<[C6<3B( /8K9XMMKW*'
M6#,.*L#E/;TCZ'AJJ*97>C6OPSW$H\!#&Q'YN.I\EG3[_D;6><8Y:QMGCZ>%
M^'X! -B"RKPZGY?Z&_9F':FK*&?/K!4Y'PPW9BW.626QO;\F3W% E6 0KLKH
MLM9^[NJ RDQ")>=ZE%PLOGY77F__KF>^Y17U7"KD+C:[9ACLD.72O<?B;$J>
M1. ATY082\\*2U:THG$4$6_W:P%>R=?E WV"&DA#QD:SR87NB S6-L2\FDH+
M<K5IM$)Q9V/L0*&$)9>L>3HUE5>V@!=J7@A;>^P+09.((/\F7!2UNR\.+GF!
MT$Q_.38-6B['.?-'R%KKPW&.U'%3F*&WE$IBY*V=0="S"[9=0Q8XH(("A$DT
MPK%V29J#%1/V.FC%6L/!4!J(>3CWL"MUR3?E#]CV64@4[#0VM5MA7T1U$"NK
MG<G4%EVFT2;[9)<']1>3*;9_;^P#SW:-V8*)O9$@#) ^O<MD[4=_HU=(%H1K
MN^VXHPN^=$,W>,#<W.%S ?," ^LG_UNX*W:+."X PK'Z$6Q.TMUD\<%,0!85
M7XZ\J3'I24S_=<W#:2QA( .[8J=X->"LKJ&LB=X\:VB*?18KJ.IQ%6'Z F)/
M- JJR;HA"U5\=(1.#^^-?[$QU8F95P16"7-XIV0/(#-QH$@IU?3[U%8XDB2Z
MGUE4[;BCT_>C_Q/NS9DJNI8S,$3=T&_J1UP5NZ%_:SG+C0W1A3<53,]NB8(6
ML[E9NU  >UZ=O<G,Y-(H;3"@U)?1,V\F5*0>W;#%ZN"W@@<P9(])5=H.X+9N
M8Q7)Z;EI*KFGNE"8A;D,+N*'2@0000.CZ<7UF)AZ>HE36WI]6"H?2?>@1^G3
ME0=UQ-;S];'RW>%6V+&Q)0I;[Q(1.I[Z]\:^J65:FI*J1E]M=DALHDR??IAR
MJA"I9-59*5H):Y*PCQOEU$&]T<6RFS 2L3YZ8:SZ?3Z;#4['#7W:K(Y/6_L9
M&LIU&4&+#;V:(2WHABI]?<WGG82PG7,Z0,XRVJS4Z:[\*(*[3V)SBH;:"W,D
M26R3NR;:H_[3?$Y>&Y^EYQ$T=\1FKGC.PB#TTX.2"&LR9!L;8S.A%63;?L;G
MII^Q3!GE0+A*4I7%O.IN-.RKB;*3DA?*45G(D<IBJPUH5I9MWJ,;/A#M4J1?
M-%_YQL^H\,_)&X'( OB>?GQ8+J\,<7"FANAV%E:0BMMBVXE[/5(XAU% W%1+
MLO4C8:UKW)6:G]'%+9&;U5V TM 4^WIO/9Z?D]QJ++;WP&:G[N.V2_&&MG/)
MD5>JX5HWEK4#]GH<^YZW\[--$(7R-BMX7(\6[!!A&OBI2&M"@@SN>XF<UUVP
MJJL3/E/Z3"GK^>CNA6V<5^*H.\/Z,E-<G_4;3#P$J@6-OC8Q(/Y^"B-"A9>8
M9&*.3WO*QOHE)*_2.$.7G9[.AV(-Y;FNJ*H.U63:5K6Q%-%U"X:[S=,V[L/L
M=PXG#O^FURF,S;&=.>,"$2X/>@(FE=OA<-AB:1C#Q<W6]<9?,YN="%&Z3-(T
M>8,'R]_37TS(N?W[SRRKH(4J8&UXED GPJ)!I0]-#FV+=3?#X%]Y9O0:2P!O
MGW[8EZ ]JGN]+G8%BVS]F"99]A2GA ?K?*3OTB79)+"SOVFONRD(SP)*I87E
M1E4YR!M^3"JXG=8Y&-0;^_YFSI<E1VPJ 4R7MNCNCB[S  _OY;_L"QH^G!CV
MI>5G+XWX(,"E?TG2G%=/D5@<>D]4[][8;-;$!C,ZJ*X=MKFB81*R1X&9&F-_
M_RJ+^Y6H:AW=+E!GU/"SFCUAO6FFI#]/9!,1!FZ5K8XD@;TW:F?.I!BU6V%/
M6\#+-V066]JMI0,R,Q])3+=*1$_+(MB%<9CE_*R(A\S,5*^.V,D7?1#;RBJ)
M3,_('I,<DF;J&;Z?D_P?)*_PW)0:/-H]>Y*!T8_!;@>&:(@UI=*L;?MK&LX@
M[$V/^J.OF#VD'R92$)\!#\R'."@#G(2IW:Q@XTP/0KO57/0)@VG_*2.;(EJ&
MF_XUB ;30H8M2EYY^N73?IOZ@7P$VF :YJ:X# 02%(/IXA![O(. <:6^-$_9
M!_%JM:&+P#0Z#7O'$<+V^9!]2N@%;:IEHOZ.#8L)@ON&I$S=9*\K*V%>AE<K
MY7;A=LCT/YGUP"GI8S_0;1V]E2%4_X/2\C8&QP/E_3K,]DGF1Q_3I-C#DP?0
MKI!V6Y! [&F#$'3*\;%5=5XD3F:=:. 5C<$KUE[8^2E5HJ5>++(V1 _Y%_F5
MXO] S7_7%(2,#7&+#:6$!(_)G7\0[R5'(N(O)ONO&Z*K/-2GVPP23#DP =WX
M29HW%T37!ML'4B;5:=,J!;0'2&):1T?OWG.-9[G=4:TG;>)/#NB&&VL+3G-Z
M.<7!:K.ANG@Y/V/,K;T#>NRM^F#:;V536W0MKZR,QT1_ ;"F5_6T3?$9:-0O
M&9#(V;LS/I.M((5>57GF!U)QZ4<0//CP0D@NX__-&H"Y]2RD,5ZQMU^M.'L/
M[/=&I.T])HLUO6)38GQ)M,].[][S.T?=95^US;'5R6/+",/Y:=@@IZ(Y![7/
M!*C_F;RQG\RJ7V=/7"-Y%7ZMK;[("TJQ4'29(:CQB(RE=98Q<5I44\>5OFR#
M8;OA-AL"4 ZDO-R@+A XM6)PZO*(5O9455@F6J_:$710=0_^SM[1Q\GH-FKK
M'STZS24IZ/)0_NM?0RK$THD>EC!-D^NF7T_L6UU[$D7Y@9@>+0A$I;L0) V!
M-JB]XH>3P<^>!6B<IDE&^0G[(NG,Q)]7ROW1N2WFN@V-"!_Y:+),\_Z[T-T<
M\*7MIG8-#T)E^U#4H)[:N;$_MCHHS0;\-81 8JT.V&XVBWCBNM6#;S8(>LY)
MK$5'[>Z%S5:U,^QF.6U#=+-BA4]M-HVT6\W&-%_#N^O(+.WNA7^+2;.GOPMC
M=F7?$3I?EAL!L@.OW2U,.QV6TSXD9AN.98PDZ=4+6P HXWDF"%/N4:%VJE%0
M0<&3^"B]J6<_[ N+'[>[--G0]XS=03?$:L.U]T /'*IE;35RNJJL+9 Z)/"A
M/L!H.!UL<Z@.B\V27V)NCAXG ="'J2BW6U-E#4WF*&C9E$)K!VPOB&(:A;U.
M;ZM/?@X'X;#:?/+3WPDO\%@>#H,/?A@15*NJ']5Q/.ALZ96]*>* !.)\,%52
MIK:W3:5#*:!K:CPD-"#?(#Z'V?8E7!$$$9IOC7X]T=D3.IE.5C,V0K_UQ O*
M0XRXFREO8]W;VF)+EWH?$C.JZJHYLTSJ <XH.R'$];M=;U)AE%SD.9T@CVV+
M_&US]<PML==N.@RHNJO'->)48S1L<=I<*J4F4=KDZV$DSMD?J61^VDRX+*5/
M6D@4&#>=B#6G>6$?:2T48<_HJ=Z=9\=D/VZP[XD*3X3#,K21;,WYB[T[SR"T
M&O(F9+9Q &4'-X3>6FO]YAO4$7OC507"C!=V/1*@&P1U+$UT$?;1_W8;@!=Y
M$_(X15N! T/C69BZ2P!U&7!ISOTT-L?>H,<^@OR"5)+'V"7S^.+'=0\LE$;A
M@OE1?M[IAL<VO%5ZO[$H4K,-NG<-<!I)($'[E!<%2GBN]<'OW;UF$(YA2*4P
M-,$^H_+>X)L>3DH2,_^(J0Z"K0-V)BRE3E\N$0UK7@)=.^PCK"U/UP,WOE='
M;/,T80&M-GMTK<4\0>PJ]#F AVBI?'T[HGH2R5M9_LV0[-5N@B\.->*/1!P\
M@ "#\ E*<"NAHU\D4Q]*Z"+MAQU)MW1??4R3M_Q%%+[0"[3:IG.SA=ON 6/C
M&?FDA!^);@T6<'&0X0108RJS*4Y=?JJC":-;X)3JDE:+6+L=;B)L&?Q!]0)Y
MZ2GHG"TF.GM@2W.E^LX$_<L#\['W")-I-4>7&/(<8/HXTIU9DM.UPUZ#8ST+
M9?C_(LN*G70S[,F:)<-/73FC<[2Y/!NU%."PA/YGM0W[O"0]^L\Z9,AX>GMT
M0Y==OB01E:_\E$?+&%S)C4;XAG%]EN7[7]_]^=>_6(WBW1W1S2X\ M#,1;T%
MME:LWFD C92'*7]R>V4.#^@^ T<%BSD->1ER&PY,LQWV>6$81YHB5]HS8FH\
MAT?;B:VXGH3:<.:R'R%KN_PBIS5D#YP<\B)]3N*DGKHCM$3=1S,VQCXN#9-#
MR]X@<?*5/U7'1(1<6"V"TXZ ?3"K8KO&",BNMNB/F#['H&<<Q(#NZ(SN=F%>
M6BT8).&6Q.O:_NK@=0@%[*TY-H]4AO+@9;(.F@'^Q=D5<P*6=UE^^<BP%94$
M,L.Z*'5S;KVY-;H2J+B>K24;^O5 5]8WA+Z0 53X9L+L((RF_KVQ'=F-8GKU
MH!\KWD"OGO-P\3&OXWV5'2DA-N,<$F$/+=B5([ICR\PDMR?#UQJ@GZWA.6^R
MH(O\;RV3DQ">I4'45DS/W@-;>BI]#ZHEFC#!3U%,/M&I4YDO6,7WL'Z0BD&%
MF=!2A<S) -BRCSX]WV*+M'7 9J:5A>WK$Z\M[ TC@>T\%D^!!#9.Z.L/!2XA
M')QN-[B%M(*\UE]\)"UT%W%K1JIJHJRGJIZH%_5BNTW)EO)\%&C<-(.A/X\-
MX=$<<M1+]C1WQZT\ BA@T8&%YY% Q<%,8OJO:W[L+:%Q(\A@,GX3IEG^L/IJ
M",RJ_XRNU-V3+2MP%N<Z@#1=&VSKE#90<I'+JC3FR.D^';&EJ7K=#+K'MZF_
MDR(LUZ$71?Z2I"#F/B:72BB./GA^#,&9Z:Y6,='8&'M%J]@<K05/182%'<BU
MZRJ68XB /,4(Z %#NO+*QM@)2W-T#_TKB0T0R?(W[*W96UJ=E2RJA%SJ36Z?
MR;!R'I_1JI0Q@0"BM%:;,@JQ)3 T?I_#IAF1</^%UP6-@S)(+8$_F1.E[PD
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M=GYZ6&VLH=U+79C_,?UG)]8E2? 61A%=&BIE4"DEA+).[*=^PIZY/[I=X(K
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M^W/I(_*Y*XQ;4.HUKO7RWV JV)M=6E%N8[H^V1( C?]HV>WFYMCP,,R:+=)
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M,6:$5O"7J%K&:QK^)?578.W=)#Z9WE]_J*WG]0E&/R9P^>[C^_<_O=OU8K;
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M$^?4JS49:%+8H@XWI0.:I$0\QW8QB*@K8.MA_%X#3?W1>[T.L ,3/S;"$Q&
MRVH_&-(9P-=<G)K9R[Q29>! 3&T^& -=OOHK+UX"ACY.;380DK,@@,7#4/R?
M&W0L?V#"2&MK;)H?%:;Y<>!IGF/++WQ$&K=HDK66PTZ1")HYO(/)<X@38 OF
MV6X^[&3O$G061_\OW' %*;5Q__=&_&4(/,;4&C_W/AF<N#VZ6Z$['E-^'S09
MS)8SB^/<BXI['<>,TV@VG!D36^J)H5HXP8.F_9LW"TW_*H3KZX!FWFS\/M1T
M&*=9_=>AIE(5+&!/9]=B,(I*]XH=",ZV]Z ,ZGD$K]D9^M!W#HF)^S:64?=0
MS&!S21[TJP^A/QZX3IH%%\H6[S8DGORMOPJC';TM8+*F>1JJKR44P_^;! 8
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MRW *45Y"=GLS+Z4IEL%R9DP2Y_4Q029(AE:@%K101;;P=T+<S\!BKN-GD)(
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M*3!<$;E3#]JI)5"WG<>8@4<"GA/W,Y,XFSXI>2N4TA"FV55Z\UJ1J H@N<_
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MLI$V,7B3Q,M' -<-4OSX_L//B$C1?W[Y M9/ -($G61/FZO7N5W$;\=\2&Z
M:_1'%@-0&AK5> \JWLU>/!B0PZ6(PTVQLZ00I>AL61?_IJ@5:_F()3#5Z;&^
M@IF/^+)2"[M HSBPB0?F";&J@V ?DT F6B@F2@!T&LHH!53)D!^0PA7Z@+YO
MLXA, P>Q+["#8!F'?R"B!TCG*J26/&'H_I[ALX$Q_WTAO?1L2Q<3*I5.=7S%
M]'V KNPU;&8-/<OQJ!^ZQK:['LGJ5(ZCI+]<;IL,'0>0K<#1S6%Z]";'0:5=
M"&F"K.)MQ^$02W8:%3J>7:4[XZEJXA.0G75XQY/8J-*@]KN XPEOY/#5?ET8
M(CF.566XQV75'G$Q[IHH:,T*APO[.(%"&.5(MBI:@]1&,^LJ1[>M $\+W;GV
M49&7KWZ4(W(J$B*L-WE62D#5\N4]?,BT%%2I>]Z9P!Q7H;MAJ(]6W7\;5"LZ
M/Z[C9/2EY_?T>E&2#YH:[96*XJ&B-IK9TW2Q /@*LJ?">Z0Y'O6 H<.01DIG
ME4^P]U8C='UX(:$<PBI:$EU-RVT)YJ2+;D56</SXZPQC%\9RW%ZBBJ44APYA
M*#&K'Y35W$>E&M!+UK?D:*N1D:HL: ;8-"1UQ+%:ZPM7(ID3?P?A<H43SCP#
MZ"V1R,"F>J0=D\]CSQL2R*TVF%CP2WTL8L1!G'U\1C,&\PW Z9?C)9I$\6"^
M8(/J(-I^\3)\J>#'/F@8T+3,I#-2,]TF@X8=/YG9R/3'2XX?T%*0=F9-]T_J
M6[QRI/N=Y6D8([!F01 6Z[J.%PE<DZ]>@,P+H[$<Y'.X].+P#S*Q1DT*M/MW
MM4G7\IKL? ^B\U_/V(;J0K:2 J$I/ZP2F!61,;NG\(R5*PQ@IM1;+0'2+;JP
M%(]Z&8MA-C<R=<1<,0@J@^+,]_-U3B)RT+TV]$/V(H0=34MGK:S8KN(@2\Z.
M*Q6]8<SF*<=UBAX1%;.Z^RJ'7"9)!Q21H@;/E><3'9/[FHC:U(AU(4/$,E\4
M\Z&^->(V-:'9-*#C/"NC-#0PW4<T]GQ!$O0B>N4B3&UJ8,I[YD1B+@X\&*1?
M-T@B AP[_?Y7[AKD^II85/"/O%01KA+(2?G+H2BU,?2]E)82H#>,1V:=AC"R
M0=4!0,UI6@:MX\LZ<W>D!S#*5"9R#Q]%6;0'QLK=#=V!ZQ>&[-R#<(MF1E(]
M<NZ]G$Z&EL&9K#YJ:&;!W!G+'J$7ITC[3,] ]@) ?(/+ 'T@__\1.U[Q'WZ:
MK?&NTXA$PZ@FCFTO7H:(;LFD]W6TSE<>7 +6^2#H9$2_:]A#B17T$AU.2$?V
MD:Y1!,<_)I=$:68J?BIC6++(SBNS<SG8R($?<<5\9Z6PHQ%[%ZF&=8>_CTZ(
M".>S"D+$%M>Q7]201 =VDF:(DIZRPO4A6.<Q(]H$P,[5<P<@N?)B?GJ*PF5Y
M]TU]&!)J5,5!?F #<.Q"+"Y?O748E]?X[R *5TD2S!=?XX7WG,"B7&:&;OQK
MMEVWVU@F7LGG^-Z#A67)G&4M)=9)PFYO0@%9X0<6UW']MA/&?KB) /.Z5U:D
M8>DM1XPX)@ PMZ$_ZT:A&G8D4%RO<=ES&"()12+.-,)Q,+1I6S+/!M@,B: 9
MWAQW7;!-=PU?#Q5"QZ'AF0GKX$C:YAQ'JY,QKPXC'6Y'43O&B-B@/04+G:-0
MREOS]KD:56QLCL+6U=C(/A:<3G.CBV%%!E!'_?HZJ$WQA)F0%!*BLPDCCB&W
M;@!/0%*I39L3P]',&[JX6>0;&2+%QHCA4_3)E&BZ5H*^3S09$+I6D+Y/"-L.
MIQ)"UXK3ZX+P*"=7B:UK]>Q[QU;!?U9"[%J]>UT0=_3)5;>>Z?[-R*O']OI5
MT$TW1L:-\1B?8P7N=$'2#.[.GUDA/%V1]"%\Z":M4'8X6:$<UON<)<WL)$A#
MI3X,:SYE&M<K$K.!PEJB50]<0PJQM^*^QI^;,L.Q&HWL>/3;G-0!:]1:(ATP
MR@.$,F+.39)ZT6>8Y!N25#!%/(?H*P=!J<DDL<*SX?ZF, XOH")G..K3ZH99
MF_$<];-T)ZCAV+T7IT.2>=%H=9&O*5CDT4VX(+7&#ZMJCTOO8!9=/E!T6R)?
MHJ--1;7WNZ:ZGEK/DWM IC&?)[NZ-Z^0I6QWFTCM;(OCS'B5+R5ZVK0@/"E^
ME4R)GMK>JQ7YF0%$WYDOD+@&NZ^QBV8*^]@$]V6:A=@F$%22YYGY]$QM# .+
MO,IA'.+<4R0GURO^4\I]2<[I8&#Z?-)BM3*5+Q+7)+]>;V#R7 0I"1([L'N8
M5HCEE9)&"2F9LW^Z9U&3 HM.9\=A4U53I,BNK@<XCI^"+B0%75WC.%7H#K6N
M7;2;6 4Z5="Z'1!TC<MQJU,O,N_F9(H5*O*MC$(\(49#C"7;7'/S'PD3]P8P
M1&BS62ON+@"\EJ[Q.D:J;TZ V L[?'9Z\?;A//+2-%R$("B*B7Q!^*%Q@EFV
M'RJ^QQ6B(-*F<:FM=%R6W=TR]B");(?<+CTE'*IP;X/-3#^ETMVXT_C0\T?_
M5^Y5_:@A#4#P)8G!]HL'OX/L*H\#_N(8C8VD**G2"6-)>X[TP242E46"6.X2
M)#J:" M(UFL L1R\\]"!PET!O:WQ/>#8T"D-3>0+J]X7X;34I (PDC_T$PA/
M,Z7_Q+6M:_V$$3*$FP0BGK@ 3]F^XJ* ''E]3)BQJS/G;+O[X]]" )%6M]J2
M5V0<4I7L;')9Y2E:/'P]F".7/M7&,+MWM2E>0?#/',0^+Y6P3$][8NTX*9'9
M'2PANAVFRJ36[FEB08?RED=4C-8F=^(ZWN196CR.Y7OG.#TL(:5T=P^06PFO
MZ\!7G@/CI?JUY\9D\ U=SE NE4IRBM9?V\9\?7B$!$H<PO4Y>08P)F;,)%[B
MMY 2.DOG82QA^(_*#/_1ANN! ED).EG#*'R5V+([/HTP?E(FI9_,+:"P^LE3
M$;O]."TLWWXR;NF6L5 R,GP(K(:.NS]UV!CKO@,6.3D.H[S!KQ%_3[>KG116
MK( .&40=!ZH/DV"3_+CV-,?153/$-1SO:K8N1W'LZH"C(LDSJ#F*G[P-COV>
M3?6\=AQ*!?NLB)\/S(BN0\>W/#:RMVD]EES'M8M?A$J<-,OJ"8+'L.\+S^<#
M6ZZCV!UC)!8_-J<:.1Q%LMO=KKLMV-&83<UZ(E=7=Q3"7@^3CQ/]20E$D</
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M>MBD>-NI&QWF=R:_9/^)%S_#)-5.[YPOV9:BLQZB5XE]9EXS]8%&2!]7"5R
M$!</ZRW/&^=+(P3,F(#\]J<QPE4\7,&7CLJ[D^!_&@I%Z<^/$-I:Q<E>,3S\
MS@C!DE3_^V=F[M=M!):I\LL\+=0"KL89C!'@:@5&,5:;Q!AAIN@G)H!6G8:-
M4+L@B[]]&%<R9VF%QP#D1TYJA-M0TYD,X"W[]3&]L!!R[SW 5GOT[^=)3$RU
MN1=AV_E'W4\OCIC)" %7YEW6ZK4_@=$_P1%N#YO5A]Z'+C,9H62OT=4U6DT8
MIZ'?9\T:]O>L\?HU[U]<5/K_W@A)ZN!N15)9#$)=4I^VAM!J=Z-"WH>P"+H<
MCO94IS!"<K1&PGW[.,H30JR0S)9+")9>!@;!M_M\QJT/-1<S@-K3_J#IX+SI
M;=OTMFUZVS9X$"K;4=S'/FR*J(3,@YDENS&5/I@>9IT.FU,#K/IX#X..E:?$
MFKT8R;N+Z462$B]TB)W3^L#E4P%T3"XC@=-0]Q&WI_51R[07QX3J]9+FO-#U
M+N-I-[1$'$XYS@UL#R5J<4I?;E9H\2,4^DA@;M^EU<P>Z8RMG'*8F]@AQ>#,
M*9.YB4U2#NT<)$?ZZ>V3OLC,W0YIO>!/^O4 $:;5SDTI,0RIW7+;,U6C4]Z>
MH<-:JZV:2JD-N54Z V*K'9Q,$$/N8*>8V6JK)BN%(96P'2M5;<ADF)#?E@'"
M?:MMF>P0!M0[00AQM3>3^6$P9E$.6:[\J9/IP8IS!L<@[_9D,C;89VQ@QE)7
MFS;9&0SIU@?QU]6.3$DWNR;=O"-4L0)9Z'O1H!DXIX21PR6,5,*ZOHK:XNHK
MF3TC.L$<B901N:<G_7]OBOIO1OT/L,-#A >/4_K>(Y4";5A&NJV3F$CC2@Z/
M*]'Q YH3(0]NPM=F(P//O(H 8/0!3NK-9AMK'J%.1Y9=Z9OV9!('4FF^>_F4
M <CV4HO(*VH6<7Y;(^E92]%S< MAR:B;4:93K@X<!'M.:&J.U';XN/+BDE=O
MD_B97&[[R=VH_'VGP&V:J ?'MO5YIZ M+#+&H&U]WBEH2UNQ070/9^ 4P);)
MW)%E=)9?7DOY).+P AWGN_(\YI 73\VI+>$&D%NP+ZKS<VISFF>9?9NC.C^G
M-J?FN+5O9Y0FY]2V.''&?/MDWGM(M1/6/8$M$YVCR26LLKO1_+&M?7)T&X8P
M ]9A9=C.7$>7:7S3$K.A?O\ZB81(5%^'GO=M/*(_%5IFIY&A4+OK:6$,,WC;
M[NI^'B3#@+>ML>YGXS$,.,5&ZW[6';O4AE/)KF,+ZA(W[3XRZ5BGQYG>$&5;
MKNMY=:PZ>^7W0^N#M6D_.EIL74^7,YK3X]NG?M+BT([S<8:G,OKA)S%Q"M*1
M!:CNE[7>1,D6@ < GT,?,&@Q(M- ?\)ANGZRC,,_$"F2O3U/TBSEQKGV\BT#
M_A1$&<D:['FZG"8G>);78PJE'6YJ]A +-R:6W\? (O0P[,'AUUJV[J^8B*0O
M9@<"^N3+0X(58B_7V4QP,T#:S@HQV 5X!E&RP7193D@4ZBSL:6!!GT&,Q$=$
M!,8ZC$,L'_!9+[,DN;[&5<X^3_:ZULH]#1UU>UAUJ-%N$OULOJ.[J:#721#^
MB7C\>E()&C$ODH>IXTA+:9"M< KQ:>TX:(,=?]KYP'&GN#(U2ZIJ0\#FI,'J
M;+N+6QF9[<K;Y>K D3;SQ2/2O%*D$8FNUQ(=3=ZQA<]':2U-A!5/MD,[G]H?
MO[/Y4QH&H0>W-5;A3)C=?C)N.FW<G/($'"?F"PJ0%_:-]I,=V%X[,'W.2J3M
M0!(+$_<^::60>HD[I><'0]V03^/IDK3NU+#32E"KHWA9I3I-)O21O1CC:%&.
M(SR]7QJI-X.E$CJ.[&!J!N?@==RD;L<S78>?E8W=E]1KTG6S3I'S)$+WTJ0H
MXS!;0E 0_%[=NXX7"5P7/J91N3<P6\X7]13#; ,LO:T)\W9-Z""9<HMV8/\O
MM<M-RC4MJ(ZB:Z$IS&J+1'_;+Q#]Y=L]G@)E%YJ_#3D9*HKM7XW8D2(<MW'G
MP6Q;WZ^S;?T7#D$K#&!X>5RC-:7A0.3Q)8S#=;YF$DCS=P,8U@3W,SAD>)_Q
M<YT81'9DK9_0YLFBGUA?-TCGB#,T+=0WCP.L(CP"?Q4GZ$S<SGP?I.D5H%8&
M.&Y  UM_YB%5$ZLW ,C%PW,ZZ-N6'$+R0,M["B.D.P#Z$<5OJVTVGU&+97(6
M)B\)_)Y>QSY[,JRF1B,"-+">7#B M@^9$(&1EZ;SQ>]$N<GF\!Y;,+F,P.NA
MC?;N(+C*L=);?H;#"*RF)E.9%^%.^,:4Q(00.'$+W#XF_*O->7!I@=Y6&Q7<
M)XC'FD=+7)K==V<,FS 4>AO1/79U1;CWD,-V!B8[ATL/7?$)B.=(7"51&%2(
MWM4NK_/%51BC8S+THAU=L^)6](YMB^CD<#J[O27Z#V?NS.9#726\5_Y5HO&[
MOF,HR7 XJQ=]"2.09DC(I:7I\NL&UV5;A>"9$")2 @#,D/![R(E6>P[##,#0
MHQY81P^J;7VSIZ??0B A2^D-]<T#X>&'&Z^HM[2)0&5:I#TBN(/)/X"?I=2,
M^$</IVU-Y>6GW-H#>PVMB;9O[RB+]_7#1D;,&,\@S@';!E/^;.2$+BJ^_QYF
MJ_,<(;4&L+IN;<OK%_/0ENAJ1$%%:L1UFN8@N,AA&"\+HB=&_O06O)"?V)JJ
M5&=;3N(B-=A\\0!\-%M\03[WH@@$9]OJHE V5#JO%4;5;19 RM"=%P9T*<8Q
M$?#[:9LENNEVG:AL5_>$P+</'[1>FC>%*'],ZE;?JP32[7.,Z[3B(/JN>W2#
M._VSUW&(=:A' -?4RU_7L4P[>KDNMT9(HZJ;R]$@#ZI7C!10;7NH' 6@N\.K
M&5AQZ$]R%#"&Z[*BF9;;RE$0^O2![<H7'^EG<AQZL0]J#R33,^0X1FPW]PX;
MII^J#V@L#0K3[>NJGPP,C<1QPI-PC.THD.FM<APC*7]7([B0[EMR'*:. 6D[
M\E)Q@SD.)=<Y6:<TBGO-<6BT^NCHKY#TG3*.[X70-=@@5=Y)XSA0(C=D'2>>
MNNPH3**;:M,KZO@3DUYOJAH\O8[#W^]EHV7%<QS+8S5"AM_><=1Z%0!'A2 ,
M\<;)6=87ZP*.P]LK71^$H6@M3F8?F,/0JHJOQ7' >Z5>2B!3'X7>+()S&/H5
M6.X<Q[@ODCT,:NNC#-X)NB X]I0^$#XA4I6+;W*];N P1*QU*QW?DK[I7C82
MMH\*C58)\-X%S+&QN8Z79>PW_D8J(+>/6HLG0>-J<<^5=<XU)X5-J@J.I]X!
MK=4.&CF-<=?X\0KJR337 >_N\>X5[+W:E,PFU;K%1N 46]B)3E97T=>;O IE
M.//2T,>"-HQR!&6KT[B2;;6RQ^YT)**2UK+,"MY3*P]CX%6-[!S)]AZYSF(,
M$XD4/!BC[^^H$2?*BWUT6A6,S=]%R<X&EH5XK*B?A#EM]HP8C,1O)[6(JU42
M(?F4EDPI6&GW\4PO7F9!%G%7"=\!@ZCQ%W,4"SB,)R[H;2V8= FHY+2KUJ85
MHZZ'55VA5SP%G _G5SLPZD@>(9,=C9S3=EHQ878>NAY9G'T4.9_(N3N3J^^'
MX_%@.@B4H4+T$7%D%1GV@=U.D^DCXN40/4OM$[M(XFA;'C($T\M7/\H#$%RA
M;3CW(C^/2A/&J&T6;1)0O-4:K1NXVS$<^AE@V@V?P=XCU=BPNLVIO0BY)*%:
M/F(BF_IQ\S[;T@?@E1[M\8O6 "BL-2GL9LU2I'?FP!*N=^-O3!9;/'+NLW62
M,Q,)Z1E;7V*[^!FDZ)QOE6(A=5PX>7IENDVU4#OD<ZL79L$%=+C3Y_4PK9.*
ME GZHU0]I[?C=_D!3O%&;BKAF3?AK712BL%5/FI.<@?HQ<7DCS7'0>OG3J21
M>/F"R/'=42%I"?7&<>N@];1\<Q#,[>I6="%<KFKK?DW!PL_TZ+T"%^H([E8S
MR[,5V2^N[8/9W%1-EUD<X!?)T7\ATDV#T!?>$D6]M%W&=U#M28=E9A&W-P#O
M;CZ7KYC3P1F(P2)D64)8K:?BB]3I#%N:LN]R?_(<0+/(\]N:I/R=D./8Q!F-
M34Y[#Z' Z</K807N0EL\MXN1)2!E!>D#Y3OCLE3S]?T#]TP2];)F+Y3X8-?!
MP/31/,Z1>AEFYQZ$6Z2;D7KFG!+)S/:V3%[("J)>1DK(%.^MN,3?:F1@FA?E
M9003;YJ"+/W-B_+B%A9%R0M.?<.8NTQ/1^IP'8WR? /PPYEXB6,JZC3*XDE.
M!VTJ"OL;#_D33B3UF""%-BQ>_-#T%K4!!ICW;9(=/77&& /,?O^UOR.AH#;K
M5E];!#?7@<SKH;&F--S@1VN@U//Q+6VQ0+M[!Z"/K1)+1N5H<3=M<[Q\]<,4
MJP_\.=&:F;T;>^LP+LTZWT$4KI(DF"^^Q@OO&6&'+C /(,LB6DV?X\8RL.BO
M,01^LHS#/\B!5][P6=*;U=J2W;H#2-\F_HDX(.HW2+.9[\.<^=Y#=11+%GH!
M4A^&&\HA(-O+M(U:9*(\R)[%LPDZZHB2MCC6P6):^)Q]SW/R%:FF DL<9F&Z
M$UD&04?Q43 H[F(TV'">"D@<HV63E@06PI/$BQ6NQD?7<:B$1LQ&+2B1T? 4
MP>*S8ML\Z3A"?+<6G^L<)Z).ZK.4V=C95[-3 10]FN3^]#LQC+B\Q7,6.%IS
M0)J6Z 593@4.*MET\>4XFOQ?621QM,P3@Z@+:;'<;8[FZ9<74F*,3PRB+M35
M=H<ZFE*_DXK =;8ZFH-=G;:D?+]]I%*/1@84U0'=1X;S$0%SI+N[C^SE8V-"
MH?/<U=SCV@B-ZZGO):&X2^@UW/^#Y 2WYG76_IGA(UCC0Q!N+T)T]B',?9">
M@>P%@!AG%4OGBP-;'HXA*#/8(](;UYNNVF)J:[@%F> Y@+B?MG O^J=(81%T
MG*2@V 1:!)ADS^G]A88X:"62.>QBPQ*4HXY51K!A@=1KD/3B&+T-+FS'$S7N
M%JR&VL62O:G^K0RQPBY'^$QT&:+#>%%:ZC+RRSUZ>!N@L?*)Q3$+NH,)$A39
M%C^&SQ#^N'SGAA/VJS" #<MK*@2R:VKUZD-]*#\$/*2$,EE(LI,-0!\R=3W5
M J*+ZNI8)<4MJJ)7#<Z35'IW='S*!L@^)TGP$D91<4'TXF7X%-$UR$Y#]$>U
MLW4"L_ /;#>I8E'(1J#S&*F"<D0L&L.&#9IG*^;S/T9C&Z;]&;)+B3 :FX[Q
MD;[Z[>R>LC<QK9$_GXJ[>PR6N,R69>%1_&A7N<N2HW%2*C=%+E@2\1VN8M>=
MSE@<[6C@D#9B8UV1'<>M(Z'1+^!:HXR:XO\QR;S(#LATD%JW&[^C45RZ#E=.
M:*V>Z"0;-9*CJ9%CDW TM$L7O;7-';W$*HU/[LD:7QP-[>KQF.A@Y'$T&$P;
MR%RSD*,!8GH86FB7ZB-@;(3HB0Q>?82/N013:6#K)4ZL=;A:$Y72K"HX7^",
M%7F6P.T50"C@3,)ETWNDB))JF!LOWCX409OA,VC\/JZXE-$'2- WH54G,BLW
M<K>QC<:,A>H8V5) &BE9:HQP!!+,(2V%X#;!')>C9NA$+14^GD_DN#$M!6%G
MA3MFYVN#6+I,L@>SX!]YFN&;]C&+/1C*TB6?K_!KQ.NX>Y"'[J]8 ]1Y$F=A
MG(?QLO1X)+$:15 ',*WX*5I7M!R;DU=(%5+VP3LY/E2QY)S@D^5>%<RZ)C#9
MH571.U0P'+>V]H"ADL;BN)U5"[QT/:<7(ZNMAIW]<Z-#(IKL-%.T^3$+HE%4
M<Z*51.-F&U<>QK6]^_9Q;.)6Y83J(S;S#J 1 W25@-DHCRMUSIDN1XKTAYBJ
MS_"P@@(OX\#<H;^'BOCC[\$FA_[*2P&G &0ZT&G/>&O0GBC]_.8V-5+2,?&_
M[Z=R!Y,E]-:W.4XB.%^0B:9EYCR<1R$YJ\V;E;?_N#$-@'#G;<G%[BJ!^YG,
M%^?)>HV-.F@UC)5*=-3VED5N9MRFVN8R6RXAD15WY7=HLSALU-_WJSK"4O/8
M-3:::T(@+P[J_W9G4D<-N:HHRG!Y'ZJ(!>F')%#BRQA'3:Y*X%"$7A^VU!&1
M"T<,]V$AC6RQ09'P6Q=JD3^BL>>+&83X0H:%(Z]@)[6M 6VM-@7\QN,6[<#^
M7Q[1GU*/%"!*N44P54>9RFI3IS-P6>TA2VZFP/]QF3R_"T!8S G]83\=])=O
M-TCX19=Q1J]736O1^Y2*;U'+UA[\;(!W;T":@D)^UO*DW;1SK+5X5=1+XQT+
M26F<4W'C^> K$LJ0?'2&CCE:04&Y/D9@)@<4WX70:F0--= JULOTT$8%7[P4
MZ:;8P8:!*>L%I;L-I4L?^8[Z;L%__)'#SS#)-S?A.LSV[QNW90PS>Z:R78>2
MZ\TJ:(=RO?%[#U5Q"2M@3BXC369QG..*48BUH^K>2,-1<01M,[\%+Q+T2&EE
MC,N;2#T"N,97S)@OH(0=M0'Z"&(OSJ[7&Y@\$[RNXV=0Q'O,GZ)P62:9/\18
MKJ,)V-'QB) B83]7GD^8N]2/SA((DQ<$Z;F'#BWT[ZP-4!G"$LJZ1&I6AO.-
MSA?SXG!(+LD%2X'(V&-8LD@D5L"+%V%F4%A6O9<E"Z$@C:>'4^GR50"%8?2=
MMSXZS?%E\2NVC^WU/:YZ*.ZD489AV<B=3;N)1HM\.>2^@,+%X1YRF^K4XI/G
M(A+WZV8)O:"*'Z4>X9S6!IBD2=<,U4/0V+3#FVM5JEODE2TYKGHRIB+)'4K;
MN08"QZ*$@3BT[CB*@Z*MJ.:\$AEOG >,9O6I"URNP<5Q=#JZ#7;D)6D5<AQ%
M"9,=NV*B:Z"P#.Y[!ZFLA<Y1@$3G>M/LYW@<J.IYIFJ==!R^8^4WS63J.&22
MPEIP;SM)D*ALJ6+1=C1B2I&TJ'>:DX2&+><E70^.O]M5E%5"D$\2+K[44G((
M.?[$69/4YWB;''_$K G AB?+\121_=%<S6?61Z+(9P"?DA&B*.NU<SQKI+I"
MTO(C.EI6N#-%L7R=KE86/L(BSW3$NEI'^ AAS_+]GD 1X<+$A8VB28P7/5^0
M?\%IMZ\2V+*$C>N-Q3"QN%(1CAA.WKMD3FOCH1"<,GN4AD8RAL 0WU9%LSUL
MIW^WD< 534>B@WD1RO)G"FG;57^*'$^S#Y5&'8,)'1K3.FKN5@!'1I;T8L.U
M*M%8(7T>\O7:@]OYXG> "S2"8(8NP]X2W /L\*T;_Q%.K39X+)SA!J=KF[08
M SH#9S_N /0/8V0[#V/;4@_)\T.7I=*&L5<KZ$X$CAZ(FB"C$M,0QZ15!\ 7
M+\OQ,LNK::WZUB3;#0B\&OZ5I>0B%V7-5!K"DB<RNY"QVAQO$;4\OH#H&7Q)
MXFS%?S?=83B+E_YWX,''E^3(%5>CV+Y0]$V5=U#\<2Q?[%62LY)U* ]C^U+#
M9QW;2H:Q>*FS!3K1-:VW.9;%BSYRG=8M[6L<E"HS+IU)?*F\C,?=QK)&G6 ]
MA6:UMF?BYSF$LC?:@T[V+.,VB?TN*ZGU&]MU2Z3*.GX[[:+7BV)DY)3F"5@M
MP.Y4<D=-YT;P+#1_QT.EAT2TN%XX'A8\**!$J7<\3G@H0%M7)<>#AX="=9B"
M2*X"R;[Y.5Z-_EA4F5?+7@*-W:%&T<VVCSADJV+;>P*P?J?N)4;Y$$2SKKO+
M]29*M@"<@1@LPLR%5-TX-A;$:4&-<7 /LA"2('3IDG$J(Y@I0Q;&(" O:,.G
M',_R+O+B<BOA%R]#C!,O&[\7_GOBF_57C&4?/ZX]8)3/]8KW__4?4S3EBNCY
MH2TZ1K8'$(E=U$X6%BX?<S $1,+!;;T1UU1_Y*"F#\L.$K%59^U8>>.X_; ?
M@-5DF.,F16,T[+QIL5]DA0)W"#NC61W['D2D6*0'LVT]_8X#NC9K:6?;^B^<
M6CD* QA0)NISH%8*X334]E;I,VJQ3,["Y"6!W]/KV&>GL6<U-0Q=@^CY5R]A
M-Q.5/W?5T^6HE5>6H]M8]NS?C:  C;";@:74ZO,5%2#G>99F7AR@ Y]M 6!W
MT<;9=Q!L"G/58U('[BJ!YTF$II04;^:YB<K5!]&8/IRZV?3/7L?HL*-FXC]N
M+&VK*8VG",\[+T1J4 J0#K5"&M$%> 91LF%M@%0_??5,$"8=)RK;52]]LS[#
MRS0OU]&TXJRN_-3U9IINX?@UF:U.[1Y3,I6=$X*&IRXUBAUWTTM.$\D#Q:6.
M)%]#<!RPH]1;ED03R4/',54APJZJ8!\&/ZM\O'T3YLU!#DQ7C:?*Y-A=L^_#
M6&H552IC*:>N]V$&'3=NTC<=QP,KNYTEXFO7$)&39@WO#_E3"OZ9XU4_XY@@
MCL%]CZ+E%O?6FG F>JYEFMW>A"6U.1ENV7EZVX'*[-[!),C]; [+ZC6,.O/4
M9L-.$>=KK4KL4 F!W]8\$8@LRLSF>BLR!H_)G;<M\W 6GM B$R?YV]7!XW*5
MG@-1Q#W8Y$C>URMYG9.89+C!9\>MMZ:+"K6^>HMR"PIOF_-?'9P=?+\5L[GY
MJ7/=4;2F Y%KF[X8,I;:S )4T:<X?FU6:VW<<Q7"-'N8_\YFH%8+?7X2ZB6P
MEKJ7ZB01=M*'3)+#;,6'IM5$V[<OTRQ<$VT=)O\ ?H93 %['S<3J5:[G8)_L
M.1!71]8TLNG+C%!];1BXZ>JBH[9#D=Y9U8+C*'Z.(B.K.3;SSDMH=([BU4D9
M;)9B=)S79+4\CC1RVYLF4M!VI4OER<Q1I&2T;AX9[?1(1_&1LE7LA$];K744
M%,E+A8!N3I.SV,>^Q,W$<4>?2 BQ=4Q'@5&4/NVKHZ.H*'.6KGNMXT]I9-B/
MKE6=.#!B@C3Z3*C\ ?_?$U)U_^/_ U!+ P04    " #A,WU6"!"!#/D?  #D
M 0( $    '-Y8G@M97@Q,%\S,BYH=&WM77MSVSB2_WOW4^ R-U/.G$2+>OF5
M39UB*S/>C1]K.9/=NKJZ@DA(PI@B&#[L*)_^N@&2HAZV)8>2*!F9FL0F01!L
M=/_0W6ATOQN$0^?]7\F[ :,V_$O>A3QTV/OVO\IFY=V^^@5N[\?WWW6%/2)!
M.'+8W]X,J=_G[C&A42C^@P\]X8?4#4\\:MO<[1^30^_;R1O9J9<\$K)O89F[
M-G/#XXI1^?FD)]RP'/#O[-B$W[WP1'5:#H5WK"[(%CTZY,[H^)8/64 NV0.Y
M$4/J)HV[(@S%\-BLR@?D.ZC#^^ZQPWHA#.$=]I$,X6' 0U8./&JQ8\]GY0>?
M>MEA5&?>^LO72(0G4^]6%TLD8#[OG0QA% _<#@?'/1Z6+7@8OA#>_,M/9K-R
M\FX?NWO_;M^;I$8\?!SE<=,TFC^?9.E3K1NU2C-?$E46H5"76G=]7T2N#5_B
M"/_8[W?I7J4D_WM[,G/-?'OR.%$?&.\/PN.N<.SLEYAY4KG];<"[/"1 GUKU
M,6*OE/46HNMSG)<K39[FO,T38^N8[']^_?77_R5_(Z?MF]O6^24YO;K\>'[6
MOKP];WTBYY<?KVXN6K?G5_(&-FB?P55R^_MYAYQ=G7Z^@)8E<M&Z^0?<^/!O
M\N&F=?J/]FVG1'YO=<B'=ON27%V<W][BW?9IZW.G#<^V)SK>.W]+H+?+JUOH
MY[9]@R]N79[!=;CQY>KS)WP47G]QW;X]OSW_H_WIW]#YS<7'SS# C^3Z\X=/
MYZ=P[>R\<_KIJM,^,Q9A#[-FU&JU%7/(GU$0\MY(2\R/T6.-:]=ZZ6'!:YB_
M]1C2_M?OYQ_.;TFKR%1]M4*W9B:3;[:9)7P:<N$>PQN8[W"7K8S8'4MXC(@>
M^2+\.[+7N?KRMLB4?RV,V-PRLT430Q,C%V*8RZ)&XS'8X,,^"7SK;V_@AX99
M:S0.CBK_5S'^]/IO"'7"N=<3\LFOK!_6O&\G P7/9J4F71?)QSYAME=-XW#2
M;%\]$[P,+8O+!EHFLC+16#\UZIMQ>=4JQF%]2>&I&]7E"!1/=7S1E_(M7US[
M>3.ZGRO\(76R'WFX,ATOF87L-Q5QT$2SRX8H?UTV*XW&8;EBDO8WN!: )?*X
M>5K4Z7@)Z.5*1KT>KHH8M;QTI;DJHOF(BFC.41&KA_6,BEA]4D4L_C[7T6;6
M_*I1.Z@MB1I@Z-=^'#:J1N.@OIL@/NG7Z0F?G#J,NKX00U(CGP.V]7I  >1I
M/7R1*Q#_9=Z\;^%WF 5FB\VOK ,_&8M'^ZS<]1F]*],>0-LQ=1[H*-!!&'IU
MVB"H[[4\GSO$7#,8W3,_Y!9U8G(&D0?4G&2Q9GX?&82;P]I<9ZM$JI5JC82"
MG#&+#;O,)S4]=5LQ=7+F-,QMB/I?>#@@5QYNY08D',#@^P/RSSI.2GTSVZQ:
MKRWX=VPF5G%;-+2E]=HLQ %1EM^7J_\XP.%[%W$5%VA+9B+F6/ITBPQ"YF'I
ML%$R&_47"G"^ 37,0KPG)BF3#^DG[$M_S$;VR'-Q!J\QKF92*UEZ/R$."5B6
M/I/;"<:AV7AV-V$]JTNNE&]]_QYE/($!N7)!IX?';;+WRT_?JA73.CF].E,_
MVB=O28]:W.$AAU=1GQ&;!4 -9DN'HN5PZ#5 NR *H=5W1O!-OG <:&'A2_ A
M"H]"_S"P>VY!/SYS: @-X#%&?6=$O $-X-'?+JX)C"2"5X:1S]V^06X'/"!3
M$6K),#M77\;#A&8XHB,RA $, B!#U/T3!!%? D@[5$. T=E<*6.!QRS>XS ,
M[H)F-M<;NL+Y77^<'UG7%VXHCO'3^6G[LM.6P>^=]LT?\&MGK9^L)^Z%D/3;
M3;N-)R$VI\#G^CTEA"HKW6N) -K&T'I3&V.6!,7(PR-R*2:F($E#1"4"6)Q
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ML"EUJ#]D]F.+T\N\IHUE(SUV>C]J-=380NZ]84.!N260Y3 ' NVK$\4\2'(
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MFA(9B"A@=XQYR<:0*]QR?^BE#CJ]#A5DYK2P;"(*!^Q"K$0W%/?Q>2/\1!'
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M[,AL?@6QCB5'K?4-C28%Y&R-)AM%$PTF&DPTF&@P60F8Y.WQW0!*O$*7;P%
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MY/FX$;2R4U>A?%N]:IBU)BZ%[_9#^Y%&YH%Q4*\^TZ@*2T+37+X1_.!/?\%
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M0@/@UG&7!D -@ 5GT;P L.T.J&LQF[0O?M78I[%/8Y\.SR\^D^:O_MWZE+M
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M J0!HVP0J'SF2,:#SNY31CU2#!<HW@84(RW/YPZI5JHUZ)2<,8L-N\Q7%WA
M_G,>WVVA6F&6#BH'I<I!?7/?DRL3& 16(H):*:Y6)8DK*0IU90I&Q)A=F;X)
MK7#+IVX_QOP)&=ZIB2([,E-R%:=.(' I3]9GD+P6N9:%4P!IK]!^)'M*5[1.
MKJ_43_;)VU3MF)AG@-1TH4\:^ PQFDJU$V06+XWA?"Z4!QZS>(_#)>Y">^BT
M<_5E>U2$+=,1MM6P6Y9 K\*N:X[MNI;G^>)^,DO_RZE=-YK+67(S/IP=T4\!
MBLAOJ=W3'9&]TZNSM\>:R'D2^0R(>TRJ57(I[E%9K_Y%TS=/^E[2(=!W/]@G
M9]3ES '+R'?A.P::S'F2N3VDW#DFMJ2Q8<<T_F_Z_7OD&Y88;H;:N^WOU<R7
M6:A:EL6\9)WJC%Q']+FE%ZN<%ZO6;?N8$&*:^]7J/JY6.L]V?M35>;97G&?[
M2.?9UHO5IC'TLG4!&'K!K0$%;?3ON('EELCIQRO 5513)^]H?-7XNC7X:E9>
M!+#O]KO"'KW_Z[O]03ATWO\_4$L#!!0    ( .$S?5;A8><OP@(  ",8   /
M    <WEB>"UE>#(Q7S$N:'1M[5EM:]LP$/[>7^%UK*Q0YPTVANP%MK0;&5L+
MS0;;1]FZV**RI$F7.MZOGRPG)4M2NM%F--0$XE@^W3U^[KF34.(<"S$\".(<
M*'/7($:. H9GW\-!/^XV-^YQ=_$\3A2K HN5@+>'!349ER2@,U3/>*&502HQ
MTI0Q+C,2O-'SZ- [U<LI"',,N60@D?0ZO1?15$D,+?\%I._N-4:-TQ"5)LV
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M   /    <WEB>"UE>#,Q7S(N:'1M[5MM;]LX$OZ^OX*WB^TE@!R_Y&6OLJ]
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MS8EY[!J6LLI#SJ,I),2&Z!JK]\O%73.AJC85T&P]4TI3;3)O@.?W8U&" "F
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MY=9P)O@M,95 ;3U7\:3<'ZLO#O:^"&S-+BZ<ONRHNCQ#1RN61?=A8#9<'GT
M+E#N*/ E"[)DZP+1A//\;)JU;><9Z$9=;C%VN$TC,8G<H%A$B+CP-0Z8\5^
M-."*PM(LRZE64T'K<\G'S?<XIBF+HJB4G@N\G4UT*(1\ [J V@ZJLD+)WK@\
MV0<$G;.3G\Y>_KBXW]*A>,5G)^>GI\_R&HOS&^Z-JT#!)70=:)@@)X7Q!M)=
MH-[0BW<4GV,S!/5W(AN&H?H]?VN@Z0!$*UY9$=NP"Q<+Y_CK*T&WOU,$ \QB
M=#H3" 4A7O1OA""5+5WFASN[H-'@S:[+'A+YK,1Y[YX(?C'WK9J$=&M"L6W/
M[MP>G)]'B__(Y@78&B#U93F<P5.=!/7S-O8_.]2P.^VG1"Q F!L@!8 M=0:7
M-EHQF8>N="R ]"WQ_0<L?+\ K3%[RPU6N,'+B UZ@].UG-D)IV^/ 2AI ? X
M /AY'C^]>#<YWY37900&YQ5<34?X;-.).[&Q(U:_%U:^W6V[1T9+UW;9V^O+
M?[R^^A?[]>KF_=7-+O"T"\N!Z\I3A +;(EA/I'@4,LN4^//&]5$OU#[9J'XJ
M6]M*?W@@;%[T;:O\4ZT&S[7*_]GCVE;YMLH?+KU#?S(SE@YS2#]S;'8YD2)G
M;Y:'CK^%;WC6 =/Z_N"^/_IWN%L#AV^YWG\OL'K_>G4AIQ$X_M0:C4\ZRFS/
MB9_VGSL^36=,EO2NXF,1"GN'Y\C"F*L9GUM/]$9=^C/;5]^-NO[/<_\/4$L#
M!!0    ( .$S?5:D@ +9\04  !4R   /    <WEB>"UE>#,R7S$N:'1M[5MM
M;^(X$/Z^OV)N5UVU$@$22E\2KA+;4EUU=Z4JK+3WT20.\:WC9&U3X'[]C4U"
M::&]2M?NTFY4"L09SXQGGF?L)*:3Z)2?O(-.0DF$G]#13'-ZTOOBM+Q.8W&
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MAP[,Q$GL$%[L'#-I"%-Z+71(.M/[J-ARK*LLNY)"DOOUMY+M$"#0SART@6:
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M.>T3/B5S9:\$.PWS=8KC5YV&_1K&?U!+ 0(4 Q0    ( .$S?5:MU#U2$]L
M # ( 0 2              "  0    !I;6<Q,3DW.3 U,3!?,"YJ<&=02P$"
M% ,4    " #A,WU6TMC;'4!2  ".90  $@              @ %#VP  :6UG
M,3$Y-SDP-3$P7S$N:G!G4$L! A0#%     @ X3-]5M+8VQU 4@  CF4  !,
M             ( !LRT! &EM9S$Q.3<Y,#4Q,%\Q,"YJ<&=02P$"% ,4
M" #A,WU6K7?N]N!Z 0"3M0$ $@              @ $D@ $ :6UG,3$Y-SDP
M-3$P7S(N:G!G4$L! A0#%     @ X3-]5A?QL%KX/ $ T)8! !(
M     ( !-/L" &EM9S$Q.3<Y,#4Q,%\S+FIP9U!+ 0(4 Q0    ( .$S?58%
MG@X8B0,! ,)G 0 2              "  5PX! !I;6<Q,3DW.3 U,3!?-"YJ
M<&=02P$"% ,4    " #A,WU6Z%[:]$\T @!3?@( $@              @ $5
M/ 4 :6UG,3$Y-SDP-3$P7S4N:G!G4$L! A0#%     @ X3-]5CAMO/$ Z@$
M>S<" !(              ( !E' ' &EM9S$Q.3<Y,#4Q,%\V+FIP9U!+ 0(4
M Q0    ( .$S?590S)/BF%8  #EH   2              "  <1:"0!I;6<Q
M,3DW.3 U,3!?-RYJ<&=02P$"% ,4    " #A,WU6S85*.>;N  !13P$ $@
M            @ &,L0D :6UG,3$Y-SDP-3$P7S@N:G!G4$L! A0#%     @
MX3-]5M=!60P,[0  '!@! !(              ( !HJ * &EM9S$Q.3<Y,#4Q
M,%\Y+FIP9U!+ 0(4 Q0    ( .$S?5;_D=8M.'H$ #7!/0 1
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M>"UE>#$P7S,R+FAT;5!+ 0(4 Q0    ( .$S?5;A8><OP@(  ",8   /
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I(*01 '-Y8G@M97@S,E\R+FAT;5!+!08     &  8 /<%   \JA$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
